{"meta":{"query_hash":"0fcb7d059508","filters":{"venue":"The Oncologist"},"cohort_total":406,"direct_labels_cover":2,"predictions_cover":406,"exported":406,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/0fcb7d059508","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Oncologist"},"results":[{"id":"W1973742157","doi":"10.1634/theoncologist.2013-0359","title":"Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Hospital; Royal Victoria Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Conjoint analysis; Breast cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Preference; Statistics","score_opus":0.0910081580114505,"score_gpt":0.3948186789986069,"score_spread":0.3038105209871564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973742157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919852,0.00007769598,0.0006550067,0.005304767,0.00017859605,0.0010351073,0.00007327474,0.000023365279,0.0006669657],"genre_scores_gemma":[0.99537754,0.0000777648,0.00059360656,0.0030400094,0.00012751583,0.00041867854,0.000016410148,0.0000075231055,0.00034096203],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99929774,0.00008980313,0.00017523521,0.0001684783,0.00010624532,0.00016249983],"domain_scores_gemma":[0.99873227,0.0007516299,0.00012654181,0.00019938008,0.00011770139,0.00007248046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015405392,0.00010955726,0.00041637634,0.0000674519,0.00004784053,0.0000095638425,0.00007790407,0.000048906182,0.00012710669],"category_scores_gemma":[0.000052244934,0.00006151853,0.00014316586,0.00023523082,0.000104350715,0.000021987302,0.000022836024,0.0000550556,0.000003280652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009106521,0.002088216,0.23651107,0.0003234262,0.007849892,0.0000075924713,0.0020640574,0.002190837,0.0756422,0.00047053045,0.022948574,0.6407971],"study_design_scores_gemma":[0.0041479226,0.0057000155,0.8547455,0.000070146896,0.005419485,0.000007875396,0.000089963156,0.0012884237,0.08078411,0.00018470942,0.04734866,0.00021318493],"about_ca_topic_score_codex":0.0015612766,"about_ca_topic_score_gemma":0.0012472556,"teacher_disagreement_score":0.64058393,"about_ca_system_score_codex":0.00013275295,"about_ca_system_score_gemma":0.000083197476,"threshold_uncertainty_score":0.25086528},"labels":[],"label_agreement":null},{"id":"W1988674152","doi":"10.1634/theoncologist.2014-0078","title":"Pre-Exercise Participation Cardiovascular Screening in a Heterogeneous Cohort of Adult Cancer Patients","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Physical therapy; Cohort; Internal medicine; Sports medicine; Risk stratification; Adverse effect; Metabolic equivalent; Disease; Risk assessment; Physical activity","score_opus":0.018076689303366512,"score_gpt":0.2949200106106782,"score_spread":0.27684332130731165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988674152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974621,0.0002038283,0.00067004695,0.00014677075,0.000077292905,0.0007458909,0.00000464313,0.00002407827,0.0006653816],"genre_scores_gemma":[0.9990703,0.00020929142,0.00013533825,0.0002556682,0.000086462445,0.00016983949,0.000019208945,0.000012773587,0.00004115519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990425,0.00011211315,0.00024559372,0.00016560158,0.00027405587,0.0001601205],"domain_scores_gemma":[0.9993836,0.00005240825,0.000097672135,0.00030110474,0.000121619574,0.000043594515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040623028,0.00009330667,0.0003546689,0.000039739873,0.000042916756,0.0000054113802,0.00007376246,0.000090007954,0.000014196245],"category_scores_gemma":[0.00015372524,0.000067524255,0.00017410555,0.00014124787,0.00009616532,0.000033417018,0.000021831176,0.00011740035,0.0000024692094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007404446,0.0004258345,0.77439296,0.00014143762,0.00047183683,0.0000050502545,0.0015577433,0.01156194,0.009171901,0.000039080536,0.00013554243,0.2013562],"study_design_scores_gemma":[0.0027986844,0.00035837304,0.8353321,0.00026730835,0.00040676183,0.000004476425,0.000047939153,0.0026767035,0.15745325,0.000053817723,0.0004845296,0.00011608123],"about_ca_topic_score_codex":0.0012877363,"about_ca_topic_score_gemma":0.00030160113,"teacher_disagreement_score":0.20124012,"about_ca_system_score_codex":0.00009302064,"about_ca_system_score_gemma":0.000035297024,"threshold_uncertainty_score":0.2753559},"labels":[],"label_agreement":null},{"id":"W1991358323","doi":"10.1634/theoncologist.2013-0290","title":"Barriers and Challenges to Global Clinical Cancer Research","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Health and Surgery","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Test (biology); Cancer; Clinical research; Family medicine; Medical education; Political science; Internal medicine","score_opus":0.30175418580204844,"score_gpt":0.536503614276339,"score_spread":0.23474942847429053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991358323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75057554,0.005591358,0.0000011011869,0.21336977,0.00035513993,0.0005265738,0.0000060031775,0.000028845709,0.02954564],"genre_scores_gemma":[0.9802111,0.00941892,0.00009890673,0.008948721,0.0004254183,0.00012840144,6.0333156e-7,0.000004770022,0.0007631559],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859726,0.00029197196,0.00020827795,0.00020373234,0.00023417453,0.0004645606],"domain_scores_gemma":[0.99836314,0.00047929637,0.000023529057,0.00025038683,0.00016324533,0.0007204021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024769253,0.00006641121,0.00022419711,0.000019961297,0.00015896029,0.000014612208,0.000106263025,0.000108565815,0.00029491773],"category_scores_gemma":[0.0014099239,0.000037401413,0.000035627763,0.00015048383,0.00042944655,0.000022025746,0.000107598906,0.00027041673,0.00035349836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052540953,0.00007735563,0.22848597,0.00010046061,0.000033235334,0.000043646014,0.00019685809,8.209681e-7,0.00001550552,0.003749942,0.35716558,0.40960523],"study_design_scores_gemma":[0.00039832504,0.0006112142,0.6581264,0.00003622843,0.00001002519,0.000018486804,0.0010590036,0.000015091211,0.0000030516562,0.0009690015,0.338706,0.000047140096],"about_ca_topic_score_codex":0.0030654538,"about_ca_topic_score_gemma":0.0008029801,"teacher_disagreement_score":0.42964047,"about_ca_system_score_codex":0.00017708358,"about_ca_system_score_gemma":0.00044295078,"threshold_uncertainty_score":0.46340695},"labels":[],"label_agreement":null},{"id":"W1993411111","doi":"10.1634/theoncologist.2014-0097","title":"Radiation Therapy for Liver Tumors: Ready for Inclusion in Guidelines?","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Context (archaeology); Liver transplantation; Hepatocellular carcinoma; Radiofrequency ablation; Selective internal radiation therapy; Radiology; Transplantation; Surgery; Ablation; Internal medicine","score_opus":0.3872888074408159,"score_gpt":0.4455272626865611,"score_spread":0.058238455245745224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993411111","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000087006396,0.9892082,0.0002544979,0.0011720044,0.0001788887,0.008515267,0.00006404184,0.000046097586,0.0004739618],"genre_scores_gemma":[0.00041455135,0.99066937,0.0012295117,0.00063875306,0.0010711461,0.003461649,0.0015018788,0.000062042716,0.00095107243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982788,0.0002181028,0.00072562095,0.00033866178,0.00016612049,0.00027271832],"domain_scores_gemma":[0.99787444,0.0010755335,0.0004201129,0.00041393883,0.00015790349,0.00005807761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019045175,0.00032775922,0.0014832632,0.00013495023,0.00020514498,0.000019062862,0.00025352024,0.00035794664,0.000023978459],"category_scores_gemma":[0.00054642506,0.00017222932,0.0005452982,0.00017014144,0.000066484215,0.000026243464,0.00015698971,0.0001764132,0.00003252487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016361495,0.00013171483,0.00018504336,0.0030721086,0.00007670218,0.000011712591,0.000072278955,8.870384e-8,7.7956184e-7,0.0001475029,0.010083086,0.9860554],"study_design_scores_gemma":[0.0019235199,0.0013593824,0.000025256528,0.002520819,0.00071506004,0.000019976902,0.0000054254665,0.00055789435,0.00000899612,0.00017955748,0.9925069,0.00017718704],"about_ca_topic_score_codex":0.00015398923,"about_ca_topic_score_gemma":0.0000410574,"teacher_disagreement_score":0.98587817,"about_ca_system_score_codex":0.00042041004,"about_ca_system_score_gemma":0.00040951697,"threshold_uncertainty_score":0.70233077},"labels":[],"label_agreement":null},{"id":"W2025163366","doi":"10.1634/theoncologist.6-suppl_4-17","title":"Optimizing the Use of Irinotecan in Colorectal Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Irinotecan; Medicine; Colorectal cancer; Tolerability; Capecitabine; Oncology; Internal medicine; Clinical trial; Combination therapy; Cancer; Adverse effect","score_opus":0.225416423760074,"score_gpt":0.4210969218419179,"score_spread":0.19568049808184387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025163366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00080585893,0.99317455,0.0000012389255,0.00069789833,0.00025486803,0.0016024068,0.000050285962,0.000021598296,0.0033913061],"genre_scores_gemma":[0.0007729597,0.99692905,0.000078343146,0.00012113239,0.00017983136,0.0007186165,0.000013559294,0.00002795841,0.0011585362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861014,0.0001797133,0.0004871354,0.00025075336,0.00018972377,0.0002825633],"domain_scores_gemma":[0.99850875,0.00074969284,0.00034138796,0.0003080264,0.00005651529,0.000035644574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023296336,0.00030405444,0.001595333,0.00007628293,0.00012011101,0.000017358474,0.00023284653,0.00016354873,0.00010418629],"category_scores_gemma":[0.00013330566,0.00012310165,0.00035947928,0.0005237443,0.00050333457,0.000024012232,0.00017519646,0.00047424735,0.000007103673],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014560038,0.00018219485,0.00022837675,0.0010535471,0.00040882596,0.0000829369,0.00031859105,0.000026740217,4.3624667e-7,0.000030134075,0.0015964351,0.9959262],"study_design_scores_gemma":[0.00041305332,0.00058156834,0.0007676006,0.0035620376,0.0014085894,0.00006216312,0.00009406575,0.000010261774,0.0000018240037,0.000004385794,0.9929715,0.00012296924],"about_ca_topic_score_codex":0.0038907828,"about_ca_topic_score_gemma":0.0063843033,"teacher_disagreement_score":0.99580324,"about_ca_system_score_codex":0.0008793058,"about_ca_system_score_gemma":0.0005295267,"threshold_uncertainty_score":0.58817255},"labels":[],"label_agreement":null},{"id":"W2027587146","doi":"10.1634/theoncologist.2012-0226","title":"The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada","keywords":"Cardiotoxicity; Medicine; Cancer; Discontinuation; Adverse effect; Cancer therapy; Disease; Toxicity; Bioinformatics; Pharmacology; Internal medicine; Biology","score_opus":0.03731525061052608,"score_gpt":0.34261238579630016,"score_spread":0.30529713518577406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027587146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00559585,0.9893244,0.00018066735,0.00029197262,0.00030671124,0.0036555754,0.00006672496,0.000036088168,0.0005420443],"genre_scores_gemma":[0.027641008,0.97070867,0.0001932386,0.00016630719,0.00024183266,0.00044736924,0.0000341819,0.00006488047,0.00050252257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99774307,0.0003261287,0.00077298563,0.00032630668,0.0004837748,0.00034772675],"domain_scores_gemma":[0.9977752,0.00016142205,0.0006581425,0.0009899801,0.00031255095,0.000102693004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006312333,0.0003934691,0.0019698073,0.00008784753,0.00015436907,0.000026882908,0.0005461796,0.0004569942,0.000034101293],"category_scores_gemma":[0.000049935996,0.00020576564,0.0010144699,0.0004408666,0.00041892164,0.000033001754,0.00012111148,0.00053811335,0.000016849992],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009791954,0.00008218348,0.0000016892751,0.0014814149,0.0009991362,0.00000404979,0.00018005112,0.00007993174,0.058241036,0.000051651063,0.0002101967,0.93857074],"study_design_scores_gemma":[0.0011109828,0.0006807955,0.00013644533,0.007748188,0.00769167,0.0000699791,0.0002976693,0.0001222123,0.13019006,0.00038827214,0.85098803,0.00057570095],"about_ca_topic_score_codex":0.00055270945,"about_ca_topic_score_gemma":0.00002825643,"teacher_disagreement_score":0.937995,"about_ca_system_score_codex":0.0003085396,"about_ca_system_score_gemma":0.0006110725,"threshold_uncertainty_score":0.8390879},"labels":[],"label_agreement":null},{"id":"W2036207363","doi":"10.1634/theoncologist.2009-0275","title":"Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Cost effectiveness; Internal medicine; Cost-effectiveness analysis; Quality-adjusted life year; Cancer","score_opus":0.07588753672040834,"score_gpt":0.38078216170724855,"score_spread":0.3048946249868402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036207363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817586,0.0003704133,0.00011735126,0.00019520649,0.00020080528,0.00043249974,0.00031205,0.000007284487,0.00018852057],"genre_scores_gemma":[0.9990893,0.00022428679,0.00019470691,0.00003455001,0.00009552616,0.0002764001,0.000046972,0.000011732267,0.000026519821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889666,0.00019947455,0.00021440764,0.00034226125,0.000108530185,0.00023868777],"domain_scores_gemma":[0.99915415,0.00009330473,0.00016565426,0.00042741158,0.00011875263,0.00004072566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036372425,0.00019189803,0.00038175046,0.000085262014,0.00008820097,0.000011726011,0.00020131582,0.000114734015,0.000020883863],"category_scores_gemma":[0.00005143968,0.00012606721,0.0001542937,0.00049355754,0.00034123647,0.0000040067525,0.000100802754,0.000089922636,0.0000013023225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040233327,0.00034874192,0.74590397,0.000008025271,0.001256878,0.0000053904437,0.00018454996,0.0016116666,0.24004176,0.000029134537,0.000017457376,0.010190081],"study_design_scores_gemma":[0.0009733881,0.00014385894,0.924239,0.000017233147,0.0007383799,0.000013385219,0.00003877586,0.0001739598,0.07333502,0.000017809007,0.00017024213,0.0001389391],"about_ca_topic_score_codex":0.01301713,"about_ca_topic_score_gemma":0.0146472445,"teacher_disagreement_score":0.17833503,"about_ca_system_score_codex":0.00022751771,"about_ca_system_score_gemma":0.00019241081,"threshold_uncertainty_score":0.99355525},"labels":[],"label_agreement":null},{"id":"W2047262695","doi":"10.1634/theoncologist.2009-s106","title":"Imaging in Radiation Oncology: A Perspective","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Radiation oncology; Medical physics; Perspective (graphical); Medicine; Radiology; Oncology; Nuclear medicine; Radiation therapy; Computer science; Artificial intelligence","score_opus":0.028152886793410395,"score_gpt":0.4226798123966626,"score_spread":0.3945269256032522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047262695","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.4633105e-7,0.94109905,0.003504772,0.00028670245,0.0002304946,0.0009589627,0.000027294762,0.00008184257,0.05381023],"genre_scores_gemma":[0.00003031004,0.9952984,0.0028900092,0.00006536745,0.00076296064,0.00053986395,0.000033030163,0.000048122667,0.000331948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987181,0.0002782824,0.0003437681,0.00031466372,0.00008118799,0.00026399872],"domain_scores_gemma":[0.9986854,0.0003973412,0.0004420654,0.00040731608,0.000036089437,0.000031797237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004503048,0.00028664098,0.00088416785,0.00011759444,0.000101247046,0.00003055368,0.00048485617,0.0001633941,0.00015437424],"category_scores_gemma":[0.000025538242,0.00018145468,0.0002521849,0.00024212958,0.00026770838,0.0000752798,0.000070619164,0.0011820241,0.000021122625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000026071332,0.00006814799,0.000046119643,0.000040951527,0.00002277413,0.0000047344824,0.00016200017,7.6204526e-7,0.0000010846957,0.014402449,0.0003717083,0.98487663],"study_design_scores_gemma":[0.00014601111,0.000035748402,0.00000691549,0.00028954557,0.00008773611,0.0000067368774,0.00015056752,0.000012158526,0.0000015363006,0.004801104,0.99426347,0.0001984455],"about_ca_topic_score_codex":0.00044794337,"about_ca_topic_score_gemma":0.000036869314,"teacher_disagreement_score":0.9938918,"about_ca_system_score_codex":0.0010317322,"about_ca_system_score_gemma":0.0004895874,"threshold_uncertainty_score":0.7399507},"labels":[],"label_agreement":null},{"id":"W2086678943","doi":"10.1634/theoncologist.2009-0042","title":"Studying Genetic Variations in Cancer Prognosis (and Risk): A Primer for Clinicians","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Candidate gene; Single-nucleotide polymorphism; Computational biology; Genome-wide association study; Genetic association; Primer (cosmetics); Bioinformatics; Gene; Genetic variation; Genetics; Genotype; Biology","score_opus":0.09955752394625256,"score_gpt":0.4293655560473131,"score_spread":0.3298080321010605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086678943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039569353,0.9956657,0.00068251847,0.00021965924,0.00025410918,0.0023911363,0.00018178402,0.000011112682,0.00019825844],"genre_scores_gemma":[0.00044291595,0.9915679,0.0035208939,0.00014045907,0.0005315228,0.0033315509,0.00007781408,0.000041035823,0.0003459131],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99838763,0.00028306525,0.0005074216,0.0004835029,0.0000795491,0.00025882784],"domain_scores_gemma":[0.9988706,0.00020376788,0.00042840603,0.0003959473,0.00006743334,0.000033839067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056250696,0.0002588481,0.0005894973,0.00006336086,0.00018166845,0.000034504003,0.00035022557,0.00035402965,0.0000074267],"category_scores_gemma":[0.00027559325,0.00018288322,0.00019902174,0.00019161685,0.000154111,0.0000016236696,0.00011350629,0.00024301546,0.0000033511021],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000114790755,0.00009388129,0.0004789151,0.00036952982,0.0002011819,7.3614746e-7,0.000063264895,0.000058042075,0.0000036231504,0.000018071358,0.0016432503,0.99705803],"study_design_scores_gemma":[0.00034467145,0.00029480507,0.0010634428,0.0004339093,0.001054403,0.0000070533943,0.000030364428,0.000025939942,0.0000075912117,0.000106029234,0.99639034,0.00024147508],"about_ca_topic_score_codex":0.00022087655,"about_ca_topic_score_gemma":0.001865662,"teacher_disagreement_score":0.9968166,"about_ca_system_score_codex":0.00022495027,"about_ca_system_score_gemma":0.00092580257,"threshold_uncertainty_score":0.7457761},"labels":[],"label_agreement":null},{"id":"W2094948739","doi":"10.1634/theoncologist.2014-0229","title":"Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Medicine; Chemotherapy-induced nausea and vomiting; Antiemetic; Adverse effect; Vomiting; Nausea; Oncology; Pharmacology; Internal medicine; Intensive care medicine","score_opus":0.1153224472111678,"score_gpt":0.4187728673947717,"score_spread":0.3034504201836039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094948739","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000068836025,0.9708206,0.0000037499583,0.00082372164,0.00007200613,0.0023999189,0.00003080425,0.000038355392,0.025803963],"genre_scores_gemma":[0.00001429543,0.9968644,0.00021975298,0.0002718806,0.00014215375,0.000056858837,0.000039237497,0.000030023062,0.002361435],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813133,0.00030530282,0.0007349494,0.00035541094,0.00026228672,0.00021073662],"domain_scores_gemma":[0.9980189,0.00052280887,0.0005356667,0.00068870425,0.00010423913,0.00012964281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024790096,0.00029485155,0.0022410017,0.00006427668,0.00006486623,0.000012606641,0.00019904831,0.00015312845,0.00011289656],"category_scores_gemma":[0.0010448914,0.00015542678,0.0001823468,0.0002071648,0.00038451728,0.000018678424,0.00036390705,0.0002940215,0.000043207532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006881313,0.000078857665,0.0000035434375,0.14250489,0.00021694614,0.000030928255,0.000030484336,8.112478e-9,1.339445e-7,0.00064576516,0.019245751,0.8371739],"study_design_scores_gemma":[0.0007793343,0.000495668,0.000040007697,0.09583086,0.003490797,0.00011582443,0.000020794067,5.145062e-7,1.1127175e-7,0.000046292018,0.8990443,0.0001355382],"about_ca_topic_score_codex":0.000014552511,"about_ca_topic_score_gemma":0.0000017969398,"teacher_disagreement_score":0.87979853,"about_ca_system_score_codex":0.0001317814,"about_ca_system_score_gemma":0.0002463695,"threshold_uncertainty_score":0.63381207},"labels":[],"label_agreement":null},{"id":"W2095839943","doi":"10.1634/theoncologist.2009-0298","title":"Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Stage (stratigraphy); Oncology; Current (fluid); Lung cancer; Internal medicine; Cancer; Intensive care medicine","score_opus":0.14461746522540633,"score_gpt":0.4771418083636698,"score_spread":0.3325243431382635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095839943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005373179,0.98314786,0.000006941882,0.0011998623,0.0012467195,0.00499349,0.00025028057,0.00015971405,0.0089413775],"genre_scores_gemma":[0.000006687213,0.9726223,0.00010452428,0.00013773429,0.002009457,0.003428889,0.000120621386,0.000121118814,0.021448666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713236,0.00027247562,0.00062159466,0.00071664806,0.00043781224,0.0008191082],"domain_scores_gemma":[0.99716157,0.0006149225,0.00051294366,0.0013326787,0.000104144194,0.0002737207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004812404,0.0008049084,0.0030600815,0.0001490854,0.0002967784,0.000066633496,0.00067138195,0.00038674215,0.0003372088],"category_scores_gemma":[0.000081053906,0.00039418004,0.0008650989,0.00040491816,0.0006401873,0.000025807261,0.00017014873,0.0015467497,0.00009808387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005761911,0.00047905772,0.00015866227,0.013730279,0.0006233564,0.00009389944,0.00022026707,8.4489545e-7,0.0000027354577,0.000044972923,0.011712076,0.97287625],"study_design_scores_gemma":[0.0013637318,0.00064955745,0.000028328037,0.0041139373,0.0027415555,0.000034853634,0.000020540943,0.000016643387,0.00001657425,0.0000031960794,0.99064505,0.0003660548],"about_ca_topic_score_codex":0.00073967065,"about_ca_topic_score_gemma":0.00056183286,"teacher_disagreement_score":0.978933,"about_ca_system_score_codex":0.0042408803,"about_ca_system_score_gemma":0.0029219373,"threshold_uncertainty_score":0.999851},"labels":[],"label_agreement":null},{"id":"W2097068862","doi":"10.1634/theoncologist.2008-0184","title":"Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Genomic Health; Pfizer","keywords":"Medicine; Breast cancer; Estrogen receptor; Hormone receptor; Distress; Cancer; Oncology; Receptor; Estrogen; Hormone; Internal medicine; Gynecology; Clinical psychology","score_opus":0.018827514875361384,"score_gpt":0.24858736979699678,"score_spread":0.2297598549216354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097068862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97884446,0.0018459012,0.00000523436,0.017338866,0.00013304471,0.00013840412,0.0013009518,0.000010940218,0.00038217157],"genre_scores_gemma":[0.9961953,0.0004819703,0.0001504988,0.0023801103,0.00039696434,0.00010467863,0.00023543449,0.000013072365,0.000041933105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991684,0.00007242774,0.00015223557,0.00024619067,0.00011621197,0.00024456123],"domain_scores_gemma":[0.9995367,0.00008249867,0.000080025355,0.00021539243,0.000038989445,0.000046394143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005310347,0.00015298951,0.00016839821,0.000008497687,0.00021108257,0.00000643031,0.0002283251,0.000050617116,0.000035731697],"category_scores_gemma":[0.000019006933,0.00010929442,0.000028067378,0.00010015923,0.00024123822,0.0000022307468,0.00015276365,0.00009975017,0.000002325871],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005157685,0.00020687241,0.7145061,0.0000040770997,0.00018112465,0.00006653307,0.00016640157,0.00019649664,0.028845333,0.0000020054058,0.24382803,0.011481267],"study_design_scores_gemma":[0.001396721,0.00010005306,0.976134,0.00002254057,0.00003201996,0.00003773393,0.00031312666,0.000022066828,0.0040611858,0.00001545718,0.017637253,0.00022786844],"about_ca_topic_score_codex":0.9061356,"about_ca_topic_score_gemma":0.7765838,"teacher_disagreement_score":0.26162788,"about_ca_system_score_codex":0.0003440701,"about_ca_system_score_gemma":0.00028933358,"threshold_uncertainty_score":0.44568974},"labels":[],"label_agreement":null},{"id":"W2098169322","doi":"10.1634/theoncologist.8-3-232","title":"Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer","year":2003,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ottawa Regional Cancer Foundation","funders":"","keywords":"Docetaxel; Medicine; Capecitabine; Taxane; Oncology; Population; Metastatic breast cancer; Internal medicine; Quality-adjusted life year; Anthracycline; Breast cancer; Cost effectiveness; Cancer; Colorectal cancer; Environmental health","score_opus":0.0934897234531395,"score_gpt":0.41733139480526843,"score_spread":0.32384167135212893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098169322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716966,0.0008293407,0.008702306,0.010211421,0.0007066626,0.0058666137,0.0012599141,0.00015078981,0.0005763223],"genre_scores_gemma":[0.9890024,0.00014150677,0.0042129867,0.0010376518,0.00015016095,0.00270511,0.0004992949,0.000042260173,0.0022086445],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9988165,0.00007826883,0.00037248628,0.00031199897,0.00007957335,0.00034117966],"domain_scores_gemma":[0.9987072,0.0006090915,0.00025012315,0.00019028889,0.0001491217,0.000094193645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000272956,0.000253279,0.00048004804,0.00008199555,0.00029797613,0.00002029269,0.000079138925,0.00006254788,0.0002624617],"category_scores_gemma":[0.000054100343,0.0001706062,0.00022371815,0.00011072014,0.00008073917,0.00006768435,0.000006082784,0.00007211029,0.000005516945],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029080251,0.02199086,0.3221763,0.0013004644,0.006639931,0.000044756594,0.0019265375,0.40789998,0.024421798,0.0068087406,0.022195144,0.15551525],"study_design_scores_gemma":[0.04579712,0.0019511365,0.015337827,0.000048316404,0.0038869842,0.000027064669,0.00011759779,0.9213776,0.005408615,0.0006745871,0.0050020297,0.0003711095],"about_ca_topic_score_codex":0.00067211397,"about_ca_topic_score_gemma":0.00050067034,"teacher_disagreement_score":0.5134776,"about_ca_system_score_codex":0.0012784966,"about_ca_system_score_gemma":0.0004405524,"threshold_uncertainty_score":0.6957119},"labels":[],"label_agreement":null},{"id":"W2100458353","doi":"10.1634/theoncologist.2011-0448","title":"Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; University of Waterloo","funders":"","keywords":"Medicine; Zoledronic acid; Prostate cancer; Internal medicine; Hazard ratio; Parathyroid hormone; Placebo; Urology; Bone remodeling; Gastroenterology; Oncology; Cancer; Endocrinology; Confidence interval; Pathology; Calcium","score_opus":0.025674338114922663,"score_gpt":0.33319968739375033,"score_spread":0.3075253492788277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100458353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924954,0.0046221227,0.0000017458743,0.0007160637,0.00008129851,0.001198988,0.000041785243,0.000024655037,0.0008179387],"genre_scores_gemma":[0.99883145,0.0003292633,0.0001348455,0.00016178055,0.000031170628,0.0002409934,0.000025641206,0.000013960728,0.00023091062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989246,0.000067783134,0.00031370658,0.00013296043,0.00016699046,0.00039394113],"domain_scores_gemma":[0.99937207,0.00009225221,0.00019633387,0.00016863886,0.000055264532,0.00011542434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019848351,0.0001240439,0.00023966187,0.000037284604,0.00006892872,0.0000044532067,0.000056174922,0.00006973895,0.000017141809],"category_scores_gemma":[0.00011761133,0.000081790495,0.000032518263,0.00015865495,0.00008091269,0.000119086784,0.00002608816,0.00015093193,0.000023160237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006289234,0.0010780565,0.97785604,0.000059204944,0.000029302088,0.000004190986,0.0007053242,0.000011757971,0.0020601656,0.00006574957,0.000042788295,0.017458476],"study_design_scores_gemma":[0.0037452353,0.0020448198,0.98920643,0.00007309339,0.00006869548,0.0000052403598,0.000221318,0.000027995113,0.004155939,0.000105691324,0.00027284626,0.000072700575],"about_ca_topic_score_codex":0.00012820256,"about_ca_topic_score_gemma":0.0009999541,"teacher_disagreement_score":0.017385775,"about_ca_system_score_codex":0.0003175125,"about_ca_system_score_gemma":0.00047478467,"threshold_uncertainty_score":0.33353198},"labels":[],"label_agreement":null},{"id":"W2101024529","doi":"10.1634/theoncologist.2014-0059","title":"Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Genentech","keywords":"Medicine; Capecitabine; Metastatic breast cancer; Taxane; Adverse effect; Internal medicine; Cohort; Breast cancer; Cancer; Pharmacy; Leukopenia; Anemia; Chemotherapy; Oncology","score_opus":0.024192563102551974,"score_gpt":0.34294199914562395,"score_spread":0.318749436043072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101024529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936029,0.000023843982,0.000013714065,0.003742748,0.0001144863,0.0010664129,0.00006873802,0.000019189,0.001348006],"genre_scores_gemma":[0.99833256,0.000018729797,0.00025591487,0.0003492104,0.00003754385,0.00020424681,0.00007277768,0.000011738335,0.0007172902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928397,0.00011110507,0.00022997639,0.00012762779,0.00009737545,0.0001499503],"domain_scores_gemma":[0.9992659,0.00028228696,0.00021102336,0.00010591755,0.0000905757,0.00004429689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003048276,0.000093113194,0.00023976306,0.000068882044,0.000041797048,0.0000015512267,0.00005234037,0.000027596452,0.00008684885],"category_scores_gemma":[0.00002907668,0.000054996533,0.000037388752,0.00023003209,0.00016050815,0.000037666516,0.000013576784,0.000087914275,0.000002383203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018853846,0.00025893672,0.98350877,0.000096112206,0.00018558881,0.0000026560904,0.00052577053,0.00023639006,0.00070496264,0.0003501123,0.0013903552,0.010854961],"study_design_scores_gemma":[0.010331023,0.0010903383,0.9855129,0.00017294675,0.00048387385,0.0000030176454,0.000082084945,0.0010306285,0.00047940997,0.00021276022,0.00052199094,0.000079040954],"about_ca_topic_score_codex":0.0016896861,"about_ca_topic_score_gemma":0.0054138447,"teacher_disagreement_score":0.010775921,"about_ca_system_score_codex":0.00036727916,"about_ca_system_score_gemma":0.00015367159,"threshold_uncertainty_score":0.30210525},"labels":[],"label_agreement":null},{"id":"W2101719282","doi":"10.1634/theoncologist.2010-0278","title":"In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; University of Alberta; Bibliographical Society of Canada; Jewish General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"University of Toronto; Eli Lilly and Company","keywords":"Medicine; Clinical trial; Metastatic breast cancer; Clinical research; Clinical endpoint; Breast cancer; Phases of clinical research; Oncology; Drug; Food and drug administration; Cancer; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.19286006184339724,"score_gpt":0.5378821186998671,"score_spread":0.3450220568564699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101719282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037360303,0.979382,9.7193826e-8,0.014258152,0.0009617501,0.002720001,0.00007690419,0.000008885636,0.0025548807],"genre_scores_gemma":[0.00002491466,0.97854954,0.000019927556,0.01933411,0.0003314728,0.0010735681,0.000051338484,0.000027436176,0.0005876872],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965667,0.0011882922,0.0013896679,0.00036492702,0.00018038238,0.0003100354],"domain_scores_gemma":[0.99738395,0.0011114948,0.000803435,0.00059711846,0.00004493134,0.000059061487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021355,0.0003410028,0.0028278271,0.000091326954,0.000024421539,0.000007777063,0.00053424033,0.00024497378,0.0024828892],"category_scores_gemma":[0.00008734454,0.00015529658,0.0004982724,0.00049841637,0.0004960319,0.00008750129,0.00010120782,0.00091159815,0.0000656332],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022537439,0.0005265479,0.00012244789,0.027019687,0.00015304785,0.00014624328,0.0001226563,5.642379e-8,1.6450409e-7,0.000034754194,0.024259279,0.9473897],"study_design_scores_gemma":[0.0012791953,0.00027421888,0.0006553286,0.092566706,0.0016436094,0.0002429457,0.000055647997,1.6768155e-7,2.7516978e-7,0.000021571701,0.90313756,0.00012275638],"about_ca_topic_score_codex":0.00083410466,"about_ca_topic_score_gemma":0.0009629887,"teacher_disagreement_score":0.947267,"about_ca_system_score_codex":0.0003605595,"about_ca_system_score_gemma":0.0008999554,"threshold_uncertainty_score":0.998429},"labels":[],"label_agreement":null},{"id":"W2102718441","doi":"10.1634/theoncologist.2010-0307","title":"Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":253,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Texas MD Anderson Cancer Center; Merck KGaA","keywords":"Medicine; Keyhole limpet hemocyanin; Cyclophosphamide; Adjuvant; Metastatic breast cancer; Internal medicine; Breast cancer; Population; Seroconversion; Immunology; Cancer; Gastroenterology; Oncology; Chemotherapy; Antibody","score_opus":0.11081854182778034,"score_gpt":0.4328358542687114,"score_spread":0.32201731244093107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102718441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938134,0.00015732167,0.00068894157,0.0017298725,0.000469501,0.0020142556,0.00023141867,0.000010128412,0.00088518666],"genre_scores_gemma":[0.99666876,0.00012982819,0.0003934989,0.0004675223,0.00040472345,0.00017646088,0.000030899562,0.000018939481,0.0017093692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984433,0.0003243744,0.0005029083,0.00028062187,0.0001761138,0.00027266174],"domain_scores_gemma":[0.9988534,0.000101574915,0.00027353986,0.0004991998,0.00019535555,0.00007691796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011441369,0.00014439056,0.00027513824,0.000021398688,0.0001458976,0.000014354187,0.00054488576,0.000122572,0.00022654838],"category_scores_gemma":[0.00039236795,0.00007731902,0.00026964655,0.00010428541,0.00025971656,0.000004420971,0.00021452238,0.00017523443,0.000010072832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46577385,0.015560435,0.0044976496,0.00017339115,0.0014131849,0.000012216704,0.0008138465,0.00009589807,0.32950664,0.00093141035,0.0532832,0.12793829],"study_design_scores_gemma":[0.47252223,0.015696017,0.009094536,0.00007196281,0.00063703366,0.000059363123,0.0008275042,0.0027918932,0.32090956,0.00053010904,0.17614166,0.0007181329],"about_ca_topic_score_codex":0.00033918375,"about_ca_topic_score_gemma":0.00046209656,"teacher_disagreement_score":0.12722015,"about_ca_system_score_codex":0.000023865183,"about_ca_system_score_gemma":0.00019102884,"threshold_uncertainty_score":0.3152978},"labels":[],"label_agreement":null},{"id":"W2102727846","doi":"10.1634/theoncologist.2011-0450","title":"The Utility of Hedgehog Signaling Pathway Inhibition for Cancer","year":2012,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hedgehog signaling pathway; Hedgehog; Signal transduction; Cancer research; Smoothened; Metastasis; Biology; Downregulation and upregulation; Cancer; Bioinformatics; Medicine; Cell biology; Genetics","score_opus":0.1417067204821225,"score_gpt":0.3886677874465042,"score_spread":0.24696106696438172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102727846","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025475034,0.99648297,0.00033371375,0.00008854399,0.0005669334,0.001236726,0.00034829322,0.000014147884,0.0006739405],"genre_scores_gemma":[0.009897726,0.9871577,0.00007915823,0.000052184656,0.0010987725,0.00095144665,0.00016500222,0.000045709825,0.0005523232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981493,0.00037141962,0.00060025096,0.00033543643,0.00014073643,0.0004028869],"domain_scores_gemma":[0.9980306,0.0004938254,0.00063387235,0.00060930505,0.00018523009,0.000047144396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016988479,0.00033227805,0.00078614766,0.000021065956,0.00044014366,0.000021649106,0.00045394085,0.0003679445,0.000012819398],"category_scores_gemma":[0.00037862945,0.00016727482,0.00055351964,0.00011257952,0.00063110667,0.0000018838407,0.00025901842,0.00021669934,0.00000621838],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047568297,0.00006860123,0.000007531741,0.0031933212,0.00036581457,5.7700015e-7,0.00006720268,0.0000024440467,0.0017711867,0.00012382901,0.0028721918,0.99147975],"study_design_scores_gemma":[0.0001264921,0.00014629556,0.0000035424691,0.0006776257,0.0004879588,0.000004513106,0.00006414607,0.0000023579976,0.005453493,0.000065386994,0.99277055,0.000197656],"about_ca_topic_score_codex":0.00003502553,"about_ca_topic_score_gemma":0.00015616616,"teacher_disagreement_score":0.99128205,"about_ca_system_score_codex":0.000055669043,"about_ca_system_score_gemma":0.000454038,"threshold_uncertainty_score":0.6821269},"labels":[],"label_agreement":null},{"id":"W2103017000","doi":"10.1634/theoncologist.2013-0175","title":"Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Medical Research Council; National Health and Medical Research Council; Ovarian Cancer Research Foundation","keywords":"Medicine; Quality of life (healthcare); Depression (economics); Chemotherapy; Anxiety; Internal medicine; Odds ratio; Ovarian cancer; Confidence interval; Cancer; Oncology; Psychiatry","score_opus":0.05196534679095932,"score_gpt":0.359249558680084,"score_spread":0.3072842118891247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103017000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97856325,0.0037004224,0.000010456457,0.012457599,0.0004257411,0.004325056,0.00028505648,0.00005289789,0.00017951717],"genre_scores_gemma":[0.9914327,0.0014510384,0.00012888943,0.0023297614,0.00036262558,0.003859322,0.000019513154,0.000040316863,0.00037577777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721324,0.00028581504,0.0010418218,0.000583792,0.00036874137,0.0005066059],"domain_scores_gemma":[0.9957322,0.002481681,0.0007013471,0.00076635845,0.00014557249,0.00017283658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001391447,0.00038475884,0.0011438389,0.00007465834,0.00021510969,0.00005692922,0.00041264706,0.00015706738,0.0005917616],"category_scores_gemma":[0.0003270081,0.00021876703,0.00012467071,0.00022919581,0.00033884018,0.000102560276,0.00014144946,0.0003008691,0.0000034894606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077085444,0.0048657297,0.6905769,0.00022209038,0.0016315652,0.0000039783026,0.06421379,0.000096690674,0.0018804647,0.00030462476,0.0010429157,0.22745267],"study_design_scores_gemma":[0.008756887,0.0037974152,0.9684411,0.00017425514,0.00012823417,4.604234e-7,0.014950128,0.00009008,0.000092779206,0.0012680958,0.0020466503,0.00025385717],"about_ca_topic_score_codex":0.1529753,"about_ca_topic_score_gemma":0.14866304,"teacher_disagreement_score":0.27786422,"about_ca_system_score_codex":0.0017192302,"about_ca_system_score_gemma":0.0003200175,"threshold_uncertainty_score":0.8921061},"labels":[],"label_agreement":null},{"id":"W2105446438","doi":"10.1634/theoncologist.2013-0249","title":"Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stage (stratigraphy); Lymphoma; Internal medicine; Radiation therapy; Confidence interval; Diffuse large B-cell lymphoma; Chemotherapy; Gastroenterology; International Prognostic Index; Surgery","score_opus":0.016547005499426972,"score_gpt":0.288071779150658,"score_spread":0.27152477365123107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105446438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407697,0.00007135316,0.0000020125049,0.0006483857,0.00011156205,0.0011307191,0.000051645166,0.000010650954,0.0038966914],"genre_scores_gemma":[0.9983332,0.00012599175,0.0001931851,0.00022029477,0.0000348218,0.00007263545,0.000018958139,0.000011130381,0.0009897427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987165,0.0002318112,0.00037718684,0.00019493341,0.00035183234,0.000127781],"domain_scores_gemma":[0.99863684,0.00023996431,0.0004186509,0.0005361802,0.00012687493,0.000041490995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052359357,0.00013156819,0.00034267805,0.00003211088,0.00008412332,0.0000115909825,0.00027152486,0.000053030188,0.000010312631],"category_scores_gemma":[0.00009009116,0.0000522391,0.000084982246,0.00011748742,0.0004784639,0.000050935472,0.00022588173,0.00006445269,8.574644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009569748,0.025957216,0.9616462,0.00005617509,0.0003511032,0.000005887521,0.00044484652,0.0000010748894,0.0000062724757,0.00083669764,0.00046418075,0.009273388],"study_design_scores_gemma":[0.017767478,0.00368607,0.9713962,0.00006077521,0.00046472868,0.0000032434261,0.0007621249,0.000020228794,0.00046601726,0.000021615057,0.0052979644,0.000053553347],"about_ca_topic_score_codex":0.00011286124,"about_ca_topic_score_gemma":0.0002504637,"teacher_disagreement_score":0.022271147,"about_ca_system_score_codex":0.00004225726,"about_ca_system_score_gemma":0.000030268606,"threshold_uncertainty_score":0.21302487},"labels":[],"label_agreement":null},{"id":"W2106800598","doi":"10.1634/theoncologist.2011-0446","title":"Shared Decision-Making in Pediatric Allogeneic Blood and Marrow Transplantation: What If There Is No Decision to Make?","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Grandparent; Transplantation; Context (archaeology); Sibling; Interview; Family medicine; Legal guardian; Pediatrics; Developmental psychology; Surgery; Psychology","score_opus":0.13220681816854635,"score_gpt":0.42895530111885155,"score_spread":0.2967484829503052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106800598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704273,0.01586288,0.0002858531,0.007053037,0.0015892688,0.002219175,0.0000572541,0.00009146389,0.0024137746],"genre_scores_gemma":[0.9789715,0.0064804866,0.007988025,0.0054845,0.00037898365,0.000514178,0.000016600809,0.000034181023,0.0001315479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967781,0.0010486821,0.00081766257,0.0003361124,0.00036877644,0.0006506724],"domain_scores_gemma":[0.9921346,0.006189036,0.0003058433,0.0009475778,0.00020651649,0.00021647308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011576815,0.00021601407,0.00031479483,0.00018420476,0.0008998249,0.00004585645,0.0007129984,0.00029926185,0.0005177426],"category_scores_gemma":[0.0008544227,0.0001549448,0.00005255154,0.00052669697,0.00007048722,0.00039094346,0.00036286944,0.0006826536,0.0006476261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067194516,0.0002072936,0.89639693,0.00031236425,0.000015848369,0.000012604194,0.04428963,0.00003691236,0.000057416644,0.0003116173,0.0040646205,0.053622827],"study_design_scores_gemma":[0.0020664677,0.00029108324,0.9671494,0.0013746336,0.00011140681,0.000021061522,0.014922279,0.000107067885,0.00001264661,0.0025962417,0.010965525,0.00038220332],"about_ca_topic_score_codex":0.00020239643,"about_ca_topic_score_gemma":0.0014461109,"teacher_disagreement_score":0.070752464,"about_ca_system_score_codex":0.00025775732,"about_ca_system_score_gemma":0.00024998395,"threshold_uncertainty_score":0.832414},"labels":[],"label_agreement":null},{"id":"W2107249625","doi":"10.1634/theoncologist.2012-0384","title":"Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Research Manitoba; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Otsuka Canada Pharmaceutical; Otsuka Pharmaceutical","keywords":"Medicine; Melphalan; Multiple myeloma; Busulfan; Lenalidomide; Thalidomide; Bortezomib; Regimen; Oncology; Conditioning regimen; Transplantation; Internal medicine; Surgery; Hematopoietic stem cell transplantation","score_opus":0.11800804324453118,"score_gpt":0.4107763555520448,"score_spread":0.2927683123075136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107249625","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002662849,0.98977184,0.0001703329,0.00037038815,0.00008389918,0.007390093,0.00046963847,0.000052363102,0.0014251671],"genre_scores_gemma":[0.0024178843,0.9907308,0.0025060605,0.000062900675,0.00016772868,0.0012336319,0.0012064544,0.00005794301,0.0016165918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830395,0.00020692323,0.00054201926,0.0003444439,0.00023238413,0.0003703058],"domain_scores_gemma":[0.9948552,0.0038548445,0.0004253608,0.000538514,0.00015580097,0.00017025105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044298585,0.0003238828,0.0015467696,0.000117409734,0.00021584715,0.000022371587,0.00019262727,0.00025009995,0.00011299628],"category_scores_gemma":[0.0012917055,0.00017466926,0.00032733887,0.00015826026,0.0005621293,0.000024918518,0.000071936025,0.0002952113,0.00004935093],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056668004,0.00026030204,0.000062945415,0.008158258,0.0005480467,0.000024606841,0.000020946647,0.0000014294648,0.000008372835,0.00012401344,0.002331247,0.98789316],"study_design_scores_gemma":[0.007394303,0.0012995644,0.0014515395,0.0059044296,0.0014557202,0.00005554513,0.000025642732,0.00015799435,0.000033287066,0.000022057251,0.98200965,0.00019024142],"about_ca_topic_score_codex":0.00012327463,"about_ca_topic_score_gemma":0.00002169456,"teacher_disagreement_score":0.9877029,"about_ca_system_score_codex":0.00022951582,"about_ca_system_score_gemma":0.00054458535,"threshold_uncertainty_score":0.7122806},"labels":[],"label_agreement":null},{"id":"W2107480310","doi":"10.1634/theoncologist.2014-0009","title":"Adolescents and Young Adults With a “Rare” Cancer: Getting Past Semantics to Optimal Care for Patients With Germ Cell Tumors","year":2014,"lang":"en","type":"editorial","venue":"The Oncologist","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Teenage Cancer Trust","keywords":"Germ cell tumors; Young adult; Germ cell; Medicine; Semantics (computer science); Cancer; Oncology; Internal medicine; Biology; Chemotherapy; Computer science","score_opus":0.004093347523698311,"score_gpt":0.2515041690484088,"score_spread":0.24741082152471047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107480310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.864056,0.0015805995,0.00015926149,0.00027752088,0.123118624,0.007688993,0.0026831385,0.0001681811,0.00026771476],"genre_scores_gemma":[0.87381685,0.00005706791,0.0012794316,0.0001106046,0.12255932,0.00054233667,0.0012741465,0.00012062573,0.00023959669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980101,0.000044403158,0.0002617559,0.0005882097,0.00062271755,0.00047279743],"domain_scores_gemma":[0.9980421,0.00019119703,0.0004031928,0.0004371253,0.0006360369,0.00029036202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007885337,0.00047248247,0.0006922701,0.00005741399,0.00027126225,0.000066791894,0.00019157119,0.0002447431,0.0000037096559],"category_scores_gemma":[0.00020957162,0.0002540204,0.00008941531,0.00009901439,0.00016266853,0.000030153145,0.00011093033,0.00033989394,0.0000038767726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013527805,0.0013003367,0.7111484,0.005220515,0.0004884539,0.00026378184,0.0024806072,0.00012806893,0.0000012599365,0.0000014257524,0.25636026,0.009079098],"study_design_scores_gemma":[0.07644541,0.04682929,0.46361953,0.028787047,0.014436651,0.000040095027,0.004634534,0.00030910975,0.000044630266,0.0000061004635,0.36204973,0.0027978646],"about_ca_topic_score_codex":0.00059937756,"about_ca_topic_score_gemma":0.0005888474,"teacher_disagreement_score":0.24752885,"about_ca_system_score_codex":0.000393562,"about_ca_system_score_gemma":0.00050296914,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W2107651401","doi":"10.1634/theoncologist.12-10-1156","title":"Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor–Positive Operable Breast Cancer","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cardiorespiratory fitness; Cardiology; Cardiac function curve; Oncology; Brain natriuretic peptide; Tamoxifen; Cancer; Endocrinology; Heart failure","score_opus":0.013212033564643616,"score_gpt":0.2841265179975229,"score_spread":0.2709144844328793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107651401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976046,0.005975638,0.00015875058,0.0010918388,0.00008117162,0.001678378,0.00030675135,0.000031285617,0.0009157184],"genre_scores_gemma":[0.9917723,0.0056496356,0.0005873115,0.00040756338,0.00038469135,0.00046546388,0.00003214588,0.00002931905,0.00067156606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988261,0.000083839375,0.00024225903,0.00026383554,0.00023206932,0.00035191618],"domain_scores_gemma":[0.9990548,0.00015446632,0.000110259905,0.0003432912,0.0002386221,0.000098591336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254049,0.00016579573,0.00046904702,0.00004547927,0.00012246564,0.000013110609,0.000091003836,0.00010090859,0.00008871272],"category_scores_gemma":[0.00005074804,0.00010879037,0.00015589724,0.00016486117,0.00027412598,0.00006933964,0.00003729416,0.0002040793,0.0000022976471],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026095515,0.0005498536,0.008910538,0.00014216309,0.0034493066,0.000032036543,0.0040665627,0.000023919125,0.785472,0.00006122753,0.0021182033,0.1690787],"study_design_scores_gemma":[0.009437905,0.0030322282,0.24283963,0.00008641605,0.00033784236,0.00016063258,0.001453423,0.00003256453,0.72967803,0.00013554095,0.012545965,0.00025978824],"about_ca_topic_score_codex":0.0011255712,"about_ca_topic_score_gemma":0.000057955225,"teacher_disagreement_score":0.2339291,"about_ca_system_score_codex":0.0003241897,"about_ca_system_score_gemma":0.00011269867,"threshold_uncertainty_score":0.44363427},"labels":[],"label_agreement":null},{"id":"W2107752418","doi":"10.1634/theoncologist.2006-0214","title":"A Case of Small Bowel Obstruction Due to Intraluminal Metastases from Metastatic Renal Cell Cancer","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bowel obstruction; Nausea; Vomiting; Perforation; Renal cell carcinoma; Cancer; Colorectal cancer; Metastasis; Surgery; Diarrhea; Disease; Internal medicine","score_opus":0.07083448650561572,"score_gpt":0.32438910693756134,"score_spread":0.25355462043194565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107752418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540657,0.0013638155,0.00014664563,0.0016974065,0.00019065315,0.00047134372,0.0002711444,0.000020913303,0.0004315078],"genre_scores_gemma":[0.99341553,0.00031677086,0.0051290453,0.00042314193,0.0001691834,0.00021356501,0.000027318416,0.0000123126365,0.00029314923],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915314,0.00007461909,0.00025522042,0.00021055977,0.00013090164,0.00017555093],"domain_scores_gemma":[0.9991948,0.00020861292,0.00013005768,0.00028436302,0.00007066676,0.00011152321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011576242,0.00013474027,0.00037760814,0.000046231162,0.00010607169,0.000005818881,0.000069945265,0.000028917042,0.00046250332],"category_scores_gemma":[0.00004656391,0.00008192737,0.000109263485,0.00014698239,0.00019698388,0.000022758655,0.000037859198,0.000102172366,0.000020275424],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012393268,0.014368602,0.09698439,0.0007926356,0.0066131745,0.21264349,0.025620349,0.0065456145,0.060647245,0.0009475709,0.13374093,0.42870274],"study_design_scores_gemma":[0.017238209,0.011003475,0.4195369,0.00050786283,0.011173009,0.035937015,0.005218349,0.00056429935,0.4683158,0.0007984444,0.028737418,0.0009692094],"about_ca_topic_score_codex":0.032342527,"about_ca_topic_score_gemma":0.007487198,"teacher_disagreement_score":0.42773354,"about_ca_system_score_codex":0.00026055358,"about_ca_system_score_gemma":0.00019691094,"threshold_uncertainty_score":0.9741012},"labels":[],"label_agreement":null},{"id":"W2108248587","doi":"10.1634/theoncologist.2013-0427","title":"Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification?","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Saskatchewan","funders":"National Center for Advancing Translational Sciences; Fogarty International Center; American Cancer Society","keywords":"Medicine; Breast cancer; Estrogen receptor; Oncology; Internal medicine; Hormone receptor; Progesterone receptor; Receptor; Primary tumor; Epidemiology; Cancer; Gynecology; Hormone; Metastasis","score_opus":0.050056378111768426,"score_gpt":0.32662751271552665,"score_spread":0.2765711346037582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108248587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069616754,0.9897585,0.000056872614,0.00017929937,0.0001660717,0.0011489915,0.000968334,0.00002387997,0.0007363719],"genre_scores_gemma":[0.0038588769,0.99202657,0.00048737743,0.00018034452,0.0002492177,0.0010588316,0.0011566667,0.00004536531,0.0009367583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972577,0.0005512527,0.00062286167,0.00087937794,0.00015380474,0.000534973],"domain_scores_gemma":[0.99825233,0.0003350864,0.00057001464,0.00067279977,0.000052342715,0.0001174452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036279525,0.0006027764,0.0015579939,0.000055761295,0.00016697944,0.00005385016,0.000502128,0.0002802345,0.00003815515],"category_scores_gemma":[0.00011371098,0.00031516238,0.00017975576,0.00019794078,0.0012735031,0.000006486001,0.00045356914,0.0003512175,0.000012346885],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005746496,0.00033417362,0.0033104513,0.003047092,0.0007509746,0.000018291857,0.00010857258,9.991171e-7,0.0003050123,0.00007516106,0.004442857,0.98703176],"study_design_scores_gemma":[0.0010512003,0.00054443,0.10943963,0.000973404,0.0004046788,0.00010633442,0.00010961709,9.756495e-7,0.0000078692765,0.00002634715,0.88669616,0.0006393833],"about_ca_topic_score_codex":0.00026244667,"about_ca_topic_score_gemma":0.0017604099,"teacher_disagreement_score":0.9863924,"about_ca_system_score_codex":0.0006137465,"about_ca_system_score_gemma":0.00068722497,"threshold_uncertainty_score":0.99993},"labels":[],"label_agreement":null},{"id":"W2108261465","doi":"10.1634/theoncologist.2010-0093","title":"Understanding Micrometastatic Disease and <i>Anoikis</i> Resistance in Ewing Family of Tumors and Osteosarcoma","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Institutes of Health Research; University College London Hospitals NHS Foundation Trust; National Institutes of Health; Michael Smith Health Research BC","keywords":"Anoikis; Osteosarcoma; Medicine; Cancer research; Metastasis; Primary tumor; Disease; Pathology; Oncology; Cancer; Internal medicine","score_opus":0.17445346071956425,"score_gpt":0.3616517035293135,"score_spread":0.18719824280974923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108261465","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067214244,0.990651,0.0000049458254,0.00039370707,0.00006117135,0.0011635224,0.00007292348,0.000014421606,0.0009168903],"genre_scores_gemma":[0.019866623,0.979207,0.000491707,0.00011911141,0.000034403904,0.0001236724,0.000030926734,0.000032758948,0.00009380623],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854565,0.00018238265,0.0005249956,0.000338555,0.00016854244,0.00023988316],"domain_scores_gemma":[0.9980753,0.0010704012,0.0003180191,0.00038184124,0.000018135983,0.00013630796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046912688,0.00030203137,0.0014642102,0.00015869497,0.0000844901,0.000027062853,0.00011876606,0.00011590016,0.0000055645805],"category_scores_gemma":[0.0001735905,0.00017565455,0.00015306655,0.0002511913,0.00052937935,0.000029223836,0.00010921419,0.00038423506,0.0000022543138],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005408205,0.0017866244,0.020262541,0.06448654,0.0009127557,0.0042029293,0.00092770066,2.3735218e-7,0.000058304806,0.010036829,0.0013768721,0.89540786],"study_design_scores_gemma":[0.0049139806,0.0006052539,0.035635512,0.070367284,0.009615688,0.00034369252,0.0011397179,0.000004747931,0.000007453275,0.0038495183,0.8726665,0.00085067085],"about_ca_topic_score_codex":0.000054936252,"about_ca_topic_score_gemma":0.00022163533,"teacher_disagreement_score":0.8945572,"about_ca_system_score_codex":0.00027075273,"about_ca_system_score_gemma":0.0002674724,"threshold_uncertainty_score":0.7162985},"labels":[],"label_agreement":null},{"id":"W2108757112","doi":"10.1634/theoncologist.2014-0438","title":"Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Antiemetic; Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Intensive care medicine; Chemotherapy; Quality of life (healthcare); Anesthesia; Internal medicine; Nursing","score_opus":0.09718358085502046,"score_gpt":0.3713657553445975,"score_spread":0.27418217448957705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108757112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9391181,0.000078832345,0.000054353994,0.03229797,0.00014028842,0.0011707318,0.0000072640414,0.00015866467,0.02697382],"genre_scores_gemma":[0.9835105,0.000022143184,0.00077821873,0.006286387,0.00050825067,0.00009553844,0.000014492873,0.00003711066,0.008747347],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989681,0.000049430124,0.00019519585,0.00026821918,0.00022705086,0.00029200426],"domain_scores_gemma":[0.9989881,0.00028866794,0.00010274062,0.00037037404,0.00009287282,0.00015722835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008711724,0.00016864752,0.0003017044,0.000059216418,0.00013923943,0.000038329712,0.00014842056,0.000093992676,0.00003113661],"category_scores_gemma":[0.00043376983,0.000105826985,0.00007254148,0.00011428177,0.00016163498,0.000032045606,0.00006364697,0.00014336065,0.000084223335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013360468,0.0027736805,0.018492647,0.00052634545,0.0014677912,0.00025027123,0.0056950324,0.000033957414,0.03132046,0.009277328,0.6557427,0.26105934],"study_design_scores_gemma":[0.051866088,0.018181674,0.093502775,0.00047503074,0.0012624804,0.00019471873,0.0034857416,0.0043144776,0.0376932,0.0046405466,0.78305507,0.0013281938],"about_ca_topic_score_codex":0.000033585853,"about_ca_topic_score_gemma":0.0000051713105,"teacher_disagreement_score":0.25973114,"about_ca_system_score_codex":0.00015779382,"about_ca_system_score_gemma":0.00008593902,"threshold_uncertainty_score":0.4315499},"labels":[],"label_agreement":null},{"id":"W2108979762","doi":"10.1634/theoncologist.12-3-331","title":"Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer—How to Handle Stage I Disease","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Adjuvant; Adjuvant therapy; Oncology; Disease; Chemotherapy; Adjuvant chemotherapy; Internal medicine; Cancer; Intensive care medicine; Breast cancer","score_opus":0.0861324768492604,"score_gpt":0.4181407240567727,"score_spread":0.3320082472075123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108979762","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002563665,0.98523307,0.00032238188,0.0021616402,0.0006854984,0.009455375,0.0008316904,0.00006224827,0.0009917041],"genre_scores_gemma":[0.00015400059,0.974108,0.00086164894,0.001112683,0.0011436656,0.007113448,0.00024209086,0.00010835994,0.015156133],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979944,0.00007351707,0.00042045876,0.00064802717,0.00025868544,0.00060491654],"domain_scores_gemma":[0.99772394,0.0005418549,0.00033482077,0.0008342004,0.00011724453,0.00044794712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046244307,0.00057389436,0.0017845049,0.000102262806,0.00019851548,0.000068145375,0.0003919882,0.00021810795,0.00015277028],"category_scores_gemma":[0.000045388613,0.00029684562,0.00078211346,0.00022787065,0.00010899752,0.000023178016,0.000100844474,0.0002947864,0.000032105756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066193053,0.0010030232,0.00035753514,0.01625841,0.00072517205,0.00020601586,0.00016125753,0.000034961853,6.588526e-7,0.000029455688,0.05750576,0.9230558],"study_design_scores_gemma":[0.0022688643,0.0012873741,0.00020475539,0.006381276,0.0034276964,0.0000041228022,0.000036107285,0.000028015786,0.0000197272,0.0000012874857,0.986009,0.0003317705],"about_ca_topic_score_codex":0.00027458917,"about_ca_topic_score_gemma":0.00020070882,"teacher_disagreement_score":0.9285032,"about_ca_system_score_codex":0.0018484601,"about_ca_system_score_gemma":0.0017630681,"threshold_uncertainty_score":0.9999484},"labels":[],"label_agreement":null},{"id":"W2109116356","doi":"10.1634/theoncologist.5-4-302","title":"SPIKES—A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3045,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Protocol (science); Medicine; Cancer; Medical information; Medical emergency; Medical physics; Medical education; Family medicine; Alternative medicine; Pathology; Internal medicine","score_opus":0.1853504159787481,"score_gpt":0.4751298314215793,"score_spread":0.28977941544283115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109116356","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024672965,0.00017070187,0.004956186,0.116717495,0.0003573615,0.8307795,0.00015191348,0.0004089424,0.021784918],"genre_scores_gemma":[0.11950208,0.000013621515,0.002776545,0.008134561,0.00024950947,0.8684321,0.000014104909,0.000033299057,0.0008441701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978448,0.000610892,0.0005329441,0.00029439025,0.00023971291,0.0004772323],"domain_scores_gemma":[0.9971414,0.00082505366,0.0003342939,0.0012728242,0.00031259717,0.00011382429],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00032250522,0.00016835213,0.00019524776,0.00002832801,0.0019376688,0.000015583291,0.0008012139,0.00011593837,0.00038529636],"category_scores_gemma":[0.00011394902,0.00008624288,0.00004238243,0.00028229042,0.00011686493,0.000069544054,0.00016826704,0.00045477043,0.00031526363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039077103,0.0003390663,0.024478931,0.00064812874,0.000049918996,0.0000012581794,0.034612183,0.008852124,0.00011553399,0.0024680754,0.10500316,0.81952393],"study_design_scores_gemma":[0.001074393,0.00062723196,0.00496862,0.00021244476,0.000017125765,0.0000011356549,0.004846278,0.0018256622,0.00003097159,0.00012111963,0.9861271,0.00014793206],"about_ca_topic_score_codex":0.011118969,"about_ca_topic_score_gemma":0.025537008,"teacher_disagreement_score":0.8811239,"about_ca_system_score_codex":0.00065364083,"about_ca_system_score_gemma":0.0004992679,"threshold_uncertainty_score":0.9993617},"labels":[],"label_agreement":null},{"id":"W2110202780","doi":"10.1634/theoncologist.2015-0058","title":"Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Body mass index; Lean body mass; Toxicity; Body surface area; Afatinib; Lung cancer; Body surface; Internal medicine; Cancer; Oncology; Gastroenterology; Body weight; Gefitinib","score_opus":0.013567195967992085,"score_gpt":0.29274849743977227,"score_spread":0.27918130147178016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110202780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960229,0.00012217974,0.000037899637,0.0012199002,0.00009246683,0.0013861768,0.00020620535,0.000034331402,0.0008779536],"genre_scores_gemma":[0.99765974,0.000028268272,0.0010494913,0.00015193874,0.000039589144,0.00009579401,0.00022090909,0.000024115065,0.000730133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987655,0.00006840195,0.0002492982,0.0003461445,0.0002517601,0.0003188637],"domain_scores_gemma":[0.9991223,0.00005345519,0.00017364726,0.00017319445,0.00021119272,0.0002661859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001717016,0.0002088956,0.00028278562,0.00006567929,0.00012176056,0.000033221862,0.00006057414,0.00008558928,0.000029507157],"category_scores_gemma":[0.0000453335,0.00014433812,0.00001914682,0.00023878698,0.00012396074,0.00010339526,0.000038380324,0.000299583,0.0000021966996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014580076,0.00064933917,0.9884712,0.0000650006,0.00006197859,0.00002198642,0.0004465843,0.00030070913,0.0055189123,0.000007489024,0.002870218,0.00012856022],"study_design_scores_gemma":[0.012472127,0.0020970416,0.98233455,0.00035193327,0.00018268345,0.000029197688,0.0011737081,0.0005188851,0.00047368638,0.00006698548,0.00010068407,0.00019852415],"about_ca_topic_score_codex":0.0011706772,"about_ca_topic_score_gemma":0.00023958764,"teacher_disagreement_score":0.01101412,"about_ca_system_score_codex":0.0007852288,"about_ca_system_score_gemma":0.00042595775,"threshold_uncertainty_score":0.5885938},"labels":[],"label_agreement":null},{"id":"W2110525437","doi":"10.1634/theoncologist.2014-0130","title":"The Opioid Rotation Ratio of Hydrocodone to Strong Opioids in Cancer Patients","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; National Cancer Institute; U.S. Food and Drug Administration","keywords":"Hydrocodone; Medicine; Opioid; Anesthesia; Morphine; Oxycodone; Internal medicine","score_opus":0.02047041567370187,"score_gpt":0.3158234698289761,"score_spread":0.2953530541552742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110525437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778975,0.00007101963,0.0006437799,0.0035490005,0.0002073401,0.00088424614,0.0000020836785,0.000017610988,0.0068351435],"genre_scores_gemma":[0.996749,0.000071668954,0.000118405835,0.00070481724,0.000117564814,0.00012840217,0.000009817495,0.0000075591865,0.002092786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921346,0.000100556805,0.00022257546,0.000111828755,0.00018285564,0.00016872954],"domain_scores_gemma":[0.99935365,0.00022020882,0.000095247466,0.00023871136,0.000056473833,0.000035733054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063080044,0.000075889446,0.00014972538,0.000043470212,0.00009231834,0.000013022197,0.00017349466,0.000032392236,0.000019899438],"category_scores_gemma":[0.00031756607,0.000040893847,0.00003073441,0.0001818423,0.000093725735,0.000030357663,0.00006289428,0.000098332515,0.000021322718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071822805,0.00048551508,0.85574913,0.00010141287,0.00006792475,0.000001763678,0.0022417821,0.0019070292,0.0022184646,0.0062935273,0.020767098,0.10944814],"study_design_scores_gemma":[0.0014459152,0.00061956665,0.9557556,0.000061018407,0.000040349587,4.425618e-8,0.0003099512,0.0041942303,0.00076371536,0.00030962023,0.036427505,0.000072494906],"about_ca_topic_score_codex":0.00042261387,"about_ca_topic_score_gemma":0.0008398394,"teacher_disagreement_score":0.10937565,"about_ca_system_score_codex":0.00011846376,"about_ca_system_score_gemma":0.00004889974,"threshold_uncertainty_score":0.16676027},"labels":[],"label_agreement":null},{"id":"W2110859080","doi":"10.1634/theoncologist.2012-0228","title":"The Case for Chemotherapy Alone for Limited-Stage Hodgkin's Lymphoma","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Hodgkin lymphoma; Lymphoma; Chemotherapy; Stage (stratigraphy); Oncology; Disease; Radiation therapy; Internal medicine","score_opus":0.052371290433459845,"score_gpt":0.3465056750231264,"score_spread":0.29413438458966656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110859080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9455801,0.003891815,0.00049489905,0.040701646,0.00075959164,0.004245403,0.00013251131,0.00012040249,0.0040735793],"genre_scores_gemma":[0.98768723,0.00038302373,0.001343102,0.0032105306,0.00076522696,0.0016752452,0.000029886842,0.000027529017,0.0048782052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901974,0.000042928496,0.00020342751,0.0001628814,0.000097528005,0.00047347],"domain_scores_gemma":[0.99777496,0.001430638,0.00011898251,0.0004780855,0.0000766172,0.000120691235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067331083,0.00016969723,0.00026864506,0.000018709625,0.00057206897,0.000038788443,0.00013213484,0.00009218223,0.000022853415],"category_scores_gemma":[0.00019854371,0.000076251075,0.00021038952,0.000077271514,0.00018317265,0.00004393159,0.00003116278,0.000034966855,0.000027436541],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032607159,0.003447182,0.0126077635,0.00009973048,0.00079086935,0.00028775967,0.0011002279,0.0000035691264,0.00039372183,0.016807638,0.16527295,0.7959279],"study_design_scores_gemma":[0.010464717,0.0014709467,0.016010007,0.000015691043,0.00033823657,0.00091475225,0.0009454235,0.00019610755,0.005345615,0.0002659189,0.9638876,0.00014503933],"about_ca_topic_score_codex":0.00018348338,"about_ca_topic_score_gemma":0.00013566256,"teacher_disagreement_score":0.7986146,"about_ca_system_score_codex":0.00034796906,"about_ca_system_score_gemma":0.000098694036,"threshold_uncertainty_score":0.43999496},"labels":[],"label_agreement":null},{"id":"W2111879300","doi":"10.1634/theoncologist.2010-0081","title":"A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; BC Cancer Agency; AstraZeneca","keywords":"Pazopanib; Medicine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Oncology; Neutropenia; Progressive disease; Breast cancer; Progression-free survival; Chemotherapy; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Sunitinib","score_opus":0.020701137887031117,"score_gpt":0.30937759705815965,"score_spread":0.28867645917112855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111879300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974599,0.000048745555,0.000005024342,0.00012552852,0.0003320931,0.0017704034,0.00019432695,0.0000027840124,0.00006120245],"genre_scores_gemma":[0.99957764,0.000010780634,0.000033792967,0.00003466466,0.00007785701,0.00016495794,0.000029836223,0.000013389661,0.000057081845],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99879193,0.00017030023,0.00037649713,0.00026498127,0.00021133208,0.0001849497],"domain_scores_gemma":[0.99882764,0.00004434923,0.00042215295,0.000503502,0.00016255109,0.000039828763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031313943,0.0001659407,0.00030469443,0.000025000327,0.00012980199,0.0000065753197,0.0004271243,0.00006574669,0.000030679515],"category_scores_gemma":[0.00013940249,0.00007863723,0.00008797093,0.00015765501,0.00040974203,0.00000459705,0.00031174053,0.00013434626,2.40837e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.356763,0.22478227,0.29927206,0.00018781492,0.0012570714,0.000038903443,0.0066714557,0.000045665543,0.069442734,0.00015457904,0.002248741,0.03913571],"study_design_scores_gemma":[0.45580423,0.32608026,0.16294341,0.0000891001,0.0007783699,0.000017668435,0.004114299,0.000023642291,0.047738373,0.000030788997,0.0017032793,0.00067658303],"about_ca_topic_score_codex":0.00018425069,"about_ca_topic_score_gemma":0.0021786473,"teacher_disagreement_score":0.13632865,"about_ca_system_score_codex":0.000022492706,"about_ca_system_score_gemma":0.00035521493,"threshold_uncertainty_score":0.32067335},"labels":[],"label_agreement":null},{"id":"W2112098903","doi":"10.1634/theoncologist.2015-0023","title":"Geriatric Assessment of Older Adults With Cancer During Unplanned Hospitalizations: An Opportunity in Disguise","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"National Cancer Institute","keywords":"Medicine; Psychosocial; Activities of daily living; Population; Depression (economics); Geriatric oncology; Patient-Reported Outcomes Measurement Information System; Cancer; Physical therapy; Gerontology; Psychiatry; Internal medicine","score_opus":0.038526120285594385,"score_gpt":0.35430732410554067,"score_spread":0.3157812038199463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112098903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915981,0.00019364269,0.000061540486,0.0024747562,0.00014716848,0.00085593085,0.000026964664,0.000053896973,0.004587962],"genre_scores_gemma":[0.99802524,0.00011488273,0.0006090311,0.0001560149,0.00009674435,0.0001494783,0.000053910248,0.000019013887,0.000775673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988887,0.00011173747,0.000287062,0.00020411807,0.00029574364,0.00021265846],"domain_scores_gemma":[0.9989263,0.000057686248,0.00017879014,0.0004415008,0.00020387245,0.00019188682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033737672,0.00013200584,0.00028700405,0.00008883862,0.000045361456,0.0000101972855,0.00017596499,0.00006952732,0.00009403178],"category_scores_gemma":[0.0002051974,0.00008031272,0.00002545452,0.00037837052,0.00018545892,0.00010484701,0.0000575632,0.0001728327,0.0000021587837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011739066,0.0018062984,0.9829271,0.0003037623,0.0000809937,0.0002275162,0.0055878703,0.0017877236,0.0001318144,0.000201599,0.0022659171,0.00350554],"study_design_scores_gemma":[0.0056727375,0.0010528284,0.98838484,0.00033802306,0.00008124808,0.000029447177,0.0029578242,0.00095948676,0.00017770566,0.00004147936,0.00017507776,0.00012927747],"about_ca_topic_score_codex":0.0024175267,"about_ca_topic_score_gemma":0.0031914753,"teacher_disagreement_score":0.006427114,"about_ca_system_score_codex":0.00040180754,"about_ca_system_score_gemma":0.000725205,"threshold_uncertainty_score":0.36545932},"labels":[],"label_agreement":null},{"id":"W2112422374","doi":"10.1634/theoncologist.2009-0237","title":"Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Dacarbazine; Temozolomide; Chemotherapy; Internal medicine; Oncology; Melanoma; Multivariate analysis; Survival analysis; Cancer; Univariate analysis; Surgery; Cancer research","score_opus":0.021188396224277452,"score_gpt":0.27461178080380977,"score_spread":0.25342338457953234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112422374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269396,0.0000054109623,0.00004583303,0.0005706774,0.00015338633,0.0010431666,0.0000042579927,0.00008289423,0.0054004216],"genre_scores_gemma":[0.99401104,0.000003876496,0.00029134323,0.00025911268,0.00004346227,0.000059504775,0.000022954682,0.00002437016,0.005284306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898547,0.0000782644,0.00020196888,0.00023064765,0.0002493302,0.0002542946],"domain_scores_gemma":[0.99921036,0.00013812984,0.000105723666,0.00039793304,0.000061293926,0.000086572334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022350924,0.00017377365,0.00032298217,0.00009498302,0.00008013455,0.00002585167,0.0001276907,0.000046514997,0.0004178963],"category_scores_gemma":[0.000071226765,0.00007679652,0.000029785895,0.00027740654,0.00022686685,0.000034798984,0.00003875154,0.00029702586,0.00006683222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008358261,0.000872331,0.9795158,0.000053511627,0.00020904213,0.0012011236,0.00012174959,0.000010917219,0.00023864715,0.00008059003,0.00014900543,0.009189058],"study_design_scores_gemma":[0.0062844767,0.004402687,0.9873086,0.00003951747,0.0002872927,0.00021851993,0.00014189136,0.00002878438,0.00021209475,0.0000060853886,0.0009237268,0.0001462936],"about_ca_topic_score_codex":0.0002564338,"about_ca_topic_score_gemma":0.011154951,"teacher_disagreement_score":0.010898517,"about_ca_system_score_codex":0.00011269917,"about_ca_system_score_gemma":0.00008190937,"threshold_uncertainty_score":0.62247247},"labels":[],"label_agreement":null},{"id":"W2112983735","doi":"10.1634/theoncologist.6-2-147","title":"Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Eastman Kodak","keywords":"Medicine; Baseline (sea); Lung cancer; Action (physics); Oncology; Internal medicine; Intensive care medicine","score_opus":0.12643529530993078,"score_gpt":0.4413769561260123,"score_spread":0.31494166081608155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112983735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031226,0.99061,0.0000059791573,0.0015702838,0.00048699815,0.0028517414,0.000104606195,0.000038494454,0.0040196413],"genre_scores_gemma":[0.00034550886,0.9927746,0.000044023658,0.00032611663,0.00058898673,0.0009715551,0.000047157424,0.000043568372,0.0048584626],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839175,0.000248287,0.00043899263,0.0003265878,0.00034312753,0.00025123465],"domain_scores_gemma":[0.9983257,0.0005052403,0.0004518197,0.0006088109,0.000066161185,0.000042283165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004882839,0.00032052293,0.0011154225,0.0000876963,0.00016059278,0.00001754113,0.00027138914,0.00022184184,0.000106752384],"category_scores_gemma":[0.00010853638,0.00013429638,0.0005451024,0.0005153852,0.00016240461,0.000025737436,0.00009489272,0.0005393667,0.000008466348],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118233256,0.00029115495,0.0015218789,0.00517035,0.0006411644,0.000021951202,0.000076283235,0.0000040006253,4.1240327e-7,0.000038345162,0.040289726,0.9518265],"study_design_scores_gemma":[0.0006453263,0.00040779516,0.0014752407,0.03182466,0.0044370666,0.00003202096,0.000022772994,0.000013073872,0.000008634223,0.000002180825,0.9609987,0.00013250679],"about_ca_topic_score_codex":0.0033542046,"about_ca_topic_score_gemma":0.00039203407,"teacher_disagreement_score":0.951694,"about_ca_system_score_codex":0.0012703211,"about_ca_system_score_gemma":0.0007735755,"threshold_uncertainty_score":0.54764473},"labels":[],"label_agreement":null},{"id":"W2113167936","doi":"10.1634/theoncologist.2011-0379","title":"Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genentech; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Regimen; Cost effectiveness; Oncology; Adjuvant; Quality of life (healthcare); Internal medicine; Quality-adjusted life year; Cancer","score_opus":0.1251169310672112,"score_gpt":0.4951463378981687,"score_spread":0.37002940683095753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113167936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572618,0.0010928325,0.000054289183,0.0053463234,0.00041842292,0.0022040068,0.000076523094,0.000037054648,0.03350873],"genre_scores_gemma":[0.99810666,0.00026527766,0.000037641417,0.00028059632,0.00036238017,0.00048013416,0.000008917397,0.00003159313,0.0004268203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718416,0.0012055548,0.0003151288,0.00022291839,0.0004759725,0.0005962775],"domain_scores_gemma":[0.99727565,0.0018130735,0.00014700106,0.00046975497,0.0001724568,0.00012209029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003683753,0.0001764974,0.00048347632,0.00010054421,0.00013847002,0.000030872816,0.0003235161,0.00009049332,0.00023428095],"category_scores_gemma":[0.00016723307,0.0000922778,0.00009234797,0.0006641687,0.0007698597,0.00015480562,0.00013916941,0.0006671869,0.000019737601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017414079,0.0011937898,0.8300159,0.00040327522,0.00019073486,0.000077436205,0.0024689669,0.00018785715,0.016205188,0.0011195183,0.0011465992,0.1452493],"study_design_scores_gemma":[0.0012378071,0.00020252242,0.98984915,0.0006642818,0.000083640545,0.00006047906,0.0010732482,0.00010703899,0.005458059,0.00007198261,0.001086306,0.000105490544],"about_ca_topic_score_codex":0.019114083,"about_ca_topic_score_gemma":0.0036065802,"teacher_disagreement_score":0.15983322,"about_ca_system_score_codex":0.0020519714,"about_ca_system_score_gemma":0.0007719591,"threshold_uncertainty_score":0.9874177},"labels":[],"label_agreement":null},{"id":"W2113825200","doi":"10.1634/theoncologist.2014-0268","title":"The Value of Personalizing Medicine: Medical Oncologists’ Views on Gene Expression Profiling in Breast Cancer Treatment","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; Canadian Centre for Applied Research in Cancer Control; Cancer Care Ontario","keywords":"Medicine; Breast cancer; Test (biology); Family medicine; MEDLINE; Clinical Practice; Precision medicine; Personalized medicine; Oncology; Internal medicine; Cancer; Bioinformatics; Pathology","score_opus":0.0673460606571507,"score_gpt":0.38438444260291743,"score_spread":0.3170383819457667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113825200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95443976,0.009013746,0.00018248385,0.029044816,0.00091685104,0.00070457015,0.000038425194,0.00001680819,0.005642552],"genre_scores_gemma":[0.9942769,0.0026709163,0.00047068342,0.00097027206,0.00073090056,0.00034639175,0.000026402153,0.000018256545,0.000489315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998455,0.00035342434,0.0003294709,0.00027468894,0.00035495422,0.00023250094],"domain_scores_gemma":[0.9990493,0.00016481183,0.00018841977,0.00041192042,0.00009923802,0.00008628936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012758916,0.00015607718,0.0002130695,0.000026067499,0.00013206319,0.000007962059,0.00042403696,0.00017039216,0.000035116766],"category_scores_gemma":[0.00035256284,0.00007371746,0.000060737453,0.00012701073,0.00067622645,0.0000028732475,0.000116649724,0.00014023489,0.0000047693648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045185243,0.0013459262,0.04547402,0.00007079203,0.0003875418,0.000076755845,0.005414591,0.015172905,0.69138616,0.0028382181,0.08797083,0.14534374],"study_design_scores_gemma":[0.009064399,0.005005888,0.020260539,0.00044982752,0.00015480943,0.0002187152,0.009680756,0.0019190662,0.6603461,0.0008488163,0.29138607,0.00066504546],"about_ca_topic_score_codex":0.0005707399,"about_ca_topic_score_gemma":0.0006734532,"teacher_disagreement_score":0.20341524,"about_ca_system_score_codex":0.0006096493,"about_ca_system_score_gemma":0.0010629382,"threshold_uncertainty_score":0.30061108},"labels":[],"label_agreement":null},{"id":"W2114029286","doi":"10.1634/theoncologist.2007-0234","title":"Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?","year":2008,"lang":"en","type":"review","venue":"The Oncologist","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Genitourinary system; Tamoxifen; Population; Cancer; Estrogen; Gynecology; Intensive care medicine; Menopause; Oncology; Internal medicine","score_opus":0.034860762930713475,"score_gpt":0.32379934626937695,"score_spread":0.28893858333866346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114029286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028570687,0.9692768,0.000003055167,0.00020778403,0.00012616064,0.0007697397,0.00015968399,0.000029505789,0.00085661426],"genre_scores_gemma":[0.0040104548,0.99427587,0.00003408353,0.00011928741,0.00037255124,0.00025131035,0.00032556005,0.000074373194,0.00053649663],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979854,0.00038673374,0.00038781605,0.00057026796,0.0001900404,0.00047971742],"domain_scores_gemma":[0.9990084,0.00006385474,0.00021404121,0.00055378786,0.00004173301,0.0001181829],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000114871575,0.0005361068,0.0009513248,0.00006798115,0.0001341204,0.00002462603,0.0005003619,0.0008758865,0.000027601225],"category_scores_gemma":[0.000015786482,0.00028778953,0.0004323824,0.0002858899,0.0005027976,0.000002862611,0.0001640792,0.0006693403,0.000023962168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011254716,0.0010348008,0.006860986,0.0017912351,0.0029735586,0.0021611908,0.00008394734,0.0001469812,0.00047441942,0.00013896052,0.0072205225,0.9759879],"study_design_scores_gemma":[0.00071288034,0.00078796665,0.0002342589,0.00052263064,0.0006144254,0.0024427366,0.000019141527,0.0000047779668,0.00014283795,0.0000017106229,0.99389976,0.0006168465],"about_ca_topic_score_codex":0.0008802017,"about_ca_topic_score_gemma":0.00052607554,"teacher_disagreement_score":0.98667926,"about_ca_system_score_codex":0.00014032188,"about_ca_system_score_gemma":0.0004854211,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W2115861091","doi":"10.1634/theoncologist.2010-0387","title":"Targeting Angiogenesis in Esophagogastric Adenocarcinoma","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"AstraZeneca; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Sorafenib; Bevacizumab; Sunitinib; Angiogenesis; Internal medicine; Receptor tyrosine kinase; Oncology; Cancer research; Cancer; Vascular endothelial growth factor; Chemotherapy; Receptor; Hepatocellular carcinoma","score_opus":0.11466906553746307,"score_gpt":0.36169405916973296,"score_spread":0.24702499363226987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115861091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024419502,0.9917206,0.000011917162,0.000144897,0.000356757,0.0012523356,0.0000067952783,0.00006590025,0.006416342],"genre_scores_gemma":[0.00026821296,0.9941111,0.00022558673,0.0001840612,0.00046996347,0.00018804257,0.000055410834,0.00004674275,0.0044508325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983022,0.00016487151,0.0005881553,0.00036235212,0.00016749797,0.0004149121],"domain_scores_gemma":[0.9988654,0.00020430869,0.000334002,0.00050025014,0.000025255205,0.00007073688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005987323,0.00035484787,0.0015374891,0.00034740867,0.00006815703,0.000018525381,0.00043844554,0.00021310645,0.000372664],"category_scores_gemma":[0.00013557656,0.00020224288,0.00051270187,0.0008686887,0.00013034763,0.000028664404,0.00023934281,0.00039728172,0.00028969304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024858418,0.000078043064,0.0046805036,0.0038163608,0.00016122575,0.00027610984,0.00005235932,4.885306e-7,2.9466861e-8,0.00019906119,0.007929848,0.9827811],"study_design_scores_gemma":[0.000434891,0.00016514483,0.004590507,0.0013773328,0.0017758944,0.00006397818,0.00006152001,0.0000015092787,7.627778e-8,0.000023331593,0.99133945,0.00016638656],"about_ca_topic_score_codex":0.00027006387,"about_ca_topic_score_gemma":0.000031371907,"teacher_disagreement_score":0.9834096,"about_ca_system_score_codex":0.00046825188,"about_ca_system_score_gemma":0.00026853965,"threshold_uncertainty_score":0.8247225},"labels":[],"label_agreement":null},{"id":"W2116280772","doi":"10.1634/theoncologist.2008-0070","title":"Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Sanofi; AstraZeneca; Pfizer","keywords":"Anthracycline; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Stage (stratigraphy); Topoisomerase; Cancer; Chemotherapy; Trastuzumab","score_opus":0.11737981977320233,"score_gpt":0.4823295088974135,"score_spread":0.36494968912421116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116280772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023267588,0.9795146,1.8208266e-7,0.010529056,0.00036697395,0.0014764812,0.0004962148,0.000022954422,0.005266751],"genre_scores_gemma":[0.0021946926,0.9894931,0.00001717643,0.0013705688,0.00080023566,0.00021942354,0.00006771428,0.00002851455,0.0058085998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824846,0.00032990266,0.00060031126,0.00031807183,0.00019472485,0.0003085314],"domain_scores_gemma":[0.99842197,0.0004056927,0.00047519658,0.0005716888,0.0000536715,0.00007177308],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045422858,0.000348422,0.0016171734,0.000097543896,0.00008792127,0.000013471316,0.0004465875,0.00026116578,0.0015104216],"category_scores_gemma":[0.000017246335,0.00015800225,0.0003367682,0.00037060844,0.0006097388,0.000040510953,0.000065383385,0.0006516707,0.000032757638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022278837,0.00065697514,0.00031730815,0.0013403299,0.00024567192,0.0001098068,0.00040266934,0.0000015721157,0.0000023686723,0.00004242866,0.008040124,0.98861796],"study_design_scores_gemma":[0.0010307381,0.00074406044,0.0030958313,0.001902546,0.0019293408,0.00014845277,0.0000647226,0.000005305575,0.000007094534,0.000021828377,0.9908972,0.00015288884],"about_ca_topic_score_codex":0.0062509836,"about_ca_topic_score_gemma":0.0038939957,"teacher_disagreement_score":0.9884651,"about_ca_system_score_codex":0.00038937342,"about_ca_system_score_gemma":0.0008603686,"threshold_uncertainty_score":0.99940234},"labels":[],"label_agreement":null},{"id":"W2116338644","doi":"10.1634/theoncologist.2013-0469","title":"Measuring the Population Impact of Introducing Stereotactic Ablative Radiotherapy for Stage I Non-Small Cell Lung Cancer in Canada","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"SABR volatility model; Medicine; Pneumonectomy; Lung cancer; Radiation therapy; Population; Quality-adjusted life year; Cancer registry; Surgery; Cost effectiveness; Oncology; Environmental health; Economics","score_opus":0.023859573479758457,"score_gpt":0.32158829061413097,"score_spread":0.2977287171343725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116338644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955941,0.00073614164,0.00019426676,0.001787475,0.00017266138,0.0011563953,0.000025205354,0.000005348175,0.00032839962],"genre_scores_gemma":[0.9990112,0.00015835547,0.00012454418,0.0001777936,0.00016255995,0.0001983707,0.000005945061,0.000015156117,0.00014604682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922717,0.00008632682,0.00021057068,0.00015721776,0.00012570414,0.00019300402],"domain_scores_gemma":[0.9989632,0.00048209337,0.00019324802,0.00027206592,0.000054635453,0.000034802863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041992683,0.00011356783,0.0002804404,0.00002744039,0.000073435614,0.000009230756,0.00009527144,0.000026507869,0.000043210715],"category_scores_gemma":[0.000052498683,0.00005499462,0.000074078634,0.00009956767,0.00002964288,0.000026478461,0.000013444314,0.0001051401,1.5352997e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030358954,0.000080985075,0.97413564,0.00011353429,0.00023264962,0.0000019570468,0.00090717495,0.01873493,0.00045612443,0.000021295402,0.00048665833,0.0045254757],"study_design_scores_gemma":[0.0022942403,0.00043098917,0.98004615,0.00012318109,0.00015765804,0.0000012515779,0.00018781275,0.015006007,0.0014902224,0.000011493007,0.00017939767,0.00007159059],"about_ca_topic_score_codex":0.92353237,"about_ca_topic_score_gemma":0.8824399,"teacher_disagreement_score":0.041092493,"about_ca_system_score_codex":0.0049655666,"about_ca_system_score_gemma":0.0008175413,"threshold_uncertainty_score":0.9988542},"labels":[],"label_agreement":null},{"id":"W2116456578","doi":"10.1634/theoncologist.11-90001-13","title":"The Role of Bisphosphonates in Early Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.03476832903059714,"score_gpt":0.3826331772062494,"score_spread":0.3478648481756523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116456578","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023386047,0.9919934,3.98729e-8,0.0006308512,0.00015724619,0.0010485575,0.00011263912,0.000016295,0.0058070878],"genre_scores_gemma":[0.0018502651,0.99428916,0.000009670152,0.000062853316,0.00006315542,0.00036994836,0.000026296475,0.000024839192,0.0033038117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873865,0.00012518108,0.00049184804,0.00017400709,0.00016585342,0.0003044616],"domain_scores_gemma":[0.99877524,0.0003913409,0.0003449005,0.0003866392,0.000044138167,0.000057751884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030770383,0.00021212394,0.0010129063,0.000042161253,0.000098671095,0.000008905143,0.00020852262,0.00020127956,0.000027701493],"category_scores_gemma":[0.000026212389,0.00008490512,0.00020350424,0.0002831267,0.00026986707,0.000011685416,0.000049643506,0.00038649866,0.000049291386],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060919992,0.00013899253,0.0040177535,0.0010303041,0.00007835921,0.000017713784,0.000019133942,1.4583262e-7,4.1388493e-8,0.00013442436,0.0007062937,0.99379593],"study_design_scores_gemma":[0.00041791622,0.00012319071,0.016059512,0.0027293426,0.00049031444,0.000060119182,0.0000141723,0.0000010052387,9.614595e-7,0.00013729939,0.9798961,0.00007004995],"about_ca_topic_score_codex":0.03830037,"about_ca_topic_score_gemma":0.006065038,"teacher_disagreement_score":0.9937259,"about_ca_system_score_codex":0.00038786954,"about_ca_system_score_gemma":0.00087811623,"threshold_uncertainty_score":0.96810365},"labels":[],"label_agreement":null},{"id":"W2116488544","doi":"10.1634/theoncologist.2011-0151","title":"Preliminary Report: Vitamin D Deficiency in Advanced Cancer Patients with Symptoms of Fatigue or Anorexia","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Medicine; Vitamin D and neurology; Internal medicine; vitamin D deficiency; Cancer; Anorexia; Cachexia; Gastroenterology; Appetite; Vitamin; Endocrinology","score_opus":0.05281606135876366,"score_gpt":0.3459507428955177,"score_spread":0.29313468153675404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116488544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98860776,0.00032234835,0.000021834065,0.00022224276,0.00008239902,0.0009431626,0.000011316207,0.000027414773,0.009761507],"genre_scores_gemma":[0.9973339,0.00008503039,0.0006434549,0.00005699373,0.000018975728,0.00024938388,0.000008430166,0.000015920084,0.0015879516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862,0.00007337219,0.00035088265,0.0002547878,0.0003768714,0.0003240902],"domain_scores_gemma":[0.9988844,0.0001801728,0.00022272057,0.0004292771,0.00022443684,0.00005898479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000340757,0.0001452774,0.00035810322,0.00008888213,0.00007373084,0.0000027374922,0.0002053193,0.00005997631,0.00011518679],"category_scores_gemma":[0.0005982278,0.000067483474,0.000036276804,0.00039555918,0.00073400064,0.000062885636,0.00015040586,0.00020655766,0.000004052746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024001175,0.0012169295,0.98000747,0.00015727365,0.000054267657,0.0004488904,0.0022858432,0.000019356223,0.0002097285,0.00003241433,0.0005249593,0.012642739],"study_design_scores_gemma":[0.00215322,0.0072266296,0.98850095,0.0002693238,0.00005774973,0.00002716619,0.0007295772,0.000016307562,0.00078770623,0.000024398021,0.00011219883,0.00009478121],"about_ca_topic_score_codex":0.0005773544,"about_ca_topic_score_gemma":0.00090892334,"teacher_disagreement_score":0.012547958,"about_ca_system_score_codex":0.0001994746,"about_ca_system_score_gemma":0.00026963127,"threshold_uncertainty_score":0.27518964},"labels":[],"label_agreement":null},{"id":"W2117590220","doi":"10.1634/theoncologist.11-6-590","title":"Cancer in 15- to 29-Year-Olds by Primary Site","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Medicine; Ethnic group; Race (biology); Cancer survival; Demography; Quarter (Canadian coin); Incidence (geometry); Cancer; Cancer incidence; Gerontology; Internal medicine","score_opus":0.0429315510139662,"score_gpt":0.3956065011842133,"score_spread":0.3526749501702471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117590220","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000060756083,0.9580952,0.000023624363,0.0016273311,0.00023461804,0.0023393054,0.0003379068,0.00007116902,0.037210096],"genre_scores_gemma":[0.000017425651,0.95639753,0.00017756864,0.0013353709,0.00071582047,0.0007387652,0.000329778,0.00009460095,0.040193122],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970993,0.00031434424,0.00067725097,0.00056549977,0.0006277452,0.0007158607],"domain_scores_gemma":[0.9978964,0.0007716692,0.00021174416,0.0008354043,0.00007833407,0.00020649296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083786657,0.00044388455,0.0019875306,0.00021877905,0.00007253229,0.00003614266,0.0006463529,0.00054628716,0.00045666884],"category_scores_gemma":[0.00026145414,0.00025346657,0.0002825998,0.0009006607,0.00031664062,0.000029762732,0.00043679946,0.0010669321,0.0012050708],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076117525,0.00012880604,0.00008674953,0.003978653,0.00007628042,0.00021379699,0.000030461095,0.0000032951434,0.000006482178,0.000015233106,0.49908978,0.49629435],"study_design_scores_gemma":[0.00098772,0.00025581283,0.00020177149,0.004792381,0.0004427816,0.000077738136,0.000008624914,0.0000063793527,0.0000014829848,0.0000069324565,0.99296457,0.0002537911],"about_ca_topic_score_codex":0.0031419622,"about_ca_topic_score_gemma":0.0008236799,"teacher_disagreement_score":0.49604055,"about_ca_system_score_codex":0.008618591,"about_ca_system_score_gemma":0.0040336265,"threshold_uncertainty_score":0.9999918},"labels":[],"label_agreement":null},{"id":"W2119824367","doi":"10.1634/theoncologist.6-suppl_4-12","title":"Answering Patients' Needs: Oral Alternatives to Intravenous Therapy","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Quality of life (healthcare); Medical prescription; Patient education; Tegafur; Intensive care medicine; Bolus (digestion); Oncology; Internal medicine; Colorectal cancer; Chemotherapy; Cancer; Pharmacology; Nursing","score_opus":0.10779214304453844,"score_gpt":0.4047876122001642,"score_spread":0.29699546915562575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119824367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010695616,0.97957087,0.0000072417292,0.00034105353,0.00047655508,0.0020725199,0.000033662014,0.000068083886,0.01636048],"genre_scores_gemma":[0.0006235283,0.9952789,0.00007378035,0.00047289903,0.00038659075,0.00044418374,0.000041312298,0.000042909312,0.0026358801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868923,0.00010302013,0.0003528103,0.0002753694,0.00021559099,0.00036398842],"domain_scores_gemma":[0.99912435,0.00016619847,0.00017700615,0.00034890007,0.00007878034,0.00010476708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016557047,0.00038936568,0.0015068206,0.000125531,0.00017705803,0.000030844432,0.00025188422,0.000093212744,0.0001274998],"category_scores_gemma":[0.000075812946,0.00018609526,0.00031086445,0.00045116275,0.00015309073,0.000020661048,0.00013330375,0.00028089122,0.00010136736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012889436,0.00032556304,0.00015695386,0.00035135448,0.0005463534,0.000058854803,0.0005749897,3.4546898e-7,5.7593365e-8,0.00002314594,0.0012950796,0.9965384],"study_design_scores_gemma":[0.00069135736,0.003006102,0.0006959862,0.0014419358,0.0004945867,0.00003559858,0.00014773475,2.05318e-7,5.668422e-7,0.000014099512,0.99328345,0.00018835034],"about_ca_topic_score_codex":0.00031259144,"about_ca_topic_score_gemma":0.00011873849,"teacher_disagreement_score":0.99635005,"about_ca_system_score_codex":0.0007179033,"about_ca_system_score_gemma":0.00018566339,"threshold_uncertainty_score":0.7588745},"labels":[],"label_agreement":null},{"id":"W2120603700","doi":"10.1634/theoncologist.2014-0437","title":"A Time-Trend Economic Analysis of Cancer Drug Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Interior Health; Cancer Care Ontario; University of Toronto; University of British Columbia; St. Michael's Hospital; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Reimbursement; Medicine; Clinical trial; Cost effectiveness; Health care; Cost–benefit analysis; Colorectal cancer; Cancer drugs; Drug; Intensive care medicine; Oncology; Cancer; Internal medicine; Pharmacology; Risk analysis (engineering)","score_opus":0.6119905934439245,"score_gpt":0.5361387412957954,"score_spread":0.07585185214812906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120603700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8859741,0.0073887147,0.00022521087,0.068679556,0.0013055452,0.00095370755,0.0022490842,0.000074595126,0.033149507],"genre_scores_gemma":[0.9840549,0.00035127992,0.0005900571,0.005443174,0.00073160377,0.0002528944,0.000095457064,0.000032854878,0.008447729],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99379444,0.001005615,0.0044399826,0.00038897927,0.00007362361,0.00029733567],"domain_scores_gemma":[0.9919687,0.0028529612,0.0042984937,0.00067512615,0.00004479932,0.00015994918],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.050290696,0.00016539759,0.00223373,0.00043034102,0.00010212141,0.000045749694,0.0005145838,0.000108542714,0.0021679844],"category_scores_gemma":[0.004096405,0.00014540488,0.00038341922,0.0003856713,0.0002725747,0.000174503,0.000081258564,0.00011993095,0.0022280873],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023381384,0.00032490538,0.14083794,0.00011509257,0.006335026,0.0000017690975,0.011740244,0.07507384,0.0000109347,0.0875077,0.676253,0.0015657324],"study_design_scores_gemma":[0.005270766,0.00036921658,0.08669422,0.00007129208,0.0020542645,0.0000031243253,0.007931361,0.16252463,0.00006597497,0.033526402,0.70022476,0.0012639994],"about_ca_topic_score_codex":0.0132657625,"about_ca_topic_score_gemma":0.0077454345,"teacher_disagreement_score":0.09808087,"about_ca_system_score_codex":0.001191877,"about_ca_system_score_gemma":0.00037676145,"threshold_uncertainty_score":0.9987442},"labels":[],"label_agreement":null},{"id":"W2121508408","doi":"10.1634/theoncologist.2015-0026","title":"Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":237,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health","keywords":"Interquartile range; Medicine; Psychosocial; Distress; Quality of life (healthcare); Confidence interval; Hospital Anxiety and Depression Scale; Anxiety; Internal medicine; Psychiatry; Clinical psychology","score_opus":0.05155118971980753,"score_gpt":0.28822914647198816,"score_spread":0.23667795675218062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121508408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99513847,0.0011693675,0.000031173335,0.00044150493,0.0001078537,0.00017796371,0.00077197386,0.000008424576,0.0021532448],"genre_scores_gemma":[0.9993355,0.0002021385,0.000026907663,0.00013603995,0.000099264274,0.000025564146,0.000012484133,0.000007714741,0.00015437935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993058,0.000019793579,0.0002888038,0.00020124202,0.000036569625,0.00014778525],"domain_scores_gemma":[0.9992067,0.00010491574,0.0004365904,0.000087759094,0.000071237046,0.00009275907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027647644,0.000102402424,0.00036647305,0.000026857748,0.00010121397,0.000027919916,0.00007681957,0.00006179766,0.0000075754974],"category_scores_gemma":[0.00048429868,0.000081754966,0.000022799437,0.00006303403,0.00031450516,0.00022322012,0.00006282893,0.00009521795,0.0000023979692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084112755,0.0000929548,0.92971975,0.000016434347,0.000026303613,1.0075255e-7,0.00054469396,0.00006324245,0.0000016391066,0.06763284,0.00013639055,0.0016815542],"study_design_scores_gemma":[0.0013362153,0.00021995214,0.9914308,0.000013464223,0.000008058944,1.215925e-7,0.000043246393,0.0002698753,0.0000066276402,0.0061007314,0.00045100725,0.00011987448],"about_ca_topic_score_codex":0.00075402256,"about_ca_topic_score_gemma":0.0007553134,"teacher_disagreement_score":0.061711088,"about_ca_system_score_codex":0.000101187354,"about_ca_system_score_gemma":0.00006736648,"threshold_uncertainty_score":0.33338708},"labels":[],"label_agreement":null},{"id":"W2121803170","doi":"10.1634/theoncologist.2012-0432","title":"Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Intrahepatic Cholangiocarcinoma; Adjuvant; Adjuvant therapy; Internal medicine; Oncology; Cancer","score_opus":0.06203818774280435,"score_gpt":0.3306661924151549,"score_spread":0.26862800467235054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121803170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278659,0.035345696,0.00015891246,0.022644054,0.0008403604,0.0017818926,0.00001694347,0.00010739643,0.011238826],"genre_scores_gemma":[0.9911783,0.0006082159,0.00015202854,0.004415161,0.0013590836,0.00043538294,0.000012740379,0.000024737168,0.0018143842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989154,0.0000806085,0.00021491524,0.00015922426,0.0001674036,0.0004624817],"domain_scores_gemma":[0.9988081,0.0004837309,0.00010074568,0.00043755255,0.0000889001,0.000080975195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068470254,0.00017887908,0.0003329936,0.000025653993,0.00035814184,0.000028745606,0.0002288982,0.00006222829,0.00004578962],"category_scores_gemma":[0.0001590165,0.000077373166,0.0002006159,0.00011959879,0.00036573908,0.00006328019,0.000065989785,0.00018934289,0.000044324144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016382791,0.00060309854,0.67846245,0.0000800234,0.0007739928,0.000016809876,0.01085495,0.0000013215201,0.0022564468,0.0026199378,0.18921854,0.113474175],"study_design_scores_gemma":[0.0021508106,0.00061227166,0.78811383,0.000019889401,0.0002328399,0.00007581285,0.0010719678,0.000027520513,0.001150381,0.00022829718,0.20618528,0.00013110187],"about_ca_topic_score_codex":0.00015128439,"about_ca_topic_score_gemma":0.00007273837,"teacher_disagreement_score":0.113343075,"about_ca_system_score_codex":0.00009533627,"about_ca_system_score_gemma":0.000062266525,"threshold_uncertainty_score":0.31551862},"labels":[],"label_agreement":null},{"id":"W2123632377","doi":"10.1634/theoncologist.2011-0324","title":"Retinopathy Associated with Adjuvant High-Dose Interferon-α2b in a Patient with Resected Melanoma: A Case Report and Review of the Literature","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"3M (Canada); Queen's University","funders":"","keywords":"Medicine; Discontinuation; Asymptomatic; Melanoma; Cotton wool spots; Interferon; Adjuvant; Dermatology; Retinal; Retinopathy; Alpha interferon; Surgery; Oncology; Ophthalmology; Immunology; Cancer research; Endocrinology","score_opus":0.013974257052632538,"score_gpt":0.27720175270548164,"score_spread":0.2632274956528491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123632377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809087,0.014559709,6.3241635e-7,0.0021277545,0.000086883614,0.001098429,0.000017119153,0.00001793112,0.0011828789],"genre_scores_gemma":[0.9983429,0.0004713626,0.00011029214,0.00059891224,0.000024472132,0.00009038957,0.000041331157,0.000013630304,0.00030673755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986483,0.00043839097,0.00031448324,0.00018401333,0.00018215366,0.00023267104],"domain_scores_gemma":[0.99878377,0.00017567161,0.00036564522,0.0004660309,0.00014003358,0.000068838795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070876273,0.00016238965,0.00046163896,0.00003558517,0.00008406785,0.000005316626,0.00007182845,0.000119150354,0.000017815886],"category_scores_gemma":[0.00056498684,0.00006296608,0.000041457388,0.0003896723,0.00033639118,0.000048969523,0.000082639315,0.00037876205,0.000001410065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056957086,0.003706737,0.7143082,0.0013814139,0.00083844474,0.2606669,0.0065863435,0.0000010277021,0.00018861132,0.00014835905,0.001553544,0.0049247094],"study_design_scores_gemma":[0.008585899,0.011770774,0.7223282,0.022363564,0.0015730246,0.2304816,0.00073378574,0.000005415965,0.00089598907,0.000042839696,0.0009572577,0.00026165234],"about_ca_topic_score_codex":0.00019096091,"about_ca_topic_score_gemma":0.000786799,"teacher_disagreement_score":0.03018531,"about_ca_system_score_codex":0.00021529889,"about_ca_system_score_gemma":0.00014973908,"threshold_uncertainty_score":0.2567682},"labels":[],"label_agreement":null},{"id":"W2123662332","doi":"10.1634/theoncologist.2014-0180","title":"How to Implement a Geriatric Assessment in Your Clinical Practice","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Psychosocial; Geriatric oncology; Medicine; Psychological intervention; Clinical Practice; Population; Disease; Health care; Family medicine; Cancer; Gerontology; Intensive care medicine; Nursing; Psychiatry; Pathology; Internal medicine","score_opus":0.22050453729119543,"score_gpt":0.5553935414049408,"score_spread":0.33488900411374534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123662332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000060697207,0.9232586,0.0003632498,0.05321865,0.001420335,0.0054396945,0.000034554934,0.00008357995,0.01617524],"genre_scores_gemma":[0.000044085784,0.9782564,0.009699274,0.0028552685,0.0019522721,0.00078050245,0.000083071835,0.00006539706,0.0062637213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99510914,0.0016374988,0.0014480731,0.0006717788,0.00057598855,0.0005575266],"domain_scores_gemma":[0.9932988,0.0039990386,0.0009459464,0.0013417474,0.00015364708,0.000260802],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0061128684,0.0004616549,0.0027837385,0.00019760705,0.00007119367,0.00009878332,0.0006669436,0.0004513623,0.000091445654],"category_scores_gemma":[0.0074753836,0.00026138176,0.00055660727,0.0006099196,0.000108158834,0.00005763123,0.00046907717,0.0017692391,0.00035364673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038559927,0.00042253194,0.000042520285,0.0028652519,0.00017265163,0.00019225372,0.000040861054,2.915307e-7,4.9844715e-8,0.00026192542,0.06729791,0.92866516],"study_design_scores_gemma":[0.0010670226,0.0017092493,0.0005181553,0.0029359956,0.0019228755,0.00032073536,0.0001751432,0.000003939469,3.01968e-8,0.000017301603,0.99106365,0.00026588867],"about_ca_topic_score_codex":0.00020003344,"about_ca_topic_score_gemma":0.00023049652,"teacher_disagreement_score":0.9283993,"about_ca_system_score_codex":0.0013645614,"about_ca_system_score_gemma":0.001767287,"threshold_uncertainty_score":0.99998385},"labels":[],"label_agreement":null},{"id":"W2123863371","doi":"10.1634/theoncologist.2013-0022","title":"Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Neoadjuvant therapy; Colorectal cancer; Radiation therapy; Magnetic resonance imaging; Stage (stratigraphy); Disease; Oncology; Risk stratification; Internal medicine; Cancer; Radiology","score_opus":0.08088204818895696,"score_gpt":0.4086585103131368,"score_spread":0.3277764621241799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123863371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018814835,0.98235476,0.000028179404,0.0001221083,0.00040156394,0.0104792565,0.0001667522,0.00014831926,0.0044175694],"genre_scores_gemma":[0.00096050097,0.9836783,0.0008136407,0.000060733662,0.0003115251,0.011156612,0.0003003265,0.00011516547,0.002603198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978096,0.00013359409,0.00054163404,0.00062924495,0.00030299227,0.00058297307],"domain_scores_gemma":[0.99784714,0.0007128373,0.0005494677,0.0004621311,0.00026786915,0.00016056838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000119081866,0.00070262584,0.0022199547,0.000070396636,0.00023019477,0.00007000461,0.00022167621,0.00026797553,0.00016406272],"category_scores_gemma":[0.000072774514,0.00030666997,0.0004792292,0.00033424003,0.00022565134,0.0000898679,0.00006047524,0.00031631708,0.000045965044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007497578,0.000440317,0.00015142625,0.0017013529,0.00088304636,0.000022706763,0.00005611301,0.00001277891,2.600509e-7,0.000019882806,0.00018872831,0.9957736],"study_design_scores_gemma":[0.0045528347,0.010774729,0.0003018904,0.005776635,0.0033250486,0.000033591292,0.000082940714,0.000010052638,0.0000047262893,0.000023558869,0.97471434,0.00039964623],"about_ca_topic_score_codex":0.0005341498,"about_ca_topic_score_gemma":0.0006593299,"teacher_disagreement_score":0.99537396,"about_ca_system_score_codex":0.003139702,"about_ca_system_score_gemma":0.0019852899,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W2124443610","doi":"10.1634/theoncologist.10-10-780","title":"Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epirubicin; Medicine; Trastuzumab; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Anthracycline; Internal medicine; Chemotherapy; Doxorubicin; Cancer","score_opus":0.0729664907286145,"score_gpt":0.3820396497003825,"score_spread":0.309073158971768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124443610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035035887,0.9954965,0.00006940696,0.0005889528,0.0001992364,0.0011466747,0.0020495772,0.00001545292,0.00008380183],"genre_scores_gemma":[0.00044368862,0.99573714,0.00069069164,0.00020067419,0.0009798161,0.00082754256,0.00020431192,0.00007142198,0.0008447234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857146,0.00010139694,0.0004404231,0.00044059157,0.00011268032,0.00033344913],"domain_scores_gemma":[0.9986151,0.00013086449,0.00050493155,0.00058376766,0.00011831636,0.00004703973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016428142,0.00042978628,0.0011952425,0.00003454454,0.00011043345,0.000017795133,0.000433426,0.00031922708,0.000029307754],"category_scores_gemma":[0.000030454912,0.00025674098,0.00057069736,0.000098881064,0.0003909548,0.0000034795557,0.0001470603,0.00013104524,0.0000060472216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021773623,0.00013174811,0.00006881282,0.00063550536,0.0008039755,0.0000010678946,0.000029876504,0.000016568483,0.000021254571,0.000018713668,0.006546022,0.9915087],"study_design_scores_gemma":[0.0006807274,0.00026662368,0.0006350703,0.000708468,0.0008668666,0.000040326315,0.000010226119,0.0000013255632,0.000083312494,0.0000026354332,0.99643713,0.0002673029],"about_ca_topic_score_codex":0.00048980047,"about_ca_topic_score_gemma":0.00022190249,"teacher_disagreement_score":0.9912414,"about_ca_system_score_codex":0.00015946841,"about_ca_system_score_gemma":0.0003684804,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W2124531563","doi":"10.1634/theoncologist.2008-0061","title":"Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency","keywords":"Medicine; Bevacizumab; Colorectal cancer; Irinotecan; Internal medicine; Chemotherapy; Oxaliplatin; Oncology; Cetuximab; Geriatric oncology; Clinical trial; Medical record; Cancer","score_opus":0.08099379445058258,"score_gpt":0.3781104254251143,"score_spread":0.2971166309745317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124531563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956054,0.001014452,0.0000028514103,0.0073227095,0.0000689443,0.0016581797,0.000051320167,0.000008642379,0.00031234414],"genre_scores_gemma":[0.9916339,0.0052540945,0.00017743565,0.002243923,0.000038997492,0.0005813452,0.000026318383,0.000009749707,0.00003423717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879867,0.00042459113,0.00026580234,0.00012764295,0.00015515076,0.00022816448],"domain_scores_gemma":[0.9974553,0.0021299475,0.00014267204,0.00018064793,0.000075636504,0.000015768168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005345906,0.00014980837,0.00037508964,0.000036688405,0.00039540118,0.000011693903,0.00019390172,0.00006818251,0.0000051336397],"category_scores_gemma":[0.00013307972,0.00006622961,0.00006442055,0.0001654885,0.000691241,0.000058578404,0.000038859318,0.00032588904,1.2376034e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049630846,0.0017726134,0.89208645,0.000030563966,0.00010457212,0.00001195593,0.024295103,0.000025778832,0.00038816885,0.00007237738,0.0009445767,0.07530474],"study_design_scores_gemma":[0.0054429374,0.005821147,0.97927076,0.000034085344,0.000026857839,0.00001630876,0.0029330074,0.00006365303,0.00015935354,0.00012181707,0.0060366658,0.00007341118],"about_ca_topic_score_codex":0.0077516213,"about_ca_topic_score_gemma":0.011801352,"teacher_disagreement_score":0.08718429,"about_ca_system_score_codex":0.00017239738,"about_ca_system_score_gemma":0.0001225091,"threshold_uncertainty_score":0.9988558},"labels":[],"label_agreement":null},{"id":"W2124870334","doi":"10.1634/theoncologist.2014-0295","title":"Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Clinical trial; Breast cancer; Randomized controlled trial; Radiation therapy; Nuclear medicine; Cancer; Medical physics; Radiology; Internal medicine","score_opus":0.35488795266247003,"score_gpt":0.5036175293651448,"score_spread":0.14872957670267478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124870334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98489594,0.0026489813,0.0000027308984,0.011550647,0.00014052862,0.00030182244,0.000010478495,0.00002166453,0.00042722406],"genre_scores_gemma":[0.9976767,0.0010320243,0.000023061577,0.000974287,0.00018760248,0.00007200272,0.000005919858,0.000008111759,0.000020347221],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982187,0.00074936874,0.000552739,0.00017080523,0.00011889694,0.00018945213],"domain_scores_gemma":[0.99836516,0.0011530623,0.00025251883,0.000090169386,0.000041122115,0.00009798183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071797576,0.00008401675,0.00040569424,0.00007759368,0.000045542747,0.000039215956,0.00003914342,0.000060344188,0.000012851515],"category_scores_gemma":[0.005464825,0.000057120662,0.000025246352,0.00019538392,0.00011586509,0.00012325976,0.000033119704,0.00022458321,0.0000019199579],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013447627,0.00005930944,0.837495,0.0000041754643,0.000012292869,0.000008662561,0.00062801107,0.00012682282,0.0000278853,0.000014605978,0.00043138044,0.16105735],"study_design_scores_gemma":[0.004291502,0.000055407447,0.9817741,0.0000958797,0.000059913564,0.000012616049,0.00056235364,0.012781335,0.00005282471,0.00010116579,0.00014801817,0.000064871754],"about_ca_topic_score_codex":0.0031209076,"about_ca_topic_score_gemma":0.0011773579,"teacher_disagreement_score":0.16099249,"about_ca_system_score_codex":0.00017848678,"about_ca_system_score_gemma":0.00016997935,"threshold_uncertainty_score":0.65423006},"labels":[],"label_agreement":null},{"id":"W2124957996","doi":"10.1634/theoncologist.2011-0164","title":"Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Antiandrogen; Ovarian cancer; Oncology; Prostate cancer; Cancer; Internal medicine","score_opus":0.08430796692686533,"score_gpt":0.388245100507742,"score_spread":0.3039371335808767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124957996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025624531,0.96800005,0.0000010361971,0.00065179146,0.00011476481,0.001066355,0.00004142443,0.000012201869,0.030086767],"genre_scores_gemma":[0.0034882955,0.9953134,0.000052229647,0.00006725165,0.00045951767,0.00043358514,0.00001750193,0.000028046943,0.0001401752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865234,0.00022223839,0.00052020926,0.00024673645,0.00012556455,0.00023288668],"domain_scores_gemma":[0.99862015,0.00027200856,0.00046450782,0.00056518207,0.0000413664,0.00003679838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053786125,0.00025402525,0.0013036075,0.000056821842,0.00006946054,0.000022350705,0.00030356305,0.00017133214,0.00033160034],"category_scores_gemma":[0.000034561086,0.0001073793,0.0003121367,0.00027678226,0.00022349105,0.000027161841,0.000084501444,0.00035715886,0.000024939804],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017157221,0.00007531666,0.0007436545,0.002107237,0.00034234172,0.000033609085,0.00019185014,8.189509e-7,3.9406683e-7,0.0068696574,0.00009830789,0.98951966],"study_design_scores_gemma":[0.0003567369,0.00010962963,0.001361018,0.010744231,0.0019523569,0.000046319346,0.00034743437,0.0000011276181,0.000007631336,0.00036793345,0.9845945,0.00011103702],"about_ca_topic_score_codex":0.003349622,"about_ca_topic_score_gemma":0.0003438994,"teacher_disagreement_score":0.9894086,"about_ca_system_score_codex":0.00027515652,"about_ca_system_score_gemma":0.0010638763,"threshold_uncertainty_score":0.5063649},"labels":[],"label_agreement":null},{"id":"W2125128981","doi":"10.1634/theoncologist.7-suppl_1-14","title":"Molecular Targets of Arsenic Trioxide in Malignant Cells","year":2002,"lang":"en","type":"review","venue":"The Oncologist","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Medicine; Cancer research; Apoptosis; Signal transduction; Intracellular; Leukemia; Cell biology; Immunology; Chemistry; Biology; Biochemistry; Cell culture; Retinoic acid; Genetics","score_opus":0.030062198932065857,"score_gpt":0.30761009359995994,"score_spread":0.2775478946678941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125128981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00093784794,0.99392337,0.00008348929,0.000020604995,0.00019816356,0.0005759331,0.000022734457,0.000008467001,0.004229411],"genre_scores_gemma":[0.0026871117,0.9952077,0.00017281299,0.00005670609,0.00012658874,0.00010772682,0.00008932934,0.00005125503,0.0015007374],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979127,0.0003738558,0.0007097985,0.00047484835,0.00017443595,0.00035433966],"domain_scores_gemma":[0.99853843,0.0000706684,0.00051676866,0.00077535864,0.000049234717,0.000049505292],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049651496,0.00038494784,0.0010557678,0.000074394695,0.000039163413,0.000014426823,0.000882281,0.00059254747,0.000039549857],"category_scores_gemma":[0.00013503374,0.00024553787,0.00048547488,0.00024737924,0.00033601368,0.0000015006802,0.00024763937,0.00034191608,0.00003920129],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007752347,0.0006915429,0.00002365244,0.015776731,0.00057365914,0.0004883246,0.00007925192,0.00019364688,0.050542362,0.00045639684,0.009105516,0.9219914],"study_design_scores_gemma":[0.00023726567,0.00021956883,5.447886e-7,0.00095798756,0.00021890686,0.000035121484,0.000023534934,0.0000035612197,0.029205637,0.000045038778,0.9687569,0.00029591573],"about_ca_topic_score_codex":0.000026361808,"about_ca_topic_score_gemma":0.000019215737,"teacher_disagreement_score":0.9596514,"about_ca_system_score_codex":0.00008906928,"about_ca_system_score_gemma":0.00040968606,"threshold_uncertainty_score":0.9999997},"labels":[],"label_agreement":null},{"id":"W2125385675","doi":"10.1634/theoncologist.2013-0292","title":"Advancing Cervical Cancer Prevention in India: Implementation Science Priorities","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"World Bank Group","keywords":"Cervical cancer; Medicine; Cancer prevention; Scale (ratio); Health care; Quarter (Canadian coin); Cancer; Family medicine; Economic growth","score_opus":0.13150389422321318,"score_gpt":0.5411910074762077,"score_spread":0.40968711325299456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125385675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011080742,0.9807369,0.000006432252,0.00045679274,0.00024076512,0.0025303853,0.000014469403,0.00002811097,0.015875319],"genre_scores_gemma":[0.000985235,0.9962751,0.00009263585,0.00013566107,0.00042694726,0.0012500385,0.000034277225,0.000021568341,0.00077853166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99784535,0.00017427185,0.00051071035,0.0003639794,0.0005814545,0.00052425556],"domain_scores_gemma":[0.99897677,0.00022859105,0.00018482485,0.00032373006,0.00016130657,0.00012480856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013283617,0.00020222926,0.0008748267,0.00025833954,0.00017399318,0.00007014648,0.0003887373,0.00015283922,0.004155025],"category_scores_gemma":[0.00016477752,0.00011676295,0.00016504015,0.0009372634,0.0005516341,0.00013392641,0.00025708912,0.000726682,0.000086816006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013796305,0.000041648174,0.0002330363,0.004493634,0.000017162234,0.00000770932,0.00006866905,1.7913804e-7,0.0000011775356,0.00034411854,0.00038522668,0.99439365],"study_design_scores_gemma":[0.0008460254,0.0004306053,0.024606803,0.0023023363,0.00035704818,0.000030160993,0.00044791674,0.0000082886145,0.0000066185,0.0004347939,0.9703197,0.00020971826],"about_ca_topic_score_codex":0.0016044528,"about_ca_topic_score_gemma":0.0018256446,"teacher_disagreement_score":0.9941839,"about_ca_system_score_codex":0.0023595793,"about_ca_system_score_gemma":0.0037829066,"threshold_uncertainty_score":0.9967553},"labels":[],"label_agreement":null},{"id":"W2125598437","doi":"10.1634/theoncologist.10-1-63","title":"Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; Alberta Cancer Foundation; Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Epoetin alfa; Erythropoietin; Relative risk; Placebo; Blood transfusion; Confidence interval; Internal medicine; Anemia; Cancer; Surgery","score_opus":0.043849160933739466,"score_gpt":0.3523709464523417,"score_spread":0.3085217855186022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125598437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05859684,0.9125059,0.0000042174756,0.0027256461,0.0003231911,0.01394295,0.00031723228,0.00011053016,0.011473446],"genre_scores_gemma":[0.012013873,0.9797591,0.0005039703,0.0000953454,0.00010705771,0.0016013306,0.00011726095,0.00010287122,0.0056991684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961065,0.00084027834,0.001229005,0.0006886204,0.00056866324,0.0005669171],"domain_scores_gemma":[0.9974767,0.0003490882,0.0007799198,0.001115054,0.00010219393,0.00017702128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007974762,0.0007374059,0.0022087237,0.00018429935,0.0005307663,0.000020411613,0.00056268333,0.0003165703,0.00073520705],"category_scores_gemma":[0.000031195534,0.0002900946,0.0005767613,0.00067357847,0.0008188177,0.000029527995,0.000110563305,0.001069197,0.000015443518],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015006454,0.022077035,0.009155912,0.014147522,0.0022754292,0.00057815196,0.0022396366,0.000014772684,0.000008702113,0.00010081554,0.0029281399,0.94497323],"study_design_scores_gemma":[0.016557584,0.006406523,0.0057313927,0.027047876,0.031142004,0.00013064264,0.0013055343,0.0000040178993,0.000026435557,0.000017141954,0.9108285,0.0008023484],"about_ca_topic_score_codex":0.005499612,"about_ca_topic_score_gemma":0.014153728,"teacher_disagreement_score":0.9441709,"about_ca_system_score_codex":0.0007002481,"about_ca_system_score_gemma":0.0006406936,"threshold_uncertainty_score":0.9999551},"labels":[],"label_agreement":null},{"id":"W2125976746","doi":"10.1634/theoncologist.7-6-481","title":"The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy","year":2002,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Zoledronic acid; Medicine; Bisphosphonate; Malignancy; Bone resorption; Clinical trial; Internal medicine; Osteoporosis; Urology; Oncology; Gastroenterology","score_opus":0.24410217519784713,"score_gpt":0.39480416255587153,"score_spread":0.1507019873580244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125976746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002468733,0.9924813,0.000022194223,0.0008131003,0.00035659855,0.0053440756,0.00047265308,0.000017554055,0.00024568013],"genre_scores_gemma":[0.0018716664,0.9921144,0.00040185003,0.000075383694,0.000044230714,0.0010532062,0.000060752573,0.00005214325,0.0043263645],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975904,0.0001361868,0.0012189944,0.0002947092,0.00031306376,0.0004466369],"domain_scores_gemma":[0.9948665,0.002393659,0.0012475325,0.001209999,0.00018491411,0.00009742447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003186657,0.00044126064,0.002131158,0.000057372654,0.00021274702,0.000009059363,0.00037166302,0.00030840447,0.00002411789],"category_scores_gemma":[0.00015361613,0.00015385373,0.0010018147,0.00030330225,0.0006604869,0.000021406438,0.000055028544,0.00019807235,0.0000141370665],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004196246,0.0017637858,0.000036591075,0.0038727066,0.0012465533,0.0000101779115,0.000093880895,0.0000029190944,0.0000037725995,0.00036793185,0.0013275649,0.9908545],"study_design_scores_gemma":[0.0025542993,0.0043003964,0.00018509857,0.002743552,0.0053922236,0.00007564708,0.000026971458,0.00002546877,0.00007922769,0.000017687937,0.9844858,0.000113644746],"about_ca_topic_score_codex":0.0016043175,"about_ca_topic_score_gemma":0.0002979719,"teacher_disagreement_score":0.99074084,"about_ca_system_score_codex":0.0006113003,"about_ca_system_score_gemma":0.00080636574,"threshold_uncertainty_score":0.6273973},"labels":[],"label_agreement":null},{"id":"W2125984241","doi":"10.1634/theoncologist.6-2-114","title":"George Wesley Santos","year":2001,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cuban History and Society","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"George (robot); Medicine; Environmental ethics; Classics; Art history; History; Philosophy","score_opus":0.05802392085245066,"score_gpt":0.359659550879684,"score_spread":0.3016356300272333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125984241","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1836983,0.00022765761,0.00004898656,0.009848829,0.00059511967,0.00015156688,0.0000017872995,0.00013038806,0.8052974],"genre_scores_gemma":[0.91976506,0.00036568625,0.000051338055,0.0014598699,0.0005587494,0.00001166105,9.827507e-7,0.0000043788486,0.07778228],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991333,0.00025630285,0.000088319655,0.00010455611,0.00017817621,0.00023935903],"domain_scores_gemma":[0.9994988,0.00019736205,0.000046350873,0.00016928591,0.000028735383,0.000059507114],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011953427,0.000053254025,0.00008446079,0.00000814281,0.0012549524,0.00003121501,0.0003395205,0.000082762475,0.0016063291],"category_scores_gemma":[0.00018111317,0.000036961916,0.000070989474,0.0001724749,0.0008449051,0.000067502086,0.000033730368,0.00013447911,0.0004114017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059566748,0.00024455303,0.027784165,0.0000042879956,0.000032741216,0.00006053492,0.08492802,0.00001655527,0.00025516728,0.3093069,0.5510191,0.026288481],"study_design_scores_gemma":[0.00009304021,0.000022860426,0.004916383,0.0000015568353,0.0000073908977,0.0000016693051,0.0062003587,0.000004032709,0.000004713089,0.001819385,0.98686755,0.00006106894],"about_ca_topic_score_codex":0.003028405,"about_ca_topic_score_gemma":0.0076023987,"teacher_disagreement_score":0.73606676,"about_ca_system_score_codex":0.00024960286,"about_ca_system_score_gemma":0.00013630878,"threshold_uncertainty_score":0.9993063},"labels":[],"label_agreement":null},{"id":"W2126451936","doi":"10.1634/theoncologist.2011-0458","title":"Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors","year":2012,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Cancer research; Somatostatin receptor; Pharmacology; Internal medicine; Oncology","score_opus":0.06464550285194756,"score_gpt":0.4085036108327406,"score_spread":0.3438581079807931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126451936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002075125,0.9921477,0.0000012887275,0.000280982,0.00030079795,0.0031647037,0.000025625122,0.000072331175,0.0019314827],"genre_scores_gemma":[0.005529812,0.99250346,0.0001327659,0.00011278524,0.00019161929,0.00036066902,0.000045720495,0.00009496365,0.0010282258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961808,0.0008585211,0.0010283915,0.00046187584,0.000546283,0.0009241591],"domain_scores_gemma":[0.99591374,0.0021895848,0.0006545175,0.00095562823,0.0000643416,0.00022217551],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034389622,0.00053049217,0.0029759004,0.00046689052,0.000058383546,0.000015372398,0.0006739275,0.000021530012,0.000073568466],"category_scores_gemma":[0.0016310838,0.00030382889,0.00045459234,0.0009949121,0.0007169964,0.00008697944,0.00039328588,0.0012497214,0.00015101738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017142601,0.0013246958,0.0013912162,0.12544388,0.00018011243,0.04512895,0.000036315778,0.0000013918678,0.000049891332,0.00061823084,0.0015615138,0.8240924],"study_design_scores_gemma":[0.0012385763,0.0012879033,0.00094363827,0.010988307,0.00087166455,0.0100415675,0.00002603451,0.0000022622205,0.00022100593,0.00006292218,0.9740223,0.00029379776],"about_ca_topic_score_codex":0.00016487841,"about_ca_topic_score_gemma":0.00007423188,"teacher_disagreement_score":0.9724608,"about_ca_system_score_codex":0.00022418232,"about_ca_system_score_gemma":0.0005679892,"threshold_uncertainty_score":0.9999414},"labels":[],"label_agreement":null},{"id":"W2126653682","doi":"10.1634/theoncologist.11-3-261","title":"Oxaliplatin-Related Acute Myelogenous Leukemia","year":2006,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kellogg's (Canada)","funders":"","keywords":"Medicine; FOLFOX; Oxaliplatin; Pancytopenia; Colorectal cancer; Internal medicine; Leukemia; Bone marrow; Oncology; Chemotherapy regimen; Gastroenterology; Bevacizumab; Chemotherapy; Surgery; Cancer","score_opus":0.01542555954039006,"score_gpt":0.2863170583020318,"score_spread":0.27089149876164176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126653682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76466155,0.0010381133,0.000006439661,0.0034594594,0.00020400187,0.0003417034,0.000010307188,0.0001105826,0.23016784],"genre_scores_gemma":[0.9769555,0.00012153405,0.00013841054,0.00044190726,0.0001675162,0.00005018201,0.000025141728,0.000011851269,0.02208798],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99927604,0.000027473234,0.00018287818,0.00015790071,0.00013328585,0.00022242067],"domain_scores_gemma":[0.99956214,0.00008221245,0.000068784946,0.00021126818,0.000043935914,0.000031677842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010755986,0.00012576174,0.00024937387,0.000022453056,0.00025069935,0.00001195808,0.000079983416,0.00006908334,0.0001784144],"category_scores_gemma":[0.000018796218,0.0000666701,0.00008866113,0.00014772156,0.00024797258,0.000016628996,0.000054670945,0.000138993,0.00013655028],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006627871,0.0028618418,0.2114935,0.00013740192,0.006981924,0.005917194,0.0054523624,0.00075277186,0.033523474,0.030664494,0.44321868,0.25236848],"study_design_scores_gemma":[0.0051632277,0.0029315373,0.8460618,0.000038067035,0.0013787071,0.00059137394,0.00043956723,0.00017339822,0.001875235,0.0040729814,0.13696097,0.0003131089],"about_ca_topic_score_codex":0.001422576,"about_ca_topic_score_gemma":0.00054429396,"teacher_disagreement_score":0.63456833,"about_ca_system_score_codex":0.00056454627,"about_ca_system_score_gemma":0.00013771653,"threshold_uncertainty_score":0.2718728},"labels":[],"label_agreement":null},{"id":"W2127779058","doi":"10.1634/theoncologist.2014-0381","title":"Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Complementary and Integrative Health; National Center for Complementary and Alternative Medicine; National Institutes of Health","keywords":"Medicine; Observational study; Randomized controlled trial; Placebo; Internal medicine; Toxicity; Chemotherapy; Meta-analysis; Vitamin; Cancer; Oncology; Pathology; Alternative medicine","score_opus":0.10093488176845763,"score_gpt":0.4190439661201262,"score_spread":0.3181090843516685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127779058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062344945,0.9875884,0.0000070205497,0.00027647242,0.00016201587,0.0109434575,0.00032208167,0.000045610457,0.00059260713],"genre_scores_gemma":[0.00011957269,0.99324113,0.0001390409,0.00025466675,0.000104337225,0.003909311,0.000080211044,0.00011100244,0.0020407182],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99607307,0.0011511794,0.0010483752,0.00052030385,0.0005241488,0.0006829252],"domain_scores_gemma":[0.9971182,0.0009046534,0.00093187054,0.00069285865,0.00024928598,0.00010315704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019709773,0.0005532509,0.003742556,0.00012499116,0.00019518693,0.0001048202,0.00089399936,0.00025141757,0.000070180045],"category_scores_gemma":[0.0007384782,0.00023848237,0.00030611883,0.0007070518,0.0001873805,0.000083064144,0.00011479586,0.0005543219,0.0000607221],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009672772,0.0001747205,0.000028228435,0.5676585,0.00012094209,0.000013437384,0.00020088938,3.0947336e-7,2.8249758e-8,0.0000043525515,0.0013229345,0.43037894],"study_design_scores_gemma":[0.0010264234,0.0014771767,0.000018370683,0.7718532,0.0023315544,0.000022445674,0.00020501508,0.0000230319,3.4438025e-7,0.000022414239,0.2226142,0.00040582826],"about_ca_topic_score_codex":0.00061505736,"about_ca_topic_score_gemma":0.001110381,"teacher_disagreement_score":0.4299731,"about_ca_system_score_codex":0.001149715,"about_ca_system_score_gemma":0.0006794665,"threshold_uncertainty_score":0.9725029},"labels":[],"label_agreement":null},{"id":"W2128422065","doi":"10.1634/theoncologist.2012-0461","title":"Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexpression Predicts for Increased Distant Metastasis and Shorter Survival","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Ohio State University; Pennsylvania Department of Health","keywords":"Medicine; Bladder cancer; Vascular endothelial growth factor; Cystectomy; Radiation therapy; Urology; Metastasis; Internal medicine; Oncology; Pathology; Cancer; VEGF receptors","score_opus":0.08997251775910423,"score_gpt":0.3525537434276973,"score_spread":0.2625812256685931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128422065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789637,0.0021657306,0.002739083,0.0025113728,0.0006274126,0.011424839,0.0009041157,0.00011561936,0.0005481654],"genre_scores_gemma":[0.98748446,0.0052637993,0.0007015055,0.0017422154,0.00089018577,0.0034649926,0.00027386213,0.0000767887,0.00010220018],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997257,0.0006408715,0.0006229106,0.0006219479,0.0003866004,0.00047067332],"domain_scores_gemma":[0.9960073,0.0028023433,0.00039467268,0.00038208428,0.00020215184,0.00021140734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013410959,0.0004217061,0.0009594434,0.00011386327,0.0003855153,0.000108146865,0.00016242823,0.00027391885,0.00021442844],"category_scores_gemma":[0.0006988544,0.00024396485,0.0002661357,0.000118587246,0.0002484076,0.00030354233,0.00003928648,0.00019008211,0.000002099406],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041839853,0.0027277882,0.026036417,0.0003803379,0.007854313,0.000011885099,0.0056844684,0.00002798052,0.24742822,0.0024970374,0.018481137,0.6470306],"study_design_scores_gemma":[0.16252539,0.04487615,0.50872076,0.00044300192,0.0032225535,0.000027180002,0.0016971097,0.0049827336,0.09108465,0.011990088,0.1685497,0.0018806739],"about_ca_topic_score_codex":0.0025411162,"about_ca_topic_score_gemma":0.00015792881,"teacher_disagreement_score":0.6451499,"about_ca_system_score_codex":0.00040253391,"about_ca_system_score_gemma":0.00029070053,"threshold_uncertainty_score":0.9948598},"labels":[],"label_agreement":null},{"id":"W2128730708","doi":"10.1634/theoncologist.2011-0127","title":"Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Oncology; Primary tumor; Cancer; Internal medicine; Cancer research; Pathology; Metastasis","score_opus":0.0218103041826829,"score_gpt":0.2918508419238959,"score_spread":0.27004053774121295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128730708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9250468,0.0148241315,0.00042651469,0.057086773,0.00021094146,0.0008331282,0.00021677163,0.000018597892,0.0013363565],"genre_scores_gemma":[0.9948778,0.00046584877,0.00007320419,0.0034658164,0.0004975817,0.00044853782,0.000043360928,0.000014949789,0.0001128865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990702,0.00021487947,0.00015100354,0.00016829351,0.00013188273,0.00026370335],"domain_scores_gemma":[0.99928313,0.00015138881,0.00010579783,0.00036165575,0.00005117795,0.00004683213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040063285,0.00015841417,0.00016688382,0.000009126357,0.0004108478,0.000031585685,0.00024482558,0.000028199194,0.000011243838],"category_scores_gemma":[0.000030859428,0.00006649045,0.00007802008,0.00007271646,0.0011084636,0.000005329776,0.00020883983,0.000103429156,0.0000073319097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030640422,0.0012904691,0.7832037,0.00019566537,0.007764288,0.000044505898,0.004677706,0.0010500823,0.027409546,0.04465206,0.05507931,0.07156862],"study_design_scores_gemma":[0.0031268802,0.000107939035,0.9475891,0.000025253948,0.0008933041,0.00033730094,0.00059982005,0.000020174113,0.004315544,0.0009270786,0.041716415,0.00034119634],"about_ca_topic_score_codex":0.00025137133,"about_ca_topic_score_gemma":0.00008714623,"teacher_disagreement_score":0.1643854,"about_ca_system_score_codex":0.000065750886,"about_ca_system_score_gemma":0.00008930731,"threshold_uncertainty_score":0.40841803},"labels":[],"label_agreement":null},{"id":"W2130164418","doi":"10.1634/theoncologist.2015-0220","title":"Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Docetaxel; Prostate cancer; Temsirolimus; Oncology; Castration; Internal medicine; Cancer; Discovery and development of mTOR inhibitors; Apoptosis; PI3K/AKT/mTOR pathway; Hormone","score_opus":0.09766706703691744,"score_gpt":0.3809797610678705,"score_spread":0.28331269403095305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130164418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748202,0.0044910978,0.0000016800724,0.015385893,0.000245182,0.0009905486,0.000018106643,0.00003550166,0.004011776],"genre_scores_gemma":[0.9886984,0.0019393985,0.000055968685,0.0004905182,0.0002110661,0.00068755867,0.000012883763,0.000014509058,0.007889658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989414,0.00008692219,0.0001927194,0.00020503782,0.0002598572,0.00031404317],"domain_scores_gemma":[0.9994244,0.000032303495,0.00006361465,0.00023093293,0.00014582601,0.000102950224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045686224,0.00012397402,0.00019145601,0.00006315844,0.00005785792,0.00002862357,0.000087095,0.00006927661,0.00006751722],"category_scores_gemma":[0.000045131274,0.00006378746,0.00003857663,0.0002637002,0.0002710706,0.00008511274,0.000025992342,0.0002512841,0.00003312915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09557745,0.0032008851,0.5491411,0.0002332939,0.00054868305,0.0030614662,0.02223073,0.0005802512,0.07776073,0.00069454586,0.049683534,0.1972873],"study_design_scores_gemma":[0.020012124,0.0032965078,0.86081606,0.0002731043,0.000067114546,0.000105860556,0.0038653347,0.00016707851,0.009130439,0.0014103366,0.1004891,0.00036696508],"about_ca_topic_score_codex":0.0019977333,"about_ca_topic_score_gemma":0.0016871684,"teacher_disagreement_score":0.3116749,"about_ca_system_score_codex":0.0006954014,"about_ca_system_score_gemma":0.000621568,"threshold_uncertainty_score":0.30199885},"labels":[],"label_agreement":null},{"id":"W2130207808","doi":"10.1634/theoncologist.11-90001-42","title":"The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Capecitabine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Colorectal cancer","score_opus":0.050020701675656275,"score_gpt":0.3936264737207917,"score_spread":0.3436057720451354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130207808","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005005748,0.99229676,0.0000014073639,0.00073163083,0.00016385941,0.0045101503,0.0010771728,0.000013253149,0.00070518366],"genre_scores_gemma":[0.0014274963,0.99234116,0.000050625902,0.0000348932,0.00022131842,0.0035230427,0.00042575784,0.000040832754,0.001934847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99869454,0.000105987005,0.0005070546,0.0002445433,0.00014564452,0.00030223976],"domain_scores_gemma":[0.99818754,0.0009014758,0.00045308316,0.00031406968,0.00009906699,0.000044776058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015715256,0.0003460828,0.0014506937,0.00006594903,0.000117043346,0.00000791068,0.0001698885,0.00008681992,0.00007823724],"category_scores_gemma":[0.000012647168,0.00012935298,0.00028250183,0.00023473313,0.00026115176,0.000015108432,0.000027584529,0.0001398019,0.00000443374],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010689562,0.0019013894,0.0017711344,0.0013632129,0.0008757654,0.000008381553,0.00004496674,0.000015157766,1.10771204e-7,0.00004055935,0.0009852668,0.9919251],"study_design_scores_gemma":[0.0058554723,0.0027249206,0.0012220588,0.001167398,0.005713233,0.000016971124,0.00001660378,0.000011157899,0.0000014526307,0.000043591717,0.98310095,0.00012621889],"about_ca_topic_score_codex":0.0028020479,"about_ca_topic_score_gemma":0.01260405,"teacher_disagreement_score":0.9917989,"about_ca_system_score_codex":0.001169311,"about_ca_system_score_gemma":0.0005835936,"threshold_uncertainty_score":0.7033356},"labels":[],"label_agreement":null},{"id":"W2130730771","doi":"10.1634/theoncologist.2007-0245","title":"Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"Novartis Pharmaceuticals Corporation; Amgen","keywords":"Medicine; Denosumab; Zoledronic acid; Breast cancer; Clinical trial; Osteonecrosis of the jaw; Internal medicine; Multiple myeloma; Oncology; Adverse effect; Cancer; Surgery; Osteoporosis; Bisphosphonate","score_opus":0.0494458585787789,"score_gpt":0.3779195865178927,"score_spread":0.3284737279391138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130730771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681014,0.00070978137,9.731389e-7,0.0011786349,0.00021408737,0.00043869507,0.000038076643,0.000015448783,0.0005941458],"genre_scores_gemma":[0.9969604,0.00021114433,0.0020861712,0.00047630942,0.000022980563,0.000051205712,0.000019703644,0.00001079636,0.00016131435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991278,0.000041493095,0.00033214383,0.00015093012,0.00014990082,0.00019773156],"domain_scores_gemma":[0.9991979,0.00024256742,0.00016544489,0.00021335064,0.0000874218,0.000093302784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033726773,0.000095679556,0.0003502366,0.000035189565,0.000043949196,0.0000032704531,0.00006508524,0.000076930766,0.00008797782],"category_scores_gemma":[0.00012414888,0.000048018755,0.000042623655,0.00015170363,0.00024552364,0.000028923685,0.00003109212,0.0002941832,0.000007706563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010266323,0.0013094589,0.95766133,0.00002263944,0.00005061566,0.000011509563,0.000078298035,0.000022108332,0.000017340115,0.00008759941,0.00019947274,0.039513007],"study_design_scores_gemma":[0.0048359893,0.0013195773,0.9914365,0.000068958645,0.00012471864,0.0000037130087,0.000029713261,0.000023998075,0.000620781,0.000019339797,0.0014608633,0.000055850687],"about_ca_topic_score_codex":0.0034977237,"about_ca_topic_score_gemma":0.008222076,"teacher_disagreement_score":0.039457157,"about_ca_system_score_codex":0.00003937495,"about_ca_system_score_gemma":0.00019520526,"threshold_uncertainty_score":0.5287535},"labels":[],"label_agreement":null},{"id":"W2130760214","doi":"10.1634/theoncologist.2009-0122","title":"The Assessment and Management of Delirium in Cancer Patients","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Institute of Nursing Research; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Delirium; Cancer; Medicine; Intensive care medicine; Psychology; Internal medicine","score_opus":0.06672662386925798,"score_gpt":0.43852848822329704,"score_spread":0.37180186435403906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130760214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007880342,0.9779359,0.0000037874056,0.0018206838,0.00019808376,0.001956127,0.000021743517,0.000007690222,0.01797715],"genre_scores_gemma":[0.00023185281,0.9961401,0.000040473114,0.0027291651,0.000027864487,0.00023708872,0.000042717893,0.000016426759,0.0005343078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988193,0.00018669765,0.0004001627,0.00018967957,0.00020482964,0.00019931135],"domain_scores_gemma":[0.99772733,0.00030319576,0.0002763017,0.00025704148,0.0014081098,0.000028017963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035176845,0.00020361866,0.0007639904,0.00006538295,0.000067570305,0.000009876481,0.00017987602,0.000104907645,0.000012549622],"category_scores_gemma":[0.0002827045,0.000094014875,0.00013969751,0.0001952606,0.00033163352,0.00000995835,0.00011453473,0.000355257,0.000004023813],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019956795,0.000111500034,0.0002572867,0.0025500867,0.00017742462,0.000018574552,0.000019560854,1.2501373e-7,2.4185226e-8,0.0003415539,0.0049069673,0.99159694],"study_design_scores_gemma":[0.0006948775,0.0003395304,0.016707463,0.010964806,0.0012621921,0.000004123207,0.0006897797,0.0000018359851,1.5924965e-7,0.00005200894,0.9691665,0.00011667937],"about_ca_topic_score_codex":0.00008269037,"about_ca_topic_score_gemma":0.00009914542,"teacher_disagreement_score":0.99148023,"about_ca_system_score_codex":0.00042973223,"about_ca_system_score_gemma":0.00020493237,"threshold_uncertainty_score":0.38338155},"labels":[],"label_agreement":null},{"id":"W2131178461","doi":"10.1634/theoncologist.2010-0137","title":"Treatment Beyond Progression: Is It Moving from Belief to Evidence?","year":2010,"lang":"en","type":"letter","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; MEDLINE; Internal medicine; Family medicine; Cancer","score_opus":0.17719670831203707,"score_gpt":0.4723174421791335,"score_spread":0.2951207338670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131178461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004025612,0.0022165591,0.000009061978,0.9682551,0.0012220059,0.0026189045,0.0001714337,0.00010986318,0.021371432],"genre_scores_gemma":[0.002609836,0.0009955929,0.0025687073,0.89580494,0.018522747,0.0014899123,0.00019518004,0.00013125238,0.07768183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612296,0.00028609324,0.0004889391,0.00089840253,0.0013448809,0.00085874327],"domain_scores_gemma":[0.995799,0.0014975067,0.00021314812,0.0020023088,0.0002151642,0.00027283968],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000620178,0.00050999166,0.000896127,0.0001442987,0.00029249038,0.00013479471,0.00096384634,0.0017649942,0.006573674],"category_scores_gemma":[0.00072297,0.00027960358,0.00026802026,0.000288596,0.0005526681,0.000051553074,0.00044495557,0.0048365216,0.0026165748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019282279,0.00010650049,0.0006398753,0.00009342603,0.00014954926,0.002094521,0.0010478038,2.9677207e-7,0.0007517574,0.0000016971585,0.92232144,0.07260029],"study_design_scores_gemma":[0.0006327607,0.0027446747,0.0005022687,0.0011244192,0.00029449674,0.00008465634,0.00010341214,0.000012153116,0.0018025782,0.00012670338,0.9922872,0.0002846578],"about_ca_topic_score_codex":0.0035100405,"about_ca_topic_score_gemma":0.00057332206,"teacher_disagreement_score":0.07245019,"about_ca_system_score_codex":0.0018833694,"about_ca_system_score_gemma":0.0015874007,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2132177175","doi":"10.1634/theoncologist.2008-0166","title":"Cancer and Immune Response: Old and New Evidence for Future Challenges","year":2008,"lang":"en","type":"review","venue":"The Oncologist","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; York University; Pfizer Pharmaceuticals; Pfizer","keywords":"Immune system; Medicine; Tumor microenvironment; Antigen; Cancer research; Cancer; Cytotoxic T cell; Immunology; Immunotherapy; Monoclonal antibody; T cell; Tumor antigen; Antigen presentation; Antibody; Biology; Internal medicine","score_opus":0.17279561935091028,"score_gpt":0.3999065979431267,"score_spread":0.22711097859221643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132177175","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002668777,0.9919268,0.0000039649663,0.004913809,0.0012654283,0.0014351874,0.00006477651,0.00006685908,0.000056325014],"genre_scores_gemma":[0.000023849836,0.9711765,0.00004105509,0.0001783633,0.00030158393,0.00045764347,0.000022849401,0.000055690787,0.02774244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971272,0.0012632745,0.0005660462,0.00052771735,0.000038803842,0.00047700581],"domain_scores_gemma":[0.9936027,0.0051998366,0.0004682318,0.00065040967,0.000051702427,0.000027105101],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097038655,0.00054604217,0.0016440767,0.000118043325,0.0006432573,0.00003386546,0.00058696925,0.00094002066,0.000093693845],"category_scores_gemma":[0.00052003196,0.00031860257,0.0003053245,0.00012341116,0.0010281658,0.00009274557,0.00021751516,0.0007052438,0.00004403081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030365807,0.000030988234,5.451465e-7,0.0011684909,0.00056551,0.000005196764,0.00074929284,3.567852e-8,0.00028295853,0.00037756356,0.005977316,0.98780555],"study_design_scores_gemma":[0.00091432105,0.0007283536,0.00032098277,0.0042418637,0.00044846296,0.0008685091,0.00022362854,4.4178947e-8,0.00006159619,0.00004740262,0.9917652,0.00037962984],"about_ca_topic_score_codex":0.00024210272,"about_ca_topic_score_gemma":0.0000386525,"teacher_disagreement_score":0.98742586,"about_ca_system_score_codex":0.00012823909,"about_ca_system_score_gemma":0.0008190558,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W2132357234","doi":"10.1634/theoncologist.2013-0314","title":"An mHealth Model to Increase Clinic Attendance for Breast Symptoms in Rural Bangladesh: Can Bridging the Digital Divide Help Close the Cancer Divide?","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Mobile Health and mHealth Applications","field":"Health Professions","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"Grand Challenges Canada; International Breast Cancer Research Foundation","keywords":"Medicine; mHealth; Attendance; Family medicine; Phone; Breast cancer; Health promotion; Randomized controlled trial; Health care; Nursing; Public health; Cancer; Surgery; Psychological intervention","score_opus":0.05753068777894978,"score_gpt":0.4429766403923279,"score_spread":0.38544595261337816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132357234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7152504,0.00034985912,0.0073923673,0.25986198,0.0007951845,0.012385283,0.0018878817,0.00021953286,0.001857526],"genre_scores_gemma":[0.9276105,0.00019596818,0.000114348004,0.043928694,0.0018117931,0.02510956,0.0000849947,0.00005942007,0.0010846971],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951271,0.0011865433,0.0011833567,0.00058006885,0.00033699258,0.001585947],"domain_scores_gemma":[0.992966,0.004066733,0.00059278397,0.0015110434,0.00019555015,0.00066788646],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.005391389,0.00032186793,0.0005133068,0.00007710877,0.0032760513,0.000066634224,0.0014456323,0.00021416608,0.00006174642],"category_scores_gemma":[0.0007995977,0.00016801916,0.00011433509,0.00047545874,0.00038510576,0.0001483653,0.00030961417,0.0011820626,0.00013109627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011628158,0.0004578547,0.17241253,0.00053693145,0.00003294859,0.0000012259445,0.0048014913,0.0030991898,0.000043232125,0.019150788,0.08113462,0.71716636],"study_design_scores_gemma":[0.005380397,0.001030879,0.6515917,0.0008691493,0.00017113471,0.000023640385,0.004269723,0.082217,0.0000054379084,0.017418843,0.23615286,0.00086920854],"about_ca_topic_score_codex":0.016752334,"about_ca_topic_score_gemma":0.059412263,"teacher_disagreement_score":0.71629715,"about_ca_system_score_codex":0.00085362286,"about_ca_system_score_gemma":0.0021024463,"threshold_uncertainty_score":0.99802154},"labels":[],"label_agreement":null},{"id":"W2132590238","doi":"10.1634/theoncologist.2010-0107","title":"The Invisible Effects of Therapeutic Failure","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics and Legal Issues in Pediatric Healthcare","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.015616589142856945,"score_gpt":0.35310643369741407,"score_spread":0.3374898445545571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132590238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78417414,0.006040817,0.000061937026,0.17219093,0.00231216,0.0013299428,0.0000034578788,0.00009645466,0.03379014],"genre_scores_gemma":[0.9952103,0.00045213217,0.00021040213,0.0019931956,0.00052714045,0.000026168442,0.0000014131518,0.0000107767355,0.0015684649],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991741,0.00011555239,0.00018649966,0.000105239014,0.00021836776,0.00020021149],"domain_scores_gemma":[0.99711776,0.002074969,0.000095306095,0.0005238576,0.0001236346,0.000064452106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010574895,0.00008123757,0.00017405381,0.000018109837,0.00024412455,0.000015618292,0.0002564519,0.00017523748,0.000029525128],"category_scores_gemma":[0.0008809538,0.000034621637,0.00006727059,0.00016294033,0.0005630269,0.000015860813,0.000056234152,0.0010500882,0.000028002027],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068451714,0.000807791,0.05710438,0.0020825018,0.00040081237,0.00017386182,0.009445859,0.0000058824867,0.064228356,0.48941964,0.051114902,0.3245315],"study_design_scores_gemma":[0.0010423587,0.0012884458,0.036864,0.000052494186,0.00017723376,0.000049092156,0.0006199925,0.00007243314,0.007501525,0.013037483,0.93917227,0.00012264866],"about_ca_topic_score_codex":0.00028740076,"about_ca_topic_score_gemma":0.0006150741,"teacher_disagreement_score":0.8880574,"about_ca_system_score_codex":0.000021858239,"about_ca_system_score_gemma":0.0002272299,"threshold_uncertainty_score":0.4562169},"labels":[],"label_agreement":null},{"id":"W2133017309","doi":"10.1634/theoncologist.6-3-257","title":"Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Field cancerization; Lung cancer; Bronchoscopy; Malignancy; Radiology; Autofluorescence; Sputum; Occult; Lung; Cancer; Airway obstruction; Pathology; Airway; Surgery; Internal medicine; Tuberculosis","score_opus":0.0421778709408694,"score_gpt":0.4129237320005013,"score_spread":0.3707458610596319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133017309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000111675545,0.99570656,0.000012506454,0.00042793044,0.00024339552,0.002389803,0.000035866655,0.00000817798,0.0011645792],"genre_scores_gemma":[0.00006177153,0.99894536,0.000057574674,0.00019379877,0.000080650585,0.00053040124,0.000059037255,0.000021978003,0.000049436807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997942,0.0002529485,0.0009775299,0.0002985065,0.00024691946,0.00028214089],"domain_scores_gemma":[0.9985687,0.00018151634,0.00069713197,0.00040233813,0.000096048054,0.000054279633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039254015,0.00026171622,0.0019177673,0.00009987954,0.000016214059,0.0000032068983,0.00021778244,0.0001478145,0.00026801246],"category_scores_gemma":[0.000134176,0.00014933558,0.00020148167,0.0008827972,0.00018402287,0.000052022508,0.000046235713,0.00026111538,0.0000027521396],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003984229,0.00037547352,0.011163768,0.12514189,0.000058481277,0.000018902243,0.00005885643,0.00002137633,5.644223e-8,0.00002839724,0.0014237959,0.8616692],"study_design_scores_gemma":[0.0004810785,0.00021573559,0.00063590327,0.30566606,0.0007187608,0.0000041642306,0.000005841947,0.0000090156245,0.000006025951,0.000004040846,0.69216204,0.000091362395],"about_ca_topic_score_codex":0.0013034026,"about_ca_topic_score_gemma":0.0012928819,"teacher_disagreement_score":0.8615778,"about_ca_system_score_codex":0.0019509374,"about_ca_system_score_gemma":0.0008448464,"threshold_uncertainty_score":0.6089728},"labels":[],"label_agreement":null},{"id":"W2133116306","doi":"10.1634/theoncologist.9-5-561","title":"Management of Bleeding in Patients with Advanced Cancer","year":2004,"lang":"en","type":"review","venue":"The Oncologist","topic":"Spinal Hematomas and Complications","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; MEDLINE; General surgery; Internal medicine","score_opus":0.052212947890718744,"score_gpt":0.40066858651916787,"score_spread":0.34845563862844914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133116306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042445827,0.9910386,0.000011098964,0.00009413525,0.000046707562,0.0014264297,0.000008993342,0.000014794805,0.0069347443],"genre_scores_gemma":[0.0019964185,0.9966058,0.00056626985,0.000020396481,0.000017074346,0.0004655817,0.000020578771,0.000016087763,0.00029175196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930996,0.000013786327,0.00026886348,0.00014882455,0.00013893512,0.00011960371],"domain_scores_gemma":[0.999393,0.00002422515,0.00022640155,0.0002900876,0.000042274256,0.000024040448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007157432,0.00013014536,0.00065951375,0.000053441694,0.000027484031,0.0000026122223,0.00015407283,0.00005299066,0.000029923709],"category_scores_gemma":[0.0000032097519,0.00006473749,0.00007779905,0.00031279738,0.00008290224,0.000011516559,0.000051022686,0.00014861752,0.000008855353],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047131063,0.00025699404,0.0004077995,0.014075633,0.00013067629,0.000010122503,0.000012966035,0.0000072877274,1.35787035e-8,0.002388305,0.000023339437,0.98263973],"study_design_scores_gemma":[0.0021903543,0.00096407783,0.023035387,0.13014966,0.0020429573,0.000009855644,0.00008760824,9.89009e-7,5.7945584e-7,0.00011973537,0.84117985,0.00021891955],"about_ca_topic_score_codex":0.000046038742,"about_ca_topic_score_gemma":0.000014837621,"teacher_disagreement_score":0.9824208,"about_ca_system_score_codex":0.00039885475,"about_ca_system_score_gemma":0.00014772233,"threshold_uncertainty_score":0.26399183},"labels":[],"label_agreement":null},{"id":"W2133193675","doi":"10.1634/theoncologist.12-7-785","title":"First-Line Treatment Options for Patients with HER-2–Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Pfizer","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Adjuvant; Oncology; Adjuvant therapy; Clinical trial; Quality of life (healthcare); Chemotherapy; Cancer; Randomized controlled trial; Internal medicine; Intensive care medicine","score_opus":0.1131886795486073,"score_gpt":0.466774363464914,"score_spread":0.35358568391630674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133193675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010851176,0.98494,0.00013144994,0.0010480393,0.0001544994,0.008474263,0.0038718802,0.000033565277,0.00026121826],"genre_scores_gemma":[0.0034031433,0.9919574,0.00025619255,0.0001079028,0.000281781,0.0023728514,0.000402886,0.00007095688,0.001146856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845594,0.00013969658,0.0005110796,0.00032581974,0.00019203124,0.00037540775],"domain_scores_gemma":[0.9973818,0.0011312593,0.0007146671,0.0004543749,0.00021920398,0.00009866446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021843862,0.0005403591,0.001953226,0.00008811624,0.00019751654,0.000010896681,0.00022809533,0.00012308462,0.00033387815],"category_scores_gemma":[0.000014193382,0.00019111908,0.00082739134,0.00030295126,0.00047833798,0.000027745971,0.000025945175,0.00021378914,0.000005876633],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022007027,0.002955715,0.00028941513,0.0010920017,0.005862131,0.0000076647375,0.00038609758,0.00020450268,2.346837e-7,0.000012169765,0.0012403295,0.985749],"study_design_scores_gemma":[0.033769023,0.03812722,0.007789719,0.005983018,0.042005233,0.00021973446,0.00008840701,0.00046294968,0.000009276451,0.00039587604,0.8703015,0.00084804336],"about_ca_topic_score_codex":0.0021181009,"about_ca_topic_score_gemma":0.0010824562,"teacher_disagreement_score":0.984901,"about_ca_system_score_codex":0.0021652814,"about_ca_system_score_gemma":0.0011379938,"threshold_uncertainty_score":0.779361},"labels":[],"label_agreement":null},{"id":"W2135108459","doi":"10.1634/theoncologist.5-6-471","title":"The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Bladder cancer; Urology; Cystoscopy; Radiation therapy; Concomitant; Cisplatin; Cystectomy; Surgery; Urinary bladder; Chemotherapy; Urinary system; Cancer; Internal medicine","score_opus":0.09270750294284641,"score_gpt":0.3860997258673921,"score_spread":0.2933922229245457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135108459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99227095,0.00075396465,0.000018725392,0.0030153594,0.00018567753,0.0026095272,0.00026747902,0.000025121672,0.00085318775],"genre_scores_gemma":[0.9974539,0.0013011022,0.00000848375,0.00023307443,0.0002162435,0.00047671393,0.000050909366,0.000029467721,0.00023008024],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99692774,0.0012000685,0.0007053377,0.00032374702,0.00051601627,0.00032709763],"domain_scores_gemma":[0.9945543,0.0045477855,0.0004089757,0.00029946555,0.00012600825,0.0000634727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020909673,0.0002707472,0.00054966885,0.000078806625,0.00037048923,0.000030448855,0.00015993702,0.00015071606,0.0001254395],"category_scores_gemma":[0.0005385877,0.00012432563,0.00010929971,0.0004529897,0.00042679804,0.00014942801,0.000016851525,0.00038500456,8.3768265e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8586194,0.0011875469,0.00037173822,0.000022768807,0.0005669504,0.000033254397,0.00832435,0.00013497069,0.0036796334,0.000027232281,0.0034596839,0.123572506],"study_design_scores_gemma":[0.76312935,0.07062022,0.03623755,0.0011688374,0.0014258449,0.00007934706,0.0032800885,0.0027394455,0.10368836,0.00017367894,0.01644246,0.001014841],"about_ca_topic_score_codex":0.0013085299,"about_ca_topic_score_gemma":0.0010869146,"teacher_disagreement_score":0.12255766,"about_ca_system_score_codex":0.00030407854,"about_ca_system_score_gemma":0.00095838215,"threshold_uncertainty_score":0.5069852},"labels":[],"label_agreement":null},{"id":"W2135678986","doi":"10.1634/theoncologist.10-6-412","title":"AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymphoma; Sarcoma; Disease; Immunology; Cancer; Malignancy; Population; Oncology; Internal medicine; Pathology","score_opus":0.08541992104712179,"score_gpt":0.36949023867191405,"score_spread":0.2840703176247923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135678986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011177734,0.97580874,4.386666e-7,0.00297701,0.00020825,0.0014082106,0.000031542546,0.00004539214,0.018402634],"genre_scores_gemma":[0.01647771,0.98231155,0.000016152331,0.00039883037,0.00019455835,0.00016929134,0.000045094628,0.00004804086,0.00033878812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974092,0.0006414431,0.0007414871,0.0003693878,0.00039943034,0.0004390343],"domain_scores_gemma":[0.9980378,0.00046604773,0.0007794012,0.0006130534,0.00006470809,0.000038956252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011317028,0.00042851653,0.0018479156,0.00012755186,0.00011936444,0.000015129815,0.00060190185,0.00049776654,0.00009260204],"category_scores_gemma":[0.00014933347,0.00020298554,0.00060985377,0.0006433088,0.00040309192,0.000057832218,0.00005855728,0.0012929799,0.00002739843],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009783969,0.00025166804,0.000016128877,0.00076049584,0.00032031798,0.00002816984,0.0019756204,0.0000027618466,0.0000018981337,0.0007080865,0.00073013536,0.9951069],"study_design_scores_gemma":[0.0020729566,0.0020063508,0.0003028211,0.004786115,0.0007270323,0.00003074915,0.0045897835,0.0000033795684,0.00000256364,0.0001795032,0.98502094,0.00027782502],"about_ca_topic_score_codex":0.00032553432,"about_ca_topic_score_gemma":0.0001432093,"teacher_disagreement_score":0.99482906,"about_ca_system_score_codex":0.0004934264,"about_ca_system_score_gemma":0.0006161162,"threshold_uncertainty_score":0.827751},"labels":[],"label_agreement":null},{"id":"W2135743613","doi":"10.1634/theoncologist.12-9-1035","title":"Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Waterloo","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Breast cancer; Internal medicine; Bisphosphonate; N-terminal telopeptide; Oncology; Post-hoc analysis; Creatinine; Multiple myeloma; Bone metastasis; Metastatic breast cancer; Hazard ratio; Cancer; Osteoporosis; Urology; Surgery; Confidence interval; Alkaline phosphatase; Osteocalcin","score_opus":0.015697575009305784,"score_gpt":0.30163218920294516,"score_spread":0.28593461419363936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135743613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979039,0.00033082845,0.0000041432263,0.0009078518,0.000037802038,0.0004448636,0.00008365088,0.000011432447,0.00027553207],"genre_scores_gemma":[0.9996036,0.00014768023,0.000048698203,0.00010240643,0.0000087423905,0.000014065982,0.000011212387,0.00000894461,0.00005459222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924105,0.0000696513,0.00015776078,0.00014937317,0.00014381346,0.00023837478],"domain_scores_gemma":[0.9994798,0.00013273205,0.00011453417,0.000120280885,0.000048576047,0.00010409566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004007996,0.000110120774,0.00029895816,0.000052217627,0.00005035576,0.0000036747608,0.000025094378,0.00004958699,0.000021442818],"category_scores_gemma":[0.000019940991,0.0000614232,0.000013935734,0.00015635884,0.0002751474,0.000044027995,0.000030291218,0.00013172257,7.844372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007693669,0.0004636952,0.9664475,0.0000690619,0.00007186394,0.000030302492,0.00005888809,4.900942e-7,0.0004235584,0.000006149753,0.000026493026,0.02470837],"study_design_scores_gemma":[0.0057576806,0.00093178765,0.9921776,0.00006431407,0.0001158819,0.000025973988,0.00009039496,0.000009813898,0.0006956768,0.000004966337,0.00007040455,0.00005550763],"about_ca_topic_score_codex":0.003994483,"about_ca_topic_score_gemma":0.00866829,"teacher_disagreement_score":0.02573014,"about_ca_system_score_codex":0.00013775459,"about_ca_system_score_gemma":0.00013041408,"threshold_uncertainty_score":0.603849},"labels":[],"label_agreement":null},{"id":"W2136121072","doi":"10.1634/theoncologist.2013-0343","title":"Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Residence; Rural area; Confidence interval; Hazard ratio; Diffuse large B-cell lymphoma; Cancer registry; Demography; Cancer; Lymphoma; Internal medicine; Pathology","score_opus":0.006921278772214086,"score_gpt":0.24701985129497664,"score_spread":0.24009857252276257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136121072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983286,0.00006034771,1.7502741e-7,0.00009021408,0.000030582723,0.00072702277,0.000027695127,0.0000070643055,0.00072829565],"genre_scores_gemma":[0.9995048,0.00006699903,0.00001833543,0.000042231975,0.0000058162664,0.000067646884,0.000009568674,0.000008817949,0.00027580117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902266,0.00024386612,0.00021310548,0.0001786058,0.00018000127,0.0001617716],"domain_scores_gemma":[0.9985477,0.0010376435,0.00011690965,0.00023611303,0.00002161213,0.000040051887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003533274,0.000101811325,0.0005428338,0.000029501129,0.000027313523,0.000012091713,0.00005791881,0.000051963387,0.00000720055],"category_scores_gemma":[0.00013138838,0.00007035921,0.000038310012,0.00008687208,0.00012866703,0.000018647735,0.00003021195,0.000028637329,0.0000017700706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091442064,0.0096120825,0.97557145,0.000046170364,0.000028081495,0.000036230147,0.00010260801,0.0000021141407,0.000005283741,0.000008159672,0.00004522548,0.013628187],"study_design_scores_gemma":[0.05821368,0.014507005,0.92635155,0.0002012995,0.00007286193,0.0000017721067,0.000034466648,0.000013884055,0.0004985019,0.000004560212,0.00004484462,0.00005559177],"about_ca_topic_score_codex":0.029659165,"about_ca_topic_score_gemma":0.11364881,"teacher_disagreement_score":0.08398964,"about_ca_system_score_codex":0.00029236524,"about_ca_system_score_gemma":0.000043702326,"threshold_uncertainty_score":0.9768024},"labels":[],"label_agreement":null},{"id":"W2139768542","doi":"10.1634/theoncologist.2013-0173","title":"Lost in Transition? Thoughts on Retirement—“Will You Still Need Me, Will You Still Feed Me, When I'm Sixty-Four?”","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Ottawa Hospital; Credit Valley Hospital; University of Ottawa","funders":"","keywords":"Transition (genetics); Plan (archaeology); Psychology; Gerontology; Business; Medicine; History","score_opus":0.02565525011998069,"score_gpt":0.3326521737490066,"score_spread":0.30699692362902586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139768542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8543211,0.0016480658,0.0023735778,0.089769475,0.002949615,0.0046186517,0.00009225063,0.0003927363,0.043834515],"genre_scores_gemma":[0.9649835,0.0011180714,0.003838854,0.012424428,0.0022287949,0.00022767932,0.000054632972,0.000085206666,0.015038785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969824,0.00044989624,0.000703365,0.000633853,0.00048748558,0.00074297545],"domain_scores_gemma":[0.9977231,0.00072753325,0.00029075547,0.0008664862,0.00017434367,0.00021775728],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000838857,0.00047252027,0.00085394346,0.00019616706,0.00021770153,0.000033970286,0.0005200691,0.00047529206,0.0014432066],"category_scores_gemma":[0.0002975392,0.00029772086,0.00019295921,0.00040001175,0.0010891162,0.00035124758,0.0000565611,0.00095880823,0.00040580594],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04694873,0.026514748,0.08898117,0.0014022515,0.0044727875,0.005278433,0.09862545,0.0130619295,0.119930044,0.0306833,0.4046267,0.15947446],"study_design_scores_gemma":[0.032453258,0.015862081,0.1043684,0.0009802029,0.00084869214,0.0005255546,0.0069578495,0.0039025294,0.0055432296,0.034898292,0.7914639,0.0021960235],"about_ca_topic_score_codex":0.0002734241,"about_ca_topic_score_gemma":0.00034354618,"teacher_disagreement_score":0.38683718,"about_ca_system_score_codex":0.00079599646,"about_ca_system_score_gemma":0.00020084102,"threshold_uncertainty_score":0.9999475},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.13005089114996987,"score_gpt":0.5312090846097777,"score_spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139939379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048244226,0.9918813,0.000028822333,0.0023140938,0.00042432974,0.0030508095,0.000039890565,0.000024520607,0.002187969],"genre_scores_gemma":[0.0005840316,0.99723613,0.000105319465,0.00032259975,0.00019930532,0.00030141618,0.00006199741,0.000021867354,0.001167357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979765,0.00029380576,0.0009788941,0.00026837373,0.00024267318,0.00023977231],"domain_scores_gemma":[0.9967241,0.0013604834,0.00092455756,0.0007104091,0.0002133877,0.000067018045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043846876,0.000319641,0.0028347464,0.00009321517,0.00019697845,0.0000062761032,0.00037238843,0.0000825932,0.00004308552],"category_scores_gemma":[0.0009386429,0.00013271965,0.00064448337,0.0004353654,0.00039954652,0.000013878963,0.00012709846,0.0002515511,0.000008685005],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001169376,0.00045158205,0.000001191399,0.014968085,0.0014519069,0.000016309745,0.00013366864,1.00254624e-7,0.0000018522758,0.0003201208,0.00931328,0.97322494],"study_design_scores_gemma":[0.0033865098,0.0011549103,0.000008244431,0.06865012,0.01647945,0.00005038065,0.00014018235,3.2998352e-7,0.0000023239222,0.000026378353,0.9099799,0.00012128362],"about_ca_topic_score_codex":0.000072859875,"about_ca_topic_score_gemma":0.000033639237,"teacher_disagreement_score":0.9731037,"about_ca_system_score_codex":0.0005451803,"about_ca_system_score_gemma":0.0006003399,"threshold_uncertainty_score":0.54121506},"labels":[],"label_agreement":null},{"id":"W2140300450","doi":"10.1634/theoncologist.2007-0185","title":"The Ethical Justification for Minor Sibling Bone Marrow Donation: A Case Study","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Sibling; Minor (academic); Donation; Medicine; Sister; Duty; Bone marrow; Surgery; Family medicine; Immunology; Developmental psychology; Psychology; Law","score_opus":0.3481356631908239,"score_gpt":0.4929653174632175,"score_spread":0.14482965427239358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140300450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97436494,0.0013155796,0.00069544243,0.02060292,0.00021127918,0.0010537477,0.000007001428,0.00003803538,0.0017110304],"genre_scores_gemma":[0.9957492,0.00028758857,0.0011090545,0.00054799416,0.00030479935,0.00016116691,0.000008797947,0.000008386648,0.0018230092],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991598,0.00012100714,0.00025330912,0.00013655683,0.00019376336,0.00013553121],"domain_scores_gemma":[0.9975122,0.0017794272,0.00012407741,0.00027996968,0.00026560476,0.000038686023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097493216,0.00008046612,0.00018674514,0.00003186457,0.00045224742,0.000009398065,0.00010077281,0.00009864607,0.000010203213],"category_scores_gemma":[0.0015196659,0.000041269726,0.00006869968,0.00017091515,0.0003546041,0.000019276084,0.000027287615,0.00024151544,0.000008479859],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010890622,0.007546323,0.26771358,0.0008862652,0.001742084,0.012715285,0.18951303,0.00037415093,0.014744862,0.017695362,0.28662944,0.18954898],"study_design_scores_gemma":[0.013970198,0.008100725,0.046894666,0.0003417094,0.0016783971,0.0068053342,0.19038048,0.004403722,0.0065479805,0.0013214084,0.71893144,0.00062396005],"about_ca_topic_score_codex":0.0002562039,"about_ca_topic_score_gemma":0.000415932,"teacher_disagreement_score":0.43230197,"about_ca_system_score_codex":0.00007712761,"about_ca_system_score_gemma":0.0001189242,"threshold_uncertainty_score":0.34783673},"labels":[],"label_agreement":null},{"id":"W2142170680","doi":"10.1634/theoncologist.2011-0237","title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Angiosarcoma; Medicine; Sorafenib; Sarcoma; Soft tissue sarcoma; Clinical endpoint; Internal medicine; Surgery; Toxicity; Oncology; Chemotherapy; Clinical trial; Pathology; Hepatocellular carcinoma","score_opus":0.022873127416478768,"score_gpt":0.29801002391551856,"score_spread":0.2751368964990398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142170680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900924,0.0015550652,0.0006054003,0.0032311569,0.000597955,0.0030590033,0.00013697472,0.00009354351,0.0006284835],"genre_scores_gemma":[0.9938969,0.000017825187,0.0022732832,0.001146978,0.0014708694,0.00039483522,0.00036057524,0.00004538592,0.00039334153],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982258,0.00015100367,0.00033533984,0.0002927571,0.00038844213,0.0006066605],"domain_scores_gemma":[0.99824476,0.00053012784,0.00021188128,0.0007377879,0.00010304645,0.00017237852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056468946,0.0002807323,0.00048076495,0.000031647916,0.0005967571,0.000029430936,0.00037022989,0.00010366675,0.00010413441],"category_scores_gemma":[0.00027636127,0.00012626502,0.00033138893,0.00020595218,0.0003290772,0.0001376975,0.00014087821,0.00026786188,0.000025539573],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21760046,0.069348685,0.15562153,0.00015216431,0.0028565193,0.00012034699,0.009987747,0.000012193742,0.0037453533,0.005735107,0.13295409,0.4018658],"study_design_scores_gemma":[0.4133177,0.03521223,0.19404791,0.00017235908,0.0016592598,0.000035356905,0.0008777402,0.00013258477,0.0004458637,0.0010645876,0.3523201,0.0007143124],"about_ca_topic_score_codex":0.00022810219,"about_ca_topic_score_gemma":0.00012249497,"teacher_disagreement_score":0.40115148,"about_ca_system_score_codex":0.00010751453,"about_ca_system_score_gemma":0.00008473209,"threshold_uncertainty_score":0.51489383},"labels":[],"label_agreement":null},{"id":"W2143006986","doi":"10.1634/theoncologist.2010-0263","title":"Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"Genentech; GlaxoSmithKline; Pfizer","keywords":"Sunitinib; Medicine; Dosing; Renal cell carcinoma; Intensive care medicine; Tyrosine-kinase inhibitor; Toxicity; Oncology; Internal medicine; Cancer","score_opus":0.20589735659080372,"score_gpt":0.37857232910030164,"score_spread":0.17267497250949793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143006986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002228863,0.9690383,0.00011607671,0.00011739892,0.00016650188,0.004404604,0.00016034726,0.000020886278,0.025752977],"genre_scores_gemma":[0.0014812172,0.9868333,0.005782584,0.000037441238,0.000080731545,0.0018549281,0.0004905438,0.00006315984,0.0033761018],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977276,0.0004139904,0.00092452427,0.000373772,0.00021240306,0.00034772695],"domain_scores_gemma":[0.9979677,0.00047730753,0.00049869344,0.00089392817,0.00008934027,0.000073032716],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010598795,0.00041145174,0.0021842706,0.000244664,0.000073588024,0.000010468733,0.0003486465,0.00013663019,0.000113701026],"category_scores_gemma":[0.000026716858,0.00024823679,0.0011948983,0.00031792466,0.00022631855,0.000027581582,0.00014496138,0.00030209686,0.00003083713],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015381309,0.0008669683,0.000011906734,0.052027747,0.0021128026,0.00042221285,0.0003633979,0.0000028183758,0.0000010708341,0.0016561351,0.00394697,0.9384342],"study_design_scores_gemma":[0.0017531287,0.0008860298,0.000103213686,0.0044205794,0.011708489,0.00011894578,0.0005671959,0.0000016976112,0.00006891748,0.0001511128,0.9799892,0.00023154807],"about_ca_topic_score_codex":0.00020740947,"about_ca_topic_score_gemma":0.000032665197,"teacher_disagreement_score":0.97604215,"about_ca_system_score_codex":0.0005490051,"about_ca_system_score_gemma":0.0002973305,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W2143008582","doi":"10.1634/theoncologist.2013-0390","title":"Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"Terry Fox Research Institute; Canada Research Chairs; Genome British Columbia; Genome Canada","keywords":"Transcriptome; Medicine; DNA sequencing; Genome; Precision medicine; Cancer; Personalized medicine; SMARCB1; Computational biology; Oncology; Bioinformatics; Genetics; Pathology; Internal medicine; Gene; Biology","score_opus":0.05352112794267109,"score_gpt":0.2999288822729578,"score_spread":0.2464077543302867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143008582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968294,0.00021252579,0.0018443263,0.000083377425,0.00011205613,0.00009661446,0.0000029650355,0.000007081406,0.0008116525],"genre_scores_gemma":[0.99856824,0.000031166826,0.00061626674,0.0003062986,0.00036970963,0.000015396223,0.000034620934,0.000008813232,0.00004946564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934787,0.0001429902,0.00016719251,0.00015469124,0.000069977585,0.00011730329],"domain_scores_gemma":[0.9995721,0.00005101004,0.00007637157,0.00024152161,0.00003488526,0.000024109997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040353654,0.00007242568,0.000100287994,0.000012605208,0.000044726803,0.00001265262,0.00015343676,0.000055112672,0.0000061520554],"category_scores_gemma":[0.00034333798,0.000052926644,0.000028951607,0.000049406095,0.00009290185,0.0000031281668,0.00003911196,0.000058825477,0.000002781013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019647427,0.000031030748,0.0015628727,0.000010968808,0.00000458553,0.0000010446465,0.00009810509,0.03244934,0.960567,0.00036148744,0.00018712884,0.0047068195],"study_design_scores_gemma":[0.0010770948,0.0016394539,0.008470537,0.000050556457,0.00003770005,0.000023090697,0.0005689612,0.18467858,0.80023926,0.00095089,0.0019414301,0.0003224635],"about_ca_topic_score_codex":0.00032896711,"about_ca_topic_score_gemma":0.0007974966,"teacher_disagreement_score":0.16032773,"about_ca_system_score_codex":0.000057048284,"about_ca_system_score_gemma":0.00012129455,"threshold_uncertainty_score":0.2158286},"labels":[],"label_agreement":null},{"id":"W2143013795","doi":"10.1634/theoncologist.2015-0008","title":"Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Oncology; Cancer; Pharmacology; Intensive care medicine; Internal medicine; Medical physics","score_opus":0.9526026533308177,"score_gpt":0.7811456566783852,"score_spread":0.17145699665243253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143013795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93317574,0.0008564728,0.033187974,0.01361251,0.003935706,0.00929845,0.0007377764,0.00015808358,0.0050372775],"genre_scores_gemma":[0.7115814,0.00015644604,0.28441986,0.0009855578,0.0016346086,0.00090339885,0.000002974493,0.00006115763,0.0002545872],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9887731,0.0059573716,0.0041181566,0.00038706147,0.0003155613,0.00044876485],"domain_scores_gemma":[0.67537636,0.32232815,0.0013659338,0.0005255276,0.00019100323,0.00021302246],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0858764,0.00019877678,0.0019021658,0.00007550434,0.000058767597,0.000021625234,0.00054270035,0.0002817732,0.00013694017],"category_scores_gemma":[0.5888545,0.00012532661,0.00028566862,0.00031065533,0.00068978185,0.000045665147,0.00015085415,0.0005099968,0.000006157949],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017224401,0.016579904,0.03536968,0.0013946285,0.00056745665,0.00008776113,0.0017611466,0.00031925098,0.0031198158,0.621682,0.029677946,0.27221602],"study_design_scores_gemma":[0.02567507,0.0012819354,0.0008961904,0.00021197116,0.0002608516,4.0873414e-7,0.0002097055,0.0021876586,0.0014968703,0.9604361,0.0071193064,0.00022392513],"about_ca_topic_score_codex":0.0003262133,"about_ca_topic_score_gemma":0.00097064726,"teacher_disagreement_score":0.5029781,"about_ca_system_score_codex":0.00020527384,"about_ca_system_score_gemma":0.00024048254,"threshold_uncertainty_score":0.94128263},"labels":[],"label_agreement":null},{"id":"W2143483266","doi":"10.1634/theoncologist.11-5-488","title":"Primary Mediastinal Large B-Cell Lymphoma","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Cancer research; Oncology; Internal medicine","score_opus":0.051360434164611356,"score_gpt":0.350298974765783,"score_spread":0.29893854060117164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143483266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027532282,0.8802553,0.0000034893826,0.00025511865,0.00036300468,0.0012462818,0.00012413936,0.000101167905,0.11762398],"genre_scores_gemma":[0.0000647275,0.9875488,0.00020182361,0.00062567875,0.00095187896,0.00053766504,0.0009014849,0.000062951854,0.009104954],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99782234,0.00020291211,0.00061563007,0.00045417293,0.0003869401,0.0005179828],"domain_scores_gemma":[0.9979427,0.0006623587,0.0004330945,0.00077004224,0.000050460658,0.00014133344],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004294306,0.00053054764,0.0020680204,0.00008895083,0.00018015607,0.00003526672,0.0003402487,0.00038505957,0.00014831053],"category_scores_gemma":[0.000054888656,0.00025934246,0.00080561533,0.00024997926,0.00021878898,0.000022472801,0.00019878427,0.00020955855,0.0011830527],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002161828,0.0037485333,0.000063731706,0.0054764366,0.00017369307,0.00086411205,0.0000121278745,3.389251e-8,6.2990665e-8,0.00016306528,0.071579814,0.91789675],"study_design_scores_gemma":[0.00370566,0.00042535202,0.00084646733,0.0027837143,0.003925146,0.00061902095,0.0000085599795,6.3880833e-7,0.0000012300842,0.00001497687,0.98742837,0.00024088149],"about_ca_topic_score_codex":0.00012810239,"about_ca_topic_score_gemma":0.000032260115,"teacher_disagreement_score":0.9176559,"about_ca_system_score_codex":0.0016023683,"about_ca_system_score_gemma":0.0013916912,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W2144226378","doi":"10.1634/theoncologist.2011-0011","title":"<i>KRAS</i> and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Food and Drug Administration; National Comprehensive Cancer Network","keywords":"Panitumumab; KRAS; Medicine; Cetuximab; Colorectal cancer; Timeline; Clinical trial; Vetting; Oncology; Internal medicine; Cancer","score_opus":0.24113086418533014,"score_gpt":0.5272951237733174,"score_spread":0.2861642595879873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144226378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95455813,0.006574801,3.6226606e-7,0.02758857,0.00015811104,0.0016240478,0.0000068867503,0.000030501775,0.00945859],"genre_scores_gemma":[0.9537882,0.04275358,0.0006361672,0.0019725738,0.00023096551,0.0005320886,0.0000023038476,0.000013514997,0.00007060681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588567,0.0027836442,0.0006176321,0.0003379456,0.00011754284,0.0002575432],"domain_scores_gemma":[0.987373,0.012089655,0.00028266374,0.00010775306,0.000048499947,0.00009843065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010187769,0.00017668294,0.0011427768,0.00006254479,0.000105553736,0.000016188173,0.000050815557,0.00033752542,0.000035754238],"category_scores_gemma":[0.007443794,0.00010410146,0.00004133045,0.000146231,0.0007113165,0.000073706455,0.00013482406,0.0006626331,0.000002949946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022431845,0.0016387814,0.5134592,0.00031811578,0.0005417898,0.0010155509,0.04902834,2.0306248e-7,0.0013929524,0.0008137624,0.0014345183,0.40792492],"study_design_scores_gemma":[0.009105554,0.009732413,0.9686298,0.00032414895,0.0006617689,0.0003843194,0.0030437154,0.00016509813,0.00014015967,0.0004452636,0.007153212,0.0002145471],"about_ca_topic_score_codex":0.01244284,"about_ca_topic_score_gemma":0.013151566,"teacher_disagreement_score":0.45517057,"about_ca_system_score_codex":0.00019460829,"about_ca_system_score_gemma":0.00013512904,"threshold_uncertainty_score":0.9941334},"labels":[],"label_agreement":null},{"id":"W2144498495","doi":"10.1634/theoncologist.2012-0342","title":"Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; World Bank Group; GlaxoSmithKline","keywords":"Medicine; Trastuzumab; Institutional review board; Lapatinib; Clinical trial; Breast cancer; Interquartile range; Randomized controlled trial; Informed consent; Internal medicine; Cancer; Surgery; Alternative medicine","score_opus":0.1228155068648815,"score_gpt":0.4756288442860815,"score_spread":0.35281333742119997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144498495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980798,0.00034491208,0.0011247726,0.015718354,0.00018209624,0.0015938869,0.00016655435,0.000026531652,0.00004488048],"genre_scores_gemma":[0.99633753,0.00047928802,0.0008307553,0.0010379591,0.00026600293,0.0008022986,0.00003496645,0.000009123079,0.00020209556],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984274,0.00019124943,0.0006315945,0.0003066978,0.00022804196,0.00021500974],"domain_scores_gemma":[0.9987829,0.00034102474,0.0002646164,0.0003656036,0.00014105193,0.00010483939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031701737,0.00017623855,0.0006837583,0.000064273976,0.00008320784,0.00001564968,0.00017737722,0.00007381519,0.00044962266],"category_scores_gemma":[0.000099201585,0.000081170176,0.00014145211,0.00076300366,0.00051085936,0.00007228844,0.000049717833,0.00009236022,0.0000031011232],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25806212,0.0022734688,0.02676769,0.000014432714,0.0016210757,0.00002063676,0.010265158,0.035782613,0.0001339712,0.000079614845,0.00082447374,0.66415477],"study_design_scores_gemma":[0.40481713,0.01963179,0.3605564,0.0003005687,0.0053868196,0.0002775337,0.028208096,0.17046171,0.00014055194,0.0001273858,0.009267543,0.00082446064],"about_ca_topic_score_codex":0.0039367476,"about_ca_topic_score_gemma":0.001568009,"teacher_disagreement_score":0.6633303,"about_ca_system_score_codex":0.00041466294,"about_ca_system_score_gemma":0.00029858443,"threshold_uncertainty_score":0.5951211},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","score_opus":0.2509656558099983,"score_gpt":0.5050140510855577,"score_spread":0.25404839527555945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144648936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085443025,0.97499794,0.000015735128,0.00081785355,0.0016866432,0.004815883,0.00015956798,0.00025714678,0.016394807],"genre_scores_gemma":[0.001170985,0.9925544,0.0003061966,0.0006061313,0.0016977626,0.00031986064,0.0002365285,0.00015617172,0.002951924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99201244,0.002213276,0.0023969477,0.0009924154,0.0010849261,0.0012999641],"domain_scores_gemma":[0.9941779,0.0033101446,0.00072921434,0.0011742662,0.00015161111,0.00045686404],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005214107,0.00069312984,0.00323603,0.00032711047,0.0001877309,0.00010485001,0.001084568,0.0011733877,0.0009907439],"category_scores_gemma":[0.0025960836,0.00045674888,0.0007404728,0.0009537217,0.0008560323,0.000096061915,0.00044769832,0.0034408972,0.0005204474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015343732,0.0008835969,0.0007536177,0.007352759,0.00042767808,0.0024838615,0.00019651666,5.363864e-7,2.443877e-7,0.0001816145,0.014480523,0.97308564],"study_design_scores_gemma":[0.00097463786,0.0015857074,0.00055799703,0.013269978,0.00049689546,0.00021279854,0.00023124268,0.00001830358,0.0000011456889,0.000082096245,0.98206234,0.00050688087],"about_ca_topic_score_codex":0.00044118165,"about_ca_topic_score_gemma":0.0005070983,"teacher_disagreement_score":0.97257876,"about_ca_system_score_codex":0.004655972,"about_ca_system_score_gemma":0.00116641,"threshold_uncertainty_score":0.9999225},"labels":[],"label_agreement":null},{"id":"W2145295241","doi":"10.1634/theoncologist.2009-0265","title":"Changes in Functional Performance Measures in Adults Undergoing Chemoradiation for Primary Malignant Glioma: A Feasibility Study","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health","keywords":"Medicine; Cohort; Quality of life (healthcare); Glioma; Cardiorespiratory fitness; Prospective cohort study; Internal medicine; Physical therapy; Cohort study; Magnetic resonance imaging; Radiology","score_opus":0.0867454477016953,"score_gpt":0.35122269367165077,"score_spread":0.2644772459699555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145295241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952,0.000061255945,0.00002914718,0.0075794994,0.00032098158,0.0018138341,0.0000033772783,0.00003352138,0.0006383874],"genre_scores_gemma":[0.99817294,0.000036224952,0.0003739711,0.0007379357,0.0002490862,0.00033785004,0.000016275202,0.000008100505,0.00006761418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991184,0.00006206331,0.00023720674,0.00020239061,0.00017430783,0.00020564478],"domain_scores_gemma":[0.9993851,0.00023079955,0.00008163602,0.00018452325,0.00007320513,0.00004472055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016637426,0.00008394191,0.0002036742,0.000118105745,0.00011182904,0.000009192869,0.00006706138,0.00006893174,0.000023770557],"category_scores_gemma":[0.0002889104,0.00005872859,0.000023964705,0.00021366001,0.00007146693,0.000047418038,0.000022955026,0.00028594772,0.0000045990746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033209235,0.0017517398,0.9747646,0.0006296283,0.0000075707517,0.0000141295895,0.0010388311,0.000013697531,0.0053031445,0.00012609606,0.00024619023,0.012783489],"study_design_scores_gemma":[0.006714,0.00081466883,0.9898534,0.00013548581,0.000011596788,0.000021047437,0.00089934195,0.0004895051,0.0004808604,0.00017100289,0.0003433397,0.00006575046],"about_ca_topic_score_codex":0.00011169846,"about_ca_topic_score_gemma":0.017087689,"teacher_disagreement_score":0.01697599,"about_ca_system_score_codex":0.00034835492,"about_ca_system_score_gemma":0.00023873571,"threshold_uncertainty_score":0.9535331},"labels":[],"label_agreement":null},{"id":"W2145362773","doi":"10.1634/theoncologist.6-4-353","title":"Hormone Replacement in Women with a History of Breast Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hormone replacement therapy (female-to-male); Estrogen; Menopause; Endometrial cancer; Internal medicine; Osteoporosis; Cancer; Oncology; Hypoestrogenism; Gynecology; Testosterone (patch)","score_opus":0.0196726031997262,"score_gpt":0.2962291045613742,"score_spread":0.276556501361648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145362773","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015621154,0.9928984,0.0000022277602,0.000044573855,0.00010940439,0.0005699589,0.00002932994,0.000007118408,0.004776887],"genre_scores_gemma":[0.00039020952,0.99375355,0.000014832861,0.00006156217,0.00013017355,0.00043062362,0.000037539332,0.00002927283,0.005152228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987558,0.00020099385,0.00032777767,0.00031210904,0.000115025876,0.00028830694],"domain_scores_gemma":[0.99906033,0.000025800862,0.00035306532,0.00047519105,0.000031801927,0.000053778815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036116343,0.0002663505,0.00072030385,0.00005285618,0.000021062839,0.0000035913615,0.00032398565,0.00036688705,0.000035408273],"category_scores_gemma":[0.000011660987,0.00014310227,0.00011261327,0.00015051935,0.0002987544,0.0000011963233,0.00011320154,0.0003030141,0.0000066240627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018490453,0.00038720755,0.000034335757,0.0021789067,0.00076952844,0.00006986102,0.00014390935,0.000022348046,0.00059112435,0.000020483285,0.033828244,0.960105],"study_design_scores_gemma":[0.0005554897,0.0009584085,0.000054894226,0.0008353328,0.00019555014,0.0001515295,0.000025425148,7.4033125e-7,0.0000065614117,0.0000016124029,0.99701756,0.00019687026],"about_ca_topic_score_codex":0.00020599723,"about_ca_topic_score_gemma":0.00004964968,"teacher_disagreement_score":0.96318936,"about_ca_system_score_codex":0.00090650126,"about_ca_system_score_gemma":0.00095767353,"threshold_uncertainty_score":0.58355415},"labels":[],"label_agreement":null},{"id":"W2146383436","doi":"10.1634/theoncologist.9-90005-70","title":"Epoetin Alfa: Future Directions and Future Research","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Epoetin alfa; Intensive care medicine; Erythropoietin; MEDLINE; Internal medicine","score_opus":0.05167018119413207,"score_gpt":0.38307059997183895,"score_spread":0.3314004187777069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146383436","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36316076,0.013190726,0.0000035973683,0.5396091,0.00067524903,0.000614989,0.000007485282,0.00013965186,0.08259847],"genre_scores_gemma":[0.93418723,0.035244167,0.003278031,0.001976899,0.00895033,0.00014079706,0.000030352658,0.000037781178,0.016154408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991606,0.0000877725,0.00010704739,0.0001902016,0.00020975634,0.00024466382],"domain_scores_gemma":[0.99942905,0.00009481439,0.000025840507,0.000275442,0.00007670705,0.00009812364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044038237,0.00009673366,0.00015487679,0.000043065516,0.0004669673,0.000021396214,0.00007220382,0.00011685345,0.00015448325],"category_scores_gemma":[0.00004540027,0.000051291016,0.000046538265,0.00022933369,0.000497902,0.000018730323,0.00005766578,0.0004422648,0.00010737984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012369995,0.004128374,0.0144129,0.0002877114,0.00049943465,0.0018586065,0.013841248,0.000009000176,0.0054518688,0.07850725,0.23166403,0.6481026],"study_design_scores_gemma":[0.0015092095,0.00075229874,0.028773926,0.000033226665,0.000051784475,0.0003755458,0.006024983,7.3549654e-7,0.00046659552,0.0011947715,0.9607512,0.00006571845],"about_ca_topic_score_codex":0.00027106455,"about_ca_topic_score_gemma":0.00024203525,"teacher_disagreement_score":0.7290872,"about_ca_system_score_codex":0.00022826245,"about_ca_system_score_gemma":0.00013406848,"threshold_uncertainty_score":0.35915822},"labels":[],"label_agreement":null},{"id":"W2147758491","doi":"10.1634/theoncologist.2009-s503","title":"Pathophysiology and Animal Models of Cancer-Related Painful Peripheral Neuropathy","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Pain Mechanisms and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; Louise and Alan Edwards Foundation; Canada Research Chairs","keywords":"Medicine; Pathophysiology; Peripheral neuropathy; Neuropathic pain; Cancer; Chemotherapy; Bioinformatics; Inflammation; Neuroscience; Pathology; Anesthesia; Surgery; Internal medicine; Diabetes mellitus","score_opus":0.05423585709037299,"score_gpt":0.3663754116518573,"score_spread":0.3121395545614843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147758491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030578251,0.9944622,0.000007106384,0.00014801955,0.0002510074,0.0009540365,0.000059851878,0.000052502997,0.0010074475],"genre_scores_gemma":[0.0020998723,0.99665034,0.00032616395,0.0001556028,0.00011820442,0.00015297928,0.000038159,0.000041986015,0.00041668117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985449,0.00032820943,0.0004305027,0.00033086978,0.00011967749,0.00024588514],"domain_scores_gemma":[0.9988447,0.00020290575,0.00039647575,0.0004189187,0.000051577623,0.000085457126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032909453,0.0003243905,0.0015769539,0.00004950487,0.00008492135,0.000007051603,0.00017137003,0.00044767815,0.00006287273],"category_scores_gemma":[0.000054636173,0.00016828006,0.00027063015,0.00012535918,0.00028714075,0.000021395408,0.00011143337,0.00062969833,0.00000765744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006350454,0.00022952807,0.0000150166015,0.002165285,0.000266086,0.00015561562,0.00010638326,0.0000013616796,0.0001317885,0.0010894738,0.000071979804,0.995704],"study_design_scores_gemma":[0.0023321174,0.0049185,0.0003610654,0.00426021,0.0072861887,0.00037750218,0.000047950874,0.0010531127,0.000010300957,0.004300729,0.97451437,0.00053792883],"about_ca_topic_score_codex":0.00017347759,"about_ca_topic_score_gemma":0.000025583584,"teacher_disagreement_score":0.99516606,"about_ca_system_score_codex":0.00009743982,"about_ca_system_score_gemma":0.00034828138,"threshold_uncertainty_score":0.6862262},"labels":[],"label_agreement":null},{"id":"W2148381189","doi":"10.1634/theoncologist.2008-0018","title":"Homage to Judah Folkman","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Jewish and Middle Eastern Studies","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09070523643718799,"score_gpt":0.34614805340371024,"score_spread":0.25544281696652227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148381189","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4156767,0.00046997023,0.00012927265,0.01180139,0.00065108493,0.00024087359,0.0000032463033,0.00009213301,0.5709353],"genre_scores_gemma":[0.9520965,0.000064434586,0.00013259768,0.0012315417,0.00044206026,0.000022782147,4.158446e-7,0.0000038829635,0.046005756],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928564,0.00010411239,0.00007850766,0.00010563842,0.00017178187,0.00025433925],"domain_scores_gemma":[0.9996129,0.000109752385,0.000028630631,0.00013672377,0.000036323472,0.00007563482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003626355,0.000056116685,0.000096763935,0.00001659105,0.0010401512,0.000018906303,0.00029567527,0.000028516984,0.000038569142],"category_scores_gemma":[0.0001756856,0.00003666776,0.00003859277,0.00016351182,0.00056826416,0.00004191099,0.00009459231,0.00006345294,0.0006207669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006286131,0.0003199192,0.32110494,0.00000663281,0.00009752227,0.00017156932,0.09031219,0.000014329772,0.00027000767,0.1781678,0.2836007,0.12587154],"study_design_scores_gemma":[0.00018234794,0.000116884745,0.060574483,0.00000453143,0.0000111621775,0.0000035962319,0.016352843,5.64889e-7,0.000038958824,0.0033885892,0.9191981,0.00012792046],"about_ca_topic_score_codex":0.0022207752,"about_ca_topic_score_gemma":0.008214009,"teacher_disagreement_score":0.6355974,"about_ca_system_score_codex":0.00005798638,"about_ca_system_score_gemma":0.00008538352,"threshold_uncertainty_score":0.80001074},"labels":[],"label_agreement":null},{"id":"W2150013126","doi":"10.1634/theoncologist.2009-0116","title":"Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Systematic review; Intensive care medicine; Treatment of lung cancer; MEDLINE; Medical physics; Oncology","score_opus":0.10961618221409285,"score_gpt":0.48448823342484315,"score_spread":0.3748720512107503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150013126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004306231,0.97719693,0.0000037966227,0.010314573,0.00025350376,0.011937918,0.000077947305,0.000042097265,0.00013015294],"genre_scores_gemma":[0.00012374953,0.990524,0.00005646975,0.002108175,0.00029473036,0.005641802,0.000019271962,0.000041768093,0.0011900628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967317,0.00090284226,0.0010889511,0.00046084783,0.00042539838,0.00039027393],"domain_scores_gemma":[0.997199,0.00088893203,0.0005607853,0.0010610461,0.00010879614,0.0001814404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018253175,0.00048778846,0.0028873235,0.00010495629,0.000111453344,0.00009335556,0.00036386668,0.00025961932,0.00044970846],"category_scores_gemma":[0.00039349936,0.00022758245,0.00046462534,0.0006969086,0.00005750907,0.000063874686,0.000042456122,0.0005345188,0.00006782841],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016839823,0.00015445183,0.000038118847,0.2629292,0.00031450915,0.00011699388,0.0012335262,7.059867e-7,0.000002233176,0.00018141278,0.0021398792,0.73272055],"study_design_scores_gemma":[0.0005288385,0.0008596516,0.000004676929,0.41364503,0.0008884612,0.00006964604,0.000036465495,0.0000019498302,0.000009560613,0.000009702981,0.58380234,0.00014366608],"about_ca_topic_score_codex":0.00011989094,"about_ca_topic_score_gemma":0.00017019772,"teacher_disagreement_score":0.7325769,"about_ca_system_score_codex":0.0018320137,"about_ca_system_score_gemma":0.0010876684,"threshold_uncertainty_score":0.9280543},"labels":[],"label_agreement":null},{"id":"W2150141450","doi":"10.1634/theoncologist.2010-0421","title":"Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET)","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Positron emission tomography; Scintigraphy; Neutropenia; Cancer; Malignancy; Febrile neutropenia; Nuclear medicine imaging; Gold standard (test); Radiology; Nuclear medicine; Internal medicine; Chemotherapy","score_opus":0.04325586301881398,"score_gpt":0.3175688953059096,"score_spread":0.27431303228709564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150141450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9691428,0.00006331336,0.000008421261,0.0012951148,0.00007336035,0.00025932209,0.000003253694,0.000024248677,0.029130176],"genre_scores_gemma":[0.9981449,0.00020190477,0.000060778413,0.001515291,0.000022969041,0.00001619458,0.0000057463026,0.00000908424,0.000023092562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939865,0.000038326805,0.00018078893,0.00011286548,0.00013610718,0.00013324007],"domain_scores_gemma":[0.99952567,0.00014444785,0.00008916622,0.00014210385,0.00005718502,0.000041413557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012572364,0.00008337448,0.00023300106,0.000052961754,0.000035657762,0.0000015319877,0.000051365016,0.000030488427,0.00061831024],"category_scores_gemma":[0.00035053462,0.000039610582,0.00001988296,0.00015577079,0.00030082682,0.00002104094,0.00002163596,0.00012564044,0.000017326758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051852956,0.0008920703,0.98987293,0.000027819358,0.000013649635,0.000032259293,0.00041282715,0.0000046387595,0.0000116837355,0.00096583663,0.0023767722,0.00487101],"study_design_scores_gemma":[0.001996354,0.0019649912,0.9934296,0.00017835147,0.000055404045,0.000004294776,0.0001441584,0.000040815274,0.00006838387,0.00025725088,0.0018050204,0.00005537443],"about_ca_topic_score_codex":0.003647686,"about_ca_topic_score_gemma":0.0003998309,"teacher_disagreement_score":0.029107084,"about_ca_system_score_codex":0.00006285419,"about_ca_system_score_gemma":0.000027956037,"threshold_uncertainty_score":0.67700636},"labels":[],"label_agreement":null},{"id":"W2150866539","doi":"10.1634/theoncologist.2014-0028","title":"An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; FOLFOX; Bevacizumab; Oncology; Colorectal cancer; Neutropenia; Progression-free survival; Oxaliplatin; Regimen; Phases of clinical research; Adverse effect; Chemotherapy; Cancer","score_opus":0.07877267716082854,"score_gpt":0.4312235175892444,"score_spread":0.35245084042841585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150866539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951223,0.0008143944,0.0008180404,0.00074743206,0.00006933182,0.0022218642,0.000048064772,0.0000072889957,0.00015127023],"genre_scores_gemma":[0.9979634,0.00031085123,0.00043893847,0.0004626638,0.00011981375,0.00047017355,0.000041910665,0.000024877621,0.00016734462],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988203,0.0002845005,0.00025265676,0.00031483552,0.00013542408,0.00019227108],"domain_scores_gemma":[0.9989421,0.00023749477,0.00023638632,0.00039482952,0.00014516115,0.000044036024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014407283,0.00017015664,0.0002915426,0.00001118159,0.0005436042,0.0000367558,0.0005125443,0.000048463713,0.000027008418],"category_scores_gemma":[0.00013434287,0.00008301771,0.000035935936,0.00008417764,0.00031070688,0.0000057686602,0.00016799281,0.00005872687,3.617262e-7],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.101534165,0.0135745285,0.0020170133,0.000044852346,0.001665022,0.000001957034,0.0023196547,0.0025731483,0.44288793,0.0007552431,0.0010281936,0.4315983],"study_design_scores_gemma":[0.13617307,0.7009736,0.010567014,0.000064997475,0.001043546,0.000019951647,0.0022097651,0.015731659,0.11381892,0.00041352469,0.0181558,0.00082818815],"about_ca_topic_score_codex":0.00028213582,"about_ca_topic_score_gemma":0.0010288745,"teacher_disagreement_score":0.687399,"about_ca_system_score_codex":0.000021860104,"about_ca_system_score_gemma":0.00016756488,"threshold_uncertainty_score":0.4181019},"labels":[],"label_agreement":null},{"id":"W2151287258","doi":"10.1634/theoncologist.2013-0217","title":"HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital; St. Michael's Hospital; University of Toronto; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Disease; Breast cancer; Clinical trial; Cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2","score_opus":0.25965523279335295,"score_gpt":0.48847452959125165,"score_spread":0.2288192967978987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151287258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010008291,0.9739714,0.0000036625486,0.012468346,0.0006894482,0.008984207,0.00014546113,0.00012730055,0.0035100465],"genre_scores_gemma":[0.00012810105,0.97708374,0.00011218418,0.0012143479,0.0010713924,0.009923153,0.000036849702,0.00015979366,0.010270451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969179,0.0006224199,0.0005729641,0.00061146717,0.00049553724,0.00077971997],"domain_scores_gemma":[0.9967415,0.0012731127,0.00036781753,0.001214793,0.0002580153,0.00014479959],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015739738,0.0005500502,0.0018228964,0.00013865653,0.00022972954,0.00007001686,0.0009838364,0.0004369195,0.0022984114],"category_scores_gemma":[0.00020118443,0.00024329036,0.00048321567,0.00047873968,0.00069251156,0.000073396404,0.00014869735,0.0015849624,0.0002528569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022755905,0.000115682094,0.000022315373,0.0018051172,0.00018926452,0.000013836315,0.00013757982,0.0000014884642,0.000007672252,0.000084436906,0.017000556,0.9803945],"study_design_scores_gemma":[0.0013770596,0.00037149945,0.00026694342,0.0046450947,0.00019300374,0.00007241337,0.000105104424,0.000021639498,0.0000020284854,0.000042457323,0.9926241,0.00027862657],"about_ca_topic_score_codex":0.0013745392,"about_ca_topic_score_gemma":0.0009957473,"teacher_disagreement_score":0.9801159,"about_ca_system_score_codex":0.0015087955,"about_ca_system_score_gemma":0.001492895,"threshold_uncertainty_score":0.9986136},"labels":[],"label_agreement":null},{"id":"W2151507583","doi":"10.1634/theoncologist.12-4-426","title":"Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Clinical trial; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Drug; Toxicity; Safety profile; Phases of clinical research; Internal medicine; Medical physics; Adverse effect; Hepatocellular carcinoma","score_opus":0.07306418962376841,"score_gpt":0.4061245175451803,"score_spread":0.3330603279214119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151507583","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014436416,0.982094,0.0000513755,0.00001695019,0.0001241218,0.002377074,0.0003499078,0.0000057302723,0.00054446433],"genre_scores_gemma":[0.015294903,0.983953,0.00019136883,0.00005513,0.0000918709,0.00006934455,0.00025046172,0.000036086407,0.000057831487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969282,0.0009414047,0.00125477,0.00040847712,0.00020998644,0.00025713418],"domain_scores_gemma":[0.99687874,0.00032638406,0.002046304,0.0005431658,0.00013657582,0.00006879766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025282253,0.00037882884,0.002687295,0.00008980659,0.000036303332,0.000004059964,0.00035722248,0.00022201035,0.000016729466],"category_scores_gemma":[0.0008430054,0.0002237392,0.0002925249,0.00017363047,0.00034855542,0.0000054032184,0.00021224089,0.00027691794,0.0000010331061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021084812,0.0008143817,0.000032171363,0.03626572,0.00015990651,0.000019974004,0.000009222145,6.8726536e-7,0.0010416255,0.0000051288353,0.0003713441,0.95917135],"study_design_scores_gemma":[0.0063548284,0.010962876,0.0004801076,0.048626393,0.0015156688,0.000035595185,0.000011166451,0.0000012565481,0.004239493,0.000004528715,0.9271909,0.0005771985],"about_ca_topic_score_codex":0.000010229779,"about_ca_topic_score_gemma":0.000007816653,"teacher_disagreement_score":0.95859414,"about_ca_system_score_codex":0.000043598717,"about_ca_system_score_gemma":0.00039328472,"threshold_uncertainty_score":0.912382},"labels":[],"label_agreement":null},{"id":"W2151595350","doi":"10.1634/theoncologist.10-6-438","title":"Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve","year":2005,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Area under the curve; Receiver operating characteristic; Quartile; Anemia; Epoetin alfa; Internal medicine; Clinical trial; Clinical significance; Logistic regression; Confidence interval","score_opus":0.3144654092705074,"score_gpt":0.4611387039297435,"score_spread":0.14667329465923606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151595350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9232112,0.002096973,0.000073669755,0.0689985,0.0003992755,0.00074532354,0.000006981588,0.000043127762,0.004424934],"genre_scores_gemma":[0.9916121,0.00068994606,0.00091157656,0.005219263,0.000965714,0.000028340282,0.000008631077,0.000024366045,0.00054006244],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981852,0.00036157985,0.00051091384,0.00025282413,0.00035511723,0.000334334],"domain_scores_gemma":[0.9980111,0.0007933009,0.00031808866,0.0007073362,0.000094991025,0.00007515791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013802593,0.00020518378,0.00039509492,0.00002350349,0.00037327188,0.00004861287,0.00032327577,0.00014140352,0.00023167122],"category_scores_gemma":[0.00014191815,0.00008197,0.00023423272,0.0002159856,0.001315184,0.00008090082,0.00017556606,0.00041791043,0.000046888195],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009133285,0.01201993,0.35807222,0.00037055084,0.002348101,0.00021988983,0.012804495,0.004439204,0.0018967864,0.009941626,0.06754122,0.52943265],"study_design_scores_gemma":[0.007679153,0.002102944,0.89995354,0.0010176152,0.0024072218,0.00083621766,0.020789716,0.008101513,0.0020104693,0.0007614985,0.05374242,0.00059766986],"about_ca_topic_score_codex":0.0002812372,"about_ca_topic_score_gemma":0.00014450199,"teacher_disagreement_score":0.5418813,"about_ca_system_score_codex":0.000247406,"about_ca_system_score_gemma":0.00016279418,"threshold_uncertainty_score":0.48458505},"labels":[],"label_agreement":null},{"id":"W2151979638","doi":"10.1634/theoncologist.10-5-345","title":"HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Rash; Medicine; Dermatology; Acne; EGFR inhibitors; Adverse effect; Etiology; Epidermal growth factor receptor; Pathology; Internal medicine; Cancer","score_opus":0.06765387642643766,"score_gpt":0.36904424410560627,"score_spread":0.3013903676791686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151979638","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042998942,0.9668371,0.00003665835,0.015993327,0.0018928724,0.010824108,0.0003028295,0.00028906608,0.0033940466],"genre_scores_gemma":[0.0003203413,0.97106045,0.0008466061,0.0018187043,0.0028332178,0.002669672,0.00095175236,0.00016061646,0.019338615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952219,0.00065608945,0.0011866796,0.0010003337,0.0009616412,0.0009733287],"domain_scores_gemma":[0.9954547,0.0019991195,0.0007255999,0.0013820288,0.00017233346,0.0002662195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001742594,0.0008477163,0.002094452,0.00021965573,0.00086071354,0.00021942002,0.00081345637,0.00072106573,0.000119528624],"category_scores_gemma":[0.0003768025,0.00045933836,0.00074155326,0.0007671631,0.00074971514,0.00011782791,0.00087799155,0.0010061511,0.00013374868],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008916452,0.0002956603,0.00016642238,0.0046702363,0.00283228,0.00008559924,0.00031881148,0.000002887964,4.5740063e-7,0.0009735762,0.15465178,0.8359131],"study_design_scores_gemma":[0.0083155185,0.0001924832,0.00069197244,0.0049839537,0.0042310352,0.000040646104,0.0012984531,0.00008448099,0.0000021812523,0.00040096208,0.9792988,0.00045952798],"about_ca_topic_score_codex":0.0007082001,"about_ca_topic_score_gemma":0.00202077,"teacher_disagreement_score":0.8354536,"about_ca_system_score_codex":0.024640918,"about_ca_system_score_gemma":0.0017109034,"threshold_uncertainty_score":0.99978584},"labels":[],"label_agreement":null},{"id":"W2152078521","doi":"10.1634/theoncologist.2010-0279","title":"Early Breast Cancer in the Older Woman","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Contraindication; Trastuzumab; Cancer; Oncology; Internal medicine; Adjuvant; Systemic therapy; Disease; Gynecology; Alternative medicine; Pathology","score_opus":0.04541263312813848,"score_gpt":0.35289623139835535,"score_spread":0.3074835982702169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152078521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001616643,0.99388266,0.0000016511364,0.0005670407,0.00023852248,0.0006588593,0.00022961192,0.00001059997,0.004249401],"genre_scores_gemma":[0.0022645493,0.9949466,0.000008197303,0.00041459274,0.0005989073,0.001068894,0.000052930263,0.000035985817,0.00060936593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985953,0.00032544785,0.0002700932,0.00038457796,0.00010107964,0.00032350433],"domain_scores_gemma":[0.99896854,0.00005974592,0.00021274184,0.0006996628,0.00003271514,0.000026584423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028310643,0.00035989535,0.00060865894,0.00002968705,0.00013613081,0.000025863614,0.00084848964,0.00026271504,0.000075044976],"category_scores_gemma":[0.000015011967,0.00016164115,0.0002703192,0.000160724,0.00035958056,0.0000017103589,0.00024187696,0.0002725979,0.000056094723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037327565,0.00017092442,0.0004318126,0.0005001672,0.0003915846,0.000017580069,0.00035402752,3.210718e-7,9.5229376e-7,0.0001293926,0.010456348,0.98750955],"study_design_scores_gemma":[0.00023282159,0.0000650622,0.014019131,0.00063859404,0.00043575844,0.00011732255,0.00007204075,2.7534197e-8,0.000001044329,0.000021094864,0.9841811,0.00021599549],"about_ca_topic_score_codex":0.0014498738,"about_ca_topic_score_gemma":0.0015687562,"teacher_disagreement_score":0.98729354,"about_ca_system_score_codex":0.00011495851,"about_ca_system_score_gemma":0.00022857363,"threshold_uncertainty_score":0.65915346},"labels":[],"label_agreement":null},{"id":"W2152531047","doi":"10.1634/theoncologist.2008-0193","title":"Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Neurocognitive; Medulloblastoma; Ependymoma; Choroid plexus; Oncology; Chemotherapy; Brain tumor; Central nervous system; Glioma; Radiation therapy; Internal medicine; Pathology; Cognition; Cancer research; Psychiatry","score_opus":0.09317912667532544,"score_gpt":0.3399365523694173,"score_spread":0.24675742569409184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152531047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036705306,0.99635875,0.000640095,0.000023966364,0.00021641348,0.0016600345,0.00015218639,0.000034072367,0.0005474308],"genre_scores_gemma":[0.0024516322,0.99468654,0.00030284122,0.000016273374,0.0007998339,0.00071425,0.0005999608,0.000048547354,0.00038010342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984611,0.00012952415,0.00038367588,0.0004886675,0.00011441013,0.00042257734],"domain_scores_gemma":[0.9989205,0.000030406767,0.0003572262,0.000578418,0.0000335916,0.00007985547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018707513,0.0004391787,0.0009001312,0.000023287264,0.00014879076,0.000038909777,0.00036196847,0.00021628503,0.0000013685622],"category_scores_gemma":[0.000013432593,0.00020998175,0.00040587253,0.00006789632,0.00011783718,0.000001117241,0.000048981667,0.00011103304,0.00000477321],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059277874,0.000098931,0.0000017253684,0.0026329288,0.00015907304,0.0000046133305,0.000021044068,0.00018054502,0.000002440687,0.00007693519,0.00061042386,0.99615204],"study_design_scores_gemma":[0.00043718325,0.0012426294,0.0000070590736,0.0033135703,0.00077942776,0.00015436656,0.00005689831,0.00015323427,0.000037212332,0.000005151781,0.9934749,0.00033834213],"about_ca_topic_score_codex":0.000031901945,"about_ca_topic_score_gemma":0.000046267556,"teacher_disagreement_score":0.9958137,"about_ca_system_score_codex":0.00035203894,"about_ca_system_score_gemma":0.0006865114,"threshold_uncertainty_score":0.85628074},"labels":[],"label_agreement":null},{"id":"W2154006657","doi":"10.1634/theoncologist.10-9-760","title":"Nimotuzumab: Evidence of Clinical Benefit Without Rash","year":2005,"lang":"en","type":"letter","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rash; Nimotuzumab; Dermatology; Pharmacology; Oncology; Intensive care medicine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.23652912594375666,"score_gpt":0.4906644354273119,"score_spread":0.2541353094835552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154006657","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024244474,0.0025950808,0.000016353275,0.9332659,0.0008557102,0.0016853908,0.000026667205,0.00011471098,0.03719566],"genre_scores_gemma":[0.02609547,0.0051509864,0.00094680843,0.61606956,0.026464086,0.00012030656,0.000083135055,0.00016309187,0.3249066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99571157,0.0005378022,0.0012336024,0.00062964275,0.0012518585,0.00063552783],"domain_scores_gemma":[0.993413,0.0035672504,0.0006314551,0.0018823413,0.00037555877,0.00013042033],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0034634396,0.00037796484,0.0016303386,0.00013421208,0.000091121,0.000030688927,0.0010956991,0.0013810855,0.0076520178],"category_scores_gemma":[0.0016626972,0.0002284113,0.000670132,0.00026603646,0.0017624139,0.00005177561,0.0003375774,0.005065183,0.00050963147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011771302,0.00014497955,0.008969498,0.00029503714,0.00029114244,0.0003598841,0.000062608,0.0000036111583,0.0006354377,0.00001419549,0.9238102,0.06423627],"study_design_scores_gemma":[0.0014414742,0.0017004982,0.009269919,0.00077952497,0.00036235055,0.00014959804,0.000021320993,0.000049583603,0.00025417414,0.00011390519,0.98563087,0.00022677502],"about_ca_topic_score_codex":0.00037349653,"about_ca_topic_score_gemma":0.00018288873,"teacher_disagreement_score":0.31719643,"about_ca_system_score_codex":0.0004398674,"about_ca_system_score_gemma":0.0010297264,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W2154336771","doi":"10.1634/theoncologist.2011-0337","title":"Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer","year":2011,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine","score_opus":0.13268345324556344,"score_gpt":0.4542650043348345,"score_spread":0.3215815510892711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154336771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6729042,0.0008221239,0.0000035066978,0.31453088,0.0007717299,0.0017872859,0.0005016295,0.00003360824,0.008645047],"genre_scores_gemma":[0.8393052,0.0014178253,0.00010136807,0.15600644,0.00097419065,0.00034098176,0.0002871536,0.00004406591,0.0015227303],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9983964,0.00025069024,0.00058169215,0.00028283228,0.00024608686,0.00024227815],"domain_scores_gemma":[0.9981979,0.00080320763,0.00042937257,0.00047299764,0.00005093984,0.000045558114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031974536,0.00025491332,0.0010497906,0.00009646711,0.000026586418,0.000006865307,0.00014984774,0.000254504,0.0005863534],"category_scores_gemma":[0.000029903193,0.00012596408,0.0005700401,0.00008241369,0.00024426405,0.000013562939,0.00003695112,0.0010147345,0.00004682741],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006445712,0.0021883156,0.24850127,0.00008608379,0.0008696391,0.0006398216,0.00007352097,0.000017078903,0.000027781618,0.000006625599,0.7453428,0.0016024794],"study_design_scores_gemma":[0.0042872056,0.008672664,0.9552887,0.00040251,0.0016206075,0.000013825123,0.000006894227,0.000006584519,0.00022257272,0.00008068304,0.029208863,0.00018890864],"about_ca_topic_score_codex":0.009997223,"about_ca_topic_score_gemma":0.0004406687,"teacher_disagreement_score":0.71613395,"about_ca_system_score_codex":0.0007813787,"about_ca_system_score_gemma":0.00038307163,"threshold_uncertainty_score":0.99659526},"labels":[],"label_agreement":null},{"id":"W2155750728","doi":"10.1634/theoncologist.2011-0384","title":"A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Celgene; Eisai; Sanofi; Breast Cancer Research Foundation; Pfizer; GlaxoSmithKline","keywords":"Breast cancer; Medicine; Clinical trial; Oncology; Clinical decision making; Medical decision making; Cancer; Family medicine; Internal medicine; Gerontology","score_opus":0.35969123631201794,"score_gpt":0.6029037017443813,"score_spread":0.2432124654323634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155750728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461377,0.00021379263,0.000012585634,0.0032276826,0.00010556329,0.00093985785,0.00002952994,0.000005628852,0.00085156935],"genre_scores_gemma":[0.9974146,0.0002597198,0.00028733528,0.0018632984,0.00007769283,0.000066558954,3.340045e-7,0.000008747806,0.000021738982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640715,0.0011160558,0.0012208248,0.0002547565,0.00074882933,0.00025235466],"domain_scores_gemma":[0.95495147,0.04343774,0.00067340664,0.0005900399,0.0002650797,0.00008226185],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013307718,0.000117321906,0.0009854937,0.000112250505,0.000066733744,0.000009774027,0.00022997805,0.0001883986,0.000042472806],"category_scores_gemma":[0.028860157,0.000057089983,0.0002672044,0.00052673044,0.0011869415,0.000040029037,0.0003428287,0.0010207499,0.0000013648101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015905648,0.00093870296,0.95330673,0.00004871605,0.0006855685,0.0000073571086,0.0034966983,0.0010464684,0.00046460182,0.0012385084,0.00008066323,0.03709542],"study_design_scores_gemma":[0.0011105367,0.0003146588,0.99141496,0.0009598497,0.0005081614,0.0000012599032,0.00055226986,0.00012230831,0.00023684274,0.004682239,0.000039605264,0.000057308356],"about_ca_topic_score_codex":0.00050351344,"about_ca_topic_score_gemma":0.0009974677,"teacher_disagreement_score":0.042321686,"about_ca_system_score_codex":0.00022710476,"about_ca_system_score_gemma":0.000288327,"threshold_uncertainty_score":0.97932017},"labels":[],"label_agreement":null},{"id":"W2155848488","doi":"10.1634/theoncologist.2012-0260","title":"Compliance in Early-Phase Cancer Clinical Trials Research","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Compliance (psychology); Clinical trial; Protocol (science); Informed consent; Intensive care medicine; Action (physics); Alternative medicine; Medical emergency; Pathology; Psychology; Social psychology","score_opus":0.9924332197048782,"score_gpt":0.8700124277728657,"score_spread":0.1224207919320125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155848488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073304356,0.9712412,0.0000071133695,0.0077367323,0.00095864694,0.0070744464,0.000073284515,0.000048770667,0.012786505],"genre_scores_gemma":[0.000058185546,0.96801776,0.00025778715,0.00046211903,0.0024774345,0.0026306915,0.000029706143,0.00008600356,0.025980312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9657779,0.024314808,0.0051335217,0.001198296,0.0023528382,0.0012226454],"domain_scores_gemma":[0.57944727,0.4131326,0.0015402775,0.003446153,0.0016836758,0.00075001473],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.2245766,0.00043312565,0.0065723597,0.00033026488,0.00023102779,0.0001272708,0.002159757,0.0028066575,0.0015928338],"category_scores_gemma":[0.2939093,0.00021839418,0.0012999974,0.0013438093,0.0046691257,0.000047570862,0.0011370499,0.023345934,0.0038937798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024480728,0.0009097834,0.00009791664,0.009350967,0.00020617354,0.00019008837,0.000032080326,7.0124756e-8,2.1990371e-7,0.002422405,0.021441497,0.965104],"study_design_scores_gemma":[0.0023326478,0.0014929016,0.000104706545,0.032344688,0.0004006539,0.000015177386,0.000034212797,0.000013782798,2.864884e-7,0.0068642534,0.95619285,0.00020386405],"about_ca_topic_score_codex":0.002395524,"about_ca_topic_score_gemma":0.0013535748,"teacher_disagreement_score":0.96490014,"about_ca_system_score_codex":0.0012244727,"about_ca_system_score_gemma":0.008501511,"threshold_uncertainty_score":0.99931985},"labels":[],"label_agreement":null},{"id":"W2155895485","doi":"10.1634/theoncologist.2013-0159","title":"Screening for Lung Cancer With Low-Dose Computed Tomography","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; National Lung Screening Trial; Lung cancer screening; Lung cancer; Computed tomography; Radiology; Cancer; Lung; Oncology; Internal medicine","score_opus":0.022751318131551155,"score_gpt":0.3275069069583498,"score_spread":0.3047555888267986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155895485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417093,0.003970754,0.0044644284,0.038384356,0.00037825952,0.0055798334,0.000045190303,0.00023573909,0.0052321446],"genre_scores_gemma":[0.9904953,0.00007921948,0.004644688,0.0021599275,0.00025336974,0.001795069,0.000021610189,0.000019321118,0.00053149665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933535,0.00001892279,0.00011728686,0.00018217639,0.00011990129,0.0002263459],"domain_scores_gemma":[0.9993523,0.00016161162,0.000071369956,0.00023502983,0.0001006477,0.00007903791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008525566,0.00012091288,0.00021873348,0.000032639102,0.00013915778,0.000029482624,0.00008929327,0.000041334162,0.00016639681],"category_scores_gemma":[0.000008189901,0.00005878447,0.00008346465,0.00015207705,0.00013735246,0.000040149887,0.000025173673,0.00008141441,0.000006190966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012260594,0.001125116,0.68440336,0.0004440332,0.0018420027,0.00004561453,0.00059682806,0.0008964047,0.0003124195,0.0008334826,0.21639779,0.09187688],"study_design_scores_gemma":[0.011488667,0.0027238529,0.9531607,0.00093945075,0.0012221293,0.00003283362,0.00029707077,0.011781811,0.0018745819,0.000109197856,0.016047064,0.00032263732],"about_ca_topic_score_codex":0.0015848182,"about_ca_topic_score_gemma":0.00033899746,"teacher_disagreement_score":0.26875734,"about_ca_system_score_codex":0.0001579274,"about_ca_system_score_gemma":0.00008616939,"threshold_uncertainty_score":0.23971611},"labels":[],"label_agreement":null},{"id":"W2156070031","doi":"10.1634/theoncologist.11-3-227","title":"Too Much, Too Little, Too Late to Start Again? Assessing the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Natural history; Bone metastasis; Oncology; Cancer; Internal medicine","score_opus":0.044214047789870946,"score_gpt":0.37743343132559865,"score_spread":0.3332193835357277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156070031","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07551653,0.91514325,0.000003757074,0.0016317134,0.00032579523,0.0040885424,0.00248332,0.00005455552,0.0007525135],"genre_scores_gemma":[0.025950897,0.96443856,0.00085684145,0.0022755659,0.00020105059,0.00087719003,0.0023165466,0.00016946413,0.0029139086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99692065,0.00041113136,0.0010033017,0.00054327404,0.0005323456,0.000589326],"domain_scores_gemma":[0.996888,0.0011408451,0.0007638174,0.0008453733,0.00017615396,0.00018579858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005029834,0.0005742678,0.0022856595,0.00013610283,0.0001755841,0.000051471903,0.0003259188,0.00023123427,0.00008156423],"category_scores_gemma":[0.00012517901,0.00025314224,0.00026947315,0.00075141806,0.00030751686,0.00007888357,0.00014540253,0.00058424205,0.000037057733],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064321986,0.0016518519,0.01976323,0.0014957828,0.0005771631,0.00009871603,0.00012777545,0.000015012174,2.792243e-7,0.000010299586,0.0061588283,0.96945786],"study_design_scores_gemma":[0.005008146,0.0008382284,0.28843933,0.008809042,0.0035704102,0.000016034941,0.000052439646,0.000003074894,0.000004730763,0.000024584924,0.6928183,0.00041571603],"about_ca_topic_score_codex":0.031306174,"about_ca_topic_score_gemma":0.002574817,"teacher_disagreement_score":0.9690421,"about_ca_system_score_codex":0.0007824866,"about_ca_system_score_gemma":0.0012886535,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W2156097169","doi":"10.1634/theoncologist.6-suppl_4-1","title":"Thymidine Phosphorylase (TP) Activation: Convenience Through Innovation","year":2001,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Thymidine phosphorylase; Medicine; Tolerability; Colorectal cancer; Fluorouracil; Oncology; Internal medicine; Bolus (digestion); Regimen; Pharmacology; Cancer; Adverse effect","score_opus":0.0672375730742489,"score_gpt":0.3522997622602957,"score_spread":0.2850621891860468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156097169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89566386,0.00046288606,0.00022014619,0.018791063,0.00019393204,0.00039655287,0.00000252495,0.000075423326,0.084193595],"genre_scores_gemma":[0.99167025,0.0004903718,0.00017398245,0.0025521186,0.00018875329,0.000087284345,0.00001366841,0.0000070655556,0.004816512],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993476,0.000019696827,0.0001684661,0.00015426015,0.00015584598,0.00015410528],"domain_scores_gemma":[0.9994643,0.0000967182,0.00008940595,0.00019494012,0.0001365276,0.000018140936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013630497,0.00010219649,0.00017406899,0.000023313603,0.00022639135,0.000010928284,0.00006609378,0.00004042003,0.00029135036],"category_scores_gemma":[0.00015218189,0.00005714798,0.0000341909,0.00056060497,0.00022823617,0.0000773978,0.000043750493,0.0001103164,0.00005082722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015120994,0.0036736731,0.20382144,0.00016347645,0.0014005299,0.0008679375,0.019027567,0.00015319265,0.026719393,0.117971435,0.16292767,0.4481527],"study_design_scores_gemma":[0.0039263624,0.0028658842,0.18302946,0.000078840894,0.00017354736,0.00016870815,0.0032109267,0.00010767716,0.020716634,0.0030830181,0.782387,0.00025190445],"about_ca_topic_score_codex":0.00025333845,"about_ca_topic_score_gemma":0.00004672982,"teacher_disagreement_score":0.6194594,"about_ca_system_score_codex":0.00024086749,"about_ca_system_score_gemma":0.000087844775,"threshold_uncertainty_score":0.3190082},"labels":[],"label_agreement":null},{"id":"W2156648140","doi":"10.1634/theoncologist.2015-0012","title":"Frequency, Predictors, and Medical Record Documentation of Chemical Coping Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Multinational Association of Supportive Care in Cancer","keywords":"Medicine; Coping (psychology); Medical record; Confidence interval; Odds ratio; Concordance; Palliative care; Psychiatry; Internal medicine; Family medicine; Nursing","score_opus":0.02101207527441902,"score_gpt":0.3204544320849842,"score_spread":0.2994423568105652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156648140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953521,0.0002249488,0.00004681288,0.001393713,0.00022681944,0.00034683422,0.0000029209193,0.000029297575,0.0023765601],"genre_scores_gemma":[0.99841213,0.00032271596,0.00042825946,0.00044990281,0.00010727349,0.00003960629,0.000026399044,0.0000066442526,0.0002070705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919945,0.000047333895,0.00019927934,0.00011991274,0.00031604405,0.000117991745],"domain_scores_gemma":[0.99950045,0.000085634616,0.000110891815,0.00011688451,0.00007312301,0.00011300066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003439742,0.00007122124,0.00016648843,0.000024262896,0.00002290461,0.00000620258,0.00009234372,0.000064795364,0.000089246845],"category_scores_gemma":[0.0003916628,0.000045498797,0.000021160273,0.00008161212,0.00028134458,0.000071028524,0.000052042178,0.000110693385,0.0000029395567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011099894,0.000080107275,0.9847733,0.000041588934,0.00003074403,0.000003877004,0.00039662846,9.520808e-7,0.000312323,0.00007395716,0.0052138665,0.008961669],"study_design_scores_gemma":[0.005735606,0.00068684435,0.985566,0.0002972283,0.00017684435,7.533406e-7,0.0003841636,0.00045139462,0.0015602803,0.0007199476,0.0042832387,0.00013766148],"about_ca_topic_score_codex":0.00040649777,"about_ca_topic_score_gemma":0.00008591194,"teacher_disagreement_score":0.008824008,"about_ca_system_score_codex":0.00012217904,"about_ca_system_score_gemma":0.00007920287,"threshold_uncertainty_score":0.18553871},"labels":[],"label_agreement":null},{"id":"W2157027442","doi":"10.1634/theoncologist.12-9-1114","title":"Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Temozolomide; Medicine; Dacarbazine; Oncology; Internal medicine; Clinical trial; Melanoma; Thalidomide; Meta-analysis; Randomized controlled trial; Phases of clinical research; Adverse effect; Chemotherapy; Cancer research; Multiple myeloma","score_opus":0.15281898241311778,"score_gpt":0.42483401823406086,"score_spread":0.2720150358209431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157027442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.1246345e-7,0.97646296,0.00033449283,0.0005284388,0.00034567082,0.020473843,0.000034852972,0.000044517394,0.0017750221],"genre_scores_gemma":[0.0000036038966,0.98365676,0.00019852312,0.00044811738,0.00013684039,0.0034574438,0.000035843692,0.000040403815,0.012022475],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771917,0.00030270137,0.0012182303,0.00025575567,0.00025132918,0.00025279188],"domain_scores_gemma":[0.99475336,0.0030160223,0.0010206954,0.0010677625,0.00008316978,0.000058969374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014582346,0.00038208658,0.003691832,0.000094855255,0.00012937332,0.000013406422,0.00031113566,0.00009422924,0.000072934396],"category_scores_gemma":[0.00042835256,0.00013755493,0.0012976223,0.00029419767,0.00018271888,0.0000075574267,0.000035273064,0.00013361355,0.00009008648],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028678092,0.00022231306,2.9374045e-8,0.6955155,0.0016051222,0.0000508447,0.000028831404,1.2965891e-7,5.4205515e-8,0.00018447521,0.0022589061,0.30010512],"study_design_scores_gemma":[0.0003469609,0.0015534469,1.15236595e-7,0.1461417,0.044936128,0.00084768754,0.00008412012,0.00000569092,6.622994e-7,0.0000093760555,0.8059739,0.00010023323],"about_ca_topic_score_codex":0.00004728267,"about_ca_topic_score_gemma":0.000058307447,"teacher_disagreement_score":0.803715,"about_ca_system_score_codex":0.0005809466,"about_ca_system_score_gemma":0.00019702263,"threshold_uncertainty_score":0.56093276},"labels":[],"label_agreement":null},{"id":"W2157270051","doi":"10.1634/theoncologist.11-2-165","title":"Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Foothills Medical Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Glioma; Multidisciplinary approach; MEDLINE; Intensive care medicine; Oncology; Cancer research","score_opus":0.08917163167619094,"score_gpt":0.38126598461418376,"score_spread":0.2920943529379928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157270051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021284057,0.98273873,0.0000042619054,0.0015315342,0.00025574106,0.0031015975,0.00007730762,0.00006016552,0.010102238],"genre_scores_gemma":[0.0054508485,0.9923226,0.00015520483,0.00009685286,0.00020700277,0.0009283297,0.00023193448,0.000058127152,0.0005490742],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793696,0.0002760022,0.0005887661,0.00042219184,0.00035222966,0.0004238615],"domain_scores_gemma":[0.9978241,0.0003244956,0.00051725184,0.0012310435,0.000030269279,0.000072850235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007573431,0.00045069444,0.0013302168,0.00019710608,0.00025878276,0.000025297495,0.00047943817,0.00016455991,0.00007367177],"category_scores_gemma":[0.000010027232,0.00017979383,0.0005457077,0.00051458256,0.00025072534,0.000019738833,0.00026866238,0.00025465665,0.00018787374],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071163406,0.0022975432,0.000020166697,0.005984424,0.001236772,0.0029041902,0.000100461184,0.000013970778,0.0000013962502,0.021688577,0.0036313327,0.96205],"study_design_scores_gemma":[0.00082050887,0.0009997879,0.00034363195,0.013960841,0.0051239952,0.00026924556,0.00030389268,0.000021710122,0.00004768786,0.0001991931,0.97762775,0.00028174845],"about_ca_topic_score_codex":0.00004479822,"about_ca_topic_score_gemma":0.000011984245,"teacher_disagreement_score":0.9739964,"about_ca_system_score_codex":0.00028730594,"about_ca_system_score_gemma":0.000071476126,"threshold_uncertainty_score":0.73317796},"labels":[],"label_agreement":null},{"id":"W2158430615","doi":"10.1634/theoncologist.9-1-1","title":"The Means, the Mission, and the Pledge of <i>The Oncologist</i>","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in medical practice","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pledge; Radiation oncologist; Internal medicine; Radiation therapy","score_opus":0.08498701638529445,"score_gpt":0.47568134161404774,"score_spread":0.3906943252287533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158430615","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017919324,0.0035908243,0.00025767027,0.82091063,0.0030657875,0.0026230288,0.000011691471,0.000080245714,0.15154082],"genre_scores_gemma":[0.93947464,0.0032997096,0.00022849703,0.04663516,0.000889083,0.00023805359,0.0000015708231,0.00003346406,0.009199832],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9857344,0.01171967,0.00084948563,0.00028611653,0.0007945617,0.00061579177],"domain_scores_gemma":[0.92467904,0.07222797,0.000977638,0.0016938783,0.0003099154,0.00011158176],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch","sts"],"category_scores_codex":[0.031052215,0.00022332923,0.0003639066,0.000013347137,0.009422885,0.000038475522,0.002516094,0.00046244546,0.000116209056],"category_scores_gemma":[0.04791247,0.000061598286,0.00014710071,0.0003619924,0.010857031,0.00006885368,0.0011952564,0.006495365,0.00013935896],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009367628,0.00020867563,0.0016073508,0.00010224281,0.00011703697,0.000007653321,0.019350283,0.000116612035,0.00017598753,0.7989001,0.17325181,0.0052254596],"study_design_scores_gemma":[0.002652347,0.00015401542,0.004708795,0.00016954933,0.0001782929,0.000016585162,0.019204974,0.000063118736,0.00006834318,0.26159453,0.7110751,0.0001143141],"about_ca_topic_score_codex":0.0019569735,"about_ca_topic_score_gemma":0.004443036,"teacher_disagreement_score":0.9215553,"about_ca_system_score_codex":0.0003328499,"about_ca_system_score_gemma":0.0014646936,"threshold_uncertainty_score":0.9977356},"labels":[],"label_agreement":null},{"id":"W2158925468","doi":"10.1634/theoncologist.2009-0219","title":"Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?","year":2009,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Stage (stratigraphy); Cancer; Oncology; Adjuvant; Adjuvant chemotherapy; Internal medicine","score_opus":0.04782780240256192,"score_gpt":0.3933731187100704,"score_spread":0.3455453163075085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158925468","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.114347845,0.00076987146,2.2486398e-7,0.87971824,0.0004904467,0.0008565233,0.0008453992,0.00002323307,0.0029482194],"genre_scores_gemma":[0.092410825,0.002343523,0.000024903879,0.8935205,0.00428872,0.00013473268,0.00033788604,0.000033232936,0.0069056978],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824893,0.00030089528,0.00043830954,0.0003311581,0.00028238972,0.00039832736],"domain_scores_gemma":[0.9985587,0.00038062877,0.000341055,0.0006118043,0.00005972427,0.000048067486],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031960662,0.00033164475,0.0007366765,0.00009378151,0.000117231415,0.000017337998,0.00048270702,0.00039017404,0.0024306427],"category_scores_gemma":[0.000007039965,0.00017319061,0.00016958694,0.00020729138,0.0008630871,0.00005056927,0.00007515161,0.0015839137,0.000017639119],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067616266,0.000479774,0.0085694315,0.00006561482,0.00022272719,0.00049960415,0.00088768906,0.000005229896,0.0000901668,0.0000037632674,0.97952497,0.0089748455],"study_design_scores_gemma":[0.0026328566,0.0012337293,0.04819363,0.00012083519,0.0006445318,0.000089313115,0.00014530706,0.000026010335,0.0002908797,0.00005741433,0.9463848,0.00018073317],"about_ca_topic_score_codex":0.032468155,"about_ca_topic_score_gemma":0.007381742,"teacher_disagreement_score":0.039624196,"about_ca_system_score_codex":0.00044499332,"about_ca_system_score_gemma":0.00026797992,"threshold_uncertainty_score":0.9984813},"labels":[],"label_agreement":null},{"id":"W2160175915","doi":"10.1634/theoncologist.11-5-503","title":"Ewing's Sarcoma Family of Tumors: Current Management","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":518,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; CD99; Sarcoma; Ewing's sarcoma; Rhabdomyosarcoma; Radiology; Pathology","score_opus":0.12088628657714595,"score_gpt":0.40478320808142126,"score_spread":0.2838969215042753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160175915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000050170103,0.9678236,0.000006091842,0.00012836908,0.00031536413,0.0019774034,0.000049880746,0.000053846346,0.029595252],"genre_scores_gemma":[0.00030042956,0.9976968,0.00024580446,0.00007642928,0.00027618234,0.0005510839,0.00018886148,0.000045585777,0.0006188046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798113,0.00016972478,0.00078928913,0.00037054316,0.00036963628,0.0003196797],"domain_scores_gemma":[0.9982067,0.00030520838,0.0005223167,0.0008485919,0.00004714218,0.00007007412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034741368,0.00042643296,0.0019960976,0.00014790214,0.000075230375,0.000016572882,0.0003584593,0.00013192938,0.00004216264],"category_scores_gemma":[0.000022358585,0.0002184876,0.0007952611,0.00030922046,0.00024117868,0.0000139500935,0.00021058445,0.0003269485,0.00017918609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010682176,0.00125426,0.00011947186,0.009425408,0.00036116753,0.00028170558,0.000007780977,2.4284304e-7,4.3082093e-8,0.0009545529,0.018063588,0.9695211],"study_design_scores_gemma":[0.0006431589,0.000255728,0.0023903563,0.0139133595,0.0042628297,0.00007650813,0.000023881807,7.7248774e-7,7.081005e-7,0.000079663136,0.9781788,0.0001742172],"about_ca_topic_score_codex":0.00011842881,"about_ca_topic_score_gemma":0.000007820899,"teacher_disagreement_score":0.9693469,"about_ca_system_score_codex":0.00047837308,"about_ca_system_score_gemma":0.00018273087,"threshold_uncertainty_score":0.8909666},"labels":[],"label_agreement":null},{"id":"W2160326987","doi":"10.1634/theoncologist.9-2-232","title":"Highlights from the Tenth World Conference on Lung Cancer","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Vinorelbine; Lung cancer; Gemcitabine; Oncology; Internal medicine; Taxane; Gefitinib; Chemotherapy; Cancer; Breast cancer; Cisplatin; Epidermal growth factor receptor","score_opus":0.06200918382975023,"score_gpt":0.35023634560874084,"score_spread":0.2882271617789906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160326987","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41326696,0.003432176,0.000019612808,0.52833015,0.00096641644,0.0011260976,0.00007633322,0.00011206033,0.052670185],"genre_scores_gemma":[0.988436,0.001251368,0.000059880815,0.00711838,0.0005168398,0.00025512144,0.000015173297,0.000011162483,0.0023360762],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992339,0.00003890163,0.00012739134,0.00020893129,0.00020166699,0.00018922595],"domain_scores_gemma":[0.9991846,0.0002193197,0.00007073484,0.00042484654,0.0000406602,0.000059805065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009144307,0.00013117597,0.00019514459,0.000014725902,0.00018574906,0.000029505272,0.00018119907,0.000037417445,0.0005216391],"category_scores_gemma":[0.000017702005,0.000051407238,0.00007136248,0.000116195806,0.00019131687,0.000019216977,0.0000388755,0.00016762674,0.00010983495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001956936,0.0037246435,0.25252762,0.000077268574,0.0022787603,0.00060417183,0.0047086296,0.0010736386,0.00072997744,0.2840637,0.4206811,0.02757354],"study_design_scores_gemma":[0.006977656,0.0009841296,0.8180047,0.0010546936,0.0012125181,0.000009096929,0.00024408862,0.000081921426,0.0070239967,0.004698279,0.15942931,0.00027955332],"about_ca_topic_score_codex":0.008278888,"about_ca_topic_score_gemma":0.014186918,"teacher_disagreement_score":0.575169,"about_ca_system_score_codex":0.0008593937,"about_ca_system_score_gemma":0.00025000196,"threshold_uncertainty_score":0.99832505},"labels":[],"label_agreement":null},{"id":"W2162200636","doi":"10.1634/theoncologist.2013-0160","title":"Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Bevacizumab; Breast cancer; Newspaper; Headline; Food and drug administration; Family medicine; Clinical trial; Metastatic breast cancer; Cancer; Oncology; Internal medicine; Advertising; Pharmacology; Chemotherapy","score_opus":0.024574839051825687,"score_gpt":0.35788425867525075,"score_spread":0.3333094196234251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162200636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680918,0.0026616068,0.000015573582,0.025420953,0.00022860851,0.0011832844,0.0000898693,0.00003120216,0.0022771026],"genre_scores_gemma":[0.9934361,0.0013861391,0.00046382277,0.00087076845,0.00025702832,0.0004964293,0.00001485462,0.000012679792,0.0030622077],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9994471,0.000021680751,0.00016316179,0.0001352501,0.000062788575,0.00016999034],"domain_scores_gemma":[0.99940044,0.00017499698,0.00009200111,0.00014011766,0.00013305854,0.000059402348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007924684,0.00009869097,0.00028413386,0.000028656328,0.00007117541,0.000005875123,0.0000701094,0.00005316589,0.0003223216],"category_scores_gemma":[0.000018323635,0.000059837417,0.000052704574,0.00008673441,0.00025866056,0.000044583812,0.000031926844,0.000068265756,0.0000076216756],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050772442,0.0009428392,0.03313624,0.00037797683,0.00051372044,0.000009850852,0.0006863078,0.000051524523,0.060551476,0.0006691035,0.077755205,0.8202285],"study_design_scores_gemma":[0.053340115,0.011486178,0.64630514,0.00033287305,0.002811851,0.0008181471,0.0017006447,0.0017004772,0.03436203,0.0043895356,0.24195477,0.0007982104],"about_ca_topic_score_codex":0.0011536613,"about_ca_topic_score_gemma":0.0003295299,"teacher_disagreement_score":0.8194303,"about_ca_system_score_codex":0.000085744454,"about_ca_system_score_gemma":0.00011622723,"threshold_uncertainty_score":0.35291958},"labels":[],"label_agreement":null},{"id":"W2162278616","doi":"10.1634/theoncologist.2013-0442","title":"Effect of M1a and M1b Category in Metastatic Colorectal Cancer","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Metastasis; Hazard ratio; Internal medicine; Oncology; Colorectal cancer; Cancer; Proportional hazards model; Univariate analysis; Primary tumor; Surgical oncology; Survival analysis; Multivariate analysis; Confidence interval","score_opus":0.01799191052558404,"score_gpt":0.34086446671635745,"score_spread":0.32287255619077343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162278616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727125,0.0019217799,0.000002852915,0.0009224974,0.000088677436,0.00041066998,0.000004584134,0.000011982361,0.00936569],"genre_scores_gemma":[0.99910295,0.00030022935,0.000022277141,0.00010888914,0.000034554865,0.00014942682,0.0000017434916,0.000006057647,0.00027387275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993993,0.00013960087,0.00012977449,0.00011719666,0.00008624508,0.00012789445],"domain_scores_gemma":[0.9992949,0.0005136244,0.000056708403,0.00008589506,0.000020531197,0.000028367567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043450543,0.00009499212,0.00036586708,0.00003126,0.00004528024,0.000003524906,0.000041671967,0.00002383843,0.00003693858],"category_scores_gemma":[0.00013854542,0.000046990186,0.000036514564,0.0000979377,0.0002815948,0.000013470809,0.000042682143,0.00008459385,0.0000026601572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068999566,0.00041099556,0.6175282,0.00055281876,0.0005441929,0.00007103035,0.0026507715,0.00004532985,0.0061051915,0.0008039866,0.0016619943,0.36272556],"study_design_scores_gemma":[0.006913002,0.013714615,0.9592395,0.0001053915,0.000699551,0.000040344195,0.00034419558,0.00046776948,0.01389664,0.00032533094,0.004100968,0.00015269218],"about_ca_topic_score_codex":0.0021119595,"about_ca_topic_score_gemma":0.002770188,"teacher_disagreement_score":0.36257285,"about_ca_system_score_codex":0.00011002722,"about_ca_system_score_gemma":0.00004356997,"threshold_uncertainty_score":0.3192665},"labels":[],"label_agreement":null},{"id":"W2162313743","doi":"10.1634/theoncologist.2010-0214","title":"Factors Associated with Response to Methylphenidate in Advanced Cancer Patients","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Methylphenidate; Medicine; Cancer-related fatigue; Breast cancer; Cancer; Clinical trial; Internal medicine; Physical therapy; Attention deficit hyperactivity disorder; Psychiatry","score_opus":0.0882969024258374,"score_gpt":0.3333576239215738,"score_spread":0.2450607214957364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162313743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551374,0.00005554477,0.0000071722475,0.0006503547,0.00024583505,0.00046761057,0.000033265875,0.000048123788,0.0029783277],"genre_scores_gemma":[0.9977877,0.000007477372,0.000022559125,0.00091457204,0.000016286976,0.00011370765,0.000012218676,0.00001776923,0.0011077151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990382,0.00018508236,0.00015166677,0.00018782134,0.00019173208,0.000245503],"domain_scores_gemma":[0.999291,0.00019736237,0.00007703299,0.00023531479,0.00010523714,0.00009405356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003839757,0.00012771357,0.00024903688,0.00006420778,0.000049068374,0.0000054568004,0.00013754868,0.00006402411,0.00020305213],"category_scores_gemma":[0.0003896231,0.00006839775,0.0000377741,0.00039111756,0.00008704476,0.000037988953,0.000044662556,0.00017254826,0.000009997022],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010922785,0.0003826338,0.9666033,0.000008326263,0.000073432806,0.000020746025,0.014672483,0.000015043302,0.0009300717,0.00001768207,0.00045029412,0.0059031937],"study_design_scores_gemma":[0.0015250974,0.0014172897,0.99001086,0.00008080908,0.000048079983,1.5306541e-7,0.0013353283,0.0000016281917,0.0026635625,0.00002097878,0.0027868187,0.0001093878],"about_ca_topic_score_codex":0.0030329144,"about_ca_topic_score_gemma":0.038180478,"teacher_disagreement_score":0.035147563,"about_ca_system_score_codex":0.00047228942,"about_ca_system_score_gemma":0.00015206437,"threshold_uncertainty_score":0.97937024},"labels":[],"label_agreement":null},{"id":"W2163214112","doi":"10.1634/theoncologist.2009-0331","title":"Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Tolerability; Carboplatin; Regimen; Medicine; Gemcitabine; Internal medicine; Oncology; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.05658101786179498,"score_gpt":0.3669097908403569,"score_spread":0.31032877297856193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163214112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013474728,0.97509485,0.0000070618985,0.0012213766,0.0003260307,0.021420494,0.00035688354,0.000018919533,0.00020688045],"genre_scores_gemma":[0.019285139,0.976534,0.00017405547,0.000026125219,0.000083643106,0.0036393488,0.00017531062,0.000046165766,0.00003621897],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99672806,0.0005293468,0.0016068061,0.00050452224,0.00034374595,0.00028751654],"domain_scores_gemma":[0.991509,0.0055951974,0.0017009089,0.0008555801,0.00026285884,0.00007645672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009534991,0.0005740497,0.0044136764,0.000106522435,0.00010872302,0.000014545734,0.00018638081,0.0002801016,0.000017381728],"category_scores_gemma":[0.00039853726,0.0002528804,0.0003889121,0.00046683336,0.0004081573,0.000025497282,0.00004613905,0.00035710627,9.597177e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032559107,0.002514226,0.00011499642,0.42294547,0.0027084246,0.000028234306,0.00094177487,0.000012456069,0.0000025248444,0.0005894467,0.000034013072,0.5668525],"study_design_scores_gemma":[0.03395355,0.024424449,0.002988609,0.849458,0.060603723,0.00013965736,0.00027683316,0.0003276665,0.000058077636,0.000022532991,0.027052468,0.00069446553],"about_ca_topic_score_codex":0.0012146459,"about_ca_topic_score_gemma":0.0026310016,"teacher_disagreement_score":0.56615806,"about_ca_system_score_codex":0.0011064054,"about_ca_system_score_gemma":0.000782883,"threshold_uncertainty_score":0.9999924},"labels":[],"label_agreement":null},{"id":"W2163216057","doi":"10.1634/theoncologist.2014-0006","title":"How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer","year":2014,"lang":"en","type":"review","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Ramucirumab; Crizotinib; Biomarker; Disease; Cancer; Oncology; Internal medicine; Predictive marker; Trastuzumab; MEDLINE; Bioinformatics; Breast cancer; Lung cancer","score_opus":0.08941645987040653,"score_gpt":0.35814495783542843,"score_spread":0.2687284979650219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163216057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078011915,0.99204856,0.0015892463,0.0017613326,0.00021723045,0.0030891125,0.00004192669,0.000036383317,0.0011382055],"genre_scores_gemma":[0.007982406,0.9904671,0.0002606543,0.00003858089,0.00008853164,0.0002963361,0.000018861127,0.000030050587,0.0008175039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998757,0.00007331568,0.000324297,0.0003410089,0.0002289628,0.00027541834],"domain_scores_gemma":[0.9990492,0.00015748729,0.00046552948,0.00022308387,0.00002587037,0.00007882163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034036647,0.00031822236,0.0012779884,0.00018331684,0.000106433654,0.00003689486,0.00013651093,0.00011005098,0.0000030747376],"category_scores_gemma":[0.00003593596,0.0001884911,0.00016321022,0.00035894706,0.00019780392,0.000053213626,0.00010885122,0.00020504063,3.7755527e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001073693,0.000029269808,0.0010153987,0.047315974,0.0013387143,0.000041496663,0.000060116196,0.0000016056782,1.831168e-7,0.00026452093,0.00058057107,0.9492448],"study_design_scores_gemma":[0.0035902262,0.0012155075,0.0055315383,0.052817047,0.022200739,0.00011327403,0.01215358,0.000053319567,6.2264206e-7,0.0001448658,0.9016773,0.0005019889],"about_ca_topic_score_codex":0.000015616159,"about_ca_topic_score_gemma":0.00003445035,"teacher_disagreement_score":0.9487428,"about_ca_system_score_codex":0.00044504117,"about_ca_system_score_gemma":0.000061775325,"threshold_uncertainty_score":0.7686444},"labels":[],"label_agreement":null},{"id":"W2165229942","doi":"10.1634/theoncologist.2010-0197","title":"Effect of Exercise Training on Peak Oxygen Consumption in Patients with Cancer: A Meta-Analysis","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Meta-analysis; Confidence interval; VO2 max; Randomized controlled trial; Physical therapy; Adverse effect; Pooled variance; Internal medicine; Heart rate","score_opus":0.16104487862887207,"score_gpt":0.39103577701304354,"score_spread":0.22999089838417147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165229942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001991346,0.99474174,0.0000015558293,0.000029671235,0.00011466241,0.0018862977,0.00015239324,0.000020992156,0.0010613293],"genre_scores_gemma":[0.013695283,0.9846827,0.0000060835637,0.000041190564,0.00003246836,0.000946332,0.00017031904,0.00003379771,0.00039187277],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9980373,0.0005995381,0.0004922713,0.00035204997,0.00030075558,0.00021810575],"domain_scores_gemma":[0.99823123,0.00045529185,0.0005777389,0.0006102997,0.00006219816,0.00006325052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007747,0.00036750964,0.0047121425,0.0002895547,0.000034952656,0.0000070956394,0.00023165309,0.00027698264,0.0005951841],"category_scores_gemma":[0.000047522313,0.00016188179,0.0014607836,0.0006518836,0.00018666896,0.000018007964,0.000038625076,0.0005217519,0.000017146398],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010252716,0.0001521172,0.0017480495,0.010378709,0.04207208,0.000011440288,0.0008709575,0.000005758854,1.4385045e-8,0.000015420128,0.00009170178,0.9436285],"study_design_scores_gemma":[0.0012140374,0.0023327742,0.0029880682,0.003738001,0.82502645,0.0000016740318,0.000043397682,0.0000012057499,9.939793e-7,0.0000017061026,0.16438767,0.00026401159],"about_ca_topic_score_codex":0.0027184682,"about_ca_topic_score_gemma":0.00425191,"teacher_disagreement_score":0.94336444,"about_ca_system_score_codex":0.00030648636,"about_ca_system_score_gemma":0.00020097714,"threshold_uncertainty_score":0.6601348},"labels":[],"label_agreement":null},{"id":"W2165595478","doi":"10.1634/theoncologist.2009-0150","title":"Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"American Society of Clinical Oncology; Sanofi; Eli Lilly and Company","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Hazard ratio; Metastatic breast cancer; Breast cancer; Regimen; Estrogen receptor; Odds ratio; Confidence interval; Cancer","score_opus":0.019327851943031174,"score_gpt":0.30794130428793387,"score_spread":0.2886134523449027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165595478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99800676,0.00046221475,0.000032897417,0.00051203993,0.00006124386,0.0006446297,0.00023089493,0.000005252824,0.000044044304],"genre_scores_gemma":[0.9986715,0.00018880983,0.00074447255,0.000051429837,0.00004119323,0.00019497769,0.00007634329,0.000009803974,0.000021525108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986364,0.00047476686,0.00036188352,0.0002462829,0.00012855316,0.00015206332],"domain_scores_gemma":[0.9988326,0.00038816364,0.00037443844,0.0002710402,0.00009529029,0.000038456838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093977543,0.00015947933,0.0009404604,0.00007106076,0.000059038008,0.000010936091,0.00013555754,0.00005958598,0.00004466088],"category_scores_gemma":[0.0004591826,0.000079802696,0.00016853941,0.00021992032,0.00037384604,0.0000035494177,0.00008497751,0.00008294649,5.3529504e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26705062,0.0023618683,0.53564525,0.000049391554,0.020273613,0.0000039967613,0.0007102585,0.0005951519,0.14419523,0.00013229926,0.0005530093,0.028429298],"study_design_scores_gemma":[0.20013393,0.00031798455,0.77405936,0.00004410675,0.009199168,0.0000030853494,0.000130131,0.000045224984,0.015533268,0.000030392723,0.00023201575,0.00027135416],"about_ca_topic_score_codex":0.0005112617,"about_ca_topic_score_gemma":0.0006622937,"teacher_disagreement_score":0.23841408,"about_ca_system_score_codex":0.000020636013,"about_ca_system_score_gemma":0.000064910135,"threshold_uncertainty_score":0.32542595},"labels":[],"label_agreement":null},{"id":"W2165702053","doi":"10.1634/theoncologist.2012-0316","title":"Recursive Partitioning Analysis for the Prediction of Stereotactic Radiosurgery Brain Metastases Lesion Control","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Radiosurgery; Medicine; Recursive partitioning; Lesion; Radiology; Medical physics; Internal medicine; Pathology; Radiation therapy","score_opus":0.06091035380502197,"score_gpt":0.31731968977001895,"score_spread":0.256409335964997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165702053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7966684,0.0037814698,0.09436249,0.095881164,0.00062829023,0.0069140596,0.00090346264,0.00011567923,0.00074497965],"genre_scores_gemma":[0.99738425,0.00007428078,0.0005608493,0.0009717267,0.00011412055,0.00046539615,0.000100808575,0.000009036724,0.00031952804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893516,0.00025502744,0.00030603222,0.00015667068,0.0001699937,0.00017708645],"domain_scores_gemma":[0.99571985,0.0034692218,0.00025441,0.0003560781,0.00015006115,0.0000503943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009065024,0.00011038438,0.00038328717,0.00007175634,0.00021594607,0.000023424134,0.00007775646,0.000041037525,0.00026963555],"category_scores_gemma":[0.000630385,0.000050829323,0.00033966615,0.0002866278,0.00021050734,0.00006394599,0.000015505742,0.000087499226,0.000010698844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067340117,0.005320881,0.35883564,0.0004601065,0.07286195,0.00010598599,0.0027181578,0.015285958,0.008094191,0.012609274,0.28313327,0.23384057],"study_design_scores_gemma":[0.011723949,0.0052131144,0.88203144,0.00014837371,0.04082402,0.00011748956,0.004050963,0.022222215,0.004903255,0.0023285907,0.026149558,0.00028703487],"about_ca_topic_score_codex":0.00045355133,"about_ca_topic_score_gemma":0.000049277936,"teacher_disagreement_score":0.5231958,"about_ca_system_score_codex":0.000085164764,"about_ca_system_score_gemma":0.000057763376,"threshold_uncertainty_score":0.29523203},"labels":[],"label_agreement":null},{"id":"W2166003630","doi":"10.1634/theoncologist.11-6-624","title":"End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?","year":2006,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Surrogate endpoint; Clinical endpoint; Clinical trial; Adjuvant therapy; Adjuvant; End point; Endpoint Determination; Intensive care medicine; Disease; Oncology; Internal medicine; Cancer","score_opus":0.10893625307390128,"score_gpt":0.37209338186582086,"score_spread":0.26315712879191955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166003630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6317188,0.006751855,0.0005295354,0.31287146,0.0025801507,0.019013366,0.0031541532,0.00033168585,0.023048993],"genre_scores_gemma":[0.98003674,0.00030671706,0.00034684816,0.0035875926,0.0014708721,0.0024512368,0.00020111458,0.00007276249,0.0115261255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975393,0.00039173473,0.000584679,0.00045650487,0.00045639934,0.0005713783],"domain_scores_gemma":[0.99399394,0.004603472,0.00025592858,0.00077329733,0.0002145238,0.00015886335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029303525,0.000378865,0.001106156,0.000053687556,0.0006656713,0.00011318874,0.00047512783,0.000080907506,0.0005821984],"category_scores_gemma":[0.0017707561,0.00017622772,0.00057355844,0.00014801444,0.00041252296,0.000056589648,0.00019173235,0.00013468837,0.000057077577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19761509,0.0063336273,0.015246486,0.00028760234,0.0056402944,0.00023751415,0.0045102346,0.00021495977,0.0043550166,0.02568391,0.5747033,0.16517201],"study_design_scores_gemma":[0.038985364,0.010403919,0.25424373,0.0001033783,0.0014479972,0.000019415007,0.000932583,0.00023127104,0.0010735248,0.037678983,0.654183,0.00069687905],"about_ca_topic_score_codex":0.0018594827,"about_ca_topic_score_gemma":0.002399992,"teacher_disagreement_score":0.34831792,"about_ca_system_score_codex":0.00039290203,"about_ca_system_score_gemma":0.00032322513,"threshold_uncertainty_score":0.7186358},"labels":[],"label_agreement":null},{"id":"W2166336441","doi":"10.1634/theoncologist.8-4-381","title":"Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey","year":2003,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Venous thromboembolism; Cancer; Thrombosis; Malignancy; Venous thrombosis; Intensive care medicine; MEDLINE; Low molecular weight heparin; Surgery; Internal medicine","score_opus":0.05359443108603156,"score_gpt":0.3261288330397681,"score_spread":0.2725344019537365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166336441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844777,0.0017437349,0.000013120191,0.0031869058,0.000640097,0.0008789964,0.00004408233,0.000033759952,0.008981593],"genre_scores_gemma":[0.99275804,0.0013921573,0.000052566083,0.0052294666,0.00013040147,0.00016227628,0.000065086264,0.000021027781,0.00018899946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985057,0.00042912317,0.0002920342,0.00025750996,0.00024637202,0.00026925257],"domain_scores_gemma":[0.9987313,0.0005267079,0.000117621734,0.00048749766,0.00008317259,0.0000536651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049431884,0.0001640001,0.0004508358,0.000030703544,0.00017420654,0.00002675403,0.00025295786,0.00008050812,0.00039104908],"category_scores_gemma":[0.00043231956,0.000080903206,0.00006589562,0.0002602641,0.0001876977,0.000040558447,0.00007720661,0.00024353198,0.00008938554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015181414,0.007870054,0.8623499,0.000023073631,0.00043556662,0.00002374677,0.004144402,0.00018560387,0.00012403246,0.0026835355,0.116128504,0.005879727],"study_design_scores_gemma":[0.0012973689,0.0004246586,0.94942844,0.000050754454,0.00013210949,2.4154005e-7,0.0003506943,0.000018412104,0.00010058814,0.00048566514,0.047606602,0.000104454826],"about_ca_topic_score_codex":0.034150247,"about_ca_topic_score_gemma":0.048345186,"teacher_disagreement_score":0.08707851,"about_ca_system_score_codex":0.00030778718,"about_ca_system_score_gemma":0.00011987481,"threshold_uncertainty_score":0.97228146},"labels":[],"label_agreement":null},{"id":"W2166883496","doi":"10.1634/theoncologist.2011-0171","title":"Re: Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers","year":2011,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Breast cancer; Ultrasonography; Ultrasound; Radiology; Surgery; Cancer; Internal medicine","score_opus":0.016734165932575065,"score_gpt":0.27324199349885264,"score_spread":0.2565078275662776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166883496","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.118457064,0.021453565,0.0034808838,0.7805497,0.0025252295,0.020571493,0.018920558,0.00025177395,0.03378975],"genre_scores_gemma":[0.9414808,0.0015109007,0.00056358357,0.047864597,0.002403072,0.002930544,0.00278019,0.00007485438,0.00039142114],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985247,0.00016075427,0.0002876491,0.0005721869,0.00013257927,0.00032213327],"domain_scores_gemma":[0.9983789,0.00018255951,0.00051577744,0.00047681358,0.00041806238,0.000027886255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016673321,0.00036779352,0.00043886626,0.000048243757,0.00019594927,0.000012609849,0.00043456245,0.0005111561,0.000006362138],"category_scores_gemma":[0.000084036896,0.0002562581,0.00022070251,0.00016026504,0.0007350178,0.00000471131,0.00010902106,0.00031286324,0.0000026244809],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009397599,0.000105864885,0.0058833975,0.000112191534,0.0018468961,0.000003609095,0.0007417333,0.000016931408,0.004646021,0.000028233355,0.98301864,0.0026567252],"study_design_scores_gemma":[0.006015325,0.005985296,0.06080912,0.00046078188,0.0030486237,0.00020797276,0.004493266,0.000010791267,0.50767106,0.00071138766,0.40801772,0.0025686638],"about_ca_topic_score_codex":0.0016876996,"about_ca_topic_score_gemma":0.0017462418,"teacher_disagreement_score":0.8230238,"about_ca_system_score_codex":0.00030230437,"about_ca_system_score_gemma":0.00043194965,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W2167419679","doi":"10.1634/theoncologist.2013-0091","title":"Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study","year":2013,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; William Osler Health System; University of Alberta","funders":"Genentech; Sanofi","keywords":"Medicine; Docetaxel; Trastuzumab; Tolerability; Breast cancer; Internal medicine; Regimen; Oncology; Carboplatin; Taxane; Adjuvant; Chemotherapy; Cancer; Adverse effect; Cisplatin","score_opus":0.009473063582280821,"score_gpt":0.24856754078916854,"score_spread":0.23909447720688773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167419679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990355,0.0005615042,0.000017962975,0.00447635,0.000029656618,0.0015539215,0.0029388906,0.000011178536,0.00005551081],"genre_scores_gemma":[0.998965,0.00012767983,0.00013909965,0.00037797508,0.000028906989,0.00018620174,0.0001385927,0.000022113458,0.000014398073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761796,0.0008417782,0.0004541783,0.0005576102,0.000239064,0.0002894016],"domain_scores_gemma":[0.99817,0.00044229385,0.00064843945,0.00041039864,0.00024235088,0.000086513945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036072146,0.00030182573,0.0005642686,0.00002334002,0.00027490492,0.000028506329,0.00017262106,0.00008897097,0.0000044112753],"category_scores_gemma":[0.00007550035,0.00015346135,0.00003177578,0.00015962671,0.0009370947,0.000013649829,0.00012221953,0.00020965566,0.0000010268764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008427173,0.00088811177,0.9836331,0.000008251352,0.00069833075,0.0000019343333,0.0031980528,0.00017369093,0.00004679506,0.0000047925696,0.00013839359,0.002781345],"study_design_scores_gemma":[0.014205788,0.0029578009,0.98024994,0.00009968098,0.00013425223,0.0000010940969,0.0018953452,0.000011773498,0.00022560277,0.00002188032,0.0000024174112,0.00019441696],"about_ca_topic_score_codex":0.31192574,"about_ca_topic_score_gemma":0.0397254,"teacher_disagreement_score":0.27220035,"about_ca_system_score_codex":0.00013899933,"about_ca_system_score_gemma":0.00022162593,"threshold_uncertainty_score":0.9777971},"labels":[],"label_agreement":null},{"id":"W2167634945","doi":"10.1634/theoncologist.2011-0079","title":"Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Stage (stratigraphy); Cancer research; Internal medicine; Pharmacology","score_opus":0.06412952942016496,"score_gpt":0.38629462010173876,"score_spread":0.3221650906815738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167634945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98172563,0.00044566987,0.000016991651,0.0001979023,0.00009111477,0.00048484185,0.000022007547,0.000011092012,0.017004771],"genre_scores_gemma":[0.99420613,0.00023040986,0.00012896604,0.0001911636,0.00003781844,0.000022100816,0.0000068852646,0.000012771728,0.0051637455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995001,0.000022410411,0.00012972832,0.00012405585,0.000073996904,0.00014971757],"domain_scores_gemma":[0.9996318,0.000034397726,0.0000798378,0.00016667259,0.000022106173,0.000065164764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008639865,0.00010065278,0.00020037557,0.00003988616,0.000028343138,0.0000037635975,0.000061865845,0.000046224897,0.00052404904],"category_scores_gemma":[0.0000065220893,0.000056656878,0.000048634072,0.00010146825,0.000063817024,0.000018103596,0.000016280092,0.0000895472,0.0000027889992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066081743,0.000652879,0.98323303,0.00006495728,0.0002936153,0.000022209046,0.0069740713,0.000066924644,0.0019798316,0.000030438168,0.0010894536,0.0049317926],"study_design_scores_gemma":[0.003284685,0.0008248491,0.9932617,0.000045330933,0.00018055864,9.842355e-7,0.00022786371,0.00021761631,0.0016561652,0.000024042434,0.0002155189,0.000060660932],"about_ca_topic_score_codex":0.01618761,"about_ca_topic_score_gemma":0.0009992163,"teacher_disagreement_score":0.015188393,"about_ca_system_score_codex":0.00028036436,"about_ca_system_score_gemma":0.0003444445,"threshold_uncertainty_score":0.99036366},"labels":[],"label_agreement":null},{"id":"W2167723770","doi":"10.1634/theoncologist.2009-0277","title":"Review of the Clinical Studies Using the 21-Gene Assay","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cyclophosphamide; Breast cancer; Oncology; Internal medicine; Chemotherapy; Fluorouracil; Methotrexate; Doxorubicin; Adjuvant; Cancer","score_opus":0.2377358967915531,"score_gpt":0.5080055087202885,"score_spread":0.2702696119287354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167723770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002164412,0.99573296,0.000005484216,0.0013563083,0.0012068377,0.0010325112,0.000082999104,0.000006846799,0.0005543885],"genre_scores_gemma":[0.000033397795,0.9970019,0.0001343183,0.0013049546,0.0009949015,0.00017229839,0.000029183057,0.000032559787,0.0002964905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970698,0.0013078833,0.00081789243,0.0003895397,0.00017559288,0.0002393217],"domain_scores_gemma":[0.99666625,0.0005754464,0.0010500816,0.0014956777,0.00018597936,0.00002656273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022778732,0.00038292015,0.001484453,0.0000098211885,0.000324166,0.000009429122,0.0011572122,0.0003317538,0.000008439257],"category_scores_gemma":[0.0015187337,0.0001328479,0.0010400724,0.00017921955,0.001816731,0.0000011316407,0.001105342,0.0005487903,0.000008304018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001705149,0.00014952007,0.000086479005,0.014490615,0.0023613544,0.0000024857832,0.00002688635,5.156389e-7,0.000025241046,0.000049934217,0.03269957,0.95009035],"study_design_scores_gemma":[0.0001142509,0.000063849955,0.00003660492,0.011457855,0.0027800181,0.00006341773,0.000029047109,9.015005e-8,0.000038388727,0.000021294183,0.9852462,0.00014900931],"about_ca_topic_score_codex":0.00002976754,"about_ca_topic_score_gemma":0.00010344018,"teacher_disagreement_score":0.9525466,"about_ca_system_score_codex":0.000075140124,"about_ca_system_score_gemma":0.0005479299,"threshold_uncertainty_score":0.6693821},"labels":[],"label_agreement":null},{"id":"W2168507982","doi":"10.1634/theoncologist.2014-0372","title":"Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Federación Española de Enfermedades Raras; Cancer Research UK; Breast Cancer Research Foundation","keywords":"Breast cancer; Expression (computer science); Cancer; Cancer research; Computational biology; Biology; Oncology; Medicine; Genetics; Computer science","score_opus":0.02440197533705295,"score_gpt":0.3159511142045415,"score_spread":0.29154913886748857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168507982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651399,0.01856994,0.00020805729,0.008977433,0.0007912595,0.00030077551,0.0005366989,0.000059720765,0.005416169],"genre_scores_gemma":[0.9973756,0.00056657445,0.0006199311,0.00046485726,0.00018875136,0.00012065888,0.00010269361,0.000017506054,0.0005433972],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923676,0.000102816695,0.000114680945,0.0002409117,0.00010905033,0.00019575571],"domain_scores_gemma":[0.9994782,0.000042783922,0.00009528753,0.0002173545,0.00010562886,0.00006074618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016875226,0.00013898309,0.0001392908,0.000011392367,0.0001343419,0.000016385988,0.00018247658,0.000078696015,0.00003199153],"category_scores_gemma":[0.00008957897,0.00008621373,0.000040083083,0.000072292554,0.00025288062,0.0000040908303,0.00016752812,0.00007475627,0.00006136834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002341612,0.0003134524,0.060136355,0.000014020274,0.00030076923,0.000004518456,0.0011828212,0.00010122371,0.11955837,0.00093230605,0.7918496,0.023264918],"study_design_scores_gemma":[0.006217277,0.0017383033,0.084162064,0.0001571868,0.00024123708,0.00008664557,0.008166548,0.000019874315,0.35588133,0.00060469523,0.5415782,0.0011466615],"about_ca_topic_score_codex":0.00055575435,"about_ca_topic_score_gemma":0.0002563315,"teacher_disagreement_score":0.25027144,"about_ca_system_score_codex":0.000097473516,"about_ca_system_score_gemma":0.00012755489,"threshold_uncertainty_score":0.35156938},"labels":[],"label_agreement":null},{"id":"W2171469985","doi":"10.1634/theoncologist.11-1-73","title":"Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ozmosis Research (Canada); Regional Municipality of Durham; Royal Columbian Hospital; Saint John Regional Hospital; Mount Sinai Hospital; Lakeridge Health; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epoetin alfa; Erythropoietin; Anemia; Placebo; Internal medicine; Blood transfusion; Clinical trial; Hemoglobin; Randomized controlled trial; Chemotherapy","score_opus":0.048760332779745,"score_gpt":0.32552822682743127,"score_spread":0.27676789404768626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171469985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2885262,0.6785749,0.000057285164,0.0017962117,0.00045646355,0.020855948,0.008525117,0.00021785272,0.0009899923],"genre_scores_gemma":[0.036908973,0.94004756,0.0003552625,0.0003104713,0.0001284088,0.001744705,0.0067299195,0.00014813516,0.01362658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964046,0.0007778078,0.0009907432,0.00077274774,0.00047201646,0.00058210664],"domain_scores_gemma":[0.9969692,0.00038472528,0.00083801156,0.0011658937,0.0003158662,0.00032628272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048551985,0.0007372529,0.002593855,0.00021482678,0.00062665984,0.000024506577,0.0004899905,0.00047017346,0.00083582103],"category_scores_gemma":[0.000088347784,0.0002877941,0.0010213533,0.0016150785,0.000749787,0.000028708104,0.000031270345,0.00038752923,0.0000064600013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011122983,0.010297981,0.18870845,0.017267508,0.017371187,0.00095151004,0.0057508326,0.0003910323,0.000028865954,0.000021584123,0.018326173,0.7297619],"study_design_scores_gemma":[0.0055809445,0.0031602713,0.008446465,0.0061539724,0.04380345,0.00005685802,0.00031447993,0.000100761776,0.00013041132,6.566651e-7,0.9315793,0.00067244895],"about_ca_topic_score_codex":0.15750174,"about_ca_topic_score_gemma":0.84269077,"teacher_disagreement_score":0.9132531,"about_ca_system_score_codex":0.0039526857,"about_ca_system_score_gemma":0.001100963,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W2171987744","doi":"10.1634/theoncologist.2009-0186","title":"Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Stage (stratigraphy); Clinical trial; Disease; Adjuvant therapy; Radiation therapy; Randomized controlled trial; Adjuvant; Chemotherapy","score_opus":0.03930313211394137,"score_gpt":0.3853508005870658,"score_spread":0.3460476684731244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171987744","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004928859,0.99163544,3.8688606e-7,0.0014824504,0.001958528,0.0024527102,0.000066268105,0.000033782726,0.0018775235],"genre_scores_gemma":[0.00007670142,0.9953004,0.000033570803,0.00011971358,0.0017556268,0.0022431458,0.00005077093,0.000040323994,0.0003797232],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987687,0.00010027091,0.00034538365,0.0003933164,0.00012248306,0.00026985182],"domain_scores_gemma":[0.9989794,0.00018979509,0.00023544299,0.00045495474,0.000038029222,0.00010236323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021709391,0.00036662526,0.0012964794,0.00009096583,0.00011743896,0.000026999787,0.0001593419,0.00028504248,0.0000955007],"category_scores_gemma":[0.0000066236985,0.00017937769,0.00025712806,0.00022917187,0.00012315564,0.000016163132,0.000060090406,0.000951885,0.000011869445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000125679035,0.00041317192,0.0015507892,0.003254706,0.00009635329,0.000023807586,0.00016759904,8.889339e-8,1.5934269e-7,0.000013454164,0.0027815346,0.99168575],"study_design_scores_gemma":[0.0010326768,0.00022364763,0.0027729846,0.0047940514,0.0012618407,0.00002641898,0.000022423083,0.0000028753295,0.0000015585254,0.000004225556,0.98967975,0.00017755544],"about_ca_topic_score_codex":0.00074691186,"about_ca_topic_score_gemma":0.0021168452,"teacher_disagreement_score":0.9915082,"about_ca_system_score_codex":0.0007680438,"about_ca_system_score_gemma":0.00065624196,"threshold_uncertainty_score":0.731481},"labels":[],"label_agreement":null},{"id":"W2172085565","doi":"10.1634/theoncologist.2008-0017","title":"Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial","year":2008,"lang":"en","type":"article","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Darbepoetin alfa; Aerobic exercise; Cardiorespiratory fitness; Randomized controlled trial; Quality of life (healthcare); Clinical endpoint; Anemia; Epoetin alfa; Dosing; VO2 max; Physical therapy; Internal medicine; Erythropoietin; Heart rate; Blood pressure","score_opus":0.0195430276610687,"score_gpt":0.29278919327578745,"score_spread":0.27324616561471876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172085565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98534787,0.0017637291,0.0000033376432,0.00075155165,0.00047020352,0.0071381913,0.0000012707014,0.000037557696,0.0044863],"genre_scores_gemma":[0.9942006,0.0026643113,0.00019788506,0.00015111407,0.00013210693,0.0016293077,0.000008190798,0.0000184863,0.0009980225],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809927,0.00047081194,0.00067510246,0.00021811711,0.0002567032,0.00028001066],"domain_scores_gemma":[0.99720544,0.002100802,0.00037632824,0.00018775082,0.00006440806,0.00006528747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093029765,0.00020222848,0.0019414888,0.00008237764,0.00009543589,0.000004391371,0.000110037654,0.000117281925,0.000061947976],"category_scores_gemma":[0.0013643168,0.00010743073,0.00032905463,0.0001693787,0.0005255044,0.000023219698,0.00003307978,0.0002325103,0.000006518719],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9852982,0.0011317986,0.0013618165,0.00009747922,0.00016389256,0.00009511791,0.00454356,0.000015990683,0.00094308023,0.0000141452365,0.00081176835,0.005523151],"study_design_scores_gemma":[0.99374795,0.0009477352,0.0020229854,0.00066010474,0.0005476943,0.000010919585,0.0002255257,0.000052898507,0.0015735788,0.000031995045,0.00007440845,0.00010422757],"about_ca_topic_score_codex":0.0005503745,"about_ca_topic_score_gemma":0.00009547803,"teacher_disagreement_score":0.0088527175,"about_ca_system_score_codex":0.00022419695,"about_ca_system_score_gemma":0.0003237245,"threshold_uncertainty_score":0.4380898},"labels":[],"label_agreement":null},{"id":"W2172287368","doi":"10.1634/theoncologist.2010-s1-24","title":"Drug Pricing and Value in Oncology","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Formulary; Reimbursement; Medicine; Incentive; Pharmacy; Actuarial science; Cancer drugs; Medical prescription; Medicare Part D; Cost sharing; Prescription drug; Specialty; Leverage (statistics); Drug prices; Negotiation; Value (mathematics); Drug; Family medicine; Business; Public economics; Pharmacology; Health care; Economics; Nursing","score_opus":0.028503005344527776,"score_gpt":0.2669798053598916,"score_spread":0.2384768000153638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172287368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7937152,0.0006777774,0.000071608025,0.006226446,0.00071921444,0.00015271771,0.000010927216,0.000018091449,0.19840805],"genre_scores_gemma":[0.9964103,0.0002878324,0.0005230474,0.0012525544,0.00021479791,0.000020978625,0.0000010356832,0.000011217532,0.0012782492],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99912745,0.000015348975,0.000364808,0.00022680007,0.0000112730795,0.00025432973],"domain_scores_gemma":[0.9993152,0.00018642035,0.00020999291,0.00022684308,0.000008805834,0.000052717205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011593507,0.00009578207,0.0003084208,0.00008329068,0.000096373304,0.000039233222,0.00022893764,0.0001162474,0.00014955248],"category_scores_gemma":[0.0002704407,0.00008191539,0.00003567067,0.00009887736,0.00027851452,0.00013694448,0.0000854711,0.00039592638,0.00020282822],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003421967,0.0000802276,0.09952162,0.000007728215,0.000011000758,0.000008868901,0.0012150084,0.00007916583,0.000118744414,0.877458,0.0025790662,0.018886369],"study_design_scores_gemma":[0.00091936707,0.00012556884,0.27512658,0.0000062575637,0.0000039830197,0.000018555476,0.00020833824,0.0011240937,0.00007259272,0.14931072,0.57284683,0.00023712785],"about_ca_topic_score_codex":0.0024448012,"about_ca_topic_score_gemma":0.0029724825,"teacher_disagreement_score":0.72814727,"about_ca_system_score_codex":0.00014450308,"about_ca_system_score_gemma":0.00005520266,"threshold_uncertainty_score":0.3695824},"labels":[],"label_agreement":null},{"id":"W2201187369","doi":"10.1634/theoncologist.2015-0266","title":"The Effect of Introducing the Spinal Instability Neoplastic Score in Routine Clinical Practice for Patients With Spinal Metastases","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Spine Surgery Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Medicine; Radiation therapy; Surgery; Spinal surgery; Clinical Practice; Spinal disease; Physical therapy; Lumbar","score_opus":0.05544374934467581,"score_gpt":0.3984314944545013,"score_spread":0.3429877451098255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2201187369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985291,0.00031674496,0.00072628097,0.009650554,0.00032478574,0.0030799098,0.000015828631,0.000019772488,0.00057511625],"genre_scores_gemma":[0.9978802,0.000009714609,0.00130989,0.00040263758,0.00014929248,0.00017338249,0.000015105884,0.00001469798,0.000045029203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968024,0.001371171,0.0006605722,0.0003037407,0.00056759553,0.00029453938],"domain_scores_gemma":[0.9936787,0.004548822,0.00051527494,0.0008176527,0.0003240774,0.00011550834],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01133911,0.00018352701,0.00048201747,0.000034869892,0.00014766418,0.000031821557,0.00033675157,0.0000369091,0.000006811466],"category_scores_gemma":[0.04001316,0.000068063564,0.00011220634,0.00026398932,0.0008525327,0.0000944149,0.00016271167,0.00033635803,0.000006482122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15139201,0.0028979164,0.7617529,0.0005882992,0.00056020776,0.000044017062,0.00025799708,0.00030037996,0.0000028126324,0.0013413376,0.0049320287,0.07593011],"study_design_scores_gemma":[0.020912603,0.05826095,0.9010541,0.0002978468,0.003038349,0.000016372895,0.0022417107,0.0009718576,0.000034156274,0.00027472223,0.012707474,0.00018989618],"about_ca_topic_score_codex":0.00015014729,"about_ca_topic_score_gemma":0.00013561087,"teacher_disagreement_score":0.13930118,"about_ca_system_score_codex":0.00013410745,"about_ca_system_score_gemma":0.00028454702,"threshold_uncertainty_score":0.9680732},"labels":[],"label_agreement":null},{"id":"W2214942476","doi":"10.1634/theoncologist.2015-0295","title":"S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Imatinib; Oncology; Internal medicine; Stromal cell; Phases of clinical research; Imatinib mesylate; Chemotherapy","score_opus":0.06706704764157113,"score_gpt":0.36808130624342006,"score_spread":0.30101425860184894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2214942476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99225074,0.000014228876,0.00017609423,0.00014489477,0.00001109405,0.006490689,0.000030392806,0.00006146973,0.00082037726],"genre_scores_gemma":[0.98997766,7.426674e-7,0.008537951,0.000023505108,0.000018375633,0.000537442,0.00005837248,0.0000424381,0.00080351805],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963657,0.000771908,0.0007491655,0.00042311565,0.0010107518,0.0006793352],"domain_scores_gemma":[0.9971964,0.0008180296,0.0004689838,0.00054029777,0.0005738849,0.00040245228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012889962,0.00040943862,0.0016872833,0.00021945128,0.000098696364,0.00003759582,0.00026190578,0.000017499822,0.00016009787],"category_scores_gemma":[0.0017258815,0.00015879504,0.000068552574,0.0007313318,0.0007438746,0.00011139465,0.00010370825,0.0003921215,0.000012449701],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7139068,0.0123851225,0.26938373,0.000057678604,0.00030130212,0.0027736782,0.00071549375,0.00012702112,0.000018689887,0.00000802652,0.000050036284,0.00027242277],"study_design_scores_gemma":[0.7911855,0.1681892,0.027577719,0.0007591417,0.00081719604,0.0015999429,0.008184319,0.0013905435,0.000095615775,0.000016922228,0.0000030271954,0.0001808792],"about_ca_topic_score_codex":0.0037031856,"about_ca_topic_score_gemma":0.0038113089,"teacher_disagreement_score":0.241806,"about_ca_system_score_codex":0.0003929327,"about_ca_system_score_gemma":0.0012436982,"threshold_uncertainty_score":0.64754736},"labels":[],"label_agreement":null},{"id":"W2234005477","doi":"10.1634/theoncologist.2015-0209","title":"Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Erlotinib; Medicine; Oncology; Erlotinib Hydrochloride; Epidermal growth factor receptor; Internal medicine; Lung cancer; Chemotherapy; EGFR inhibitors; Gefitinib; Cancer","score_opus":0.04183407779112243,"score_gpt":0.362706235453725,"score_spread":0.3208721576626026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2234005477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027914655,0.97118574,0.000012604347,0.0014533949,0.00032301477,0.0033893508,0.00024959104,0.000010660732,0.020584151],"genre_scores_gemma":[0.22212507,0.7753933,0.000050792496,0.00012165592,0.0001166145,0.00034408137,0.000053055453,0.00002308275,0.0017723588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985512,0.0003318079,0.0005103659,0.00018367736,0.00024875093,0.00017420709],"domain_scores_gemma":[0.9985174,0.0003586311,0.00052523066,0.0005230246,0.000052919753,0.00002277306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000298201,0.0002059294,0.00068456266,0.000056039677,0.00007237735,0.0000056588215,0.00024597833,0.0001171593,0.00012936418],"category_scores_gemma":[0.000026301423,0.00006897824,0.00032980886,0.00025036404,0.00023209189,0.000022917959,0.00009529133,0.00020260234,0.000012228347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017196128,0.0023513625,0.0018716363,0.076770484,0.0009789016,0.00017885833,0.003303512,0.0000020279672,0.00002581064,0.006487714,0.033067256,0.8747905],"study_design_scores_gemma":[0.0038624518,0.000822461,0.013173656,0.016229382,0.0075009917,0.000064392276,0.0009419698,0.0000015097602,0.00021886683,0.00019757649,0.9566548,0.0003319645],"about_ca_topic_score_codex":0.00016601651,"about_ca_topic_score_gemma":0.000016182406,"teacher_disagreement_score":0.9235875,"about_ca_system_score_codex":0.00045724315,"about_ca_system_score_gemma":0.00024558077,"threshold_uncertainty_score":0.28128508},"labels":[],"label_agreement":null},{"id":"W2239866897","doi":"10.1634/theoncologist.2015-0352","title":"Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; University of British Columbia, Okanagan Campus; University of British Columbia; BC Cancer Agency; Interior Health","funders":"National Cancer Institute; Canadian Institutes of Health Research; Michael Smith Health Research BC; Canadian Cancer Society","keywords":"Medicine; Cardiology; Internal medicine; Ejection fraction; Contractility; Anthracycline; Breast cancer; Subclinical infection; Arterial stiffness; Chemotherapy; Cancer; Heart failure; Blood pressure","score_opus":0.01337261817468551,"score_gpt":0.2811754560489555,"score_spread":0.26780283787427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2239866897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295837,0.00012742628,0.00008170218,0.005817216,0.00015110428,0.00065665465,0.00003340983,0.000037652462,0.00013645728],"genre_scores_gemma":[0.9979428,0.00043120806,0.000046803034,0.00080135395,0.00040335904,0.0002278617,0.000010796581,0.000024011846,0.0001117954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990838,0.000030226118,0.00021124967,0.00023705477,0.00018071258,0.00025696665],"domain_scores_gemma":[0.9994844,0.00007052651,0.000104640174,0.00021337466,0.00006444793,0.000062579915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014322989,0.00017137222,0.0003229098,0.000044171073,0.000060488088,0.000014329512,0.000057252808,0.00008940187,0.00016621135],"category_scores_gemma":[0.000008294935,0.00007707658,0.00007905483,0.000118973745,0.00013904282,0.00006910479,0.000011655115,0.00008005093,0.0000099454455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013624814,0.0013311314,0.79265165,0.000023479239,0.0002702574,0.00022240118,0.0010297584,0.000053780925,0.0653912,0.000012002399,0.00010145134,0.12528807],"study_design_scores_gemma":[0.025371416,0.0020273975,0.911735,0.00053732714,0.00013624583,0.000062913714,0.00021144333,0.00016547408,0.05747647,0.00002936322,0.0019918226,0.00025515727],"about_ca_topic_score_codex":0.00026933092,"about_ca_topic_score_gemma":0.00022783443,"teacher_disagreement_score":0.12503292,"about_ca_system_score_codex":0.00076221884,"about_ca_system_score_gemma":0.00013754344,"threshold_uncertainty_score":0.31430915},"labels":[],"label_agreement":null},{"id":"W2271999910","doi":"10.1634/theoncologist.2014-0412","title":"Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Mayo Clinic","keywords":"Medicine; Breast cancer; Pregnancy; Oncology; Obstetrics; Phenotype; Family history; Cohort; Cancer; Prospective cohort study; Young adult; Biomarker; Cohort study; Gynecology; Internal medicine; Gene; Biology","score_opus":0.0205317983764983,"score_gpt":0.31800519575887376,"score_spread":0.29747339738237544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271999910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939237,0.0005857984,0.00004952284,0.00057153765,0.00010431553,0.0004655272,0.00007777757,0.000015316044,0.0042064805],"genre_scores_gemma":[0.99934757,0.000059643167,0.000051822022,0.00015291623,0.000044702414,0.00006761429,0.0000037096177,0.000014069852,0.00025793834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911684,0.00004089343,0.00023751312,0.00014946451,0.0002105497,0.0002447507],"domain_scores_gemma":[0.9993651,0.00003119829,0.00012025827,0.0002651658,0.0001164757,0.00010179982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003579478,0.00009707782,0.00037219323,0.000058923022,0.000015873959,0.0000040636596,0.00014700548,0.00005358529,0.0000726663],"category_scores_gemma":[0.00008230748,0.00006588332,0.000039967435,0.0003096276,0.00009309589,0.000032021253,0.00009619342,0.000113314796,0.000012916649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091624615,0.00034219451,0.9654292,0.00007924919,0.000089234876,0.000036717465,0.0032576656,0.0002976343,0.022261504,0.00019290354,0.00046334107,0.006634144],"study_design_scores_gemma":[0.0030943467,0.0008619944,0.9868442,0.0009222429,0.00011210694,0.00002291305,0.002494144,0.0002633608,0.0036005666,0.000096672695,0.0014883801,0.00019909789],"about_ca_topic_score_codex":0.0030874603,"about_ca_topic_score_gemma":0.0007166235,"teacher_disagreement_score":0.02141501,"about_ca_system_score_codex":0.000471239,"about_ca_system_score_gemma":0.00030158667,"threshold_uncertainty_score":0.4667337},"labels":[],"label_agreement":null},{"id":"W2281889317","doi":"10.1634/theoncologist.2014-0341","title":"Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Cancer; Emergency department; Presentation (obstetrics); Palliative care; Disease; Intensive care medicine; Health care; Quality of life (healthcare); Malignancy; Medical diagnosis; Medical emergency; Nursing; Internal medicine; Surgery; Pathology","score_opus":0.046443827871196046,"score_gpt":0.4155791656044463,"score_spread":0.36913533773325025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281889317","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031010457,0.98284984,0.0000060963885,0.0009807455,0.0010296323,0.0015636466,0.0016767569,0.000060611834,0.008731601],"genre_scores_gemma":[0.00081347954,0.98544204,0.000016337053,0.0001858554,0.00026728612,0.0005466101,0.00013997342,0.00005415319,0.01253428],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985338,0.000121158984,0.00045632513,0.00024548045,0.00027992524,0.00036329823],"domain_scores_gemma":[0.99839675,0.0001105757,0.00045345412,0.00059206114,0.0003131024,0.0001340576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015513589,0.00032108912,0.0014315207,0.00032532593,0.00015986564,0.000017949467,0.00030945963,0.00016806499,0.00033779434],"category_scores_gemma":[0.000034986453,0.0001429799,0.0002451973,0.0014920742,0.00018745882,0.000031998145,0.00015112384,0.00028849268,0.000041941916],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052509626,0.000073878655,0.0016222765,0.0010772445,0.00044839387,0.0000074574896,0.0004820773,2.3331911e-7,0.0000018053094,0.00002226488,0.0047910064,0.99094826],"study_design_scores_gemma":[0.0012845291,0.0010896653,0.0015459228,0.008682634,0.0017754617,0.00000996119,0.00013220418,5.0559756e-9,0.000009980667,4.2591083e-7,0.985292,0.00017722206],"about_ca_topic_score_codex":0.00013377694,"about_ca_topic_score_gemma":0.0001907875,"teacher_disagreement_score":0.99077106,"about_ca_system_score_codex":0.0011202347,"about_ca_system_score_gemma":0.0004877944,"threshold_uncertainty_score":0.58305514},"labels":[],"label_agreement":null},{"id":"W2287831934","doi":"10.1634/theoncologist.2015-0056","title":"Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Grand River Hospital; Foothills Medical Centre; University of Ottawa","funders":"University of Ottawa; University of Calgary; American Society of Clinical Oncology","keywords":"Social media; Medicine; Clinical trial; Newspaper; Citation; The Internet; Internal medicine; Advertising; World Wide Web; Computer science","score_opus":0.5674891192042176,"score_gpt":0.6463256784029308,"score_spread":0.07883655919871313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287831934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8238542,0.0001472888,0.00007600618,0.15118122,0.0044125444,0.0015172823,0.000004435098,0.000054515494,0.018752517],"genre_scores_gemma":[0.99437124,0.0008535179,0.0015429689,0.00046283694,0.002368193,0.0003420889,6.145644e-7,0.000008853218,0.000049706887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9842463,0.011793445,0.0028503386,0.00026487402,0.0003981329,0.00044687497],"domain_scores_gemma":[0.5978387,0.38157204,0.018764198,0.0005227814,0.0010092211,0.00029308186],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0991713,0.000083909305,0.00087467406,0.00012433172,0.0002689641,0.000011748726,0.0003056416,0.0001232375,0.00003212493],"category_scores_gemma":[0.82439923,0.000048669783,0.00014403177,0.0010310631,0.0023607833,0.00014084863,0.00006061368,0.00029915682,0.000018887717],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020065623,0.00029636212,0.2847159,0.0000034664274,0.000028551574,0.000015860658,0.18631144,6.518426e-7,0.0000136955105,0.014424178,0.00033692966,0.5136523],"study_design_scores_gemma":[0.000614688,0.0004352477,0.53376406,0.000051145602,0.00007260845,0.0000024634533,0.38843513,0.0000018611915,0.00001099734,0.001922408,0.074565426,0.00012397933],"about_ca_topic_score_codex":0.034075424,"about_ca_topic_score_gemma":0.08956916,"teacher_disagreement_score":0.7252279,"about_ca_system_score_codex":0.0017215379,"about_ca_system_score_gemma":0.002907219,"threshold_uncertainty_score":0.97235674},"labels":[],"label_agreement":null},{"id":"W2300207219","doi":"10.1634/theoncologist.2016-0069","title":"Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?","year":2016,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Cardiotoxicity; Dexrazoxane; Trastuzumab; Anthracycline; Cardioprotection; Oncology; Doxorubicin; Regimen; Internal medicine; Pharmacology; Adverse effect; Clinical trial; Cardiology; Chemotherapy; Cancer; Myocardial infarction; Breast cancer","score_opus":0.062470239359428435,"score_gpt":0.3184028482091724,"score_spread":0.255932608849744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300207219","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042116545,0.0016983144,0.00007300255,0.9270547,0.0012043762,0.0014823395,0.000022586219,0.00017906909,0.026169082],"genre_scores_gemma":[0.24832807,0.007032334,0.0004112037,0.678217,0.025220234,0.0003930954,0.00023981505,0.00023387231,0.03992439],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974603,0.00038983393,0.00044179274,0.0006006741,0.00048231854,0.0006250484],"domain_scores_gemma":[0.99768436,0.0009860233,0.0003313886,0.00080644136,0.00012849408,0.000063300045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090368185,0.00040955198,0.0010190429,0.00014265098,0.00013041947,0.000100886835,0.00020246154,0.0011426756,0.00007951151],"category_scores_gemma":[0.00040940105,0.00026024505,0.00030898914,0.00024261656,0.00044086998,0.00016744508,0.000093393246,0.0021663276,0.000140821],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016607731,0.000070025824,0.00015919282,0.0003093159,0.00030562206,0.0012029958,0.0013327779,0.0000062179574,0.24069723,0.000017429786,0.5938072,0.1619259],"study_design_scores_gemma":[0.001988087,0.0004949103,0.00045411786,0.0025827973,0.00022412176,0.00018315695,0.00085367844,0.000008021395,0.10289709,0.00044004197,0.8893846,0.00048936123],"about_ca_topic_score_codex":0.00016392469,"about_ca_topic_score_gemma":0.000026717007,"teacher_disagreement_score":0.2955774,"about_ca_system_score_codex":0.000733954,"about_ca_system_score_gemma":0.00041276528,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W2309664335","doi":"10.1634/theoncologist.2015-0239","title":"Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Debulking; Medicine; Ovarian cancer; Randomized controlled trial; Clinical trial; Oncology; Internal medicine; Cancer; Serous fluid; Surgery","score_opus":0.0784323802967087,"score_gpt":0.382023392231853,"score_spread":0.3035910119351443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309664335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013756056,0.97132164,0.000049362327,0.001247736,0.0018728136,0.009310424,0.0022912067,0.000030873336,0.000119858254],"genre_scores_gemma":[0.03780784,0.9571972,0.00051450374,0.00028027577,0.00024193976,0.0035450142,0.00022837336,0.00009485999,0.00008998703],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9908787,0.0025374219,0.004691564,0.0009124768,0.0003656978,0.0006141203],"domain_scores_gemma":[0.9616855,0.030518502,0.0064266967,0.0007999102,0.00044804005,0.00012136573],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076082707,0.00084920507,0.012712884,0.0004051344,0.0001437351,0.000024641768,0.00041900334,0.00039895915,0.000032542004],"category_scores_gemma":[0.0084813535,0.0003850994,0.0016605627,0.0005495604,0.0014019985,0.00014044667,0.00043372097,0.000409086,2.6077456e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06547386,0.00042256105,0.004197675,0.018139731,0.0020534908,0.000014001708,0.00039295442,0.0000015776549,0.000013017273,0.00008495103,0.000317396,0.90888876],"study_design_scores_gemma":[0.28276753,0.0023559975,0.030507535,0.33128768,0.021279326,0.00009412443,0.00029349627,0.00001727558,0.0007152346,0.0010538409,0.32763794,0.001990012],"about_ca_topic_score_codex":0.0025057162,"about_ca_topic_score_gemma":0.0013647192,"teacher_disagreement_score":0.9068988,"about_ca_system_score_codex":0.0010657441,"about_ca_system_score_gemma":0.0031839495,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W2345838610","doi":"10.1634/theoncologist.2015-0248","title":"Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; National Institute for Health and Care Research; Cancer Research UK","keywords":"PI3K/AKT/mTOR pathway; Medicine; Protein kinase B; Phosphatidylinositol; Kinase; RPTOR; Incidence (geometry); Sirolimus; Cancer research; Internal medicine; Signal transduction; Cell biology; Biology","score_opus":0.02312363592342188,"score_gpt":0.30505262826347057,"score_spread":0.2819289923400487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345838610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935872,0.0033516744,0.0005785878,0.00044353833,0.00026835897,0.0011250481,0.00018114023,0.00002206449,0.00044237377],"genre_scores_gemma":[0.997711,0.00075394794,0.0006306217,0.000094542345,0.00024752272,0.00017811242,0.000030654355,0.000031235268,0.0003223885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976642,0.00044975348,0.00067921577,0.0005810697,0.00025242573,0.00037331335],"domain_scores_gemma":[0.9986464,0.00022788419,0.00044250424,0.00047652007,0.00008068944,0.00012604741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014842768,0.00033033802,0.00055794785,0.00010056729,0.00011133789,0.000027692138,0.00034044092,0.00026609795,0.000035481626],"category_scores_gemma":[0.0005945059,0.00019689233,0.00010357954,0.00017257278,0.00071930327,0.000018839675,0.00031230834,0.00014631217,0.0000020512475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003110407,0.00038446477,0.047807198,0.00012778235,0.00020240819,0.000053654963,0.00029913336,0.000022891605,0.9257313,0.00025051998,0.0025156084,0.019494599],"study_design_scores_gemma":[0.006652177,0.0025436536,0.009506489,0.00028737704,0.00010500484,0.000007741442,0.00046481643,0.000027827673,0.96520716,0.00040467724,0.0144133875,0.00037967385],"about_ca_topic_score_codex":0.00019109009,"about_ca_topic_score_gemma":0.00012405291,"teacher_disagreement_score":0.039475843,"about_ca_system_score_codex":0.00012472304,"about_ca_system_score_gemma":0.000119673,"threshold_uncertainty_score":0.8029036},"labels":[],"label_agreement":null},{"id":"W2345972868","doi":"10.1634/theoncologist.2015-0336","title":"The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Canadian Institutes of Health Research; National Institute for Health and Care Research; National Cancer Institute; Ovarian Cancer Research Fund; National Institutes of Health; Cancer Research UK; American Society of Clinical Oncology; National Institute for Health and Care Excellence; Royal Marsden NHS Foundation Trust; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Medicine; Prostate cancer; Oncology; Prostate cancer screening; Family history; Internal medicine; Prostate-specific antigen; Logistic regression; Population; Single-nucleotide polymorphism; Prostate; Gynecology; Cancer; Genotype","score_opus":0.05336829173518951,"score_gpt":0.3218246425786746,"score_spread":0.26845635084348507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345972868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815223,0.006257841,0.000013631883,0.0029509948,0.000089202054,0.0027878722,0.000078241574,0.000028240527,0.0062716655],"genre_scores_gemma":[0.99467355,0.00060972985,0.00012800218,0.00007222562,0.00002852219,0.0006766451,0.0000025828508,0.000013125651,0.0037956377],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998972,0.00012391407,0.00026572522,0.00019820993,0.0002504837,0.00018964321],"domain_scores_gemma":[0.99874854,0.00025763162,0.00028281804,0.00046250634,0.00020104072,0.000047467176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054818386,0.0001188174,0.00031031534,0.000017939818,0.000067896435,0.0000027489666,0.00013580528,0.00002671731,0.00004731474],"category_scores_gemma":[0.000071879054,0.000039858995,0.000052430485,0.00009014836,0.0006776317,0.000032228374,0.000055350556,0.000073514486,0.0000019381555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004746923,0.0013444698,0.8957831,0.000058834143,0.00050391885,0.0000205122,0.0021814432,0.0000054119355,0.0060682218,0.000077779994,0.011373553,0.077835806],"study_design_scores_gemma":[0.005899823,0.0062881345,0.96088886,0.00026113205,0.00034807454,0.0000022155396,0.0023359808,0.000017347515,0.0070666024,0.00006435266,0.016727692,0.00009978474],"about_ca_topic_score_codex":0.0017696975,"about_ca_topic_score_gemma":0.00050674775,"teacher_disagreement_score":0.07773602,"about_ca_system_score_codex":0.00092801073,"about_ca_system_score_gemma":0.0006508527,"threshold_uncertainty_score":0.2675265},"labels":[],"label_agreement":null},{"id":"W2397623993","doi":"10.1634/theoncologist.2016-0006","title":"Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Referral; Palliative care; Medicine; Family medicine; Cancer; Nursing; Internal medicine","score_opus":0.4229028458163722,"score_gpt":0.5719189273617419,"score_spread":0.14901608154536966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397623993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.253484e-7,0.9872998,0.0000482273,0.00065261836,0.00060435565,0.008722604,0.0006805745,0.00004019087,0.0019511266],"genre_scores_gemma":[0.0000038393055,0.9900745,0.00027042592,0.0007383151,0.0004091401,0.005972205,0.00017649902,0.000055331602,0.0022997323],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99723303,0.00053380575,0.001235962,0.0003716965,0.00029965074,0.00032585242],"domain_scores_gemma":[0.99585164,0.0014335614,0.0013340409,0.0007660845,0.00052128156,0.000093373004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006747163,0.00046821282,0.0049343337,0.00006518659,0.00007744069,0.000010329043,0.0004181002,0.00027411492,0.00012232902],"category_scores_gemma":[0.0020783527,0.0001966808,0.0009917355,0.00018940118,0.0002357495,0.000026302083,0.00009603033,0.0002565582,0.00007006662],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030665793,0.00003729346,0.0000034835311,0.9316694,0.000555747,0.00000644952,0.00050373224,6.1111893e-9,1.4567739e-7,0.00013330855,0.012389002,0.054670762],"study_design_scores_gemma":[0.00021624986,0.0003083342,4.916351e-7,0.49759144,0.0054759365,0.000003065558,0.00009935058,1.488027e-7,9.275907e-7,0.000011281078,0.49617055,0.00012222613],"about_ca_topic_score_codex":0.00007569896,"about_ca_topic_score_gemma":0.000041147734,"teacher_disagreement_score":0.48378155,"about_ca_system_score_codex":0.0010203277,"about_ca_system_score_gemma":0.00070491526,"threshold_uncertainty_score":0.80204105},"labels":[],"label_agreement":null},{"id":"W2464278690","doi":"10.1634/theoncologist.2015-0433","title":"Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Oral Health Pathology and Treatment","field":"Dentistry","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Simon Fraser University; Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Terry Fox Research Institute; Provincial Health Services Authority; Canadian Cancer Society; Genome British Columbia; Canadian Centre for Applied Research in Cancer Control","keywords":"Loss of heterozygosity; Medicine; Dysplasia; Internal medicine; Biology; Genetics","score_opus":0.06110671640983808,"score_gpt":0.35818234342944655,"score_spread":0.2970756270196085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464278690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982406,0.000045653538,0.00023186168,0.00006419668,0.00021166881,0.0006829038,0.00040185667,0.000008711803,0.00011254524],"genre_scores_gemma":[0.99947417,0.000007145848,0.00011821281,0.00006451361,0.000007974792,0.00004665528,0.0000063537786,0.0000070034434,0.00026799494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998382,0.0005744643,0.00036441506,0.00024014634,0.00016854738,0.0002704453],"domain_scores_gemma":[0.9989271,0.00041219598,0.0002064472,0.0003287754,0.00006320981,0.000062243125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067931705,0.00008316809,0.00053698965,0.000057993573,0.00008992933,0.000010805167,0.00021161493,0.00009209374,0.00011642137],"category_scores_gemma":[0.000065677996,0.00007378331,0.000080448204,0.0004150161,0.00021652563,0.000038693765,0.000113839975,0.00007063045,0.000005707877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011722382,0.00020018673,0.9934603,0.00006188137,0.00022864348,0.000943853,0.00003730661,0.00027427648,0.00038908992,0.0000127043395,0.000053765765,0.0042207795],"study_design_scores_gemma":[0.00078576116,0.00015438335,0.99758095,0.00010248023,0.00035604628,0.000042063024,0.000050247458,0.00004240303,0.0006678479,0.000049727834,0.00008843546,0.000079664285],"about_ca_topic_score_codex":0.95641035,"about_ca_topic_score_gemma":0.99880666,"teacher_disagreement_score":0.04239625,"about_ca_system_score_codex":0.0007672921,"about_ca_system_score_gemma":0.00018922731,"threshold_uncertainty_score":0.3008796},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","score_opus":0.009780463777112593,"score_gpt":0.29616004749887154,"score_spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474699717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98201805,0.00049047207,0.0053257626,0.0030710162,0.00004696229,0.008514379,0.0003606701,0.00007728184,0.00009541795],"genre_scores_gemma":[0.99254215,0.00044800062,0.0014856479,0.00021976637,0.000040355484,0.0049997875,0.000036464357,0.00005300854,0.00017481748],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99547243,0.0015627366,0.001007919,0.00073442305,0.0005777818,0.00064473005],"domain_scores_gemma":[0.99534905,0.0028727467,0.0007854419,0.0005480141,0.00026828324,0.0001764918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001637433,0.00053853006,0.0027820186,0.00036830205,0.00013999983,0.000030405226,0.00027838966,0.00007535746,0.00029839991],"category_scores_gemma":[0.00019845543,0.00024887366,0.00016241241,0.0012771174,0.00093293976,0.00032975874,0.000051799645,0.00037786967,0.0000072603143],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.922018,0.0041006897,0.010059341,0.0000107019305,0.005557809,0.00015909175,0.008550045,0.0008919238,0.0021198953,0.000012757032,0.0000019427885,0.046517815],"study_design_scores_gemma":[0.86781025,0.0032054796,0.111497134,0.00036665506,0.0024774289,0.000012691158,0.013169265,0.00072004594,0.0002259359,0.00015139133,0.000011074955,0.00035265417],"about_ca_topic_score_codex":0.0032583743,"about_ca_topic_score_gemma":0.017618505,"teacher_disagreement_score":0.10143779,"about_ca_system_score_codex":0.0020841865,"about_ca_system_score_gemma":0.0003142217,"threshold_uncertainty_score":0.99999636},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2477946877","doi":"10.1634/theoncologist.2016-0176","title":"Early Palliative Care and Its Role in Oncology: A Qualitative Study","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society; Ministry of Health, Ontario","keywords":"Medicine; Palliative care; Oncology; Family medicine; Intervention (counseling); Focus group; Qualitative research; Internal medicine; Nursing","score_opus":0.20370539117459793,"score_gpt":0.5117691189028938,"score_spread":0.3080637277282958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2477946877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816822,0.004304461,0.00000978719,0.0020249966,0.000055397268,0.000692426,0.000024297418,0.000023055458,0.011183416],"genre_scores_gemma":[0.99831337,0.000642234,0.00018338721,0.00016022287,0.00006043293,0.000088603934,0.000001997616,0.000009887054,0.0005398792],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99868697,0.00047743582,0.0002600856,0.00021551238,0.00016685054,0.00019313153],"domain_scores_gemma":[0.99802285,0.0014283715,0.00013607492,0.00017161577,0.00017958206,0.000061505176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005318834,0.00012921127,0.00042941148,0.00006667093,0.000046464,0.0000041410585,0.000114771756,0.000087571694,0.000031268486],"category_scores_gemma":[0.0007702653,0.000062751664,0.000043491884,0.00016461339,0.00027625554,0.00004970359,0.00008328286,0.00014922152,0.000030653016],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009389294,0.00049859675,0.24221848,0.000043483233,0.0001446895,0.00009499112,0.72970384,4.1007087e-7,0.0023748784,0.0008527279,0.00019579158,0.022933146],"study_design_scores_gemma":[0.005777651,0.008300212,0.29362765,0.00050064083,0.00012098282,0.0000020067605,0.6798367,0.000004010139,0.0020509262,0.0007557144,0.008872731,0.00015077459],"about_ca_topic_score_codex":0.00050463877,"about_ca_topic_score_gemma":0.000966946,"teacher_disagreement_score":0.051409174,"about_ca_system_score_codex":0.00029166223,"about_ca_system_score_gemma":0.00014501161,"threshold_uncertainty_score":0.25589386},"labels":[],"label_agreement":null},{"id":"W2486839133","doi":"10.1634/theoncologist.2016-0186","title":"Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Agència de Gestió d'Ajuts Universitaris i de Recerca; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Hedgehog signaling pathway; Vismodegib; Basal cell carcinoma; Discontinuation; Medicine; Dysgeusia; Adverse effect; Quality of life (healthcare); Hedgehog; Smoothened; Internal medicine; Oncology; Signal transduction; Biology; Basal cell; Nursing","score_opus":0.013263329222364192,"score_gpt":0.25382602863173337,"score_spread":0.24056269940936917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486839133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47963628,0.5173507,0.00004889326,0.000015744454,0.00025163896,0.0020138111,0.000197719,0.00001152071,0.0004737161],"genre_scores_gemma":[0.16524965,0.83332014,0.00006315994,0.00001695472,0.000046187022,0.00015055054,0.00050538115,0.00004712679,0.0006008707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850726,0.00020779343,0.00048849825,0.0004168665,0.00014640107,0.00023319072],"domain_scores_gemma":[0.99898,0.000027371747,0.0005057852,0.0003811981,0.00006696444,0.00003869191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023889217,0.0003231323,0.0006420708,0.0000623726,0.000059123027,0.0000022729512,0.00023589673,0.0002302845,0.0000038908706],"category_scores_gemma":[0.000017759849,0.00018265864,0.00010031796,0.00013968493,0.00018468821,0.0000044360363,0.0002856654,0.000119293036,0.0000074634168],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000530902,0.00079948164,0.013534248,0.01375332,0.0005423033,0.00003110361,0.00018730471,0.000007842125,0.0026920496,0.000039849285,0.000053026157,0.9678286],"study_design_scores_gemma":[0.010591783,0.004334833,0.11099866,0.019533372,0.00092566473,0.0000057838456,0.00016467588,0.0000017473434,0.004192306,0.000017053319,0.84745413,0.0017799719],"about_ca_topic_score_codex":0.000003086998,"about_ca_topic_score_gemma":0.000006390554,"teacher_disagreement_score":0.9660486,"about_ca_system_score_codex":0.0000755789,"about_ca_system_score_gemma":0.00009092309,"threshold_uncertainty_score":0.7448603},"labels":[],"label_agreement":null},{"id":"W2518422528","doi":"10.1634/theoncologist.2016-0164","title":"Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Adverse effect; Tolerability; Lung cancer; Oncology; Chemotherapy; Immune system; Immunotherapy; Monoclonal antibody; Internal medicine; Intensive care medicine; Immunology; Antibody","score_opus":0.03120782614683579,"score_gpt":0.34147288587707575,"score_spread":0.31026505973023993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518422528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021672653,0.9717781,7.2061493e-7,0.00008905067,0.00022336506,0.005379034,0.000022171418,0.000041615214,0.00079330994],"genre_scores_gemma":[0.014116152,0.9817603,0.000055258733,0.00000454344,0.00004746945,0.0013146492,0.000016939433,0.00004985392,0.0026347807],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.998,0.00021215183,0.00081071147,0.0003339754,0.00028996266,0.00035317012],"domain_scores_gemma":[0.9985762,0.00009026571,0.0008762006,0.00034994684,0.000054290653,0.000053061838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080184476,0.00036340283,0.0011911322,0.0001268499,0.00006870634,0.000005505658,0.0002035789,0.00029036473,0.000028085678],"category_scores_gemma":[0.000018245151,0.00018049173,0.00025281904,0.0004645463,0.0002266684,0.000037196594,0.00010197502,0.00034853947,0.0000018729926],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007513978,0.00038783334,0.0045053675,0.015667792,0.002085956,0.0001074885,0.00014847181,4.7726473e-7,0.000058750284,0.00000504222,0.00002423571,0.9762572],"study_design_scores_gemma":[0.02020069,0.0023711505,0.030102018,0.65653867,0.0071160337,0.000043991568,0.0004887935,0.00000637303,0.00048491804,0.000016858601,0.2813655,0.0012650058],"about_ca_topic_score_codex":0.0005806276,"about_ca_topic_score_gemma":0.00004821754,"teacher_disagreement_score":0.97499216,"about_ca_system_score_codex":0.0012276446,"about_ca_system_score_gemma":0.00031268457,"threshold_uncertainty_score":0.7360239},"labels":[],"label_agreement":null},{"id":"W2519439632","doi":"10.1634/theoncologist.2016-0161","title":"Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; National Cancer Institute; Prostate Cancer Foundation","keywords":"Enzalutamide; Prostate cancer; Androgen receptor; Abiraterone; Cancer research; Abiraterone acetate; Population; Cancer; Medicine; Mechanism (biology); splice; Bioinformatics; Computational biology; Biology; Gene; Internal medicine; Genetics; Androgen deprivation therapy","score_opus":0.04893143347236359,"score_gpt":0.3605005743744425,"score_spread":0.3115691409020789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519439632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8889562,0.020250458,0.0006143167,0.0758244,0.00048752173,0.010920451,0.000366141,0.000039879513,0.0025406505],"genre_scores_gemma":[0.9476102,0.011976865,0.0017665831,0.00020915814,0.0005324057,0.0020459963,0.00001805164,0.000038149934,0.03580261],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989211,0.0001267978,0.0002408279,0.00018543756,0.00023689622,0.00028896471],"domain_scores_gemma":[0.99857473,0.0005911813,0.00021375211,0.00047940994,0.00009538768,0.000045560057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004729558,0.00014171834,0.00026628177,0.000015158861,0.00026772878,0.000007992312,0.00031586882,0.0000463746,0.000074354146],"category_scores_gemma":[0.00007332744,0.00003429445,0.00017364125,0.00015300233,0.00079082587,0.000026436459,0.000057527424,0.00007237468,0.0000026432404],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015480881,0.0015308253,0.022607261,0.00025703406,0.0014893176,0.000010287275,0.01563823,0.00031116,0.11856457,0.00068423175,0.030203314,0.7932229],"study_design_scores_gemma":[0.031506617,0.008593428,0.008299659,0.0005064583,0.0013731811,0.00006602275,0.011127847,0.00040004245,0.23560295,0.0017809126,0.70036316,0.00037970545],"about_ca_topic_score_codex":0.0002933813,"about_ca_topic_score_gemma":0.000057816527,"teacher_disagreement_score":0.79284316,"about_ca_system_score_codex":0.00032615993,"about_ca_system_score_gemma":0.0004813504,"threshold_uncertainty_score":0.2913831},"labels":[],"label_agreement":null},{"id":"W2529995173","doi":"10.1634/theoncologist.2016-0222","title":"Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Medicine; Carcinoembryonic antigen; Interquartile range; Asymptomatic; Colorectal cancer; Positron emission tomography; Confidence interval; Radiology; Occult; Cancer; Internal medicine; Nuclear medicine; Pathology","score_opus":0.01338134069089638,"score_gpt":0.28322510132026457,"score_spread":0.2698437606293682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529995173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541944,0.0003317112,0.000060752223,0.0013001115,0.00052464753,0.0012384198,0.000056197892,0.00010845869,0.00096026564],"genre_scores_gemma":[0.9992417,0.000010021663,0.00017621428,0.00015941983,0.000049498667,0.00020743778,0.000030568153,0.000039506023,0.000085614745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972769,0.00028809652,0.0005616282,0.000527714,0.00065075216,0.0006949096],"domain_scores_gemma":[0.9986778,0.0005637565,0.00022240596,0.00025811495,0.000114384566,0.00016354967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049140194,0.0003818627,0.0007613779,0.00040332036,0.00015639424,0.000037433507,0.0002613803,0.00007886618,0.00012902837],"category_scores_gemma":[0.00008295221,0.00020644067,0.00032148816,0.0008157594,0.00029411647,0.0002454823,0.00014509472,0.00026429925,0.0000062934155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001264494,0.0005851651,0.98982847,0.000026827573,0.00019069476,0.00020821962,0.00013833195,0.000011181428,0.003026705,0.000009175105,0.000021644288,0.004689089],"study_design_scores_gemma":[0.014623826,0.00035061673,0.9819978,0.0006008501,0.000100647885,0.000010696948,0.00008387928,0.00025305816,0.001627713,0.000046736943,0.000020701918,0.0002834965],"about_ca_topic_score_codex":0.0011600219,"about_ca_topic_score_gemma":0.0006588057,"teacher_disagreement_score":0.013359332,"about_ca_system_score_codex":0.0009841679,"about_ca_system_score_gemma":0.00029705706,"threshold_uncertainty_score":0.8418407},"labels":[],"label_agreement":null},{"id":"W2534012350","doi":"10.1634/theoncologist.2016-0188","title":"The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Genome Alberta; Genome Canada","keywords":"Biomarker; Medicine; Interim; Precision medicine; ERCC1; Companion diagnostic; Personalized medicine; Translational research; Biomarker discovery; Bioinformatics; Nucleotide excision repair; Cancer; Internal medicine; Pathology; DNA repair; Proteomics","score_opus":0.0905969875901333,"score_gpt":0.36914266392083955,"score_spread":0.27854567633070626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534012350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849141,0.009721288,0.000057752906,0.0027814943,0.00048124045,0.00088584033,0.000032392894,0.00004418328,0.0010816546],"genre_scores_gemma":[0.99931514,0.00034805993,0.000041543786,0.000025198633,0.00005668608,0.00012246006,0.0000031610255,0.000009810369,0.00007794396],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973271,0.0011866166,0.0008657501,0.00024391839,0.00008158914,0.00029505414],"domain_scores_gemma":[0.9592746,0.039248068,0.0005857102,0.0007471273,0.00013253909,0.000011970395],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004319027,0.00014978518,0.00030738054,0.000045782654,0.00043173268,0.000006628282,0.000624401,0.00006855039,0.00016185267],"category_scores_gemma":[0.0119919805,0.00005244478,0.00008370762,0.0001503057,0.001338837,0.000043169573,0.00043814193,0.00012885273,0.000017924052],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001047722,0.00091277686,0.23729497,0.00032379804,0.00041627107,0.0002466836,0.005524751,0.00007667555,0.1875529,0.05672239,0.011515047,0.498366],"study_design_scores_gemma":[0.0085507175,0.0046768244,0.8985181,0.0043416144,0.00030767047,0.0011395684,0.026542043,0.00007623757,0.01579625,0.01981655,0.01971278,0.00052168535],"about_ca_topic_score_codex":0.0014392738,"about_ca_topic_score_gemma":0.0020529097,"teacher_disagreement_score":0.66122305,"about_ca_system_score_codex":0.00009355182,"about_ca_system_score_gemma":0.000040969328,"threshold_uncertainty_score":0.99633044},"labels":[],"label_agreement":null},{"id":"W2547499110","doi":"10.1634/theoncologist.2015-0084","title":"Targeting the KRAS Pathway in Non-Small Cell Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Lung cancer; Medicine; Targeted therapy; Cancer research; Adenocarcinoma; Cancer; Oncogene; Oncology; Internal medicine; Colorectal cancer; Cell cycle","score_opus":0.024955253064500485,"score_gpt":0.3139234364054693,"score_spread":0.28896818334096885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547499110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015182617,0.99577993,0.00038368333,0.00020740993,0.0002512121,0.0011202806,0.000049582854,0.00001132097,0.0020447236],"genre_scores_gemma":[0.0013773477,0.99463874,0.000064519474,0.00020438552,0.00085398695,0.00056412094,0.00008016896,0.000043801716,0.0021729078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833524,0.00039138098,0.00043040107,0.0003852438,0.00011055635,0.0003471785],"domain_scores_gemma":[0.99891156,0.00010255534,0.00038995163,0.0005079623,0.000043701744,0.000044251046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009122072,0.00031383176,0.0005149034,0.000036387424,0.00017349639,0.000034512508,0.0006336508,0.00037062934,0.000069007285],"category_scores_gemma":[0.000091103575,0.0001410949,0.0002706814,0.00013663145,0.0001713518,0.0000016654508,0.0002771262,0.00030699596,0.000029553505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023598252,0.00006977569,0.000031718257,0.0028062824,0.00011091499,0.000024918007,0.000070137336,0.00009980767,0.0050449325,0.00010357201,0.0057830005,0.9858313],"study_design_scores_gemma":[0.00020322559,0.000035215853,0.0000036866272,0.0017392511,0.00006916202,0.000005495317,0.000017582128,0.000022499857,0.0011544764,0.000015356783,0.99649316,0.00024091473],"about_ca_topic_score_codex":0.00008414759,"about_ca_topic_score_gemma":0.0001019139,"teacher_disagreement_score":0.99071014,"about_ca_system_score_codex":0.0001191219,"about_ca_system_score_gemma":0.0005197517,"threshold_uncertainty_score":0.5753683},"labels":[],"label_agreement":null},{"id":"W2549108333","doi":"10.1634/theoncologist.2016-0153","title":"Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Alliance for Clinical Trials in Oncology Foundation; Mayo Clinic","keywords":"Medicine; Metformin; Internal medicine; Hazard ratio; Folinic acid; Cetuximab; Oxaliplatin; FOLFOX; Proportional hazards model; Colorectal cancer; Oncology; Cancer; Confidence interval; Insulin","score_opus":0.039866502888569584,"score_gpt":0.28391484069314665,"score_spread":0.24404833780457708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2549108333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983246,0.014455486,0.000020874952,0.00015535098,0.00015105451,0.00049244316,0.0014458422,0.000010729607,0.000022204486],"genre_scores_gemma":[0.9601862,0.03881313,0.00010532395,0.00007309931,0.00019124075,0.0001100312,0.00021377983,0.000019505149,0.000287736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854296,0.00020640294,0.00027463707,0.00047542306,0.00014771128,0.00035288424],"domain_scores_gemma":[0.9990317,0.00027890588,0.0002127615,0.00030908908,0.000070356255,0.00009719109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023110652,0.00021333579,0.0003049551,0.000022114,0.00012327649,0.00003502381,0.00014016885,0.00012795796,0.000014808339],"category_scores_gemma":[0.00016802068,0.000117001415,0.000026548401,0.000118818636,0.000258746,0.000025415413,0.00005815076,0.000101106365,4.5018982e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001501892,0.00005435024,0.8943183,0.0000054973916,0.000055806515,9.026048e-7,0.00027101595,0.000008102439,0.0003695316,0.000006571107,0.000118922224,0.10328915],"study_design_scores_gemma":[0.0062125777,0.00048032135,0.9717843,0.000074234056,0.000052210773,7.399054e-8,0.00003750401,0.000003943042,0.001751228,0.000018510487,0.019389052,0.0001960406],"about_ca_topic_score_codex":0.00608237,"about_ca_topic_score_gemma":0.061717216,"teacher_disagreement_score":0.1030931,"about_ca_system_score_codex":0.0001909272,"about_ca_system_score_gemma":0.00013613084,"threshold_uncertainty_score":0.955404},"labels":[],"label_agreement":null},{"id":"W2554177440","doi":"10.1634/theoncologist.2016-0185","title":"Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of Calgary; Nova Scotia Cancer Centre; BC Cancer Agency; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Exemestane; Letrozole; Everolimus; Oncology; Breast cancer; Internal medicine; Sunitinib; Adverse effect; Combination therapy; Cancer; Metastatic breast cancer; Tamoxifen","score_opus":0.0302134003723064,"score_gpt":0.3549598303514997,"score_spread":0.3247464299791933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554177440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92547876,0.012167003,0.009296892,0.0470726,0.00082302047,0.0039506545,0.00032139802,0.00017733725,0.00071230636],"genre_scores_gemma":[0.9916287,0.00495423,0.0004943271,0.00037309533,0.00031162598,0.0009760051,0.0000069401976,0.0000337899,0.0012212644],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989354,0.000055645232,0.00028397446,0.00022571003,0.00018981742,0.00030947715],"domain_scores_gemma":[0.9982805,0.00078162993,0.00023992502,0.0004236275,0.00023086897,0.000043406897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015092726,0.00021533298,0.00035632498,0.00003457707,0.000179521,0.00001328643,0.0001774557,0.000044395514,0.00017426308],"category_scores_gemma":[0.000020514906,0.00008241984,0.00010464321,0.00012170002,0.00046100444,0.00013260791,0.000015580456,0.000053728894,0.0000046026757],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047039273,0.0005985061,0.00057016494,0.00002269685,0.00031750323,0.0000036598433,0.0009105768,0.0000646412,0.29233745,0.0033190649,0.000043637643,0.69710815],"study_design_scores_gemma":[0.055180207,0.029470026,0.16254427,0.00057934405,0.0007687004,0.00039031636,0.010250924,0.00012793405,0.5457477,0.01623028,0.17794314,0.000767135],"about_ca_topic_score_codex":0.00029930382,"about_ca_topic_score_gemma":0.0003813544,"teacher_disagreement_score":0.69634104,"about_ca_system_score_codex":0.0005279523,"about_ca_system_score_gemma":0.00029277624,"threshold_uncertainty_score":0.33609834},"labels":[],"label_agreement":null},{"id":"W2587511691","doi":"10.1634/theoncologist.2016-0371","title":"Predatory Invitations from Journals: More Than Just a Nuisance?","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Academic integrity and plagiarism","field":"Social Sciences","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology; Institute of Cancer Research; University of Alberta; Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Family medicine","score_opus":0.14680079515793984,"score_gpt":0.44178195580643137,"score_spread":0.29498116064849156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587511691","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3998292,0.0010262454,0.00055709865,0.18230228,0.0019864135,0.000374099,0.00017006455,0.000112575115,0.41364202],"genre_scores_gemma":[0.99007463,0.00052336854,0.00033412734,0.0015982984,0.0014462848,0.000017177845,0.0000046402542,0.000005481482,0.0059959763],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880564,0.0003483093,0.000155319,0.00013673631,0.00031059686,0.00024339507],"domain_scores_gemma":[0.9985413,0.0006280849,0.00027380834,0.00037760235,0.000092681956,0.00008654264],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0020746095,0.00007707935,0.00012920747,0.000018620642,0.0039082,0.00028781462,0.0012980138,0.00041536073,0.0006691541],"category_scores_gemma":[0.0032121614,0.00005217419,0.00006593126,0.00004687191,0.0017583611,0.00032697862,0.00010526325,0.0010791428,0.00021864528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000836543,0.00016520254,0.07630448,0.0000074209784,0.00013886408,0.00004680063,0.22367734,0.000029944249,0.00038245384,0.14045595,0.528881,0.02982686],"study_design_scores_gemma":[0.00026370585,0.000030975836,0.14835027,0.000055103406,0.000054504424,0.0000019045413,0.04946883,0.00006928159,0.00006641406,0.07244872,0.7290161,0.00017419408],"about_ca_topic_score_codex":0.023395304,"about_ca_topic_score_gemma":0.017386599,"teacher_disagreement_score":0.5902454,"about_ca_system_score_codex":0.00013233977,"about_ca_system_score_gemma":0.00028739678,"threshold_uncertainty_score":0.9973886},"labels":[],"label_agreement":null},{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","score_opus":0.051736645608612145,"score_gpt":0.408330866346466,"score_spread":0.35659422073785385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891515,0.00007089614,0.000022034761,0.0010959059,0.000043600365,0.009430049,0.000037780017,0.000025415658,0.00035914854],"genre_scores_gemma":[0.9970621,0.00008245041,0.0001917395,0.000062352214,0.000015935471,0.0015563157,0.000021820928,0.000039636754,0.0009676574],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972031,0.00061212626,0.00064845354,0.00038774306,0.00072517176,0.0004234215],"domain_scores_gemma":[0.99760807,0.0004310566,0.0005529641,0.00085676357,0.00044859527,0.0001025267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014714467,0.0002647377,0.0013206742,0.00019149666,0.00020135644,0.000033149292,0.0004341512,0.00005648376,0.00033675515],"category_scores_gemma":[0.0007681215,0.00011558262,0.00004146208,0.0004528445,0.00075279915,0.00016582078,0.00012054826,0.0003701422,0.0000025472277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.847567,0.015221726,0.0712094,0.0001468837,0.00030598167,0.00025690324,0.0024620327,0.00021114419,0.000032763575,0.000008308796,0.00005916362,0.06251866],"study_design_scores_gemma":[0.82426274,0.03221455,0.14033847,0.0008267986,0.00033557523,0.000016550888,0.0010796249,0.0006211613,0.00008850764,0.000009453064,0.000036436286,0.0001701138],"about_ca_topic_score_codex":0.0092335045,"about_ca_topic_score_gemma":0.06360273,"teacher_disagreement_score":0.069129065,"about_ca_system_score_codex":0.00081220997,"about_ca_system_score_gemma":0.0010029355,"threshold_uncertainty_score":0.9973641},"labels":[],"label_agreement":null},{"id":"W2591210005","doi":"10.1634/theoncologist.2016-0078","title":"Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"National Cancer Institute; CRIS Cancer Foundation; Sociedad Española de Oncología Médica","keywords":"Medicine; Hazard ratio; Proportional hazards model; Concordance; Renal cell carcinoma; Oncology; Internal medicine; Clinical endpoint; Gene signature; Overall survival; Confidence interval; Gene; Gene expression; Clinical trial; Biology","score_opus":0.041624701129055905,"score_gpt":0.3126501555619361,"score_spread":0.2710254544328802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591210005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808455,0.0005285788,0.0013612554,0.0015528308,0.0002767011,0.0013311999,0.00013161333,0.000033109965,0.013939173],"genre_scores_gemma":[0.9943088,0.000027658292,0.004175527,0.00014043973,0.00008193823,0.0001554667,0.000105893254,0.000031917578,0.0009723172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982567,0.000108976674,0.00042733998,0.00038617267,0.00050431525,0.0003165174],"domain_scores_gemma":[0.99763465,0.0002771889,0.0005161276,0.0011831103,0.0002479608,0.00014098124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047210348,0.00025004573,0.00044077056,0.00007103282,0.00019018521,0.000054433407,0.0006150612,0.00006238841,0.00004415964],"category_scores_gemma":[0.0009615907,0.00015857285,0.00017133918,0.00005020384,0.00069285877,0.00010125783,0.00031323553,0.00025081466,0.000037069516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028590271,0.0038727906,0.33016035,0.00094688544,0.0010476528,0.0044000717,0.00066946086,0.0047343206,0.63848644,0.008472697,0.0012975578,0.0030527532],"study_design_scores_gemma":[0.0089237215,0.0041001914,0.2848784,0.00025629802,0.0043731346,0.00031987252,0.00029550507,0.1272874,0.5670239,0.0015790283,0.00036963707,0.0005929273],"about_ca_topic_score_codex":0.00032771446,"about_ca_topic_score_gemma":0.000028118333,"teacher_disagreement_score":0.12255308,"about_ca_system_score_codex":0.00017884841,"about_ca_system_score_gemma":0.00049519684,"threshold_uncertainty_score":0.64664125},"labels":[],"label_agreement":null},{"id":"W2611234918","doi":"10.1634/theoncologist.2016-0500","title":"Implementation of the Edmonton Symptom Assessment System for Symptom Distress Screening at a Community Cancer Center: A Pilot Program","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Medicine; Psychosocial; Referral; Distress; Triage; Family medicine; Palliative care; Cancer; Emergency medicine; Psychiatry; Nursing; Internal medicine; Clinical psychology","score_opus":0.08253998639699035,"score_gpt":0.441523884883796,"score_spread":0.3589838984868057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611234918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893872,0.00012898997,0.00019721329,0.003171099,0.0007118389,0.002561559,0.00043746232,0.0000690235,0.0033355781],"genre_scores_gemma":[0.99790514,0.000028446559,0.00010071897,0.00012549054,0.00017392391,0.0012600392,0.0000710615,0.000017852373,0.00031733804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882394,0.00024387086,0.00027329655,0.00014375483,0.0002696475,0.00024551523],"domain_scores_gemma":[0.9981087,0.00016545955,0.00050259795,0.0010144467,0.0001533836,0.000055450524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006740758,0.00014080321,0.00029572664,0.000015276046,0.0012963702,0.00006500502,0.00056657754,0.00004774883,0.000023393426],"category_scores_gemma":[0.000029937497,0.000077725665,0.00015212732,0.00004834033,0.00031930825,0.00005233881,0.00035842348,0.00022275714,5.534617e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007715864,0.00047709228,0.88853306,0.0009926781,0.00028655157,0.000002151717,0.002081509,0.000008964994,0.0011707857,0.0006516155,0.0015301768,0.103493825],"study_design_scores_gemma":[0.003474622,0.0013656851,0.9740977,0.0006521625,0.00036754127,0.000011121075,0.00986879,0.0002023863,0.0020606725,0.000013147455,0.0077692214,0.00011690084],"about_ca_topic_score_codex":0.057349704,"about_ca_topic_score_gemma":0.17748316,"teacher_disagreement_score":0.120133445,"about_ca_system_score_codex":0.0008001623,"about_ca_system_score_gemma":0.00015105268,"threshold_uncertainty_score":0.9970762},"labels":[],"label_agreement":null},{"id":"W2611921030","doi":"10.1634/theoncologist.2016-0356","title":"Prospective Evaluation of the Relationship Between Mechanical Stability and Response to Palliative Radiotherapy for Symptomatic Spinal Metastases","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre; Vancouver Spine Surgery Institute; Vancouver Coastal Health; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Radiation therapy; Lumbosacral joint; Odds ratio; Prospective cohort study; Palliative care; Confidence interval; Lumbar; Spinal disease; Thoracic vertebrae; Surgery; Internal medicine; Lumbar vertebrae","score_opus":0.23570749795307425,"score_gpt":0.4604883266165991,"score_spread":0.22478082866352486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611921030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97706604,0.00008583284,0.002693263,0.015113969,0.00006143228,0.0047216206,0.00007181788,0.0000138078185,0.00017221089],"genre_scores_gemma":[0.9960737,0.0000017413142,0.003200538,0.00017833983,0.000041432446,0.0004003675,0.0000037242664,0.000009388241,0.000090719695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979484,0.0009331663,0.00027862942,0.00021365854,0.00049748435,0.00012865002],"domain_scores_gemma":[0.99641585,0.002113922,0.00033786547,0.0008154014,0.00024708972,0.000069891394],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0080485055,0.00010669795,0.00028956955,0.00003328529,0.0003883306,0.00003349164,0.00024328957,0.000034842367,0.000038415095],"category_scores_gemma":[0.023354257,0.00005742972,0.00008971559,0.000075347365,0.0003725304,0.000058047597,0.000098459175,0.0000963633,0.0000016704765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015086183,0.00049951597,0.95696455,0.0003235474,0.0005919054,0.0000014600861,0.0024409546,0.000014602857,0.0015338155,0.012830478,0.00048920605,0.009223797],"study_design_scores_gemma":[0.002994153,0.0011554145,0.97684366,0.00008375373,0.0012248383,6.2956497e-7,0.0007377274,0.00065202016,0.00091168156,0.015275792,0.000060292285,0.00006006649],"about_ca_topic_score_codex":0.000031465588,"about_ca_topic_score_gemma":0.000030608906,"teacher_disagreement_score":0.019879097,"about_ca_system_score_codex":0.00029803067,"about_ca_system_score_gemma":0.00024428163,"threshold_uncertainty_score":0.98487246},"labels":[],"label_agreement":null},{"id":"W2613439971","doi":"10.1634/theoncologist.2016-0415","title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","year":2017,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Oncology; Germline mutation; Cancer; Family history; Gastroenterology; Mutation; Gene; Genetics","score_opus":0.2001530791259961,"score_gpt":0.4553380343336708,"score_spread":0.2551849552076747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613439971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033357356,0.95896316,5.574302e-7,0.00017694186,0.0011092088,0.0027786617,0.00022443554,0.000049557595,0.0033401106],"genre_scores_gemma":[0.21791153,0.78023046,0.000008919825,0.00004448007,0.0005698621,0.000074972355,0.000060392445,0.00004670443,0.0010526895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968914,0.00060639443,0.0011635472,0.0006050038,0.0003814144,0.00035228932],"domain_scores_gemma":[0.99643666,0.0005876708,0.0015327716,0.0010631147,0.00025638274,0.00012341735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016569577,0.00049218297,0.004251034,0.000083938896,0.00026808208,0.000058539397,0.00044453423,0.00036978684,0.000021683063],"category_scores_gemma":[0.00172793,0.00028637945,0.00081053906,0.00009872433,0.000799141,0.00004307849,0.00053846434,0.0010173084,0.000017404474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000267542,0.0019087285,0.74059415,0.0020375273,0.003916485,0.0002835883,0.0005255997,1.7664379e-9,1.2920538e-7,0.000027823751,0.001445323,0.24899313],"study_design_scores_gemma":[0.0027844075,0.0016402977,0.8509332,0.0019492136,0.007138746,0.00002389206,0.00017612086,0.0000010769888,2.642431e-8,0.0000048777283,0.13511631,0.00023180676],"about_ca_topic_score_codex":0.00038924214,"about_ca_topic_score_gemma":0.0003694791,"teacher_disagreement_score":0.24876131,"about_ca_system_score_codex":0.0003993873,"about_ca_system_score_gemma":0.00034800146,"threshold_uncertainty_score":0.9999588},"labels":[],"label_agreement":null},{"id":"W2621574813","doi":"10.1634/theoncologist.2016-0455","title":"Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Clalit Health Services; Burroughs Wellcome Fund","keywords":"Medicine; Bevacizumab; Colorectal cancer; Incremental cost-effectiveness ratio; Quality-adjusted life year; Cost effectiveness; Cost-effectiveness analysis; Willingness to pay; Cost–benefit analysis; Adverse effect; Oncology; Demography; Internal medicine; Chemotherapy; Cancer","score_opus":0.0896050830222645,"score_gpt":0.4412394298392327,"score_spread":0.3516343468169682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621574813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802601,0.0013641706,0.0005303075,0.0067166258,0.00035254008,0.002871797,0.00046697448,0.000057362646,0.0073801484],"genre_scores_gemma":[0.9964966,0.00020891539,0.00020758192,0.00014357253,0.000109965426,0.0024683129,0.000023104716,0.000008587575,0.00033331363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905956,0.00007025433,0.00015782376,0.00027285714,0.0001606057,0.00027890154],"domain_scores_gemma":[0.9988903,0.00031091826,0.00018739444,0.00038757347,0.00015291902,0.0000709296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035129001,0.00017061988,0.0006220611,0.000028982438,0.00085994235,0.00006724479,0.0002191874,0.00004114519,0.000058406604],"category_scores_gemma":[0.00031420105,0.00009540648,0.00032899226,0.00017020536,0.00043333453,0.000047043934,0.00011077462,0.000073050236,0.0000073473666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017084662,0.0011164255,0.62155217,0.00022008119,0.023187662,0.0001703416,0.000720642,0.00038388086,0.0002877734,0.0020484705,0.0024180023,0.33080992],"study_design_scores_gemma":[0.0045515914,0.0016559947,0.9756374,0.00002596624,0.0085225925,0.000017197719,0.00025798377,0.0008971201,0.00034203654,0.0007048373,0.0072483174,0.000138962],"about_ca_topic_score_codex":0.0033852863,"about_ca_topic_score_gemma":0.012183984,"teacher_disagreement_score":0.35408524,"about_ca_system_score_codex":0.00094449567,"about_ca_system_score_gemma":0.00021434797,"threshold_uncertainty_score":0.67989486},"labels":[],"label_agreement":null},{"id":"W2624530626","doi":"10.1634/theoncologist.2017-0047","title":"Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"UCLH Biomedical Research Centre; Medical Research Council; National Health and Medical Research Council; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK; American Society of Clinical Oncology","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Proportional hazards model; Quality of life (healthcare); Carboplatin; Cancer; Logistic regression; Cisplatin","score_opus":0.031498484669945155,"score_gpt":0.3183567643721904,"score_spread":0.28685827970224526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624530626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890907,0.0005043303,0.000001188462,0.0065927273,0.00030512045,0.0012116636,0.000044142733,0.00002751382,0.002404246],"genre_scores_gemma":[0.9984382,0.00034359872,0.000031149426,0.00012256618,0.00028354747,0.00015269886,0.0000057947263,0.000027681217,0.00059476163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848765,0.00012319694,0.00040492398,0.0003751016,0.00031525278,0.00029387954],"domain_scores_gemma":[0.99814725,0.00037204617,0.0003911649,0.0009329515,0.0000767386,0.00007986041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009509816,0.00021916258,0.00057250034,0.000059365426,0.00042957847,0.00007594623,0.0003410864,0.0000981963,0.0000967833],"category_scores_gemma":[0.000116957264,0.00012570011,0.000063548614,0.00010567728,0.0004192068,0.00008059559,0.00011443258,0.00025352262,0.000002836309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019046399,0.0011436419,0.9594512,0.0000414761,0.00084443105,0.000083757404,0.0066377083,0.0001576284,0.0024255735,0.00020371114,0.00027039569,0.026835816],"study_design_scores_gemma":[0.004437987,0.0016587739,0.99127823,0.00026064852,0.00027480483,0.0000033727247,0.00089119596,0.00014761658,0.00015081318,0.00007748391,0.0006954739,0.00012357067],"about_ca_topic_score_codex":0.02074672,"about_ca_topic_score_gemma":0.0062575717,"teacher_disagreement_score":0.03182704,"about_ca_system_score_codex":0.00044246536,"about_ca_system_score_gemma":0.00025258953,"threshold_uncertainty_score":0.9857742},"labels":[],"label_agreement":null},{"id":"W2637410905","doi":"10.1634/theoncologist.2017-0235","title":"Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pregabalin; Neuropathic pain; Oxaliplatin; Anesthesia; Allodynia; Placebo; Analgesic; Chronic pain; Duloxetine; Peripheral neuropathy; Randomized controlled trial; Nociception; Internal medicine; Colorectal cancer; Hyperalgesia; Cancer; Physical therapy","score_opus":0.2068603240696497,"score_gpt":0.45655941135312983,"score_spread":0.24969908728348014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2637410905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640816,0.0002804282,0.00026178473,0.013797821,0.0016253738,0.010705898,0.000012469121,0.000031966916,0.009202698],"genre_scores_gemma":[0.99189645,0.00011125721,0.000072805306,0.00021864328,0.00096865115,0.0013582555,0.0000145387585,0.000013724922,0.0053456803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989334,0.00024067027,0.0003492833,0.00016586234,0.00013996492,0.00017082343],"domain_scores_gemma":[0.9971223,0.0016266798,0.00057457393,0.0005480059,0.000091005444,0.000037459682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019311749,0.00012709852,0.00051284384,0.000024923325,0.0004116987,0.00003378392,0.00029600298,0.00008600718,0.00010622031],"category_scores_gemma":[0.00057786464,0.00005904128,0.00034251102,0.000037462192,0.00043589622,0.000045932557,0.00006853008,0.00014778515,0.00000700684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9843045,0.0003952004,0.00006897576,0.000027213042,0.00033014503,0.0000046104365,0.0002470378,0.000006673038,0.0023989049,0.00095991493,0.0016163884,0.009640456],"study_design_scores_gemma":[0.9826572,0.002725803,0.00042956212,0.000026172982,0.001712452,0.0000109940365,0.00005676545,0.00040230103,0.0055252886,0.00077319413,0.0056129876,0.000067301284],"about_ca_topic_score_codex":0.00031195622,"about_ca_topic_score_gemma":0.0001865757,"teacher_disagreement_score":0.027814882,"about_ca_system_score_codex":0.000052731015,"about_ca_system_score_gemma":0.00021462532,"threshold_uncertainty_score":0.31664953},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","score_opus":0.022065930195343083,"score_gpt":0.3371386426214998,"score_spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2719623628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813605,0.0003978201,0.0000052089695,0.015161294,0.00006601561,0.0016484973,0.00005621009,0.00008880354,0.0012156677],"genre_scores_gemma":[0.9970024,0.0005228762,0.0007079193,0.00041459233,0.00012415356,0.0007225432,0.0000076279034,0.000048999114,0.0004488642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982732,0.000068380075,0.0002704791,0.0004886982,0.00035996462,0.00053931016],"domain_scores_gemma":[0.99841225,0.00011125685,0.00038226662,0.0008507885,0.00009553602,0.00014789033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029951823,0.0003219509,0.00049763237,0.000053138687,0.0003886244,0.00006266612,0.0002871,0.000060885395,0.000028358754],"category_scores_gemma":[0.000037761514,0.00015319734,0.000016383947,0.00010683305,0.000988199,0.00018077697,0.00007025772,0.00037680252,0.0000025231554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2487009,0.0007418265,0.0403353,0.00007491041,0.0001767207,0.0003994837,0.002023934,0.000091349866,0.007364981,0.000108116816,0.000022493701,0.69996],"study_design_scores_gemma":[0.037270974,0.014761856,0.93988013,0.0009472894,0.000036160684,0.00029353547,0.0007724527,0.000022479193,0.0024956432,0.00015028828,0.0030810444,0.00028812257],"about_ca_topic_score_codex":0.00018742996,"about_ca_topic_score_gemma":0.00072567974,"teacher_disagreement_score":0.89954484,"about_ca_system_score_codex":0.00034486214,"about_ca_system_score_gemma":0.00024477823,"threshold_uncertainty_score":0.62472063},"labels":[],"label_agreement":null},{"id":"W2759254671","doi":"10.1634/theoncologist.2017-0205","title":"Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Pulmonary embolism; Lung cancer; Internal medicine; Thrombosis; Deep vein; Cancer; Prospective cohort study; Venous thrombosis; Proportional hazards model; Population; Cohort study; Surgery","score_opus":0.031006028234536936,"score_gpt":0.355612829883407,"score_spread":0.32460680164887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759254671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877183,0.00050640677,0.0000018618388,0.000945034,0.00042442707,0.002284611,0.00024065372,0.00003339996,0.00784532],"genre_scores_gemma":[0.9989761,0.00049425435,0.000026708296,0.00007755135,0.00020294896,0.00016440124,0.000005852694,0.000011623044,0.000040573395],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846065,0.0001006776,0.0004343048,0.00041883864,0.0003146501,0.00027089665],"domain_scores_gemma":[0.9984203,0.00008720832,0.0004218812,0.0009167026,0.000072565665,0.00008133184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006606799,0.00018274917,0.0008650654,0.000030257837,0.00026749144,0.00005605254,0.00035680752,0.000085553096,0.000015607713],"category_scores_gemma":[0.00027812918,0.00012316903,0.000059764392,0.000087083296,0.0005156067,0.00009405438,0.0003506347,0.00021043257,0.0000016552825],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041495674,0.0024668702,0.9886906,0.00003090528,0.0006501182,0.00008758536,0.005449755,0.000013668925,0.000023811715,0.0003645783,0.0005419732,0.0012651371],"study_design_scores_gemma":[0.004343794,0.0013379672,0.99101675,0.00012264671,0.0008767058,0.0000013339184,0.0013118346,0.00004393196,0.000046948986,0.0007085299,0.00007744324,0.00011213843],"about_ca_topic_score_codex":0.28363582,"about_ca_topic_score_gemma":0.06158033,"teacher_disagreement_score":0.2220555,"about_ca_system_score_codex":0.00037361335,"about_ca_system_score_gemma":0.0001672309,"threshold_uncertainty_score":0.9555434},"labels":[],"label_agreement":null},{"id":"W2761496515","doi":"10.1634/theoncologist.2017-0248","title":"Outcomes of a Specialized Interdisciplinary Approach for Patients with Cancer with Aberrant Opioid-Related Behavior","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Opioid; Psychological intervention; Cancer pain; Anxiety; Internal medicine; Intervention (counseling); Cancer; Medical record; Morphine; Chronic pain; Outpatient clinic; Physical therapy; Psychiatry","score_opus":0.0300207352605767,"score_gpt":0.3519193241832878,"score_spread":0.3218985889227111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761496515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901566,0.000076736134,0.00008295934,0.0012744649,0.00015602325,0.003102128,0.00010784654,0.000033691962,0.005009555],"genre_scores_gemma":[0.99379796,0.000018557357,0.0029464823,0.00005168207,0.000034770965,0.0011784963,0.000101664235,0.00003316997,0.0018372443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990279,0.000024193407,0.00024464104,0.00025080034,0.00022887158,0.00022358731],"domain_scores_gemma":[0.9986231,0.00005675386,0.00037560478,0.0007380651,0.00014718223,0.00005931939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010636915,0.00020046855,0.0005283216,0.000035929705,0.0003167707,0.000020902646,0.00027831548,0.000074221636,0.000057329828],"category_scores_gemma":[0.000032953707,0.00008904612,0.00009844367,0.00004636913,0.000541473,0.000055141692,0.000145617,0.00011503508,0.000002575587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033313371,0.003090417,0.9857061,0.000085574284,0.0005018508,0.000010343083,0.0018415762,0.000011097324,0.00002026226,0.0000886508,0.00039260165,0.004920175],"study_design_scores_gemma":[0.012787973,0.0028657692,0.98202634,0.000088138215,0.0011231285,0.0000034177892,0.0006127293,0.00004591372,0.000091789574,0.000045169276,0.00018350198,0.00012610885],"about_ca_topic_score_codex":0.00047343603,"about_ca_topic_score_gemma":0.00023667984,"teacher_disagreement_score":0.009456635,"about_ca_system_score_codex":0.00016435963,"about_ca_system_score_gemma":0.00017397702,"threshold_uncertainty_score":0.36311954},"labels":[],"label_agreement":null},{"id":"W2763843183","doi":"10.1634/theoncologist.2017-0141","title":"Effectiveness of Oncologist-Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Medicine; Physical therapy; Breast cancer; Quality of life (healthcare); Referral; Adverse effect; Randomized controlled trial; Aerobic exercise; Clinical trial; Cancer; Adjuvant therapy; Internal medicine; Family medicine; Nursing","score_opus":0.036725446287990134,"score_gpt":0.3759492769604419,"score_spread":0.33922383067245176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763843183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928384,0.0024066044,0.00002768783,0.0006170199,0.00042620345,0.0023037088,0.00025070133,0.000028424072,0.0011012964],"genre_scores_gemma":[0.9984452,0.00031617467,0.00011014894,0.000047037964,0.00012294382,0.00080490625,0.000020402915,0.000021324577,0.000111833426],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987671,0.00012236607,0.00033007603,0.0002842101,0.00019776059,0.0002984837],"domain_scores_gemma":[0.9980352,0.00037928435,0.0005769963,0.00047607347,0.00042667484,0.00010575547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007526175,0.00016820214,0.0007219236,0.000036825033,0.00032205283,0.000024486551,0.00021321021,0.00012795832,0.00001736876],"category_scores_gemma":[0.0002465583,0.00011134689,0.0001346116,0.0000654959,0.00073964166,0.00006737542,0.00011992412,0.00016305006,6.7031897e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016369933,0.00029246358,0.45479867,0.0055663195,0.00018144012,0.000025716015,0.009212953,0.000006151012,0.0013067845,0.00023372487,0.00009082953,0.511915],"study_design_scores_gemma":[0.004493987,0.0049306387,0.97017485,0.0029791514,0.0005522466,0.00003099019,0.00962235,0.000016514978,0.004851718,0.00012940122,0.0020199083,0.00019825545],"about_ca_topic_score_codex":0.0238615,"about_ca_topic_score_gemma":0.0066032936,"teacher_disagreement_score":0.51537615,"about_ca_system_score_codex":0.00023959129,"about_ca_system_score_gemma":0.00054038205,"threshold_uncertainty_score":0.9826387},"labels":[],"label_agreement":null},{"id":"W2763983027","doi":"10.1634/theoncologist.2017-0277","title":"Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; University of Toronto; University of Waterloo","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canadian Liver Foundation","keywords":"Medicine; Nivolumab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Internal medicine; Radiology; Surgery; Immunotherapy; Radiation therapy; Cancer","score_opus":0.11201356065839797,"score_gpt":0.3941711687163503,"score_spread":0.2821576080579523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763983027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503906,0.0024889922,0.0000071569348,0.0007729382,0.00017422243,0.00076722825,0.000009964011,0.000008629956,0.0107318],"genre_scores_gemma":[0.99940526,0.0001512815,0.00008451935,0.00005320519,0.000030920924,0.00008923948,0.0000019397467,0.000007753439,0.00017586267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924135,0.00014614643,0.00016866253,0.0001602398,0.000106042986,0.00017754102],"domain_scores_gemma":[0.99907553,0.0003471247,0.00011925509,0.0003646821,0.00004686196,0.000046540805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058477535,0.000101732585,0.00044824122,0.00003129649,0.00016156129,0.000010925668,0.00012555927,0.000031986303,0.000009807581],"category_scores_gemma":[0.0002805687,0.00006305256,0.000041251078,0.00004311688,0.00041493418,0.000032691645,0.00011010848,0.00015068412,0.0000048838774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048100254,0.0015789616,0.906252,0.0023625058,0.00006369171,0.00031246105,0.00308698,0.000010772569,0.0042205728,0.0003683464,0.0015517633,0.07538189],"study_design_scores_gemma":[0.0051022004,0.0022136625,0.9874672,0.00015652011,0.0000822155,0.000016169071,0.000304857,0.00006915851,0.0029525866,0.00013224629,0.0014296102,0.00007351591],"about_ca_topic_score_codex":0.0017550642,"about_ca_topic_score_gemma":0.0014611022,"teacher_disagreement_score":0.08121523,"about_ca_system_score_codex":0.00013292526,"about_ca_system_score_gemma":0.00011029235,"threshold_uncertainty_score":0.26531437},"labels":[],"label_agreement":null},{"id":"W2767785601","doi":"10.1634/theoncologist.2017-0297","title":"A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve","year":2017,"lang":"en","type":"review","venue":"The Oncologist","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Quality of life (healthcare); Randomized controlled trial; MEDLINE; Systematic review; Disease; Internal medicine; Physical therapy; Intensive care medicine","score_opus":0.6354246175069749,"score_gpt":0.6413765227387773,"score_spread":0.005951905231802446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767785601","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020880796,0.9779684,0.0000107886835,0.0046779807,0.0008013039,0.01584984,0.00019414662,0.000016861968,0.00045977466],"genre_scores_gemma":[0.0005195513,0.9951564,0.000103817554,0.000768381,0.0002196346,0.002892065,0.00005985767,0.000038791088,0.00024151201],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9632074,0.009105986,0.026196964,0.000653298,0.00048054574,0.00035579913],"domain_scores_gemma":[0.9364689,0.0053337645,0.055356808,0.0023109596,0.00026210386,0.00026746807],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.10041934,0.00044783924,0.023949273,0.0001227342,0.00008635579,0.000014827819,0.00048345458,0.00040261235,0.00011725599],"category_scores_gemma":[0.103704125,0.00022611396,0.002155721,0.00035377883,0.00017622547,0.00002660673,0.00015648338,0.00066554267,0.000011195041],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001128901,0.00088230276,0.000044223496,0.66453004,0.0014418932,0.000029717548,0.00005262143,1.038011e-7,7.4181784e-8,0.000064365166,0.00079218164,0.33204958],"study_design_scores_gemma":[0.005192083,0.0012138581,0.00013405994,0.94419307,0.008742192,0.000019004434,0.00003507718,0.0000013994592,3.5348515e-7,0.000014532299,0.04026975,0.00018462876],"about_ca_topic_score_codex":0.009180958,"about_ca_topic_score_gemma":0.00050910277,"teacher_disagreement_score":0.33186495,"about_ca_system_score_codex":0.0010146714,"about_ca_system_score_gemma":0.0064362474,"threshold_uncertainty_score":0.99919635},"labels":[],"label_agreement":null},{"id":"W2772890129","doi":"10.1634/theoncologist.2017-0103","title":"Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Population; Confidence interval; Propensity score matching; Oncology; Dexamethasone; Surgery; Lenalidomide; Environmental health","score_opus":0.13851089506331335,"score_gpt":0.4163297299963975,"score_spread":0.2778188349330841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772890129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99448246,0.0015561965,0.00002812536,0.0006213064,0.000043824148,0.0019598957,0.000033426997,0.000015238563,0.001259554],"genre_scores_gemma":[0.99832755,0.00041313967,0.0009114629,0.00002744723,0.000042938293,0.00012664172,0.000023939083,0.00001361932,0.00011327907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825734,0.0004422253,0.0004288743,0.00025662495,0.00031266277,0.0003022533],"domain_scores_gemma":[0.9967702,0.0018217299,0.0004454132,0.00081341347,0.000067631,0.00008160212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005120262,0.00022848844,0.0009962607,0.0000967499,0.00032126607,0.0000393513,0.00034205185,0.00008721014,0.000015444055],"category_scores_gemma":[0.00024539648,0.000113194794,0.00011811683,0.00012123636,0.000849212,0.000061590654,0.000058987036,0.00019490287,0.0000054035518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045755647,0.014665331,0.69005674,0.00023091312,0.002000209,0.0004903029,0.09110261,0.00052711024,0.020815477,0.00019067124,0.00021467695,0.13395032],"study_design_scores_gemma":[0.029551098,0.0031276138,0.94578165,0.00012984521,0.0001346254,0.00002571596,0.0029770255,0.0030705337,0.01487927,0.000044484354,0.0001798284,0.00009831251],"about_ca_topic_score_codex":0.0049937833,"about_ca_topic_score_gemma":0.0034023714,"teacher_disagreement_score":0.2557249,"about_ca_system_score_codex":0.00024996354,"about_ca_system_score_gemma":0.00014254247,"threshold_uncertainty_score":0.754914},"labels":[],"label_agreement":null},{"id":"W2781449980","doi":"10.1634/theoncologist.2017-0237","title":"Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Microsoft","keywords":"Medicine; Clinical trial; Ethnic group; Drug; Cancer; Clinical research; Pharmacology; Internal medicine","score_opus":0.8741845997911862,"score_gpt":0.7193066874101237,"score_spread":0.15487791238106252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781449980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7952857,0.001306109,0.000023203756,0.19931331,0.0007330347,0.0005836072,0.00004366579,0.000019655308,0.0026917076],"genre_scores_gemma":[0.9777617,0.01774961,0.00021036601,0.00059287134,0.0009189188,0.000022742,0.0000026113805,0.000008655956,0.002732552],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976793,0.0009093901,0.00050670723,0.00023961686,0.00048735674,0.0001776425],"domain_scores_gemma":[0.9788983,0.019102274,0.00079933245,0.00074530387,0.00032191206,0.00013289106],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.018377142,0.00008913393,0.0006902253,0.000024022618,0.00034606137,0.00004164152,0.00041356898,0.0003301009,0.00011359086],"category_scores_gemma":[0.042818747,0.000050930445,0.00018062873,0.000038208524,0.0032636959,0.00005188335,0.00042223756,0.0015129022,0.000011790232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012237841,0.0016248142,0.516929,0.0008695472,0.0007691807,0.00023883171,0.0023540207,0.000005933238,0.0032761327,0.0087328805,0.035010386,0.41795146],"study_design_scores_gemma":[0.0077674952,0.0013316377,0.9649667,0.0008597695,0.0005974789,0.0000058783353,0.0016310277,0.00018635235,0.001087388,0.013880905,0.007530993,0.00015435611],"about_ca_topic_score_codex":0.00052149233,"about_ca_topic_score_gemma":0.0044090557,"teacher_disagreement_score":0.44803774,"about_ca_system_score_codex":0.00006955068,"about_ca_system_score_gemma":0.0003203333,"threshold_uncertainty_score":0.99944884},"labels":[],"label_agreement":null},{"id":"W2784883128","doi":"10.1634/theoncologist.2017-0346","title":"Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Genomic Health","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Oncology; Confidence interval; Prospective cohort study; Adjuvant; Stage (stratigraphy); Cancer; Lymph node","score_opus":0.02940338891775906,"score_gpt":0.32099860819347475,"score_spread":0.2915952192757157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784883128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626994,0.00012508783,0.00000680679,0.0005692466,0.00012188511,0.0011889426,0.0008737371,0.0000012443776,0.00084312924],"genre_scores_gemma":[0.9990369,0.000021602795,0.000019399557,0.000058285357,0.000052784788,0.0006827348,0.000010647204,0.000008422074,0.00010923364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903274,0.00015536632,0.0001509191,0.00023230586,0.00023534226,0.00019331838],"domain_scores_gemma":[0.9988592,0.00009680756,0.0002152667,0.0004012962,0.00040411475,0.000023274568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029470632,0.00015568182,0.00019697101,0.000011089215,0.00015996,0.0000041352346,0.00022452245,0.000044301574,0.000023356604],"category_scores_gemma":[0.00008804845,0.000060528884,0.0000671938,0.00012741989,0.00039284115,0.0000024913895,0.00007580054,0.000058593858,1.4164883e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006810218,0.000812103,0.94158256,0.00000508158,0.0011257965,6.934795e-7,0.0034043426,0.0052099354,0.01305364,0.00002902035,0.0010397936,0.026926836],"study_design_scores_gemma":[0.0015760693,0.0012826151,0.95870394,0.000078101126,0.00010376649,0.0000056696927,0.00026294,0.000036474892,0.037747603,0.00009474241,0.000035979003,0.00007212565],"about_ca_topic_score_codex":0.7724951,"about_ca_topic_score_gemma":0.9872353,"teacher_disagreement_score":0.21474023,"about_ca_system_score_codex":0.0037299236,"about_ca_system_score_gemma":0.0037647267,"threshold_uncertainty_score":0.97536206},"labels":[],"label_agreement":null},{"id":"W2800380359","doi":"10.1634/theoncologist.2018-0153","title":"Can We Hang Our Hats on One Percent?","year":2018,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Hang; Breast cancer; Oncology; Chemotherapy; Residual; Neoadjuvant therapy; Internal medicine; Cancer","score_opus":0.04305294382414494,"score_gpt":0.3000418980827577,"score_spread":0.2569889542586128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800380359","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035056665,0.000948684,0.000005856106,0.98605144,0.0009999761,0.00035961295,0.00025659558,0.00003751238,0.007834667],"genre_scores_gemma":[0.13630295,0.0017284718,0.00017001964,0.8091584,0.026021086,0.00029044555,0.0012911278,0.00012375109,0.024913741],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984123,0.000155129,0.00017971543,0.00056005316,0.00023165657,0.00046115468],"domain_scores_gemma":[0.99884343,0.000032503638,0.00017137892,0.0008357388,0.00008000847,0.00003695428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012198944,0.00038437115,0.0003478288,0.000033471526,0.0002674698,0.00003668641,0.0005373016,0.00064330694,0.000038241167],"category_scores_gemma":[0.000052351013,0.0002555303,0.00016983096,0.00005410202,0.00032138886,8.6597845e-7,0.00028769593,0.0005216982,0.00022388146],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008980318,0.000070642,0.00010493911,0.000024541825,0.0003240304,0.000044989112,0.000078188765,0.0000011774043,0.000506798,0.000005408937,0.99653393,0.002215567],"study_design_scores_gemma":[0.00049385807,0.0006726748,0.0012108574,0.000076601624,0.00017638066,0.0000226303,0.00012727211,3.759877e-7,0.0023780195,0.0001277534,0.9943939,0.000319678],"about_ca_topic_score_codex":0.00036024404,"about_ca_topic_score_gemma":0.0007377816,"teacher_disagreement_score":0.17689303,"about_ca_system_score_codex":0.00021234213,"about_ca_system_score_gemma":0.0001428796,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W2804901132","doi":"10.1634/theoncologist.2017-0668","title":"Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Palliative care; Intervention (counseling); Multivariate analysis; Cancer; Physical therapy; Quality of life (healthcare); Internal medicine; Psychiatry; Nursing","score_opus":0.0397346557057647,"score_gpt":0.4027323460979189,"score_spread":0.36299769039215424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804901132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087423,0.00068593223,0.0000012030673,0.0033465428,0.00096709875,0.00044447684,0.00004600597,0.000027968224,0.0036065495],"genre_scores_gemma":[0.99444103,0.0005352676,0.000014658371,0.004463387,0.0002639561,0.00008355594,0.00000811277,0.000008283793,0.00018171783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989749,0.00014111308,0.00020570337,0.00025824024,0.0002107015,0.0002093435],"domain_scores_gemma":[0.9993824,0.00012956712,0.00010578115,0.00019836603,0.00009207252,0.00009183403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002042045,0.000119532226,0.00027007487,0.000019642008,0.00007595191,0.000009769132,0.00008155623,0.00010563815,0.00014575361],"category_scores_gemma":[0.00014487484,0.00006960554,0.00004569989,0.00012404172,0.00038955058,0.00002120882,0.00008151684,0.00015198972,0.0000135407945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029256425,0.00032183033,0.6538802,0.000019240262,0.000023356011,0.000007819713,0.0013718251,5.852031e-7,0.000100999794,0.00008953889,0.0025926195,0.33866635],"study_design_scores_gemma":[0.00449503,0.006922671,0.9259057,0.00031358542,0.000053447926,0.0000024412773,0.0009913173,0.000025233794,0.00036816188,0.00009605508,0.060680475,0.00014588414],"about_ca_topic_score_codex":0.0009730243,"about_ca_topic_score_gemma":0.010808156,"teacher_disagreement_score":0.33852047,"about_ca_system_score_codex":0.0002595053,"about_ca_system_score_gemma":0.00007469656,"threshold_uncertainty_score":0.60312045},"labels":[],"label_agreement":null},{"id":"W2808946203","doi":"10.1634/theoncologist.2017-0136","title":"Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"European Society for Medical Oncology","keywords":"Sarcoma; Oncology; Retrospective cohort study; Medicine; Overall survival; Internal medicine; Pathology","score_opus":0.028485064380589776,"score_gpt":0.32010100933809843,"score_spread":0.29161594495750864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808946203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242336,0.0013615333,0.00017479013,0.0017484407,0.000071106086,0.0009273126,0.0029354831,0.00005052119,0.00030747816],"genre_scores_gemma":[0.99746144,0.00010762864,0.0010303125,0.0002573326,0.00024366577,0.00006146654,0.0007277661,0.00002354913,0.00008686531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979185,0.000529304,0.0003992183,0.00050267833,0.00029580228,0.00035452243],"domain_scores_gemma":[0.9956625,0.0028307126,0.00032698747,0.00086314016,0.00016328432,0.00015337618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033507016,0.00039916008,0.0009891484,0.00009617242,0.00028681773,0.0000511009,0.00022320579,0.000100609286,0.0006813227],"category_scores_gemma":[0.00077620905,0.0001608589,0.00059724844,0.0006760989,0.0010819825,0.000063089516,0.00010714029,0.00017353825,0.000015796695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033178905,0.00088274595,0.9801596,0.000003344209,0.010481356,0.000046184115,0.0015439247,0.000002445698,0.0005164259,0.0001353302,0.0017396411,0.0041572363],"study_design_scores_gemma":[0.0029675025,0.008298167,0.97602737,0.0000291728,0.009502031,0.000009551342,0.0008830924,0.00020528997,0.00053251756,0.0011106706,0.00028656056,0.000148055],"about_ca_topic_score_codex":0.11507927,"about_ca_topic_score_gemma":0.023633735,"teacher_disagreement_score":0.091445535,"about_ca_system_score_codex":0.00056992954,"about_ca_system_score_gemma":0.0001521869,"threshold_uncertainty_score":0.9941824},"labels":[],"label_agreement":null},{"id":"W2888017273","doi":"10.1634/theoncologist.2018-0089","title":"Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Placebo; Lung cancer; Confidence interval; Gastroenterology; Population; Oncology; Cancer; Pathology","score_opus":0.015630401558201345,"score_gpt":0.35533037232813364,"score_spread":0.3396999707699323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888017273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779929,0.000042980293,0.000059044683,0.00011861792,0.00006944951,0.01585702,0.00007187894,0.00005626534,0.0057318415],"genre_scores_gemma":[0.9958356,0.000014560131,0.0008836068,0.00005184488,0.000054596916,0.0024222275,0.0000385252,0.00005405495,0.0006449927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780935,0.00014554599,0.0006010133,0.0005791697,0.00035926804,0.0005056361],"domain_scores_gemma":[0.99838036,0.00013995971,0.00056410447,0.0004815638,0.00032651497,0.00010751183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035979899,0.00037476697,0.0009863687,0.00017607049,0.00014994724,0.00002429875,0.00021099589,0.00007765336,0.000058546484],"category_scores_gemma":[0.000046091012,0.00021883464,0.0000468463,0.00070407725,0.00030019606,0.00010974321,0.00008259565,0.0003881909,0.0000015725801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075966753,0.005925601,0.9748159,0.00011456247,0.00024547806,0.00006600258,0.009743454,0.00080057397,0.00016900898,0.0000044393255,0.00002868814,0.00048959034],"study_design_scores_gemma":[0.11266833,0.015747584,0.86380446,0.0008426683,0.0005881744,0.000003851657,0.0021762843,0.0034332003,0.0004898127,0.0000014808733,0.0000120965715,0.00023207293],"about_ca_topic_score_codex":0.0047945473,"about_ca_topic_score_gemma":0.022108084,"teacher_disagreement_score":0.11101148,"about_ca_system_score_codex":0.0028093169,"about_ca_system_score_gemma":0.0015695269,"threshold_uncertainty_score":0.9957359},"labels":[],"label_agreement":null},{"id":"W2888939095","doi":"10.1634/theoncologist.2018-0103","title":"The Role of Primary Care Physicians in Childhood Cancer Survivorship Care: Multiperspective Interviews","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Council NSW; National Health and Medical Research Council; Kids' Cancer Project; Medical Research Council; McGill University; Kids Cancer Alliance; Cancer Institute NSW","keywords":"Survivorship curve; Cancer survivorship; Childhood cancer; Primary care; Cancer; Medicine; Family medicine; Nursing; Psychology","score_opus":0.027361689225604904,"score_gpt":0.3321610920573526,"score_spread":0.3047994028317477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888939095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90556777,0.03030828,0.000011648067,0.008488701,0.0008657082,0.0015652492,0.000088055465,0.00008850647,0.05301607],"genre_scores_gemma":[0.9959771,0.0006224116,0.00008189304,0.0019293979,0.0010351264,0.00014876673,0.000019689787,0.000036890047,0.0001487331],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9977477,0.0005356896,0.00051495415,0.0003727348,0.00041713132,0.0004117809],"domain_scores_gemma":[0.99784714,0.0005531148,0.00032991433,0.00083743094,0.00036767116,0.0000647306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007835136,0.0002442285,0.00061604165,0.000058178754,0.00025310196,0.000021253865,0.00057259476,0.00012060457,0.000033392993],"category_scores_gemma":[0.00026202205,0.00014488828,0.00020622098,0.00040418364,0.0011926907,0.000058426325,0.00020499315,0.0004833265,0.000028064678],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013662932,0.00082639017,0.096263215,0.0003866334,0.00035583446,0.000010542364,0.5719861,0.000018357074,0.0016420193,0.0014833562,0.0013729295,0.32428834],"study_design_scores_gemma":[0.0025312428,0.0013309577,0.70747226,0.00079027435,0.0001760874,0.000007928987,0.25239715,0.00002292324,0.007253395,0.0005881961,0.027121529,0.00030803742],"about_ca_topic_score_codex":0.034309573,"about_ca_topic_score_gemma":0.21176508,"teacher_disagreement_score":0.6112091,"about_ca_system_score_codex":0.0010907126,"about_ca_system_score_gemma":0.00051381794,"threshold_uncertainty_score":0.97212106},"labels":[],"label_agreement":null},{"id":"W2892457888","doi":"10.1634/theoncologist.2018-0081","title":"Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Venous thromboembolism; Retrospective cohort study; Sarcoma; Intensive care medicine; Internal medicine; Oncology; Pathology; Thrombosis","score_opus":0.01287297081359609,"score_gpt":0.2784377941867393,"score_spread":0.26556482337314324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892457888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97048587,0.000028520024,0.000007978922,0.0009386973,0.00021254567,0.0022016119,0.000003541036,0.00006885255,0.0260524],"genre_scores_gemma":[0.99831563,0.000009145772,0.00010304275,0.0009769315,0.00023709562,0.000120465535,0.000005788094,0.000025845546,0.00020607814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986029,0.000100676036,0.00023033851,0.00033652587,0.0003733307,0.0003561781],"domain_scores_gemma":[0.99907047,0.00003613485,0.00010674109,0.00056586304,0.00015638617,0.00006439496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004243597,0.00017893531,0.0006100928,0.00008797951,0.00019275302,0.000026061203,0.0002150036,0.000053834694,0.0001595309],"category_scores_gemma":[0.000073653864,0.00009997298,0.000041176445,0.00037110577,0.00040307638,0.000054487493,0.00014528401,0.00022825893,0.0001446414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004923465,0.01587694,0.9705824,0.000012915933,0.00023767434,0.00006872358,0.0043656244,0.0000023763264,0.0000070812284,0.0009417818,0.004448685,0.0029634496],"study_design_scores_gemma":[0.0044645187,0.015662136,0.97659683,0.00003882581,0.00020634537,0.000002404489,0.001216648,0.0000057627894,0.000013384839,0.00027007112,0.0013969712,0.00012608062],"about_ca_topic_score_codex":0.00080446305,"about_ca_topic_score_gemma":0.0016545994,"teacher_disagreement_score":0.027829755,"about_ca_system_score_codex":0.0003735708,"about_ca_system_score_gemma":0.000074151816,"threshold_uncertainty_score":0.40767798},"labels":[],"label_agreement":null},{"id":"W2892659800","doi":"10.1634/theoncologist.2017-0583","title":"Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Cancer pain; Logistic regression; Internal medicine; Anxiety; Prospective cohort study; Odds ratio; Cancer; Anesthesia; Physical therapy; Psychiatry","score_opus":0.02215017312329074,"score_gpt":0.3137666455798363,"score_spread":0.29161647245654554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892659800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796342,0.000069153575,0.004936931,0.009941231,0.00013620639,0.0048003644,0.000024881316,0.0000740613,0.00038294148],"genre_scores_gemma":[0.9826734,0.000014704726,0.0035667436,0.009940286,0.0001923254,0.0013271712,0.000041771957,0.000047119865,0.00219649],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99751663,0.0008317107,0.00035099237,0.00040168987,0.00033858852,0.0005603778],"domain_scores_gemma":[0.9974702,0.0014795052,0.00017285094,0.0004637385,0.00025381823,0.00015988681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045861346,0.00028162298,0.00062103965,0.00012307671,0.00016481325,0.0000353006,0.0002500224,0.0000883147,0.000087613924],"category_scores_gemma":[0.0013066732,0.0001500171,0.00006675843,0.00044065344,0.00036515374,0.00009515088,0.000056522338,0.00016956037,0.00002753043],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.674687,0.001287384,0.21904285,0.00012208647,0.00036624572,0.00006637061,0.0012930084,0.0003045468,0.00030291645,0.00018113619,0.022044811,0.08030163],"study_design_scores_gemma":[0.111271255,0.046486095,0.745591,0.00051877083,0.00036555366,5.541327e-7,0.0018424037,0.002652993,0.00012452337,0.00012885922,0.09038897,0.0006290134],"about_ca_topic_score_codex":0.00042929946,"about_ca_topic_score_gemma":0.0025066286,"teacher_disagreement_score":0.56341577,"about_ca_system_score_codex":0.0004077925,"about_ca_system_score_gemma":0.00027142,"threshold_uncertainty_score":0.61175203},"labels":[],"label_agreement":null},{"id":"W2892927588","doi":"10.1634/theoncologist.2018-0290","title":"A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; Central China Normal University","keywords":"Bevacizumab; Glioblastoma; Medicine; Oncology; Randomized controlled trial; Internal medicine; Chemotherapy; Cancer research","score_opus":0.09663458954944744,"score_gpt":0.42544317385276065,"score_spread":0.3288085843033132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892927588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775446,0.0010588615,0.00009844722,0.0025380724,0.00031912964,0.00790017,0.00007994255,0.000023260242,0.00022764904],"genre_scores_gemma":[0.99693847,0.00030124612,0.0012389096,0.00005708643,0.0003956292,0.0009333403,0.000020124391,0.000015472087,0.000099702935],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983188,0.00034577915,0.0006824803,0.00024184081,0.00019989604,0.00021118397],"domain_scores_gemma":[0.99404883,0.004688482,0.00054276374,0.00040406207,0.00027103815,0.00004480072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001261686,0.00021094807,0.0010650348,0.000034281766,0.00030579537,0.000009586312,0.00011093658,0.00007331678,0.000028555825],"category_scores_gemma":[0.0024858976,0.00008162397,0.0003123368,0.00012351655,0.0009882044,0.000023834433,0.000069953996,0.000059618837,0.0000016791116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8961071,0.004497379,0.000031849177,0.00002760646,0.00061801623,0.0000025788054,0.002392475,0.0000083775685,0.0016900752,0.00021847434,0.00021927645,0.094186835],"study_design_scores_gemma":[0.8428766,0.13370478,0.000085982,0.00013143136,0.0017739218,0.000016289712,0.00035210876,0.003117057,0.015535113,0.0001706169,0.0021599862,0.00007612002],"about_ca_topic_score_codex":0.00019591607,"about_ca_topic_score_gemma":0.00018919655,"teacher_disagreement_score":0.1292074,"about_ca_system_score_codex":0.00013573818,"about_ca_system_score_gemma":0.00014912496,"threshold_uncertainty_score":0.36410803},"labels":[],"label_agreement":null},{"id":"W2893040167","doi":"10.1634/theoncologist.2018-0150","title":"Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; St. Joseph’s Healthcare Hamilton","funders":"Canadian Institutes of Health Research","keywords":"Osimertinib; Medicine; Cost effectiveness; Lung cancer; Quality-adjusted life year; Oncology; Epidermal growth factor receptor; Internal medicine; Erlotinib; Cancer; Risk analysis (engineering)","score_opus":0.02511183467803173,"score_gpt":0.38573719465674927,"score_spread":0.36062535997871753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893040167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791571,0.00069249654,0.0014525835,0.00034461418,0.00022634545,0.0023442935,0.00004859994,0.000027312548,0.01570668],"genre_scores_gemma":[0.9970995,0.00007939826,0.000969098,0.00022656664,0.00009725004,0.00097285915,0.00004140933,0.000020776513,0.00049311947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901503,0.00014181553,0.00025740665,0.00023576364,0.00011923071,0.00023075717],"domain_scores_gemma":[0.9983171,0.0010285497,0.00018594084,0.00020991394,0.00020136643,0.000057101337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025617421,0.00014990207,0.0003229522,0.000066916495,0.00012607135,0.000009649208,0.000097573524,0.00006602218,0.000092589806],"category_scores_gemma":[0.0001269869,0.00009927531,0.00006632087,0.00030764885,0.00022771556,0.00006373535,0.000031929594,0.00012187071,0.0000077612285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071097524,0.0040132036,0.6638082,0.0012014585,0.0011351561,0.00052262045,0.033775028,0.01130671,0.05392562,0.0009961592,0.0013996687,0.22080638],"study_design_scores_gemma":[0.021154016,0.0029335185,0.86293334,0.0015518029,0.0011608702,0.000017815624,0.0030803073,0.002775932,0.10341302,0.00027925917,0.0003803883,0.00031972068],"about_ca_topic_score_codex":0.00405714,"about_ca_topic_score_gemma":0.0016730224,"teacher_disagreement_score":0.22048666,"about_ca_system_score_codex":0.0006860003,"about_ca_system_score_gemma":0.00041382792,"threshold_uncertainty_score":0.6133209},"labels":[],"label_agreement":null},{"id":"W2894135776","doi":"10.1634/theoncologist.2018-0049","title":"A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; University of Alberta","funders":"International Business Machines Corporation","keywords":"Medicine; Breast cancer; Blood pressure; Internal medicine; Chemotherapy; Aerobic exercise; Cancer; Cardiology; Heart rate; Radiation therapy; Tachycardia; Oncology","score_opus":0.07737978190183593,"score_gpt":0.35204089321258497,"score_spread":0.27466111131074905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894135776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851686,0.00018582234,0.000017849487,0.00020443325,0.00010438767,0.00062877726,0.000010651242,0.0000071090176,0.0003241151],"genre_scores_gemma":[0.99952006,0.00016923479,0.000020876274,0.000017489048,0.00017395047,0.000029561326,0.0000011546365,0.000005956386,0.000061738596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991792,0.00014269672,0.0002829041,0.00013082876,0.00018942039,0.00007495268],"domain_scores_gemma":[0.99912506,0.000104859384,0.0003933079,0.00022634734,0.00012961686,0.000020826745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008676806,0.00007385209,0.00047227796,0.000022991413,0.00006118562,0.0000030970032,0.000049351645,0.00007339679,0.000009061809],"category_scores_gemma":[0.000031389744,0.0000363051,0.0001468545,0.000116927724,0.00026427608,0.00002863762,0.000015694486,0.00007981633,1.985372e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014640111,0.0006829954,0.87881684,0.000033011413,0.0027335358,7.353015e-7,0.0063168914,0.00011980892,0.00264884,0.000010770695,0.000018568428,0.107153974],"study_design_scores_gemma":[0.0037686785,0.0028492478,0.9815122,0.000103457845,0.001994798,0.000008306574,0.0028838008,0.000033886492,0.006682097,0.000009989444,0.00011721292,0.000036361263],"about_ca_topic_score_codex":0.0014777181,"about_ca_topic_score_gemma":0.00080108934,"teacher_disagreement_score":0.10711761,"about_ca_system_score_codex":0.00015978768,"about_ca_system_score_gemma":0.00019954347,"threshold_uncertainty_score":0.22338776},"labels":[],"label_agreement":null},{"id":"W2898225012","doi":"10.1634/theoncologist.2018-0244","title":"Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Delirium; Medicine; Palliative care; Nausea; Depression (economics); Anxiety; Cancer; Intensive care medicine; Internal medicine; Psychiatry; Nursing","score_opus":0.020069111794756858,"score_gpt":0.34724141998073726,"score_spread":0.3271723081859804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898225012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524826,0.000045128836,0.00023377668,0.0013644192,0.000066794724,0.0014051322,0.000072122784,0.000046013232,0.0015183642],"genre_scores_gemma":[0.9857187,0.000015113647,0.0008190105,0.012898864,0.000046980454,0.00016958725,0.0001160566,0.000038248778,0.00017740959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875414,0.00010520635,0.00016668755,0.00038314442,0.00026039992,0.00033044224],"domain_scores_gemma":[0.991423,0.000057572848,0.00012224865,0.00027939602,0.007954863,0.00016293547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006860731,0.00023661845,0.00033275998,0.00011111824,0.00013413653,0.0000148590225,0.00012094775,0.00007851594,0.00006332497],"category_scores_gemma":[0.00043651156,0.00012859279,0.000017548871,0.00032831874,0.0005983056,0.00010996872,0.000073267445,0.00024077183,0.0000090872845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010193255,0.0001290303,0.9778476,0.000018559469,0.000086391796,0.00002084579,0.006858378,0.000010766471,0.0010443628,0.000005949275,0.00022381032,0.003561092],"study_design_scores_gemma":[0.0061325356,0.009837583,0.952192,0.0005327466,0.00017670645,0.0000025423658,0.026097445,0.00001730581,0.0043438086,0.0000053762797,0.0004375762,0.00022437533],"about_ca_topic_score_codex":0.0002216718,"about_ca_topic_score_gemma":0.0025640894,"teacher_disagreement_score":0.025655558,"about_ca_system_score_codex":0.00020650557,"about_ca_system_score_gemma":0.00024842238,"threshold_uncertainty_score":0.52438617},"labels":[],"label_agreement":null},{"id":"W2898510460","doi":"10.1634/theoncologist.2018-0434","title":"Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University; AstraZeneca","keywords":"Medicine; Blockade; Rash; Immune checkpoint; Multidisciplinary approach; Immune system; Oncology; Internal medicine; Pharmacology; Immunology; Receptor","score_opus":0.029282654386571155,"score_gpt":0.28493885733428814,"score_spread":0.25565620294771696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898510460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464686,0.00065556087,0.0001689134,0.008384595,0.000063733154,0.0023561667,0.000043822973,0.00011544696,0.0035649033],"genre_scores_gemma":[0.99397725,0.000023910556,0.0015378314,0.0011209858,0.00040947634,0.00027680275,0.00004321433,0.000044286367,0.0025662272],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983741,0.00013516791,0.0003458293,0.00041576676,0.00034380183,0.00038530896],"domain_scores_gemma":[0.9984197,0.00024262763,0.00020920447,0.00086903287,0.00011367468,0.00014578673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023641017,0.0002991318,0.00043381413,0.000042723565,0.0003538109,0.00004989706,0.00032180373,0.00006734816,0.00011551176],"category_scores_gemma":[0.000072390685,0.000118861935,0.00011571652,0.00049497065,0.00086515583,0.00004106631,0.00015425896,0.0002441427,0.000030188303],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50326574,0.007262923,0.12381691,0.0001381493,0.0061756372,0.0014118192,0.059141133,0.0002073213,0.1728097,0.00002925583,0.08122859,0.044512846],"study_design_scores_gemma":[0.031943318,0.03031456,0.79365677,0.0010792421,0.001273124,0.0015383747,0.018054176,0.0010367215,0.07123514,0.000026036334,0.048964918,0.00087759324],"about_ca_topic_score_codex":0.0290534,"about_ca_topic_score_gemma":0.0032737518,"teacher_disagreement_score":0.6698399,"about_ca_system_score_codex":0.0002350266,"about_ca_system_score_gemma":0.0003471629,"threshold_uncertainty_score":0.9774122},"labels":[],"label_agreement":null},{"id":"W2898956824","doi":"10.1634/theoncologist.2018-0285","title":"Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Takotsubo Cardiomyopathy and Associated Phenomena","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Dalhousie University","funders":"","keywords":"Medicine; Metastatic breast cancer; Cardiomyopathy; Oncology; Breast cancer; Internal medicine; Cancer; Cardiotoxicity; Heart failure; Chemotherapy","score_opus":0.03175590898587456,"score_gpt":0.3230132588942679,"score_spread":0.29125734990839336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898956824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854541,0.0012285162,0.00015806653,0.0056720143,0.0007949682,0.0012876822,0.0002845259,0.00018118632,0.004938958],"genre_scores_gemma":[0.99404204,0.0004686683,0.00024373057,0.0011402968,0.0022144357,0.00037125297,0.000018273679,0.000052092513,0.0014492247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983655,0.00014175463,0.0003041138,0.00036456692,0.00027259847,0.0005514199],"domain_scores_gemma":[0.998735,0.0001618673,0.00019384107,0.0005021065,0.00027972952,0.00012745016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007182416,0.00025857377,0.000625407,0.00007130588,0.00047801857,0.00004427647,0.00025186798,0.0000880739,0.00020473995],"category_scores_gemma":[0.00007101923,0.00015938203,0.0003366207,0.00034424718,0.00046863614,0.00007593029,0.00006036032,0.00022231013,0.00006611393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020180492,0.004520077,0.3344046,0.0011356135,0.012780437,0.00070341525,0.023242598,0.00036398738,0.26255545,0.0053424747,0.070372686,0.26439816],"study_design_scores_gemma":[0.010124493,0.0014385188,0.919988,0.00013918547,0.0008687918,0.00048425223,0.000945912,0.00013546988,0.011203987,0.0008340559,0.053292,0.0005453367],"about_ca_topic_score_codex":0.00034457035,"about_ca_topic_score_gemma":0.000050625567,"teacher_disagreement_score":0.5855834,"about_ca_system_score_codex":0.000303833,"about_ca_system_score_gemma":0.00023140473,"threshold_uncertainty_score":0.6499411},"labels":[],"label_agreement":null},{"id":"W2902282658","doi":"10.1634/theoncologist.2018-0501","title":"Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Hôpital Charles-Le Moyne; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Systemic therapy; Internal medicine; Mesothelioma; Radiation therapy; Surgery; Pneumonectomy; Oncology; Retrospective cohort study; Chemotherapy; Lung; Cancer; Pathology","score_opus":0.03152490983254817,"score_gpt":0.2983456519169877,"score_spread":0.2668207420844395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902282658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962883,0.0012729727,0.000033417262,0.0012571143,0.00009121764,0.0007825256,0.00020851557,0.000026738935,0.000039176644],"genre_scores_gemma":[0.9975251,0.0003048181,0.00022939031,0.0010447751,0.00016188274,0.00017835206,0.00005367667,0.000012983636,0.0004890097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993595,0.00007815618,0.00014572014,0.00019294019,0.0001041241,0.000119571996],"domain_scores_gemma":[0.9993733,0.00034401764,0.000056910652,0.0001365255,0.000024887757,0.00006433553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001026751,0.00012194862,0.00018558216,0.000022993272,0.00014507424,0.000037359998,0.0000387887,0.000047339112,0.000054115153],"category_scores_gemma":[0.00006995292,0.00006422946,0.00004428438,0.000029220002,0.00033649924,0.000119514654,0.000027594862,0.000050035884,0.000011350728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020374744,0.000077085766,0.98862284,0.000012901936,0.00009323841,0.000007422388,0.0006523517,8.712913e-7,0.005980996,0.00007633584,0.00029770285,0.0021407686],"study_design_scores_gemma":[0.0018326316,0.0007063799,0.99513495,0.000032547836,0.000100403515,0.000026884027,0.0002145274,0.00023425532,0.00082046934,0.00018095333,0.00062790164,0.0000880948],"about_ca_topic_score_codex":0.0001735926,"about_ca_topic_score_gemma":0.000040717,"teacher_disagreement_score":0.0065121003,"about_ca_system_score_codex":0.00005515635,"about_ca_system_score_gemma":0.000019089124,"threshold_uncertainty_score":0.26192012},"labels":[],"label_agreement":null},{"id":"W2907407844","doi":"10.1634/theoncologist.2018-0838","title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Weill Cornell Medical College; AstraZeneca; Genentech; Eli Lilly and Company; Agios Pharmaceuticals; Exelixis","keywords":"Medicine; Hepatocellular carcinoma; Cohort; Pharmacokinetics; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Toxicity; Gastroenterology; Phases of clinical research; Small interfering RNA; RNA","score_opus":0.06688128871368598,"score_gpt":0.3491842452595836,"score_spread":0.2823029565458976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907407844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048716,0.00016400316,0.00018403438,0.000498727,0.000059553284,0.008426675,0.000034277622,0.00003602694,0.00010953696],"genre_scores_gemma":[0.9983654,0.0000656095,0.00088185986,0.00012363157,0.00007289739,0.0003591849,0.00005374025,0.000041279654,0.00003641517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803776,0.00037961276,0.00037111808,0.00053495384,0.0003257481,0.0003508227],"domain_scores_gemma":[0.9985447,0.00016717655,0.00023450039,0.0006807623,0.00018722062,0.00018563418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007496428,0.00032494398,0.0005859021,0.00010686413,0.00034938296,0.000040184008,0.00032846117,0.000063455926,0.000028324721],"category_scores_gemma":[0.00004210244,0.00017223423,0.000021194592,0.00040312682,0.00042244885,0.00021342472,0.00023922813,0.00021951145,0.0000028588952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09249515,0.02461972,0.62933505,0.000050301067,0.00013183066,0.0008310854,0.0037328869,0.0000045610445,0.12743646,0.0000021021854,0.000014690171,0.12134617],"study_design_scores_gemma":[0.07414326,0.34169406,0.37503725,0.00022742915,0.0011318345,0.00019969427,0.0011616503,0.03586861,0.17002383,0.0000033023116,0.00012826669,0.00038081768],"about_ca_topic_score_codex":0.0008967217,"about_ca_topic_score_gemma":0.00056081725,"teacher_disagreement_score":0.31707433,"about_ca_system_score_codex":0.00013806473,"about_ca_system_score_gemma":0.00016290459,"threshold_uncertainty_score":0.7023508},"labels":[],"label_agreement":null},{"id":"W2914157560","doi":"10.1634/theoncologist.2018-0332","title":"Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Terminology; MEDLINE; Clinical trial; Family medicine; Internal medicine","score_opus":0.2136689892187956,"score_gpt":0.4715527577252995,"score_spread":0.25788376850650385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914157560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722494,0.00007819906,0.000014032369,0.008094526,0.0005424773,0.001755818,0.000064767904,0.0000139072645,0.0022113523],"genre_scores_gemma":[0.9981657,0.000028546068,0.00041376852,0.0012080392,0.000025263294,0.000016105045,0.0000102715785,0.000008478978,0.00012378933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986572,0.00036912985,0.00042874445,0.00015860792,0.00020911494,0.00017718697],"domain_scores_gemma":[0.9972346,0.0015786857,0.00057707616,0.0005121323,0.00006694614,0.000030599964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005326694,0.00011500852,0.000408604,0.000014444133,0.00018046245,0.0000034085654,0.0002622929,0.00006091545,0.00017249679],"category_scores_gemma":[0.00025236103,0.00004757259,0.0001800009,0.00009852456,0.00033751084,0.000084580955,0.0003925627,0.00020113244,0.0000018279393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009262711,0.00035870934,0.99007833,0.00013741312,0.00019398885,0.0000022935621,0.0001702046,0.000014473797,0.006215648,0.00011524873,0.0005315124,0.0012559112],"study_design_scores_gemma":[0.0020889102,0.0005902587,0.9746774,0.000060011706,0.00041532455,0.000013632478,0.00086487207,0.0026028864,0.0010535427,0.0002586725,0.017309973,0.000064547516],"about_ca_topic_score_codex":0.00013016006,"about_ca_topic_score_gemma":0.0000106790285,"teacher_disagreement_score":0.016778462,"about_ca_system_score_codex":0.000082747385,"about_ca_system_score_gemma":0.00009649242,"threshold_uncertainty_score":0.1939954},"labels":[],"label_agreement":null},{"id":"W2917215615","doi":"10.1634/theoncologist.2018-0570","title":"Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Cordotomy; Medicine; Randomized controlled trial; Palliative care; Refractory (planetary science); Cancer pain; Anesthesia; Surgery; Cancer; Internal medicine; Nursing; Spinal cord","score_opus":0.025206983129715532,"score_gpt":0.32027818486016446,"score_spread":0.29507120173044893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917215615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9189053,0.000801195,0.00025413558,0.010522623,0.0015014784,0.03531925,0.000007473667,0.000112390415,0.03257616],"genre_scores_gemma":[0.93335253,0.00050359993,0.00039007017,0.008109537,0.0010709701,0.0073981793,0.000023965187,0.00002767135,0.04912347],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99812907,0.0007226329,0.00044502324,0.00022626639,0.00021186034,0.00026515484],"domain_scores_gemma":[0.989778,0.009356005,0.00033765426,0.00034453667,0.000124227,0.000059596718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059769405,0.00017232972,0.0013870663,0.00006058087,0.00008198582,0.000025418532,0.00020111099,0.00009991853,0.00051963894],"category_scores_gemma":[0.0054964633,0.00008763285,0.00051360845,0.0000804946,0.0002160058,0.000033945853,0.00004615008,0.00015742102,0.000078127705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9711023,0.00019650374,0.0010341145,0.00008130199,0.00054405705,0.000008224571,0.00017022497,0.000004444699,0.00055079395,0.0004111221,0.02489451,0.0010023895],"study_design_scores_gemma":[0.9330241,0.0012031855,0.00042741603,0.0000633173,0.0007099849,1.8638418e-7,0.00026623518,0.00085619924,0.000037102447,0.0002696849,0.06302907,0.00011352343],"about_ca_topic_score_codex":0.000105601226,"about_ca_topic_score_gemma":0.00007780562,"teacher_disagreement_score":0.038134567,"about_ca_system_score_codex":0.000146333,"about_ca_system_score_gemma":0.00035154208,"threshold_uncertainty_score":0.6580177},"labels":[],"label_agreement":null},{"id":"W2919830364","doi":"10.1634/theoncologist.2018-0341","title":"Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Biosimilar; Filgrastim; Medicine; European union; Business; Neutropenia; Internal medicine; International trade; Chemotherapy","score_opus":0.018386966891525917,"score_gpt":0.2894433573541078,"score_spread":0.2710563904625819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919830364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676261,0.00020999063,0.0000017810951,0.016623242,0.0001476143,0.0003350071,0.0000016684958,0.000009362672,0.015045235],"genre_scores_gemma":[0.99593735,0.000104250925,0.0000075905214,0.0033344575,0.00011333289,0.000020023628,0.0000010953337,0.000006202541,0.0004756788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989522,0.0005170418,0.00013972301,0.0001458749,0.00012753143,0.000117592535],"domain_scores_gemma":[0.9992822,0.00032807136,0.000053357075,0.00027825992,0.000021159827,0.000036976264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011697294,0.00007508665,0.00012818971,0.000010253214,0.00016693502,0.000022870934,0.00013991534,0.00002202195,0.00003414531],"category_scores_gemma":[0.000037333946,0.000027053147,0.000014767031,0.000097458236,0.0006352573,0.000022851775,0.000046615805,0.00023111016,0.0000030850254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013951323,0.00008956071,0.9518949,0.000016629006,0.00004891759,0.000053728094,0.004393747,0.000009897442,0.00010089599,0.00037953988,0.034543354,0.008329324],"study_design_scores_gemma":[0.00064055197,0.0005211952,0.929498,0.000025372738,0.00004444569,0.00013696376,0.020591902,0.000009462478,0.000023645856,0.000011435486,0.04844295,0.00005406419],"about_ca_topic_score_codex":0.05732076,"about_ca_topic_score_gemma":0.3840939,"teacher_disagreement_score":0.32677317,"about_ca_system_score_codex":0.000035881243,"about_ca_system_score_gemma":0.00021454481,"threshold_uncertainty_score":0.9489566},"labels":[],"label_agreement":null},{"id":"W2920656486","doi":"10.1634/theoncologist.2018-0808","title":"Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Society for Medical Oncology; National Cancer Centre of Singapore; Princess Margaret Cancer Foundation","keywords":"Phase (matter); Family medicine; Medicine; Physics","score_opus":0.03733968357720229,"score_gpt":0.3652438090691786,"score_spread":0.3279041254919763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920656486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165857,0.0006176694,0.00023173554,0.0029454627,0.00016832462,0.0008476335,0.00001319793,0.0000032216622,0.003514182],"genre_scores_gemma":[0.99359584,0.0001950582,0.00031674985,0.0052827396,0.00018521099,0.000083409795,0.000018323692,0.000009099633,0.00031355006],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992208,0.00011529469,0.00018352957,0.00022105733,0.00008477561,0.00017453615],"domain_scores_gemma":[0.99939716,0.00011245091,0.000057353005,0.00037763987,0.000017374596,0.000038022314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073183636,0.00009488256,0.0001302046,0.000018247641,0.000049094233,0.00003961769,0.00025725158,0.00007266342,0.000026419333],"category_scores_gemma":[0.00018281688,0.000057639907,0.000050081602,0.00006519144,0.000057508892,0.0000011912731,0.00015059634,0.00011063514,0.000024528903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.079569615,0.0021556728,0.0043880586,0.000050311097,0.0003111451,0.00012733233,0.0023258226,0.0022330205,0.74203366,0.0046880026,0.056979697,0.10513765],"study_design_scores_gemma":[0.09478772,0.019549958,0.006084196,0.000046980724,0.00011563569,0.000039550327,0.001818132,0.00021413808,0.025582997,0.0009900713,0.8500391,0.0007315062],"about_ca_topic_score_codex":0.000083986946,"about_ca_topic_score_gemma":0.00013184226,"teacher_disagreement_score":0.7930594,"about_ca_system_score_codex":0.00001823176,"about_ca_system_score_gemma":0.000070630704,"threshold_uncertainty_score":0.23504873},"labels":[],"label_agreement":null},{"id":"W2921192143","doi":"10.1634/theoncologist.2018-0711","title":"What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Oncology; Clinical decision making; Qualitative research; Internal medicine; Intensive care medicine; Cancer; Sociology","score_opus":0.043849595869289194,"score_gpt":0.43253152101234943,"score_spread":0.3886819251430602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921192143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937626,0.0029164348,0.00023466867,0.0017049306,0.00015886816,0.0010065819,0.00010544432,0.000013739034,0.000096700365],"genre_scores_gemma":[0.9949348,0.0011792372,0.002950059,0.0007085901,0.000009592233,0.0001325896,0.000009735695,0.000019213316,0.000056193414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781483,0.00026384147,0.0008226384,0.000439849,0.00033666322,0.0003221672],"domain_scores_gemma":[0.99643373,0.0024257172,0.00049994874,0.00045314242,0.00013954703,0.000047925227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007887172,0.0002466203,0.0010966108,0.00059761625,0.000050607956,0.000029210963,0.00017632594,0.000078322155,0.00019898661],"category_scores_gemma":[0.00019582165,0.00015103756,0.00015252842,0.0012064966,0.0003129798,0.00021218378,0.00010996843,0.0001721672,0.000003833767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003582674,0.0007723554,0.61365795,0.000021202106,0.0011851373,0.000044623685,0.030742364,0.00089175394,0.0000780777,0.0001450996,0.000011885017,0.34886688],"study_design_scores_gemma":[0.005074163,0.0008309171,0.95917684,0.0011292411,0.0010158074,0.000010969624,0.02579295,0.0014365916,0.000026148009,0.0050988686,0.00023058662,0.00017692962],"about_ca_topic_score_codex":0.0011410326,"about_ca_topic_score_gemma":0.00819488,"teacher_disagreement_score":0.34868997,"about_ca_system_score_codex":0.0016850063,"about_ca_system_score_gemma":0.00026262432,"threshold_uncertainty_score":0.6159133},"labels":[],"label_agreement":null},{"id":"W2929364833","doi":"10.1634/theoncologist.2018-0613","title":"Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Health and Medical Research Council; Medical Research Council","keywords":"Medicine; Hazard ratio; Confidence interval; Oncology; Internal medicine; Proportional hazards model; Survival analysis; Cancer","score_opus":0.027073408286832062,"score_gpt":0.32788491364721906,"score_spread":0.300811505360387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929364833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919824,0.0013790448,0.000081063496,0.002924129,0.0001503109,0.0024556834,0.000015107239,0.000030297491,0.000981978],"genre_scores_gemma":[0.99585146,0.0005361332,0.0017757333,0.00019442008,0.000044126504,0.00023091913,0.000007856254,0.000012755524,0.0013466169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99910986,0.000032932145,0.00024840486,0.00024201366,0.00012316694,0.00024364304],"domain_scores_gemma":[0.9981272,0.0014106357,0.00017903918,0.00018232185,0.00005617988,0.00004462382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039492472,0.0001360364,0.00043722588,0.00007351622,0.00003919435,0.0000139077965,0.00010875339,0.000052926298,0.00006125207],"category_scores_gemma":[0.0005721683,0.00008873749,0.000036676684,0.00021053782,0.00023596697,0.00006172068,0.00008631578,0.00011281684,0.000004551698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009796753,0.00012659258,0.9365432,0.00045739725,0.000054933524,0.000008174704,0.0001659221,0.00037796263,0.00444104,0.00014402019,0.0005202641,0.0561808],"study_design_scores_gemma":[0.0049076797,0.0016082734,0.98584294,0.00017552712,0.00019109949,0.00000922737,0.0003863374,0.0033926603,0.00028287029,0.00025923364,0.0027987086,0.00014543315],"about_ca_topic_score_codex":0.0002828946,"about_ca_topic_score_gemma":0.00019620132,"teacher_disagreement_score":0.056035366,"about_ca_system_score_codex":0.000117676005,"about_ca_system_score_gemma":0.0001312153,"threshold_uncertainty_score":0.361861},"labels":[],"label_agreement":null},{"id":"W2930221971","doi":"10.1634/theoncologist.2019-0039","title":"Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Guideline; Systemic therapy; Oncology; Internal medicine; Chemotherapy; Targeted therapy; Cancer; Pathology","score_opus":0.02766453742285076,"score_gpt":0.3211048916340345,"score_spread":0.29344035421118375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930221971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92664653,0.0017661335,0.00000393327,0.0049159545,0.00047486267,0.0014587151,0.00010620083,0.000024619529,0.06460306],"genre_scores_gemma":[0.9870902,0.00033070214,0.0002461037,0.0016097436,0.0003951189,0.00023337339,0.000059198162,0.000035455618,0.010000131],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986009,0.00017247607,0.00039484806,0.00032393893,0.0002608781,0.0002469581],"domain_scores_gemma":[0.9980647,0.0008714297,0.00028972162,0.0006171744,0.00008437761,0.000072577044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024448524,0.0002129263,0.00045048204,0.00008672865,0.00009015839,0.00001156707,0.00021368658,0.0000942505,0.00047999577],"category_scores_gemma":[0.0000774806,0.00010674074,0.00016799009,0.0002788418,0.00022980208,0.0000806465,0.00006853379,0.00021567864,0.000047155198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14049354,0.007752056,0.15753926,0.00026763827,0.0009893037,0.00012264609,0.019541882,0.0002658709,0.5131162,0.0015395673,0.020752756,0.1376193],"study_design_scores_gemma":[0.04168803,0.007161643,0.40453067,0.00008735505,0.00040868795,0.00000896543,0.0016937249,0.000091872935,0.3009468,0.000617358,0.2423619,0.00040299245],"about_ca_topic_score_codex":0.004884917,"about_ca_topic_score_gemma":0.003719772,"teacher_disagreement_score":0.24699141,"about_ca_system_score_codex":0.0003604333,"about_ca_system_score_gemma":0.0002987803,"threshold_uncertainty_score":0.7384566},"labels":[],"label_agreement":null},{"id":"W2934360602","doi":"10.1634/theoncologist.2018-0544","title":"The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of British Columbia; Sunnybrook Health Science Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neurocognitive; Oncology; Brain metastasis; Internal medicine; Psychiatry; Cancer; Cognition; Metastasis","score_opus":0.059878475264912,"score_gpt":0.3970551460321346,"score_spread":0.3371766707672226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934360602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688394,0.0013615552,0.0000024553137,0.009247258,0.000019341345,0.0011660028,0.0001241128,0.000021939946,0.0011734123],"genre_scores_gemma":[0.99827605,0.0010226334,0.000026136166,0.00045135015,0.000010408267,0.000025492063,0.00004051845,0.0000099000235,0.00013747721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743575,0.0013361183,0.0003533647,0.00032789548,0.00024398582,0.00030285845],"domain_scores_gemma":[0.994458,0.0046681613,0.00031952263,0.00035859982,0.00008380496,0.000111910274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002549395,0.00018859735,0.0006930852,0.00016572683,0.00014205353,0.000030458694,0.00008947138,0.000039009028,0.000042922216],"category_scores_gemma":[0.0015545523,0.00009010541,0.00016168326,0.00096709316,0.00040689722,0.000047876958,0.000061959574,0.00025066047,0.0000028692173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008211758,0.0016584928,0.903764,0.0000966822,0.0052300342,0.00023757566,0.0020359873,0.00012772066,0.0007728641,0.00045193743,0.0017812416,0.07563172],"study_design_scores_gemma":[0.0021776946,0.0032954204,0.99222857,0.00019278316,0.0005816972,0.000007907833,0.00041478535,0.0006060379,0.000091557915,0.00030659675,0.00002483788,0.00007210212],"about_ca_topic_score_codex":0.024292557,"about_ca_topic_score_gemma":0.02871439,"teacher_disagreement_score":0.088464595,"about_ca_system_score_codex":0.0002648287,"about_ca_system_score_gemma":0.00025961938,"threshold_uncertainty_score":0.989009},"labels":[],"label_agreement":null},{"id":"W2935205376","doi":"10.1634/theoncologist.2018-0621","title":"Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Docetaxel; Pantoprazole; Autophagy; Medicine; Prostate cancer; Oncology; Internal medicine; Cancer; Pharmacology; Cancer research; Chemistry; Apoptosis","score_opus":0.024193007141688032,"score_gpt":0.3156571043337689,"score_spread":0.2914640971920809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935205376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901659,0.0026062867,0.000049688446,0.0007808649,0.0005720719,0.004199252,0.00020183736,0.00014120451,0.0012828872],"genre_scores_gemma":[0.99564296,0.00035958373,0.00056819204,0.0003483596,0.0002975969,0.0005307232,0.000079379126,0.00007712468,0.002096091],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960555,0.00039367224,0.0011693753,0.0007471235,0.00083277794,0.0008015483],"domain_scores_gemma":[0.9971144,0.0004658606,0.0009784586,0.0009870416,0.0002369857,0.00021720449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013021872,0.00056214613,0.0013523499,0.00021350116,0.00031993224,0.000058639078,0.00038401873,0.00017229731,0.00038177488],"category_scores_gemma":[0.00013898268,0.00036150182,0.00023213937,0.0007834602,0.00051117304,0.00031439724,0.00011435623,0.0006156666,0.000030340774],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4204403,0.014523632,0.0014752959,0.0015656832,0.0014889009,0.0021496785,0.0082465345,0.0015228054,0.5131842,0.0034384218,0.00071413256,0.031250425],"study_design_scores_gemma":[0.5406058,0.028547399,0.031209037,0.0018432039,0.001757711,0.00015735482,0.003141411,0.0014305593,0.38243693,0.0031609656,0.00409922,0.0016104083],"about_ca_topic_score_codex":0.0016713061,"about_ca_topic_score_gemma":0.0018828522,"teacher_disagreement_score":0.13074727,"about_ca_system_score_codex":0.00043904668,"about_ca_system_score_gemma":0.0011713081,"threshold_uncertainty_score":0.9998837},"labels":[],"label_agreement":null},{"id":"W2935807963","doi":"10.1634/theoncologist.2018-0695","title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Population; ERBB3; Cancer; Confidence interval","score_opus":0.011574831623580938,"score_gpt":0.32075461059253885,"score_spread":0.30917977896895793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935807963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903402,0.00007800538,0.00001442367,0.00047179984,0.00019922334,0.0052372436,0.000011451512,0.00001141812,0.003636254],"genre_scores_gemma":[0.99823713,0.00003701756,0.00013765902,0.000099535086,0.000022470354,0.00026169408,0.0000745957,0.000015017001,0.0011148829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991131,0.00010311627,0.00028349028,0.00016753541,0.0001774209,0.00015537185],"domain_scores_gemma":[0.9992712,0.00014269508,0.00023063534,0.00020184912,0.00012277572,0.00003085003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029435873,0.00012441374,0.0005319866,0.000081997074,0.000037899285,0.0000058022783,0.00007384952,0.000052633124,0.00007579957],"category_scores_gemma":[0.000028824026,0.000063068306,0.000037226884,0.000280626,0.000109384404,0.00005272959,0.000019422174,0.00012830879,0.0000018772067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87583256,0.005738535,0.114378504,0.000083344385,0.0001586174,0.000007837846,0.0020921608,0.00036062268,0.000055595483,0.00006156745,0.000105464,0.0011251827],"study_design_scores_gemma":[0.96112263,0.010308517,0.026895465,0.00020979949,0.00040533056,4.8693926e-7,0.00017522597,0.00049134245,0.00019332953,0.000013270597,0.0000990982,0.0000855199],"about_ca_topic_score_codex":0.0016380319,"about_ca_topic_score_gemma":0.0008304395,"teacher_disagreement_score":0.08748303,"about_ca_system_score_codex":0.00032892273,"about_ca_system_score_gemma":0.00044763065,"threshold_uncertainty_score":0.2571851},"labels":[],"label_agreement":null},{"id":"W2947039620","doi":"10.1634/theoncologist.2019-0043","title":"The Development of an International Oncofertility Competency Framework: A Model to Increase Oncofertility Implementation","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Reproductive Biology and Fertility","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncofertility; Medicine; Fertility preservation; Psychosocial; Delphi method; Family medicine; Referral; Survivorship curve; Service (business); Documentation; Nursing; Fertility; Cancer; Internal medicine; Population","score_opus":0.05400106707867692,"score_gpt":0.4023251791756242,"score_spread":0.3483241120969473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947039620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98812515,0.000032041808,0.0019377999,0.0032584907,0.00033538954,0.001072369,0.00001952394,0.000037466736,0.0051817833],"genre_scores_gemma":[0.9881566,0.000005722578,0.010784618,0.0005632245,0.0000745189,0.00007951369,0.000042082604,0.0000072756666,0.00028642744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982793,0.0002610635,0.0005455097,0.0003932854,0.0002813482,0.00023949711],"domain_scores_gemma":[0.9982383,0.00029724967,0.00015758992,0.00091393234,0.00028856058,0.00010431283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025042654,0.00013987046,0.00027541944,0.000030805248,0.0002370627,0.000012991391,0.00044875755,0.00010616032,0.00018698683],"category_scores_gemma":[0.0006278305,0.00007439367,0.000076319346,0.00012612657,0.0003007212,0.000091186055,0.00020598683,0.0002792004,0.000057640314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049731243,0.0026228433,0.64397615,0.00009655243,0.000507902,0.0000046670975,0.010159673,0.0002974928,0.033211455,0.006668568,0.00040462782,0.25231886],"study_design_scores_gemma":[0.00055337744,0.0004205314,0.9846771,0.000015467658,0.000029669043,0.0000037319242,0.0010607506,0.0013882897,0.006288844,0.0031672488,0.0023108847,0.000084137355],"about_ca_topic_score_codex":0.0001703574,"about_ca_topic_score_gemma":0.0005783146,"teacher_disagreement_score":0.34070095,"about_ca_system_score_codex":0.00032889057,"about_ca_system_score_gemma":0.0006390814,"threshold_uncertainty_score":0.30336857},"labels":[],"label_agreement":null},{"id":"W2947290320","doi":"10.1634/theoncologist.2019-0027","title":"Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Toronto; University Health Network; Royal Victoria Hospital; University of Alberta; Royal Victoria Regional Health Centre; Juravinski Cancer Centre; Montreal General Hospital; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Atezolizumab; Oncology; Lung cancer; Internal medicine; Nivolumab; Bevacizumab; Pemetrexed; Anaplastic lymphoma kinase; Chemotherapy; Ipilimumab; Cancer; Immunotherapy; Cisplatin","score_opus":0.029609471225638256,"score_gpt":0.3227680076414282,"score_spread":0.2931585364157899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947290320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.975667,0.0009138962,0.00006839034,0.012123469,0.0007327239,0.0011475995,0.000012424867,0.000045919092,0.009288603],"genre_scores_gemma":[0.9903433,0.00045957093,0.00012645066,0.001992748,0.000103606246,0.00015531972,0.000013104674,0.000020896508,0.0067850323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899036,0.000036246063,0.0003363287,0.00021553182,0.00015273022,0.00026880528],"domain_scores_gemma":[0.99921125,0.00019544661,0.00013311928,0.00036228777,0.000051763534,0.000046157373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044790964,0.0001549798,0.00032593563,0.000080148064,0.00009711964,0.000021470078,0.00017568422,0.00010576932,0.00043889912],"category_scores_gemma":[0.00003455734,0.000097168944,0.00012933345,0.00027019007,0.00011010334,0.00004034645,0.0000652258,0.00028431832,0.00006248389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011612569,0.0011617824,0.9651487,0.0004578355,0.00016177965,0.000030725372,0.0022539445,0.00029857282,0.019803638,0.0000843875,0.0043237302,0.005113634],"study_design_scores_gemma":[0.018294044,0.0008263615,0.9397931,0.00056407176,0.00015479328,0.000013753264,0.0011562126,0.0019299933,0.0075415093,0.00008711338,0.029258525,0.00038053968],"about_ca_topic_score_codex":0.002545775,"about_ca_topic_score_gemma":0.0034594757,"teacher_disagreement_score":0.02535563,"about_ca_system_score_codex":0.00060686556,"about_ca_system_score_gemma":0.00021437356,"threshold_uncertainty_score":0.48056376},"labels":[],"label_agreement":null},{"id":"W2948431030","doi":"10.1634/theoncologist.2019-0304","title":"Why “Reply All” Can Push All the Wrong Buttons","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Etiquette; Medicine; Advice (programming); Internet privacy; Law; Computer science","score_opus":0.15568255928481467,"score_gpt":0.43558072621781196,"score_spread":0.2798981669329973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948431030","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39338607,0.00023980296,0.000003838426,0.5447311,0.009007156,0.0018645846,0.0000050518843,0.000113376795,0.05064906],"genre_scores_gemma":[0.9548756,0.00021559194,0.00008441774,0.03969484,0.002054796,0.0005537969,0.000006346022,0.000015126022,0.0024995282],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979561,0.0007847365,0.00019666736,0.00019057127,0.0003888753,0.00048307097],"domain_scores_gemma":[0.99523216,0.0039825975,0.000169663,0.00041198265,0.00008704851,0.00011654983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023804607,0.000092245544,0.00014113655,0.000020718915,0.00076712196,0.00008383212,0.0007931851,0.000111559726,0.0005273847],"category_scores_gemma":[0.002572123,0.000055300636,0.000057618185,0.00026828662,0.0008021525,0.000074156305,0.000067411514,0.0003031913,0.00045162207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046165776,0.0002408459,0.06771166,0.000028030863,0.00008218083,0.000003981562,0.31720382,0.00003484728,0.00018075197,0.122857586,0.45839846,0.033211697],"study_design_scores_gemma":[0.00009786572,0.00005979893,0.025119158,0.0000059329163,0.000021431886,6.121139e-7,0.019286785,0.000006141215,0.000013125363,0.0023363996,0.95297277,0.0000799834],"about_ca_topic_score_codex":0.1258928,"about_ca_topic_score_gemma":0.07690894,"teacher_disagreement_score":0.5614895,"about_ca_system_score_codex":0.0006432746,"about_ca_system_score_gemma":0.0008032215,"threshold_uncertainty_score":0.9399351},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","score_opus":0.006386544342530553,"score_gpt":0.2729757012801935,"score_spread":0.26658915693766294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950856878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973256,0.00049290544,0.00008447516,0.0046951137,0.00014689685,0.003255115,0.00009032962,0.000059280705,0.0014433402],"genre_scores_gemma":[0.99730515,0.000121712,0.00032462084,0.00076802936,0.000065835084,0.0006696353,0.000014380927,0.00003596873,0.00069464004],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739134,0.0004888927,0.00063352083,0.00043752338,0.00051367184,0.00053506054],"domain_scores_gemma":[0.9975091,0.0006617699,0.00067869184,0.00090571615,0.00015841545,0.0000862832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739283,0.00034076843,0.002030791,0.00016005232,0.0001025222,0.00001311234,0.00042904975,0.00011373512,0.0006128011],"category_scores_gemma":[0.000073513715,0.00014009922,0.00018804573,0.0016817419,0.0010853962,0.0001005537,0.00009426703,0.00041037754,0.0000066665225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.948518,0.00038586618,0.03558128,0.00005046358,0.0024025873,0.000022024073,0.0010732216,0.0055027083,0.0011111214,0.00034836362,0.000006766729,0.004997637],"study_design_scores_gemma":[0.8193256,0.0031967727,0.16930538,0.0002681282,0.0023503406,0.00014658147,0.0032015536,0.00037833297,0.00038987453,0.00023373262,0.00082874217,0.0003749496],"about_ca_topic_score_codex":0.00071227626,"about_ca_topic_score_gemma":0.0014256554,"teacher_disagreement_score":0.13372411,"about_ca_system_score_codex":0.0007656435,"about_ca_system_score_gemma":0.00045777086,"threshold_uncertainty_score":0.67097425},"labels":[],"label_agreement":null},{"id":"W2954003036","doi":"10.1634/theoncologist.2019-0112","title":"Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Manitoba; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Institute for Clinical Evaluative Sciences","keywords":"Medicine; Neuroendocrine tumors; Prospective cohort study; Population; Oncology; Internal medicine; Environmental health","score_opus":0.017433329605233833,"score_gpt":0.33207714291055607,"score_spread":0.3146438133053222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954003036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996983,0.000024482522,0.0000058473565,0.0011518972,0.00005246521,0.0012821311,0.000035027937,0.00003284426,0.00043231266],"genre_scores_gemma":[0.99933946,0.0000051133493,0.000052428444,0.00012744212,0.000011481758,0.000066715234,0.00004643775,0.0000175447,0.00033338866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979697,0.00016392932,0.0007048116,0.00030786236,0.00055312866,0.00030055564],"domain_scores_gemma":[0.99805367,0.0005516121,0.00048919657,0.00066964846,0.00017182519,0.00006407024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013562632,0.00016371778,0.00085619744,0.0005240806,0.000020809466,0.0000060658676,0.0002071055,0.0000070223687,0.00020956565],"category_scores_gemma":[0.00078546285,0.000103155864,0.0002245084,0.00112443,0.00009811607,0.00005779217,0.00009231505,0.00023091436,0.000005243676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004597923,0.0003312751,0.992809,0.00008267324,0.00032486653,0.00056509464,0.000065674685,0.0036798841,0.0011859402,0.000068559304,0.0000050382055,0.00042223313],"study_design_scores_gemma":[0.0019387845,0.0013252732,0.99105006,0.000061689025,0.00034429916,0.000037920512,0.00023959526,0.0015251215,0.003320561,0.00004982709,0.000028326616,0.000078510646],"about_ca_topic_score_codex":0.0049398732,"about_ca_topic_score_gemma":0.0008356762,"teacher_disagreement_score":0.004104197,"about_ca_system_score_codex":0.00015186459,"about_ca_system_score_gemma":0.00011608639,"threshold_uncertainty_score":0.74676436},"labels":[],"label_agreement":null},{"id":"W2958239779","doi":"10.1634/theoncologist.2019-0263","title":"Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Impact","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Adjuvant; Breast cancer; Internal medicine; Randomized controlled trial; Asymptomatic; Clinical trial; Intensive care medicine; Cancer; Chemotherapy","score_opus":0.020489147009520346,"score_gpt":0.2785177104400517,"score_spread":0.2580285634305313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958239779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97019607,0.0012254836,0.000033906723,0.014942616,0.00017174195,0.00082089484,0.000008015681,0.00007094595,0.012530324],"genre_scores_gemma":[0.99265134,0.0024972076,0.0000771331,0.0023597663,0.000202303,0.000014997936,0.0000123867785,0.000016725988,0.0021681073],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992301,0.00006554523,0.00015178995,0.00020491624,0.0001574109,0.00019024491],"domain_scores_gemma":[0.99935395,0.00016895322,0.000065210465,0.00031572703,0.0000305745,0.000065614404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027613805,0.00012578678,0.00029475454,0.000023988126,0.000090818474,0.000016188216,0.000093702234,0.00009647821,0.00013212953],"category_scores_gemma":[0.000032436637,0.00007702767,0.00006348033,0.00010470101,0.00016682922,0.00002957687,0.000021748125,0.000220854,0.00004640143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021005396,0.00032012805,0.0062344824,0.00007239185,0.00022802614,0.000026703392,0.003205311,0.000029313416,0.56377196,0.0011709199,0.001887945,0.42095226],"study_design_scores_gemma":[0.030196037,0.005118049,0.42170626,0.00043243874,0.00019970852,0.00058564916,0.0022801056,0.00043378066,0.23458956,0.0014915651,0.30227032,0.0006965319],"about_ca_topic_score_codex":0.00006467332,"about_ca_topic_score_gemma":0.000025265097,"teacher_disagreement_score":0.42025572,"about_ca_system_score_codex":0.00013976672,"about_ca_system_score_gemma":0.000108386244,"threshold_uncertainty_score":0.3141097},"labels":[],"label_agreement":null},{"id":"W2961237381","doi":"10.1634/theoncologist.2019-0149","title":"Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Manitoba","funders":"Engineering and Physical Sciences Research Council; Medical Research Council; Versus Arthritis","keywords":"Medicine; Breast cancer; Hazard ratio; Population; Internal medicine; Osteoporosis; Aromatase inhibitor; Cohort; Cohort study; Body mass index; Cancer; Gynecology; Confidence interval; Aromatase","score_opus":0.01965315509597552,"score_gpt":0.3419158688717647,"score_spread":0.3222627137757892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961237381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967165,0.00020269502,0.000001909125,0.005939301,0.0000621744,0.0031613912,0.000089851965,0.000051113795,0.00081989926],"genre_scores_gemma":[0.99442047,0.0001117797,0.000045146673,0.0041595213,0.00017153425,0.00085519475,0.000018879357,0.000028126407,0.00018934299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979829,0.0003430797,0.000297393,0.00034703204,0.00049862685,0.00053093326],"domain_scores_gemma":[0.9985377,0.00030723753,0.00021482281,0.0006428537,0.000106607025,0.00019077984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001556505,0.00018030716,0.0004417629,0.000079865495,0.00014587566,0.00003250544,0.00018066312,0.00011446141,0.00053333177],"category_scores_gemma":[0.00011003302,0.00009399377,0.000028109822,0.00038760173,0.00016716293,0.0000533659,0.00004041783,0.00086858735,0.000052495237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069419183,0.0008672494,0.98402315,0.000065050524,0.000050400475,0.00009763844,0.0009593639,0.00009650808,0.00012126862,5.628399e-7,0.0013219817,0.0054548886],"study_design_scores_gemma":[0.007263639,0.002690202,0.9836844,0.00013387621,0.000021897575,0.000028376895,0.0033197529,0.00013628248,0.00006213717,0.0000060858206,0.0025343143,0.00011903978],"about_ca_topic_score_codex":0.008600432,"about_ca_topic_score_gemma":0.0019269467,"teacher_disagreement_score":0.0066734855,"about_ca_system_score_codex":0.0006227412,"about_ca_system_score_gemma":0.0011106661,"threshold_uncertainty_score":0.9980014},"labels":[],"label_agreement":null},{"id":"W2963339930","doi":"10.1634/theoncologist.2019-0272","title":"Chemotherapy Toxicity in <i>BRCA</i> Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Medicine; Neutropenia; BRCA mutation; Chemotherapy; Internal medicine; Germline mutation; Oncology; Ovarian cancer; Absolute neutrophil count; Mitoxantrone; Febrile neutropenia; Toxicity; Germline; Mutation; Cancer; Gastroenterology; Genetics","score_opus":0.02314792721266745,"score_gpt":0.30981821872294474,"score_spread":0.2866702915102773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963339930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95999587,0.00020200193,0.0015016068,0.025808072,0.00036516355,0.0013512693,0.000013608791,0.0001677232,0.010594698],"genre_scores_gemma":[0.97940964,0.00019349689,0.0008601158,0.01818439,0.00024185493,0.0000997667,0.000037284975,0.000052372394,0.0009211075],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983286,0.00011260895,0.00043269503,0.00038242966,0.00036012795,0.0003835058],"domain_scores_gemma":[0.9984597,0.00058699644,0.00023206057,0.00055416714,0.00007632534,0.00009072963],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066120876,0.00025212314,0.00044249065,0.00011349844,0.0001207371,0.00002858706,0.00020923876,0.00019354648,0.0010144378],"category_scores_gemma":[0.000086300155,0.00018809114,0.00013484883,0.00046217418,0.00024844732,0.000087819506,0.000016204287,0.00038438506,0.00012155126],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032462038,0.0049835974,0.44964805,0.0015128187,0.0010180685,0.00046413642,0.015784722,0.09646598,0.23740165,0.0034104604,0.034022264,0.12282621],"study_design_scores_gemma":[0.1571185,0.010332219,0.17241889,0.0020273228,0.00019565805,0.0002878808,0.0033082115,0.043861423,0.4677334,0.0087563535,0.13158871,0.0023714132],"about_ca_topic_score_codex":0.00018832125,"about_ca_topic_score_gemma":0.00067241304,"teacher_disagreement_score":0.27722916,"about_ca_system_score_codex":0.000953765,"about_ca_system_score_gemma":0.00045504599,"threshold_uncertainty_score":0.9998988},"labels":[],"label_agreement":null},{"id":"W2965982329","doi":"10.1634/theoncologist.2019-0261","title":"Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Centers for Disease Control and Prevention; National Comprehensive Cancer Network; American Association for Cancer Research; Bristol-Myers Squibb; American Society of Clinical Oncology; American College of Radiology; U.S. Food and Drug Administration; Memorial Sloan-Kettering Cancer Center; Flatiron Health; Oncology Nursing Society; Merck; Helsinn Therapeutics; Pfizer; Cancer Research Society; American Cancer Society; Livestrong Foundation","keywords":"Medicine; Cancer; Patient care; Medical physics; Pathology; Intensive care medicine; Nursing; Internal medicine","score_opus":0.06185223611591327,"score_gpt":0.31472269836428424,"score_spread":0.25287046224837095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965982329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97219133,0.003739881,0.00012223842,0.0053609367,0.0015030305,0.0007675927,0.00032176598,0.00004126745,0.01595197],"genre_scores_gemma":[0.9919151,0.0009478184,0.00021703127,0.005777937,0.00018793943,0.0006133822,0.000005663757,0.000020409985,0.00031472955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984337,0.000043223576,0.0005598326,0.00052149984,0.000030343206,0.00041138427],"domain_scores_gemma":[0.9987075,0.00021212846,0.0004847988,0.00043493192,0.000048353217,0.000112301415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005311171,0.00018781442,0.00056957203,0.000084061365,0.00016363911,0.0001371992,0.00046454443,0.00016728957,0.0007123944],"category_scores_gemma":[0.00027008975,0.0001551563,0.00007471844,0.00014681155,0.0001614137,0.00026320198,0.00041284156,0.00020483723,0.0004441937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014624378,0.00010993004,0.72736907,0.000073480296,0.000043934724,0.000009917747,0.0020522512,0.0004285239,0.00006852571,0.06915053,0.0055053825,0.19504222],"study_design_scores_gemma":[0.0008741656,0.0008674092,0.84012365,0.00001638066,0.000014587097,0.0000034099999,0.0004921983,0.000034922537,0.00031112967,0.009199159,0.1476048,0.00045820477],"about_ca_topic_score_codex":0.008642988,"about_ca_topic_score_gemma":0.0016272352,"teacher_disagreement_score":0.19458403,"about_ca_system_score_codex":0.0005890832,"about_ca_system_score_gemma":0.00007607858,"threshold_uncertainty_score":0.99795854},"labels":[],"label_agreement":null},{"id":"W2967092667","doi":"10.1634/theoncologist.2018-0830","title":"Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Sunnybrook Health Science Centre; Public Health Ontario; University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"University of Toronto","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Family medicine; Feeling; Adverse effect; Logistic regression; Cancer; Patient-reported outcome; Odds ratio; Internal medicine; Quality of life (healthcare); Nursing","score_opus":0.11625246028930719,"score_gpt":0.4370898867345482,"score_spread":0.320837426445241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967092667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953239,0.00014755047,0.000022006183,0.00035886158,0.0010735388,0.0025406727,0.00032643945,0.000022247634,0.00018477114],"genre_scores_gemma":[0.99898565,0.000015647794,0.00013134103,0.00038664276,0.00001970361,0.0003101297,0.0000324677,0.00002407949,0.000094331415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99743533,0.00021571251,0.0012373833,0.0004123315,0.00036836474,0.0003308891],"domain_scores_gemma":[0.99757814,0.00028471168,0.00105763,0.00063862646,0.00036871442,0.00007215682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003841732,0.00024025314,0.0008563556,0.00010150231,0.00006118127,0.000005784641,0.00018118715,0.00014809331,0.00076078915],"category_scores_gemma":[0.0003921969,0.00016844974,0.00014289402,0.00023929142,0.0003088014,0.00013748047,0.00016438188,0.00014874028,5.324858e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070166955,0.0004461568,0.97773904,0.00019044115,0.00013075637,0.000002919063,0.008970588,0.000107993,0.0007054239,0.000013411523,0.000008809445,0.010982775],"study_design_scores_gemma":[0.002971905,0.0004194291,0.98768085,0.00015036743,0.00026090437,0.000005202586,0.005927828,0.0005259563,0.0014884773,0.000034171426,0.0003604192,0.00017451444],"about_ca_topic_score_codex":0.020513976,"about_ca_topic_score_gemma":0.012097537,"teacher_disagreement_score":0.010808261,"about_ca_system_score_codex":0.0004723305,"about_ca_system_score_gemma":0.00027591307,"threshold_uncertainty_score":0.9860085},"labels":[],"label_agreement":null},{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","score_opus":0.009872657720289805,"score_gpt":0.3163407426654571,"score_spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968495081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946492,0.00011134847,0.000015332902,0.00036727334,0.00007727388,0.0043044523,0.00003705981,0.000034673867,0.00040343578],"genre_scores_gemma":[0.9987894,0.000019421706,0.0003474029,0.00015490972,0.000029900682,0.00032844907,0.00011308124,0.000030187506,0.00018723466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986803,0.000094668496,0.0003451528,0.00032434895,0.0003517685,0.00020376487],"domain_scores_gemma":[0.9988884,0.00013364942,0.00029020492,0.00033530686,0.00027432264,0.00007815511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014024532,0.00022641553,0.0004390922,0.0001128471,0.00013461348,0.000031164567,0.000078693796,0.00004226327,0.000025999578],"category_scores_gemma":[0.000019582885,0.00011673631,0.000019700556,0.00041357824,0.00018773178,0.0002029881,0.000022542867,0.00016072713,0.0000024630694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016312726,0.028998153,0.9314007,0.00006812712,0.00040560975,0.00003829009,0.008857426,0.0003489198,0.0011861258,0.00013950451,0.000110016364,0.012134411],"study_design_scores_gemma":[0.16218482,0.113033034,0.70665556,0.00045297583,0.0004194385,0.000010266822,0.0058632893,0.00013482837,0.010597373,0.00001837958,0.00029267275,0.00033733808],"about_ca_topic_score_codex":0.00018565745,"about_ca_topic_score_gemma":0.00028523643,"teacher_disagreement_score":0.22474511,"about_ca_system_score_codex":0.00014733104,"about_ca_system_score_gemma":0.00023188627,"threshold_uncertainty_score":0.47603685},"labels":[],"label_agreement":null},{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.37189936812377367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969017474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876633,0.00011494247,0.000023906976,0.0044504963,0.00014344066,0.0031240436,0.00008192358,0.000016504366,0.004381408],"genre_scores_gemma":[0.998541,0.000080562335,0.000093265575,0.00015659635,0.000057559853,0.000375214,0.00002200162,0.000025360323,0.00064843916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978405,0.0004951544,0.00043292367,0.00028477353,0.0005963234,0.00035031018],"domain_scores_gemma":[0.9988879,0.0003526602,0.00018259081,0.0003486449,0.00015807139,0.00007013085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014391551,0.00016179318,0.00058797555,0.00021196499,0.000029710425,0.000014249267,0.00021922159,0.00008072417,0.00042948133],"category_scores_gemma":[0.00012895152,0.00010218353,0.000055696368,0.0007204659,0.0003655858,0.00008136027,0.000052253716,0.00052039616,0.00002901439],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61182743,0.03997851,0.06717616,0.0012155832,0.0007212221,0.0009163432,0.013416724,0.00083722,0.009461508,0.002148534,0.0015879701,0.25071278],"study_design_scores_gemma":[0.71137464,0.046402566,0.2257129,0.0018267084,0.0003125333,0.00022401719,0.0049155,0.0030311698,0.0041812556,0.000616808,0.0009084901,0.0004934141],"about_ca_topic_score_codex":0.009825579,"about_ca_topic_score_gemma":0.0063539958,"teacher_disagreement_score":0.25021935,"about_ca_system_score_codex":0.0013740386,"about_ca_system_score_gemma":0.0012358011,"threshold_uncertainty_score":0.99676806},"labels":[],"label_agreement":null},{"id":"W2972627853","doi":"10.1634/theoncologist.2019-0314","title":"Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Colorectal cancer; Public health; Family medicine; Business; Cancer; Internal medicine","score_opus":0.1516429570092212,"score_gpt":0.40838842309651435,"score_spread":0.25674546608729315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972627853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97343594,0.0017320618,0.000002949005,0.02219564,0.0005503421,0.0006623578,0.00011959065,0.0000047459293,0.0012963832],"genre_scores_gemma":[0.99702275,0.000080216676,0.0000067561723,0.0022505254,0.00012569044,0.000034439636,0.0000012639988,0.000012477833,0.00046591024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791455,0.00027259873,0.0012108072,0.00024204496,0.00008478649,0.00027519185],"domain_scores_gemma":[0.99766785,0.0005775736,0.0012104606,0.0004565025,0.000027001712,0.000060625232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006717425,0.00010754298,0.00044578506,0.000049140097,0.000121524674,0.000030392484,0.0005175079,0.000051392908,0.00029653942],"category_scores_gemma":[0.0006387348,0.00006769751,0.00007009388,0.00016837026,0.00016413983,0.00011111662,0.0000959817,0.0002108888,0.000047783193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024228859,0.000020199543,0.96628684,0.00009225592,0.00005215123,4.1435143e-7,0.0020794948,0.015149786,0.000005088,0.0028515225,0.013329906,0.00010814006],"study_design_scores_gemma":[0.00039776516,0.000020377998,0.98969936,0.000042745865,0.0000048905927,0.0000022502527,0.0026503368,0.0043654507,0.0000041712083,0.0019007846,0.000811226,0.000100665435],"about_ca_topic_score_codex":0.8295079,"about_ca_topic_score_gemma":0.60983557,"teacher_disagreement_score":0.21967237,"about_ca_system_score_codex":0.0016764881,"about_ca_system_score_gemma":0.002181576,"threshold_uncertainty_score":0.4383958},"labels":[],"label_agreement":null},{"id":"W2979515484","doi":"10.1634/theoncologist.2019-0446","title":"De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Breast cancer; Pertuzumab; Clinical endpoint; Oncology; Proportional hazards model; Metastasis; Trastuzumab; Confidence interval; Cancer; Chemotherapy; Cancer registry; Progression-free survival; Clinical trial","score_opus":0.05891216506106133,"score_gpt":0.37614151386067546,"score_spread":0.3172293487996141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979515484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797112,0.0013582802,0.0000070565256,0.012386159,0.0009814736,0.0011500297,0.0012192917,0.000037060243,0.0031494936],"genre_scores_gemma":[0.9965105,0.0017102091,0.000056102897,0.00043935128,0.0003396144,0.00017529921,0.00006547668,0.000030605155,0.0006728252],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982873,0.0004341767,0.00023887517,0.00033059664,0.0003099093,0.00039914326],"domain_scores_gemma":[0.9978916,0.0010978729,0.00016362268,0.0005901649,0.000107852786,0.00014885937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043071073,0.00020894433,0.0004033241,0.000020332885,0.00015417412,0.00006695794,0.00022671102,0.00006707442,0.00045330066],"category_scores_gemma":[0.00013836352,0.00010780604,0.00008049235,0.00011926879,0.00046877915,0.000029688275,0.00010089859,0.00033222456,0.00008613988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02363884,0.0017621779,0.36519197,0.00031151707,0.0031064833,0.0006207976,0.011621795,0.000031869735,0.0033095975,0.00077074626,0.010340463,0.5792937],"study_design_scores_gemma":[0.013092078,0.009863459,0.86100155,0.0010823183,0.0016046492,0.00036980957,0.01272623,0.0005864356,0.000946547,0.00012340797,0.09796723,0.0006362979],"about_ca_topic_score_codex":0.01270134,"about_ca_topic_score_gemma":0.0013235445,"teacher_disagreement_score":0.57865745,"about_ca_system_score_codex":0.0015533908,"about_ca_system_score_gemma":0.0006325571,"threshold_uncertainty_score":0.9938732},"labels":[],"label_agreement":null},{"id":"W2980349677","doi":"10.1634/theoncologist.2019-0512","title":"Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Anxiety; Breast cancer; Psychosocial; Cancer; Mastectomy; Psychological intervention; Internal medicine; Prospective cohort study; Oncology; Physical therapy; Psychiatry","score_opus":0.007887843030105068,"score_gpt":0.24207633286700117,"score_spread":0.2341884898368961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980349677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978307,0.0003416312,1.3305875e-7,0.00036096128,0.00005099767,0.0009433419,0.000047397563,0.000016986163,0.00040788707],"genre_scores_gemma":[0.99887854,0.00056081056,0.0000032098958,0.00013540103,0.000035096324,0.00006943637,0.000024343175,0.000014161357,0.00027899817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992881,0.00006547192,0.00010071377,0.00020715693,0.00017930089,0.00015929548],"domain_scores_gemma":[0.9995215,0.0001229952,0.000068841975,0.00019639498,0.000039464223,0.00005079199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050451774,0.0001561851,0.00035816937,0.000033241384,0.000022625034,0.0000065353906,0.000046775378,0.000055012377,0.000048051337],"category_scores_gemma":[0.0000014067153,0.00006445969,0.000027181632,0.00009664721,0.00012645939,0.00002166969,0.000010306823,0.00008958869,0.000001816125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020625433,0.0005933897,0.9569731,0.000038275244,0.0000944311,0.00003340887,0.00039881034,0.00003305022,0.000047012763,0.000052965857,0.00002431893,0.021085806],"study_design_scores_gemma":[0.016864765,0.009237107,0.9721673,0.00024218402,0.000055705095,0.000012377405,0.000042857,0.000005870111,0.0008426359,0.0000038357834,0.0004366239,0.0000887343],"about_ca_topic_score_codex":0.017105954,"about_ca_topic_score_gemma":0.004269943,"teacher_disagreement_score":0.020997072,"about_ca_system_score_codex":0.00020909666,"about_ca_system_score_gemma":0.000076010525,"threshold_uncertainty_score":0.98943925},"labels":[],"label_agreement":null},{"id":"W2982225675","doi":"10.1634/theoncologist.2019-0553","title":"Medical Oncologists’ Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"National Center for Advancing Translational Sciences","keywords":"FOLFOX; Medicine; Oxaliplatin; Confidence interval; Colorectal cancer; Odds ratio; Adjuvant; Internal medicine; Oncology; Family medicine; Stage (stratigraphy); Cancer","score_opus":0.03702173781733555,"score_gpt":0.3772266499945785,"score_spread":0.34020491217724297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982225675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9232094,0.0020201285,0.0000011735607,0.059481718,0.00048418174,0.0027839406,0.00025007143,0.00002707332,0.0117422715],"genre_scores_gemma":[0.9918736,0.0014318005,0.000006786217,0.00033503043,0.00019225646,0.00028339674,0.000011396631,0.000017908094,0.0058478066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733675,0.000668179,0.00041735204,0.00034549827,0.0009259212,0.00030629098],"domain_scores_gemma":[0.9959571,0.0020455439,0.00060529937,0.0010233556,0.00028223518,0.00008649147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009362784,0.00027193452,0.00066576997,0.00003468809,0.0002221178,0.000022639268,0.00050666067,0.00017668084,0.00038378173],"category_scores_gemma":[0.00080366863,0.00008305121,0.00032413262,0.0006024862,0.0013391105,0.000039439346,0.00012228313,0.00029680828,0.000012245297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23341316,0.024205042,0.29365018,0.00038954205,0.010388512,0.00048251083,0.14710842,0.008074023,0.021665024,0.0146713285,0.05991196,0.1860403],"study_design_scores_gemma":[0.025154594,0.0368453,0.838185,0.00036347663,0.0009890599,0.00004962992,0.035455395,0.0010236136,0.0148229,0.00014938692,0.046634793,0.00032686224],"about_ca_topic_score_codex":0.004316255,"about_ca_topic_score_gemma":0.0046364176,"teacher_disagreement_score":0.5445348,"about_ca_system_score_codex":0.0023543213,"about_ca_system_score_gemma":0.0014560103,"threshold_uncertainty_score":0.6524915},"labels":[],"label_agreement":null},{"id":"W2990253155","doi":"10.1634/theoncologist.2019-0501","title":"Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Clinical trial","score_opus":0.1282177910948125,"score_gpt":0.3195378907818478,"score_spread":0.1913200996870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990253155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799269,0.001684148,0.000044896606,0.001650054,0.00021092786,0.002289813,0.000058715625,0.0000739235,0.014060633],"genre_scores_gemma":[0.9947489,0.00031398184,0.00015805203,0.00006323496,0.00010625559,0.00023088533,0.00027651392,0.000028027183,0.0040741884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789727,0.00019511173,0.00052188116,0.00050467433,0.00040957762,0.00047151145],"domain_scores_gemma":[0.99762523,0.00061038934,0.00025852348,0.0011524895,0.00017434199,0.00017900628],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044315486,0.00034950516,0.0010509733,0.00018573806,0.00016402666,0.000022021391,0.00022658662,0.00019441932,0.0019474953],"category_scores_gemma":[0.0001100252,0.00021589398,0.0007057885,0.0010306959,0.0002709842,0.00005885539,0.00007549889,0.00014869162,0.00038098177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003499177,0.0014262913,0.9880076,0.00006711474,0.0018262578,0.00016841611,0.0004243231,0.000026094109,0.0005072031,0.00013839157,0.00014292239,0.003766224],"study_design_scores_gemma":[0.054818403,0.041199926,0.55807066,0.00009694787,0.028230514,0.00007666246,0.0015188112,0.11458418,0.09854074,0.00040599343,0.10125954,0.0011976449],"about_ca_topic_score_codex":0.004879827,"about_ca_topic_score_gemma":0.00064749434,"teacher_disagreement_score":0.42993695,"about_ca_system_score_codex":0.0004702627,"about_ca_system_score_gemma":0.00031406083,"threshold_uncertainty_score":0.99896485},"labels":[],"label_agreement":null},{"id":"W2990484449","doi":"10.1634/theoncologist.2019-0628","title":"Supervised, Multimodal Exercise: The Chemotherapy Supportive Therapy That Almost Does It All","year":2019,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Susan G. Komen","keywords":"Medicine; Context (archaeology); Chemotherapy; Physical therapy; Psychological intervention; Randomized controlled trial; Intensive care medicine; Exercise therapy; Clinical trial; Oncology; Internal medicine; Nursing","score_opus":0.0479219492012831,"score_gpt":0.3185474806793348,"score_spread":0.2706255314780517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990484449","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010083815,0.002529405,0.0000120897075,0.9670048,0.0033210197,0.0032837277,0.00024385976,0.00016685193,0.01335445],"genre_scores_gemma":[0.035969183,0.00823036,0.000025694448,0.89131063,0.005809827,0.00046607916,0.00070046645,0.0001796539,0.05730811],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965891,0.0003473253,0.00046807792,0.00078553986,0.000940931,0.00086898485],"domain_scores_gemma":[0.9963859,0.00092165073,0.00038458488,0.0020271896,0.00019912029,0.000081561215],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000786052,0.0007585679,0.001157924,0.000082220584,0.0002456627,0.00013075267,0.0012747886,0.0011517125,0.0037470185],"category_scores_gemma":[0.000040689116,0.00031063403,0.0006841485,0.00020422786,0.00089168287,0.000075496755,0.00016048644,0.002933297,0.00045487724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010077611,0.0001042422,0.0012640639,0.00013239049,0.00043278138,0.0002629771,0.005584822,0.0000010344869,0.00008634648,0.000004364015,0.97160953,0.019509675],"study_design_scores_gemma":[0.002452615,0.00052585406,0.001814051,0.0001952831,0.00033541102,0.000070671274,0.002925642,0.00002322003,0.0007739652,0.00008626273,0.99031466,0.00048236494],"about_ca_topic_score_codex":0.0039428645,"about_ca_topic_score_gemma":0.0012505382,"teacher_disagreement_score":0.07569415,"about_ca_system_score_codex":0.0004013311,"about_ca_system_score_gemma":0.00051880255,"threshold_uncertainty_score":0.99993455},"labels":[],"label_agreement":null},{"id":"W2996147814","doi":"10.1634/theoncologist.2019-0437","title":"Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Canadian Cancer Society Research Institute; NRG Oncology; ECOG-ACRIN Cancer Research Group; Sanofi","keywords":"Medicine; Bevacizumab; Oxaliplatin; Fluorouracil; Colorectal cancer; Clinical endpoint; Surgery; Neutropenia; Internal medicine; Leukopenia; Chemotherapy; Randomized controlled trial; Cancer","score_opus":0.06494311937460169,"score_gpt":0.39106730842488907,"score_spread":0.3261241890502874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996147814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98017335,0.00021492076,0.000010921454,0.00058205187,0.00051421527,0.017530974,0.00020903748,0.000027478922,0.0007370259],"genre_scores_gemma":[0.99515647,0.00013595498,0.00020939484,0.000040644918,0.00012211462,0.0023434306,0.000046350156,0.00004455581,0.0019010955],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99573845,0.0012331365,0.00097100425,0.00071327196,0.0008753574,0.00046875892],"domain_scores_gemma":[0.993757,0.0039701173,0.00069211033,0.0006055849,0.000834507,0.00014064174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021524234,0.0004354668,0.0016476533,0.00012388702,0.0005440682,0.00005725194,0.00029843787,0.00015982712,0.0002558892],"category_scores_gemma":[0.0013476012,0.00021551776,0.00016078149,0.0005807879,0.0008544412,0.00028438456,0.00048830215,0.00054581155,0.0000012268239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96314114,0.0032741297,0.009449531,0.000108937544,0.0010870645,0.000008812956,0.014600234,0.000042964977,0.00033765056,0.000084032814,0.00009150238,0.0077740094],"study_design_scores_gemma":[0.9088368,0.0716545,0.0078691915,0.00029003792,0.0006263073,0.000007662391,0.008168536,0.0007095406,0.0012134722,0.000018989715,0.00032102346,0.0002839557],"about_ca_topic_score_codex":0.0033147375,"about_ca_topic_score_gemma":0.0049463827,"teacher_disagreement_score":0.06838037,"about_ca_system_score_codex":0.00072386785,"about_ca_system_score_gemma":0.00047305843,"threshold_uncertainty_score":0.87885594},"labels":[],"label_agreement":null},{"id":"W2996280469","doi":"10.1634/theoncologist.2019-0562","title":"Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Oncology; Marital status; Proportional hazards model; Hazard ratio; Multivariate analysis; Pancreatic cancer; Survival analysis; Univariate analysis; Population; Cancer registry; Cancer","score_opus":0.025035103920083644,"score_gpt":0.3365644235079453,"score_spread":0.3115293195878617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996280469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98554325,0.00029950964,0.000002056406,0.00030784853,0.000051109222,0.0009024675,0.00019201529,0.000012244658,0.012689504],"genre_scores_gemma":[0.998099,0.00044305262,0.0004457972,0.000079381316,0.000023647905,0.000034353954,0.00013856165,0.000014183145,0.0007219777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976582,0.00044829323,0.00058515574,0.00035041585,0.0005029355,0.00045501508],"domain_scores_gemma":[0.99765575,0.00096663676,0.00034385937,0.0005842931,0.0002989128,0.00015056333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014549913,0.00017041284,0.001376715,0.00029846816,0.000048974143,0.000006682793,0.00017904115,0.00018874567,0.00014422598],"category_scores_gemma":[0.00038393761,0.000102669124,0.00007072124,0.00079622923,0.00062501605,0.00008977102,0.00012124785,0.00032554765,0.0000029523794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014067072,0.000874357,0.9812941,0.00010407,0.0009578295,0.000020743959,0.0006485195,0.00012978769,0.00021571625,0.00012191133,0.00007537521,0.0014905011],"study_design_scores_gemma":[0.01109832,0.006993021,0.9780712,0.00008329469,0.0013112788,0.0000019379318,0.0005972668,0.0013605512,0.00005177824,0.00006247496,0.000262382,0.0001064898],"about_ca_topic_score_codex":0.014016562,"about_ca_topic_score_gemma":0.009611145,"teacher_disagreement_score":0.012555799,"about_ca_system_score_codex":0.0004351876,"about_ca_system_score_gemma":0.00092220266,"threshold_uncertainty_score":0.9925492},"labels":[],"label_agreement":null},{"id":"W3000094994","doi":"10.1634/theoncologist.2019-0777","title":"Exercise Intolerance in Anthracycline-Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Innovates; Susan G. Komen for the Cure","keywords":"Bioenergetics; Anthracycline; Skeletal muscle; Breast cancer; Exercise intolerance; Medicine; Internal medicine; Composition (language); Cancer; Oxygenation; Endocrinology; Biology; Heart failure; Biochemistry","score_opus":0.013371865050071291,"score_gpt":0.2708306323130751,"score_spread":0.25745876726300376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000094994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97919655,0.0011687117,0.000035621444,0.018768247,0.00004036134,0.00037780413,0.000032856628,0.00002627705,0.00035354446],"genre_scores_gemma":[0.99757725,0.0014281723,0.00004514244,0.00073167856,0.00014223465,0.000028190016,0.000024417124,0.0000097495595,0.000013187555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993298,0.000076743,0.00020790003,0.00014596859,0.00013296395,0.000106625965],"domain_scores_gemma":[0.9995638,0.00006648524,0.00010245956,0.00013384172,0.00009023453,0.00004313875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019029234,0.00009237564,0.00022078805,0.000024239558,0.00006984864,0.000010149653,0.0000822896,0.00006980627,0.000025729403],"category_scores_gemma":[0.000022211585,0.000056177196,0.000046789988,0.00023957907,0.00029110876,0.000047811947,0.000026062738,0.00014748417,0.0000018224082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003009161,0.0001660029,0.012179654,0.000056805537,0.00003797695,0.000004308989,0.0022603548,0.0002718388,0.8989793,0.00016510925,0.000107341184,0.08547041],"study_design_scores_gemma":[0.0020300199,0.00019808572,0.45383036,0.00023191476,0.0001168795,0.00002220524,0.001599539,0.006242686,0.5337072,0.00026700363,0.0016061194,0.00014794931],"about_ca_topic_score_codex":0.0022250891,"about_ca_topic_score_gemma":0.00067584624,"teacher_disagreement_score":0.44165072,"about_ca_system_score_codex":0.000057722118,"about_ca_system_score_gemma":0.000043541306,"threshold_uncertainty_score":0.33636838},"labels":[],"label_agreement":null},{"id":"W3001231147","doi":"10.1634/theoncologist.2019-0605","title":"Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"","keywords":"Sunitinib; Renal cell carcinoma; Medicine; Oncology; Internal medicine","score_opus":0.07169468822399246,"score_gpt":0.3543708603305172,"score_spread":0.28267617210652474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001231147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98118037,0.000049096638,0.00020348391,0.003068025,0.00021461412,0.0013885293,0.000677105,0.000046834397,0.013171925],"genre_scores_gemma":[0.9946897,0.00013164217,0.0020707774,0.001035714,0.0001498773,0.00008575516,0.0008520434,0.00004732857,0.00093713304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641085,0.00063509296,0.0011450385,0.0005316365,0.0009261469,0.0003512606],"domain_scores_gemma":[0.9954836,0.0020649068,0.0011155307,0.0008078046,0.00024178554,0.00028638262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012031219,0.00035886542,0.0008536819,0.00006128281,0.0001947752,0.0000370646,0.00061242876,0.00006757535,0.00036604187],"category_scores_gemma":[0.00030765074,0.00017452765,0.00028806884,0.00025847467,0.00085532264,0.000094956034,0.00033412484,0.000772382,0.000028700826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015689034,0.0017972848,0.98707426,0.000076020486,0.0003244876,0.0001265781,0.00016738095,0.000076007585,0.00007476886,0.00005255148,0.008192038,0.00046972613],"study_design_scores_gemma":[0.00854943,0.0046458277,0.9787424,0.000032729185,0.0013221938,0.0000034523039,0.00041695146,0.0011682115,0.00093085784,0.000009604755,0.003987485,0.0001908189],"about_ca_topic_score_codex":0.003721129,"about_ca_topic_score_gemma":0.0015703817,"teacher_disagreement_score":0.013509342,"about_ca_system_score_codex":0.00022627237,"about_ca_system_score_gemma":0.00026076677,"threshold_uncertainty_score":0.7117031},"labels":[],"label_agreement":null},{"id":"W3003473057","doi":"10.1634/theoncologist.2019-0581","title":"A Randomized Trial of Real-Time Geriatric Assessment Reporting in Nonelectively Hospitalized Older Adults with Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"National Cancer Institute; John A. Hartford Foundation","keywords":"Medicine; Polypharmacy; Psychological intervention; Randomized controlled trial; Anxiety; Population; Referral; Cancer; Geriatrics; Intervention (counseling); Physical therapy; Internal medicine; Family medicine; Psychiatry","score_opus":0.02714126691220669,"score_gpt":0.345100156033863,"score_spread":0.3179588891216563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003473057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966449,0.00009420985,0.000099617486,0.010390416,0.0001346945,0.0053408127,0.000008265224,0.00008736988,0.017395578],"genre_scores_gemma":[0.99566543,0.00022867642,0.002043694,0.00034700002,0.00027932337,0.0007851035,0.000014086899,0.000030994273,0.00060567056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99712133,0.0004019834,0.001370398,0.00037664198,0.00043418497,0.0002954294],"domain_scores_gemma":[0.99688834,0.00066767324,0.0018299195,0.00031221024,0.00019868038,0.00010315979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017516001,0.00021119897,0.0014305579,0.00006758488,0.000046701552,0.000012688165,0.00016627043,0.00010907808,0.00021889669],"category_scores_gemma":[0.0028372535,0.00011827645,0.00018976588,0.0005989621,0.0003110357,0.000052279956,0.00006523923,0.00032759443,0.000005441727],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9881439,0.00048886705,0.0036169102,0.00015309328,0.00023766843,0.00018183075,0.0027477723,0.00007145655,0.0010017866,0.000033084758,0.0011740163,0.002149618],"study_design_scores_gemma":[0.95702213,0.0024821116,0.03682617,0.00036250876,0.00037756603,0.00002184334,0.00028372937,0.0019479247,0.00042128828,0.000025257115,0.00006387404,0.00016561884],"about_ca_topic_score_codex":0.0037606065,"about_ca_topic_score_gemma":0.000135618,"teacher_disagreement_score":0.03320926,"about_ca_system_score_codex":0.0003017594,"about_ca_system_score_gemma":0.0007660224,"threshold_uncertainty_score":0.5684937},"labels":[],"label_agreement":null},{"id":"W3005570342","doi":"10.1634/theoncologist.2019-0674","title":"Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Medicine; Nivolumab; Adverse effect; Pembrolizumab; Pneumonitis; Hazard ratio; Ipilimumab; Internal medicine; Melanoma; Cancer; Immunotherapy; Confidence interval; Lung","score_opus":0.03187919730524732,"score_gpt":0.31172232012643114,"score_spread":0.27984312282118384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005570342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815397,0.0005016867,0.0000029662447,0.014175982,0.00030737792,0.00048802665,0.0000064075493,0.00006081245,0.0029170145],"genre_scores_gemma":[0.99793965,0.0002408549,0.000058039186,0.0012344948,0.000030923373,0.000017246028,0.00000946726,0.000015854956,0.0004534652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989424,0.00010959143,0.00035491263,0.0002208597,0.00015353283,0.00021875119],"domain_scores_gemma":[0.99944806,0.0001242219,0.000119266166,0.0002178104,0.000021588663,0.000069031936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034697886,0.00015336281,0.00044947708,0.000035390334,0.00007772815,0.0000043579853,0.00014126141,0.00010390431,0.00011559132],"category_scores_gemma":[0.00013949825,0.000095873074,0.00010690279,0.00024826065,0.00014285541,0.000054931796,0.00006938997,0.00024257075,0.000027080734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006113067,0.00038032667,0.7659393,0.000075270196,0.00047967027,0.00023301158,0.001977296,0.000018769737,0.18610074,0.00013779828,0.00015437593,0.03839041],"study_design_scores_gemma":[0.0077000163,0.00080662745,0.98660743,0.000045128494,0.000053881457,0.00001767239,0.0007981452,0.00008598569,0.0018555112,0.000039740407,0.0018522108,0.00013762728],"about_ca_topic_score_codex":0.00031136887,"about_ca_topic_score_gemma":0.00009590297,"teacher_disagreement_score":0.22066818,"about_ca_system_score_codex":0.000102963226,"about_ca_system_score_gemma":0.000081319646,"threshold_uncertainty_score":0.39095905},"labels":[],"label_agreement":null},{"id":"W3008706206","doi":"10.1634/theoncologist.2019-0709","title":"Gaps in the Management of Depression Symptoms Following Cancer Diagnosis: A Population-Based Analysis of Prospective Patient-Reported Outcomes","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; University of Manitoba; Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Depression (economics); Medicine; Prospective cohort study; Management of depression; Cancer; Population; Psychiatry; Family medicine; Internal medicine; Environmental health; Primary care","score_opus":0.025126573153505534,"score_gpt":0.33180545258232175,"score_spread":0.3066788794288162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008706206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557,0.00054295035,0.000036597412,0.0023675135,0.00009192683,0.0006735721,0.000018522001,0.000016151176,0.00068274915],"genre_scores_gemma":[0.9984311,0.000032338587,0.000027958271,0.00089329405,0.00001309356,0.00055895577,0.00002584839,0.0000063772354,0.0000110395085],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989388,0.00009435407,0.0003474691,0.00017098903,0.00034358032,0.00010481429],"domain_scores_gemma":[0.9992227,0.00017933882,0.00024686844,0.00027726308,0.00004729062,0.000026572967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021721299,0.00009230075,0.00039129308,0.00007428228,0.000038245344,0.0000050532867,0.00012991726,0.000037740763,0.000053522035],"category_scores_gemma":[0.000059946244,0.00004750093,0.00024740663,0.0010235425,0.000041839052,0.000019908754,0.000036638947,0.00009337007,3.0108777e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019101037,0.00014315818,0.98989326,0.00007308392,0.001264057,0.000028042996,0.002781556,0.0013471798,0.00001723207,0.000036584515,0.000043329062,0.0041815336],"study_design_scores_gemma":[0.0008750984,0.00015478476,0.992085,0.00013024658,0.003036615,1.2941108e-7,0.0027719603,0.0004927145,0.00031031435,0.000018615832,0.00007298166,0.00005153493],"about_ca_topic_score_codex":0.007991065,"about_ca_topic_score_gemma":0.004857913,"teacher_disagreement_score":0.0041299984,"about_ca_system_score_codex":0.00012783363,"about_ca_system_score_gemma":0.00004022711,"threshold_uncertainty_score":0.9986148},"labels":[],"label_agreement":null},{"id":"W3014203766","doi":"10.1634/theoncologist.2019-0950","title":"Identifying Geriatric Oncology Competencies for Medical Oncology Trainees: A Modified Delphi Consensus Study","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences; National Institute on Aging; Canadian Institutes of Health Research","keywords":"Internal medicine; Oncology; Medicine; Geriatric oncology; Delphi method; Psychosocial; Oncology nursing; Delphi; Curriculum; Family medicine; Cancer; Nursing; Psychology; Nurse education; Psychiatry","score_opus":0.15512981236419615,"score_gpt":0.40303296866355676,"score_spread":0.2479031562993606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014203766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70208526,0.0007317508,0.004372488,0.267081,0.0015565996,0.0068767373,0.0000694419,0.000604439,0.016622297],"genre_scores_gemma":[0.982653,0.000072751696,0.0038632837,0.011040269,0.0012082737,0.0005388648,0.000033418746,0.00005032529,0.0005398203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964849,0.00059399556,0.0009777058,0.00061291904,0.0006626541,0.00066784763],"domain_scores_gemma":[0.9943827,0.003978846,0.00033972136,0.00048807982,0.00028478215,0.00052587327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018892062,0.0003358233,0.0011558898,0.000107275635,0.00032969197,0.000032385266,0.0006838068,0.00043433646,0.00034029887],"category_scores_gemma":[0.00645935,0.00022813983,0.00025416716,0.0004851563,0.00097612065,0.000036241454,0.00028388004,0.00081808993,0.0001271231],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025872061,0.017406382,0.0065106084,0.0016311188,0.0039938004,0.012836647,0.18128112,0.0007691092,0.013742173,0.0067366627,0.43936184,0.28985846],"study_design_scores_gemma":[0.09557472,0.09783019,0.023690904,0.00025075936,0.004146726,0.0045428257,0.20159529,0.04415965,0.00053615886,0.002433141,0.5234568,0.0017828491],"about_ca_topic_score_codex":0.0002807808,"about_ca_topic_score_gemma":0.00101683,"teacher_disagreement_score":0.28807563,"about_ca_system_score_codex":0.0006227857,"about_ca_system_score_gemma":0.001901632,"threshold_uncertainty_score":0.93032724},"labels":[],"label_agreement":null},{"id":"W3014319236","doi":"10.1634/theoncologist.2020-0213","title":"A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":719,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Juravinski Cancer Centre; University of Toronto; McMaster University; Windsor Regional Hospital; Impact","funders":"F. Hoffmann-La Roche","keywords":"Pandemic; Medicine; Outbreak; Disease; Public health; Cancer; Population; Intensive care medicine; Transmission (telecommunications); Coronavirus; Pneumonia; Infectious disease (medical specialty); Coronavirus disease 2019 (COVID-19); Environmental health; Virology; Internal medicine; Pathology","score_opus":0.3677715450091028,"score_gpt":0.5553454666213564,"score_spread":0.1875739216122536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014319236","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006721226,0.9224732,0.00083637144,0.053855892,0.0013071656,0.015378596,0.003445407,0.00013148651,0.0018997694],"genre_scores_gemma":[0.0034373149,0.98542273,0.00034433077,0.0081396615,0.00063121127,0.0012269411,0.00029662118,0.00004561647,0.00045555094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973787,0.00044536678,0.00062549196,0.0005078361,0.0007116645,0.00033094984],"domain_scores_gemma":[0.9972276,0.0006815934,0.00061942334,0.0007148582,0.00018684671,0.0005696691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008119101,0.00035317938,0.0008931069,0.00006463896,0.0002951703,0.000051153645,0.0007974349,0.00014100898,0.00005736179],"category_scores_gemma":[0.0008318127,0.00015184491,0.00021656287,0.00053996727,0.00029423102,0.000078465666,0.00051446556,0.0007125893,0.000026138932],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038132472,0.0030471436,0.0051527303,0.02613962,0.0026210775,0.0001445448,0.002794366,0.00008413098,9.702047e-7,0.004798951,0.0054109883,0.94599223],"study_design_scores_gemma":[0.0009885723,0.00032838518,0.019913211,0.0012376495,0.0015724474,0.000016051828,0.00039051197,0.000031734795,4.3025853e-8,0.000010018184,0.975349,0.00016237293],"about_ca_topic_score_codex":0.0013652252,"about_ca_topic_score_gemma":0.0005220914,"teacher_disagreement_score":0.96993804,"about_ca_system_score_codex":0.0023631414,"about_ca_system_score_gemma":0.0028224722,"threshold_uncertainty_score":0.6192056},"labels":[],"label_agreement":null},{"id":"W3016237720","doi":"10.1634/theoncologist.2020-0040","title":"Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Retrospective cohort study; Cohort; Blockade; Immune checkpoint; Internal medicine; Progression-free survival; Oncology; Chemotherapy","score_opus":0.03091760045063636,"score_gpt":0.33629506853513286,"score_spread":0.3053774680844965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016237720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889195,0.00094400643,0.000002116966,0.0054136193,0.000019542082,0.00087427313,0.000013061721,0.000035255292,0.003778655],"genre_scores_gemma":[0.9989727,0.00020457259,0.00039280514,0.0000942314,0.00006483615,0.00015956772,0.000022803351,0.000015990523,0.00007250217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999018,0.00006417093,0.00030053649,0.00022183232,0.00016392965,0.00023154069],"domain_scores_gemma":[0.99928665,0.00009321324,0.00016936634,0.0002977781,0.00003570689,0.000117290314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010885505,0.00020069926,0.00048813975,0.00003721201,0.000044840326,0.000009676673,0.00009676606,0.00006765895,0.00008232352],"category_scores_gemma":[0.000038378443,0.00008408921,0.00017949588,0.00024762738,0.00019122947,0.00002600433,0.000045521545,0.00004699284,0.000022625789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006470014,0.006856691,0.7891256,0.00005970313,0.00076180935,0.0008587074,0.00295964,0.00018615073,0.01879682,0.00007677578,0.00023784918,0.1736102],"study_design_scores_gemma":[0.013079427,0.025097732,0.9116787,0.00012795962,0.0002466608,0.000101681326,0.00023398227,0.00021304785,0.04834739,0.000022416334,0.00073758943,0.00011344606],"about_ca_topic_score_codex":0.0014574503,"about_ca_topic_score_gemma":0.00008760302,"teacher_disagreement_score":0.17349675,"about_ca_system_score_codex":0.0011596158,"about_ca_system_score_gemma":0.00047313687,"threshold_uncertainty_score":0.34290585},"labels":[],"label_agreement":null},{"id":"W3019309608","doi":"10.1634/theoncologist.2019-0887","title":"Oncology in 2050 – A Retrospective?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Oncology; MEDLINE; Internal medicine","score_opus":0.02291055533458568,"score_gpt":0.28886977021186433,"score_spread":0.26595921487727864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019309608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9051027,0.0011430611,0.00025432216,0.021240462,0.0003783271,0.0003548024,0.000035457644,0.000019122443,0.07147172],"genre_scores_gemma":[0.99422735,0.0005222026,0.00018659938,0.0042107496,0.0005160704,0.000028757971,0.000025149457,0.000010920931,0.00027217256],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993482,0.000055554552,0.000147861,0.00022192785,0.000052447867,0.00017399958],"domain_scores_gemma":[0.9996249,0.000037003978,0.00006066111,0.00019046475,0.000028784802,0.000058164627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017382822,0.00008441282,0.0001317033,0.000010096887,0.000045127912,0.000009765991,0.00024140363,0.00010612905,0.00005173353],"category_scores_gemma":[0.00038461213,0.0000637268,0.000048674425,0.000101676385,0.00014609667,9.334897e-7,0.0001687575,0.00013028618,0.000039949293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017913663,0.00062163087,0.110182755,0.000034080615,0.00013457506,0.00012977347,0.0015042435,0.0019760819,0.4588738,0.009401436,0.39554703,0.019803213],"study_design_scores_gemma":[0.0008882434,0.00149549,0.038866717,0.0000025749837,0.000011663336,0.000007768051,0.00020218822,0.00013409716,0.005230563,0.0004615164,0.95254934,0.00014986064],"about_ca_topic_score_codex":0.00013213833,"about_ca_topic_score_gemma":0.0008728926,"teacher_disagreement_score":0.55700225,"about_ca_system_score_codex":0.000086384534,"about_ca_system_score_gemma":0.00012459494,"threshold_uncertainty_score":0.25987035},"labels":[],"label_agreement":null},{"id":"W3019602056","doi":"10.1634/theoncologist.2020-0194","title":"Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Blockade; Tocilizumab; Melanoma; Immunotherapy; Oncology; Immune checkpoint; Immune system; Adverse effect; Cytokine; Chimeric antigen receptor; Internal medicine; Immunology; Cancer research; Receptor; Disease","score_opus":0.038032293583396076,"score_gpt":0.3468623536365209,"score_spread":0.30883006005312486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019602056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027280284,0.9650594,0.000005347837,0.002067148,0.000030681887,0.0046364367,0.00057760085,0.000023558216,0.00031953547],"genre_scores_gemma":[0.005751826,0.9921499,0.00039670934,0.0001298399,0.00007807497,0.0006369423,0.000652124,0.00005678966,0.00014780692],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965302,0.0005324503,0.0015905921,0.0005972472,0.00048165367,0.000267907],"domain_scores_gemma":[0.99753714,0.0003976029,0.0007796274,0.0008679379,0.00020795218,0.00020976081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056784204,0.00047792337,0.0033853638,0.00020921727,0.000055221073,0.000021169693,0.00011673437,0.00023085972,0.00033644077],"category_scores_gemma":[0.00021928301,0.00026560389,0.00045426344,0.0011448724,0.00027254192,0.000039620874,0.00008259982,0.00056019623,0.0000036339256],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091167126,0.0007598585,0.000010631326,0.057538573,0.00063106715,0.5150143,0.0017674464,0.0000014484013,0.00023397514,0.0000046747023,0.000044627403,0.42308173],"study_design_scores_gemma":[0.0022117244,0.009243421,0.000020903508,0.2988981,0.0025863925,0.29506516,0.00026064445,0.0000033116098,0.00043647396,0.000010620711,0.39092973,0.00033350912],"about_ca_topic_score_codex":0.0012633586,"about_ca_topic_score_gemma":0.00022990645,"teacher_disagreement_score":0.4227482,"about_ca_system_score_codex":0.0006892948,"about_ca_system_score_gemma":0.0007782516,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W3022563976","doi":"10.1634/theoncologist.2019-0676","title":"Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombosis; Internal medicine; Oncology; Medical physics; Family medicine","score_opus":0.37416401922442544,"score_gpt":0.46257101003916545,"score_spread":0.08840699081474002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022563976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90854526,0.0005657984,0.000013524223,0.07255028,0.00021840628,0.0010526758,0.000016162405,0.000047325717,0.016990552],"genre_scores_gemma":[0.9921719,0.0012077962,0.00016855494,0.0057907877,0.00019269803,0.00010668479,0.000029121162,0.000020162466,0.0003123323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979111,0.0006554083,0.0003009465,0.00036956643,0.0003226891,0.00044031604],"domain_scores_gemma":[0.9987052,0.00071057025,0.00006292125,0.00026660284,0.00007543355,0.00017928386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027175671,0.00013960079,0.0005841618,0.00008692814,0.00017056569,0.00003474917,0.00021731354,0.00011580121,0.00022837457],"category_scores_gemma":[0.00045325106,0.00009318123,0.000053179,0.00046777568,0.0005262339,0.000045071458,0.00041370268,0.00049727224,0.00012403968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028810054,0.0040995674,0.510211,0.0003493601,0.0005696418,0.00055903796,0.012073846,0.000028154844,0.003448708,0.00482509,0.3891553,0.07179931],"study_design_scores_gemma":[0.003389661,0.0035801744,0.89752823,0.000041027943,0.000071243674,0.000009478466,0.0027951358,0.00024359394,0.00008608584,0.00021331229,0.09192087,0.0001211733],"about_ca_topic_score_codex":0.004191291,"about_ca_topic_score_gemma":0.0069938614,"teacher_disagreement_score":0.38731727,"about_ca_system_score_codex":0.00035667297,"about_ca_system_score_gemma":0.00018386228,"threshold_uncertainty_score":0.6336006},"labels":[],"label_agreement":null},{"id":"W3023770233","doi":"10.1634/theoncologist.2020-0329","title":"In Reply","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Impact; Western University; Juravinski Cancer Centre; McMaster University; University of Toronto","funders":"Roche","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); Medicine; Intensive care medicine; Philosophy; Internal medicine; Infectious disease (medical specialty)","score_opus":0.05260909331288252,"score_gpt":0.3349026653436883,"score_spread":0.28229357203080574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023770233","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020254614,0.000109337045,0.0000029348182,0.90494823,0.00062840484,0.0003538396,0.000007913032,0.00005713916,0.093689665],"genre_scores_gemma":[0.0019746933,0.000092543014,0.000025729358,0.9660534,0.0060192365,0.00010550582,0.00003367283,0.000023622917,0.025671558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99920213,0.000075232834,0.00017932133,0.00021901564,0.0001401267,0.00018418596],"domain_scores_gemma":[0.9993827,0.00011276994,0.000075509,0.00038014512,0.000021995284,0.000026922064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008057464,0.0001270509,0.00031846235,0.000041587788,0.000052361265,0.0000139247995,0.00015915392,0.000183361,0.0006471792],"category_scores_gemma":[0.00006931372,0.00007637087,0.00009939566,0.00018757673,0.00017019405,0.000017492455,0.000055296874,0.0020142698,0.0006308055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037385504,0.000016179834,0.00021951056,0.000043775362,0.000022174188,0.0027486167,0.000047291942,4.8348534e-7,0.000053837248,0.000027848124,0.996482,0.0003008839],"study_design_scores_gemma":[0.00039227278,0.0002705939,0.00059543154,0.00003797021,0.00009344522,0.00019723018,0.000013095894,0.0000011293656,0.000050273746,0.00030533606,0.997962,0.00008119433],"about_ca_topic_score_codex":0.0003927724,"about_ca_topic_score_gemma":0.00005727984,"teacher_disagreement_score":0.0680181,"about_ca_system_score_codex":0.00024898208,"about_ca_system_score_gemma":0.00023905832,"threshold_uncertainty_score":0.8751112},"labels":[],"label_agreement":null},{"id":"W3027051509","doi":"10.1634/theoncologist.2019-0384","title":"Frequency, Timing, and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Covenant Health; Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Cancer; Odds ratio; Palliative care; Cancer registry; Family medicine; Tertiary care; Residence; Logistic regression; Confidence interval; Health care; Emergency medicine; Gerontology; Internal medicine; Demography; Nursing","score_opus":0.11321776236724916,"score_gpt":0.4174774897412399,"score_spread":0.3042597273739907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027051509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911561,0.0039261263,0.000020571175,0.0007515113,0.00003097794,0.0005576542,0.0033680573,0.000010155572,0.00017887286],"genre_scores_gemma":[0.9960043,0.0018845891,0.00049882237,0.00047196366,0.000013949459,0.000028373464,0.0010741237,0.000008582485,0.000015337055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989164,0.00010041767,0.00041322125,0.0002378765,0.00020040403,0.00013171717],"domain_scores_gemma":[0.998706,0.00018692494,0.0005302776,0.00021415255,0.0002953729,0.000067263645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082701394,0.00011624122,0.000611338,0.00008599038,0.00003492323,0.0000017591966,0.00013237308,0.000043821237,0.000053251766],"category_scores_gemma":[0.00023360638,0.00007481407,0.000032034157,0.0007016794,0.0002631071,0.000051565017,0.00009019027,0.00011152617,1.0289546e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001041312,0.00008332358,0.97522974,0.0003011261,0.0006964586,0.0000017137737,0.01969914,0.00017146725,0.00017084774,0.0000015474766,0.00033622372,0.002267106],"study_design_scores_gemma":[0.0041413065,0.0007503165,0.9899539,0.0005335468,0.00057334953,4.3518757e-8,0.0027202116,0.00049998605,0.00047099436,7.317885e-7,0.00029043076,0.00006520234],"about_ca_topic_score_codex":0.005277833,"about_ca_topic_score_gemma":0.019314181,"teacher_disagreement_score":0.016978927,"about_ca_system_score_codex":0.00026203247,"about_ca_system_score_gemma":0.00047805544,"threshold_uncertainty_score":0.99858075},"labels":[],"label_agreement":null},{"id":"W3033163494","doi":"10.1634/theoncologist.2020-0416","title":"Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Stereotactic radiotherapy; Pandemic; Radiation therapy; Medical physics; Radiology; Internal medicine; Virology; Radiosurgery","score_opus":0.11875690017119633,"score_gpt":0.32598310306311906,"score_spread":0.20722620289192273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033163494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70939696,0.0129798185,0.0015947726,0.2695963,0.00012319355,0.0060887192,0.000038710936,0.00004619242,0.00013529211],"genre_scores_gemma":[0.9773345,0.00048260365,0.00050913636,0.019339968,0.00085825083,0.0012682198,0.00003979495,0.000033400436,0.00013411642],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985799,0.00027098632,0.00027588202,0.00033820127,0.00019185955,0.0003431669],"domain_scores_gemma":[0.9973107,0.0019667952,0.00012471921,0.00040525378,0.000043338514,0.00014920662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011190004,0.00023772138,0.00040265403,0.000035636473,0.0003968851,0.000072986775,0.00032384007,0.00012462473,0.000034416105],"category_scores_gemma":[0.00025189662,0.000105215106,0.0002063935,0.0002203328,0.00024056551,0.000042716707,0.000037893613,0.00025820246,0.000004331041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036519924,0.00031930266,0.9587923,0.00035002094,0.0003434525,0.0001694531,0.009834469,0.0000027116766,0.0014238456,0.0017962042,0.01422951,0.009086728],"study_design_scores_gemma":[0.013180285,0.0054446883,0.06873009,0.000019551419,0.001258514,0.00023491409,0.0027815455,0.047479037,0.0012337735,0.000506566,0.8587703,0.00036069565],"about_ca_topic_score_codex":0.00022213532,"about_ca_topic_score_gemma":0.00006210147,"teacher_disagreement_score":0.8900622,"about_ca_system_score_codex":0.00018966373,"about_ca_system_score_gemma":0.00027104074,"threshold_uncertainty_score":0.42905477},"labels":[],"label_agreement":null},{"id":"W3033319492","doi":"10.1634/theoncologist.2019-0875","title":"Neurological and Dexterity Assessments in a Woman with Radiation-Induced Brachial Plexopathy After Breast Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Peripheral Nerve Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Brachial Plexopathy; Medicine; Breast cancer; Complication; Cancer; Physical therapy; Physical medicine and rehabilitation; Surgery; Brachial plexus; Internal medicine","score_opus":0.02715071571202974,"score_gpt":0.32369098163615684,"score_spread":0.2965402659241271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033319492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692377,0.00013007788,0.000012015862,0.02983904,0.000037844,0.00037443676,0.00001850398,0.000039184266,0.00031121442],"genre_scores_gemma":[0.9816145,0.000041191983,0.000111548274,0.017942281,0.00012343678,0.0001284846,0.000004842843,0.0000117363115,0.000022000479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991331,0.00012704014,0.00014076367,0.0002533289,0.000145495,0.00020028542],"domain_scores_gemma":[0.9996344,0.000051893705,0.000053986452,0.00012778532,0.000020873571,0.00011108874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110810906,0.0001258548,0.00022626041,0.00001812142,0.00004836347,0.000023094133,0.000091355825,0.000070157774,0.00018290548],"category_scores_gemma":[0.000053077347,0.00007256077,0.000026655984,0.00016130214,0.00016207714,0.0000644799,0.00006187591,0.0002955797,0.000005337237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040843287,0.00018046985,0.977611,0.000022030474,0.000022449549,0.00022095535,0.00038192788,0.000015691909,0.0025066175,0.000014922667,0.00019547415,0.0147441495],"study_design_scores_gemma":[0.0018281664,0.0011669426,0.99531037,0.000014694636,0.000033225828,0.000062795494,0.000079528945,0.0010069325,0.000015702502,0.000015645715,0.00037758105,0.00008842952],"about_ca_topic_score_codex":0.00052549713,"about_ca_topic_score_gemma":0.0009058772,"teacher_disagreement_score":0.017699372,"about_ca_system_score_codex":0.000060191633,"about_ca_system_score_gemma":0.000113258146,"threshold_uncertainty_score":0.29589424},"labels":[],"label_agreement":null},{"id":"W3035631034","doi":"10.1634/theoncologist.2020-0451","title":"Evolution of Cancer Care in Response to the COVID-19 Pandemic","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Impact; Western University; Juravinski Cancer Centre; McMaster University; University of Toronto","funders":"Genentech; Pfizer","keywords":"Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Betacoronavirus; Medicine; Virology; Internal medicine; Outbreak; Infectious disease (medical specialty); Disease","score_opus":0.15634369681455573,"score_gpt":0.4652982179968371,"score_spread":0.3089545211822814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035631034","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019757045,0.004110387,0.000035629735,0.97350395,0.00043960093,0.0016342694,0.00023237824,0.000066631605,0.00022009536],"genre_scores_gemma":[0.28749704,0.00026494623,0.00001188894,0.70939595,0.0018165143,0.00015199266,0.000037058784,0.000023582548,0.00080102007],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99747837,0.00091177743,0.00042639178,0.0003403233,0.00043977718,0.00040336527],"domain_scores_gemma":[0.9966959,0.0020720037,0.00023689115,0.00067262497,0.00012919822,0.00019341007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010069651,0.00022748866,0.00058967463,0.00016616027,0.00013383501,0.000010379879,0.00043895407,0.0004984633,0.00011735636],"category_scores_gemma":[0.0047639315,0.000122038335,0.00013118089,0.0005341277,0.00027529045,0.000014705777,0.00014384992,0.001972824,0.00005149291],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004859391,0.00001418528,0.022918332,0.0008522437,0.000029145576,0.00038528125,0.0053572063,0.00011462248,0.00021788114,0.00000563228,0.96352506,0.0017210194],"study_design_scores_gemma":[0.000889286,0.00094351114,0.040041108,0.00019674972,0.00012522562,0.000031723383,0.0008910679,0.000009377832,0.0000060497537,0.00006260604,0.9566819,0.00012141122],"about_ca_topic_score_codex":0.037633583,"about_ca_topic_score_gemma":0.03563663,"teacher_disagreement_score":0.26774,"about_ca_system_score_codex":0.0072978013,"about_ca_system_score_gemma":0.00898377,"threshold_uncertainty_score":0.99663436},"labels":[],"label_agreement":null},{"id":"W3044963562","doi":"10.1634/theoncologist.2020-0502","title":"Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an <i>HLA-DRB1-MET</i> Gene Fusion","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"EMD Serono","keywords":"Crizotinib; Cabozantinib; Fusion gene; ROS1; Medicine; Lung cancer; Cancer research; KRAS; Erlotinib; Clinical trial; Oncology; Tyrosine kinase; Gene; Cancer; Internal medicine; Bioinformatics; Biology; Genetics; Receptor; Colorectal cancer; Epidermal growth factor receptor; Adenocarcinoma","score_opus":0.023497750649620886,"score_gpt":0.3182121643940267,"score_spread":0.2947144137444058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044963562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98734045,0.0004735555,0.00033814486,0.0074029877,0.000058989383,0.0013800686,0.000035998673,0.00006523081,0.0029045935],"genre_scores_gemma":[0.991755,0.0000737904,0.0042538764,0.0032632218,0.00010769795,0.00029212295,0.000041363102,0.000037584763,0.00017531496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988171,0.00007849651,0.00022404805,0.00036510557,0.00022205847,0.00029319085],"domain_scores_gemma":[0.9992103,0.000100963414,0.00014469739,0.000290482,0.000069757334,0.00018382365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012331073,0.00020998133,0.0003401124,0.000046535017,0.00013781428,0.000029068406,0.00012663529,0.000047411133,0.00007609417],"category_scores_gemma":[0.000023018303,0.000109566936,0.000044830696,0.0004038574,0.00009589178,0.00006628906,0.00005164873,0.00021700157,0.000004738053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018326418,0.0136686,0.3513143,0.0013333716,0.0030888151,0.008065194,0.11266504,0.05555966,0.15673007,0.00026380256,0.010272603,0.26871213],"study_design_scores_gemma":[0.10885399,0.07275223,0.53044385,0.0024893864,0.013327765,0.00050383876,0.0231802,0.013470683,0.16995616,0.000022116164,0.061911676,0.0030880948],"about_ca_topic_score_codex":0.001723035,"about_ca_topic_score_gemma":0.0013084764,"teacher_disagreement_score":0.26562402,"about_ca_system_score_codex":0.0003218341,"about_ca_system_score_gemma":0.0004680253,"threshold_uncertainty_score":0.44680098},"labels":[],"label_agreement":null},{"id":"W3045831398","doi":"10.1634/theoncologist.2020-0054","title":"Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Randomized controlled trial; Medicine; Confidence interval; Guideline; Subspecialty; Brier score; Sample size determination; Medical physics; Family medicine; Statistics; Surgery; Internal medicine; Mathematics","score_opus":0.6602040357516019,"score_gpt":0.6079458512679481,"score_spread":0.052258184483653825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045831398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.53801304,0.0008386511,0.000060721864,0.41625375,0.0003202219,0.0063451882,0.00003691859,0.000081180624,0.03805031],"genre_scores_gemma":[0.99315745,0.0012774611,0.00022470523,0.00343368,0.00032831178,0.00020746402,0.000009841925,0.00001553841,0.001345567],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932042,0.004047191,0.0013452448,0.00030773034,0.00078220444,0.00031342477],"domain_scores_gemma":[0.7511322,0.24668397,0.000726866,0.00094560464,0.00026808705,0.00024330876],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.029465212,0.00015840374,0.0018220402,0.00004169252,0.000088387846,0.000015892205,0.0006299085,0.0003099205,0.00025739038],"category_scores_gemma":[0.32100546,0.00006317904,0.0004949401,0.00041144283,0.0025956992,0.000015603704,0.00024416138,0.0015698686,0.000047974743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8679041,0.0045310743,0.026763655,0.0004809859,0.002510586,0.0005525488,0.009162645,0.0003893467,0.002299254,0.030841166,0.015680082,0.038884554],"study_design_scores_gemma":[0.8593111,0.008405362,0.08255006,0.00047959117,0.0020359112,0.000022606371,0.0017937238,0.0019051842,0.0024187535,0.03510158,0.0056875385,0.0002885665],"about_ca_topic_score_codex":0.00088594994,"about_ca_topic_score_gemma":0.0006955804,"teacher_disagreement_score":0.45514438,"about_ca_system_score_codex":0.00024360765,"about_ca_system_score_gemma":0.0010929852,"threshold_uncertainty_score":0.9993698},"labels":[],"label_agreement":null},{"id":"W3046214598","doi":"10.1634/theoncologist.2020-0167","title":"Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"American Cancer Society","keywords":"Medicine; Blockade; Lymphoma; Hodgkin lymphoma; Oncology; Intensive care medicine; Internal medicine","score_opus":0.08913903546279209,"score_gpt":0.3272881326373819,"score_spread":0.2381490971745898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046214598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8398444,0.00068115216,0.000012249625,0.14780883,0.00013764086,0.0012666036,0.000022927363,0.00016255875,0.010063603],"genre_scores_gemma":[0.98240924,0.0007411147,0.0006243824,0.014319134,0.00051694806,0.00029328855,0.000025654243,0.000031420495,0.0010388303],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851644,0.00011179608,0.00029978965,0.00041689645,0.0002672973,0.00038779693],"domain_scores_gemma":[0.9988136,0.0001623415,0.000087209395,0.00048789402,0.000056331002,0.00039261437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015270966,0.0003033712,0.00050068094,0.0000327752,0.00015211735,0.00003999914,0.00014234445,0.000092032285,0.00023225255],"category_scores_gemma":[0.000065540524,0.0001581504,0.0002472807,0.00022797428,0.00013235833,0.00002059818,0.00006718213,0.000052589232,0.0008299715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00822944,0.009614936,0.05251977,0.000059890142,0.00255195,0.0068819933,0.011919993,0.00022260417,0.09127668,0.002080034,0.0397348,0.7749079],"study_design_scores_gemma":[0.017411835,0.014017837,0.2198306,0.00005475525,0.00043179284,0.00041344613,0.0008515402,0.00014367333,0.2301878,0.000101522906,0.5161153,0.00043991863],"about_ca_topic_score_codex":0.0008412731,"about_ca_topic_score_gemma":0.00007820483,"teacher_disagreement_score":0.774468,"about_ca_system_score_codex":0.0011273363,"about_ca_system_score_gemma":0.00027168327,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W3046580696","doi":"10.1634/theoncologist.2020-0420","title":"Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Ottawa; University of Manitoba; BC Cancer Agency; Ottawa Hospital; University of British Columbia; CancerCare Manitoba","funders":"","keywords":"Outbreak; Pandemic; Coronavirus disease 2019 (COVID-19); Coronavirus; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Germ cell tumors; Disease; Medicine; Infectious disease (medical specialty); Pathology; Internal medicine","score_opus":0.21996722950197187,"score_gpt":0.41524940432469926,"score_spread":0.1952821748227274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046580696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561466,0.0003167925,0.00006136659,0.012217337,0.00017663855,0.00060798647,0.00020543211,0.000015979902,0.00078379596],"genre_scores_gemma":[0.99718565,0.0002731655,0.00001911972,0.0021608775,0.00004933388,0.0000142878025,0.000009916502,0.000010945838,0.00027671063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876,0.00014210248,0.00040651235,0.00014729964,0.00037810474,0.0001659677],"domain_scores_gemma":[0.99873066,0.00029622216,0.00037905786,0.00036772192,0.00009976698,0.00012659181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005396471,0.00010699189,0.00025576295,0.000021984562,0.0000641956,0.000004544027,0.0004560078,0.000031643107,0.000050923583],"category_scores_gemma":[0.0003704004,0.00005125837,0.000119149634,0.00015918183,0.00034334717,0.000021210293,0.00029384997,0.00015625203,0.0000022715385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025956978,0.0003759149,0.9834096,0.000746301,0.00013032724,0.000024316072,0.0024277337,0.00015987737,0.0071225446,0.00009624131,0.00031940546,0.0025920544],"study_design_scores_gemma":[0.0014559663,0.00013869225,0.9951739,0.00015205557,0.00007180949,0.0000051948473,0.0007026674,0.00020657021,0.0010257999,0.0000068636095,0.001013121,0.000047379475],"about_ca_topic_score_codex":0.004879947,"about_ca_topic_score_gemma":0.00042283113,"teacher_disagreement_score":0.011764294,"about_ca_system_score_codex":0.00023947906,"about_ca_system_score_gemma":0.00026648722,"threshold_uncertainty_score":0.73770523},"labels":[],"label_agreement":null},{"id":"W3080782372","doi":"10.1634/theoncologist.2020-0572","title":"Cancer and Risk of COVID-19 Through a General Community Survey","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Engineering and Physical Sciences Research Council; Medical Research Council; Stand Up To Cancer; Stiftelsen för Strategisk Forskning; National Institute for Health and Care Research; Medical Research Council Canada; Massachusetts Consortium on Pathogen Readiness; Wellcome Trust; Alzheimer's Society; King's College London; Seerave Foundation; Crohn's and Colitis Foundation; British Heart Foundation","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cancer; Pandemic; Medicine; Geography; Virology; Pathology; Disease; Internal medicine; Outbreak; Infectious disease (medical specialty)","score_opus":0.35047692151969706,"score_gpt":0.49412428660631635,"score_spread":0.1436473650866193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080782372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92280716,0.0010612434,0.00018554942,0.07464628,0.00006163326,0.00033343185,0.00021442257,0.000041494328,0.00064878736],"genre_scores_gemma":[0.9573867,0.0029792287,0.00014951633,0.039188076,0.000144539,0.000011110625,0.00001809674,0.000008800917,0.000113981296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985273,0.0008600974,0.00019846001,0.000107648026,0.00013436697,0.00017215786],"domain_scores_gemma":[0.99785537,0.0013658336,0.00014449713,0.00028634656,0.00007451237,0.00027343593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012262285,0.000093803756,0.00032511604,0.00001260028,0.00025390065,0.0000073601245,0.00014000807,0.00007790971,0.000093522365],"category_scores_gemma":[0.0042934855,0.00005726425,0.000040687137,0.00018349606,0.0004149567,0.000026483636,0.0001212024,0.0004965432,0.000004762503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013434435,0.00012727614,0.9534321,0.0004767119,0.00011615341,0.000015451893,0.011727454,0.00007608235,0.000357459,0.00020831285,0.027501067,0.004618494],"study_design_scores_gemma":[0.0016028746,0.0010761085,0.9505158,0.000018996208,0.00012698011,0.000009179188,0.00067238027,0.00019387527,0.00015788397,0.00033698577,0.04521353,0.0000754187],"about_ca_topic_score_codex":0.3241556,"about_ca_topic_score_gemma":0.050124597,"teacher_disagreement_score":0.274031,"about_ca_system_score_codex":0.00019473088,"about_ca_system_score_gemma":0.0011299243,"threshold_uncertainty_score":0.96720815},"labels":[],"label_agreement":null},{"id":"W3080952862","doi":"10.1634/theoncologist.2020-0379","title":"Therapeutic Potential of Afatinib in<i>NRG1</i>Fusion-Driven Solid Tumors: A Case Series","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Afatinib; Series (stratigraphy); Fusion; Computer science; Computational biology; Cancer research; Medicine; Biology; Internal medicine; Cancer","score_opus":0.08401261259245403,"score_gpt":0.391276329499115,"score_spread":0.307263716906661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080952862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519199,0.00052038283,0.00009977168,0.039873514,0.0001396433,0.0009874549,0.000028941338,0.00007121366,0.006359145],"genre_scores_gemma":[0.9969335,0.00016979185,0.00036102536,0.0018720522,0.00030877005,0.00006200618,0.0000058028745,0.00002455803,0.0002624911],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984466,0.0002324352,0.00038345854,0.0002392306,0.00036836314,0.00032993944],"domain_scores_gemma":[0.99911684,0.00016545098,0.00011411992,0.00035724207,0.00010639364,0.00013995357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004458724,0.00013820852,0.00042133665,0.000052380994,0.00008671461,0.000016365697,0.0002668863,0.000089249865,0.0005554445],"category_scores_gemma":[0.0003233141,0.00008910133,0.00009292184,0.00038964103,0.00058588164,0.00004907972,0.00019950945,0.00046815723,0.00006678515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017837463,0.0030437242,0.07944156,0.0030361416,0.00076995045,0.110645846,0.039773356,0.0028915694,0.5688971,0.0033831298,0.034145743,0.13613437],"study_design_scores_gemma":[0.05617683,0.07729437,0.16912164,0.004069704,0.0020136335,0.08738582,0.10249637,0.059682783,0.23536924,0.008606142,0.19376612,0.0040173647],"about_ca_topic_score_codex":0.00053608435,"about_ca_topic_score_gemma":0.0003204407,"teacher_disagreement_score":0.3335279,"about_ca_system_score_codex":0.00013321832,"about_ca_system_score_gemma":0.00050208525,"threshold_uncertainty_score":0.6081728},"labels":[],"label_agreement":null},{"id":"W3081953801","doi":"10.1634/theoncologist.2020-0193","title":"Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McMaster University; Trillium Health Centre; Juravinski Cancer Centre; Hôpital du Sacré-Cœur de Montréal; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Université de Montréal; William Osler Health System; University of Toronto; University of British Columbia","funders":"Pfizer Canada; Merck Canada; AstraZeneca Canada","keywords":"Medicine; Oncology; Tremelimumab; Lung cancer; Chemotherapy; Internal medicine; Durvalumab; Ipilimumab; Clinical trial; Immunotherapy; Radiation therapy; Maintenance therapy; Cancer; Stage (stratigraphy); Intensive care medicine; Nivolumab","score_opus":0.08041116675697593,"score_gpt":0.41151793173614376,"score_spread":0.3311067649791678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081953801","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011829392,0.9868995,7.095136e-7,0.002659098,0.00019750746,0.005315306,0.00008244396,0.00002065964,0.003641858],"genre_scores_gemma":[0.0064212405,0.9908865,0.000016380394,0.000047321533,0.00035416908,0.0015719826,0.000017806147,0.000047320907,0.0006372733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969484,0.0008120915,0.0009619638,0.00035907532,0.0004945208,0.0004239032],"domain_scores_gemma":[0.99675816,0.0013177855,0.00083132606,0.00088803936,0.00015665308,0.000048029855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013688327,0.00042176963,0.0022395318,0.00008978189,0.000124781,0.000014676552,0.0006848615,0.00014655662,0.000029972878],"category_scores_gemma":[0.000297506,0.00015475703,0.00071863737,0.0006243269,0.000725682,0.000015903392,0.00024820108,0.00064080843,0.0000048564402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004449196,0.001190292,0.001333886,0.02700494,0.0019604298,0.00024243549,0.0190607,0.0000348388,0.00021094532,0.00011094033,0.00052579626,0.94787985],"study_design_scores_gemma":[0.00090781366,0.0011857023,0.00044092856,0.004599987,0.0020285281,0.000009411166,0.004313806,0.000036496785,0.00046936126,0.000010336034,0.9858372,0.00016041286],"about_ca_topic_score_codex":0.005150838,"about_ca_topic_score_gemma":0.0009895732,"teacher_disagreement_score":0.98531145,"about_ca_system_score_codex":0.0011278103,"about_ca_system_score_gemma":0.0011239847,"threshold_uncertainty_score":0.77865607},"labels":[],"label_agreement":null},{"id":"W3087595029","doi":"10.1002/onco.13534","title":"Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Sex and Gender in Healthcare","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical trial; Cancer; Odds ratio; Population; Incidence (geometry); Confidence interval; Hazard ratio; Colorectal cancer; Lung cancer","score_opus":0.4713897760368523,"score_gpt":0.5288085882184081,"score_spread":0.05741881218155587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087595029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558037,0.0005897995,0.000025753758,0.0420145,0.00008780738,0.001001285,0.000022127038,0.00006746337,0.0003875985],"genre_scores_gemma":[0.9954541,0.0003078346,0.00007531706,0.0035036588,0.00030920494,0.00010108147,0.000032973698,0.000012534382,0.00020333286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685663,0.0015564814,0.000765723,0.00036691112,0.00021398765,0.00024024979],"domain_scores_gemma":[0.9957212,0.0035250606,0.0003494534,0.00020376354,0.00006239375,0.00013813094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038889032,0.00013481533,0.0010094361,0.000027065422,0.00008537748,0.000017683737,0.00010666447,0.00015633798,0.000025741216],"category_scores_gemma":[0.005183235,0.00007244226,0.00007500953,0.00024174884,0.0003116993,0.000029676086,0.0000548471,0.00037044287,0.0000037166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000383018,0.000058075948,0.98674047,0.00007674242,0.00012689951,0.000050193743,0.0021543177,0.000013211824,0.000073913536,0.000021117146,0.0021404545,0.008161578],"study_design_scores_gemma":[0.0034276848,0.00070680195,0.9879342,0.00012092884,0.00022844659,0.000009543323,0.005567791,0.00031040222,0.00087131036,0.00042703637,0.00026842518,0.00012747063],"about_ca_topic_score_codex":0.0005138226,"about_ca_topic_score_gemma":0.00028266132,"teacher_disagreement_score":0.039650396,"about_ca_system_score_codex":0.000092716764,"about_ca_system_score_gemma":0.00019398911,"threshold_uncertainty_score":0.62051904},"labels":[],"label_agreement":null},{"id":"W3088260985","doi":"10.1002/onco.13540","title":"D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; National Institutes of Health","keywords":"Medicine; Apixaban; Placebo; Ambulatory; Internal medicine; Number needed to treat; Hazard ratio; Cohort; Randomization; Randomized controlled trial; Surgery; Warfarin; Confidence interval; Relative risk; Rivaroxaban; Pathology; Atrial fibrillation","score_opus":0.016637845471905083,"score_gpt":0.26783478285282286,"score_spread":0.25119693738091775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088260985","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074095,0.0006400555,0.000020080985,0.004559769,0.0001504321,0.0008654211,0.000014489353,0.00006481614,0.0029439698],"genre_scores_gemma":[0.99414504,0.000543325,0.00022493268,0.004673874,0.00015146383,0.00013617834,0.000012117032,0.00002103205,0.00009203542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989159,0.000065865206,0.00020629821,0.0002830396,0.00026876683,0.00026012262],"domain_scores_gemma":[0.9993981,0.000053349722,0.00015324466,0.00024076241,0.000060937553,0.00009358124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015073267,0.00015566361,0.00040490532,0.000027743197,0.000101477046,0.000014780859,0.00015835285,0.000056622426,0.00045585705],"category_scores_gemma":[0.00006553206,0.000084491905,0.000060732273,0.00029404662,0.0002049888,0.00005187944,0.000079651596,0.00025608155,0.00007344664],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071926217,0.0018406376,0.94524074,0.00018120717,0.00055263465,0.00003775064,0.0040823375,0.0005380455,0.0009776227,0.00022928722,0.027390094,0.018210381],"study_design_scores_gemma":[0.0017018626,0.0014221208,0.98277414,0.00005131629,0.0001700949,1.8672391e-7,0.00027676745,0.000101486374,0.00090429175,0.000035209094,0.012429136,0.00013341758],"about_ca_topic_score_codex":0.0017873684,"about_ca_topic_score_gemma":0.00072222186,"teacher_disagreement_score":0.037533373,"about_ca_system_score_codex":0.00012842855,"about_ca_system_score_gemma":0.000089465335,"threshold_uncertainty_score":0.4991315},"labels":[],"label_agreement":null},{"id":"W3097964344","doi":"10.1002/onco.13586","title":"Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Medical Research Council Canada; AstraZeneca; University College London; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Pulmonologists; Multidisciplinary approach; Medicine; Best practice; Health care; Intensive care medicine; Medical physics","score_opus":0.07099644965333216,"score_gpt":0.4012783948059526,"score_spread":0.33028194515262044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097964344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015946027,0.9773686,0.0000040139,0.012601416,0.00020961367,0.006274489,0.00012760884,0.00003675732,0.0017828975],"genre_scores_gemma":[0.003637667,0.98460215,0.00031681478,0.0017388939,0.0005186696,0.008869559,0.00018585616,0.0000682815,0.000062075866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977805,0.0003535042,0.00058432645,0.00066806405,0.00022897536,0.00038460674],"domain_scores_gemma":[0.9917272,0.007084069,0.00031136876,0.0006876458,0.000019704037,0.00017001264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029882893,0.00061739923,0.001680178,0.000035550787,0.0003632468,0.000044438057,0.00032020273,0.00020152456,0.000019154673],"category_scores_gemma":[0.00013150883,0.00026129617,0.0003635975,0.0002747436,0.00022032704,0.000019404295,0.00030537936,0.0008076809,0.000015777217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055756922,0.0018779157,0.0024919377,0.0012016676,0.00042719688,0.00021351613,0.0024620402,0.00002280167,1.9219739e-7,0.000008511703,0.02075013,0.9704883],"study_design_scores_gemma":[0.003583287,0.0025957539,0.0009813923,0.041756116,0.004381597,0.000072226125,0.0019584196,0.0007106272,0.000009496007,0.0000096876975,0.94339716,0.00054421986],"about_ca_topic_score_codex":0.0027466477,"about_ca_topic_score_gemma":0.00050482893,"teacher_disagreement_score":0.9699441,"about_ca_system_score_codex":0.0031736318,"about_ca_system_score_gemma":0.0003678241,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W3107319220","doi":"10.1002/onco.13619","title":"Edmonton Symptom Assessment Scale Time Duration of Self-Completion Versus Assisted Completion in Patients with Advanced Cancer: A Randomized Comparison","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health; American Society of Clinical Oncology","keywords":"Medicine; Interquartile range; Randomized controlled trial; Quality of life (healthcare); Physical therapy; Stopwatch; Health literacy; Cancer; Health care; Internal medicine; Nursing","score_opus":0.0220338104379046,"score_gpt":0.31391132910199093,"score_spread":0.29187751866408634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107319220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138653,0.00010610019,0.0005291323,0.0032211656,0.00021307722,0.0016486521,0.000027510534,0.000083201914,0.0027846252],"genre_scores_gemma":[0.9986187,0.00003436982,0.0005688065,0.00023395139,0.00007006656,0.00017742484,0.00026355236,0.000014469351,0.000018609304],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983538,0.0003458901,0.00047638838,0.00022984402,0.00042952498,0.00016457723],"domain_scores_gemma":[0.99886894,0.00027109717,0.00038615757,0.00018992375,0.00021454431,0.00006932442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038562564,0.00015363119,0.0007935145,0.00004428664,0.00006677983,0.000013286321,0.000103120954,0.00006965136,0.00010747059],"category_scores_gemma":[0.00006419953,0.000100053825,0.00008979034,0.00030871757,0.00015539902,0.00006470986,0.00003189911,0.0001989508,0.00000701351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55410457,0.0019942038,0.4135053,0.00035979383,0.00046093247,0.000005534797,0.0058748894,0.0015613341,0.0037900861,0.00026418065,0.0010746835,0.0170045],"study_design_scores_gemma":[0.18996635,0.0024573442,0.79318833,0.00015873167,0.0003869622,5.2669867e-7,0.0004722511,0.012000635,0.0002689879,0.000006215447,0.00093218335,0.00016147285],"about_ca_topic_score_codex":0.0011596138,"about_ca_topic_score_gemma":0.002608171,"teacher_disagreement_score":0.37968305,"about_ca_system_score_codex":0.0005848399,"about_ca_system_score_gemma":0.000159773,"threshold_uncertainty_score":0.40800768},"labels":[],"label_agreement":null},{"id":"W3107519578","doi":"10.1002/onco.13570","title":"Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Intensive care medicine; Cancer; Venous thromboembolism; Malignancy; Thrombosis; Population; MEDLINE; Best practice; Surgery; Internal medicine; Environmental health","score_opus":0.1017201912939881,"score_gpt":0.35207370136422816,"score_spread":0.2503535100702401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107519578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5432292,0.0050027105,0.001052972,0.21212138,0.00032297758,0.0026196048,0.00002665611,0.00042791254,0.23519658],"genre_scores_gemma":[0.9915211,0.0014965408,0.00026813362,0.005947741,0.00022817799,0.00025325842,0.00001073401,0.0000174326,0.0002568735],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99919164,0.0000586769,0.00015746732,0.00024325997,0.00012186816,0.00022707693],"domain_scores_gemma":[0.9994901,0.000074804535,0.00005441693,0.00016494669,0.000054166696,0.00016158032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025301994,0.00012072712,0.00034776228,0.000032622167,0.00023251396,0.00002702979,0.00012568051,0.00005465646,0.000046981513],"category_scores_gemma":[0.00016831903,0.000082174476,0.00004785289,0.0002668863,0.00008239465,0.000029178644,0.00016335824,0.00014484611,0.00005977546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001905137,0.009522477,0.009916038,0.0011404178,0.0027564105,0.000028455574,0.122962,0.0028296146,0.006371527,0.062748425,0.7134159,0.06811821],"study_design_scores_gemma":[0.0046070614,0.0028490631,0.74148935,0.0004612608,0.0023610748,0.0000082106135,0.018760042,0.012265276,0.0006022507,0.00069954694,0.21506462,0.00083221705],"about_ca_topic_score_codex":0.0002479189,"about_ca_topic_score_gemma":0.00017119189,"teacher_disagreement_score":0.73157334,"about_ca_system_score_codex":0.0001358613,"about_ca_system_score_gemma":0.000072705756,"threshold_uncertainty_score":0.3350978},"labels":[],"label_agreement":null},{"id":"W3109542415","doi":"10.1002/onco.13596","title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Clinical Practice; Disease management; Intensive care medicine; MEDLINE; Disease; Cancer; Best practice; Evidence-based practice; Alternative medicine; Family medicine; Pathology; Health management system; Political science; Internal medicine","score_opus":0.2789887118213781,"score_gpt":0.49205105712313496,"score_spread":0.21306234530175688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109542415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000034411764,0.96331805,0.000035889127,0.027016507,0.0006905168,0.0053580175,0.00020296543,0.00006829199,0.0033063362],"genre_scores_gemma":[0.000034221423,0.99163043,0.00030139036,0.0041305674,0.00042451327,0.0023989023,0.00010986567,0.00006620293,0.0009039033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792355,0.00011149364,0.00086603715,0.00039686664,0.000372462,0.00032959532],"domain_scores_gemma":[0.9976475,0.00051128445,0.00082449336,0.0007474095,0.00020799568,0.00006130372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084242277,0.00040673328,0.0023756844,0.000053227745,0.00021348342,0.00002584132,0.0007285977,0.00017059236,0.00014629046],"category_scores_gemma":[0.00016429182,0.00017947129,0.0008155142,0.00037501816,0.00019572009,0.000012777283,0.00029392596,0.0002786236,0.000064726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019042469,0.00029947428,0.0000010243872,0.0076503307,0.004483622,0.000008060162,0.00002595788,0.000011999958,6.920966e-8,0.003805158,0.2419197,0.7417756],"study_design_scores_gemma":[0.0005221573,0.00051571627,0.0001623626,0.010025767,0.018305227,9.174875e-7,0.00012558365,0.000024329556,0.0000014877068,0.000089487025,0.97005624,0.00017069868],"about_ca_topic_score_codex":0.00026925915,"about_ca_topic_score_gemma":0.00010232985,"teacher_disagreement_score":0.74160486,"about_ca_system_score_codex":0.00039869233,"about_ca_system_score_gemma":0.00018876519,"threshold_uncertainty_score":0.73186266},"labels":[],"label_agreement":null},{"id":"W3109953138","doi":"10.1002/onco.13626","title":"Implementing <i>DPYD*2A</i> Genotyping in Clinical Practice: The Quebec, Canada, Experience","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Intégré de Santé et de Services Sociaux des Laurentides; Centre Hospitalier Universitaire de Sherbrooke; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Développement Economique Longueuil; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"DPYD; Medicine; Mucositis; Internal medicine; Chemotherapy; Capecitabine; Genotyping; Dihydropyrimidine dehydrogenase; Oncology; Fluorouracil; Gastroenterology; Rash; Cancer; Pharmacogenetics; Genotype; Colorectal cancer; Genetics","score_opus":0.07498892060660377,"score_gpt":0.40888616775684533,"score_spread":0.33389724715024155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109953138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7006398,0.0028411164,0.000023657622,0.26359484,0.0003463933,0.00076222955,0.0000059783665,0.00003633324,0.031749662],"genre_scores_gemma":[0.97487307,0.0002787803,0.00012720274,0.023863288,0.00034420553,0.00008039075,0.000002417858,0.000007512193,0.00042314205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99874574,0.0001440349,0.00036923133,0.00021029373,0.00021643768,0.00031423412],"domain_scores_gemma":[0.9987601,0.00078635133,0.00014184456,0.00018931356,0.00005483688,0.00006754382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059362064,0.000105847306,0.00024943246,0.000005939515,0.0003066615,0.000022064149,0.00016849418,0.00002994548,0.00007073748],"category_scores_gemma":[0.0012654722,0.00005187604,0.000055008717,0.00017641537,0.00020509647,0.000043673666,0.00020498021,0.00029032424,0.0000068299573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037130045,0.0006400606,0.43558377,0.00008827295,0.00071401615,0.0015345564,0.042869914,0.00004860959,0.0003884559,0.0016594251,0.18771632,0.3250436],"study_design_scores_gemma":[0.00096897996,0.00029194434,0.24952935,0.000016461594,0.00009850791,0.000015404294,0.020999841,0.000108181666,0.000060513168,0.0000100067455,0.7278167,0.00008411072],"about_ca_topic_score_codex":0.6422712,"about_ca_topic_score_gemma":0.95641625,"teacher_disagreement_score":0.5401004,"about_ca_system_score_codex":0.0003604555,"about_ca_system_score_gemma":0.0007196397,"threshold_uncertainty_score":0.36011094},"labels":[],"label_agreement":null},{"id":"W3111161573","doi":"10.1002/onco.13628","title":"A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma","keywords":"Axitinib; Medicine; Renal cell carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Population; Oncology; Phases of clinical research; Nausea; Gastroenterology; Urology; Pharmacology; Randomized controlled trial; Clinical trial; Sunitinib","score_opus":0.0631375381713145,"score_gpt":0.31530819442871005,"score_spread":0.25217065625739554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111161573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901128,0.00024541627,0.0000063479733,0.0004334597,0.00003858366,0.005866497,0.000017260238,0.000038135822,0.0032414983],"genre_scores_gemma":[0.9990435,0.000009067845,0.00018555559,0.00011727532,0.000032493925,0.00034825428,0.000069122485,0.000029617036,0.00016508071],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997507,0.00071937457,0.00064264424,0.0003719818,0.00045089447,0.00030812807],"domain_scores_gemma":[0.9982857,0.00061695796,0.00037798085,0.00041528395,0.00013384853,0.00017019158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047816618,0.00029226788,0.001257682,0.00008483262,0.00008217178,0.000009606789,0.0001913696,0.000044561482,0.00009832968],"category_scores_gemma":[0.00027815375,0.00015040365,0.00015131549,0.0004299999,0.00027927037,0.00003972429,0.00009777434,0.00023487372,0.0000130342205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94024384,0.016732115,0.026589097,0.00013802623,0.0006099156,0.00094371877,0.012230214,0.00010499508,0.0005053818,0.000007919821,0.0002839728,0.0016107946],"study_design_scores_gemma":[0.89409196,0.08115951,0.017030671,0.000041091615,0.0025190315,0.000005652544,0.0018743585,0.00024073986,0.0028175663,0.0000038976573,0.000051957606,0.00016356193],"about_ca_topic_score_codex":0.00089550606,"about_ca_topic_score_gemma":0.00020317211,"teacher_disagreement_score":0.06442739,"about_ca_system_score_codex":0.00022579989,"about_ca_system_score_gemma":0.00017458372,"threshold_uncertainty_score":0.6133283},"labels":[],"label_agreement":null},{"id":"W3113051965","doi":"10.1002/onco.13625","title":"Timing of Palliative Care Referral Before and After Evidence from Trials Supporting Early Palliative Care","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Kelowna General Hospital; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Toronto","keywords":"Palliative care; Referral; Medicine; Nursing; Intensive care medicine; Family medicine","score_opus":0.40214878206941823,"score_gpt":0.4974772671245456,"score_spread":0.09532848505512737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113051965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833655,0.012477085,0.0001231717,0.002269721,0.00009012714,0.0006216294,0.00023162819,0.00003347103,0.0007877021],"genre_scores_gemma":[0.99531984,0.0006045546,0.0030875,0.0004954492,0.00033618297,0.000044753982,0.00004977413,0.000018949899,0.000043019303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981184,0.00030178693,0.00069982384,0.00032648977,0.00031820536,0.00023530962],"domain_scores_gemma":[0.997105,0.0014611592,0.00065251853,0.00024212396,0.00041170942,0.00012751229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038280143,0.00021280009,0.0009957792,0.000033516466,0.00006789378,0.000014480631,0.00017866031,0.00013895541,0.00012907835],"category_scores_gemma":[0.0045276782,0.00013169543,0.000185945,0.00017238801,0.00037941142,0.00008568611,0.0001483389,0.0002778062,0.000008208555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014288373,0.000016378059,0.7533699,0.00037768646,0.0001929565,0.00005490129,0.23534365,0.0000047927324,0.002062258,0.000019458485,0.00018187983,0.0069472785],"study_design_scores_gemma":[0.0019333351,0.0026110816,0.85400647,0.0033464695,0.00080572796,3.3519166e-7,0.11187853,0.00006885784,0.023986194,0.00014169133,0.0010140167,0.00020731168],"about_ca_topic_score_codex":0.0011437482,"about_ca_topic_score_gemma":0.00046426404,"teacher_disagreement_score":0.12346512,"about_ca_system_score_codex":0.00013740353,"about_ca_system_score_gemma":0.00016146692,"threshold_uncertainty_score":0.5420381},"labels":[],"label_agreement":null},{"id":"W3114428517","doi":"10.1002/onco.13651","title":"In Reply","year":2020,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Medicine; Intensive care medicine; Epistemology; Psychology; Philosophy; Internal medicine","score_opus":0.14115873482929422,"score_gpt":0.427964403193791,"score_spread":0.2868056683644967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114428517","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022974201,0.00031868138,0.0000039959623,0.9846633,0.00052498205,0.0006101385,0.00001478126,0.00008041164,0.013553983],"genre_scores_gemma":[0.003909056,0.00017090474,0.00004893488,0.9773286,0.007778742,0.00003412871,0.000063281586,0.000032415763,0.010633947],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986061,0.00014748833,0.00030623047,0.00029811906,0.00027207463,0.00037002936],"domain_scores_gemma":[0.99861336,0.0005694158,0.0001318428,0.00055857433,0.000038633705,0.00008814925],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00028111145,0.00018643675,0.00052889076,0.00008026268,0.000055637254,0.00001564186,0.0002343812,0.00040187337,0.00033652],"category_scores_gemma":[0.0010539688,0.0001122086,0.00010819942,0.0002218411,0.00017981298,0.000020506772,0.00008529366,0.0029866525,0.00052254734],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010031335,0.000017590432,0.00029030396,0.00033760225,0.000015405602,0.007558408,0.0002563286,2.0207666e-7,0.000011143432,0.000013639959,0.99005336,0.0013457325],"study_design_scores_gemma":[0.0005237572,0.00053286634,0.0026099219,0.0001260849,0.000056556062,0.000107736625,0.00002512279,0.0000062059485,0.000010007805,0.000492631,0.99540013,0.000108968976],"about_ca_topic_score_codex":0.0026477762,"about_ca_topic_score_gemma":0.00023946133,"teacher_disagreement_score":0.0074506714,"about_ca_system_score_codex":0.00065178314,"about_ca_system_score_gemma":0.001207036,"threshold_uncertainty_score":0.9993135},"labels":[],"label_agreement":null},{"id":"W3123647779","doi":"10.1002/onco.13684","title":"Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Internal medicine; Neutropenia; Breast cancer; Oncology; Adverse effect; Hazard ratio; Tolerability; Cumulative incidence; Febrile neutropenia; Cancer; Gastroenterology; Gynecology; Metastatic breast cancer; Chemotherapy; Confidence interval; Cohort","score_opus":0.01612740092076149,"score_gpt":0.3158817434457096,"score_spread":0.2997543425249481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123647779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029624,0.00034759572,0.0037328242,0.002554584,0.00006217592,0.0014397367,0.00147992,0.0000435363,0.0000433974],"genre_scores_gemma":[0.9955052,0.0003688488,0.0019794053,0.00025420618,0.000038758863,0.0002925017,0.001128467,0.00004849505,0.00038409152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975629,0.00028603183,0.00069763314,0.0005781936,0.0004595155,0.00041572747],"domain_scores_gemma":[0.9970128,0.0004657038,0.00069271616,0.0005393301,0.0011598748,0.00012957728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027691716,0.00034004837,0.0015661446,0.0005462464,0.00010825319,0.000014129873,0.00025255885,0.000088368404,0.00046843593],"category_scores_gemma":[0.00008919055,0.00023693588,0.0003267347,0.004427354,0.00042575982,0.00017502352,0.000058486898,0.00022674103,0.0000010473481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10125609,0.0016871373,0.5510764,0.00011498919,0.037486285,0.000056881814,0.006944628,0.0043596677,0.18849908,0.0004143239,0.00006565797,0.10803885],"study_design_scores_gemma":[0.017235262,0.0020760037,0.9260155,0.00011591228,0.0035513751,0.000007995188,0.0010943786,0.00008162158,0.04946535,0.000030289979,0.000047910984,0.00027838486],"about_ca_topic_score_codex":0.00096760824,"about_ca_topic_score_gemma":0.0054420023,"teacher_disagreement_score":0.3749391,"about_ca_system_score_codex":0.00065559574,"about_ca_system_score_gemma":0.00029824258,"threshold_uncertainty_score":0.96619654},"labels":[],"label_agreement":null},{"id":"W3125242144","doi":"10.1002/onco.13692","title":"Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neurofibromatosis and Schwannoma Cases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Malignant peripheral nerve sheath tumor; Peripheral; Peripheral nerve; Nuclear export signal; Cancer research; Surgery; Pathology; Internal medicine; Anatomy; Cell nucleus","score_opus":0.033631520149199984,"score_gpt":0.29399889639403337,"score_spread":0.2603673762448334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125242144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869201,0.0015415956,0.0000055053165,0.009680277,0.00023675652,0.000873241,0.000041786756,0.000029651455,0.0006710759],"genre_scores_gemma":[0.9965176,0.00036610808,0.000826879,0.0005375923,0.0002270541,0.00020414853,0.000016263246,0.000027243133,0.0012770909],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989243,0.00006105875,0.0003843153,0.0002448162,0.0001494696,0.0002360123],"domain_scores_gemma":[0.99892694,0.00037488114,0.0001240902,0.00043794423,0.000082047845,0.000054095453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017462039,0.00015794642,0.0004144509,0.000021698143,0.00014042233,0.000017810553,0.00010470228,0.000046138426,0.00010152733],"category_scores_gemma":[0.00012524627,0.00007670195,0.00020682353,0.0001544376,0.0001740043,0.000031563904,0.000036651916,0.000079869336,0.0000045963693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02881256,0.03016004,0.090052694,0.0016918186,0.001319065,0.021717774,0.019146781,0.0020009652,0.60468316,0.013483404,0.108529866,0.078401886],"study_design_scores_gemma":[0.01307536,0.015167291,0.07023396,0.00041312276,0.0004651687,0.0014945171,0.00899928,0.0029704846,0.068875,0.00012664938,0.8177863,0.0003928731],"about_ca_topic_score_codex":0.00008874534,"about_ca_topic_score_gemma":0.00025670175,"teacher_disagreement_score":0.7092564,"about_ca_system_score_codex":0.00017831051,"about_ca_system_score_gemma":0.00018389261,"threshold_uncertainty_score":0.31278148},"labels":[],"label_agreement":null},{"id":"W3144358433","doi":"10.1002/onco.13783","title":"Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review","year":2021,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; MEDLINE; Genomic sequencing; Exome sequencing; Inclusion (mineral); Test (biology); Medical education; Family medicine; Psychology; Genome; Genetics; Biology","score_opus":0.11855698234563061,"score_gpt":0.3682822482625384,"score_spread":0.2497252659169078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3144358433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009743801,0.9965691,0.00003978302,0.00011356778,0.00032468518,0.0011348431,0.000084805826,0.000010877331,0.000747945],"genre_scores_gemma":[0.0008320392,0.99600214,0.00044087996,0.00045452663,0.0005312414,0.00044339703,0.0009569977,0.00003706548,0.0003017174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814737,0.00041206635,0.00051637646,0.00060111785,0.000089174886,0.00023391558],"domain_scores_gemma":[0.9986022,0.00023517931,0.00043189322,0.00040757214,0.00022635121,0.00009677383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036693897,0.00036703024,0.0009552285,0.000039249335,0.00035124228,0.00009613741,0.00020792916,0.00022797195,0.00000978793],"category_scores_gemma":[0.0012106511,0.00025998917,0.00019794883,0.00015462215,0.00029872733,0.000005714354,0.00036302203,0.00023207958,0.0000050283784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012960493,0.00019164833,0.000025658795,0.00823614,0.00038930302,0.000024954754,0.0009902156,0.000004623285,0.0005937969,0.00026778254,0.05922192,0.930041],"study_design_scores_gemma":[0.00028641362,0.00032399953,0.0000062798504,0.0032323436,0.0005485683,0.000057333982,0.00040966374,0.000016895658,0.000057839774,0.000006578222,0.9947098,0.00034432052],"about_ca_topic_score_codex":0.000030482757,"about_ca_topic_score_gemma":0.00037454313,"teacher_disagreement_score":0.93548787,"about_ca_system_score_codex":0.0002572548,"about_ca_system_score_gemma":0.00089909247,"threshold_uncertainty_score":0.9999852},"labels":[],"label_agreement":null},{"id":"W314684632","doi":"10.1634/theoncologist.2019-0628","title":"Doctoral Recital: 2007-04-18 - Alfredo Arjona, piano","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Music Technology and Sound Studies","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Piano; Art; Humanities; Art history; Visual arts","score_opus":0.05259014567133634,"score_gpt":0.30740841247236217,"score_spread":0.2548182668010258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W314684632","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18038923,0.0020940157,0.21893847,0.02450002,0.00633241,0.00061132136,0.000008588543,0.0019345568,0.5651914],"genre_scores_gemma":[0.9750888,0.00005780263,0.011300243,0.0029403002,0.00038294756,0.00001905059,0.0000015770186,0.000008662695,0.010200618],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987044,0.00006350525,0.00024502762,0.0003162907,0.00019944175,0.00047133738],"domain_scores_gemma":[0.99861187,0.0003799782,0.000109978944,0.0007867249,0.00005803007,0.00005342827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012557089,0.0001526123,0.0002017544,0.00006612383,0.00048557692,0.000066926725,0.0015720058,0.0001651082,0.00013369008],"category_scores_gemma":[0.00016926552,0.00009807687,0.00007419765,0.00035678578,0.00067273166,0.0001569757,0.0005418747,0.000324878,0.00033558864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047450983,0.00019616583,0.0046725553,0.0000076238102,0.00008202943,0.0002279403,0.0018021464,0.0000093135195,0.0001775201,0.47436386,0.4236596,0.09475379],"study_design_scores_gemma":[0.00046657326,0.000338648,0.043676898,0.000010168717,0.000015481288,0.000080811296,0.00033944394,0.00017250994,0.00027124368,0.044005632,0.91033065,0.0002919295],"about_ca_topic_score_codex":0.00017394153,"about_ca_topic_score_gemma":0.0005103477,"teacher_disagreement_score":0.79469955,"about_ca_system_score_codex":0.00010474732,"about_ca_system_score_gemma":0.00005462909,"threshold_uncertainty_score":0.4313425},"labels":[],"label_agreement":null},{"id":"W3148647097","doi":"10.1634/theoncologist.9-90005-55","title":"rHuEPO and Treatment Outcomes: the Clinical Experience","year":2004,"lang":"en","type":"review","venue":"The Oncologist","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.2774252065710417,"score_gpt":0.5205807751593616,"score_spread":0.24315556858831994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148647097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021544937,0.988028,0.0000016339892,0.0049270797,0.00038238207,0.0017134814,0.000011829163,0.000061076564,0.004659061],"genre_scores_gemma":[0.000199718,0.990988,0.00022694505,0.00053550635,0.00031225616,0.0004388973,0.00002514367,0.0000296885,0.0072438344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981992,0.00027641802,0.0006529661,0.000411218,0.00018620651,0.00027396408],"domain_scores_gemma":[0.9975424,0.0011554414,0.00029750096,0.000856541,0.000021480955,0.00012663253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004054551,0.0004274084,0.0017772363,0.0000230693,0.00025577677,0.000033184075,0.00024163467,0.0002845964,0.000102655686],"category_scores_gemma":[0.0001785621,0.00013495708,0.0006668359,0.000108770444,0.0013277091,0.0000126698515,0.00011710904,0.00040228124,0.000182153],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014425392,0.0005077456,0.00054567866,0.0007073254,0.00034157056,0.000210005,0.00034431313,5.132727e-8,1.2656498e-8,0.00026325742,0.00073578296,0.99632984],"study_design_scores_gemma":[0.0010377559,0.0013170523,0.00050542125,0.0025292109,0.002065954,0.00048556048,0.00039559611,1.7926978e-7,1.7516663e-7,0.000031154126,0.9914929,0.00013901414],"about_ca_topic_score_codex":0.0001829889,"about_ca_topic_score_gemma":0.000044972065,"teacher_disagreement_score":0.99619085,"about_ca_system_score_codex":0.0006236132,"about_ca_system_score_gemma":0.00066837424,"threshold_uncertainty_score":0.55033904},"labels":[],"label_agreement":null},{"id":"W3157026044","doi":"10.1002/onco.13803","title":"Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute for Health and Care Research; Sanofi","keywords":"Medicine; Taxane; Prostate cancer; Post-hoc analysis; Internal medicine; Chemotherapy; Quality of life (healthcare); Oncology; Clinical trial; Cancer; Prostate-specific antigen; Physical therapy; Breast cancer","score_opus":0.05615861530145853,"score_gpt":0.3824828340930081,"score_spread":0.32632421879154955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157026044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572676,0.007817167,6.5420465e-7,0.03350771,0.000028470968,0.0011785812,0.00014848605,0.000011412228,0.00003995893],"genre_scores_gemma":[0.99604154,0.0018390897,0.0000468135,0.0016067579,0.000008577861,0.00035170314,0.000022694403,0.000008396205,0.00007443308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821955,0.0006011143,0.00044744686,0.00026440012,0.0002516432,0.00021581938],"domain_scores_gemma":[0.9982916,0.0007233963,0.00027143722,0.00033402926,0.00029503996,0.00008450001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013431312,0.00013094705,0.00061329565,0.00007646311,0.00014332202,0.000017658538,0.00007638132,0.00003090897,0.000009334101],"category_scores_gemma":[0.00066943595,0.000060980365,0.00005815628,0.0009636886,0.0002474399,0.000037658097,0.000075667806,0.00012949864,6.239816e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068458538,0.00039510507,0.9765685,0.000079164565,0.00095446315,0.000022235768,0.010095419,0.000114654984,0.000022199763,0.000020491965,0.00012108307,0.004760826],"study_design_scores_gemma":[0.0021009652,0.0017320488,0.98365396,0.00016277279,0.00033394428,7.062888e-7,0.011671195,0.000007723593,0.00007924657,0.000018897723,0.00016824222,0.000070283146],"about_ca_topic_score_codex":0.0033254696,"about_ca_topic_score_gemma":0.0130701475,"teacher_disagreement_score":0.038773973,"about_ca_system_score_codex":0.00040869045,"about_ca_system_score_gemma":0.0004117673,"threshold_uncertainty_score":0.7293449},"labels":[],"label_agreement":null},{"id":"W3157276232","doi":"10.1002/onco.13804","title":"Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Aromatase inhibitor; Breast cancer; Cohort; Letrozole; Metastatic breast cancer; Palbociclib; Cancer; Clinical trial; Estrogen receptor; Aromatase","score_opus":0.01295471819976937,"score_gpt":0.2979926871360865,"score_spread":0.28503796893631717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157276232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955664,0.00027745217,0.00023465442,0.00055153423,0.00010614859,0.0012077455,0.0005011473,0.00009691223,0.0014579635],"genre_scores_gemma":[0.9984083,0.000110595574,0.0005446876,0.00007887064,0.00006246689,0.000240272,0.00015030506,0.000056692174,0.00034779988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981046,0.00028481506,0.0003141922,0.0004337441,0.00047512248,0.00038752475],"domain_scores_gemma":[0.9980512,0.0002893925,0.00028862266,0.0005789495,0.0006499991,0.00014179647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018680576,0.00035180917,0.0008778638,0.000058592937,0.00013442097,0.000019445275,0.0001390151,0.00005895512,0.00014224571],"category_scores_gemma":[0.000010159527,0.00018063224,0.00008863102,0.0005900406,0.00087575294,0.00010315072,0.0000376518,0.00018855454,0.0000021837682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04621675,0.0017135576,0.926801,0.000346537,0.0014652341,0.00031564242,0.0006918163,0.004451909,0.001982386,0.000083669736,0.000042898257,0.015888603],"study_design_scores_gemma":[0.016937004,0.0025511757,0.9616889,0.0011332133,0.0005651831,0.00006694893,0.00041395877,0.000031081512,0.015823733,0.000030050116,0.0005187061,0.00024009706],"about_ca_topic_score_codex":0.004953731,"about_ca_topic_score_gemma":0.009819921,"teacher_disagreement_score":0.03488785,"about_ca_system_score_codex":0.0012095186,"about_ca_system_score_gemma":0.0008011834,"threshold_uncertainty_score":0.7488592},"labels":[],"label_agreement":null},{"id":"W3158544382","doi":"10.1002/onco.13808","title":"Lost in Transition? Thoughts on Retirement, Part 2. “Should I Stay or Should I Go Now?”","year":2021,"lang":"en","type":"letter","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University of Calgary; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Face (sociological concept); Plan (archaeology); Pandemic; Retirement planning; Transition (genetics); Burnout; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Psychology; Medicine; Business; Actuarial science; Sociology; History; Clinical psychology","score_opus":0.3115314209543923,"score_gpt":0.45137995837862516,"score_spread":0.13984853742423287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158544382","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025868788,0.00047911092,0.00002593234,0.9804053,0.0014364653,0.0016901247,0.00024741085,0.000116119656,0.013012714],"genre_scores_gemma":[0.008488053,0.0013657635,0.00006825641,0.9369541,0.013527166,0.00012929029,0.0007994194,0.000101821504,0.038566146],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99591476,0.0006365916,0.00078722934,0.00077846274,0.0009564923,0.0009264422],"domain_scores_gemma":[0.99680597,0.001314441,0.0002739596,0.0012396605,0.00016402378,0.00020196446],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010182221,0.0005717327,0.0011719989,0.0002349836,0.00018861175,0.000068298184,0.00038599496,0.0014793309,0.0017062882],"category_scores_gemma":[0.0005498549,0.0003374971,0.00027844516,0.0005506582,0.00034152388,0.0000542022,0.000076259894,0.004700419,0.00048410238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001030767,0.00029870745,0.00024205094,0.0008778415,0.00008608422,0.007886263,0.0006425221,0.0000068551117,0.000037553174,0.000021731123,0.9873563,0.001513348],"study_design_scores_gemma":[0.00189033,0.0020653335,0.0016107503,0.001392973,0.00028477935,0.00009753378,0.00019147391,0.000010957426,0.00023761888,0.00014513718,0.9916953,0.00037781466],"about_ca_topic_score_codex":0.0006587127,"about_ca_topic_score_gemma":0.008795599,"teacher_disagreement_score":0.04345116,"about_ca_system_score_codex":0.0017723128,"about_ca_system_score_gemma":0.0022313108,"threshold_uncertainty_score":0.99990773},"labels":[],"label_agreement":null},{"id":"W3159055654","doi":"10.1002/onco.13814","title":"Opportunities for Improvement in the Administration of Neoadjuvant Chemotherapy for <scp>T4</scp> Breast Cancer: A Comparison of the U.S. and Nigeria","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Breast cancer; Internal medicine; Chemotherapy; Cancer; Socioeconomic status; Psychological intervention; Retrospective cohort study; Surgery; Oncology; Population; Nursing","score_opus":0.04553570216089419,"score_gpt":0.3343260649030116,"score_spread":0.2887903627421174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159055654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858476,0.0017828554,0.00012668782,0.0107615385,0.00011168053,0.00071125745,0.00045510803,0.0000023718299,0.00020089706],"genre_scores_gemma":[0.9980139,0.0006333488,0.00012608684,0.00051884993,0.00008524099,0.00042229597,0.000041310002,0.0000075731823,0.00015139995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99940294,0.00005356472,0.00020727533,0.00014047758,0.00007317392,0.00012255939],"domain_scores_gemma":[0.9993452,0.00011533191,0.00019495703,0.00022697695,0.000106295054,0.000011231127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021346947,0.00009800311,0.0001866934,0.0000069731223,0.00009765773,0.000010041044,0.00015911934,0.000052874933,0.0000015583768],"category_scores_gemma":[0.00004737007,0.00005078876,0.000073442556,0.000043479904,0.00026049992,0.0000021080843,0.000055027784,0.000034063527,1.9867775e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031342704,0.0026261453,0.10433263,0.00068775064,0.0012683837,0.00000369835,0.010670455,0.00014882606,0.6033282,0.002197563,0.033484217,0.23811783],"study_design_scores_gemma":[0.004630917,0.0018421563,0.25100175,0.000080308484,0.00019639927,0.000032857926,0.03616422,0.00010512301,0.66692114,0.000697989,0.038204294,0.00012286306],"about_ca_topic_score_codex":0.00010865692,"about_ca_topic_score_gemma":0.0019579383,"teacher_disagreement_score":0.23799497,"about_ca_system_score_codex":0.000025649937,"about_ca_system_score_gemma":0.00021637032,"threshold_uncertainty_score":0.20711055},"labels":[],"label_agreement":null},{"id":"W3160001767","doi":"10.1002/onco.13818","title":"Moral Distress and Resilience Associated with Cancer Care Priority Setting in a Resource-Limited Context","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in medical practice","field":"Health Professions","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Fogarty International Center; University of California, San Francisco; National Cancer Institute; Greenwall Foundation","keywords":"Psychological intervention; Burnout; Workforce; Medicine; Distress; Nursing; Resource (disambiguation); Psychological resilience; Context (archaeology); Equity (law); Psychology; Social psychology; Political science; Clinical psychology","score_opus":0.08449678725474075,"score_gpt":0.46677580070948727,"score_spread":0.3822790134547465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160001767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90581787,0.001881365,0.000013690392,0.04954153,0.00024577338,0.0005825355,0.00006871974,0.00007698425,0.041771565],"genre_scores_gemma":[0.99195045,0.00012537978,0.00013268096,0.00620822,0.00010050738,0.000110240595,0.00002522173,0.000013500532,0.001333819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99348384,0.0051277434,0.00032535402,0.00029984242,0.00034730433,0.0004159102],"domain_scores_gemma":[0.9853873,0.01360581,0.0002924994,0.00031748583,0.00030301893,0.00009383977],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0034135303,0.00011559815,0.00025455334,0.000020277934,0.0011315602,0.00001808247,0.00022505377,0.0003003827,0.00012878508],"category_scores_gemma":[0.026289271,0.00007415208,0.00001645732,0.00035552713,0.0007829761,0.00007220006,0.00028768182,0.0038789853,0.000007275046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041898811,0.0001498797,0.9224889,0.00029783743,0.00004772779,0.00041980942,0.046291754,0.00006735342,0.00009209632,0.005538369,0.0068296865,0.017357573],"study_design_scores_gemma":[0.0031847903,0.00019205367,0.67977905,0.0022743326,0.000107402964,0.000007882022,0.28206658,0.00040923106,0.00007046314,0.0024137092,0.029186465,0.00030802752],"about_ca_topic_score_codex":0.0032122754,"about_ca_topic_score_gemma":0.09051327,"teacher_disagreement_score":0.24270988,"about_ca_system_score_codex":0.0006228116,"about_ca_system_score_gemma":0.00092961255,"threshold_uncertainty_score":0.9984191},"labels":[],"label_agreement":null},{"id":"W3165169142","doi":"10.1002/onco.13830","title":"Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Puma Biotechnology","keywords":"Capecitabine; Medicine; Lapatinib; Neratinib; Internal medicine; Hazard ratio; Cumulative incidence; Gastroenterology; Oncology; Confidence interval; Cancer; Breast cancer; Trastuzumab; Colorectal cancer; Cohort","score_opus":0.02765587175429207,"score_gpt":0.2690248680371248,"score_spread":0.2413689962828327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165169142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945257,0.0005328582,0.000023838875,0.0026346105,0.00021646457,0.0015644049,0.00011446452,0.000008790699,0.00037890242],"genre_scores_gemma":[0.99872714,0.00002116658,0.00024109939,0.00045278113,0.00019629361,0.00007121659,0.00022714716,0.000010021194,0.000053109685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982073,0.00055546913,0.00042768777,0.00017939795,0.00042457407,0.00020557253],"domain_scores_gemma":[0.9980999,0.00094141864,0.00024451633,0.0005821213,0.000095316595,0.00003670228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054372405,0.00014121848,0.00042595828,0.00001429089,0.00007845885,0.000014245977,0.00021043835,0.000044440112,0.00005743167],"category_scores_gemma":[0.00014149354,0.000051656243,0.00011420797,0.00022038,0.00021897987,0.000016231916,0.00006029909,0.00017092814,0.000002233649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3042484,0.037006546,0.5196094,0.0008332138,0.005449643,0.0017657253,0.041924812,0.0035016234,0.0010913976,0.030310944,0.015540499,0.038717806],"study_design_scores_gemma":[0.1254233,0.0043585,0.8586434,0.00022672402,0.0009112022,0.000012351666,0.007254599,0.00014336719,0.0005315704,0.00003101794,0.0023454097,0.00011855277],"about_ca_topic_score_codex":0.0019636091,"about_ca_topic_score_gemma":0.001360028,"teacher_disagreement_score":0.33903402,"about_ca_system_score_codex":0.0001829122,"about_ca_system_score_gemma":0.00024159918,"threshold_uncertainty_score":0.29684028},"labels":[],"label_agreement":null},{"id":"W3165681703","doi":"10.1002/onco.13827","title":"The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Calgary; University of Alberta; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Toronto","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Oncology; Gemcitabine; Internal medicine; Targeted therapy; Context (archaeology); Chemotherapy; Hazard ratio; Cancer; Clinical trial; Bladder cancer; Confidence interval; Urothelial carcinoma","score_opus":0.07377794113633378,"score_gpt":0.38916663484967917,"score_spread":0.3153886937133454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165681703","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000027917708,0.99010324,0.000005523287,0.00095755374,0.00033823383,0.007606294,0.00013538662,0.00003099171,0.0008199866],"genre_scores_gemma":[0.000100679135,0.99444693,0.000040831444,0.0005167625,0.00018200689,0.0036009066,0.0000773375,0.00007143605,0.00096312194],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957791,0.0013084293,0.001640635,0.00039689464,0.00047502364,0.00039994912],"domain_scores_gemma":[0.9957654,0.0017471899,0.0011019859,0.001103935,0.00020236328,0.00007913177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001773679,0.0005377961,0.005020386,0.000090939815,0.00017115122,0.000035435616,0.0005846513,0.00014937772,0.00036289913],"category_scores_gemma":[0.00093554973,0.00021990138,0.0008928623,0.000824409,0.00021437378,0.00003164415,0.000091714996,0.00054579234,0.000022915574],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008210858,0.00035527008,0.00003422568,0.8347336,0.002371037,0.0001304082,0.00015367415,0.0000015758145,3.9699356e-7,0.000033316384,0.0034082741,0.15869612],"study_design_scores_gemma":[0.0016024052,0.0006337711,0.0000122828515,0.6243042,0.00971675,0.00013711145,0.00007175756,0.000013377592,0.0000026402936,0.000020341336,0.36324108,0.00024430297],"about_ca_topic_score_codex":0.00049229804,"about_ca_topic_score_gemma":0.00072837627,"teacher_disagreement_score":0.3598328,"about_ca_system_score_codex":0.00040256514,"about_ca_system_score_gemma":0.0015956834,"threshold_uncertainty_score":0.89673185},"labels":[],"label_agreement":null},{"id":"W3173598219","doi":"10.1002/onco.13890","title":"Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; University of Manitoba; Manitoba Health; Research Institute in Oncology and Hematology; Health Sciences Centre; CancerCare Manitoba; Toronto General Hospital; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Comorbidity; Lung cancer; Anxiety; Nausea; Poisson regression; Stage (stratigraphy); Population; Cancer; Internal medicine; Physical therapy; Psychiatry","score_opus":0.027779213723623433,"score_gpt":0.33433370545531704,"score_spread":0.30655449173169363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173598219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99015933,0.0010798621,0.0001663275,0.00421181,0.00020388378,0.0010959529,0.0001412206,0.000024396464,0.0029171885],"genre_scores_gemma":[0.990412,0.0003040415,0.00063057855,0.0010880562,0.00003608954,0.0005367476,0.00009357363,0.00001577924,0.00688312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891555,0.000036849815,0.000379545,0.00027482747,0.00017972238,0.00021352507],"domain_scores_gemma":[0.9984661,0.00042470862,0.0003240007,0.0005001083,0.00021816789,0.00006695294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015130322,0.00014317482,0.0006028113,0.00006403375,0.00007410642,0.000012096635,0.00008494113,0.00006172706,0.00022636555],"category_scores_gemma":[0.00011542082,0.000082379964,0.00035613164,0.00034508662,0.00007627617,0.000019318424,0.000056635094,0.00007543885,0.0000013981586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013192494,0.00078121375,0.9887823,0.00021087906,0.0036291012,0.00009968713,0.00036768106,0.00054263865,0.0002459664,0.000041575568,0.0035123536,0.00165467],"study_design_scores_gemma":[0.0037749747,0.0006273502,0.9399011,0.00008965617,0.017111426,0.0000016550741,0.00072661805,0.0013423805,0.02334078,0.000013604473,0.0128993755,0.00017109358],"about_ca_topic_score_codex":0.001781538,"about_ca_topic_score_gemma":0.005694194,"teacher_disagreement_score":0.048881225,"about_ca_system_score_codex":0.0005066573,"about_ca_system_score_gemma":0.00071060844,"threshold_uncertainty_score":0.33593574},"labels":[],"label_agreement":null},{"id":"W3174787666","doi":"10.1002/onco.13894","title":"A 10-Item Frailty Index Based on a Comprehensive Geriatric Assessment (FI-CGA-10) in Older Adults with Cancer: Development and Construct Validation","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Frailty in Older Adults","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Fukuoka Foundation for Sound Health; Research Promotion Foundation","keywords":"Medicine; Comorbidity; Geriatric oncology; Gerontology; Mood; Construct validity; Activities of daily living; Cognition; Geriatrics; Cancer; Internal medicine; Physical therapy; Psychometrics; Clinical psychology; Psychiatry","score_opus":0.029225187821864753,"score_gpt":0.317493136519281,"score_spread":0.2882679486974163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174787666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865446,0.00023904677,0.00023935387,0.0046369215,0.00012340213,0.0011311416,0.000022707483,0.00006473361,0.0069980947],"genre_scores_gemma":[0.9917049,0.000043607193,0.003936518,0.0010960426,0.0000728798,0.00027415858,0.00012388863,0.000024479841,0.0027235413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820423,0.0002366173,0.00036425694,0.00045486577,0.00043582794,0.00030422842],"domain_scores_gemma":[0.9983848,0.0006413303,0.00019057168,0.00038093998,0.0002933688,0.00010899391],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025458125,0.000248553,0.00043007178,0.00012018722,0.00012542476,0.00004255418,0.00010986923,0.00012936126,0.0012777556],"category_scores_gemma":[0.0001559932,0.00016694689,0.000035084522,0.0004623754,0.00023430234,0.00005062333,0.00007581722,0.00033644636,0.000027367341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00967912,0.0031013868,0.48135662,0.0015253125,0.0005494969,0.0022129386,0.005870812,0.0034916447,0.0010521892,0.00019769352,0.016713262,0.4742495],"study_design_scores_gemma":[0.013773708,0.0009356666,0.95620537,0.0011202899,0.000106396205,0.00012445882,0.0016895127,0.0050366526,0.0025455225,0.00001197165,0.018120745,0.00032971188],"about_ca_topic_score_codex":0.0003093047,"about_ca_topic_score_gemma":0.0009881592,"teacher_disagreement_score":0.47484875,"about_ca_system_score_codex":0.0007279904,"about_ca_system_score_gemma":0.0015732321,"threshold_uncertainty_score":0.9996352},"labels":[],"label_agreement":null},{"id":"W3187302100","doi":"10.1002/onco.13927","title":"Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"PTEN; Medicine; Microsatellite instability; Endometrial cancer; Metastasis; Pathology; Brain metastasis; KRAS; Immunohistochemistry; Cancer; Lesion; Oncology; Internal medicine; Colorectal cancer; Biology; Microsatellite; Gene","score_opus":0.137793161153583,"score_gpt":0.3627381149925187,"score_spread":0.22494495383893567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187302100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883334,0.0022491117,0.00048160134,0.00805291,0.0001859383,0.00044669097,0.00011603696,0.0000022268728,0.00013210237],"genre_scores_gemma":[0.9954356,0.0017356754,0.0005529836,0.0015835353,0.00024201426,0.00034588188,0.00005492805,0.000009589764,0.00003977306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862105,0.00054216344,0.00032323494,0.00021646092,0.00016375216,0.00013336222],"domain_scores_gemma":[0.998542,0.00057492335,0.00019438576,0.0005120169,0.00014797626,0.000028658449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011785772,0.0000978341,0.00017424584,0.000047964026,0.00009959366,0.000036665802,0.00034868473,0.000050278573,0.000030104095],"category_scores_gemma":[0.002531533,0.00005538466,0.00008138678,0.00047671367,0.00011546354,0.0000058100004,0.000090093185,0.000080541344,0.0000017845031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003221466,0.0002194176,0.00069838885,0.000019824723,0.00011560805,0.0000068821896,0.0013710608,0.009489606,0.9320752,0.001908959,0.0067148013,0.047058124],"study_design_scores_gemma":[0.0010112198,0.001497745,0.0019999912,0.00003125204,0.00020259219,0.00001961304,0.0051484113,0.00078075833,0.94951195,0.00045786696,0.03916746,0.00017112482],"about_ca_topic_score_codex":0.0018778356,"about_ca_topic_score_gemma":0.019659812,"teacher_disagreement_score":0.046887,"about_ca_system_score_codex":0.00009532094,"about_ca_system_score_gemma":0.0005404224,"threshold_uncertainty_score":0.99822885},"labels":[],"label_agreement":null},{"id":"W3188534843","doi":"10.1002/onco.13922","title":"Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Winship Cancer Institute; National Institutes of Health; Society for Immunotherapy of Cancer; National Cancer Institute; Emory University","keywords":"Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Oncology; Biomarker; Body mass index; Retrospective cohort study; Odds ratio; Confidence interval","score_opus":0.012922607270704961,"score_gpt":0.2742608242748707,"score_spread":0.2613382170041657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188534843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948898,0.00025275088,0.00000834879,0.0003339265,0.00008781805,0.0012949308,0.000043476914,0.0000467773,0.0030421976],"genre_scores_gemma":[0.9991043,0.00003649278,0.000073207455,0.00016025547,0.000043517186,0.00019990889,0.00020861553,0.000025480573,0.0001481917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871856,0.00016733413,0.00027104278,0.00035463396,0.0002531694,0.00023524134],"domain_scores_gemma":[0.9993372,0.00005503752,0.00010240021,0.00025241348,0.0001450891,0.00010786501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012171333,0.00019869502,0.0003030066,0.000059890186,0.00010833292,0.000025588832,0.000060545608,0.00009376285,0.000042392938],"category_scores_gemma":[0.00004524896,0.00012249114,0.000042457155,0.00021896309,0.00020819766,0.000103126156,0.00005514302,0.00018804488,0.00000790459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071090693,0.0021506639,0.9615049,0.000036973102,0.00014112706,0.00047969454,0.00082424685,0.000007761505,0.022535581,0.000017522047,0.0000121723615,0.005180306],"study_design_scores_gemma":[0.010353204,0.005596498,0.9551203,0.00013473383,0.00022130655,0.00011953442,0.00037418088,0.00008965824,0.027761418,0.000045452907,0.000054870008,0.00012881795],"about_ca_topic_score_codex":0.00080196536,"about_ca_topic_score_gemma":0.0002274709,"teacher_disagreement_score":0.006384558,"about_ca_system_score_codex":0.00031834835,"about_ca_system_score_gemma":0.00025246252,"threshold_uncertainty_score":0.49950436},"labels":[],"label_agreement":null},{"id":"W3190487880","doi":"10.1002/onco.13923","title":"Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Temozolomide; Discontinuation; Internal medicine; Regimen; Hazard ratio; Capecitabine; Clinical endpoint; Gastroenterology; Retrospective cohort study; Neuroendocrine tumors; Adverse effect; Surgery; Radiation therapy; Confidence interval; Clinical trial; Cancer","score_opus":0.028540580612285794,"score_gpt":0.35064206726557834,"score_spread":0.3221014866532925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190487880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8961356,0.011495662,0.000012912552,0.08242365,0.00030418026,0.0020806005,0.00002146901,0.00014948683,0.0073763896],"genre_scores_gemma":[0.9646372,0.019991137,0.00066550495,0.009847824,0.00012605853,0.00023195408,0.000023066425,0.000042651605,0.004434563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973975,0.0005026855,0.00048071973,0.00049625087,0.00043678161,0.00068607985],"domain_scores_gemma":[0.9984777,0.00031952007,0.00013387665,0.0007528192,0.00014379605,0.0001722758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022832412,0.00023616922,0.00069311704,0.0000802649,0.00008062706,0.000026087173,0.00026820874,0.000005912575,0.00033869737],"category_scores_gemma":[0.0028964204,0.00015599644,0.00015812935,0.00055444863,0.00032987847,0.000100448306,0.00026869838,0.00073399674,0.00014209138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002058578,0.00348146,0.7190765,0.0035296553,0.00021988641,0.19666748,0.00011206611,0.00003255241,0.01991033,0.00046788144,0.050976615,0.0034669952],"study_design_scores_gemma":[0.017850962,0.005146717,0.75998354,0.0076438873,0.00064801093,0.060294237,0.00097407063,0.00048047001,0.03095253,0.00079231936,0.11455527,0.0006779723],"about_ca_topic_score_codex":0.000114051385,"about_ca_topic_score_gemma":0.00065460434,"teacher_disagreement_score":0.13637324,"about_ca_system_score_codex":0.0003806459,"about_ca_system_score_gemma":0.00017228995,"threshold_uncertainty_score":0.63613504},"labels":[],"label_agreement":null},{"id":"W3197137235","doi":"10.1002/onco.13971","title":"A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Princess Margaret Cancer Centre; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Bevacizumab; Term (time); Extension (predicate logic); Solid tumor; Medicine; Oncology; Internal medicine; Computer science; Cancer; Chemotherapy; Programming language; Physics","score_opus":0.026222197415164527,"score_gpt":0.3225476534188693,"score_spread":0.2963254560037048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197137235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975944,0.00020762262,7.0828685e-7,0.0002685233,0.000051727362,0.00058137655,0.0000029014661,0.000010897832,0.0012818525],"genre_scores_gemma":[0.99950874,0.000020754118,0.000017505343,0.000083341285,0.000017160597,0.000042691532,0.000007734912,0.000007039451,0.00029506293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929893,0.00005129324,0.0001723052,0.00016536623,0.00018798588,0.00012409542],"domain_scores_gemma":[0.9994833,0.000050087816,0.00007335091,0.00023398323,0.00013529956,0.000024020395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007367152,0.0000905522,0.00032763902,0.0000272938,0.00005804325,0.0000042112606,0.00004580443,0.000019901792,0.000037947953],"category_scores_gemma":[0.000051647166,0.000045473796,0.000027096557,0.00017951307,0.00009166262,0.000016355758,0.00008125385,0.00008571812,0.0000027955075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019188946,0.0037848293,0.9857187,0.000017786264,0.00010314628,0.00033888867,0.0013999724,0.0000071534655,0.000027518648,0.000003299793,0.000047480225,0.0066323266],"study_design_scores_gemma":[0.0064599467,0.007202679,0.9846148,0.0000796272,0.00012073581,0.000008587885,0.0013055796,0.0000023417558,0.00014023445,0.0000062972726,0.000011026532,0.000048178626],"about_ca_topic_score_codex":0.00017356072,"about_ca_topic_score_gemma":0.0031713855,"teacher_disagreement_score":0.006584148,"about_ca_system_score_codex":0.00015751577,"about_ca_system_score_gemma":0.000092017835,"threshold_uncertainty_score":0.18543676},"labels":[],"label_agreement":null},{"id":"W3197976653","doi":"10.1002/onco.13965","title":"Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A <scp>Single-Center</scp> Retrospective Study","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; University of Toronto","funders":"","keywords":"Medicine; Breast cancer; Interquartile range; Cancer; Internal medicine; Oncology; Retrospective cohort study; Asymptomatic; Brain metastasis; Radiosurgery; Radiation therapy; Population; Metastasis","score_opus":0.019842861684766355,"score_gpt":0.2967036262230774,"score_spread":0.27686076453831104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197976653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950258,0.00033437833,0.00002206942,0.002634375,0.000041717107,0.0013333029,0.00037933374,0.000039392675,0.00018959382],"genre_scores_gemma":[0.9982838,0.000107604305,0.0002875089,0.0003710844,0.000026802058,0.00043684355,0.000017808312,0.000026567715,0.00044194981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983257,0.00032141389,0.00032214297,0.0003811559,0.00028726878,0.00036232147],"domain_scores_gemma":[0.9984805,0.00057496864,0.00022614037,0.00044257412,0.000100230325,0.00017561395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034251704,0.00029952428,0.000932832,0.000059993916,0.00012401589,0.00004720298,0.0000661904,0.000039977796,0.000059273596],"category_scores_gemma":[0.00013229428,0.00015023998,0.000064133805,0.00019326869,0.000250424,0.00005454888,0.00009288123,0.000091298054,0.0000018039887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010674422,0.0043811277,0.9801159,0.00012758508,0.003008107,0.0004060727,0.005593114,0.000002281967,0.00007823954,0.000059704274,0.00005863484,0.0060625165],"study_design_scores_gemma":[0.008942939,0.0066255243,0.96290964,0.00013398219,0.0012687896,0.000965402,0.018800974,0.000031846695,0.000111745314,0.0000494995,0.00009022459,0.0000694514],"about_ca_topic_score_codex":0.00086720433,"about_ca_topic_score_gemma":0.00134307,"teacher_disagreement_score":0.017206252,"about_ca_system_score_codex":0.0008549201,"about_ca_system_score_gemma":0.00016552275,"threshold_uncertainty_score":0.6126609},"labels":[],"label_agreement":null},{"id":"W3198339003","doi":"10.1002/onco.13963","title":"The Looming Threat: Cancer in Sub-Saharan Africa","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Medical Research Council Canada","keywords":"Looming; Medicine; Epidemiology; Cancer; Low and middle income countries; Action (physics); Environmental health; Development economics; Economic growth; Developing country; Pathology","score_opus":0.11860425454860637,"score_gpt":0.3839400994920913,"score_spread":0.26533584494348494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198339003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66036737,0.118896306,0.00007322781,0.0977592,0.0008819396,0.0006247697,0.000017729315,0.00009171301,0.12128774],"genre_scores_gemma":[0.9887827,0.006057047,0.0000723201,0.001845045,0.00026284394,0.00006771316,0.0000023378702,0.000008696475,0.002901284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990634,0.000081990656,0.00017850134,0.00016767184,0.0002097905,0.00029864543],"domain_scores_gemma":[0.99924994,0.00025360356,0.000053532545,0.00031924038,0.000075319804,0.000048367383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053067366,0.00008810805,0.00017861961,0.000014052257,0.00022348252,0.000035473993,0.00017602908,0.00005669129,0.0001207987],"category_scores_gemma":[0.00023050582,0.00004511804,0.00006427982,0.00029859022,0.00019484712,0.000036612684,0.000080962884,0.00027120378,0.000045920588],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019103485,0.00030585664,0.11133089,0.00008098492,0.00026575816,0.0031616297,0.0027718192,0.00075149554,0.030418683,0.0037712979,0.28555724,0.559674],"study_design_scores_gemma":[0.001850993,0.00027399155,0.21398892,0.00039285596,0.00015520162,0.00020159075,0.0023682755,0.0005200942,0.007872992,0.0017039558,0.7704458,0.00022530611],"about_ca_topic_score_codex":0.000916848,"about_ca_topic_score_gemma":0.007792462,"teacher_disagreement_score":0.5594487,"about_ca_system_score_codex":0.0002854355,"about_ca_system_score_gemma":0.00036170747,"threshold_uncertainty_score":0.43483767},"labels":[],"label_agreement":null},{"id":"W3199756208","doi":"10.1002/onco.13974","title":"Changes in Cancer Patients' and Caregivers' Disease Perceptions While Receiving Early Palliative Care: A Qualitative and Quantitative Analysis","year":2021,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma; Ministero dell’Istruzione, dell’Università e della Ricerca","keywords":"Sadness; Palliative care; Psychosocial; Optimism; Anxiety; Medicine; Intervention (counseling); Psychology; Thematic analysis; Learned helplessness; Disease; Cognition; Clinical psychology; Qualitative research; Psychotherapist; Nursing; Internal medicine; Psychiatry; Anger","score_opus":0.05342108897153759,"score_gpt":0.3834297063083616,"score_spread":0.330008617336824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199756208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988235,0.004740007,0.00003184069,0.005781514,0.00009039313,0.00027347732,0.0003021959,0.00001681475,0.00052878354],"genre_scores_gemma":[0.9964519,0.002484089,0.00007659762,0.0003693097,0.000035037272,0.00013905177,0.00009215918,0.0000090327885,0.0003428301],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988757,0.00035073896,0.00012772655,0.0003065243,0.00016888164,0.0001704698],"domain_scores_gemma":[0.9989223,0.00043122494,0.000075499636,0.0001524569,0.0003026451,0.00011590472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001549381,0.00012603123,0.00031727666,0.0001038741,0.00014442895,0.00003123825,0.00004607706,0.00004987306,0.0001419426],"category_scores_gemma":[0.00022917367,0.00009304651,0.00006400816,0.00065912516,0.00031579283,0.00005265469,0.00007557865,0.00017076467,0.0000017554568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023897734,0.000076618126,0.5852456,0.000075364725,0.0002471073,0.000025896621,0.41085777,0.000009373372,0.000037812464,0.00023552706,0.000106428415,0.0028435169],"study_design_scores_gemma":[0.0006023191,0.00022820955,0.72599477,0.000073791416,0.00064056995,1.6409953e-7,0.27194527,0.000041181876,0.00000973475,0.00006526951,0.00030561237,0.00009309887],"about_ca_topic_score_codex":0.011052452,"about_ca_topic_score_gemma":0.3348171,"teacher_disagreement_score":0.32376468,"about_ca_system_score_codex":0.00030707155,"about_ca_system_score_gemma":0.0001621419,"threshold_uncertainty_score":0.99553305},"labels":[],"label_agreement":null},{"id":"W32162815","doi":"10.1634/theoncologist.2019-0501","title":"Perfil cromatográfico de oligossacarídeos na urina, atividade da alfa manosidade leucocitária e estudo histológico de caprinos intoxicados com Sida carpinifolia","year":2004,"lang":"en","type":"article","venue":"The Oncologist","topic":"Phytochemistry Medicinal Plant Applications","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science","keywords":"Sida; Geography; Biology; Human immunodeficiency virus (HIV); Viral disease; Virology","score_opus":0.024613506689255854,"score_gpt":0.2607880077771022,"score_spread":0.23617450108784635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W32162815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805579,0.00030308962,0.00013506551,0.012124569,0.00009362212,0.0005733242,0.00011612473,0.00021840371,0.0058778604],"genre_scores_gemma":[0.9970522,0.00006474063,0.0003162114,0.0011407386,0.00045534363,0.00027032132,0.00007115518,0.0000046401833,0.0006246756],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99785185,0.00015715213,0.00039732127,0.0004933408,0.00035107345,0.00074929226],"domain_scores_gemma":[0.9986378,0.0004787023,0.0002460909,0.000275562,0.00006679344,0.00029504538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005237033,0.000332365,0.0003781632,0.000014643277,0.00069650327,0.00011262628,0.0011796238,0.00028084958,0.00021418298],"category_scores_gemma":[0.00018220756,0.00014155409,0.00016167705,0.00037915603,0.0006450961,0.00008328033,0.0002186853,0.000559533,0.00016248644],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009304225,0.000519706,0.011279746,0.00002953038,0.000056325895,0.00009064593,0.00074526906,0.00014879079,0.9700097,0.0046063955,0.0043738736,0.00804696],"study_design_scores_gemma":[0.002109736,0.0013241587,0.6013141,0.0002195416,0.0003165424,0.0012698089,0.003883977,0.00025147252,0.28797868,0.024672873,0.07511117,0.0015479167],"about_ca_topic_score_codex":0.003685815,"about_ca_topic_score_gemma":0.0009633296,"teacher_disagreement_score":0.68203104,"about_ca_system_score_codex":0.000716933,"about_ca_system_score_gemma":0.00016451601,"threshold_uncertainty_score":0.5772408},"labels":[],"label_agreement":null},{"id":"W4205259021","doi":"10.1093/oncolo/oyab070","title":"Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Entertainment Industry Foundation; National Cancer Institute; National Institutes of Health; George W. Stone Family Foundation; National Center for Advancing Translational Sciences; Alliance for Clinical Trials in Oncology Foundation; American Association for Cancer Research","keywords":"Colorectal cancer; Cancer; Stage (stratigraphy); Oncology; Alliance; Medicine; Marital status; Internal medicine; Biology; Environmental health","score_opus":0.019941578214275703,"score_gpt":0.2837501192533572,"score_spread":0.26380854103908147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205259021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928391,0.0037403046,0.0000040624236,0.000816041,0.00057528174,0.0006242148,0.0007610465,0.000025599878,0.0006143805],"genre_scores_gemma":[0.9962687,0.0019040906,0.000022967999,0.0004588242,0.000070012946,0.00031745137,0.000056946195,0.000018250008,0.0008827952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986257,0.00013816362,0.00018547353,0.00036124952,0.00034816613,0.0003412368],"domain_scores_gemma":[0.9993307,0.00021989022,0.000107324275,0.00019289482,0.00004840522,0.00010078517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032151552,0.00016604563,0.00032695988,0.00003744246,0.00024761254,0.00003294282,0.00011990237,0.000044197837,0.0005310108],"category_scores_gemma":[0.000036884405,0.00012236745,0.000021319502,0.0002334794,0.00023505767,0.000071334245,0.00024158019,0.0004081635,7.2442185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011521502,0.00011047239,0.9818645,0.00004465592,0.000043999873,0.000017311977,0.0037357388,0.000019340014,0.0000363718,0.00002428323,0.000729245,0.012221919],"study_design_scores_gemma":[0.0026107286,0.00072980725,0.972735,0.0001612457,0.000075666874,7.970023e-7,0.0035275524,0.00005265296,0.000012329884,0.000013691082,0.019903108,0.00017744584],"about_ca_topic_score_codex":0.0895821,"about_ca_topic_score_gemma":0.14545186,"teacher_disagreement_score":0.055869754,"about_ca_system_score_codex":0.0006648583,"about_ca_system_score_gemma":0.00023048732,"threshold_uncertainty_score":0.9164804},"labels":[],"label_agreement":null},{"id":"W4205530749","doi":"10.1093/oncolo/oyab010","title":"Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Demographics; Disease; Oncology; Internal medicine; Stage (stratigraphy); Demography","score_opus":0.04709897848308272,"score_gpt":0.32167594623167345,"score_spread":0.27457696774859075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205530749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9579673,0.0031476195,0.000033671924,0.015289308,0.000516679,0.0008837904,0.000025148303,0.000054528715,0.022081982],"genre_scores_gemma":[0.99730116,0.00017405351,0.00005576845,0.0014128569,0.00016577549,0.0004386291,0.0000146561,0.000024119381,0.0004129521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980681,0.00038974686,0.00038381803,0.0003396471,0.00035660973,0.00046207596],"domain_scores_gemma":[0.9989053,0.00055534084,0.00011931969,0.00031899134,0.000055731623,0.000045312438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012525045,0.00019081682,0.0005052978,0.00013096996,0.0006688504,0.000035567547,0.00032439586,0.000046261503,0.00012607731],"category_scores_gemma":[0.00017413111,0.00011744427,0.0000695094,0.0009935297,0.00029868283,0.00007061688,0.00052766525,0.00079956837,0.000008284137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020313303,0.0010867126,0.9090672,0.0003627592,0.00019403503,0.0027971945,0.037866633,0.0011631148,0.0066512437,0.003355722,0.0051518604,0.030272176],"study_design_scores_gemma":[0.0026804847,0.000230086,0.9741093,0.00009035093,0.00006352704,0.000058693196,0.018305909,0.000473829,0.000160855,0.00011512758,0.003555285,0.00015655521],"about_ca_topic_score_codex":0.0035692488,"about_ca_topic_score_gemma":0.002288438,"teacher_disagreement_score":0.06504208,"about_ca_system_score_codex":0.0008563476,"about_ca_system_score_gemma":0.00040152072,"threshold_uncertainty_score":0.53956604},"labels":[],"label_agreement":null},{"id":"W4205830947","doi":"10.1093/oncolo/oyab081","title":"Methadone as First-line Opioid for the Management of Cancer Pain","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Methadone; Adverse effect; Opioid; Delirium; Anesthesia; Cancer pain; Internal medicine; Cancer; Psychiatry","score_opus":0.04345380845407366,"score_gpt":0.35047243248719895,"score_spread":0.3070186240331253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205830947","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36449826,0.03040724,0.03389803,0.4688973,0.0040345076,0.021700177,0.00024793576,0.0004952395,0.07582131],"genre_scores_gemma":[0.9417704,0.0026987272,0.0014035356,0.008481976,0.00029009147,0.0025756164,0.000032230757,0.000027223894,0.042720214],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990607,0.0001169443,0.0002024146,0.0001552849,0.00026553418,0.00019915044],"domain_scores_gemma":[0.9987381,0.0006441897,0.00012641225,0.0004319435,0.000032470594,0.000026874055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024761353,0.00009903109,0.00019429669,0.00003457317,0.0003813127,0.000007402321,0.0003791719,0.000019911644,0.00075947715],"category_scores_gemma":[0.00007169504,0.00005313203,0.00011662265,0.00022513689,0.00014107632,0.000011610071,0.00029888688,0.00014521452,0.000007608882],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004820148,0.0017805644,0.026403083,0.0021443923,0.004325862,0.00014981793,0.0028248841,0.011293884,0.0004353821,0.052417513,0.40633792,0.48706654],"study_design_scores_gemma":[0.0018866383,0.00091761485,0.022912757,0.00003806268,0.000759975,7.339443e-7,0.0027200212,0.004264428,0.00014730154,0.0021336947,0.9641238,0.00009500487],"about_ca_topic_score_codex":0.00051638787,"about_ca_topic_score_gemma":0.00013073273,"teacher_disagreement_score":0.5772721,"about_ca_system_score_codex":0.00014833358,"about_ca_system_score_gemma":0.000039603783,"threshold_uncertainty_score":0.8315742},"labels":[],"label_agreement":null},{"id":"W4206217038","doi":"10.1093/oncolo/oyac020","title":"Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; University of Calgary; Fraser Health; McMaster University; Juravinski Hospital; Queen's University","funders":"","keywords":"Medicine; Clinical trial; Cancer; Internal medicine; Oncology; Alternative medicine; Intensive care medicine; Pathology","score_opus":0.3861064120404313,"score_gpt":0.5403940469958496,"score_spread":0.1542876349554183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206217038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98276573,0.00038277585,0.000056092314,0.012635731,0.0007211487,0.0025801254,0.0002372445,0.000031152176,0.00059000455],"genre_scores_gemma":[0.99321145,0.00018017707,0.00013713166,0.004484595,0.0004320687,0.0005678949,0.0003494302,0.000017847817,0.00061937975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952564,0.0020020867,0.0013959203,0.00035905224,0.0006571566,0.00032935236],"domain_scores_gemma":[0.9950135,0.0038585693,0.0005786747,0.00033721793,0.000098445824,0.00011363397],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005730012,0.00023472386,0.0014958312,0.00013352642,0.00038253106,0.0000069319667,0.00024772098,0.0000074123077,0.006288348],"category_scores_gemma":[0.0011260764,0.00011598171,0.0001230907,0.00037994227,0.00075491745,0.00006218623,0.0003083277,0.00056007906,0.0000031457942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015017712,0.0030996292,0.91159546,0.000027441161,0.0011449653,0.00025943053,0.0015039062,0.000043093292,0.00002983005,0.00014694082,0.031411577,0.035720024],"study_design_scores_gemma":[0.19368868,0.026133925,0.63411176,0.00017171822,0.0019210471,0.000015342617,0.01264168,0.00026963223,0.000014332514,0.00017230988,0.13057394,0.00028562566],"about_ca_topic_score_codex":0.00454297,"about_ca_topic_score_gemma":0.0024510392,"teacher_disagreement_score":0.27748367,"about_ca_system_score_codex":0.00031815932,"about_ca_system_score_gemma":0.00013496309,"threshold_uncertainty_score":0.99462},"labels":[],"label_agreement":null},{"id":"W4206607110","doi":"10.1093/oncolo/oyab027","title":"Perceptions of Hope Among Bereaved Caregivers of Cancer Patients Who Received Early Palliative Care: A Content and Lexicographic Analysis","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Optimism, Hope, and Well-being","field":"Psychology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Palliative care; Perception; Cancer; Family medicine; Content analysis; Nursing; Internal medicine","score_opus":0.02837899443450177,"score_gpt":0.31420438686824603,"score_spread":0.2858253924337443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206607110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918101,0.0004812533,0.00001598752,0.00018271981,0.00020026317,0.00043367344,0.00024141074,0.000016931348,0.006617668],"genre_scores_gemma":[0.9985627,0.00030758246,0.000022494838,0.00006704826,0.000018208024,0.00017284704,0.00003422249,0.000013066853,0.00080180715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985411,0.0004318782,0.00031237403,0.00028431547,0.00021700864,0.0002133083],"domain_scores_gemma":[0.9988444,0.00018058348,0.00037750194,0.00032118143,0.00022159022,0.0000547814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020415978,0.00013931328,0.00042184666,0.00020120815,0.00028829268,0.000010694271,0.00027246572,0.000068239984,0.00068689854],"category_scores_gemma":[0.000024036879,0.00010907761,0.00020939355,0.00072823017,0.00070658943,0.000039039573,0.00013596323,0.00023068972,0.0000015274129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022567346,0.00018114982,0.92931026,0.000011429643,0.0010845673,0.0000027907179,0.065903686,0.000575395,0.00010125329,0.00020387031,0.00023509629,0.0021648183],"study_design_scores_gemma":[0.0011037174,0.000718888,0.943359,0.000011852329,0.00093996804,9.472817e-8,0.05348799,0.0000473039,0.000024690245,0.000032849603,0.0001588587,0.00011475943],"about_ca_topic_score_codex":0.034010105,"about_ca_topic_score_gemma":0.005391055,"teacher_disagreement_score":0.028619047,"about_ca_system_score_codex":0.00014435445,"about_ca_system_score_gemma":0.00003959749,"threshold_uncertainty_score":0.9724225},"labels":[],"label_agreement":null},{"id":"W4206714415","doi":"10.1093/oncolo/oyab009","title":"Exercise-based Multimodal Programming: A Treatment Gap for Older Adults with Advanced Cancer","year":2022,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Cancer; Gerontology; Cancer treatment; Physical therapy; Internal medicine","score_opus":0.03177243009764622,"score_gpt":0.32071782337206495,"score_spread":0.2889453932744187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206714415","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010437,0.008536181,0.00021977861,0.9555463,0.0025370233,0.018940283,0.0012735038,0.00053765083,0.0019722544],"genre_scores_gemma":[0.08557198,0.0011881653,0.0034101275,0.7273765,0.008124121,0.124580875,0.0070466674,0.00060096954,0.04210055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99779844,0.00008575632,0.00028698047,0.00070236286,0.00048665865,0.00063980266],"domain_scores_gemma":[0.9983583,0.00030333165,0.00029016467,0.000783069,0.00017461991,0.000090505455],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014062258,0.00052419305,0.0008565072,0.000087262095,0.00028102702,0.000035510653,0.00029541634,0.00036538212,0.00075833756],"category_scores_gemma":[0.000019586489,0.00029306134,0.00036853726,0.00022273493,0.00027118248,0.000023748978,0.000044195327,0.00086953654,0.0000062290806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0159735,0.0006599962,0.00045804874,0.0014704659,0.00040250653,0.0007142055,0.002637969,0.00015190906,0.000005194011,0.000002979386,0.44936118,0.52816206],"study_design_scores_gemma":[0.0092293555,0.005727357,0.00018281501,0.00081498706,0.0010361989,0.00001827956,0.0010266849,0.0001002967,0.00012495724,0.0000034895638,0.9813341,0.00040146336],"about_ca_topic_score_codex":0.0053068073,"about_ca_topic_score_gemma":0.005465121,"teacher_disagreement_score":0.53197294,"about_ca_system_score_codex":0.0017330932,"about_ca_system_score_gemma":0.0011023157,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4206943819","doi":"10.1093/oncolo/oyac031","title":"Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Monoclonal antibody; Confidence interval; Internal medicine; Optimism; Randomized controlled trial; Clinical endpoint; Oncology; Antibody; Immunology","score_opus":0.45022287493741125,"score_gpt":0.5122209442929506,"score_spread":0.061998069355539365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206943819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000116952324,0.98552364,0.00069762627,0.0007083729,0.0006166543,0.011023913,0.00008759916,0.000034685978,0.0011905382],"genre_scores_gemma":[0.00045621107,0.9948089,0.0010597312,0.0005668266,0.0004256946,0.0020144738,0.00014267483,0.000046798785,0.0004786707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9761591,0.019174146,0.0030883544,0.0004133935,0.00074665155,0.00041837143],"domain_scores_gemma":[0.95462954,0.04136397,0.0032436557,0.0006341208,0.0000864835,0.000042220887],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0784402,0.0005275398,0.007119113,0.00020997474,0.00027221712,0.000047181824,0.000728822,0.0002555348,0.0009831549],"category_scores_gemma":[0.011586368,0.00022935307,0.0019402852,0.00051662506,0.0008478978,0.000037108388,0.00009276616,0.00090971787,0.000004282281],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21888244,0.0004937508,7.83798e-7,0.0018797808,0.0022858873,0.00006673655,0.001113796,0.00013684394,0.00011146788,0.000032888416,0.003512896,0.7714827],"study_design_scores_gemma":[0.42913112,0.0016186049,0.0000010132472,0.0038682753,0.008956073,0.00013055251,0.00094689976,0.0016017773,0.000008636347,0.00008357445,0.55329156,0.00036188564],"about_ca_topic_score_codex":0.00035496685,"about_ca_topic_score_gemma":0.0000049488035,"teacher_disagreement_score":0.77112085,"about_ca_system_score_codex":0.0005202105,"about_ca_system_score_gemma":0.0018543531,"threshold_uncertainty_score":0.9999301},"labels":[],"label_agreement":null},{"id":"W4210388853","doi":"10.1093/oncolo/oyac030","title":"Comparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Facilitator; Medicine; Gatekeeping; Family medicine; Psychological intervention; Clinical trial; Intervention (counseling); Nursing; Psychology; Internal medicine","score_opus":0.10724082538982815,"score_gpt":0.4202037926898851,"score_spread":0.31296296730005696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210388853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879839,0.00028028982,0.00012576913,0.008875118,0.0010488725,0.0014213796,0.00010729765,0.00008422095,0.000073168514],"genre_scores_gemma":[0.9858227,0.00011139113,0.00038709433,0.013165614,0.00029299757,0.00010963347,0.000028400302,0.000024814395,0.00005737145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955379,0.0021663727,0.0009608055,0.00043209337,0.0004905528,0.00041231036],"domain_scores_gemma":[0.99681824,0.0017125912,0.0002631584,0.0006166923,0.00007704967,0.0005122841],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.008466264,0.00024963001,0.0008531821,0.00005095966,0.0014801073,0.00007988284,0.000273166,0.0001101474,0.000022216907],"category_scores_gemma":[0.0016024864,0.00020302301,0.00011228912,0.00017072399,0.00081346906,0.00004086582,0.0008004811,0.0015388028,0.000003324315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07804951,0.0012399781,0.8844264,0.0005118856,0.00029757922,0.00004510544,0.022919977,0.00058002805,0.00004787712,0.00018185373,0.0032762738,0.008423524],"study_design_scores_gemma":[0.20625038,0.021026567,0.6351074,0.00054870045,0.0005642791,0.000088402485,0.10514576,0.0036714668,0.00008275055,0.0003098733,0.026097221,0.0011071931],"about_ca_topic_score_codex":0.0021609135,"about_ca_topic_score_gemma":0.0015622748,"teacher_disagreement_score":0.249319,"about_ca_system_score_codex":0.00024826126,"about_ca_system_score_gemma":0.00025247838,"threshold_uncertainty_score":0.9998198},"labels":[],"label_agreement":null},{"id":"W4210930134","doi":"10.1093/oncolo/oyac039","title":"“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Mount Sinai Hospital; University of British Columbia; McGill University; St. Michael's Hospital; Jewish General Hospital; Memorial University of Newfoundland; Dalhousie University; University of Toronto; University Health Network; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Genetic testing; Thematic analysis; Health professionals; Test (biology); Health care; Cancer; Cancer screening; Family medicine; Qualitative research; Nursing; Internal medicine","score_opus":0.16324068950015908,"score_gpt":0.42232402391385887,"score_spread":0.2590833344136998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210930134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868298,0.0012500646,0.000019225079,0.007946743,0.0006502217,0.00090140745,0.00006618418,0.000010074183,0.0023262708],"genre_scores_gemma":[0.99383175,0.000052217616,0.00027136243,0.0047268434,0.00015124492,0.0007220493,0.000028491442,0.000014208662,0.00020182878],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99784666,0.00088896666,0.00048750825,0.00031856165,0.00022735189,0.00023096961],"domain_scores_gemma":[0.99885833,0.00024065984,0.00035257166,0.0004841411,0.000035271347,0.000029004093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003112106,0.00011141947,0.00020976574,0.000027253362,0.00026207723,0.00000516041,0.00044108034,0.000038749662,0.00013425972],"category_scores_gemma":[0.00018061623,0.000071768845,0.000072872295,0.00025735088,0.00019836356,0.0000017189856,0.0005109007,0.00032100335,0.0000024070873],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016747114,0.0068500964,0.22734444,0.001389326,0.0011831892,0.00057098793,0.0055679353,0.02495682,0.010301454,0.0021065534,0.19373798,0.5243165],"study_design_scores_gemma":[0.0021908472,0.0029754634,0.8917943,0.00043700443,0.00007566186,0.00020650143,0.010715451,0.0037328869,0.001526464,0.0017161489,0.08402042,0.00060880586],"about_ca_topic_score_codex":0.00021656297,"about_ca_topic_score_gemma":0.0003083677,"teacher_disagreement_score":0.66444993,"about_ca_system_score_codex":0.00021751449,"about_ca_system_score_gemma":0.00044181588,"threshold_uncertainty_score":0.29266486},"labels":[],"label_agreement":null},{"id":"W4212817368","doi":"10.1093/oncolo/oyac047","title":"Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Advanced Proteomics Techniques and Applications","field":"Chemistry","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Microvesicles; Disease; Cancer; Circulating tumor cell; Biomarker discovery; Cancer biomarkers; Disease monitoring; Biomarker; Bioinformatics; Internal medicine; microRNA; Proteomics; Metastasis; Biology","score_opus":0.21134661708314767,"score_gpt":0.4558295552984037,"score_spread":0.24448293821525602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212817368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008823076,0.99544597,0.0013368359,0.000034035977,0.00009387069,0.0009208944,0.00025364678,0.000094462506,0.0017320373],"genre_scores_gemma":[0.00020771177,0.990723,0.0038416418,0.000008847857,0.00017235466,0.0045719543,0.000056083518,0.000055065728,0.0003633223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989813,0.0000302346,0.00042297976,0.00026117687,0.000110839814,0.00019346514],"domain_scores_gemma":[0.9983396,0.00039117696,0.00072868465,0.00049616944,0.000023052471,0.000021297783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023943512,0.00020942977,0.00064963725,0.000028570637,0.00026093592,0.000012836436,0.0006358599,0.0001486427,0.00028199426],"category_scores_gemma":[0.000029771132,0.00014795251,0.00036363586,0.00015968364,0.00011390747,0.0000162635,0.00016154726,0.00028541675,0.0000011002559],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034340194,0.000033770946,0.000029024457,0.0044881,0.00020330212,6.2162934e-7,0.00001719439,0.000014230254,0.0004960048,0.0002177146,0.00007353454,0.9944231],"study_design_scores_gemma":[0.0000758714,0.000012079533,8.891163e-7,0.0008392121,0.00037138775,0.000004401177,0.000058492846,0.00002100563,0.0009562384,0.00037772357,0.9971176,0.00016510101],"about_ca_topic_score_codex":0.000022203332,"about_ca_topic_score_gemma":2.9276598e-7,"teacher_disagreement_score":0.9970441,"about_ca_system_score_codex":0.00032730264,"about_ca_system_score_gemma":0.00012376043,"threshold_uncertainty_score":0.6033328},"labels":[],"label_agreement":null},{"id":"W4220717070","doi":"10.1093/oncolo/oyac065","title":"Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Eisai","keywords":"Lenvatinib; Medicine; Oncology; Thyroid cancer; Adverse effect; Internal medicine; Refractory (planetary science); Cancer","score_opus":0.23130467568283522,"score_gpt":0.45538061299538324,"score_spread":0.22407593731254802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220717070","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014009606,0.98174286,0.00025728365,0.0010205674,0.0013128556,0.0126529,0.0026736949,0.000063484345,0.00013627115],"genre_scores_gemma":[0.00009350373,0.9612131,0.0004550559,0.000107501,0.0009433344,0.033238936,0.0021361606,0.00011257273,0.0016998224],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970011,0.00025704785,0.0013507855,0.00067984936,0.0002696946,0.0004415368],"domain_scores_gemma":[0.9916236,0.005737298,0.001351303,0.0010556016,0.00011420646,0.00011800391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045076726,0.0007095647,0.003019022,0.00009075813,0.00046561437,0.000029598925,0.00036755952,0.00030356724,0.00056978414],"category_scores_gemma":[0.000106755884,0.0003087261,0.0023187052,0.00022808195,0.0002939603,0.00002372921,0.000049702183,0.00018047227,0.0000034259524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084089185,0.0046742843,0.00008185673,0.0012139154,0.0042412197,0.0000053317585,0.00010730524,0.00042914427,1.5869439e-7,0.00009203813,0.0030020117,0.98531187],"study_design_scores_gemma":[0.009169377,0.02013174,0.00008925664,0.000638502,0.019732466,0.000012006939,0.000065878754,0.00038346407,0.0000065417175,0.000025355483,0.9494958,0.00024958854],"about_ca_topic_score_codex":0.00051666104,"about_ca_topic_score_gemma":0.0002477702,"teacher_disagreement_score":0.98506224,"about_ca_system_score_codex":0.0033756287,"about_ca_system_score_gemma":0.0009769901,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W4220913590","doi":"10.1093/oncolo/oyac067","title":"Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Daratumumab; Medicine; Internal medicine; Multiple myeloma; Hazard ratio; Oncology; Cohort; Bortezomib; Autologous stem-cell transplantation; Progression-free survival; Proportional hazards model; Surgery; Confidence interval; Chemotherapy","score_opus":0.026222690483483503,"score_gpt":0.32028486441752685,"score_spread":0.2940621739340433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220913590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994851,0.00083093025,0.000013191349,0.00200686,0.0001330172,0.0013392377,0.00029240176,0.00005027758,0.00048306835],"genre_scores_gemma":[0.9978752,0.0003566621,0.0008029458,0.000060902665,0.000045163404,0.00043166333,0.00007424505,0.00002544629,0.0003277488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718666,0.0010503824,0.00037387188,0.00034852966,0.00060251466,0.00043802845],"domain_scores_gemma":[0.9966531,0.0023526938,0.00016746807,0.00061467703,0.00005111034,0.00016094097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016299294,0.00020188943,0.00046839443,0.00018160255,0.00034380675,0.000016965998,0.00035837392,0.00007350394,0.0000610209],"category_scores_gemma":[0.0014811711,0.000127091,0.00007924777,0.00038787766,0.0003881629,0.000051983992,0.0003095696,0.0005322572,0.0000043943837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06560424,0.0016369123,0.84451306,0.00010176535,0.00018253927,0.0018695651,0.0013087335,0.000049982435,0.011540014,0.0000830918,0.00080339034,0.0723067],"study_design_scores_gemma":[0.019626029,0.003314084,0.97123283,0.00005404718,0.00007547799,0.00006864482,0.0007962496,0.0006804372,0.003002944,0.00016318019,0.0008572314,0.00012882691],"about_ca_topic_score_codex":0.0042178836,"about_ca_topic_score_gemma":0.0043488652,"teacher_disagreement_score":0.12671979,"about_ca_system_score_codex":0.0002018243,"about_ca_system_score_gemma":0.00029728646,"threshold_uncertainty_score":0.6376207},"labels":[],"label_agreement":null},{"id":"W4225723737","doi":"10.1093/oncolo/oyac092","title":"Longitudinal Changes in Skeletal Muscle Metabolism, Oxygen Uptake, and Myosteatosis During Cardiotoxic Treatment for Early-Stage Breast Cancer","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto","funders":"Canadian Institutes of Health Research; University Hospital Foundation; Heart and Stroke Foundation of Canada","keywords":"Medicine; Breast cancer; Skeletal muscle; Chemotherapy; Internal medicine; VO2 max; Cancer; Cardiology; Blood pressure; Heart rate","score_opus":0.03960038994207725,"score_gpt":0.30457004243541846,"score_spread":0.2649696524933412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225723737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926426,0.0011837654,0.0000068203617,0.004085309,0.00015565932,0.0012636469,0.00030702204,0.000044577315,0.00031060123],"genre_scores_gemma":[0.9959803,0.0007215093,0.000048139435,0.0002593161,0.0003702601,0.0013834507,0.000021516918,0.000026696685,0.0011887884],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989692,0.00008789051,0.00016251544,0.0002978649,0.0001921751,0.00029034592],"domain_scores_gemma":[0.99952394,0.000063876505,0.00008040579,0.00023189092,0.00002944823,0.000070461836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031210494,0.00016889528,0.000395049,0.000083978135,0.0003278939,0.000020797248,0.00007939482,0.000061321116,0.000110695364],"category_scores_gemma":[0.000011961256,0.00012516932,0.00014131398,0.00019161121,0.000111233996,0.00004508958,0.00006923969,0.00016569802,0.0000010558884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002651028,0.001182246,0.06841893,0.00038377923,0.0016614656,0.0002442688,0.011879539,0.0009411571,0.71813637,0.00038457918,0.0003421283,0.19377452],"study_design_scores_gemma":[0.004382996,0.0004764221,0.94972265,0.000021747803,0.00024654195,0.00013184935,0.0014086588,0.00005843923,0.027520956,0.000019050256,0.015848719,0.00016195663],"about_ca_topic_score_codex":0.001604735,"about_ca_topic_score_gemma":0.0013317794,"teacher_disagreement_score":0.8813037,"about_ca_system_score_codex":0.0007048277,"about_ca_system_score_gemma":0.000099085,"threshold_uncertainty_score":0.5104256},"labels":[],"label_agreement":null},{"id":"W4226080629","doi":"10.1093/oncolo/oyac085","title":"Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; London Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Medicine; Cancer; Hazard ratio; Internal medicine; Population; Retrospective cohort study; Proportional hazards model; Cohort; Health care; Bladder cancer; Lung cancer; Emergency medicine; Oncology; Environmental health; Confidence interval","score_opus":0.07398580857859918,"score_gpt":0.3731836956369571,"score_spread":0.2991978870583579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226080629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929983,0.004956844,0.000010197964,0.0001975543,0.00010654918,0.0013501672,0.00034943485,0.000017472436,0.0000134578395],"genre_scores_gemma":[0.99838537,0.000026081905,0.00002390358,0.00019586083,0.0000029420198,0.00010042918,0.0012100801,0.000016495129,0.00003881759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727935,0.001707388,0.00045457683,0.00025917124,0.000070980524,0.00022851664],"domain_scores_gemma":[0.9988276,0.0001924549,0.00041601114,0.00050351635,0.000055484477,0.000004932045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000635306,0.00014887418,0.00035303747,0.00014565421,0.00031976972,0.0000069052476,0.0004251784,0.000049627197,0.00022175745],"category_scores_gemma":[0.000037705293,0.0001049689,0.000022144892,0.00051204313,0.000102788246,0.00006680309,0.00009665847,0.00026841258,5.524169e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00793018,0.0014425911,0.97318095,0.000011724995,0.000094417956,0.0000015402742,0.0068223816,0.0019628918,0.00056261534,0.0000051291017,0.000018979352,0.007966609],"study_design_scores_gemma":[0.008266508,0.0032010307,0.97439235,0.000060536884,0.0000168965,9.357951e-7,0.01291106,0.00008166559,0.000440141,0.0000018041217,0.00050015235,0.00012693858],"about_ca_topic_score_codex":0.020300554,"about_ca_topic_score_gemma":0.005307571,"teacher_disagreement_score":0.014992983,"about_ca_system_score_codex":0.0006060958,"about_ca_system_score_gemma":0.00047597472,"threshold_uncertainty_score":0.98622334},"labels":[],"label_agreement":null},{"id":"W4234840939","doi":"10.1634/theoncologist.2017-0283","title":"In Reply","year":2017,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine","score_opus":0.07220726066017526,"score_gpt":0.3398013643898503,"score_spread":0.26759410372967507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234840939","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004348101,0.0005135271,4.5293936e-7,0.83616406,0.00047159012,0.00057135074,0.000006867434,0.000029035202,0.15789501],"genre_scores_gemma":[0.012860586,0.000078706114,0.00009024014,0.8298744,0.004498382,0.00011508694,0.00008452562,0.000037741047,0.15236032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987377,0.00011083131,0.000236656,0.0003280773,0.00027290167,0.00031385128],"domain_scores_gemma":[0.997937,0.00020341961,0.00022980344,0.0015610742,0.000036126115,0.000032546595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032394732,0.00022836245,0.00052519207,0.00007285279,0.000090937865,0.000032016927,0.000396509,0.00042604562,0.00025156958],"category_scores_gemma":[0.00019349068,0.00012227059,0.00015797146,0.000040805466,0.0003526056,0.00002464556,0.00010891822,0.001675972,0.0006602395],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006274914,0.000037409533,0.0005286522,0.00006088797,0.000043972017,0.024111697,0.000047413672,2.1270071e-7,0.000021677879,0.000005961585,0.9744424,0.0006369709],"study_design_scores_gemma":[0.000732515,0.00043237844,0.0077459477,0.00010199752,0.00016391063,0.0006608348,0.0000075052135,0.0000016921654,0.00013354955,0.00024504354,0.9896588,0.0001158553],"about_ca_topic_score_codex":0.0011176827,"about_ca_topic_score_gemma":0.00006101675,"teacher_disagreement_score":0.023450864,"about_ca_system_score_codex":0.00065403833,"about_ca_system_score_gemma":0.0002535084,"threshold_uncertainty_score":0.8486263},"labels":[],"label_agreement":null},{"id":"W4235646239","doi":"10.1634/theoncologist.2014-0036","title":"Overdiagnosing Overdiagnosis","year":2014,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Overdiagnosis; Medicine; Mammography; Confounding; Breast cancer; Mammography screening; Medical physics; Family medicine; Cancer; Pathology; Internal medicine","score_opus":0.15198976949068316,"score_gpt":0.3821809338026931,"score_spread":0.23019116431200992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235646239","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000705758,0.0009936685,0.00007390683,0.93041265,0.00073815434,0.00048909575,0.000015393915,0.00014199688,0.06642939],"genre_scores_gemma":[0.012086456,0.00029708093,0.00027231206,0.9706593,0.012353818,0.00011337616,0.00011747073,0.000051924668,0.004048276],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978607,0.00016816682,0.00033977823,0.0004304293,0.00064601575,0.0005548679],"domain_scores_gemma":[0.99777675,0.00092729554,0.00026131564,0.00085063046,0.00011037922,0.000073619325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053242006,0.00033409524,0.00069103803,0.000068030065,0.00023092591,0.00007870478,0.00043545972,0.00080427463,0.0004840939],"category_scores_gemma":[0.00044680756,0.00020831233,0.00034341204,0.00018463083,0.0003744247,0.0000496878,0.0001493792,0.0022471438,0.0005788335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038085334,0.000015416346,0.0016759483,0.00007782379,0.000080084996,0.0010655589,0.000028547125,0.0000057954803,0.0000072395096,0.000042742064,0.99377155,0.0031911936],"study_design_scores_gemma":[0.00042539948,0.00043425852,0.0022610724,0.0004238648,0.00044179254,0.00040228845,0.000028200924,0.000022501406,0.000059067657,0.0002740056,0.9949864,0.00024112061],"about_ca_topic_score_codex":0.00085532636,"about_ca_topic_score_gemma":0.00003716018,"teacher_disagreement_score":0.062381115,"about_ca_system_score_codex":0.00053776207,"about_ca_system_score_gemma":0.0002544264,"threshold_uncertainty_score":0.9762847},"labels":[],"label_agreement":null},{"id":"W4236681238","doi":"10.1634/theoncologist.2014-0232","title":"In Reply","year":2014,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Anthracycline; Radiation therapy; Lymphoma; Oncology; Chemotherapy; Internal medicine; Diffuse large B-cell lymphoma; Intensive care medicine; Cancer; Breast cancer","score_opus":0.041495251654115176,"score_gpt":0.3193977156798092,"score_spread":0.277902464025694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236681238","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013630472,0.00030246054,7.6240053e-7,0.9308006,0.00032476487,0.00041704124,0.000004674504,0.00003308722,0.06675353],"genre_scores_gemma":[0.011011043,0.00012056299,0.0000636461,0.9665466,0.003258687,0.00017736392,0.00008342246,0.000021756618,0.018716924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989942,0.00010343464,0.00021636496,0.0002524495,0.000187518,0.00024604448],"domain_scores_gemma":[0.9988475,0.00036176012,0.00010927861,0.00063356827,0.00002270137,0.00002517968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023710715,0.00017725946,0.00043692457,0.000053572705,0.000037262485,0.000014908413,0.00015460512,0.0003318393,0.00026348993],"category_scores_gemma":[0.00009529759,0.00009018664,0.000121522986,0.000077073906,0.00015240586,0.000011194498,0.000046605663,0.00060896215,0.00072781043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024746112,0.00010039005,0.0021172632,0.000037661153,0.000045342927,0.0035230985,0.000033123324,2.9006836e-7,0.0000013862652,0.000050708542,0.9927806,0.0012853841],"study_design_scores_gemma":[0.0011856646,0.00038030327,0.0069501065,0.00008746312,0.00014098677,0.00024956398,0.0000055147325,0.0000032154492,0.000033697535,0.00024016055,0.9906311,0.00009224655],"about_ca_topic_score_codex":0.00084397016,"about_ca_topic_score_gemma":0.000046117624,"teacher_disagreement_score":0.048036605,"about_ca_system_score_codex":0.0005134575,"about_ca_system_score_gemma":0.00013599705,"threshold_uncertainty_score":0.9354774},"labels":[],"label_agreement":null},{"id":"W4241446446","doi":"10.1634/theoncologist.2016-0469","title":"In Reply","year":2017,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Palbociclib; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Gynecology; Cancer","score_opus":0.049334204669764445,"score_gpt":0.36627834033573087,"score_spread":0.3169441356659664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241446446","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002567742,0.0008561598,0.000012591568,0.96192014,0.00074424024,0.00044078287,0.000013158393,0.000055296743,0.03570087],"genre_scores_gemma":[0.0014251219,0.00006593848,0.00027093192,0.91190124,0.007374626,0.000108748194,0.000035249144,0.000046649257,0.0787715],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99884474,0.000072555755,0.00021596186,0.00030583804,0.00022647424,0.0003344011],"domain_scores_gemma":[0.9981056,0.00017748616,0.00026700858,0.0013818652,0.000044051674,0.000024032142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027541624,0.0002128576,0.0005005561,0.00006426072,0.00010274232,0.000023414825,0.0004885307,0.00037529235,0.0002984657],"category_scores_gemma":[0.0002096035,0.000126273,0.00010322287,0.000050244173,0.00062533806,0.000052045838,0.00009642079,0.002057682,0.00024930958],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013656117,0.000018853803,0.00013635286,0.000058635203,0.000040365096,0.003553787,0.00009491436,9.3663084e-7,0.00003253388,0.000016000296,0.98811585,0.0077952067],"study_design_scores_gemma":[0.0008376995,0.00015116595,0.0015169522,0.00015573167,0.000055193374,0.0004874148,0.000017945667,0.0000015213677,0.00004141497,0.0015030722,0.9950961,0.00013580572],"about_ca_topic_score_codex":0.00043873547,"about_ca_topic_score_gemma":0.000055952944,"teacher_disagreement_score":0.050018895,"about_ca_system_score_codex":0.00046393857,"about_ca_system_score_gemma":0.00025436745,"threshold_uncertainty_score":0.8939719},"labels":[],"label_agreement":null},{"id":"W4245164110","doi":"10.1634/theoncologist.2015-0465","title":"In Reply","year":2016,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sarcopenia; Medicine; Cachexia; Cancer cachexia; Skeletal muscle; Computed tomography; Cancer; Muscle mass; Mechanism (biology); Bioinformatics; Intensive care medicine; Internal medicine; Surgery","score_opus":0.08351319906884719,"score_gpt":0.3955907078188597,"score_spread":0.3120775087500125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245164110","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007414528,0.00024966206,0.0000056986764,0.9204835,0.00068055815,0.00037049895,0.000008620211,0.00004802628,0.07807928],"genre_scores_gemma":[0.00021250868,0.0002704683,0.00014732376,0.9241756,0.009175754,0.00005878629,0.000020689184,0.000019422,0.06591944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989685,0.00010682998,0.00026079305,0.0001935362,0.00016698803,0.00030339416],"domain_scores_gemma":[0.99912757,0.0002747803,0.00010845638,0.00042392124,0.000033117743,0.000032154196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004742414,0.00011416712,0.00031992808,0.000090216985,0.000051490253,0.00000747905,0.00014411219,0.00032085652,0.0008838574],"category_scores_gemma":[0.000107286,0.000057408764,0.00006224398,0.00008158435,0.00018399734,0.000015912128,0.00003698557,0.0014303076,0.0006974609],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038181865,0.00001340738,0.00018985996,0.0001569191,0.0000055138216,0.0011200099,0.000030074569,5.9754046e-9,0.00001526549,0.000076584605,0.99690336,0.0014507987],"study_design_scores_gemma":[0.00084313285,0.000116031115,0.00046850488,0.00037113557,0.000018113768,0.00014934581,0.000009022869,7.3761163e-7,0.000015071946,0.001602431,0.99633455,0.00007189088],"about_ca_topic_score_codex":0.00010686504,"about_ca_topic_score_gemma":0.000015616757,"teacher_disagreement_score":0.012159849,"about_ca_system_score_codex":0.00034421956,"about_ca_system_score_gemma":0.00018359927,"threshold_uncertainty_score":0.9677619},"labels":[],"label_agreement":null},{"id":"W4248773577","doi":"10.1634/theoncologist.7-2004-14","title":"Molecular Targets of Arsenic Trioxide in Malignant Cells","year":2002,"lang":"en","type":"article","venue":"The Oncologist","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Medicine; Cancer research; Multiple myeloma; Leukemia; Apoptosis; Immunology; Chemistry; Biology; Cell culture; Biochemistry; Retinoic acid","score_opus":0.013206392662649053,"score_gpt":0.23846106538802242,"score_spread":0.22525467272537336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248773577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98370653,0.0049288403,0.00036192025,0.0002706217,0.00010637978,0.00016678087,0.0000038995445,0.000007289629,0.010447734],"genre_scores_gemma":[0.99716085,0.0009667996,0.00030746893,0.00022957641,0.000052739757,0.000020088353,0.0000076155957,0.000013372643,0.0012414897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991067,0.00010515103,0.00024487812,0.00021669433,0.000109007466,0.0002175461],"domain_scores_gemma":[0.99943143,0.000024685683,0.000112545,0.000363742,0.000036538717,0.000031037634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002652387,0.000118300464,0.00016183183,0.000026563037,0.000032579133,0.000007470485,0.00034864488,0.0001343338,0.000059450853],"category_scores_gemma":[0.00008885695,0.00008252671,0.0000849146,0.0001198281,0.0002298914,0.0000017036189,0.00009692433,0.000104927625,0.00002208096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030878076,0.00010244399,0.0006727057,0.000018826513,0.000016062913,0.00003010313,0.00004870439,0.00041937345,0.9956849,0.00016489469,0.0017122336,0.0010988641],"study_design_scores_gemma":[0.00045418495,0.00024522553,0.00017795926,0.000011303059,0.000012861927,0.000009885814,0.00011090558,0.0001418591,0.98053247,0.00018308162,0.018003486,0.0001167927],"about_ca_topic_score_codex":0.00003310614,"about_ca_topic_score_gemma":0.0000309671,"teacher_disagreement_score":0.016291253,"about_ca_system_score_codex":0.000026820626,"about_ca_system_score_gemma":0.000047034595,"threshold_uncertainty_score":0.33653417},"labels":[],"label_agreement":null},{"id":"W4255053766","doi":"10.1634/theoncologist.5-6-510","title":"The Cell Cycle","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"","field":"","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine","score_opus":0.012790185639053554,"score_gpt":0.27035796731703216,"score_spread":0.2575677816779786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255053766","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41170526,0.0003079712,0.0000013406619,0.0030185364,0.00010257994,0.0001853209,0.000010748247,0.00017296994,0.58449525],"genre_scores_gemma":[0.9493615,0.00009442,0.000051698116,0.00056506257,0.00017762845,0.000034640776,0.0000020939094,0.000032692045,0.049680255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895775,0.00023837507,0.00014106403,0.00013848275,0.00018236527,0.00034194536],"domain_scores_gemma":[0.9987875,0.00045442252,0.000059489146,0.0006354988,0.000020590363,0.000042494245],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00088800525,0.00010110404,0.00009176731,0.0000081866265,0.00070467696,0.00007819114,0.0007450394,0.00004635756,0.0016735112],"category_scores_gemma":[0.000052148567,0.000044454573,0.000060090075,0.00018898354,0.0006735321,0.000040697865,0.0000586551,0.00019929447,0.0658438],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051123335,0.00045446336,0.0006562426,0.0000045196616,0.000041105275,0.00004235301,0.0011138397,0.002541889,0.0064035747,0.004380925,0.828616,0.15523383],"study_design_scores_gemma":[0.00034485233,0.00010150787,0.0058194697,0.0000016784571,0.000020029305,0.00001017901,0.00021869829,0.0003808203,0.0015703692,0.0030110024,0.9884235,0.0000978758],"about_ca_topic_score_codex":0.0002433837,"about_ca_topic_score_gemma":0.0003671258,"teacher_disagreement_score":0.53765625,"about_ca_system_score_codex":0.00013373699,"about_ca_system_score_gemma":0.000054538476,"threshold_uncertainty_score":0.9992391},"labels":[],"label_agreement":null},{"id":"W4282973464","doi":"10.1093/oncolo/oyac101","title":"Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Quality of life (healthcare); Gynecology; Adverse effect; Internal medicine; Randomized controlled trial; Cancer","score_opus":0.018625086547519615,"score_gpt":0.3034899729161072,"score_spread":0.2848648863685876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282973464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936391,0.00029361845,0.0000061668125,0.004667103,0.0003713649,0.00025031003,0.0007060859,0.0000040016475,0.00006224743],"genre_scores_gemma":[0.998978,0.000044808752,0.000013982793,0.0006145502,0.0000565371,0.00017778257,0.00009201798,0.0000069799903,0.000015300311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992124,0.00017569,0.00016223124,0.00019150398,0.00015977705,0.00009842315],"domain_scores_gemma":[0.99961907,0.000026727881,0.00012259856,0.00016559452,0.00004522696,0.0000207813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008268002,0.0001035241,0.000106033345,0.000016611932,0.00016010572,0.000013427088,0.0000996107,0.000032084343,0.00011527692],"category_scores_gemma":[0.000013932892,0.000056705932,0.000043365246,0.000031234045,0.000070682276,0.000004404021,0.00018501758,0.00007397664,4.0124453e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010630696,0.001561714,0.786759,0.0000041088692,0.001057725,0.000019265746,0.0052130534,0.013249457,0.15942784,0.00018146313,0.0017739461,0.02012172],"study_design_scores_gemma":[0.0014131155,0.0004701666,0.9911516,0.000007738967,0.000028881177,0.00001396232,0.0013949764,0.0002228769,0.004355729,0.00015020683,0.00071189506,0.00007887802],"about_ca_topic_score_codex":0.0048800088,"about_ca_topic_score_gemma":0.0007455807,"teacher_disagreement_score":0.20439255,"about_ca_system_score_codex":0.00014290796,"about_ca_system_score_gemma":0.00008045646,"threshold_uncertainty_score":0.7377146},"labels":[],"label_agreement":null},{"id":"W4283022221","doi":"10.1093/oncolo/oyac106","title":"The Value of In Vivo Reflectance Confocal Microscopy as an Assessment Tool in Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; RWTH Aachen University; Bundesministerium für Bildung und Forschung; Medical Research Foundation; Melville Charitable Trust","keywords":"Medicine; Peripheral neuropathy; Chemotherapy-induced peripheral neuropathy; In vivo; Confocal microscopy; Chemotherapy; Confocal; Pathology; Peripheral; Radiology; Internal medicine; Optics","score_opus":0.04574533894228266,"score_gpt":0.4373136524696243,"score_spread":0.3915683135273416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283022221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99115884,0.00011428678,0.0000014663722,0.0034640487,0.00033247878,0.0016143818,0.0000063709163,0.000020935187,0.0032871838],"genre_scores_gemma":[0.99653107,0.000059755745,0.000041463507,0.0019719026,0.00007743274,0.00052913855,0.0000029962432,0.000018628458,0.00076762476],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813616,0.00078869396,0.00033148777,0.00025070575,0.00023549228,0.00025748377],"domain_scores_gemma":[0.9992337,0.00023961699,0.00013312743,0.00033796465,0.00002697262,0.000028570701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000986326,0.00014150463,0.00032709568,0.00004715346,0.00019802876,0.000014340848,0.00028295632,0.000021900181,0.00037281073],"category_scores_gemma":[0.00002444646,0.00008831251,0.000037586105,0.00030272227,0.00015755348,0.00002940579,0.0000947986,0.00044724575,0.0000014667004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017879901,0.013471023,0.14026634,0.000016155762,0.00012576963,0.00045688156,0.0063324813,0.00028866445,0.81506515,0.0012062257,0.0007369434,0.004154488],"study_design_scores_gemma":[0.036202684,0.15721954,0.75859344,0.000026028452,0.00021329758,0.00015681042,0.011504388,0.0023653586,0.021265814,0.0008021536,0.011253584,0.0003969144],"about_ca_topic_score_codex":0.0018910506,"about_ca_topic_score_gemma":0.00250363,"teacher_disagreement_score":0.7937993,"about_ca_system_score_codex":0.0007656615,"about_ca_system_score_gemma":0.00052783353,"threshold_uncertainty_score":0.4082016},"labels":[],"label_agreement":null},{"id":"W4283693701","doi":"10.1093/oncolo/oyac114","title":"Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer Canada; McGill University; Pfizer","keywords":"Randomized controlled trial; Medicine; Psychological intervention; Clinical trial; Intervention (counseling); Intensive care medicine; Alternative medicine; Real world data; Medical physics; Oncology; Internal medicine; Data science; Pathology; Nursing; Computer science","score_opus":0.3162898071314984,"score_gpt":0.4826416858563563,"score_spread":0.1663518787248579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283693701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003752589,0.9458914,3.8919148e-7,0.012279156,0.00007117236,0.0023965887,0.00011344786,0.000012018978,0.039232075],"genre_scores_gemma":[0.00005461015,0.9959335,0.00016416232,0.0015834009,0.00007129611,0.0010812739,0.000059298403,0.000019966486,0.0010325045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99806714,0.00066881033,0.00057710585,0.00032843108,0.0001734339,0.00018505797],"domain_scores_gemma":[0.9923549,0.0066513084,0.000427934,0.0003292656,0.0001078083,0.00012877383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011551213,0.00021001727,0.0013878691,0.00030959735,0.00013091096,0.00000811759,0.00015581216,0.00011150232,0.00032190635],"category_scores_gemma":[0.0027686202,0.00014916805,0.00011125979,0.00072911615,0.00051646377,0.000049910264,0.000064565145,0.00063904695,0.0000046282435],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003091055,0.00008465059,0.00003866136,0.010201617,0.00016334814,0.00006125323,0.0006646667,6.140127e-7,2.5964727e-7,0.007850686,0.009691422,0.9712119],"study_design_scores_gemma":[0.00029199832,0.00032631846,0.00025610923,0.01571446,0.0010656421,0.00012348991,0.00044531285,0.0000010366917,7.3700974e-8,0.00024384586,0.9814111,0.00012063345],"about_ca_topic_score_codex":0.036986403,"about_ca_topic_score_gemma":0.36083266,"teacher_disagreement_score":0.9717197,"about_ca_system_score_codex":0.003367831,"about_ca_system_score_gemma":0.0050706444,"threshold_uncertainty_score":0.9694264},"labels":[],"label_agreement":null},{"id":"W4285084462","doi":"10.1093/oncolo/oyac123","title":"Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University Health Centre; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Exact Sciences Corporation","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Prospective cohort study; Observational study; Cancer; Lymph node; Estrogen receptor; Progesterone receptor; Clinical trial; Gynecology","score_opus":0.018000210044577625,"score_gpt":0.3062927976328524,"score_spread":0.28829258758827475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285084462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997464,0.00013709666,0.0000011585088,0.00035815922,0.000055526332,0.0011290868,0.00078522833,0.0000021051153,0.000067609326],"genre_scores_gemma":[0.99922603,0.000063259824,0.000008061318,0.00008124058,0.000013768757,0.0005224668,0.000035932295,0.000009258901,0.000039961116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99896353,0.00028963195,0.00014922443,0.00027713832,0.00014855781,0.00017193289],"domain_scores_gemma":[0.99941546,0.000094415,0.00011622479,0.00030260446,0.00004684412,0.000024439161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012861298,0.00016433132,0.00019647786,0.000030543364,0.00015584248,0.000007971669,0.00017611336,0.000025306397,0.000009391882],"category_scores_gemma":[0.00002844052,0.00007723668,0.000048647293,0.00016564854,0.00017991742,0.0000030088095,0.0002443688,0.00009641416,2.9920167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026639143,0.00257943,0.98101526,7.9749736e-7,0.00014699761,0.0000036332333,0.0009786916,0.0010313599,0.00012382539,8.485368e-7,0.000053383315,0.011401834],"study_design_scores_gemma":[0.004525722,0.0020338064,0.992404,0.000029522158,0.00004603712,0.0000019134898,0.00062417367,0.000008989674,0.00021588647,0.0000013766401,0.000025411613,0.000083158855],"about_ca_topic_score_codex":0.044565596,"about_ca_topic_score_gemma":0.11568325,"teacher_disagreement_score":0.071117654,"about_ca_system_score_codex":0.00085047656,"about_ca_system_score_gemma":0.00018459921,"threshold_uncertainty_score":0.9617967},"labels":[],"label_agreement":null},{"id":"W4288034414","doi":"10.1093/oncolo/oyac142","title":"Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Eisai; Merck","keywords":"Lenvatinib; Medicine; Everolimus; Renal cell carcinoma; Quality of life (healthcare); Internal medicine; Oncology; Adverse effect; Clinical trial; Sorafenib; Hepatocellular carcinoma","score_opus":0.06752936432084708,"score_gpt":0.32773573030721215,"score_spread":0.26020636598636504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288034414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944321,0.00038966967,0.00003105416,0.0022257827,0.000025428979,0.002445656,0.000045153774,0.000028635222,0.00037651186],"genre_scores_gemma":[0.99877286,0.000005903974,0.00029129986,0.00016243155,0.000007319266,0.00034233698,0.00010968631,0.000024868143,0.00028331485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974795,0.00060009875,0.00091919454,0.00026316714,0.0004450581,0.000292975],"domain_scores_gemma":[0.9975726,0.00076286873,0.0010747695,0.00037776164,0.00012739164,0.000084628766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010143551,0.00020822842,0.0009779506,0.000111169546,0.00013675669,0.0000044342714,0.00014211205,0.000034883582,0.000031244024],"category_scores_gemma":[0.000116308256,0.00011152865,0.00010202787,0.00029450137,0.00019443229,0.00002827081,0.00006732144,0.00022199278,3.1710917e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009079765,0.0020350476,0.982149,0.0004045064,0.00012946762,0.000016282564,0.0021028789,0.0009412494,0.0021837114,0.00016222945,0.00006637048,0.0007294698],"study_design_scores_gemma":[0.020317351,0.016637363,0.95346427,0.00006557672,0.00016202468,0.00000974951,0.0014255297,0.00024330545,0.00745968,0.00008749611,0.000008834999,0.000118843614],"about_ca_topic_score_codex":0.0069106235,"about_ca_topic_score_gemma":0.0018248355,"teacher_disagreement_score":0.028684776,"about_ca_system_score_codex":0.00066173595,"about_ca_system_score_gemma":0.00040716646,"threshold_uncertainty_score":0.99970245},"labels":[],"label_agreement":null},{"id":"W4291209167","doi":"10.1093/oncolo/oyac165","title":"Supporting Patients with Cancer after <i>Dobbs v. Jackson Women’s Health Organization</i>","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Supreme court; Context (archaeology); Medicine; Law; Psychology; Gerontology; Political science; History","score_opus":0.009224615127688128,"score_gpt":0.3014394524339645,"score_spread":0.2922148373062764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291209167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274176,0.00022227415,0.000022020682,0.0056198305,0.00026100394,0.00048535323,0.00009286199,0.000058138765,0.0004967689],"genre_scores_gemma":[0.98820525,0.00005478222,0.000028769424,0.009814802,0.00010952953,0.00031898404,0.000058097467,0.000026990734,0.001382761],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989689,0.00005882777,0.00019316938,0.00017395064,0.0002858472,0.00031928648],"domain_scores_gemma":[0.9993991,0.00002862667,0.00018734507,0.00021092105,0.000076784956,0.0000972056],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025936123,0.00009726703,0.0002052441,0.000026501528,0.00032984948,0.000013516413,0.00009535053,0.000017999133,0.004518132],"category_scores_gemma":[0.00003291543,0.000058060352,0.000021041398,0.00032789298,0.000078571255,0.00003031262,0.00010084037,0.00022515886,0.000010317507],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029972594,0.00020057718,0.973615,0.000022750253,0.00003265943,0.000009337203,0.0044806744,0.000077435485,0.000009474702,0.000014464136,0.015246753,0.005991138],"study_design_scores_gemma":[0.0016866641,0.0012853085,0.795746,0.00001564434,0.000031829586,0.000007670697,0.0021037282,0.0000075251455,0.000030385585,0.000013461281,0.19895643,0.000115299714],"about_ca_topic_score_codex":0.00168445,"about_ca_topic_score_gemma":0.00034938566,"teacher_disagreement_score":0.18370968,"about_ca_system_score_codex":0.0015944229,"about_ca_system_score_gemma":0.00051935937,"threshold_uncertainty_score":0.9963919},"labels":[],"label_agreement":null},{"id":"W4292616279","doi":"10.1093/oncolo/oyac130","title":"The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Biomarker; Oncology; Breast cancer; Cancer; Colorectal cancer; Lung cancer; Internal medicine; Timeline; Randomized controlled trial","score_opus":0.857347171000808,"score_gpt":0.6903379268061591,"score_spread":0.1670092441946489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292616279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654118,0.0001724757,0.003959206,0.01848498,0.0029839016,0.006987078,0.00082838826,0.000037763584,0.0011344174],"genre_scores_gemma":[0.97419006,0.00026162178,0.022469461,0.0005883457,0.00054358575,0.0009591984,0.0000025658194,0.00004078519,0.0009443914],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9764141,0.020690676,0.0021337187,0.00021479822,0.00037694085,0.00016980118],"domain_scores_gemma":[0.41222408,0.58598065,0.0012893146,0.00041487964,0.000065594984,0.00002543446],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.105237454,0.00011991741,0.0009665699,0.00001590251,0.000343216,0.000025245236,0.00040163382,0.00008678642,0.00013584041],"category_scores_gemma":[0.5295992,0.00004438887,0.0003148253,0.00013317473,0.0009399996,0.000015498603,0.00019328018,0.00028969676,8.8525786e-7],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033833556,0.00058461603,0.0029832139,0.0002842513,0.0012221321,0.0000023918335,0.00054937805,0.00003873514,0.0023355817,0.43635604,0.076287195,0.4455229],"study_design_scores_gemma":[0.0077559827,0.0076189954,0.00787139,0.00008944571,0.0014071723,0.000002238458,0.00062589056,0.0034766777,0.00876667,0.9428698,0.019288763,0.00022697967],"about_ca_topic_score_codex":0.000063996515,"about_ca_topic_score_gemma":0.00002007519,"teacher_disagreement_score":0.56529,"about_ca_system_score_codex":0.000042264648,"about_ca_system_score_gemma":0.000073919495,"threshold_uncertainty_score":0.92134637},"labels":[],"label_agreement":null},{"id":"W4295898265","doi":"10.1093/oncolo/oyac184","title":"Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Placebo; Adverse effect; Cancer-related fatigue; Randomized controlled trial; Depression (economics); Physical therapy; Cancer; Internal medicine; Clinical trial; Chronic fatigue; Chronic fatigue syndrome","score_opus":0.040953403721906,"score_gpt":0.3632849129028943,"score_spread":0.3223315091809883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295898265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95178264,0.00421346,0.000016370159,0.0044311136,0.0013007214,0.03693473,0.00016707262,0.000028646224,0.001125251],"genre_scores_gemma":[0.9424857,0.00085647835,0.00003242266,0.00027782487,0.00006379241,0.05444938,0.00003566916,0.00002131491,0.0017774099],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982604,0.00048078483,0.00051171385,0.00022949764,0.0002923656,0.00022527594],"domain_scores_gemma":[0.9969877,0.00206577,0.0004560984,0.00033569481,0.00011605227,0.00003869254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094723556,0.00018150681,0.0014317761,0.000045617973,0.00023329312,0.000014252006,0.00032540265,0.000043136763,0.00024460736],"category_scores_gemma":[0.0001235695,0.00007697705,0.00017155462,0.00026717648,0.00020083351,0.000027993769,0.0000660445,0.00014346553,2.9071447e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9748158,0.0021255864,0.0011295961,0.00001326506,0.00086529565,0.0000021569592,0.0024618546,0.0010586914,0.0000069360794,0.00012420992,0.00019364317,0.017203],"study_design_scores_gemma":[0.98032486,0.009859828,0.00041343205,0.000035901117,0.0011809997,3.6056437e-7,0.00085473096,0.0008274166,0.000032063577,0.000042269065,0.00632931,0.000098839664],"about_ca_topic_score_codex":0.012326827,"about_ca_topic_score_gemma":0.01765856,"teacher_disagreement_score":0.017514652,"about_ca_system_score_codex":0.0009646111,"about_ca_system_score_gemma":0.0006625105,"threshold_uncertainty_score":0.9942502},"labels":[],"label_agreement":null},{"id":"W4296797608","doi":"10.1093/oncolo/oyac192","title":"Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Everolimus; Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Urology; Tolerability; Phases of clinical research; Clinical trial","score_opus":0.01675006100570516,"score_gpt":0.2691139331315795,"score_spread":0.25236387212587436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296797608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921189,0.00081100815,0.000005433426,0.00042715904,0.0002146149,0.005029898,0.000050323255,0.000032315515,0.001310329],"genre_scores_gemma":[0.99711317,0.000033498603,0.00023475714,0.0003989493,0.000068058216,0.001495198,0.00013192139,0.000041413343,0.0004830333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971914,0.00076240476,0.0006355575,0.00037966325,0.0006522958,0.00037866205],"domain_scores_gemma":[0.9984628,0.00029952574,0.00041285134,0.00061704573,0.00010598707,0.00010182244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075109716,0.00030011308,0.0010923995,0.00013711586,0.00017653304,0.0000073569768,0.0002470601,0.00006765081,0.0004611695],"category_scores_gemma":[0.000070730726,0.00016849398,0.00025886836,0.00033307527,0.00032080308,0.00005114814,0.00014653623,0.0003570974,0.000004493251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98151004,0.0069039697,0.0058334786,0.000018905886,0.00011123984,0.00014435292,0.0011093543,0.00010179152,0.001329385,0.0000052482437,0.00014590548,0.0027863188],"study_design_scores_gemma":[0.9072779,0.049605522,0.034455575,0.000016405804,0.00024403703,0.000005549474,0.0001608992,0.000042502666,0.00740499,0.00003212995,0.0005796802,0.00017481286],"about_ca_topic_score_codex":0.00023494476,"about_ca_topic_score_gemma":0.000028312239,"teacher_disagreement_score":0.07423215,"about_ca_system_score_codex":0.00051021785,"about_ca_system_score_gemma":0.000295965,"threshold_uncertainty_score":0.6870985},"labels":[],"label_agreement":null},{"id":"W4297232106","doi":"10.1093/oncolo/oyac197","title":"TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Medicine; Germ cell tumors; Oncology; Germ cell; Internal medicine; Cancer research; Chemotherapy","score_opus":0.01275773032340499,"score_gpt":0.23259321674310549,"score_spread":0.2198354864197005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297232106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957194,0.00007750662,0.0000059295867,0.0006827523,0.00006130126,0.00066072063,0.00019254941,0.000045534434,0.0025543587],"genre_scores_gemma":[0.9981507,0.0000011551765,0.000085433814,0.00045782235,0.000028130287,0.0001771264,0.0006005885,0.00002019129,0.00047885109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988017,0.00015922727,0.0001690388,0.00020944513,0.00042755387,0.00023300269],"domain_scores_gemma":[0.99918526,0.00022872759,0.00020949668,0.00021240504,0.00007037522,0.00009373658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016573258,0.00014531804,0.00025831195,0.000049855757,0.0002483781,0.0000146885695,0.00010726093,0.000022605596,0.00015225603],"category_scores_gemma":[0.00011029514,0.00008298478,0.000040447005,0.00026399334,0.00012975762,0.000030934018,0.00007659883,0.000219395,0.000006740836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008760595,0.0027197427,0.9946916,0.000010356702,0.000068424466,0.0005527378,0.000120348785,0.00017537357,0.0000072191515,0.000009640067,0.00040362155,0.000364851],"study_design_scores_gemma":[0.005407453,0.0024457986,0.99126464,0.000046399204,0.00024306626,0.000014956023,0.00029412427,0.00005851794,0.000008885428,0.000009479744,0.00010160152,0.00010507708],"about_ca_topic_score_codex":0.0001395938,"about_ca_topic_score_gemma":0.0002745769,"teacher_disagreement_score":0.0045313938,"about_ca_system_score_codex":0.00054562173,"about_ca_system_score_gemma":0.0003696282,"threshold_uncertainty_score":0.3384021},"labels":[],"label_agreement":null},{"id":"W4307971007","doi":"10.1093/oncolo/oyac227","title":"Perceptions of Death Among Patients with Advanced Cancer Receiving Early Palliative Care and Their Caregivers: Results from a Mixed-Method Analysis","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Associazione Italiana per la Lotta al Neuroblastoma","keywords":"Medicine; Palliative care; Psychological intervention; Cancer; End-of-life care; Cause of death; Family medicine; Internal medicine; Oncology; Disease; Nursing","score_opus":0.054616540138306,"score_gpt":0.386246523418409,"score_spread":0.33162998328010296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307971007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947546,0.001237854,0.00044474227,0.00015846145,0.00005682188,0.00032933877,0.0018688771,0.000019454386,0.0011298165],"genre_scores_gemma":[0.99489105,0.0005586664,0.004016907,0.000040613915,0.000027064832,0.000075684795,0.0002611788,0.000011625637,0.00011723865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882704,0.00026278882,0.00024566098,0.00027733934,0.00023852987,0.00014864394],"domain_scores_gemma":[0.9984228,0.0005979265,0.00031412454,0.00030275085,0.00030674532,0.000055668053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001662686,0.00014346336,0.00049136975,0.000100827536,0.00018653931,0.0000058495643,0.00013970205,0.000042256237,0.00008230206],"category_scores_gemma":[0.00018298079,0.00008621027,0.00011556072,0.0005071128,0.00023743548,0.000048572892,0.00011847106,0.00021024348,3.221529e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082836597,0.000074733936,0.9104991,0.000019101572,0.00078641635,0.0000034528564,0.07401746,0.0013965704,0.00018938664,0.0000050632134,0.000059063663,0.012121284],"study_design_scores_gemma":[0.002049344,0.0009596431,0.905433,0.0001730299,0.0009174827,8.117747e-8,0.089375615,0.00013936905,0.0003507398,0.0000196438,0.00048621077,0.000095827],"about_ca_topic_score_codex":0.014479155,"about_ca_topic_score_gemma":0.0039696973,"teacher_disagreement_score":0.015358162,"about_ca_system_score_codex":0.0002933242,"about_ca_system_score_gemma":0.000093033086,"threshold_uncertainty_score":0.9920835},"labels":[],"label_agreement":null},{"id":"W4309098807","doi":"10.1093/oncolo/oyac235","title":"Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Public Health Ontario","funders":"University Health Network","keywords":"Medicine; Internal medicine; Cancer; Proportional hazards model; Esophageal cancer; Oncology; Clinical trial; Survival analysis","score_opus":0.05138439056493653,"score_gpt":0.3854788857640811,"score_spread":0.3340944951991446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309098807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973369,0.0012731684,0.00000429363,0.0005270036,0.000110551104,0.00059333025,0.000014921355,0.0000100576835,0.00012975578],"genre_scores_gemma":[0.99930817,0.0000830214,0.00015121457,0.00025135197,0.000024305655,0.00009332559,0.000007887315,0.000007149903,0.00007359586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999166,0.000117998934,0.00027594165,0.00013309772,0.00018360688,0.0001233565],"domain_scores_gemma":[0.9994538,0.00019870064,0.0001614218,0.00012907058,0.000030417516,0.0000266112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003283984,0.00006943226,0.00027168563,0.00003961466,0.0000707735,0.00000314467,0.00008345492,0.000022641781,0.00008664111],"category_scores_gemma":[0.00005624816,0.000040824758,0.000030396968,0.000223884,0.00028424544,0.000016674958,0.00005921306,0.00021372968,3.1684462e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008590492,0.0005005554,0.9254152,0.000018941912,0.00003942252,0.000006455863,0.00013637784,0.00007044733,0.00003416354,0.0000047499034,0.0002883043,0.06489485],"study_design_scores_gemma":[0.0061779553,0.0051420406,0.9875518,0.000038638147,0.000050744693,0.0000036449392,0.00021021739,0.00008136099,0.000026499152,0.0000067036094,0.0006652272,0.000045181736],"about_ca_topic_score_codex":0.00019861992,"about_ca_topic_score_gemma":0.00020782075,"teacher_disagreement_score":0.06484967,"about_ca_system_score_codex":0.00011001605,"about_ca_system_score_gemma":0.00013888424,"threshold_uncertainty_score":0.16647853},"labels":[],"label_agreement":null},{"id":"W4310051818","doi":"10.1093/oncolo/oyac226","title":"Management of Lung Cancer in the Patient with Interstitial Lung Disease","year":2022,"lang":"en","type":"review","venue":"The Oncologist","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Interstitial lung disease; Lung cancer; Radiation therapy; Hypersensitivity pneumonitis; Exacerbation; Idiopathic pulmonary fibrosis; Population; Pulmonary fibrosis; Pneumonitis; Lung biopsy; Lung; Treatment of lung cancer; Internal medicine; Intensive care medicine; Oncology","score_opus":0.03174755358443252,"score_gpt":0.3569824644853244,"score_spread":0.32523491090089185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310051818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000067203066,0.98777384,0.000011543167,0.0005299607,0.00038088643,0.0026371889,0.00037518205,0.000018501545,0.008205726],"genre_scores_gemma":[0.008057582,0.98925716,0.000011368983,0.0002854341,0.00017506049,0.001663935,0.00014829745,0.000035142297,0.0003660365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808145,0.00035385997,0.0004940337,0.00032107907,0.0004783162,0.0002712844],"domain_scores_gemma":[0.9987821,0.00015841374,0.00034023085,0.00061145966,0.000025527632,0.000082241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032090335,0.00030562075,0.00087096094,0.00008857793,0.00012598526,0.000017619328,0.0005210604,0.0000629304,0.0007308819],"category_scores_gemma":[0.000014517401,0.00013770709,0.00042531634,0.00034945982,0.00027904956,0.000027756883,0.00027175172,0.00051892526,0.0000032470132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057429248,0.0010857801,0.000096710246,0.061610628,0.0010966054,0.006391131,0.0005517352,0.000049132766,4.8828742e-8,0.0020744624,0.007957478,0.91334337],"study_design_scores_gemma":[0.0004083321,0.0014452055,0.00012217501,0.022756102,0.0067243576,0.0000771349,0.0006135665,0.00013032286,2.4146305e-8,0.000009358229,0.9675083,0.00020508794],"about_ca_topic_score_codex":0.000255612,"about_ca_topic_score_gemma":0.000025045236,"teacher_disagreement_score":0.95955086,"about_ca_system_score_codex":0.0007682522,"about_ca_system_score_gemma":0.00046207226,"threshold_uncertainty_score":0.80026436},"labels":[],"label_agreement":null},{"id":"W4327759154","doi":"10.1093/oncolo/oyad054","title":"Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Profiling (computer programming); Oncology; Computational biology; Internal medicine; Bioinformatics","score_opus":0.0974705394661203,"score_gpt":0.3897565459270083,"score_spread":0.292286006460888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327759154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879463,0.008401736,1.7869431e-7,0.0016229621,0.000045074125,0.001189869,0.00010234595,0.0000061513256,0.0006853987],"genre_scores_gemma":[0.9893005,0.010129223,0.0000820923,0.00003759632,0.00002587243,0.00037755107,0.000016993881,0.000006389023,0.00002381144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922526,0.000079948695,0.00031763772,0.00014272325,0.00012846249,0.000105998726],"domain_scores_gemma":[0.99889696,0.0005105461,0.00019489802,0.0003184978,0.00006079135,0.000018317989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002591597,0.00009081825,0.0004416883,0.00004749211,0.000021071897,0.0000014582129,0.00007831193,0.000039240487,0.00002087568],"category_scores_gemma":[0.000041338993,0.000044401175,0.00009821605,0.00021262153,0.0003000592,0.000011250088,0.00003970857,0.000039674924,4.8284363e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038860497,0.00086273364,0.9608343,0.00037434977,0.00010735025,0.000007323903,0.003219473,0.00004765438,0.0014898792,0.000120974226,0.000065961925,0.032481346],"study_design_scores_gemma":[0.002122785,0.0019184869,0.9692296,0.00016692317,0.00028253783,0.000001321026,0.0018248978,0.000010021486,0.024118029,0.000071146256,0.00021945348,0.00003483706],"about_ca_topic_score_codex":0.004074327,"about_ca_topic_score_gemma":0.0025636037,"teacher_disagreement_score":0.032446507,"about_ca_system_score_codex":0.0003744939,"about_ca_system_score_gemma":0.00019409227,"threshold_uncertainty_score":0.6159191},"labels":[],"label_agreement":null},{"id":"W4327910154","doi":"10.1093/oncolo/oyad022","title":"Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Gemcitabine; Oncology; Internal medicine; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Cancer; Adverse effect; Adenocarcinoma; Phases of clinical research; Chemotherapy; Urology; Immunotherapy; Pembrolizumab","score_opus":0.07993181896745435,"score_gpt":0.4131683534045474,"score_spread":0.333236534437093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327910154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657995,0.0027483476,0.000012913974,0.0029532672,0.0002856218,0.004190569,0.00001811827,0.00015048658,0.003060718],"genre_scores_gemma":[0.98922783,0.005882923,0.00017854711,0.00016673775,0.00021021493,0.0011342145,0.000029770214,0.000043839376,0.0031259344],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99720454,0.00036095857,0.00064267544,0.00052590756,0.00049845135,0.0007674837],"domain_scores_gemma":[0.99702746,0.0019348225,0.00020406961,0.0005243308,0.00009328564,0.00021604488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018839918,0.0003421077,0.0017391394,0.00028599225,0.00035507994,0.000027681222,0.00029568415,0.00017197024,0.00030480282],"category_scores_gemma":[0.0008157265,0.00021822068,0.00013866732,0.0009605803,0.00088344986,0.000082345075,0.00022283549,0.00057325134,0.00006977683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74698514,0.0024761644,0.21156117,0.00019058568,0.001509112,0.0024942385,0.009933747,0.000108963846,0.0010760762,0.000241942,0.0021261214,0.021296743],"study_design_scores_gemma":[0.77763456,0.009161819,0.19141074,0.00012150336,0.0010397465,0.00022826895,0.007974469,0.011446659,0.000057750298,0.00025234703,0.00034968936,0.00032245734],"about_ca_topic_score_codex":0.0022124501,"about_ca_topic_score_gemma":0.0006229294,"teacher_disagreement_score":0.030649414,"about_ca_system_score_codex":0.00077316916,"about_ca_system_score_gemma":0.00079085375,"threshold_uncertainty_score":0.8898781},"labels":[],"label_agreement":null},{"id":"W4361245262","doi":"10.1093/oncolo/oyad008","title":"Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"Janssen Biotech; Janssen Research and Development; Amgen; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; UroGen Pharma; Dendreon Pharmaceuticals; Progenics Pharmaceuticals; Sanofi; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Prednisone; Androgen receptor; Abiraterone; Androgen deprivation therapy; Internal medicine; Oncology; Cancer research; PARP1; Testosterone (patch); Pharmacology; Cancer; Poly ADP ribose polymerase; Polymerase; Gene; Biology; Genetics","score_opus":0.08989458193043044,"score_gpt":0.41774564722702856,"score_spread":0.32785106529659813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361245262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811773,0.00035843058,0.00006614098,0.012609091,0.00014978349,0.004327928,0.000733274,0.00021209651,0.00036597784],"genre_scores_gemma":[0.99164313,0.00032938732,0.0006021159,0.00037825358,0.00013399373,0.002342287,0.00013604668,0.00003911685,0.004395666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983671,0.00013649989,0.00044200144,0.00041259965,0.00028482272,0.00035697932],"domain_scores_gemma":[0.9988224,0.00024657458,0.0002554058,0.00039018184,0.00017609485,0.0001093343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010181123,0.00021978535,0.0004212264,0.000081396414,0.0004735909,0.000053567,0.00010799991,0.0000359933,0.000018356412],"category_scores_gemma":[0.00008016164,0.00013057828,0.000036795576,0.00039668853,0.00039791683,0.0000960574,0.00004350705,0.00015762566,0.000009122232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35462525,0.016378747,0.0065137357,0.0015964865,0.0053684423,0.0017473168,0.096751854,0.0041397065,0.3096387,0.0013726213,0.11676438,0.08510273],"study_design_scores_gemma":[0.45886204,0.23863389,0.06999059,0.0014483795,0.004788694,0.00041000862,0.037504,0.0059508313,0.051245395,0.0025221894,0.1265062,0.002137802],"about_ca_topic_score_codex":0.00050885696,"about_ca_topic_score_gemma":0.0023129424,"teacher_disagreement_score":0.25839332,"about_ca_system_score_codex":0.00018817188,"about_ca_system_score_gemma":0.00033992756,"threshold_uncertainty_score":0.53248274},"labels":[],"label_agreement":null},{"id":"W4362523523","doi":"10.1093/oncolo/oyad073","title":"Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Lactate dehydrogenase; Proportional hazards model; Oncology; Melanoma; Cohort; Retrospective cohort study; White blood cell; Cancer research","score_opus":0.020070594544156505,"score_gpt":0.2679739571272112,"score_spread":0.24790336258305473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362523523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802876,0.00006410371,0.00027860762,0.00017409745,0.00001751637,0.0012964456,0.000017431135,0.000046163714,0.00007685942],"genre_scores_gemma":[0.9958975,0.000048513517,0.003472079,0.000016747339,0.000008470215,0.00023405656,0.00010119947,0.000014604148,0.00020687655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937254,0.000018582627,0.00021649305,0.00013380541,0.0001291747,0.000129384],"domain_scores_gemma":[0.9994791,0.00008421991,0.00019211041,0.0001252451,0.00009546406,0.000023817842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024471543,0.00009988043,0.00018491998,0.000045868353,0.00009417093,0.0000059308627,0.000040642713,0.00003606567,0.0000023972755],"category_scores_gemma":[0.00004874297,0.00004970158,0.000026045269,0.00020623831,0.00014643342,0.0000306854,0.000016432658,0.000049088536,8.5712077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06908932,0.0012095306,0.6661908,0.00047498682,0.0012121904,0.0000096733565,0.008096661,0.0016528782,0.021323986,0.00003020721,0.00020584966,0.23050392],"study_design_scores_gemma":[0.01747287,0.00654893,0.8834203,0.00039425105,0.00035290507,0.00000571268,0.0007887369,0.0052663675,0.08481374,0.000035726214,0.00067272474,0.00022772451],"about_ca_topic_score_codex":0.000049329134,"about_ca_topic_score_gemma":0.00004334765,"teacher_disagreement_score":0.2302762,"about_ca_system_score_codex":0.000086295324,"about_ca_system_score_gemma":0.00012553549,"threshold_uncertainty_score":0.20267716},"labels":[],"label_agreement":null},{"id":"W4366813769","doi":"10.1093/oncolo/oyad086","title":"Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; McMaster University","funders":"","keywords":"Cardiotoxicity; Medicine; Trastuzumab; Discontinuation; Ejection fraction; Heart failure; Internal medicine; Cardiology; Chemotherapy; Cancer; Breast cancer","score_opus":0.030480802115471148,"score_gpt":0.31234817447836216,"score_spread":0.281867372362891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366813769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98839843,0.000009588424,0.00001910934,0.002109512,0.00031708137,0.0007819434,0.000009866651,0.00014208205,0.008212398],"genre_scores_gemma":[0.9984506,0.0000099974395,0.00002603468,0.0009349221,0.00010153736,0.000052624608,0.000033810233,0.00002237577,0.00036814282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988056,0.0000709612,0.00021347408,0.00024523155,0.00037644818,0.00028829213],"domain_scores_gemma":[0.99927884,0.00022275474,0.00006061147,0.0003380419,0.00003282854,0.000066933906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047374069,0.00015642549,0.00040227055,0.00010594362,0.00012774178,0.000016424152,0.00013107556,0.00013458208,0.000018797908],"category_scores_gemma":[0.00031650165,0.000103177794,0.0002835187,0.00038885477,0.000084300445,0.000043312702,0.00003918697,0.00031735425,0.00014909347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033948905,0.00039827134,0.9731351,0.000025787142,0.00027375188,0.00012012182,0.0011881115,0.00023425074,0.0065545747,0.00032734463,0.0029574865,0.014445712],"study_design_scores_gemma":[0.0032689827,0.0005199462,0.98755914,0.000055493267,0.00005163156,0.0000012379014,0.00037970665,0.00007656589,0.007095483,0.00035576802,0.0005167307,0.000119309356],"about_ca_topic_score_codex":0.000119368204,"about_ca_topic_score_gemma":0.00013423688,"teacher_disagreement_score":0.014424046,"about_ca_system_score_codex":0.00043814426,"about_ca_system_score_gemma":0.00008894717,"threshold_uncertainty_score":0.42074683},"labels":[],"label_agreement":null},{"id":"W4376273227","doi":"10.1093/oncolo/oyad116","title":"Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital; University of Ottawa","funders":"National Heart, Lung, and Blood Institute; Swedish Orphan Biovitrum; LEO Pharma; Servier; Chinese Academy of Medical Sciences; KU Leuven; Ministry of Education, Culture, Sports, Science and Technology; Bayer HealthCare; Insmed; ARCA Biopharma; Kowa Company; Prothena; Five Prime Therapeutics; Agios Pharmaceuticals; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Esperion Therapeutics; Alnylam Pharmaceuticals; Cook Medical; Janssen Scientific Affairs; Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; GlaxoSmithKline; University of Ottawa; Yale University; Alexion Pharmaceuticals; Daiichi-Sankyo; McMaster University; Brigham and Women's Hospital; Moderna; Pfizer; Heart and Stroke Foundation of Canada; CSL Behring; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Janssen Pharmaceuticals; Audentes Therapeutics; Amgen; Sanofi; American Heart Association","keywords":"Thrombosis; Intensive care medicine; Cancer; Medicine; Internal medicine","score_opus":0.03496671495848225,"score_gpt":0.3464161656841737,"score_spread":0.31144945072569147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376273227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92127335,0.021102669,0.0000018110131,0.045073975,0.0011827894,0.0011319628,0.000050724757,0.00021935775,0.009963353],"genre_scores_gemma":[0.53166246,0.46642,0.00002700359,0.00033234552,0.00035604346,0.00022745004,0.000050309096,0.000016127256,0.00090828474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925035,0.00005974462,0.00018426334,0.00015242101,0.00015426727,0.0001989422],"domain_scores_gemma":[0.99948823,0.00007338987,0.0001337789,0.00019947016,0.000055372286,0.000049737057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016453622,0.00012319005,0.00041202275,0.000079575046,0.00012741263,0.000009023962,0.000054919623,0.00006687066,0.000087995184],"category_scores_gemma":[0.000028296301,0.000072595016,0.000058304988,0.0005546876,0.00011665852,0.00003259878,0.000036163096,0.000054443448,0.000012365965],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016961349,0.0022949574,0.033390034,0.0001406776,0.0009971225,0.000020128822,0.0028705047,0.00009054936,0.0012246751,0.001549488,0.04425967,0.9129926],"study_design_scores_gemma":[0.0010713257,0.0012966981,0.38447687,0.000038046564,0.00043520654,0.0000015530227,0.001868277,0.000040610645,0.0005665314,0.00011379609,0.6100204,0.00007070179],"about_ca_topic_score_codex":0.00082167034,"about_ca_topic_score_gemma":0.0010579034,"teacher_disagreement_score":0.9129219,"about_ca_system_score_codex":0.00032462634,"about_ca_system_score_gemma":0.000051308878,"threshold_uncertainty_score":0.29603386},"labels":[],"label_agreement":null},{"id":"W4378171934","doi":"10.1093/oncolo/oyad128","title":"Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Safe Handling of Antineoplastic Drugs","field":"Health Professions","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Canadian Cancer Society Research Institute; Eli Lilly Canada; American Society of Clinical Oncology; Eli Lilly and Company; Incyte; Amgen","keywords":"Cancer; Oncology; Psychology; Gerontology; Medicine; Demography; Internal medicine; Sociology","score_opus":0.16951509525966083,"score_gpt":0.46845598161689,"score_spread":0.29894088635722915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378171934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663528,0.000030511726,0.0000040484647,0.0101489,0.0013602552,0.0017625903,0.000058064972,0.00017537127,0.020107461],"genre_scores_gemma":[0.9879848,0.0000807792,0.000008680647,0.0013463505,0.00041767693,0.0008385643,0.000050804414,0.000022923645,0.0092494255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738556,0.0011721401,0.0003548287,0.00021204655,0.0003141304,0.0005613063],"domain_scores_gemma":[0.9927609,0.0065289373,0.00028289008,0.00033328103,0.000054020435,0.000039963877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239742,0.00015820847,0.00031110327,0.000058788475,0.0007424793,0.0000146890925,0.000405682,0.00015601722,0.00022376276],"category_scores_gemma":[0.0013202587,0.000069389396,0.000048629634,0.0005080257,0.00013094785,0.000040244817,0.00008149326,0.00056106446,0.00040434263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047972385,0.0020362323,0.60100234,0.000085413085,0.0009728969,0.00060812064,0.05299025,0.0006293043,0.00018293416,0.003774768,0.2836267,0.0061186617],"study_design_scores_gemma":[0.070510335,0.0014889714,0.9000582,0.0004119943,0.00023642775,0.0000018123653,0.009679051,0.0003946558,0.000010151494,0.00046147537,0.016516956,0.00022996574],"about_ca_topic_score_codex":0.0046480363,"about_ca_topic_score_gemma":0.021044675,"teacher_disagreement_score":0.29905587,"about_ca_system_score_codex":0.00040050622,"about_ca_system_score_gemma":0.00094771903,"threshold_uncertainty_score":0.9968187},"labels":[],"label_agreement":null},{"id":"W4380272263","doi":"10.1093/oncolo/oyad161","title":"Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Associated Medical Services","keywords":"Medicine; Emergency department; Cancer; Internal medicine; Medical diagnosis; Breast cancer; Chemotherapy; Oncology; Intensive care medicine; Pathology; Psychiatry","score_opus":0.19586903755817942,"score_gpt":0.4476317864169423,"score_spread":0.2517627488587629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380272263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006157944,0.98954654,0.0000026333862,0.00030917776,0.00061044225,0.008272292,0.00016002373,0.000019200199,0.00046391005],"genre_scores_gemma":[0.00036232133,0.9958719,0.000010166024,0.0003657322,0.000054236927,0.0029889832,0.00005207259,0.000033738383,0.0002608711],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99694264,0.00075945957,0.0014728074,0.00024083033,0.0003531633,0.00023107791],"domain_scores_gemma":[0.9968132,0.00070352433,0.001513103,0.00074979395,0.00018266073,0.000037714402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009638796,0.00029146517,0.0028108626,0.00008484566,0.0000615778,0.0000048074426,0.00048004944,0.00018868237,0.00007557769],"category_scores_gemma":[0.0002000159,0.00013123035,0.0005995818,0.0007991843,0.00023304975,0.00003506102,0.000092718845,0.000602863,0.000017159797],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024173858,0.0011944507,0.0018565471,0.96557504,0.0013761637,0.000015512509,0.00041805257,0.0000038818757,6.616524e-7,0.00014282092,0.0025139211,0.026878774],"study_design_scores_gemma":[0.0010578898,0.0011724549,0.0030865888,0.65017015,0.025014034,0.000021501426,0.00019478028,0.000002553546,7.4557386e-7,0.00000915418,0.31901145,0.00025871868],"about_ca_topic_score_codex":0.0011668262,"about_ca_topic_score_gemma":0.0024125609,"teacher_disagreement_score":0.31649753,"about_ca_system_score_codex":0.00063793396,"about_ca_system_score_gemma":0.0006699425,"threshold_uncertainty_score":0.5351418},"labels":[],"label_agreement":null},{"id":"W4382046230","doi":"10.1093/oncolo/oyad182","title":"Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Université Laval","keywords":"Medicine; Pembrolizumab; Lung cancer; Regimen; Internal medicine; Adverse effect; Dosing; Cancer; Surgery; Immunotherapy","score_opus":0.029539634537534293,"score_gpt":0.3284088507184091,"score_spread":0.2988692161808748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382046230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96351254,0.0029663672,0.000010794576,0.0039118743,0.0020208969,0.0008725064,0.000026126889,0.00017669302,0.026502186],"genre_scores_gemma":[0.9809042,0.003317538,0.00007144033,0.0010914637,0.00035963737,0.0002970693,0.000032108157,0.000039438077,0.013887083],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9983319,0.00009241954,0.00036574493,0.0003751358,0.00026440015,0.0005704166],"domain_scores_gemma":[0.9988107,0.00037826237,0.0001453348,0.00052648684,0.000055208515,0.00008401088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005302342,0.00024647114,0.00041362434,0.00015454485,0.00014791368,0.000023740093,0.00032355025,0.00019050355,0.00035135954],"category_scores_gemma":[0.00006199375,0.00017455815,0.0001807915,0.000785095,0.00023068258,0.00007497915,0.000117936615,0.0004312258,0.0001218256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16131337,0.0016999226,0.10828273,0.0014334685,0.0013429965,0.0019031725,0.008662671,0.0031923768,0.19521935,0.00011884474,0.2896812,0.2271499],"study_design_scores_gemma":[0.058544006,0.0032287063,0.7633959,0.0007914823,0.0004957939,0.00004320619,0.0041098148,0.0026675705,0.01161342,0.00009034527,0.15399408,0.0010256371],"about_ca_topic_score_codex":0.002331792,"about_ca_topic_score_gemma":0.0023773734,"teacher_disagreement_score":0.6551132,"about_ca_system_score_codex":0.00093639,"about_ca_system_score_gemma":0.0006316539,"threshold_uncertainty_score":0.71182746},"labels":[],"label_agreement":null},{"id":"W4383872161","doi":"10.1093/oncolo/oyad204","title":"Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoma; Diffuse large B-cell lymphoma; Oncology; Internal medicine; Dermatology","score_opus":0.04636142410425152,"score_gpt":0.3169775137070694,"score_spread":0.27061608960281786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872161","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3945966,0.0024718822,0.0000020015455,0.5766804,0.00039196477,0.0031571253,0.0010921924,0.000079450736,0.021528358],"genre_scores_gemma":[0.9121947,0.005414867,0.000031324114,0.07578962,0.0006819178,0.0012219198,0.001136254,0.00006720439,0.0034621786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981254,0.00029041598,0.0005952042,0.00032625606,0.00031411933,0.0003486486],"domain_scores_gemma":[0.9959835,0.002032679,0.00052339135,0.0013538462,0.000072364724,0.000034232587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030394172,0.00031634243,0.0008469446,0.00012905717,0.00008671616,0.000010681387,0.00037221273,0.0004372084,0.000043090567],"category_scores_gemma":[0.00006622815,0.0001467947,0.00037351952,0.0002853483,0.00020640476,0.000017727114,0.00004361688,0.00022071022,0.00007318756],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026328609,0.034068566,0.01430265,0.00021240787,0.00049913564,0.00090564194,0.002327581,5.1030855e-7,0.0003059108,0.0003881697,0.9404682,0.006257968],"study_design_scores_gemma":[0.018213939,0.003823496,0.21690895,0.00012433912,0.0008813451,0.000030207233,0.0003594157,0.0000029188445,0.00043332076,0.00014107359,0.7589435,0.00013752302],"about_ca_topic_score_codex":0.0014344635,"about_ca_topic_score_gemma":0.00031438057,"teacher_disagreement_score":0.5175981,"about_ca_system_score_codex":0.0010693431,"about_ca_system_score_gemma":0.00036154428,"threshold_uncertainty_score":0.5986114},"labels":[],"label_agreement":null},{"id":"W4385410847","doi":"10.1093/oncolo/oyad207","title":"Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Genentech; Plexxikon; Eisai; Seagen; MacroGenics; Les Laboratories Pierre Fabre; Genomic Health; F. Hoffmann-La Roche; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Novartis Pharmaceuticals Corporation; Bayer; AstraZeneca; Eli Lilly and Company; Breast Cancer Alliance","keywords":"Medicine; Quality of life (healthcare); Breast cancer; Anxiety; Physical therapy; Diarrhea; Cancer; Internal medicine; Psychiatry","score_opus":0.022455856401611768,"score_gpt":0.3213516366995914,"score_spread":0.2988957802979796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385410847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973521,0.00039505633,0.000007713256,0.00062061474,0.000108802305,0.0008949436,0.0004753359,0.000087674955,0.000057749196],"genre_scores_gemma":[0.9990931,0.00014273038,0.00015250569,0.0001674084,0.000024715902,0.00012445543,0.0001404287,0.000031515716,0.00012314822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851173,0.00027231907,0.00035516088,0.00032098047,0.00024364582,0.0002961885],"domain_scores_gemma":[0.99796563,0.0012858508,0.00021863732,0.00032922276,0.000102702026,0.00009797418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003465032,0.00022182576,0.000651946,0.000073700874,0.00006767585,0.00000774061,0.00010378613,0.00009978061,0.000024683724],"category_scores_gemma":[0.00027180108,0.00013158824,0.00003992987,0.00048197727,0.00039938174,0.00008362803,0.00004954661,0.00016358386,0.000008850527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007687491,0.00030140724,0.9466318,0.00004758424,0.0002192121,0.000009280184,0.0007282849,0.00023357278,0.0007504971,0.000008776453,0.000011031897,0.04337107],"study_design_scores_gemma":[0.016332379,0.0006791661,0.98206836,0.0001756591,0.000051355513,0.0000012961624,0.00021107569,0.000073936375,0.00014058164,0.000076791184,0.00004866031,0.00014074512],"about_ca_topic_score_codex":0.016601516,"about_ca_topic_score_gemma":0.009424921,"teacher_disagreement_score":0.043230325,"about_ca_system_score_codex":0.00044147813,"about_ca_system_score_gemma":0.0001935476,"threshold_uncertainty_score":0.989947},"labels":[],"label_agreement":null},{"id":"W4385476617","doi":"10.1093/oncolo/oyad215","title":"A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Conquer Cancer Foundation; National Cancer Institute; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Eli Lilly and Company","keywords":"Nausea; Medicine; Vomiting; Adverse effect; Dosing; Gastroenterology; Clinical endpoint; Pharmacokinetics; Internal medicine; Neutropenia; Anemia; Pharmacology; Peripheral edema; Toxicity; Clinical trial","score_opus":0.033547687745609484,"score_gpt":0.36931083232137035,"score_spread":0.33576314457576084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385476617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626964,0.000028284154,0.00012577495,0.0004690259,0.00015584622,0.0026604314,0.00007402229,0.000092662274,0.00012429968],"genre_scores_gemma":[0.99890816,0.000006019239,0.0003679786,0.00012631115,0.00006931936,0.00025449492,0.00003512656,0.000036639598,0.00019593985],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812055,0.00010734559,0.00058796053,0.00032133184,0.000585919,0.00027689108],"domain_scores_gemma":[0.9984214,0.0001596684,0.0004413792,0.00056797266,0.00028446404,0.0001251315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030628723,0.00020795179,0.0005813553,0.00015190965,0.00007663784,0.0000058456744,0.00018864608,0.000046354653,0.00003080634],"category_scores_gemma":[0.000174594,0.00013135561,0.00006262098,0.0005874577,0.00019605443,0.000067956236,0.00012014371,0.00014542686,0.000018765082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14775212,0.06147178,0.22390875,0.00082764257,0.0012012367,0.0004337588,0.032926667,0.009820418,0.12013312,0.000088414585,0.00033948346,0.4010966],"study_design_scores_gemma":[0.07621856,0.0781263,0.79576796,0.0007571286,0.00045020747,0.00001709967,0.013115193,0.0001947545,0.0341489,0.00010573789,0.000645362,0.00045276937],"about_ca_topic_score_codex":0.000074503994,"about_ca_topic_score_gemma":0.00016966402,"teacher_disagreement_score":0.57185924,"about_ca_system_score_codex":0.00021436997,"about_ca_system_score_gemma":0.00015071833,"threshold_uncertainty_score":0.53565264},"labels":[],"label_agreement":null},{"id":"W4385516321","doi":"10.1093/oncolo/oyad211","title":"Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Prospective cohort study; Proportional hazards model; Cancer; Cohort; Varimax rotation; Confidence interval; Psychometrics","score_opus":0.021964747149155698,"score_gpt":0.29145081044566484,"score_spread":0.26948606329650915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385516321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99236804,0.00006829592,0.000009415647,0.0006857151,0.00015388521,0.006146737,0.000041249285,0.00009846851,0.00042821167],"genre_scores_gemma":[0.9979752,0.000020959202,0.000011809658,0.00013002106,0.000042701733,0.0016856117,0.000013067527,0.000019704985,0.00010093473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985694,0.00012572417,0.00020318282,0.0004983115,0.000295788,0.00030754408],"domain_scores_gemma":[0.99902505,0.00027513682,0.000070900984,0.00036874306,0.00015860295,0.00010155661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000558672,0.00018390908,0.00038849196,0.000066952314,0.00009614317,0.000019089719,0.00011993939,0.000031632964,0.00002079426],"category_scores_gemma":[0.00015829297,0.00010569109,0.000022713986,0.000778291,0.0002176903,0.000050706563,0.000111226145,0.0002030744,0.000004973494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021292686,0.0005652952,0.9877084,0.000045925735,0.000064844746,0.000018271037,0.0052675363,0.000050893224,0.000015069763,0.0000036732588,0.000033224336,0.004097613],"study_design_scores_gemma":[0.0024998172,0.0043187356,0.9857643,0.00008902671,0.00008032699,9.295823e-7,0.0069718687,0.000024205021,0.00004707882,0.0000123444215,0.00005470435,0.00013666277],"about_ca_topic_score_codex":0.0021044428,"about_ca_topic_score_gemma":0.042689707,"teacher_disagreement_score":0.040585265,"about_ca_system_score_codex":0.00054145616,"about_ca_system_score_gemma":0.00015167943,"threshold_uncertainty_score":0.9747787},"labels":[],"label_agreement":null},{"id":"W4385897815","doi":"10.1093/oncolo/oyad197","title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; Revolution Medicines; Flatiron Health; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; National Center for Advancing Translational Sciences; LUNGevity Foundation","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Cancer; Progressive disease","score_opus":0.022751087646396148,"score_gpt":0.31742688171044264,"score_spread":0.2946757940640465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385897815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888659,0.0005859778,0.000009587389,0.007912502,0.00020111952,0.0006936842,0.000017066986,0.00004527356,0.001668861],"genre_scores_gemma":[0.99541825,0.0022635607,0.000055243123,0.0007340692,0.00004084124,0.000058705988,0.000012900909,0.000019594692,0.0013968606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990724,0.00004380105,0.00031287599,0.000187999,0.00015922917,0.00022371636],"domain_scores_gemma":[0.99936706,0.000176065,0.00015967725,0.0002254693,0.000038661372,0.000033056356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052616774,0.00014164796,0.0003817966,0.00011405413,0.000062458086,0.000012497903,0.00012925315,0.00010075842,0.00009429965],"category_scores_gemma":[0.000019694327,0.00009068381,0.00006653666,0.00042915758,0.00020747224,0.00003099958,0.00004182346,0.00015796527,0.0000039896418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011463929,0.00030680385,0.79578704,0.00021609175,0.00016456297,0.000030018724,0.002290266,0.000032678876,0.18883625,0.000038187714,0.0019852067,0.009166539],"study_design_scores_gemma":[0.008217159,0.00027144988,0.948275,0.00011326594,0.000062098334,0.000006421794,0.00058087823,0.0011965715,0.039539427,0.000040032664,0.0015708315,0.00012685794],"about_ca_topic_score_codex":0.0015835192,"about_ca_topic_score_gemma":0.000454084,"teacher_disagreement_score":0.152488,"about_ca_system_score_codex":0.0001478854,"about_ca_system_score_gemma":0.00013583453,"threshold_uncertainty_score":0.36979786},"labels":[],"label_agreement":null},{"id":"W4386002127","doi":"10.1093/oncolo/oyad210","title":"Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type <i>RAS</i> Metastatic Colorectal Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Array BioPharma; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Panitumumab; Medicine; Rash; Colorectal cancer; Internal medicine; Adverse effect; Tolerability; Phases of clinical research; MEK inhibitor; Oncology; Epidermal growth factor receptor; EGFR inhibitors; KRAS; MAPK/ERK pathway; Gastroenterology; Cancer; Clinical trial; Kinase","score_opus":0.08035892614467251,"score_gpt":0.3976185822566396,"score_spread":0.3172596561119671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386002127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937134,0.0005937608,0.0000021846004,0.0014213263,0.00034326696,0.0033131975,0.00019492874,0.000040241335,0.00037772555],"genre_scores_gemma":[0.99798167,0.00058259733,0.00003838705,0.00010934773,0.00006116774,0.00034491805,0.000009145057,0.000020137986,0.0008526228],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9987098,0.00012405918,0.00041963827,0.00024530455,0.0002574614,0.00024371488],"domain_scores_gemma":[0.99819416,0.0010688921,0.00026752538,0.0002647163,0.00015722691,0.000047485446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045593426,0.00019027673,0.0006972597,0.00004938145,0.00036507676,0.0000063882535,0.00016425303,0.000036394795,0.00004868085],"category_scores_gemma":[0.000506034,0.000082799634,0.00009647638,0.0006293161,0.000456068,0.000020412039,0.00023237054,0.0001168036,0.0000013812911],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4213139,0.043626018,0.03325189,0.001702505,0.018083137,0.00030689518,0.10346573,0.0007510297,0.071391344,0.0005403567,0.022821628,0.28274557],"study_design_scores_gemma":[0.26416588,0.25929177,0.31497106,0.0007509978,0.014805912,0.00012937098,0.068039775,0.0018063048,0.03051847,0.0003071716,0.044282146,0.00093115243],"about_ca_topic_score_codex":0.00077937444,"about_ca_topic_score_gemma":0.002375031,"teacher_disagreement_score":0.28181443,"about_ca_system_score_codex":0.00017085833,"about_ca_system_score_gemma":0.00036646327,"threshold_uncertainty_score":0.3376471},"labels":[],"label_agreement":null},{"id":"W4386268787","doi":"10.1093/oncolo/oyad223","title":"Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"OPKO Health; Clovis Oncology; Novavax; Karyopharm Therapeutics; INOVIO Pharmaceuticals; Sanofi; Abeona Therapeutics; Acorda Therapeutics; Pfizer","keywords":"Medicine; Melanoma; Adjuvant; Internal medicine; Adjuvant therapy; Systemic therapy; Oncology; Adverse effect; Immunotherapy; Clinical trial; Single Center; Progression-free survival; Retrospective cohort study; Stage (stratigraphy); Surgery; Cancer; Overall survival","score_opus":0.08479655175958822,"score_gpt":0.3904699091171679,"score_spread":0.30567335735757967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386268787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929925,0.00021455152,0.00015415394,0.0017701688,0.0006365046,0.0033003865,0.00002657651,0.00032781714,0.0005773254],"genre_scores_gemma":[0.98907167,0.00032490847,0.00008317708,0.00024376083,0.00023597553,0.00031711653,0.000012231295,0.000023448076,0.009687721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998626,0.0002235869,0.00037445928,0.00035023812,0.00018126654,0.0002444788],"domain_scores_gemma":[0.99894613,0.00037857058,0.00013360962,0.0003596762,0.00011086502,0.00007112861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012758627,0.00014731848,0.00044264982,0.000088431996,0.0002256509,0.0000344525,0.00011754188,0.00007988221,0.000025276799],"category_scores_gemma":[0.00036248463,0.00008661037,0.00008995423,0.00022804951,0.00019897461,0.000025286065,0.00013830718,0.00021531267,0.000037576698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012179168,0.0071858326,0.8666027,0.00041534615,0.0032996219,0.0015133353,0.017416863,0.000009907051,0.0034651554,0.0008986999,0.052524447,0.03448888],"study_design_scores_gemma":[0.025775015,0.011745903,0.89892036,0.000102938524,0.00046538978,0.00032781097,0.04112543,0.001288821,0.000040892974,0.0000835906,0.019859828,0.0002640512],"about_ca_topic_score_codex":0.00011038197,"about_ca_topic_score_gemma":0.0005415815,"teacher_disagreement_score":0.034224827,"about_ca_system_score_codex":0.00014041468,"about_ca_system_score_gemma":0.000039947372,"threshold_uncertainty_score":0.35318685},"labels":[],"label_agreement":null},{"id":"W4386438681","doi":"10.1093/oncolo/oyad253","title":"Coping Strategies and Associated Symptom Burden Among Patients With Advanced Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Coping (psychology); Denial; Clinical psychology; Breast cancer; Medicine; Emotional distress; Distress; Maladaptive coping; Anxiety; Psychology; Psychiatry; Cancer; Internal medicine; Psychotherapist","score_opus":0.01748900832477097,"score_gpt":0.2973600153115371,"score_spread":0.27987100698676615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386438681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938311,0.0002484666,0.000004642939,0.0013810614,0.00022029743,0.00033611958,0.000019852172,0.00015954461,0.003798896],"genre_scores_gemma":[0.9982354,0.00020493279,0.0000046482905,0.00023718126,0.00008120377,0.00008458578,0.000044414268,0.000015123279,0.001092495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931556,0.000039239814,0.00009976862,0.00015506335,0.00018499668,0.00020536325],"domain_scores_gemma":[0.9995273,0.00010903974,0.00007409566,0.00014421956,0.000094150564,0.000051231043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001297366,0.00009926356,0.00018964233,0.000030316207,0.00012632115,0.000040801307,0.00006796419,0.00005711479,0.000040827235],"category_scores_gemma":[0.00004311256,0.000058039972,0.000022780077,0.00027652812,0.00021440352,0.000087264,0.00004470437,0.00013685957,0.000007293213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046239205,0.00005323123,0.9688606,0.000093844275,0.0002001857,0.000033370194,0.0044146637,0.00041690844,0.00013196588,0.0002073784,0.002798734,0.022326702],"study_design_scores_gemma":[0.0015902745,0.0004080585,0.9899832,0.00017079656,0.00008696654,6.0089303e-7,0.0048074992,0.000079055586,0.000028120043,0.00006470692,0.0026775047,0.0001032039],"about_ca_topic_score_codex":0.0029519475,"about_ca_topic_score_gemma":0.009948016,"teacher_disagreement_score":0.022223499,"about_ca_system_score_codex":0.00014344609,"about_ca_system_score_gemma":0.0001349037,"threshold_uncertainty_score":0.5551227},"labels":[],"label_agreement":null},{"id":"W4386632442","doi":"10.1093/oncolo/oyad250","title":"Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Placebo; Clinical endpoint; Melatonin; Interim analysis; Breast cancer; Internal medicine; Quality of life (healthcare); Randomized controlled trial; Randomization; Radiation therapy; Cancer","score_opus":0.04681610985196225,"score_gpt":0.36119356241132783,"score_spread":0.31437745255936556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386632442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848801,0.00012718575,0.000041616106,0.004484794,0.0008764733,0.008866622,0.00024456021,0.0001322471,0.0003463823],"genre_scores_gemma":[0.99053156,0.00018239935,0.000044756616,0.00019248523,0.00025669084,0.005895121,0.0001735084,0.00004734805,0.0026761033],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99838763,0.00013761866,0.0004229241,0.00031496724,0.00034545086,0.00039142623],"domain_scores_gemma":[0.9989851,0.000298973,0.0002575364,0.00024154258,0.00014222172,0.0000745863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007413035,0.00020738633,0.0005375185,0.00015590132,0.00014854479,0.00004353681,0.0001458759,0.00012780032,0.00045554206],"category_scores_gemma":[0.000021624415,0.00012978609,0.00011142336,0.000637341,0.00008621787,0.000097312004,0.000021929434,0.00023941927,0.000003566868],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8712835,0.00023027198,0.11725858,0.000050067894,0.00040331332,0.0000052604896,0.004877226,0.0006149963,0.000041746196,0.0000672256,0.00080018555,0.0043676286],"study_design_scores_gemma":[0.8805615,0.0018624439,0.114025585,0.00014685921,0.00027876985,9.547781e-7,0.0007813786,0.0005928908,0.0000737878,0.000012721139,0.0014563978,0.00020674686],"about_ca_topic_score_codex":0.015641715,"about_ca_topic_score_gemma":0.046504367,"teacher_disagreement_score":0.030862652,"about_ca_system_score_codex":0.00088803115,"about_ca_system_score_gemma":0.0004693061,"threshold_uncertainty_score":0.9909132},"labels":[],"label_agreement":null},{"id":"W4386979571","doi":"10.1093/oncolo/oyad259","title":"Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Breast cancer; Health care; Public health care; Business; Medicine; Public health; Scale (ratio); Cancer; Sri lanka; Family medicine; Finance; Economic growth; Socioeconomics; Nursing; Economics; Internal medicine; Geography; Health policy","score_opus":0.035511579826387946,"score_gpt":0.23938320681566724,"score_spread":0.2038716269892793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386979571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96581876,0.0012831788,0.000013703293,0.0159721,0.0010712568,0.00037723835,0.0023312424,0.00018133696,0.012951177],"genre_scores_gemma":[0.9968822,0.0008735418,0.000041823136,0.0012955291,0.0003353812,0.00005898841,0.000065786466,0.000029256405,0.00041747998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981514,0.000045059936,0.0006157008,0.0005212032,0.000065779095,0.00060083513],"domain_scores_gemma":[0.99858177,0.00015168925,0.00044547938,0.00060435967,0.000069980895,0.00014674981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039699062,0.00025823608,0.00062824914,0.00024595967,0.00024309705,0.00009593717,0.00075333915,0.00030648193,0.0002786313],"category_scores_gemma":[0.00013028053,0.00021646454,0.00008555414,0.00094608817,0.00029699458,0.00042159847,0.0001939913,0.00049470103,0.00042276472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013423521,0.0006731501,0.49033523,0.00012104714,0.0003133859,0.000452631,0.00899758,0.0009838889,0.000011720681,0.48078978,0.01168695,0.0042922846],"study_design_scores_gemma":[0.0034232186,0.0003243542,0.89846057,0.00013311341,0.000016067008,0.000013021767,0.00064830395,0.0009998374,0.0000067429905,0.04553181,0.04984025,0.0006027123],"about_ca_topic_score_codex":0.024569953,"about_ca_topic_score_gemma":0.06206872,"teacher_disagreement_score":0.43525797,"about_ca_system_score_codex":0.0012415699,"about_ca_system_score_gemma":0.00049872417,"threshold_uncertainty_score":0.98192555},"labels":[],"label_agreement":null},{"id":"W4387449548","doi":"10.1093/oncolo/oyad254","title":"Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute on Minority Health and Health Disparities; Astellas Pharma; Foundation Medicine; Bayer HealthCare; Pfizer; American Association for Cancer Research; Invitae; Eli Lilly and Company; Lantheus Medical Imaging","keywords":"Docetaxel; Medicine; Placebo; Internal medicine; Clinical endpoint; Androgen deprivation therapy; Prostate cancer; Population; Adverse effect; Enzalutamide; Oncology; Randomized controlled trial; Chemotherapy; Cancer; Androgen receptor","score_opus":0.04382962024491794,"score_gpt":0.32801834829904825,"score_spread":0.2841887280541303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387449548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929966,0.00028667026,0.000003280504,0.0036823903,0.000027403772,0.0028015063,0.0000125949055,0.000011637355,0.00017793073],"genre_scores_gemma":[0.9964083,0.003269671,0.00001536354,0.00006600227,0.000022009875,0.00007170614,0.00008955558,0.000006241177,0.000051151863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99906313,0.0003018877,0.00021666894,0.00013149038,0.00017181378,0.000115010625],"domain_scores_gemma":[0.9983727,0.0013493496,0.00008876482,0.00013099528,0.000037338894,0.000020865109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000929051,0.00007597755,0.00030822758,0.000058626836,0.000048387315,0.000010478931,0.00005024754,0.000043912176,0.0000058438395],"category_scores_gemma":[0.00026912542,0.000032411728,0.000020096037,0.00026804756,0.00051303644,0.000030601805,0.0000308287,0.00012104853,0.0000013994546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8384291,0.00043231016,0.14637914,0.000009656338,0.00008656542,0.000009570141,0.0024281226,0.000023116347,0.00020365536,0.00010492266,0.000065784516,0.011828053],"study_design_scores_gemma":[0.5242274,0.0006734331,0.47383216,0.00004144568,0.000021842183,2.9786744e-7,0.00019057174,0.0003667933,0.00017696703,0.00039938453,0.000042896274,0.000026797685],"about_ca_topic_score_codex":0.00051573577,"about_ca_topic_score_gemma":0.00020047059,"teacher_disagreement_score":0.32745302,"about_ca_system_score_codex":0.00006237096,"about_ca_system_score_gemma":0.000061848135,"threshold_uncertainty_score":0.18903042},"labels":[],"label_agreement":null},{"id":"W4388000610","doi":"10.1093/oncolo/oyad291","title":"Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Referral; Cancer; Colorectal cancer; Cervical cancer; Family medicine; Health care; Internal medicine; Finance","score_opus":0.037722052113737234,"score_gpt":0.28238746535319026,"score_spread":0.244665413239453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388000610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97183377,0.0008188979,0.0000072354424,0.00279508,0.0007864166,0.00030319064,0.0002602153,0.000022858634,0.02317237],"genre_scores_gemma":[0.99774915,0.0006805373,0.0000069553375,0.0005619655,0.0003393114,0.00006178621,0.000009722617,0.000014718896,0.0005758328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989516,0.00002018311,0.00046678592,0.0002256565,0.000039077746,0.00029665584],"domain_scores_gemma":[0.99916136,0.0001594878,0.00031602161,0.00030283164,0.000036322162,0.000023998742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048745328,0.00012132686,0.00033548966,0.00011127797,0.00014378621,0.000024838977,0.00041678682,0.00010379177,0.000095423406],"category_scores_gemma":[0.00035938123,0.00008597568,0.000091996626,0.00035697443,0.00019717129,0.000071485745,0.00009495272,0.00021505069,0.00022358725],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005345992,0.0002530954,0.57422763,0.000120217526,0.00008978249,0.000012041638,0.026327668,0.054242652,0.000041254923,0.21301919,0.031426694,0.09970518],"study_design_scores_gemma":[0.0018087873,0.00047180406,0.80299515,0.00008539116,0.000011063556,1.9893707e-7,0.0014168496,0.0011249665,0.00036681103,0.02606461,0.16531469,0.0003396628],"about_ca_topic_score_codex":0.0059527433,"about_ca_topic_score_gemma":0.0022842507,"teacher_disagreement_score":0.22876754,"about_ca_system_score_codex":0.00031866855,"about_ca_system_score_gemma":0.00009611378,"threshold_uncertainty_score":0.89988065},"labels":[],"label_agreement":null},{"id":"W4388722167","doi":"10.1093/oncolo/oyad305","title":"The Use of Wearable Devices in Oncology Patients: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"CINAHL; Medicine; Wearable computer; Rehabilitation; MEDLINE; Web of science; Wearable technology; Scopus; Systematic review; Psychological intervention; Physical therapy; Meta-analysis; Medical physics; Internal medicine; Computer science; Nursing","score_opus":0.21418983090040722,"score_gpt":0.4243515335456701,"score_spread":0.2101617026452629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388722167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000037483248,0.99227035,5.2051513e-7,0.0006027781,0.00055485795,0.005389739,0.000034852226,0.000038411275,0.0011047128],"genre_scores_gemma":[0.0000063461675,0.99471736,0.000006160553,0.0007658067,0.000067965084,0.0014994623,0.000040193358,0.000042317188,0.0028543712],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961216,0.0014941657,0.0014655443,0.00026191273,0.00034721167,0.00030956534],"domain_scores_gemma":[0.99301827,0.004585115,0.0011809604,0.0009868703,0.00017327814,0.000055524808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021637175,0.00029595854,0.003699329,0.000089100504,0.00009189905,0.000023891906,0.0005477184,0.00026212237,0.000023311772],"category_scores_gemma":[0.0025161395,0.00012210477,0.0005350981,0.0008917858,0.0002731345,0.00003409983,0.00018443067,0.0005844549,0.00017009398],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015462829,0.00008041265,0.000014899225,0.87403923,0.00020679961,0.00002205435,0.00007909092,1.5700383e-7,2.896871e-9,0.00006314583,0.004523959,0.120954774],"study_design_scores_gemma":[0.00010815787,0.00019371767,0.000007479915,0.4308695,0.0023261004,0.000012280853,0.00007773371,7.246478e-7,9.547849e-9,0.000005268282,0.56633,0.000069015456],"about_ca_topic_score_codex":0.0012254985,"about_ca_topic_score_gemma":0.012045718,"teacher_disagreement_score":0.5618061,"about_ca_system_score_codex":0.0007212591,"about_ca_system_score_gemma":0.0008393546,"threshold_uncertainty_score":0.67217934},"labels":[],"label_agreement":null},{"id":"W4389005089","doi":"10.1093/oncolo/oyad312","title":"Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Alberta; Health Sciences Centre; Alberta Health Services","funders":"","keywords":"Medicine; Neuroendocrine tumors; Radionuclide therapy; Internal medicine; Oncology","score_opus":0.0848700145888727,"score_gpt":0.41599001128486035,"score_spread":0.3311199966959877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389005089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925334,0.0006783873,0.000042958407,0.0052316897,0.00046196106,0.002708503,0.0001572351,0.00036423214,0.0011016638],"genre_scores_gemma":[0.9803463,0.0006655855,0.0002779508,0.00042433897,0.00013439896,0.0017711639,0.00014645331,0.00006407876,0.01616971],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976614,0.00013147993,0.00043261758,0.0005025935,0.0004933744,0.0007785275],"domain_scores_gemma":[0.9970732,0.0018595671,0.00016532735,0.0005794067,0.00009792084,0.00022460897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009977363,0.00028226202,0.00046113718,0.00010947266,0.000460505,0.000064477805,0.00027031323,0.0000075666,0.000056398116],"category_scores_gemma":[0.0018346517,0.00017788027,0.00017589929,0.00036038586,0.0003702245,0.0001419989,0.00022498917,0.00019057519,0.00009474458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012682359,0.002546624,0.02272089,0.00037855198,0.0008698064,0.01560714,0.0026050266,0.0023453594,0.49201235,0.0011712381,0.24350917,0.20355147],"study_design_scores_gemma":[0.012511498,0.0135368155,0.006719502,0.00025602858,0.00017381582,0.00069247215,0.005565213,0.00091006665,0.2405977,0.0005322833,0.7179659,0.0005387371],"about_ca_topic_score_codex":0.00015465838,"about_ca_topic_score_gemma":0.00006573944,"teacher_disagreement_score":0.4744567,"about_ca_system_score_codex":0.00033484685,"about_ca_system_score_gemma":0.00013799268,"threshold_uncertainty_score":0.7253747},"labels":[],"label_agreement":null},{"id":"W4390590466","doi":"10.1093/oncolo/oyad337","title":"CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Astellas Pharma; Ipsen; Clovis Oncology; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Breast cancer; Oncology; Confidence interval; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer","score_opus":0.05329712438884447,"score_gpt":0.4183184199007502,"score_spread":0.3650212955119057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390590466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96467733,0.0058220183,0.00012486681,0.0194639,0.0024494524,0.003920048,0.0004019475,0.00011351038,0.0030269483],"genre_scores_gemma":[0.9971221,0.0009329684,0.00021125365,0.00020207436,0.0002905832,0.0003199018,0.000010241024,0.000036680034,0.00087421463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977093,0.00051464274,0.00069291936,0.00044444992,0.00033794562,0.0003007796],"domain_scores_gemma":[0.99636465,0.002631627,0.00038938344,0.000419434,0.00012472537,0.00007020368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095511734,0.00031069844,0.0009903804,0.00013292088,0.00018730354,0.00002051858,0.00020720364,0.00012307515,0.000095560295],"category_scores_gemma":[0.00069992687,0.00015431517,0.0002953032,0.00083760364,0.002111631,0.000129598,0.00010271064,0.00041540075,0.0000020467548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88472486,0.00037288287,0.000028774997,0.00003359886,0.00072300696,0.000017382139,0.0027452963,0.00011012429,0.004771725,0.00014842991,0.00020309452,0.1061208],"study_design_scores_gemma":[0.9785029,0.0018507318,0.001930331,0.00067555584,0.00058082,0.000035683504,0.0017623387,0.0013512579,0.010536513,0.00096189,0.0015870341,0.00022492229],"about_ca_topic_score_codex":0.0016497537,"about_ca_topic_score_gemma":0.00042183572,"teacher_disagreement_score":0.10589588,"about_ca_system_score_codex":0.0004556652,"about_ca_system_score_gemma":0.0003698395,"threshold_uncertainty_score":0.7780393},"labels":[],"label_agreement":null},{"id":"W4391282760","doi":"10.1093/oncolo/oyad324","title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck","keywords":"Chemoimmunotherapy; Chronic lymphocytic leukemia; Medicine; Internal medicine; Lymphoma; Health care; Rituximab; Leukemia; Oncology","score_opus":0.04775565335878256,"score_gpt":0.3283996721921445,"score_spread":0.28064401883336193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391282760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068826,0.0051435335,0.000035471097,0.0012073587,0.000089330315,0.002085284,0.00006320114,0.00008252809,0.0006050257],"genre_scores_gemma":[0.99622214,0.0018682393,0.000029157116,0.0005951412,0.00014196533,0.00024382872,0.0001220044,0.000055657292,0.0007218818],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973311,0.0004184996,0.00048288787,0.00053462764,0.0006323728,0.00060051],"domain_scores_gemma":[0.9975908,0.0011504579,0.00012954067,0.00085517165,0.00012817557,0.00014589189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005881432,0.00033993376,0.0005278184,0.0001751679,0.0001644572,0.00008004623,0.00037821522,0.00017371996,0.00004190741],"category_scores_gemma":[0.00016768489,0.00015032175,0.00007955597,0.00075889385,0.0006342397,0.00006149114,0.00013390624,0.00015624236,0.000021913294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021385727,0.0011640129,0.10770706,0.007311943,0.0012264574,0.006315944,0.014777972,0.0031392106,0.00004454379,0.0034729694,0.0035608239,0.82989335],"study_design_scores_gemma":[0.18683511,0.031786136,0.39495674,0.0070543527,0.0014603026,0.004334391,0.0051620933,0.26189962,0.000829591,0.00013133486,0.10425359,0.0012967591],"about_ca_topic_score_codex":0.019417511,"about_ca_topic_score_gemma":0.011356237,"teacher_disagreement_score":0.8285966,"about_ca_system_score_codex":0.22329947,"about_ca_system_score_gemma":0.049735587,"threshold_uncertainty_score":0.9871123},"labels":[],"label_agreement":null},{"id":"W4391727506","doi":"10.1093/oncolo/oyae016","title":"Consuming Patients’ Days: Time Spent on Ambulatory Appointments by People With Cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Healthcare Operations and Scheduling Optimization","field":"Health Professions","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; Pancreatic Cancer Action Network","keywords":"Ambulatory; Medicine; Ambulatory care; Cancer; Emergency medicine; Surgery; Health care; Internal medicine","score_opus":0.043064319239712746,"score_gpt":0.40458772768682616,"score_spread":0.3615234084471134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391727506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96322197,0.0005656581,0.0007470312,0.014185654,0.0014044876,0.0020430074,0.00019087091,0.00026954288,0.017371777],"genre_scores_gemma":[0.9820692,0.00017856772,0.00045424153,0.0031966066,0.00021204415,0.00051520474,0.0001935777,0.000037721267,0.013142813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985837,0.00037063612,0.00029081173,0.00024410216,0.00020679577,0.00030397097],"domain_scores_gemma":[0.9990588,0.00042138118,0.000083611005,0.00023670717,0.000117635034,0.000081892],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005351241,0.00012745355,0.00016808545,0.000039895658,0.0009121391,0.000034573124,0.00012214635,0.00011058144,0.0012840219],"category_scores_gemma":[0.00006831645,0.000071828224,0.000023886952,0.00019909306,0.00007331738,0.00007104879,0.00004318119,0.0004480109,0.0011388472],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005032864,0.0008193362,0.15010507,0.0006409773,0.00027725307,0.000019689167,0.01723309,0.008407079,0.00031116873,0.0066797948,0.785513,0.029490272],"study_design_scores_gemma":[0.0045716125,0.0030633963,0.088421255,0.0032267924,0.00028707177,0.000003765975,0.0049253637,0.07207578,0.0001814696,0.00024491773,0.82183254,0.0011660514],"about_ca_topic_score_codex":0.0010773283,"about_ca_topic_score_gemma":0.00064543355,"teacher_disagreement_score":0.0636687,"about_ca_system_score_codex":0.00057934487,"about_ca_system_score_gemma":0.00059665914,"threshold_uncertainty_score":0.99963886},"labels":[],"label_agreement":null},{"id":"W4392125982","doi":"10.1093/oncolo/oyae019","title":"Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Bayer HealthCare; Bayer","keywords":"Tolerability; Medicine; Adverse effect; Placebo; Prostate cancer; Internal medicine; Androgen deprivation therapy; Oncology; Cancer","score_opus":0.02509620189157084,"score_gpt":0.3702472411746977,"score_spread":0.34515103928312685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392125982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983877,0.006014505,0.000026572263,0.007487451,0.00005729913,0.0018344385,0.00033342247,0.000019235007,0.0003500867],"genre_scores_gemma":[0.9954763,0.0013136263,0.0002316452,0.000044856366,0.000023951645,0.00018762998,0.000029989673,0.000009845172,0.0026821357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991328,0.000058391153,0.00027127104,0.00021647762,0.00013492646,0.00018612725],"domain_scores_gemma":[0.99937886,0.00031533532,0.00004921082,0.00014101747,0.00005350336,0.0000620641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007033068,0.00010061276,0.00027203548,0.000039231658,0.000060075323,0.00001271506,0.00003831745,0.0000361302,0.000044226494],"category_scores_gemma":[0.00006811148,0.00005803084,0.000039380135,0.0001212725,0.00042686381,0.000047796213,0.000029404286,0.000114696304,0.0000017270464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07465139,0.004070791,0.091885306,0.012789771,0.002434722,0.0012197695,0.02165874,0.0013991451,0.14606905,0.0035231602,0.00447715,0.635821],"study_design_scores_gemma":[0.012256387,0.0046633207,0.93303984,0.0012055124,0.00093726354,0.00006827616,0.0025707388,0.027940746,0.0047918228,0.0033206933,0.008856457,0.0003489167],"about_ca_topic_score_codex":0.00038817019,"about_ca_topic_score_gemma":0.0005471714,"teacher_disagreement_score":0.8411546,"about_ca_system_score_codex":0.0002319153,"about_ca_system_score_gemma":0.0004565396,"threshold_uncertainty_score":0.2366429},"labels":[],"label_agreement":null},{"id":"W4392343556","doi":"10.1093/oncolo/oyae010","title":"Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Performance status; Internal medicine; Concordance; Cohort; Retrospective cohort study; Population; Cancer","score_opus":0.015566806387348388,"score_gpt":0.33139852472861997,"score_spread":0.3158317183412716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392343556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478585,0.00030688546,0.0003667075,0.002792124,0.00025374338,0.000619112,0.000056008776,0.000074214135,0.0007453568],"genre_scores_gemma":[0.9990152,0.000013438672,0.00025652224,0.00012289295,0.000046051144,0.00018421191,0.0002634616,0.000010235843,0.00008797439],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865043,0.00009849041,0.00053236354,0.0002779695,0.0003020317,0.00013872678],"domain_scores_gemma":[0.9989694,0.00032327967,0.00020227086,0.00029776295,0.00016957705,0.000037716793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005441521,0.00011571145,0.00040731643,0.00023130824,0.00004475701,0.000019555926,0.00007343918,0.00006363539,0.000034374567],"category_scores_gemma":[0.0008257995,0.00007212547,0.00015652766,0.0013198821,0.00009112031,0.000037044516,0.000020996324,0.0002181347,0.0000012577827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002593773,0.00007110943,0.98962235,0.00004441994,0.00035330415,0.000030988907,0.0014244338,0.0003958833,0.00007025429,0.00015877068,0.000057226785,0.007511853],"study_design_scores_gemma":[0.00044889632,0.00025711642,0.98970705,0.00012631428,0.000904541,0.0000012874225,0.0005165905,0.007547947,0.00020612348,0.00018759997,0.00003933707,0.00005720859],"about_ca_topic_score_codex":0.06612809,"about_ca_topic_score_gemma":0.073124036,"teacher_disagreement_score":0.0074546444,"about_ca_system_score_codex":0.0008641002,"about_ca_system_score_gemma":0.0002381679,"threshold_uncertainty_score":0.943789},"labels":[],"label_agreement":null},{"id":"W4393142464","doi":"10.1093/oncolo/oyae036","title":"Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Bruyère; University of Ottawa","funders":"Astellas Pharma","keywords":"Medicine; Prostate cancer; Zoledronic acid; Denosumab; Radiation therapy; Internal medicine; Oncology; Androgen deprivation therapy; Cancer; Osteoporosis","score_opus":0.0875235150987341,"score_gpt":0.4214431469459067,"score_spread":0.33391963184717255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393142464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855697,0.0024285866,0.0000012142208,0.0008653847,0.0003499446,0.0015977575,0.000047296704,0.000021188953,0.009118921],"genre_scores_gemma":[0.9972787,0.0003549138,0.00014316973,0.00001742607,0.000011180957,0.00021759127,0.00014233263,0.000011803403,0.0018228925],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99850017,0.00027696823,0.0005236704,0.00016475857,0.00038581016,0.00014862958],"domain_scores_gemma":[0.9992882,0.00017125433,0.00020188683,0.00017525745,0.00012275677,0.000040617502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012953804,0.00009945069,0.0002917911,0.0001329908,0.00003167274,0.0000029139226,0.000044595286,0.000040066494,0.00021164933],"category_scores_gemma":[0.00006386991,0.00006621613,0.000070738446,0.00042188156,0.00009415742,0.00007102851,0.00001562549,0.00016347771,0.000008640063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017063674,0.0045646727,0.04854011,0.00854154,0.003266232,0.00021434849,0.0056739133,0.0017229832,0.029290799,0.0031023284,0.0017125441,0.87630683],"study_design_scores_gemma":[0.011494022,0.0019252656,0.97653985,0.0010464381,0.001839978,0.000007695744,0.00022491721,0.0018473081,0.0016514322,0.0029842749,0.00033167348,0.00010716045],"about_ca_topic_score_codex":0.0042746156,"about_ca_topic_score_gemma":0.010075657,"teacher_disagreement_score":0.92799973,"about_ca_system_score_codex":0.0007699003,"about_ca_system_score_gemma":0.0020843812,"threshold_uncertainty_score":0.6461969},"labels":[],"label_agreement":null},{"id":"W4393376515","doi":"10.1093/oncolo/oyae050","title":"Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Foundation Medicine; Eisai; Flatiron Health; Teva Pharmaceutical Industries; Broad Institute; Celldex Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Palliative care; Context (archaeology); Hospital Anxiety and Depression Scale; Randomized controlled trial; Quality of life (healthcare); Clinical endpoint; Anxiety; Lung cancer; Depression (economics); Clinical trial; Randomization; Physical therapy; Internal medicine; Nursing; Psychiatry","score_opus":0.08905191217252234,"score_gpt":0.4477167426748217,"score_spread":0.35866483050229936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393376515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886577,0.0026462025,0.00048800206,0.0016075085,0.0007190515,0.0039967657,0.000032666,0.00003562414,0.0018164697],"genre_scores_gemma":[0.9969689,0.0006520254,0.00075886905,0.00042463117,0.0003430209,0.0005148264,0.00003347125,0.000020530706,0.00028371363],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99817514,0.0004928201,0.00057143735,0.00028512723,0.00027396475,0.000201525],"domain_scores_gemma":[0.99719536,0.0019791992,0.00022087849,0.00028168494,0.0002522165,0.00007066145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00103798,0.00017824923,0.0007190695,0.0000626413,0.00006208148,0.000025043128,0.00018357208,0.00010840529,0.000017344422],"category_scores_gemma":[0.00065252435,0.000080339276,0.00016334267,0.0003673143,0.00027561534,0.000050621456,0.000059890164,0.00038067496,0.00001237218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62792885,0.00034385282,0.31818882,0.00021678807,0.00027817863,0.000031168413,0.029319722,0.00035182197,0.00003160718,0.000089814894,0.0014652525,0.02175411],"study_design_scores_gemma":[0.7684308,0.00741386,0.20490044,0.0024878874,0.0010112593,1.7246069e-7,0.006256586,0.000712189,0.00068221265,0.00012345237,0.0076296222,0.00035150754],"about_ca_topic_score_codex":0.0008762294,"about_ca_topic_score_gemma":0.0010313645,"teacher_disagreement_score":0.14050195,"about_ca_system_score_codex":0.00027332723,"about_ca_system_score_gemma":0.0004240528,"threshold_uncertainty_score":0.32761407},"labels":[],"label_agreement":null},{"id":"W4394869936","doi":"10.1093/oncolo/oyae072","title":"Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Dalhousie University; Western University; Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Confounding; Logistic regression; Proportional hazards model; Univariate analysis; Oncology; Kidney cancer; Multivariate analysis","score_opus":0.04695649256119615,"score_gpt":0.3369761675759084,"score_spread":0.29001967501471226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394869936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969228,0.00024510574,0.000016447375,0.000389765,0.00006525812,0.0012965731,0.00006502086,0.00006192617,0.00093709276],"genre_scores_gemma":[0.9990031,0.000014997449,0.0003594369,0.000052391926,0.00003679016,0.00006663607,0.00014048746,0.00005756427,0.0002685577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974853,0.00025181164,0.0008174932,0.00045729525,0.000520532,0.00046756843],"domain_scores_gemma":[0.99769115,0.0010234283,0.00031013798,0.0006794887,0.00013081337,0.00016495225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056524266,0.00039399334,0.0009523748,0.00022164201,0.00006039425,0.000024997425,0.0001299017,0.000093131646,0.000061960964],"category_scores_gemma":[0.00012276474,0.00017166199,0.0003357848,0.00046987753,0.00038757586,0.000046767185,0.00004280793,0.0005042179,0.000013541296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009168602,0.0027648525,0.98443204,0.00014818805,0.0004913061,0.0007205465,0.00017184044,0.0012772984,0.0001298516,0.0000044867015,0.00007656652,0.0006143937],"study_design_scores_gemma":[0.012980037,0.04300314,0.9377832,0.00044560272,0.00077176315,0.000008664864,0.000052487696,0.00023768202,0.0045073843,0.000005806912,0.000026273397,0.00017798651],"about_ca_topic_score_codex":0.0025498774,"about_ca_topic_score_gemma":0.00038623565,"teacher_disagreement_score":0.046648894,"about_ca_system_score_codex":0.0011718442,"about_ca_system_score_gemma":0.0007024914,"threshold_uncertainty_score":0.7000173},"labels":[],"label_agreement":null},{"id":"W4394909371","doi":"10.1093/oncolo/oyae041","title":"A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Alberta; Ottawa Hospital; University of Ottawa; University of Calgary; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"Ontario Ministry of Health and Long-Term Care; Hamilton Health Sciences","keywords":"Medicine; Proportional hazards model; Internal medicine; Multiple myeloma; Population; Retrospective cohort study; Emergency medicine; Oncology; Intensive care medicine","score_opus":0.04688907369917945,"score_gpt":0.3251112198427596,"score_spread":0.27822214614358015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394909371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902345,0.000096005206,0.0036220031,0.0011033234,0.00016855574,0.0032562325,0.00024861534,0.0002528472,0.0010179488],"genre_scores_gemma":[0.99407506,0.0000074767268,0.003945705,0.00011383667,0.00005174517,0.00072743313,0.00045588275,0.000050312097,0.00057255273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982129,0.00005905797,0.00037324106,0.00039433409,0.0004963984,0.00046412076],"domain_scores_gemma":[0.9983214,0.00086086575,0.00010312837,0.00033670213,0.00020392655,0.00017395114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000264044,0.0002580386,0.00039571055,0.000100198224,0.00023121794,0.000071602895,0.00012995115,0.00008538326,0.000011973206],"category_scores_gemma":[0.00045647292,0.0001280299,0.00013703624,0.00024191457,0.00018184283,0.000098618846,0.00004238247,0.00021887793,0.000023058972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019753457,0.0006746552,0.982657,0.00022393723,0.0005685032,0.00024978747,0.0003523704,0.00025710964,0.00015079915,0.00018429541,0.00033898672,0.012367215],"study_design_scores_gemma":[0.01399315,0.004157172,0.7901895,0.00046241962,0.00086473196,0.000051893014,0.00022325726,0.18781404,0.0005580794,0.00058614614,0.0006766342,0.00042298672],"about_ca_topic_score_codex":0.0001596703,"about_ca_topic_score_gemma":0.00029627047,"teacher_disagreement_score":0.1924675,"about_ca_system_score_codex":0.00016983887,"about_ca_system_score_gemma":0.0003890508,"threshold_uncertainty_score":0.5220908},"labels":[],"label_agreement":null},{"id":"W4398131449","doi":"10.1093/oncolo/oyae089","title":"Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Immunotherapy; Melanoma; Medicine; Oncology; Targeted therapy; Internal medicine; Cancer research; Cancer","score_opus":0.013438049135509457,"score_gpt":0.2830156575480475,"score_spread":0.26957760841253803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398131449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234223,0.0036265575,0.00037051374,0.0016126815,0.00029730718,0.0013284674,0.000015027479,0.000097873024,0.00030936653],"genre_scores_gemma":[0.9939441,0.00017520359,0.0048070336,0.00040462083,0.00009790434,0.00013491827,0.000036333247,0.000044265194,0.00035562785],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99909395,0.00005263356,0.00022568264,0.00024657336,0.00014332429,0.00023782907],"domain_scores_gemma":[0.9993186,0.00034333905,0.000064600055,0.00019851427,0.000046211408,0.0000287179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005428873,0.00016236478,0.0002747293,0.0000668567,0.00011601432,0.000051371182,0.00009465473,0.00006934875,0.000075724136],"category_scores_gemma":[0.00004355287,0.00009000428,0.000055615455,0.00022780006,0.00017401928,0.00007947394,0.000015073132,0.00015724046,0.0000041265803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023672296,0.00028448453,0.07310575,0.00011467244,0.0004291553,0.000015563633,0.0014012066,0.00012952667,0.015776865,0.00003239355,0.00043979287,0.8845983],"study_design_scores_gemma":[0.021646298,0.007391433,0.9391516,0.0008504188,0.00006091687,0.000018401548,0.00018219418,0.0153860785,0.0007442899,0.00025333208,0.013872835,0.00044222086],"about_ca_topic_score_codex":0.0001147384,"about_ca_topic_score_gemma":0.00008503678,"teacher_disagreement_score":0.88415605,"about_ca_system_score_codex":0.00016439059,"about_ca_system_score_gemma":0.00011682908,"threshold_uncertainty_score":0.3670268},"labels":[],"label_agreement":null},{"id":"W4399352342","doi":"10.1093/oncolo/oyae131","title":"Has the blood-brain barrier finally been busted?","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Blood–brain barrier; Faith; Neuroscience; Psychology; Medicine; Philosophy; Central nervous system; Epistemology","score_opus":0.05261219151529272,"score_gpt":0.32228744724746117,"score_spread":0.26967525573216844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399352342","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.331734,0.011562167,0.00029277868,0.5973508,0.0009932433,0.0015605892,0.000114001516,0.0003972482,0.05599516],"genre_scores_gemma":[0.9473848,0.000093973424,0.00042208575,0.0073245056,0.0005456955,0.000092938484,0.000027182328,0.000025158444,0.0440837],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990195,0.0001431022,0.00017228929,0.00021568639,0.00020900986,0.00024041094],"domain_scores_gemma":[0.99862564,0.0007665387,0.000032171276,0.00047168348,0.000030229316,0.0000737704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008096632,0.00014304779,0.0001940769,0.00002870957,0.000262935,0.0001027117,0.00018787876,0.00006455724,0.00079209835],"category_scores_gemma":[0.0002136318,0.000058023394,0.0001566624,0.00019999396,0.0004430791,0.000026340344,0.00007736187,0.00029784453,0.00037789595],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004388146,0.00089917,0.0020854515,0.00022088028,0.0026069593,0.0046989718,0.0025621706,0.00008264303,0.0023352308,0.0593538,0.7839156,0.14080034],"study_design_scores_gemma":[0.0009327428,0.0009826595,0.0070026,0.000079769525,0.0010419337,0.0004961428,0.00035806338,0.00025306226,0.00049197784,0.0014574046,0.9868005,0.000103122875],"about_ca_topic_score_codex":0.00021411122,"about_ca_topic_score_gemma":0.00011615422,"teacher_disagreement_score":0.6156508,"about_ca_system_score_codex":0.00007328195,"about_ca_system_score_gemma":0.0002610303,"threshold_uncertainty_score":0.86729217},"labels":[],"label_agreement":null},{"id":"W4400572999","doi":"10.1093/oncolo/oyae172","title":"It is time to rethink randomized clinical trial approaches","year":2024,"lang":"en","type":"letter","venue":"The Oncologist","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"BATES; Randomized controlled trial; Clinical trial; Psychology; Medical physics; Medicine; Engineering; Internal medicine","score_opus":0.1228221381364503,"score_gpt":0.4079856865953792,"score_spread":0.2851635484589289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400572999","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008148799,0.00043226505,0.00028763324,0.89018583,0.0025257193,0.002841309,0.000017981578,0.00021090626,0.103416845],"genre_scores_gemma":[0.000040085342,0.00011696915,0.0016066085,0.7939653,0.022821976,0.00022594367,0.00018225747,0.0000939022,0.18094698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994833,0.0018115212,0.0012802039,0.00080795994,0.00074023823,0.0005271068],"domain_scores_gemma":[0.99253935,0.005884126,0.0003329966,0.0009808319,0.00006166697,0.00020102542],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.012549695,0.00044322736,0.0023895456,0.00014380811,0.00013703275,0.0001504406,0.00068156223,0.0012858934,0.0019478492],"category_scores_gemma":[0.010041318,0.00023106173,0.0012004825,0.0002285171,0.0013353347,0.000019651732,0.00032637682,0.008687273,0.006535191],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09040975,0.00006630756,7.8238486e-7,0.00012016585,0.0005435286,0.00089356524,0.00031529812,0.0000017732904,0.0000011173196,0.000017452043,0.8972538,0.01037647],"study_design_scores_gemma":[0.17633694,0.00057086407,7.6071115e-7,0.00025019675,0.0014521573,0.00013225847,0.00001154501,0.0038522452,6.943472e-7,0.00063157984,0.8165426,0.00021810981],"about_ca_topic_score_codex":0.0000425075,"about_ca_topic_score_gemma":7.8614295e-7,"teacher_disagreement_score":0.096220575,"about_ca_system_score_codex":0.00018573986,"about_ca_system_score_gemma":0.00052012585,"threshold_uncertainty_score":0.9989645},"labels":[],"label_agreement":null},{"id":"W4400968014","doi":"10.1093/oncolo/oyae187","title":"Patients’ considerations of time toxicity when assessing cancer treatments with marginal benefit","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; University of Ottawa; Queen's University","funders":"Canadian Institutes of Health Research; Pancreatic Cancer Action Network","keywords":"Toxicity; Medicine; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.040454438839272557,"score_gpt":0.2718258838074402,"score_spread":0.23137144496816767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400968014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9198242,0.0024827982,0.00041468584,0.002565661,0.00035606278,0.0002765972,0.00050278206,0.000043589425,0.07353361],"genre_scores_gemma":[0.99463624,0.00018345506,0.0006096383,0.0003368064,0.00011461127,0.000046507208,0.00001260513,0.000017826052,0.0040423144],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9991809,0.000009310832,0.00035258627,0.00023498198,0.000028229713,0.0001939934],"domain_scores_gemma":[0.99937713,0.00013111293,0.00021137444,0.00019934066,0.000039931663,0.0000411188],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021389255,0.00012457682,0.00031121966,0.000068596564,0.00013674199,0.0001334332,0.00011600547,0.000064952925,0.0015765766],"category_scores_gemma":[0.000044686138,0.00009113813,0.00006677036,0.00008586189,0.00020266337,0.0003190716,0.000033279157,0.000105182095,0.00021060527],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017500078,0.0007300968,0.38907844,0.0001285056,0.0009361784,0.000025213423,0.0025025236,0.002619498,0.00013830981,0.54197204,0.02962021,0.032073952],"study_design_scores_gemma":[0.002580187,0.0013325401,0.6514001,0.00028121556,0.00020598483,0.000013902053,0.00012115068,0.004947342,0.00084594404,0.23833266,0.099090174,0.00084880996],"about_ca_topic_score_codex":0.0012821218,"about_ca_topic_score_gemma":0.00035270123,"teacher_disagreement_score":0.3036394,"about_ca_system_score_codex":0.00035533129,"about_ca_system_score_gemma":0.00011709323,"threshold_uncertainty_score":0.9993361},"labels":[],"label_agreement":null},{"id":"W4401041181","doi":"10.1093/oncolo/oyae190","title":"Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Palliative chemotherapy; Chemotherapy; Incidence (geometry); Gastric carcinoma; Internal medicine; Oncology; Carcinoma; Palliative care; Clinical trial; Cancer; Nursing","score_opus":0.0227292670198159,"score_gpt":0.32953007751447055,"score_spread":0.30680081049465463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401041181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880291,0.0067763524,0.00003200987,0.0032899634,0.000010993251,0.0011631638,0.00001800372,0.00005693287,0.00062346586],"genre_scores_gemma":[0.9974168,0.00022790483,0.00044955043,0.00026756528,0.000024203253,0.00023125083,0.000016294725,0.000023547831,0.0013428986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899673,0.00007033175,0.0001271744,0.00027959573,0.00024132142,0.00028485744],"domain_scores_gemma":[0.99941504,0.00022808473,0.0000303425,0.00018206281,0.000036991598,0.00010750752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014229721,0.00018284075,0.00032897916,0.00010312568,0.00005139798,0.000035358753,0.00006321649,0.000027424792,0.00008640724],"category_scores_gemma":[0.000014454465,0.000075774275,0.000031705502,0.00038325612,0.00026237263,0.000047296857,0.000017536584,0.00022234792,0.000012879437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033956876,0.00038731578,0.97435355,0.00019235916,0.00036719427,0.0052802097,0.0015536322,0.0000045764064,0.000004873174,0.00010742164,0.00013017788,0.014222972],"study_design_scores_gemma":[0.00798415,0.0048210346,0.98549426,0.00020400462,0.00014603072,0.00013954185,0.0005596705,0.00023704252,0.00027536266,0.00003213586,0.000028866241,0.00007789111],"about_ca_topic_score_codex":0.0010697359,"about_ca_topic_score_gemma":0.00077581056,"teacher_disagreement_score":0.014145081,"about_ca_system_score_codex":0.0002738278,"about_ca_system_score_gemma":0.00021135877,"threshold_uncertainty_score":0.30899853},"labels":[],"label_agreement":null},{"id":"W4401363772","doi":"10.1093/oncolo/oyae181.031","title":"23 Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Muscle and Compartmental Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Medicine; Nephrectomy; Adipose tissue; Acute kidney injury; Kidney; Kidney cancer; Surgery; Cancer; Internal medicine","score_opus":0.018365667132579554,"score_gpt":0.3295378471971235,"score_spread":0.31117218006454395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985914,0.00055570685,0.00021849255,0.002033527,0.00079623394,0.0021929778,0.0017505679,0.0002640347,0.0062744957],"genre_scores_gemma":[0.9883187,0.00058138644,0.00044460525,0.00082082296,0.0006153175,0.00040928487,0.00025284017,0.000087270906,0.008469783],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99731976,0.00017294269,0.00055955205,0.0006955323,0.0005307598,0.0007214403],"domain_scores_gemma":[0.99837285,0.00044180566,0.00017537075,0.00040163152,0.000058365345,0.00054998044],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025901553,0.00042750823,0.0006077179,0.000091709706,0.00031803903,0.00012333771,0.00035227323,0.00030579325,0.0011104892],"category_scores_gemma":[0.00006073723,0.00028421398,0.00036349957,0.00028028828,0.0005162107,0.00014810727,0.00021249508,0.00077271124,0.00006742965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06880135,0.017497182,0.1439808,0.0033872693,0.005444972,0.0018119185,0.0099147465,0.00038999686,0.017091416,0.0012878871,0.6022614,0.12813105],"study_design_scores_gemma":[0.013295544,0.007637535,0.054991625,0.00039251376,0.001728964,0.000042045824,0.000102911814,0.0051527387,0.00620664,0.00009690922,0.90964735,0.00070521416],"about_ca_topic_score_codex":0.00041214202,"about_ca_topic_score_gemma":0.00012256447,"teacher_disagreement_score":0.30738595,"about_ca_system_score_codex":0.00043805628,"about_ca_system_score_gemma":0.0005418045,"threshold_uncertainty_score":0.999961},"labels":[],"label_agreement":null},{"id":"W4401363791","doi":"10.1093/oncolo/oyae181.013","title":"20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Dalhousie University; Baker Hughes (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Oncology; Cohort; Proportional hazards model; Clinical trial","score_opus":0.07293113190360824,"score_gpt":0.35448449782588676,"score_spread":0.28155336592227853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930753,0.0006665397,0.00004129513,0.0005042258,0.0002481491,0.0037962054,0.000040245224,0.00011754641,0.0015105034],"genre_scores_gemma":[0.99666005,0.000007755755,0.00071168994,0.00005113462,0.00025675283,0.00072528055,0.00016159935,0.00007741835,0.0013483046],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969912,0.0005715367,0.0007658685,0.00064145843,0.0005083823,0.0005215642],"domain_scores_gemma":[0.9983247,0.0005868492,0.00018804848,0.00062193203,0.00012561765,0.00015283277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022796297,0.00040766632,0.000741885,0.00020696879,0.00011150611,0.000092632334,0.00022890982,0.00007027401,0.00007871489],"category_scores_gemma":[0.00012896811,0.00022515301,0.0001931701,0.00034173983,0.00019930153,0.00013601335,0.0001080441,0.00042193904,0.000034015553],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04563542,0.02163951,0.29069135,0.0028254616,0.0028912902,0.020320611,0.043936413,0.0017714396,0.53183943,0.0001678667,0.0013291654,0.036952037],"study_design_scores_gemma":[0.036401756,0.092972524,0.6710734,0.00080061797,0.0039977557,0.00041154397,0.014586502,0.018167041,0.15986368,0.0003915621,0.0003153632,0.0010183054],"about_ca_topic_score_codex":0.0018379778,"about_ca_topic_score_gemma":0.0014051414,"teacher_disagreement_score":0.380382,"about_ca_system_score_codex":0.00094614,"about_ca_system_score_gemma":0.00043604223,"threshold_uncertainty_score":0.9181473},"labels":[],"label_agreement":null},{"id":"W4401363835","doi":"10.1093/oncolo/oyae181.036","title":"35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Lenvatinib; Medicine; Cabozantinib; Internal medicine; Renal cell carcinoma; Oncology; Cohort; Pembrolizumab; Discontinuation; Sorafenib; Cancer; Hepatocellular carcinoma; Immunotherapy","score_opus":0.015138111206525359,"score_gpt":0.2673251085670865,"score_spread":0.25218699736056116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401363835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854189,0.0007476309,0.000002846944,0.00040088512,0.000103242695,0.001212724,0.000038703667,0.000049113816,0.012025946],"genre_scores_gemma":[0.9978474,0.000017070297,0.00048387484,0.00009432295,0.000042919768,0.00007228942,0.00014404593,0.0000347483,0.0012633455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985867,0.0000752453,0.0003434871,0.000345907,0.00035134837,0.0002973006],"domain_scores_gemma":[0.9990057,0.00024687476,0.00010389244,0.00046947366,0.000085896594,0.00008818566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013860976,0.00023811175,0.00040133458,0.00012947794,0.000044301432,0.000012836931,0.00014390297,0.00007573218,0.00008181796],"category_scores_gemma":[0.000035164114,0.00012370694,0.00010975982,0.00034290622,0.00021143685,0.0000560435,0.000057661375,0.00021454596,0.00005414051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01270551,0.006081649,0.9011425,0.00046459114,0.00037186922,0.0013443064,0.0024166794,0.00023995343,0.011016945,0.00016336139,0.0007729565,0.063279696],"study_design_scores_gemma":[0.008699314,0.00952275,0.9663452,0.00018771892,0.0002963586,0.000013080237,0.00011994529,0.00003377668,0.014228596,0.000016206868,0.00041229968,0.0001247685],"about_ca_topic_score_codex":0.00023084487,"about_ca_topic_score_gemma":0.000044459204,"teacher_disagreement_score":0.0652027,"about_ca_system_score_codex":0.0005052388,"about_ca_system_score_gemma":0.00024076301,"threshold_uncertainty_score":0.5044623},"labels":[],"label_agreement":null},{"id":"W4401364054","doi":"10.1093/oncolo/oyae181.026","title":"8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nivolumab; Ipilimumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.07148638069975227,"score_gpt":0.3484030131394102,"score_spread":0.2769166324396579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401364054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092555,0.002124683,0.00007939475,0.00050791557,0.00036461095,0.004034341,0.000855329,0.00005980476,0.0010483636],"genre_scores_gemma":[0.9958258,0.00031374203,0.00049937266,0.000037880018,0.0002910149,0.00070818985,0.0006637903,0.00005691838,0.0016032478],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977667,0.00023465011,0.0006359862,0.000530808,0.00039330317,0.00043857787],"domain_scores_gemma":[0.997358,0.0013097879,0.0003193891,0.0007492171,0.00015400749,0.00010960272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031530357,0.00039743088,0.000895289,0.000110962974,0.00020692506,0.00004263851,0.00024169721,0.000118131764,0.000087656976],"category_scores_gemma":[0.00013765725,0.00018739061,0.00036208017,0.00041738828,0.00027955466,0.00007504169,0.00005367382,0.00021590544,0.000019801735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90770024,0.012118574,0.022025304,0.00040887794,0.0018465865,0.0006227963,0.008845437,0.0038267847,0.0031364711,0.00005844851,0.002369104,0.037041403],"study_design_scores_gemma":[0.78053266,0.1141077,0.022424476,0.00039200662,0.0060223304,0.000012548449,0.0030788798,0.004364056,0.05855854,0.00029379097,0.009650176,0.0005628513],"about_ca_topic_score_codex":0.004927036,"about_ca_topic_score_gemma":0.0035797236,"teacher_disagreement_score":0.12716757,"about_ca_system_score_codex":0.001192109,"about_ca_system_score_gemma":0.00054692366,"threshold_uncertainty_score":0.76415676},"labels":[],"label_agreement":null},{"id":"W4401364392","doi":"10.1093/oncolo/oyae181.020","title":"19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epithelioid sarcoma; Cancer research; CD3; Mucin; SMARCB1; CD30; Pathology; Medicine; Biology; Antigen; CD8; Sarcoma; Immunohistochemistry; Immunology; Gene expression","score_opus":0.03657062688265229,"score_gpt":0.3470010378014646,"score_spread":0.3104304109188123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401364392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880341,0.0016203992,0.00008504197,0.0059231776,0.00007806467,0.00034501258,0.00005489765,0.00005318276,0.0038061107],"genre_scores_gemma":[0.9982285,0.00008484401,0.00022968683,0.00041587756,0.00024729926,0.000025823643,0.000047630336,0.000013096251,0.0007072523],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986749,0.00015899343,0.00042956913,0.00025938495,0.00026408787,0.0002130558],"domain_scores_gemma":[0.9992519,0.00023757828,0.0000901724,0.0002854939,0.000034827655,0.00010003661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085243507,0.00013880669,0.00038557447,0.00025087845,0.00012505589,0.000030838237,0.000099858065,0.000085049825,0.00016062714],"category_scores_gemma":[0.00020162841,0.000086505395,0.00013825257,0.00041214595,0.00041475554,0.00004875839,0.00012334317,0.0002818648,0.0000095348805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06531295,0.011388655,0.0026603853,0.0015609178,0.000510391,0.004810936,0.010512982,0.000121815894,0.61449236,0.0037493517,0.039838415,0.24504083],"study_design_scores_gemma":[0.51052225,0.04054231,0.013076372,0.011115083,0.0030317022,0.0024914618,0.012199096,0.058013454,0.15463527,0.0042234333,0.18823247,0.0019170856],"about_ca_topic_score_codex":0.00023908906,"about_ca_topic_score_gemma":0.000044021854,"teacher_disagreement_score":0.4598571,"about_ca_system_score_codex":0.00012046472,"about_ca_system_score_gemma":0.000213951,"threshold_uncertainty_score":0.35275877},"labels":[],"label_agreement":null},{"id":"W4401380032","doi":"10.1093/oncolo/oyae181.027","title":"9 Delving into molecular underpinnings of sarcomatoid/rhabdoid dedifferentioation in renal cancers using spatial profiling","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Transcriptome; Phenotype; Biology; Clear cell renal cell carcinoma; Renal cell carcinoma; Computational biology; Exome; Pathology; Exome sequencing; Bioinformatics; Medicine; Gene; Genetics; Gene expression","score_opus":0.03754108721285215,"score_gpt":0.3317309242573873,"score_spread":0.29418983704453516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401380032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872805,0.0019649614,0.008416423,0.00057360565,0.00017355128,0.0004813509,0.0000016518898,0.00004933992,0.0010586183],"genre_scores_gemma":[0.9957116,0.00003219859,0.0039950297,0.00006654561,0.00008425709,0.000027368309,0.000015882557,0.000022257334,0.00004484566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887806,0.00009582564,0.00033584618,0.00022808842,0.00026257738,0.00019961447],"domain_scores_gemma":[0.9994934,0.00011071408,0.00009398911,0.0002050348,0.000051989267,0.00004483178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033962,0.00013926072,0.00026380672,0.00015429936,0.000053589793,0.000023142893,0.0000930414,0.00007850589,0.000023655644],"category_scores_gemma":[0.00007783951,0.0000942368,0.000094833005,0.00029333046,0.00017280929,0.00004811136,0.000061709594,0.00021796006,0.000004549752],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032007406,0.00010805187,0.029414354,0.0006109015,0.000160072,0.0005864907,0.0014010795,0.0025972526,0.9511448,0.0012703283,0.00003576897,0.012350798],"study_design_scores_gemma":[0.0022092632,0.0011664685,0.04168206,0.002121956,0.00058228243,0.00030284617,0.00113554,0.13706984,0.80968064,0.0035749911,0.0001419816,0.00033210844],"about_ca_topic_score_codex":0.005258184,"about_ca_topic_score_gemma":0.00054100575,"teacher_disagreement_score":0.14146417,"about_ca_system_score_codex":0.0015622386,"about_ca_system_score_gemma":0.00046870307,"threshold_uncertainty_score":0.7948836},"labels":[],"label_agreement":null},{"id":"W4401792490","doi":"10.1093/oncolo/oyae215","title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; EMD Serono; Eisai; National Cancer Institute; Aptitude Health; Natera; Seagen; Loxo Oncology; Astellas Pharma; Calithera Biosciences; Mirati Therapeutics; bluebird bio; Sanofi; Exelixis; Genentech; MEI Pharma; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Gemcitabine; Pembrolizumab; Avelumab; Carboplatin; Medicine; Chemotherapy; Cisplatin; Oncology; Nivolumab; Metastatic Urothelial Carcinoma; Regimen; Internal medicine; Urothelial carcinoma; Bladder cancer; Cancer; Immunotherapy","score_opus":0.041673547470804276,"score_gpt":0.360458438488445,"score_spread":0.31878489101764074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401792490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002200871,0.9851386,0.0000070700685,0.0003648256,0.00014619682,0.008419878,0.00028284403,0.000032509994,0.0034071892],"genre_scores_gemma":[0.14073104,0.8485085,0.0007415425,0.00051701244,0.0007719092,0.007559012,0.00041080936,0.00023641801,0.0005237584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811846,0.00027586514,0.0005253513,0.0003745018,0.00038936015,0.00031643815],"domain_scores_gemma":[0.9977937,0.001010695,0.00037767921,0.00069075613,0.0000940348,0.00003318698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005214799,0.00045733625,0.0011665042,0.00007730877,0.00015372377,0.000034160847,0.00037371714,0.00014697587,0.000042078966],"category_scores_gemma":[0.00008573876,0.0001494144,0.00041893998,0.00033275137,0.00017412343,0.000023016844,0.000026200805,0.0002936936,0.000008118352],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092160096,0.0006281675,0.0021141572,0.0020615184,0.0004297732,0.000008549466,0.00111426,0.000010583806,0.0000012749593,0.00003715796,0.00023324632,0.9924397],"study_design_scores_gemma":[0.015724111,0.014142,0.0029828409,0.009130603,0.009393337,0.000025773286,0.00085515075,0.0004445481,0.000031412223,0.00019600193,0.9466196,0.00045462136],"about_ca_topic_score_codex":0.00014245936,"about_ca_topic_score_gemma":0.00013850804,"teacher_disagreement_score":0.9919851,"about_ca_system_score_codex":0.00045445075,"about_ca_system_score_gemma":0.0010168551,"threshold_uncertainty_score":0.60929424},"labels":[],"label_agreement":null},{"id":"W4402326482","doi":"10.1093/oncolo/oyae219","title":"Evaluating early intervention in smoldering myeloma clinical trials: a systematic review","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Clinical endpoint; Clinical trial; Internal medicine; Randomized controlled trial; Oncology; Surgery","score_opus":0.6741545513710383,"score_gpt":0.6617437026961426,"score_spread":0.012410848674895725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402326482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026127835,0.98487216,0.000009165765,0.00026689007,0.00043243155,0.013712836,0.000020708463,0.000082615195,0.0005770433],"genre_scores_gemma":[0.000092364244,0.9937468,0.00014719041,0.000087209046,0.00031996417,0.0035886585,0.00009374207,0.00006395543,0.0018600944],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9816496,0.012214715,0.0044748164,0.00059093424,0.00064062985,0.0004293088],"domain_scores_gemma":[0.99165076,0.0057616,0.0013509917,0.00097032334,0.00009319756,0.00017312611],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.044349987,0.00046971906,0.007834544,0.00023530444,0.00006655734,0.00009088065,0.0004424587,0.00034577434,0.00011562894],"category_scores_gemma":[0.036324527,0.00021038807,0.0026017404,0.0006149003,0.0001534713,0.00004181052,0.00030075927,0.0014622657,0.0012119575],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025410416,0.0001268604,0.0000071750537,0.5309517,0.00068831816,0.00031770472,0.000010355696,1.8028631e-8,1.8113345e-8,0.000010265635,0.00023066222,0.46763152],"study_design_scores_gemma":[0.0011151682,0.0010141404,0.0000470895,0.9552773,0.020917585,0.0002452443,0.0000220005,0.00009276655,3.9839723e-8,0.000033784614,0.021071956,0.00016290953],"about_ca_topic_score_codex":0.00015527624,"about_ca_topic_score_gemma":0.000069668255,"teacher_disagreement_score":0.4674686,"about_ca_system_score_codex":0.0008365676,"about_ca_system_score_gemma":0.0005319379,"threshold_uncertainty_score":0.9995657},"labels":[],"label_agreement":null},{"id":"W4403220541","doi":"10.1093/oncolo/oyae261","title":"A rapid review of nutrition and exercise approaches to managing unintentional weight loss, muscle loss, and malnutrition in cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"State Government of Victoria","keywords":"Malnutrition; Weight loss; Medicine; Psychological intervention; Medical nutrition therapy; Intensive care medicine; Nutritional Supplementation; Randomized controlled trial; Enteral administration; Parenteral nutrition; Physical therapy; Surgery; Internal medicine; Obesity; Nursing","score_opus":0.28439050253138654,"score_gpt":0.4193227246138907,"score_spread":0.13493222208250416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403220541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015689215,0.97371566,0.0000062896274,0.022514818,0.00016822712,0.0028140815,0.0001020415,0.000032253447,0.0006309171],"genre_scores_gemma":[0.000057641148,0.996502,0.0006891266,0.00081705593,0.00025477645,0.001201943,0.00017798984,0.00003105349,0.0002684238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824053,0.0001777478,0.000735619,0.00040295348,0.0002100292,0.00023311561],"domain_scores_gemma":[0.9992467,0.00011926159,0.00022362596,0.00022807007,0.000058878166,0.00012342815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009663916,0.000264069,0.00142781,0.00032907398,0.000070373724,0.000019736499,0.000106195264,0.00016829782,0.00010562723],"category_scores_gemma":[0.000044950484,0.00017428791,0.00016661729,0.00055465056,0.00027860797,0.000045509027,0.00011730275,0.0005120757,0.000012409557],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026546444,0.00018544347,0.000011019088,0.42474458,0.00002587186,0.000042718137,0.00002517469,1.2715746e-8,2.1575667e-7,0.000968258,0.0064706868,0.56749946],"study_design_scores_gemma":[0.00043021052,0.000073411335,0.00008017446,0.38151047,0.00085234025,0.00013114454,0.000029496176,0.00000658652,3.4171615e-7,0.0006784505,0.61610323,0.00010416535],"about_ca_topic_score_codex":0.00007206087,"about_ca_topic_score_gemma":0.000028605555,"teacher_disagreement_score":0.6096325,"about_ca_system_score_codex":0.00028457417,"about_ca_system_score_gemma":0.00018926639,"threshold_uncertainty_score":0.7107254},"labels":[],"label_agreement":null},{"id":"W4403565766","doi":"10.1093/oncolo/oyae237","title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Population; Cancer; Androgen receptor","score_opus":0.2252177205887461,"score_gpt":0.48773709342720395,"score_spread":0.26251937283845783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403565766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001119114,0.98871106,0.000006364847,0.0005671501,0.00009596452,0.006778181,0.002275455,0.000025286337,0.0004214007],"genre_scores_gemma":[0.0019997437,0.98991895,0.00018307888,0.00003066157,0.00008762985,0.0016580959,0.00023991737,0.000045637335,0.0058362987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99836534,0.00013222656,0.00057656225,0.0004225459,0.00020594477,0.00029737045],"domain_scores_gemma":[0.99846256,0.00077596516,0.0003024334,0.00025690408,0.00009122192,0.00011092875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034915245,0.000408381,0.0018523387,0.0001030416,0.00017736344,0.000041765914,0.00009824118,0.000104129795,0.0000295435],"category_scores_gemma":[0.00004727301,0.000191462,0.00018419471,0.00021852464,0.00066717906,0.000030433424,0.0000807447,0.00024811635,0.0000061572255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012190096,0.0012444863,0.000098703604,0.09019083,0.018323,0.00028267177,0.0061407024,0.000048554954,0.0000766038,0.0010174167,0.0034867786,0.86690015],"study_design_scores_gemma":[0.008515986,0.003372801,0.00018743896,0.014101822,0.020305954,0.00008674699,0.00031177374,0.000100758276,0.000053422053,0.0001706424,0.9524722,0.0003204373],"about_ca_topic_score_codex":0.00044307797,"about_ca_topic_score_gemma":0.00072062213,"teacher_disagreement_score":0.94898546,"about_ca_system_score_codex":0.00058345974,"about_ca_system_score_gemma":0.0009901419,"threshold_uncertainty_score":0.78075933},"labels":[],"label_agreement":null},{"id":"W4403622778","doi":"10.1093/oncolo/oyae277","title":"Clinical impact of <i>TP53</i> functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"","keywords":"Bevacizumab; KRAS; Colorectal cancer; Medicine; Internal medicine; Oncology; Chemotherapy; Missense mutation; Population; Cancer; Gene; Mutation; Biology","score_opus":0.03163770663684876,"score_gpt":0.36591112428132244,"score_spread":0.33427341764447366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727625,0.0006512685,0.000008173177,0.0006404803,0.000039255745,0.00056896766,0.000073977855,0.000024379324,0.00071723986],"genre_scores_gemma":[0.9992865,0.00017743431,0.00009159722,0.00007643814,0.000027835742,0.00012338182,0.000032436506,0.000012854761,0.00017155465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993089,0.00004506557,0.00019355556,0.00018126372,0.00014645785,0.0001247646],"domain_scores_gemma":[0.99950117,0.00024316546,0.000057597543,0.0000753036,0.00008245779,0.00004031557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011199457,0.00012590014,0.00032914354,0.000049359707,0.000053472926,0.000011416581,0.000026263137,0.000027582044,0.000096124226],"category_scores_gemma":[0.00001737453,0.00005321316,0.00005941785,0.00027162296,0.00040485658,0.00003758939,0.000012385215,0.00012475008,0.0000013513836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007484396,0.00050684134,0.968701,0.000026768479,0.00104063,0.000026131855,0.0003672975,0.000059757847,0.000012593017,0.000017449838,0.00034207894,0.021415073],"study_design_scores_gemma":[0.0055694673,0.008273157,0.9851322,0.00008931872,0.0004128545,0.000011973621,0.000116735646,0.00013567049,0.0000254862,0.000023025996,0.00014671769,0.000063392494],"about_ca_topic_score_codex":0.00101605,"about_ca_topic_score_gemma":0.001557158,"teacher_disagreement_score":0.02135168,"about_ca_system_score_codex":0.0002754625,"about_ca_system_score_gemma":0.00030869665,"threshold_uncertainty_score":0.21699697},"labels":[],"label_agreement":null},{"id":"W4403972842","doi":"10.1093/oncolo/oyae283","title":"Breast cancer incidence and mortality, by age, stage and molecular subtypes, by race/ethnicity in Canada","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Government of Canada; Statistics Canada; University of Ottawa","funders":"Women and Gender Equality Canada; Public Health Agency; Public Health Agency of Canada","keywords":"Race (biology); Ethnic group; Incidence (geometry); Breast cancer; Stage (stratigraphy); Cancer; Medicine; Demography; Oncology; Internal medicine; Biology; Gender studies; Sociology; Anthropology","score_opus":0.04235140625839118,"score_gpt":0.3588488841069859,"score_spread":0.3164974778485947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403972842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96863735,0.022943836,0.00002715485,0.006941898,0.00009784351,0.00022365275,0.00021684598,0.000023709561,0.0008877092],"genre_scores_gemma":[0.99489075,0.0016588288,0.00001993884,0.0027772791,0.000034570072,0.000025243284,0.000012574917,0.000010120412,0.00057072303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989535,0.00006578671,0.00017860791,0.00027749012,0.00027591258,0.00024870693],"domain_scores_gemma":[0.9995658,0.00009025543,0.000029256636,0.00017540753,0.000025231971,0.000114069335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003906921,0.0001287532,0.00024065631,0.000019325445,0.000057210935,0.000042874726,0.00011242339,0.000057491212,0.00007391213],"category_scores_gemma":[0.00003491444,0.000088662666,0.000018086477,0.00019571495,0.00023071826,0.00007407063,0.000106818494,0.00030475334,0.0000012138902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031032666,0.00004700276,0.78011066,0.00034335486,0.00014323907,0.0043425825,0.00044466753,0.000070233786,0.01984195,0.00052130484,0.17088822,0.022936456],"study_design_scores_gemma":[0.0012526796,0.00028210814,0.94018793,0.0007365357,0.00027519086,0.00059381826,0.001518028,0.002137194,0.0032716629,0.0003614956,0.048877135,0.00050624716],"about_ca_topic_score_codex":0.9649527,"about_ca_topic_score_gemma":0.9478817,"teacher_disagreement_score":0.16007723,"about_ca_system_score_codex":0.0007038576,"about_ca_system_score_gemma":0.00091091,"threshold_uncertainty_score":0.36155587},"labels":[],"label_agreement":null},{"id":"W4404200415","doi":"10.1093/oncolo/oyae298","title":"Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"Faculty of Medicine, University of British Columbia","keywords":"Primary (astronomy); Multicenter study; Medicine; Oncology; Internal medicine","score_opus":0.033981990015166504,"score_gpt":0.31344354251601264,"score_spread":0.27946155250084614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404200415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812837,0.008933612,0.000001648954,0.0078092576,0.000045753775,0.00050847104,0.00004606597,0.000004677821,0.0013668095],"genre_scores_gemma":[0.99775326,0.0017363024,0.000024279225,0.00012125532,0.000034901343,0.000231549,0.000019402234,0.0000043385994,0.00007468965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941254,0.00006363236,0.00016870949,0.00013461255,0.00010240561,0.0001181246],"domain_scores_gemma":[0.9993925,0.00027914724,0.00003740134,0.00022520755,0.00002334104,0.00004239001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016296661,0.00008086521,0.0002674101,0.0001656471,0.000030466475,0.000008962359,0.00004817607,0.00003443701,0.000041212803],"category_scores_gemma":[0.000016256085,0.00003741456,0.000118628814,0.0004436583,0.00014370555,0.000015297555,0.000009593126,0.00003887718,0.0000017578046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000624099,0.0005133419,0.9792331,0.0000450772,0.00049268454,0.000077602774,0.0019350299,0.000027423053,0.000018951123,0.0006569987,0.0003273762,0.016610019],"study_design_scores_gemma":[0.00075367565,0.0008455318,0.9900399,0.000048382226,0.0019231404,0.000005157828,0.00034741504,0.0003566339,0.00013771463,0.00002993046,0.005480219,0.000032312462],"about_ca_topic_score_codex":0.37008324,"about_ca_topic_score_gemma":0.55229574,"teacher_disagreement_score":0.18221249,"about_ca_system_score_codex":0.0009722715,"about_ca_system_score_gemma":0.00022920597,"threshold_uncertainty_score":0.6341114},"labels":[],"label_agreement":null},{"id":"W4404709309","doi":"10.1093/oncolo/oyae310","title":"Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Servier; AstraZeneca; Bristol-Myers Squibb Canada; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Internal medicine; Colorectal cancer; Coronavirus disease 2019 (COVID-19); Stage (stratigraphy); Pandemic; Cancer; Propensity score matching; Oncology; Disease","score_opus":0.1278640685398695,"score_gpt":0.4997583880060044,"score_spread":0.37189431946613494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404709309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97874045,0.0006970094,0.00001141499,0.018331388,0.0007338803,0.0011066125,0.000030571613,0.00009072603,0.00025792368],"genre_scores_gemma":[0.9940861,0.0010323867,0.000012990685,0.0040110257,0.000074078955,0.00012608714,0.000039076178,0.0000144798,0.00060381455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857265,0.00031655817,0.0003268046,0.00029037092,0.00021318732,0.00028041287],"domain_scores_gemma":[0.9983937,0.0012500762,0.000055494445,0.00012327585,0.000016312488,0.00016111543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012114255,0.000127833,0.00037807072,0.0001354636,0.0000605036,0.000028438442,0.00008835189,0.000119773315,0.000033193322],"category_scores_gemma":[0.0009338879,0.00008381575,0.00005463626,0.00033046337,0.00012198079,0.000049469792,0.00008617615,0.00031991026,0.000005528029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028634805,0.00017559493,0.9841138,0.00026367573,0.000070793656,0.00008886626,0.00063273724,0.000002485737,0.000025622667,0.000028828234,0.0032313406,0.011079873],"study_design_scores_gemma":[0.0033385966,0.0004649887,0.98997104,0.0001044104,0.000072306546,0.000001326263,0.00029974105,0.00010007935,0.0000044989624,0.00008115194,0.00547581,0.000086058535],"about_ca_topic_score_codex":0.0052253767,"about_ca_topic_score_gemma":0.045268673,"teacher_disagreement_score":0.0400433,"about_ca_system_score_codex":0.0007096259,"about_ca_system_score_gemma":0.00028731299,"threshold_uncertainty_score":0.9721527},"labels":[],"label_agreement":null},{"id":"W4404711423","doi":"10.1093/oncolo/oyae321","title":"Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; EQ-5D; Meta-analysis; Prostate cancer; Observational study; Internal medicine; Systematic review; MEDLINE; Visual analogue scale; Oncology; Pooled analysis; Cancer; Health related quality of life; Surgery","score_opus":0.13686046811730865,"score_gpt":0.4540249715358743,"score_spread":0.3171645034185656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404711423","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011009429,0.963188,0.000011359358,0.022334425,0.000025652278,0.0027948956,0.00048063236,0.000023963268,0.0001316288],"genre_scores_gemma":[0.73577434,0.25742403,0.0001672252,0.0007946862,0.00000711935,0.0008289883,0.00010294969,0.000015232374,0.0048854374],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9977806,0.0007287594,0.0007038168,0.00027091155,0.00029624547,0.00021965074],"domain_scores_gemma":[0.9989659,0.00034092268,0.00017880417,0.00032187768,0.00012713,0.00006536291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002909319,0.00015801119,0.0017692379,0.00019576964,0.00006230406,0.000051047446,0.00007948063,0.00002229978,0.00012078119],"category_scores_gemma":[0.000110111534,0.000069043526,0.00030548702,0.0014571209,0.00020796714,0.00006794033,0.000031940912,0.00020643063,0.0000019294062],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046071882,0.00044657188,0.0010759257,0.7479312,0.23360093,0.0005458345,0.010435595,0.00008813828,0.00023153776,0.0004209591,0.0023760295,0.002386583],"study_design_scores_gemma":[0.0013126866,0.0013571719,0.01837373,0.025391253,0.9478131,0.000054356206,0.0013277137,0.002072224,0.0002034589,0.0010923999,0.0006789099,0.00032302632],"about_ca_topic_score_codex":0.0007260317,"about_ca_topic_score_gemma":0.0011627178,"teacher_disagreement_score":0.72476494,"about_ca_system_score_codex":0.00021011304,"about_ca_system_score_gemma":0.0004892274,"threshold_uncertainty_score":0.28155133},"labels":[],"label_agreement":null},{"id":"W4405221538","doi":"10.1093/oncolo/oyae348","title":"<i>Divinum opus est sedare dolorem</i>: the power (and beauty) of early palliative care","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto; Università Degli Studi di Modena e Reggio Emila","keywords":"Beauty; Opus; Power (physics); Palliative care; Art; Aesthetics; Nursing; Medicine; Art history; Physics","score_opus":0.10663349626890462,"score_gpt":0.42165330260910416,"score_spread":0.31501980634019955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405221538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9258194,0.035037044,0.00004750209,0.0051261904,0.00046381075,0.00046560424,0.00010621063,0.00006612204,0.032868125],"genre_scores_gemma":[0.9972653,0.0010932665,0.0002114674,0.0003554598,0.00015817284,0.000023950408,0.000012990246,0.000017629302,0.0008618057],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990001,0.00009904676,0.00024800672,0.00020098056,0.0002462821,0.00020562956],"domain_scores_gemma":[0.9985803,0.0007679423,0.00009523999,0.00032269015,0.00017674631,0.00005710933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029545525,0.00015490108,0.00034753926,0.000044110642,0.00008041141,0.000021514878,0.00020167866,0.000097400436,0.00006384194],"category_scores_gemma":[0.0003188844,0.00007373289,0.00012479057,0.00024709615,0.0007410034,0.000040619307,0.00010965663,0.00028878867,0.000023892719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017225537,0.00039273273,0.53797954,0.002493629,0.0019394144,0.0005632867,0.34119877,0.00004414612,0.01667409,0.026340064,0.032386497,0.03826528],"study_design_scores_gemma":[0.0024035624,0.0053694975,0.37789968,0.0042665936,0.0012585195,0.000034312343,0.0803947,0.00007397022,0.03836458,0.002175923,0.48724085,0.00051779],"about_ca_topic_score_codex":0.00053128495,"about_ca_topic_score_gemma":0.00013758507,"teacher_disagreement_score":0.45485437,"about_ca_system_score_codex":0.000085522755,"about_ca_system_score_gemma":0.0001844643,"threshold_uncertainty_score":0.300674},"labels":[],"label_agreement":null},{"id":"W4406529892","doi":"10.1093/oncolo/oyae309","title":"Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Mindfulness; Renal cell carcinoma; Multinational corporation; Intervention (counseling); Medicine; Oncology; Carcinoma; Psychology; Internal medicine; Clinical psychology; Nursing; Business","score_opus":0.02287640169664145,"score_gpt":0.31155423557851736,"score_spread":0.2886778338818759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406529892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633825,0.000050447943,0.0013150313,0.00010550626,0.00007854561,0.001406764,0.000034994675,0.00001485923,0.0006556146],"genre_scores_gemma":[0.99954873,4.576819e-8,0.000080936705,0.0000414404,0.0000076125043,0.00016212046,0.000027307695,0.0000045645843,0.00012724572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989256,0.00026936023,0.00025458648,0.00022676983,0.00022329322,0.00010033752],"domain_scores_gemma":[0.99907297,0.00022480762,0.0001403954,0.0002855778,0.00024198952,0.000034239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006596358,0.00010270589,0.000257011,0.000054804455,0.00007066467,0.00001029726,0.00009075156,0.000028726057,0.0001062368],"category_scores_gemma":[0.00013429728,0.00006136917,0.00006654578,0.00022300071,0.00035241107,0.000036804064,0.00005968652,0.0001281393,3.4060392e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016474037,0.0027945796,0.98750466,0.0002547437,0.00003433792,0.0000022609747,0.00046108535,0.000009951371,0.0000040824643,0.00001663373,0.000024798186,0.007245485],"study_design_scores_gemma":[0.007138404,0.0011921154,0.98713815,0.00002647666,0.00029084153,2.3828342e-7,0.0026447298,0.00016083512,0.0012542916,0.00008601499,0.000014119197,0.000053754375],"about_ca_topic_score_codex":0.0023280738,"about_ca_topic_score_gemma":0.009210043,"teacher_disagreement_score":0.007191731,"about_ca_system_score_codex":0.00018570239,"about_ca_system_score_gemma":0.0001409053,"threshold_uncertainty_score":0.513942},"labels":[],"label_agreement":null},{"id":"W4406759369","doi":"10.1093/oncolo/oyae371","title":"Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Institutes of Health; Astellas Pharma; Merck; MedImmune; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Taiho Pharmaceutical; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Perioperative; Esophageal cancer; Chemotherapy; Chemoradiotherapy; Adenocarcinoma; Esophageal adenocarcinoma; Radiation therapy; Adjuvant; Oncology; Internal medicine; General surgery; Surgery; Cancer","score_opus":0.06521482934145607,"score_gpt":0.41803361921587184,"score_spread":0.3528187898744158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406759369","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010226574,0.98374796,0.00011383827,0.0043793125,0.00009395611,0.00832541,0.0006331735,0.000057654335,0.0026384904],"genre_scores_gemma":[0.0002664515,0.9235842,0.0007276911,0.0019226833,0.00050716964,0.0030087088,0.00053541246,0.0000541615,0.06939351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973398,0.00037728736,0.0005786843,0.0007443847,0.0003757812,0.0005840698],"domain_scores_gemma":[0.99767464,0.0009761195,0.00020727694,0.00062748406,0.00015784129,0.00035665176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006380051,0.0005406517,0.001918259,0.00019851005,0.00031657214,0.0000858408,0.00032360468,0.00031782003,0.0005546656],"category_scores_gemma":[0.00044932915,0.00032166947,0.00043869726,0.00040842924,0.00027770537,0.000051642375,0.00021634773,0.0004906096,0.000420524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091608666,0.00020816443,0.0001436767,0.012157093,0.00084550696,0.00029470932,0.00037073874,0.0000016513726,1.6246385e-7,0.0001580454,0.15876982,0.8261343],"study_design_scores_gemma":[0.0035426565,0.005881841,0.00042327936,0.0056480286,0.0034655444,0.00013746566,0.000056866178,0.000084239306,0.000015290398,0.0000586351,0.98036647,0.00031971137],"about_ca_topic_score_codex":0.000081813756,"about_ca_topic_score_gemma":0.000013840866,"teacher_disagreement_score":0.8258146,"about_ca_system_score_codex":0.0010510583,"about_ca_system_score_gemma":0.0016472961,"threshold_uncertainty_score":0.9999235},"labels":[],"label_agreement":null},{"id":"W4406760478","doi":"10.1093/oncolo/oyae356","title":"Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Oncology; Lung cancer; Cancer; Adverse effect; Internal medicine; Pooled analysis; Cancer research; Colorectal cancer; Meta-analysis","score_opus":0.00639325103339201,"score_gpt":0.32502417040903736,"score_spread":0.31863091937564536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406760478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777562,0.0012578521,0.00039147897,0.0013285722,0.00015142439,0.0015305887,0.000045661352,0.000030078918,0.017508129],"genre_scores_gemma":[0.9897297,0.0017829083,0.00055371795,0.00026399057,0.00000591647,0.00019858031,0.0000722368,0.000009345615,0.007383593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989875,0.00005995837,0.00038448116,0.0002550836,0.000115463714,0.00019754402],"domain_scores_gemma":[0.999376,0.00007240099,0.00016093378,0.00027664204,0.000065899425,0.000048110887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018860283,0.00015253857,0.00041748935,0.00018689144,0.00008362441,0.0000023595255,0.000103825674,0.00006912451,0.000085969485],"category_scores_gemma":[0.00000833854,0.00010219893,0.0001117569,0.001149059,0.00009021755,0.000035100424,0.00007384651,0.00012073217,0.0000018125434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012773604,0.0011261529,0.9595804,0.00082351256,0.009128089,0.0001267377,0.0014374201,0.012452913,0.0019616291,0.00029398096,0.00038258894,0.011409215],"study_design_scores_gemma":[0.008873747,0.00013518048,0.9742987,0.00039523107,0.011059318,9.918024e-7,0.0010784564,0.002093166,0.001279148,0.00007116074,0.000591815,0.00012308681],"about_ca_topic_score_codex":0.001409639,"about_ca_topic_score_gemma":0.0012750251,"teacher_disagreement_score":0.014718299,"about_ca_system_score_codex":0.0004983275,"about_ca_system_score_gemma":0.0001736291,"threshold_uncertainty_score":0.41675514},"labels":[],"label_agreement":null},{"id":"W4407910233","doi":"10.1093/oncolo/oyae344","title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Lung cancer; Hazard ratio; Subgroup analysis; Proportional hazards model; Cancer; Confidence interval","score_opus":0.034434646915604855,"score_gpt":0.35041465106732034,"score_spread":0.31598000415171545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407910233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018407906,0.9888564,0.00028311214,0.00014522256,0.00010586264,0.008322656,0.0020188557,0.000008318317,0.00007551631],"genre_scores_gemma":[0.00032690197,0.98988426,0.00023042526,0.00039226125,0.000054708533,0.0063026976,0.00019016826,0.00004482,0.0025737626],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971971,0.0006042347,0.001196676,0.00058983825,0.00013486754,0.0002772847],"domain_scores_gemma":[0.99566185,0.0014281712,0.0014180796,0.0011670445,0.00024768506,0.0000771593],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011494233,0.00052930013,0.0052644005,0.00011867719,0.0000800549,0.000032179953,0.0007205603,0.0003531378,0.000012693501],"category_scores_gemma":[0.0007971272,0.0003119968,0.0020205383,0.00038110046,0.00013572002,0.0000015226714,0.00022071575,0.00014968445,9.2484913e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023837303,0.00009464383,0.0000010169609,0.93771845,0.058550533,0.0000027017147,0.0000426623,0.00007573689,0.00024784936,0.00001570517,0.0013595276,0.001652819],"study_design_scores_gemma":[0.0006804528,0.00085372786,3.9131612e-7,0.028165089,0.87794745,0.000019567979,0.000040329145,0.000025164898,0.00023448664,0.0000065637178,0.091576874,0.0004498949],"about_ca_topic_score_codex":0.00005502181,"about_ca_topic_score_gemma":0.000098041084,"teacher_disagreement_score":0.90955335,"about_ca_system_score_codex":0.00012371945,"about_ca_system_score_gemma":0.0010467314,"threshold_uncertainty_score":0.9999332},"labels":[],"label_agreement":null},{"id":"W4408140353","doi":"10.1093/oncolo/oyae347","title":"Real-world characteristics and outcomes of <i>ERBB2-</i> mutant NSCLC in Latin American patients (CLICaP)","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Latin Americans; Mutant; Oncology; Internal medicine; Medicine; Biology; Political science; Genetics; Gene","score_opus":0.019686864164362487,"score_gpt":0.3584937315319411,"score_spread":0.3388068673675786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408140353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845872,0.000058880436,0.000004612013,0.0031161453,0.0001451606,0.00033821937,0.000077674595,0.000034257795,0.011637852],"genre_scores_gemma":[0.99761087,0.00020062827,0.00019229882,0.0003634379,0.000034128698,0.000034376444,0.000036406,0.000011521018,0.0015163488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938744,0.000029035993,0.0002255346,0.00013442225,0.00010363315,0.000119959936],"domain_scores_gemma":[0.9995013,0.00020171753,0.000074333584,0.00015430435,0.000028298551,0.000040076116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009084872,0.000087830165,0.0002743273,0.000068866975,0.0000311583,0.000012553989,0.000045125387,0.000019434721,0.0000276621],"category_scores_gemma":[0.00005644792,0.000048473954,0.000036212834,0.00023864798,0.00024083117,0.000021938316,0.00003165414,0.00010181898,0.0000059061576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067087225,0.00023566841,0.9468202,0.00004745992,0.0000976361,0.000033462085,0.00084801443,5.7803607e-7,0.00022266166,0.0010759651,0.0004005106,0.05015078],"study_design_scores_gemma":[0.00064911065,0.00034205,0.9924736,0.00007421027,0.00016394444,0.0000012630406,0.00015600077,0.000066804954,0.00007767688,0.000082196995,0.005863009,0.000050110408],"about_ca_topic_score_codex":0.0018143251,"about_ca_topic_score_gemma":0.0008004475,"teacher_disagreement_score":0.05010067,"about_ca_system_score_codex":0.0001438028,"about_ca_system_score_gemma":0.00009139609,"threshold_uncertainty_score":0.2742729},"labels":[],"label_agreement":null},{"id":"W4408956488","doi":"10.1093/oncolo/oyaf037","title":"Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ramucirumab; Medicine; Internal medicine; Hazard ratio; Cancer; Paclitaxel; Oncology; Progression-free survival; Chemotherapy; Confidence interval; Gastroenterology; Trastuzumab; Breast cancer","score_opus":0.021550344865278712,"score_gpt":0.30250303699927994,"score_spread":0.2809526921340012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408956488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969602,0.00010556989,0.000003111906,0.0008955593,0.00006727018,0.0012292938,0.000015561873,0.000008775849,0.0007146457],"genre_scores_gemma":[0.99768305,0.0000312393,0.000038648097,0.0006019155,0.000020450932,0.00006846341,0.0000055145006,0.0000069236294,0.0015437927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99924934,0.000074153475,0.00021663739,0.00017835245,0.000111952366,0.00016955401],"domain_scores_gemma":[0.99963677,0.000067915294,0.00007454142,0.00015563685,0.00004563017,0.000019521003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015901495,0.000117435695,0.00032291494,0.00012244849,0.00002487643,0.000011704599,0.00007743152,0.000027917882,0.00008328494],"category_scores_gemma":[0.000016441862,0.00005931872,0.000021400569,0.00026188706,0.00012826538,0.000036556452,0.00006019541,0.00011068565,4.0543614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004518429,0.0012207074,0.98128456,0.000033202097,0.00009130691,0.000034161454,0.0011010651,0.0000038838307,0.0000068256345,0.0000036329147,0.00020755058,0.011494683],"study_design_scores_gemma":[0.014139294,0.0041919546,0.9801366,0.00011280776,0.000038757964,7.282375e-7,0.0011090838,0.000005317718,0.000054372278,0.000007872767,0.00015967354,0.00004357179],"about_ca_topic_score_codex":0.0007001561,"about_ca_topic_score_gemma":0.006813751,"teacher_disagreement_score":0.011451111,"about_ca_system_score_codex":0.00015735316,"about_ca_system_score_gemma":0.00005420044,"threshold_uncertainty_score":0.3802233},"labels":[],"label_agreement":null},{"id":"W4409020486","doi":"10.1093/oncolo/oyaf047","title":"A pilot survey into the landscape of neuro-oncology care in the community","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Prisma Health; Sontag Foundation; Musella Foundation For Brain Tumor Research and Information","keywords":"Oncology; Internal medicine; Medicine; Radiation oncology; Neurosurgery; Radiation therapy; Psychiatry","score_opus":0.06771435790830291,"score_gpt":0.37338338053108944,"score_spread":0.3056690226227865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409020486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525609,0.001576503,0.00001259954,0.02240335,0.00018258372,0.000763505,0.00002194755,0.0000147472165,0.022463847],"genre_scores_gemma":[0.99480313,0.0001282692,0.000056175402,0.004750222,0.000026710579,0.000074357165,0.00004345913,0.000005028585,0.00011263299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960295,0.0033852567,0.00022341027,0.00009387026,0.00011994232,0.00014800299],"domain_scores_gemma":[0.9936104,0.0054606604,0.00008605306,0.00075297075,0.00007267527,0.0000172772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028821507,0.00010139722,0.0002796697,0.000038818816,0.00025379242,0.000010280999,0.00045718538,0.000039476494,0.000028374072],"category_scores_gemma":[0.0008776163,0.00003843579,0.00006442552,0.00037039764,0.00043956545,0.0000096551075,0.00016224294,0.0005521354,0.000007051239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005943418,0.0057029575,0.7335314,0.00031887848,0.00056211965,0.00022002567,0.05323951,0.00014279134,0.000669938,0.0085465945,0.056866955,0.13425538],"study_design_scores_gemma":[0.0027137129,0.005271252,0.9380678,0.000038768063,0.00021133917,0.000024047069,0.022827607,0.000030083624,0.00012331463,0.000635635,0.030004358,0.00005211694],"about_ca_topic_score_codex":0.016922984,"about_ca_topic_score_gemma":0.0671861,"teacher_disagreement_score":0.20453633,"about_ca_system_score_codex":0.000109796005,"about_ca_system_score_gemma":0.00025179854,"threshold_uncertainty_score":0.9896234},"labels":[],"label_agreement":null},{"id":"W4409381469","doi":"10.1093/oncolo/oyaf039","title":"A scoping review of clinical communication in cancer care in Africa","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institute on Aging","keywords":"Cancer; Medicine; Geography; Internal medicine","score_opus":0.7220950195418481,"score_gpt":0.6738918870880464,"score_spread":0.0482031324538017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409381469","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.814468e-7,0.96757245,5.5575873e-7,0.002351447,0.0005572798,0.010866221,0.00008956713,0.00003519967,0.018526426],"genre_scores_gemma":[0.000037042984,0.9878027,0.00028559237,0.0010604666,0.000061594124,0.010309881,0.00016322998,0.000026611482,0.00025292445],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97370446,0.020270828,0.004960913,0.00037312447,0.00024454563,0.0004461474],"domain_scores_gemma":[0.97704935,0.016454596,0.0031317219,0.002902294,0.0004013056,0.000060720235],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0040644077,0.00029239844,0.003350144,0.00023888912,0.00031023083,0.0000034590614,0.0022898659,0.00074178237,0.00013729844],"category_scores_gemma":[0.006853396,0.00019980645,0.00033604508,0.0013454768,0.00031806593,0.000050491613,0.0013653401,0.0034844102,0.000042847027],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010171817,0.000052800988,0.00083400676,0.5900022,0.000010658973,6.293884e-7,0.0015854519,5.020123e-7,6.281965e-10,0.00017934048,0.0014566531,0.40586764],"study_design_scores_gemma":[0.00021528623,0.000030895368,0.000086057764,0.5922536,0.00009228462,1.212125e-7,0.0011070843,0.0000011385542,2.527579e-9,0.000029389115,0.40609446,0.000089667956],"about_ca_topic_score_codex":0.0039742603,"about_ca_topic_score_gemma":0.028442996,"teacher_disagreement_score":0.40577796,"about_ca_system_score_codex":0.001562722,"about_ca_system_score_gemma":0.012481691,"threshold_uncertainty_score":0.9988146},"labels":[],"label_agreement":null},{"id":"W4409773283","doi":"10.1093/oncolo/oyaf042","title":"Barriers to publishing early phase clinical trials: the oncologists’ perspective","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; BeiGene; AstraZeneca","keywords":"Publishing; Clinical trial; Thematic analysis; Medicine; Alternative medicine; Stakeholder; Family medicine; Medical education; Public relations; Qualitative research; Political science; Internal medicine; Pathology; Social science; Sociology; Law","score_opus":0.8139993364479226,"score_gpt":0.7198450436762328,"score_spread":0.09415429277168974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409773283","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20593292,0.0021635334,0.000494437,0.5941487,0.009591792,0.0035987252,0.00024944785,0.0003736417,0.1834468],"genre_scores_gemma":[0.86996806,0.00025953862,0.00006776288,0.121237256,0.0018194739,0.00041613367,0.000007726542,0.000020550962,0.006203469],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97936887,0.016969576,0.0015771561,0.0007210264,0.0003127532,0.0010506477],"domain_scores_gemma":[0.974513,0.022423193,0.0004979503,0.0007832816,0.00052194524,0.001260645],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.043362785,0.00038818957,0.00095029053,0.00013441477,0.0022420138,0.00036382952,0.002150906,0.0013873407,0.0019849204],"category_scores_gemma":[0.060753472,0.00021494394,0.00047778446,0.0010919437,0.002129707,0.00030348104,0.0005861367,0.0073254295,0.0003431443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006702901,0.0010141969,0.012675721,0.00003515196,0.0010361196,0.00013483828,0.00384779,0.00025833162,0.00064331386,0.14998469,0.63352823,0.19013874],"study_design_scores_gemma":[0.00505545,0.0009837272,0.0047007566,0.000030259383,0.00063274964,0.00001327231,0.009732326,0.00079543446,0.00083911786,0.009579418,0.96733505,0.00030245868],"about_ca_topic_score_codex":0.0005155534,"about_ca_topic_score_gemma":0.00028435493,"teacher_disagreement_score":0.66403514,"about_ca_system_score_codex":0.0008450261,"about_ca_system_score_gemma":0.0019182129,"threshold_uncertainty_score":0.99990904},"labels":[],"label_agreement":null},{"id":"W4409773286","doi":"10.1093/oncolo/oyaf041","title":"Early phase trials: the perils of nonpublication","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Medicine; Chemistry","score_opus":0.9085590211274656,"score_gpt":0.6702365555577398,"score_spread":0.2383224655697258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409773286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46647638,0.0043554585,0.069294885,0.09013238,0.0013197657,0.004091662,0.000047989106,0.000016767422,0.3642647],"genre_scores_gemma":[0.9649567,0.00002198381,0.00037855553,0.000663813,0.0000710625,0.000089060944,0.00000164091,0.0000021731378,0.03381498],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9668121,0.023210749,0.0073910384,0.0003913639,0.0020555258,0.00013926324],"domain_scores_gemma":[0.96194196,0.026567092,0.005957894,0.0044827294,0.001015153,0.000035181398],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2942688,0.000112902424,0.0020548548,0.00012817053,0.00020491012,0.000497824,0.0027161313,0.000051434767,0.0040977933],"category_scores_gemma":[0.1422545,0.000029905448,0.0011590344,0.0015536578,0.0002650165,0.00008109109,0.00012366388,0.00010484728,0.0007369113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055740307,0.00020789941,0.0019495283,0.00001653687,0.00032688028,4.713547e-7,0.0010608188,0.000032573353,0.00074384717,0.0864164,0.61017466,0.29901466],"study_design_scores_gemma":[0.000512854,0.00010479352,0.0131555945,0.000013652877,0.00044104786,0.000001248357,0.0014892735,0.0018845651,0.00020614061,0.023874488,0.95825577,0.000060549173],"about_ca_topic_score_codex":0.00004854459,"about_ca_topic_score_gemma":0.000029943505,"teacher_disagreement_score":0.49848035,"about_ca_system_score_codex":0.000026482068,"about_ca_system_score_gemma":0.00013051402,"threshold_uncertainty_score":0.9968126},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch","scholarly_communication"],"domain":"reporting","study_design":"not_applicable","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W4409832437","doi":"10.1093/oncolo/oyaf038","title":"Medical accuracy of artificial intelligence chatbots in oncology: a scoping review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Waterloo; University of Toronto","funders":"","keywords":"Readability; Workload; MEDLINE; Medicine; Oncology; Inclusion (mineral); Resource (disambiguation); Internal medicine; Medical education; Psychology; Computer science; Political science","score_opus":0.46755751671685275,"score_gpt":0.6145205468759336,"score_spread":0.14696303015908085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409832437","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000037150398,0.9834094,0.00016526018,0.008295512,0.00096599257,0.0043493393,0.000005870793,0.00003201825,0.0027728672],"genre_scores_gemma":[0.00003091877,0.99656147,0.0001581353,0.001903756,0.00047207845,0.000661881,0.00005276082,0.000018672265,0.00014032463],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99523395,0.00082755875,0.0026406494,0.00043382013,0.00046532272,0.0003986873],"domain_scores_gemma":[0.99027294,0.007570709,0.0010205286,0.0007572894,0.00021932367,0.0001592284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004103856,0.00031614234,0.0028605454,0.0002697703,0.00009161939,0.0000098988385,0.00064372306,0.00072723813,0.00065986096],"category_scores_gemma":[0.019734032,0.00019508002,0.00041235719,0.0012847517,0.00055210403,0.000041187406,0.00019289603,0.0012734786,0.00015572377],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019858662,0.0002243276,0.0000036615804,0.1765806,0.00002268522,0.00003738512,0.00010961599,2.3907745e-7,4.2620464e-8,0.00050105224,0.00059035415,0.8219102],"study_design_scores_gemma":[0.00001080554,0.00030933073,0.0000010938481,0.7723962,0.00055562716,0.00008819909,0.00020835912,0.0000149688185,0.000009471457,0.0005817497,0.22567779,0.00014641063],"about_ca_topic_score_codex":0.0006221946,"about_ca_topic_score_gemma":0.0013764001,"teacher_disagreement_score":0.82176375,"about_ca_system_score_codex":0.0006958814,"about_ca_system_score_gemma":0.015581209,"threshold_uncertainty_score":0.98999953},"labels":[],"label_agreement":null},{"id":"W4409832439","doi":"10.1093/oncolo/oyaf078","title":"Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Microsatellite instability; Oncology; Medicine; Internal medicine; Cancer; Renal cell carcinoma; Multivariate analysis; Atezolizumab; Population; Somatic cell; Cancer research; Gene; Immunotherapy; Pembrolizumab; Biology; Genetics; Allele; Microsatellite","score_opus":0.019410682986549025,"score_gpt":0.28700022419236093,"score_spread":0.2675895412058119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409832439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578005,0.00038054536,0.000047872967,0.0004918531,0.00024373073,0.0008984534,0.000029128678,0.00005649114,0.0020718465],"genre_scores_gemma":[0.9983804,0.00011365056,0.000109804714,0.00010398817,0.000045359127,0.0002179683,0.000034219407,0.0000244006,0.0009701611],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984951,0.00010364135,0.00043212663,0.00026703134,0.00043101484,0.00027110707],"domain_scores_gemma":[0.99894327,0.00008819432,0.00030980355,0.00035759067,0.0002372291,0.00006393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032450736,0.0002170625,0.0005566302,0.00009361937,0.000114753864,0.000026275315,0.00017588637,0.00005774999,0.00010321978],"category_scores_gemma":[0.000048447233,0.00010980955,0.000105906445,0.0004638184,0.0005076556,0.000085378895,0.00007456101,0.00022082434,0.0000017169799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013920448,0.0005023786,0.9941416,0.00024338345,0.00079053163,0.0000073053816,0.00030818634,0.00010740879,0.00074724073,0.00003589877,0.00038013805,0.0013439279],"study_design_scores_gemma":[0.004434077,0.0011437276,0.97336066,0.0009947523,0.0009711286,7.32983e-7,0.00048837566,0.000054369903,0.018222887,0.000010956334,0.0001879175,0.00013042666],"about_ca_topic_score_codex":0.0045447596,"about_ca_topic_score_gemma":0.0009890393,"teacher_disagreement_score":0.020780906,"about_ca_system_score_codex":0.00029111354,"about_ca_system_score_gemma":0.00025933533,"threshold_uncertainty_score":0.6870347},"labels":[],"label_agreement":null},{"id":"W4409966546","doi":"10.1093/oncolo/oyae373","title":"Examining the evolving landscape of kidney cancer mortality in the United States","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Demography; Ethnic group; Population; Medicine; Disease control; Cancer; Gerontology; Environmental health; Internal medicine","score_opus":0.07725012360541114,"score_gpt":0.35413357562602943,"score_spread":0.27688345202061826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409966546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633212,0.0010484086,0.000010491059,0.012784139,0.00009705427,0.00046701965,0.000011149061,0.000016168191,0.022244332],"genre_scores_gemma":[0.9948327,0.0002523885,0.000024232282,0.0039693024,0.000044295022,0.000098961005,0.000030641113,0.00000544149,0.0007420624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898314,0.0003000353,0.00023346722,0.00012804219,0.00018822077,0.0001670942],"domain_scores_gemma":[0.9985082,0.00081726373,0.00010021869,0.00047592528,0.00006580425,0.000032601685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010642604,0.00010130971,0.00020836986,0.000061797975,0.00009897866,0.00001557436,0.000262521,0.000042165902,0.00008951102],"category_scores_gemma":[0.00049438275,0.000038240483,0.000045625344,0.00054178823,0.00024985493,0.00001647679,0.00007149636,0.00022041996,0.0000028805214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001511454,0.00018668472,0.9704777,0.0000918478,0.00018141243,0.000054811022,0.0034721321,0.0004995919,0.0006553911,0.00042970464,0.02248233,0.0013172609],"study_design_scores_gemma":[0.0008640557,0.00020540014,0.98412675,0.00015547739,0.0002712743,0.0000064099786,0.005995184,0.0015010382,0.0009766953,0.00025558422,0.005595413,0.000046748974],"about_ca_topic_score_codex":0.007527582,"about_ca_topic_score_gemma":0.000916311,"teacher_disagreement_score":0.031511437,"about_ca_system_score_codex":0.00015065365,"about_ca_system_score_gemma":0.00029962897,"threshold_uncertainty_score":0.9990814},"labels":[],"label_agreement":null},{"id":"W4410207760","doi":"10.1093/oncolo/oyae294","title":"Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University","funders":"","keywords":"Fibroblast growth factor receptor; Fibroblast growth factor receptor 2; Cancer research; Fibroblast growth factor receptor 3; Point mutation; Mutation; Tyrosine kinase; Receptor tyrosine kinase; Fibroblast growth factor receptor 4; Fibroblast growth factor; FGF19; Receptor Protein-Tyrosine Kinases; Receptor; Growth factor receptor; Cancer; Medicine; Biology; Internal medicine; Gene; Genetics","score_opus":0.01449751654793558,"score_gpt":0.2872989245128247,"score_spread":0.2728014079648891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410207760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824506,0.00008806104,0.00014908156,0.00016724254,0.00008501901,0.0006744526,0.000017671857,0.000018611892,0.00055482605],"genre_scores_gemma":[0.9993566,0.000005168688,0.00023485596,0.000026811766,0.00006323264,0.0000952749,0.00007040991,0.000022042504,0.00012559914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983359,0.00025199083,0.00043091603,0.0004322351,0.00023034458,0.00031862967],"domain_scores_gemma":[0.99892855,0.000099450284,0.00018748768,0.00057210727,0.00013019107,0.00008222523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020661518,0.00021506117,0.00025134368,0.000117718184,0.00009974285,0.00003307253,0.00025517787,0.00013179466,0.000019839752],"category_scores_gemma":[0.0003140541,0.00014148641,0.000081311475,0.00029134162,0.00026078278,0.0000102846,0.00017757401,0.00021779496,0.0000021722742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036637771,0.002325048,0.16976422,0.00051578355,0.0003812141,0.025847405,0.0021856464,0.0004578355,0.7834209,0.0003691901,0.0008361434,0.01023282],"study_design_scores_gemma":[0.0031492466,0.0051686587,0.2314904,0.0003690961,0.000045740915,0.004961016,0.000983065,0.00020478477,0.7527827,0.00004960964,0.00032705173,0.00046862007],"about_ca_topic_score_codex":0.00049682753,"about_ca_topic_score_gemma":0.0007995245,"teacher_disagreement_score":0.061726186,"about_ca_system_score_codex":0.00012202491,"about_ca_system_score_gemma":0.00019380807,"threshold_uncertainty_score":0.57696486},"labels":[],"label_agreement":null},{"id":"W4410312427","doi":"10.1093/oncolo/oyaf048","title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician’s choice of chemotherapy in patients with HER2-low mBC","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Astellas Pharma; Oncolytics Biotech; Eisai; Les Laboratories Pierre Fabre; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; F. Hoffmann-La Roche; Chugai Pharmaceutical; Seagen; Roche; GlaxoSmithKline; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Internal medicine; Trastuzumab; Chemotherapy; Oncology; Hazard ratio; Adverse effect; Quality of life (healthcare); Cohort; Cancer; Breast cancer; Confidence interval","score_opus":0.016821581969634323,"score_gpt":0.3043310066982524,"score_spread":0.28750942472861807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410312427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99479496,0.0001397975,0.0001761159,0.0015559234,0.00025195957,0.000884835,0.000032925087,0.000077344346,0.0020861218],"genre_scores_gemma":[0.9972834,0.00000705525,0.0010964245,0.0012110752,0.000046488192,0.00009071434,0.00004018477,0.00003321217,0.00019146841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845874,0.00006994264,0.00045362857,0.00035260618,0.00034039983,0.0003246525],"domain_scores_gemma":[0.9982929,0.00049728894,0.00036080964,0.0006161678,0.00017621607,0.00005659853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091717,0.00027977265,0.0006376284,0.000095612646,0.00007064209,0.000009767025,0.00021148704,0.000092948954,0.000054257733],"category_scores_gemma":[0.000135174,0.00017519906,0.000092687216,0.0004751156,0.00043308386,0.0000780364,0.000048944137,0.0002675322,0.000004133114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012563953,0.0017453864,0.7567856,0.000042043554,0.00064571254,0.000014090402,0.00077666447,0.00017282137,0.00060305285,0.00005434172,0.000050888542,0.22654548],"study_design_scores_gemma":[0.019326923,0.0011965652,0.97429246,0.0002607073,0.0001571186,7.407286e-7,0.000627681,0.00001736781,0.0025135311,0.00029577484,0.0011435203,0.0001676275],"about_ca_topic_score_codex":0.0017419835,"about_ca_topic_score_gemma":0.00076223747,"teacher_disagreement_score":0.22637786,"about_ca_system_score_codex":0.0005336049,"about_ca_system_score_gemma":0.00025269503,"threshold_uncertainty_score":0.71444106},"labels":[],"label_agreement":null},{"id":"W4410794359","doi":"10.1093/oncolo/oyaf112","title":"Concordance with SPIRIT-AI guidelines in reporting of randomized controlled trial protocols investigating artificial intelligence in oncology: a systematic review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Concordance; Randomized controlled trial; Medicine; Medical physics; Psychology; Oncology; Internal medicine","score_opus":0.4402670868586655,"score_gpt":0.5935877669692967,"score_spread":0.1533206801106312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410794359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017705946,0.7621775,0.00022020827,0.004332865,0.0003019232,0.23224196,0.0000024042624,0.000031150114,0.00067427696],"genre_scores_gemma":[0.000057357927,0.7992847,0.0011673057,0.0011854509,0.00028660242,0.19775775,0.00001774224,0.00002636638,0.00021674036],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.972134,0.004949612,0.021341862,0.0006011604,0.0005202796,0.00045308072],"domain_scores_gemma":[0.9503636,0.022558482,0.024200067,0.0012707553,0.0014700256,0.00013711378],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0391898,0.00055591547,0.020416996,0.00042930376,0.000091212794,0.000032662112,0.0004923023,0.00048761102,0.000023059953],"category_scores_gemma":[0.25867054,0.00027325613,0.0010672711,0.0016510086,0.00082941906,0.00006252709,0.000086143715,0.0012658184,0.000010132524],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09001493,0.00026782378,0.000006990995,0.7231704,0.00016511042,0.000056340145,0.0002146694,0.000009339084,1.9343621e-7,0.0005670922,0.00007838757,0.18544874],"study_design_scores_gemma":[0.034131907,0.000880347,8.407409e-8,0.95692885,0.0034997833,0.00007776233,0.0004009939,0.00023493214,0.0000061839023,0.001320872,0.0022829655,0.00023529763],"about_ca_topic_score_codex":0.0014853626,"about_ca_topic_score_gemma":0.0019331954,"teacher_disagreement_score":0.23375848,"about_ca_system_score_codex":0.00090187,"about_ca_system_score_gemma":0.012604524,"threshold_uncertainty_score":0.999972},"labels":[],"label_agreement":null},{"id":"W4411224532","doi":"10.1093/oncolo/oyaf165","title":"The association of health care contact days with economic measures in the CCTG LY.12 trial","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Princess Margaret Cancer Centre; Canadian Cancer Society; Queen's University","funders":"Canadian Cancer Society Research Institute; Arnold Ventures; Eli Lilly and Company; Eli Lilly Canada; Incyte; Amgen","keywords":"Association (psychology); Psychology; Gerontology; Health care; Demography; Medicine; Political science; Psychotherapist; Sociology","score_opus":0.035996157980590235,"score_gpt":0.28564672313740347,"score_spread":0.24965056515681322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411224532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55733556,0.015967287,0.0003748661,0.058104318,0.0026900442,0.0026953144,0.00029849933,0.000037924543,0.36249623],"genre_scores_gemma":[0.996662,0.00095694634,0.000012270603,0.0012070785,0.00015572298,0.00006358827,0.0000058657797,0.000008659959,0.00092782476],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985598,0.00013751956,0.00075045717,0.00020696507,0.000037215643,0.0003080677],"domain_scores_gemma":[0.9978796,0.00069111376,0.00097049394,0.00041123442,0.000028540655,0.000019009065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00375303,0.00012568141,0.0004765204,0.00006619955,0.00033533075,0.000099513854,0.0005762068,0.00009923998,0.000016735965],"category_scores_gemma":[0.00033553824,0.00007151027,0.00010145614,0.00011484471,0.00013985895,0.00010603589,0.000041620828,0.0002335846,0.000026868462],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004746422,0.00014669079,0.12423336,0.000034037523,0.00021790755,0.0000010051995,0.0048915534,0.0007002888,8.4297506e-7,0.8088104,0.031509273,0.024708234],"study_design_scores_gemma":[0.016496891,0.0011833777,0.31395838,0.000038695747,0.00002589079,9.423176e-7,0.0041623753,0.00010178376,0.000015093175,0.020020064,0.6437539,0.0002425976],"about_ca_topic_score_codex":0.0042263423,"about_ca_topic_score_gemma":0.018080782,"teacher_disagreement_score":0.78879035,"about_ca_system_score_codex":0.0014988069,"about_ca_system_score_gemma":0.00044768484,"threshold_uncertainty_score":0.9998367},"labels":[],"label_agreement":null},{"id":"W4411857643","doi":"10.1093/oncolo/oyaf194","title":"Mitigation and management of adverse events associated with amivantamab therapy","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Johnson and Johnson","keywords":"Medicine; Erlotinib; Adverse effect; Rash; Oncology; Internal medicine; Epidermal growth factor receptor; Hypoalbuminemia; Chemotherapy; Paronychia; Gefitinib; Targeted therapy; Cancer; Dermatology","score_opus":0.036916925977640534,"score_gpt":0.40258748234630176,"score_spread":0.36567055636866125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411857643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026981757,0.9834701,0.000011572232,0.00017096897,0.0000708427,0.0020384893,0.000054118616,0.000023580089,0.013890527],"genre_scores_gemma":[0.00051988947,0.99282616,0.00016779114,0.00006260178,0.000014405158,0.00022458262,0.00023762057,0.000011057635,0.00593588],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993563,0.00007761645,0.00020387187,0.00014843454,0.00012353396,0.00009019872],"domain_scores_gemma":[0.9993545,0.00013340682,0.00024792066,0.00019922122,0.000042146334,0.000022832799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011385427,0.0001489208,0.0005976561,0.00004823863,0.00006116831,0.000001619987,0.00006666674,0.000078962315,0.000018540464],"category_scores_gemma":[0.000011533416,0.000070419286,0.00009531339,0.00019823555,0.00009782716,0.0000143336665,0.000026989566,0.00008816962,0.0000016437419],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005155989,0.00028123028,0.0002544947,0.0063886144,0.0031470768,0.000032005286,0.000071258975,7.6073604e-7,7.0409996e-8,0.0003618098,0.00033563207,0.9890755],"study_design_scores_gemma":[0.0048527233,0.0010730589,0.0113348365,0.058000106,0.015630616,0.000021174688,0.00024244528,0.000002028922,0.0000017634935,0.000107263404,0.90853065,0.00020332032],"about_ca_topic_score_codex":0.000024793937,"about_ca_topic_score_gemma":0.000015245404,"teacher_disagreement_score":0.9888722,"about_ca_system_score_codex":0.00026557982,"about_ca_system_score_gemma":0.0002372257,"threshold_uncertainty_score":0.28716153},"labels":[],"label_agreement":null},{"id":"W4412124266","doi":"10.1093/oncolo/oyaf145","title":"Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lagging; Immune system; Computer science; Cancer research; Medicine; Immunology; Pathology","score_opus":0.026379924789962164,"score_gpt":0.297026984113279,"score_spread":0.27064705932331684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412124266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6496676,0.005899184,0.0011905127,0.27751902,0.0018646673,0.0026802043,0.000031130578,0.00044629327,0.0607014],"genre_scores_gemma":[0.98406106,0.00037780084,0.00028542057,0.00530118,0.00027987806,0.00008109632,0.000006800278,0.000027215146,0.009579537],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880874,0.000060009028,0.00033701325,0.00024191814,0.00023308996,0.00031924987],"domain_scores_gemma":[0.99884975,0.0003379984,0.00021008067,0.00051253283,0.00005523302,0.000034408436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076953904,0.00021063114,0.0003149558,0.00008058181,0.000496519,0.000056193447,0.00027860978,0.000095195086,0.0001148638],"category_scores_gemma":[0.000126694,0.000089220244,0.00013452709,0.00034488548,0.00041551582,0.000048770922,0.00010222516,0.00044274435,0.000008747344],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09504159,0.0041143633,0.018435791,0.0012762223,0.0051138722,0.0006604215,0.028175026,0.0021831142,0.49300992,0.0032904074,0.07663673,0.27206254],"study_design_scores_gemma":[0.023430137,0.00577545,0.09589778,0.0094049405,0.0011847306,0.00034270214,0.048692014,0.0021361012,0.22299536,0.00049966294,0.58841175,0.0012293968],"about_ca_topic_score_codex":0.0006564368,"about_ca_topic_score_gemma":0.00041275044,"teacher_disagreement_score":0.511775,"about_ca_system_score_codex":0.00040869566,"about_ca_system_score_gemma":0.0002628471,"threshold_uncertainty_score":0.3818873},"labels":[],"label_agreement":null},{"id":"W4412486974","doi":"10.1093/oncolo/oyaf205","title":"Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"Qatar National Library; Qatar University","keywords":"Breast cancer; Frameshift mutation; Germline mutation; PTEN; Missense mutation; Genetics; Middle East; Cancer; Mutation; Medicine; Biology; Oncology; Gene; PI3K/AKT/mTOR pathway; Geography","score_opus":0.05731158232819013,"score_gpt":0.3238971773419466,"score_spread":0.2665855950137565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412486974","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038399874,0.9954026,0.000009437912,0.00019254768,0.00017120586,0.0030283388,0.00055306964,0.000011604063,0.00059280236],"genre_scores_gemma":[0.00020659855,0.9944131,0.000055545937,0.00023025094,0.00006823675,0.0039177374,0.00036864472,0.000028127297,0.00071179087],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9979394,0.00048774792,0.00077721727,0.00041051142,0.00014297543,0.00024215705],"domain_scores_gemma":[0.9985834,0.00014206325,0.0005069424,0.000610459,0.00011224765,0.000044893633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031571163,0.00033367283,0.0012496765,0.00007071792,0.00011593848,0.000033370827,0.00047694385,0.00019325507,0.000022002318],"category_scores_gemma":[0.00035913292,0.00021222395,0.00020357255,0.0004366253,0.00019648651,0.00000363593,0.00022902036,0.00020887733,0.000018005616],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000037809284,0.000130059,0.000043011616,0.95981985,0.0002747679,0.0000026447483,0.00017342226,0.0000073723,2.7353826e-7,0.000012819405,0.0029408657,0.03659111],"study_design_scores_gemma":[0.00050132215,0.00013287496,0.00012924026,0.75322443,0.0058691357,0.00007149055,0.00022165099,0.000008773063,3.8966087e-7,0.000038564332,0.23909442,0.0007076987],"about_ca_topic_score_codex":0.00003450284,"about_ca_topic_score_gemma":0.0007318104,"teacher_disagreement_score":0.23615356,"about_ca_system_score_codex":0.00034918482,"about_ca_system_score_gemma":0.0009651046,"threshold_uncertainty_score":0.86542416},"labels":[],"label_agreement":null},{"id":"W4412821387","doi":"10.1093/oncolo/oyaf199","title":"A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Colorectal Cancer Screening and Detection","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Research in Immunology and Cancer; Fraser Health; Occupational Cancer Research Centre","funders":"National Cancer Institute","keywords":"Blueprint; Population; Guideline; Best practice; Process (computing); Medicine; Medical education; Process management; Political science; Computer science; Business; Engineering; Environmental health","score_opus":0.040927114267063865,"score_gpt":0.4009032914234042,"score_spread":0.35997617715634034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412821387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476546,0.00005153927,0.000111421374,0.0033918568,0.00038613417,0.000982803,0.00009658809,0.000076594115,0.00013761014],"genre_scores_gemma":[0.9962206,0.00002375097,0.0002465,0.0021880714,0.000113193266,0.0010573347,0.0000536819,0.000007894393,0.00008901323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998951,0.0001836115,0.00022557688,0.0002669496,0.0001436674,0.00022919686],"domain_scores_gemma":[0.9982376,0.0013182282,0.00009889677,0.00018927178,0.00008085259,0.00007516894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005004756,0.00011751832,0.00021122022,0.000020410926,0.00045053838,0.00006516691,0.00013916113,0.000067466666,0.000010539555],"category_scores_gemma":[0.00034611154,0.00006410706,0.000051071005,0.00017580885,0.00040234785,0.000019611034,0.000050173963,0.00023551476,1.6055475e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032912266,0.00045137174,0.8007817,0.000041813902,0.00023260502,0.000017777442,0.011291552,0.0012655417,0.000079119796,0.000010221694,0.0025629376,0.15035306],"study_design_scores_gemma":[0.0023599374,0.007355361,0.87029976,0.00015647215,0.000114120536,0.000002740722,0.032793667,0.07837747,0.001302401,0.00003574587,0.0070613353,0.00014099672],"about_ca_topic_score_codex":0.8218717,"about_ca_topic_score_gemma":0.82408446,"teacher_disagreement_score":0.15021206,"about_ca_system_score_codex":0.00025367184,"about_ca_system_score_gemma":0.0005322276,"threshold_uncertainty_score":0.34652224},"labels":[],"label_agreement":null},{"id":"W4412902428","doi":"10.1093/oncolo/oyaf240","title":"Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; London Health Sciences Centre; McGill University Health Centre; University of Ottawa; Western University; University of Toronto; SAIT Polytechnic; Sunnybrook Health Science Centre; McMaster University Medical Centre; Ottawa Hospital; CancerCare Manitoba; Hôtel-Dieu de Québec; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; Queen Elizabeth II Health Sciences Centre; University of Calgary","funders":"AstraZeneca","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Clinical endpoint; Cabozantinib; Adverse effect; Gastroenterology; Oncology; Clinical trial; Urology","score_opus":0.10093807808990458,"score_gpt":0.4306932863931999,"score_spread":0.32975520830329536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412902428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9449079,0.00037934782,0.000029922612,0.0023849825,0.00016968975,0.0011239167,0.000024228792,0.000017722852,0.05096231],"genre_scores_gemma":[0.98995656,0.00054009387,0.0024801842,0.00013594097,0.000034833676,0.00011042114,0.000033362507,0.000014645065,0.006693947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973609,0.00039173433,0.001356061,0.0003254548,0.00030652946,0.00025933277],"domain_scores_gemma":[0.9967692,0.0017965209,0.00046331398,0.0007863498,0.00010173883,0.00008289706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010099992,0.00025343735,0.0013889241,0.00021864963,0.000045090157,0.00000464458,0.00019685659,0.00007810153,0.00008794915],"category_scores_gemma":[0.00012881277,0.00013690362,0.00042025422,0.00042854212,0.00036517717,0.000021682334,0.00011047938,0.0002151686,0.00000441273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048477406,0.0031648397,0.9909027,0.00018693334,0.00032688325,0.00025845837,0.00009515071,0.0001541968,0.00033443153,0.00044991562,0.00035979605,0.003281874],"study_design_scores_gemma":[0.0057316856,0.003914243,0.9814246,0.00007734055,0.000914589,0.000004426004,0.00016784103,0.00035208676,0.006203058,0.00020206197,0.0009206067,0.000087446526],"about_ca_topic_score_codex":0.005672866,"about_ca_topic_score_gemma":0.005069036,"teacher_disagreement_score":0.045048695,"about_ca_system_score_codex":0.0006683549,"about_ca_system_score_gemma":0.00075778936,"threshold_uncertainty_score":0.8575714},"labels":[],"label_agreement":null},{"id":"W4413111649","doi":"10.1093/oncolo/oyaf206","title":"The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merck","keywords":"Medicine; Von Hippel–Lindau disease; General surgery; Internal medicine; Disease","score_opus":0.018821159336587567,"score_gpt":0.3029010784945106,"score_spread":0.284079919157923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413111649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744874,0.00015800953,0.00001074519,0.00009003257,0.0008054967,0.00019951926,0.00019165142,0.000007227539,0.0010885817],"genre_scores_gemma":[0.9987736,0.00018085909,0.000003817564,0.00014373093,0.00013133054,0.000016508518,0.00042577533,0.000009510785,0.00031490042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895597,0.00028608678,0.0002211246,0.00018875669,0.00016135814,0.00018673115],"domain_scores_gemma":[0.99894446,0.0001906045,0.0002198871,0.0003575418,0.00025291374,0.000034600675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006054112,0.00012450236,0.00017169912,0.00003132906,0.00012871891,0.000026716592,0.00029319891,0.00008021113,0.0000086873215],"category_scores_gemma":[0.00057723286,0.00006232605,0.000107208325,0.00012053516,0.0001956922,0.0000040122445,0.00007876623,0.000097754186,0.0000016019471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003896994,0.0012186272,0.92838943,0.0000048235734,0.0005672509,7.7694665e-7,0.00012226084,0.0005279496,0.0030309777,0.00012624974,0.023984756,0.038129877],"study_design_scores_gemma":[0.0005440393,0.00070253515,0.98909795,0.000018941873,0.000015670128,3.2641873e-7,0.000039532482,0.000021019541,0.0024622208,0.000034021683,0.006976573,0.00008719073],"about_ca_topic_score_codex":0.0010247282,"about_ca_topic_score_gemma":0.0011221936,"teacher_disagreement_score":0.06070847,"about_ca_system_score_codex":0.00008064433,"about_ca_system_score_gemma":0.00031169335,"threshold_uncertainty_score":0.25415826},"labels":[],"label_agreement":null},{"id":"W4413452415","doi":"10.1093/oncolo/oyaf254","title":"Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fondazione Pezcoller; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Meta-analysis; Renal cell carcinoma; Biomarker; Medicine; Oncology; Carcinoma; Internal medicine; Pathology; Biology","score_opus":0.07410309311643436,"score_gpt":0.37130033521145683,"score_spread":0.29719724209502246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413452415","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001223387,0.99241114,0.00002649534,0.00063381565,0.00004381836,0.005315697,0.000033357053,0.000026395594,0.0014970301],"genre_scores_gemma":[0.0017145923,0.990447,0.00006489065,0.0004565888,0.00003142695,0.0011882754,0.00011363447,0.000028124206,0.0059554875],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99631137,0.0009975751,0.0015061478,0.0005695556,0.00030330682,0.0003120245],"domain_scores_gemma":[0.9973405,0.00093588507,0.0007674522,0.0007581203,0.00009599376,0.00010206398],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018781113,0.0005556502,0.0101288175,0.00044535878,0.00006925865,0.000051047733,0.0003582386,0.00027825576,0.00047317403],"category_scores_gemma":[0.0008034731,0.00026086654,0.0030918967,0.0015451809,0.00015574117,0.000021662221,0.00024979547,0.00058510614,0.000033106367],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009413427,0.0001217048,0.0000026257842,0.9660398,0.030968351,0.00021512227,0.000022800557,2.1185726e-7,6.9499794e-7,0.000007981534,0.0006188483,0.0019924846],"study_design_scores_gemma":[0.00021827969,0.00011201354,0.000002684356,0.05441508,0.9312424,0.00024038723,0.000022864187,0.0000125645865,8.193009e-7,0.000009067282,0.013502176,0.00022168247],"about_ca_topic_score_codex":0.00017630716,"about_ca_topic_score_gemma":0.000050003204,"teacher_disagreement_score":0.91162467,"about_ca_system_score_codex":0.00028052158,"about_ca_system_score_gemma":0.0005428319,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W4413825040","doi":"10.1093/oncolo/oyaf248.043","title":"IUC24358-87 Prognostic assessment of the Meet-URO score compared with the IMDC score in metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapies (Meet-URO 33 study)","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Oncology; Urology","score_opus":0.05024075417160601,"score_gpt":0.3132272801309929,"score_spread":0.2629865259593869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413825040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98069954,0.0022107025,0.000106448664,0.005116547,0.00024248913,0.0066211997,0.000028414222,0.00006388053,0.0049107964],"genre_scores_gemma":[0.9973689,0.00006313172,0.00027316218,0.00034771688,0.000073838026,0.00085235504,0.00001562655,0.000052532276,0.00095273595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99560964,0.0013366032,0.000947974,0.000636638,0.0008807075,0.0005884272],"domain_scores_gemma":[0.99530864,0.0020654579,0.0006712872,0.0015935184,0.0002706083,0.00009049032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001742261,0.00055926153,0.001152583,0.00019047024,0.0004604811,0.000073461364,0.0009583023,0.00008917683,0.000034009736],"category_scores_gemma":[0.00021254916,0.00023406494,0.00023491746,0.0011814067,0.000803485,0.00007570808,0.00037618796,0.0006084073,0.000004236755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011462107,0.002442014,0.9815224,0.0009503639,0.0007163979,0.00040491208,0.004926441,0.0032604232,0.0028097723,0.0002919193,0.0010286764,0.0005004899],"study_design_scores_gemma":[0.006568653,0.003681222,0.97109866,0.0016523497,0.0019822766,0.00013161745,0.011102392,0.0010917991,0.0021417593,0.000100895435,0.00017855833,0.0002698272],"about_ca_topic_score_codex":0.0014648322,"about_ca_topic_score_gemma":0.0067655467,"teacher_disagreement_score":0.01666938,"about_ca_system_score_codex":0.00096443505,"about_ca_system_score_gemma":0.0010175654,"threshold_uncertainty_score":0.9544891},"labels":[],"label_agreement":null},{"id":"W4414370371","doi":"10.1093/oncolo/oyaf279","title":"Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Toxicity; Prostate cancer; Clinical trial; Overall survival; Cancer; Radiation therapy","score_opus":0.5622597241237566,"score_gpt":0.6116115389324049,"score_spread":0.049351814808648364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414370371","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90699494,0.0002418527,0.08584509,0.0010839781,0.0010447799,0.0014121331,0.00037217472,0.00010990415,0.0028951643],"genre_scores_gemma":[0.42801446,0.00025100954,0.5697771,0.00043933658,0.00018604998,0.00015840071,0.0000025715333,0.000027119797,0.0011439901],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.994768,0.002038736,0.0020398037,0.00042229044,0.00036200616,0.0003691546],"domain_scores_gemma":[0.92289585,0.07482556,0.0012029947,0.0007405232,0.00026666568,0.000068430774],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0119039025,0.00024164791,0.0022549944,0.00023992927,0.0001915009,0.00003818848,0.0005535994,0.00019168813,0.00037483117],"category_scores_gemma":[0.08880988,0.00015082974,0.0005177065,0.002064228,0.00046559318,0.000054233107,0.00025973876,0.0003168031,0.0000021413464],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00480352,0.0018134583,0.015255509,0.0009417139,0.014723215,0.000025779153,0.0010106807,0.012768074,0.11031629,0.59064126,0.0012517669,0.24644876],"study_design_scores_gemma":[0.0018026656,0.00017293374,0.002948254,0.00032738372,0.0081418995,3.6765934e-7,0.000305447,0.008199402,0.056655005,0.9208495,0.00031646178,0.0002806841],"about_ca_topic_score_codex":0.00019151055,"about_ca_topic_score_gemma":0.00022727222,"teacher_disagreement_score":0.483932,"about_ca_system_score_codex":0.0003148488,"about_ca_system_score_gemma":0.00020436317,"threshold_uncertainty_score":0.91886544},"labels":[],"label_agreement":null},{"id":"W4414379673","doi":"10.1093/oncolo/oyaf270","title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"Genentech; Servier; European Society for Medical Oncology; Eisai; Verastem Oncology; Clovis Oncology; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Amgen; Mereo BioPharma; Pfizer; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Mersana Therapeutics; PTC Therapeutics; GlaxoSmithKline","keywords":"Clinical trial; Ovarian cancer; Immunotherapy; Bevacizumab; PARP inhibitor; Phases of clinical research; Poly ADP ribose polymerase","score_opus":0.2927783521745961,"score_gpt":0.5819201111673444,"score_spread":0.28914175899274835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414379673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85441405,0.028830525,0.02273687,0.07556572,0.004516409,0.010288778,0.001060291,0.00025019908,0.0023371866],"genre_scores_gemma":[0.9737952,0.006163277,0.0035112756,0.0044972966,0.0022051842,0.003578049,0.0002203735,0.00005800442,0.005971382],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964471,0.00077757944,0.0017274712,0.00043201252,0.00027221767,0.00034361408],"domain_scores_gemma":[0.9945984,0.0034539823,0.0009307582,0.0006426819,0.00028205005,0.00009216629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038697114,0.00029404924,0.0013651323,0.0001295232,0.00031809887,0.000025326617,0.00013646854,0.00021753536,0.00036443846],"category_scores_gemma":[0.0011264897,0.00018933784,0.00059957424,0.000347658,0.0005842538,0.0000654452,0.00002315341,0.00017346953,0.000005362629],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04050136,0.003477344,0.00021093956,0.0000971814,0.000850128,0.000008508394,0.00076865504,0.00026736804,0.08601316,0.00061018986,0.00307761,0.86411756],"study_design_scores_gemma":[0.4116598,0.045001753,0.0014689937,0.0016006834,0.002304196,0.00002645942,0.0009014685,0.0076925345,0.35567734,0.0051971637,0.16780798,0.0006616418],"about_ca_topic_score_codex":0.0004670417,"about_ca_topic_score_gemma":0.000157277,"teacher_disagreement_score":0.8634559,"about_ca_system_score_codex":0.00144925,"about_ca_system_score_gemma":0.002016494,"threshold_uncertainty_score":0.77209723},"labels":[],"label_agreement":null},{"id":"W4414606428","doi":"10.1093/oncolo/oyaf326","title":"An asynchronous electronic consent for improving consent in research among patients with cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; BC Cancer Agency","funders":"Canadian Institutes of Health Research; BC Cancer Foundation","keywords":"Cancer; Informed consent; Comprehension; Asynchronous communication; Work (physics); MEDLINE","score_opus":0.439706837222243,"score_gpt":0.6190294803774716,"score_spread":0.1793226431552286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414606428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794963,0.00030965605,0.00031921407,0.011562828,0.00012075393,0.0026365127,0.000013250935,0.000033470125,0.0055080163],"genre_scores_gemma":[0.9949192,0.00028513605,0.00024974046,0.000809279,0.000081845435,0.0007184767,0.00001304363,0.000018590654,0.0029047239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973062,0.0004593402,0.0003558472,0.0004231238,0.0006619577,0.00079351943],"domain_scores_gemma":[0.97890586,0.01940627,0.00007730746,0.0006338705,0.00086204923,0.00011466798],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008035082,0.00011616637,0.00029551514,0.00015503335,0.00026286725,0.0000422294,0.0003993306,0.00025032146,0.00006973515],"category_scores_gemma":[0.010956662,0.00006946806,0.00004581732,0.00038826332,0.00192205,0.000035224675,0.00015812466,0.0023964583,0.0000080734435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050669685,0.0017201473,0.94596773,0.0007508136,0.000121201054,0.000028631717,0.00037222973,0.00009875412,0.0007403792,0.025770778,0.001957227,0.017405119],"study_design_scores_gemma":[0.010380408,0.009815498,0.94794935,0.0009127876,0.000107841704,0.0000018023429,0.0013451794,0.0018514356,0.0013573002,0.023292042,0.0027551907,0.00023116611],"about_ca_topic_score_codex":0.0072915303,"about_ca_topic_score_gemma":0.12291916,"teacher_disagreement_score":0.11562763,"about_ca_system_score_codex":0.0017107464,"about_ca_system_score_gemma":0.008743167,"threshold_uncertainty_score":0.99990505},"labels":[],"label_agreement":null},{"id":"W4414609202","doi":"10.1093/oncolo/oyaf323","title":"Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Eisai; Regeneron Pharmaceuticals; Exelixis; GlaxoSmithKline; Massachusetts General Hospital; AstraZeneca; Université de Montréal; Bristol-Myers Squibb; Amgen","keywords":"Melanoma; Duration (music); Metastatic melanoma; Clinical trial; Radiation therapy; Cancer","score_opus":0.048488152527462865,"score_gpt":0.4062268393784344,"score_spread":0.35773868685097154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414609202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888562,0.0009885777,0.00014210808,0.0013573227,0.00057492015,0.0006953636,0.000016405087,0.00001975904,0.0073493617],"genre_scores_gemma":[0.9978645,0.0003192382,0.00012313659,0.00082505983,0.000026512002,0.000053472766,0.000042256906,0.000007877243,0.000737955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854857,0.0002476749,0.0005856974,0.00023575866,0.00016219619,0.00022008167],"domain_scores_gemma":[0.9989325,0.0004484763,0.00016588606,0.00031568165,0.00008220742,0.00005526188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005601887,0.00014947879,0.00056917383,0.000086901426,0.000056116845,0.0000038613734,0.00016746232,0.00012464405,0.00011563116],"category_scores_gemma":[0.00013009105,0.00008716537,0.00016537787,0.00023145923,0.0006461145,0.000025428742,0.00007466898,0.000289257,0.000030350368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005519359,0.0038248913,0.6464606,0.000018351342,0.00028678373,0.0000528137,0.000071696646,0.0000065950553,0.0000072573653,0.0013861408,0.0005288818,0.34680408],"study_design_scores_gemma":[0.013082194,0.0043372787,0.9743787,0.00007719793,0.00025636656,0.000005958429,0.00015534837,0.0001618711,0.00030869685,0.0008076675,0.0063500977,0.00007859963],"about_ca_topic_score_codex":0.00016828133,"about_ca_topic_score_gemma":0.00026106578,"teacher_disagreement_score":0.34672546,"about_ca_system_score_codex":0.00020330523,"about_ca_system_score_gemma":0.00022297076,"threshold_uncertainty_score":0.35545006},"labels":[],"label_agreement":null},{"id":"W4414857438","doi":"10.1093/oncolo/oyaf330","title":"Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"Daiichi Sankyo Europe; U.S. Food and Drug Administration; Celgene; MorphoSys; Gilead Sciences; Kite Pharma; Incyte; BeiGene; TG Therapeutics; Seagen; Karyopharm Therapeutics; AstraZeneca","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Standard of care; Salvage therapy; Clinical trial","score_opus":0.02572095470819502,"score_gpt":0.3219684897978651,"score_spread":0.29624753508967006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92835385,0.000038421007,6.9877814e-7,0.0016288375,0.000051565432,0.0019587094,0.000019459207,0.0000070424985,0.06794145],"genre_scores_gemma":[0.9643642,0.00010138986,0.000020384174,0.00033812664,0.000013619447,0.0001081396,0.000009269563,0.000014023546,0.0350309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778795,0.0006089992,0.00039772718,0.00023925735,0.0006201856,0.00034588636],"domain_scores_gemma":[0.99795294,0.00039974757,0.00018607626,0.0012812895,0.00012095604,0.000058979283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015421032,0.0001497378,0.00039255852,0.0005367419,0.00014148901,0.00001340004,0.0007379623,0.000055989887,0.00025815333],"category_scores_gemma":[0.000069513,0.000060355993,0.00010232012,0.0030825904,0.0002872572,0.000021208067,0.00015460813,0.00025621403,0.000003251109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047708065,0.017357757,0.9565137,0.00017196659,0.0008777835,0.00023881943,0.0057838024,0.0000093100025,0.0001195742,0.00028916163,0.0032140675,0.010653242],"study_design_scores_gemma":[0.015612142,0.0011121293,0.95633656,0.000113574984,0.0004990515,4.087946e-7,0.011777466,0.000022768347,0.00013057195,0.000017562548,0.014303623,0.00007417145],"about_ca_topic_score_codex":0.10866405,"about_ca_topic_score_gemma":0.73218834,"teacher_disagreement_score":0.6235243,"about_ca_system_score_codex":0.00067035743,"about_ca_system_score_gemma":0.0005282476,"threshold_uncertainty_score":0.89727145},"labels":[],"label_agreement":null},{"id":"W4414857553","doi":"10.1093/oncolo/oyaf327","title":"Pathomic immune biomarkers define recurrence risk in early-stage melanoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Columbia College","funders":"National Cancer Institute; National Institutes of Health","keywords":"Melanoma; Immune system; Disease; Stage (stratigraphy); Prospective cohort study; Biomarker","score_opus":0.01625427142453583,"score_gpt":0.28495570990322294,"score_spread":0.2687014384786871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9239294,0.00068995776,0.00028328944,0.0031696078,0.00064438744,0.0007254097,0.000010429998,0.000099211,0.070448294],"genre_scores_gemma":[0.986514,0.00053669594,0.00026612717,0.00041609214,0.000033266515,0.0000589252,0.0000066945595,0.000008591565,0.012159627],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99895656,0.00015238108,0.00030167907,0.00023767758,0.00011798143,0.00023370991],"domain_scores_gemma":[0.9991739,0.00018599025,0.000111932575,0.00046114408,0.000027279435,0.000039770784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006917791,0.00013075068,0.00025321974,0.00016978548,0.0001276766,0.000022809341,0.00018042311,0.00007931122,0.00013508342],"category_scores_gemma":[0.00030978487,0.00008937336,0.000088638146,0.0004593244,0.00018905182,0.000021095033,0.0001281169,0.0002924633,0.00012425166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061411033,0.0014872059,0.4249695,0.0003567636,0.00077327114,0.0020390723,0.0013252891,0.00013443836,0.011315186,0.011556977,0.018939257,0.52096194],"study_design_scores_gemma":[0.00313525,0.00079833873,0.8369676,0.0001730404,0.00019699571,0.000073885094,0.0009016018,0.0007290469,0.0015985831,0.0007344711,0.1544832,0.00020797699],"about_ca_topic_score_codex":0.0021320195,"about_ca_topic_score_gemma":0.0009434357,"teacher_disagreement_score":0.520754,"about_ca_system_score_codex":0.0002734055,"about_ca_system_score_gemma":0.000080980826,"threshold_uncertainty_score":0.36445397},"labels":[],"label_agreement":null},{"id":"W4414870711","doi":"10.1093/oncolo/oyaf333","title":"Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Comprehensive Cancer Network","keywords":"Identification (biology); Selection (genetic algorithm); Precision medicine; MEDLINE; Data collection; Urothelial cancer","score_opus":0.0884092151270177,"score_gpt":0.38047784830099896,"score_spread":0.29206863317398124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414870711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95064765,0.0016040686,0.0003357282,0.004336826,0.00059497665,0.0013221379,0.00020058353,0.00007560448,0.04088245],"genre_scores_gemma":[0.9953596,0.0005309684,0.00028545375,0.0007598428,0.00008912984,0.00019379568,0.00003748236,0.000011093688,0.0027326483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987422,0.00013970326,0.00032098917,0.00031887577,0.00015629602,0.00032188557],"domain_scores_gemma":[0.99885684,0.0004743514,0.000056863817,0.0004686052,0.000066316345,0.00007703321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003089431,0.00020971648,0.00041156626,0.000061819264,0.0001760533,0.000018389806,0.00017528878,0.00009514972,0.00005942826],"category_scores_gemma":[0.00042568147,0.0001236789,0.000113143455,0.0005313428,0.00013157842,0.000031390708,0.00007579062,0.00008157091,0.00004800387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004079904,0.0015010891,0.8931629,0.000013171241,0.0001787779,0.0002313631,0.00020974803,0.0002490513,0.00015550682,0.00063466793,0.0024144505,0.09716938],"study_design_scores_gemma":[0.010032859,0.0015457025,0.96433467,0.00009500133,0.00017296836,0.000023247401,0.00008675746,0.00010965133,0.0005492428,0.00080052915,0.022129748,0.00011962582],"about_ca_topic_score_codex":0.0075280047,"about_ca_topic_score_gemma":0.025168996,"teacher_disagreement_score":0.09704975,"about_ca_system_score_codex":0.0015731492,"about_ca_system_score_gemma":0.0005979992,"threshold_uncertainty_score":0.99908096},"labels":[],"label_agreement":null},{"id":"W4414992675","doi":"10.1093/oncolo/oyaf276.067","title":"66Patient perceptions of biomarker testing in kidney cancer (KC) from the international kidney cancer coalition (IKCC) global patient survey (GPS)","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kidney Foundation of Canada; Institute of Cancer Research; Health Care Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Biomarker; Kidney cancer; Cancer; Precision medicine; Health care; Health professionals; Kidney disease; Personalized medicine","score_opus":0.07513053520888265,"score_gpt":0.31647179660133623,"score_spread":0.2413412613924536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92052037,0.0015659211,0.0006060007,0.016688857,0.003358048,0.0005367769,0.013544627,0.000027208896,0.043152224],"genre_scores_gemma":[0.9922219,0.00063598104,0.0001141416,0.006189989,0.00013593942,0.00017248583,0.00012691267,0.000010215203,0.0003924373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846125,0.000077026634,0.0007926789,0.00034050152,0.000057815603,0.00027075774],"domain_scores_gemma":[0.99854636,0.0003587603,0.0005519537,0.00033724913,0.00012434305,0.000081353704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080259325,0.00016594195,0.00036330972,0.00007457911,0.00015796837,0.00006736801,0.0005530182,0.00011827771,0.00088414404],"category_scores_gemma":[0.0017514091,0.00012930251,0.00009617893,0.0004255121,0.00028341432,0.00015246357,0.00018537609,0.0001765786,0.000043350847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112117494,0.00012349142,0.92631227,0.000009145428,0.00008621772,5.85074e-7,0.00034033437,0.0004908358,0.000029161742,0.0072402707,0.055595007,0.009660554],"study_design_scores_gemma":[0.0006643898,0.000042891366,0.94316167,0.0001411782,0.000013879906,2.708341e-7,0.0001880602,0.0024646602,0.000017828648,0.0065282774,0.04662983,0.00014705406],"about_ca_topic_score_codex":0.18079415,"about_ca_topic_score_gemma":0.026213152,"teacher_disagreement_score":0.154581,"about_ca_system_score_codex":0.0013603806,"about_ca_system_score_gemma":0.00053136866,"threshold_uncertainty_score":0.9915559},"labels":[],"label_agreement":null},{"id":"W4414992798","doi":"10.1093/oncolo/oyaf276.051","title":"50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Refractory (planetary science); Renal cell carcinoma; Logistic regression; Population; Primary tumor; Carcinoma; Overall survival","score_opus":0.0949413080994492,"score_gpt":0.3741196405361676,"score_spread":0.2791783324367184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547786,0.0007001728,0.000046926307,0.00040581176,0.00034645604,0.0014991951,0.00014946783,0.00002820838,0.0013459019],"genre_scores_gemma":[0.9969274,0.0004502086,0.0009858485,0.0005957818,0.00006951975,0.00011222765,0.00017112067,0.000022794244,0.0006651305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730057,0.00061730016,0.0008964645,0.00049118156,0.0004273274,0.00026713454],"domain_scores_gemma":[0.9975505,0.0007888278,0.00045078696,0.0008666112,0.00019409572,0.0001491746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00125185,0.00028771666,0.0008313714,0.00015390481,0.00010499781,0.00003370568,0.00035445404,0.000050022147,0.00009618904],"category_scores_gemma":[0.00024856618,0.00017903601,0.000117462856,0.0001393095,0.00059363036,0.00012938886,0.00020201574,0.00032426964,0.000008281137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007681035,0.013453184,0.8963082,0.0003406934,0.00095265923,0.0026614156,0.001219714,0.0000022731067,0.04036496,0.000109985434,0.00049759506,0.036408298],"study_design_scores_gemma":[0.0063898647,0.005090353,0.9765418,0.00006184399,0.00079057156,0.0000894725,0.00079321803,0.00014022933,0.008862062,0.00004396126,0.0010350579,0.00016156018],"about_ca_topic_score_codex":0.00037233633,"about_ca_topic_score_gemma":0.000090028916,"teacher_disagreement_score":0.08023361,"about_ca_system_score_codex":0.00030170675,"about_ca_system_score_gemma":0.00053628365,"threshold_uncertainty_score":0.7300877},"labels":[],"label_agreement":null},{"id":"W4414992847","doi":"10.1093/oncolo/oyaf276.065","title":"64defining cancer initiating cells and their vulnerabilities in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Montreal Neurological Institute and Hospital; McGill Genome Centre","funders":"","keywords":"Transcriptome; Renal cell carcinoma; Cancer; Spheroid; Cell; Population; Clear cell renal cell carcinoma; In vivo; Cell culture","score_opus":0.03383505517727218,"score_gpt":0.30393371236642364,"score_spread":0.27009865718915144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414992847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954622,0.002960026,0.000014268092,0.0038924832,0.0001537786,0.00022866509,0.000010591827,0.000024624991,0.038093597],"genre_scores_gemma":[0.9964115,0.00029241634,0.0001337538,0.001962516,0.00008380471,0.00014644701,0.0000020750404,0.000008240617,0.00095927366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992256,0.00009281009,0.00020880884,0.00019085886,0.000072947194,0.00020894184],"domain_scores_gemma":[0.9993917,0.00031164117,0.000057307752,0.00017308434,0.000035251385,0.000031055584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004278515,0.00011499356,0.00025234354,0.000058219834,0.000122025434,0.000025979785,0.00009473932,0.00006675745,0.00007535185],"category_scores_gemma":[0.00004948488,0.00006752974,0.000041437608,0.00018668629,0.00021492704,0.00002914019,0.00009407185,0.00026987185,0.0000020261182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005103086,0.00036673865,0.8394668,0.00067781034,0.00006935256,0.000028521188,0.010662017,0.00025003147,0.040351532,0.0015877719,0.008821916,0.0972072],"study_design_scores_gemma":[0.0056172768,0.0014208535,0.6317655,0.00095392665,0.0002339183,0.000013580861,0.03296092,0.0023639954,0.29402655,0.0014299861,0.028716167,0.0004973529],"about_ca_topic_score_codex":0.0016106616,"about_ca_topic_score_gemma":0.0006673265,"teacher_disagreement_score":0.253675,"about_ca_system_score_codex":0.00016986857,"about_ca_system_score_gemma":0.00021671472,"threshold_uncertainty_score":0.2753783},"labels":[],"label_agreement":null},{"id":"W4414993075","doi":"10.1093/oncolo/oyaf276.038","title":"37Integrative multi-omic characterization of the immune landscape in renal cell carcinoma","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Mass cytometry; Immune system; Tumor microenvironment; Transcriptome; Cell; Renal cell carcinoma; Tumour heterogeneity","score_opus":0.020994979300086637,"score_gpt":0.2762426854285082,"score_spread":0.25524770612842157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414993075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855754,0.0003575228,0.000066960936,0.0029181764,0.00015905118,0.0007022783,0.000010814708,0.000012370138,0.010197459],"genre_scores_gemma":[0.99366146,0.000029337107,0.000079061225,0.00021885485,0.000026721276,0.000049693368,0.00002886326,0.000007548255,0.0058984705],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991281,0.00016577441,0.000291989,0.00015390503,0.000114887574,0.00014533591],"domain_scores_gemma":[0.9992607,0.00010538219,0.00015348637,0.00039786287,0.000063211766,0.000019344092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023334374,0.00012272922,0.00027766445,0.000070134105,0.00006118799,0.0000068640497,0.00018891807,0.00007335874,0.00004449163],"category_scores_gemma":[0.000060902614,0.000057708858,0.00010695993,0.00031263215,0.00018052745,0.000021271697,0.000088995024,0.00021658816,0.000011167242],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005524215,0.0005165328,0.21979505,0.00006324647,0.000035928835,0.000027326498,0.0009960849,0.000013594834,0.77592844,0.00024334039,0.00018773446,0.0016402921],"study_design_scores_gemma":[0.0014659017,0.00017313533,0.6855488,0.000056931767,0.00006538683,0.0000052495,0.00024778835,0.00028370196,0.3118446,0.000016286946,0.00025789434,0.000034386423],"about_ca_topic_score_codex":0.00044070763,"about_ca_topic_score_gemma":0.00018630402,"teacher_disagreement_score":0.4657537,"about_ca_system_score_codex":0.00023954462,"about_ca_system_score_gemma":0.00022102805,"threshold_uncertainty_score":0.2353299},"labels":[],"label_agreement":null},{"id":"W4415502772","doi":"10.1093/oncolo/oyaf287","title":"Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Discontinuation; Adverse effect; Crown (dentistry); Post-hoc analysis; Term (time)","score_opus":0.018162467902239843,"score_gpt":0.34178945367326324,"score_spread":0.3236269857710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415502772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933541,0.00007287519,0.0000069531475,0.00043618926,0.000038288203,0.00083216536,0.0000075419157,0.0000037921857,0.0052481405],"genre_scores_gemma":[0.99785364,0.000025158404,0.000070652175,0.00012099411,0.0000030099557,0.000079058605,0.0000041379267,0.000002879043,0.0018404688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958277,0.000052990024,0.00012415125,0.00006948492,0.000109778484,0.000060821167],"domain_scores_gemma":[0.99966955,0.00008246319,0.00006197585,0.00015147286,0.000026906355,0.0000076264064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014965606,0.000045982528,0.00012587648,0.00002891383,0.000015685506,0.0000010137429,0.000055070923,0.000014457268,0.000011137698],"category_scores_gemma":[0.00001829033,0.000022988215,0.000018300485,0.0001813709,0.00008130949,0.00000901401,0.00002969767,0.00004237553,3.4012268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010979413,0.0024482459,0.98386765,0.00008244369,0.0011224733,0.00012356344,0.0060157785,0.000058056066,0.000020713927,0.0002592762,0.00030418125,0.0045996676],"study_design_scores_gemma":[0.0042425375,0.0007865699,0.989251,0.00014104403,0.00068709155,5.734593e-7,0.004595679,0.0000056741537,0.000011938637,0.0000525155,0.00020499267,0.000020378195],"about_ca_topic_score_codex":0.00013563356,"about_ca_topic_score_gemma":0.00065510866,"teacher_disagreement_score":0.005383346,"about_ca_system_score_codex":0.000060818864,"about_ca_system_score_gemma":0.000024895486,"threshold_uncertainty_score":0.09374322},"labels":[],"label_agreement":null},{"id":"W7117146489","doi":"10.1093/oncolo/oyaf385","title":"Clinical and radiomics parameter prognostication in metastatic uveal melanoma patients treated with hepatic arterial infusion chemotherapy","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Deutschen Konsortium für Translationale Krebsforschung","keywords":"Radiomics; Melanoma; Chemotherapy; Risk stratification; Multivariate analysis; Metastatic melanoma; Overall survival; Retrospective cohort study","score_opus":0.021762291322006192,"score_gpt":0.3339066299120575,"score_spread":0.3121443385900513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117146489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99645114,0.000050700677,0.00006491054,0.0014402552,0.000092514456,0.0011907972,0.0000038231765,0.000024206565,0.0006816354],"genre_scores_gemma":[0.9972044,0.000101284204,0.0015574617,0.00079302397,0.00002309498,0.00009552795,0.000056643454,0.0000082752695,0.0001602788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900615,0.00023560348,0.00031536008,0.00021368975,0.00008152374,0.00014765635],"domain_scores_gemma":[0.9991396,0.00046845037,0.000100873905,0.00020578071,0.000043557236,0.000041727697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030894874,0.000124904,0.00035224613,0.00006478123,0.00006709425,0.00001209187,0.000057675083,0.000102588296,0.000014814604],"category_scores_gemma":[0.00022954462,0.00006817121,0.000037228703,0.00017047282,0.0003959376,0.00003275327,0.000024068717,0.0001533795,0.000007721629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025796858,0.0011296602,0.95321316,0.000018872006,0.00017375156,0.00003568432,0.000090576046,5.7991844e-7,0.00002552142,0.00007012908,0.00006794032,0.042594433],"study_design_scores_gemma":[0.012401961,0.0028452792,0.98293525,0.00006626044,0.00038416017,0.000012192272,0.00002825191,0.00042664827,0.00012671568,0.00031228035,0.00039768132,0.00006334889],"about_ca_topic_score_codex":0.00007168855,"about_ca_topic_score_gemma":0.00012284564,"teacher_disagreement_score":0.042531084,"about_ca_system_score_codex":0.00009238112,"about_ca_system_score_gemma":0.00011513984,"threshold_uncertainty_score":0.27799413},"labels":[],"label_agreement":null}]}